6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
114_CD
Shareholder_NN
information_NOMZ
Registered_NN
office_NN
address_NN
Hampshire_NN
International_NN
Business_NOMZ
Park_NN
Basingstoke_NN
,_,
Hampshire_NN
RG24_NN
8EP_NN
United_NN
Kingdom_NN
Registered_NN
in_PIN
England_NN
No._NN
._.
05492592_CD
Investor_NN
relations_NOMZ
Europe_NN
and_CC
Rest_VB
of_PIN
the_DT
World_NN
:_:
Cla_NN
Rosenfeld_NN
Tel_NN
44_CD
0_CD
1256 894160_CD
Fax_NN
44_CD
0_CD
1256 894708_CD
Email_NN
investorrelations@uk_NN
._.
com_NN
North_NN
America_NN
:_:
Brian_NN
Piper_NN
Tel_NN
1_CD
484 595 8800_CD
Fax_NN
1_CD
484 595 8151_CD
Email_NN
bpiper@us_FPP1
._.
com_NN
Registrars_NN
and_CC
transfer_VB
office_NN
All_QUAN
administrative_JJ
enquiries_NN
relating_VBG [WZPRES]
to_PIN
shareholdings_GER
should_NEMD
be_VB [PASS]
addressed_VBN
to_PIN
Lloyds_NN
TSB_NN
Registrars_NN
,_,
clearly_RB
stating_VBG [PUBV]
the_DT
registered_VBN
shareholders_NN
name_NN
and_PHC
address_NN
._.
Lloyds_NN
TSB_NN
Registrars_NN
Customer_NN
Services_NN
,_,
The_DT
Causeway_NN
Worthing_GER
,_,
West_NN
Sussex_NN
BN99_NN
6DA_NN
United_NN
Kingdom_NN
Tel_NN
44 870 600 3970_CD
114_CD
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
115_CD
This_DEMO
page_NN
has_VPRT [PEAS]
been_VBN [SPAU] [PASS]
intentionally_RB
left_VBN
blank_JJ
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
116_CD
Designed_VBN
and_PHC
produced_VBN
by_PIN
Bostock_NN
and_PHC
Pollitt_NN
Limited_NN
,_,
London_NN
The_DT
paper_NN
used_VBN [WZPAST]
in_PIN
this_DEMO
publication_NOMZ
is_VPRT [PASS]
made_VBN
from_PIN
100_CD
%_NN
recycled_JJ
fibers_NN
sourced_VBD
entirely_AMP
from_PIN
post_NN
consumer_NN
waste_NN
,_,
is_VPRT [BEMA]
Elemental_JJ
Chlorine_NN
Free_NN
ECF_NN
and_CC
is_VPRT [PASS]
accredited_VBN
to_PIN
ISO_NN
14001_CD
._.
Shire_NN
plc_NN
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
6420_CD
Cover_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:21_CD
Page_NN
fc1_CD
Shire_NN
plc_NN
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
y_JJ
Hampshire_NN
International_NN
Business_NOMZ
Park_NN
Shire_NN
plc_NN
Basingstoke_NN
,_,
Hampshire_NN
RG24_NN
8EP_NN
United_NN
Kingdom_NN
Tel_NN
44_CD
0_CD
1256 894000_CD
Fax_NN
44_CD
0_CD
1256 894708_CD
www_NN
._.
com_NN
tog_NN
Shire_NN
plc_NN
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
6361_CD
Cover_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:56_CD
Page_NN
fc1_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
together_RB
6361_CD
Cover_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:56_CD
Page_NN
fc2_CD
Contents_NN
01_CD
Introduction_NOMZ
06_CD
Financial_NN
highlights_VPRT
07_CD
Chairmans_NN
statement_NOMZ
08_CD
Chief_NN
Executives_NN
review_VPRT
12_CD
Product_NN
portfolio_NN
14_CD
Product_NN
pipeline_NN
16_CD
Operating_GER
review_NN
36_CD
Corporate_JJ
Responsibility_NOMZ
40_CD
Board_NN
of_PIN
Directors_NN
42_CD
Executive_NN
Committee_NN
44_CD
Financial_NN
review_NN
56_CD
Nomination_NOMZ
Committee_NN
report_NN
56_CD
Directors_NN
remuneration_JJ
report_NN
68_CD
Audit_NN
Committee_NN
report_NN
70_CD
Corporate_JJ
governance_NN
statements_NOMZ
77_CD
Report_NN
of_PIN
independent_JJ
registered_JJ
public_JJ
accounting_GER
firm_NN
78_CD
Consolidated_NN
balance_NN
sheets_NN
79_CD
Consolidated_NN
statements_NOMZ
of_PIN
operations_NOMZ
80_CD
Consolidated_NN
statements_NOMZ
of_PIN
changes_NN
in_PIN
shareholders_NN
equity_NOMZ
81_CD
Consolidated_NN
statements_NOMZ
of_PIN
comprehensive_JJ
income_NN
82_CD
Consolidated_NN
statements_NOMZ
of_PIN
cash_NN
flows_VPRT
84_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
128_CD
Five-year_JJ
review_NN
129_CD
Statement_NOMZ
of_PIN
Directors_NN
responsibilities_NOMZ
130_CD
Summary_JJ
financial_JJ
statement_NOMZ
140_CD
Shire_NN
head_NN
office_NN
and_CC
main_JJ
operating_GER
locations_NOMZ
141_CD
Shareholder_NN
information_NOMZ
142_CD
Shire_NN
Trade_NN
Marks_NN
142_CD
Cautionary_JJ
statements_NOMZ
143_CD
Glossary_NN
of_PIN
terms_NN
Cover_NN
:_:
Barbara_NN
Deptula_NN
Executive_NN
Vice_NN
President_NN
Business_NOMZ
Development_NOMZ
Page_NN
2_CD
:_:
Jeff_NN
Poulton_NN
Vice_NN
President_NN
Therapeutic_NN
Area_NN
Finance_NN
Page_NN
5_CD
:_:
Stephanie_NN
Read_NN
Global_NN
Medical_NN
Affairs_NN
Senior_NN
Manager_NN
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:53_CD
Page_NN
01_CD
Its_PIT
all_QUAN
coming_VBG
together_RB
for_PIN
Shire_NN
._.
Weve_NN
reorganized_VBD
the_DT
business_NOMZ
to_TO
create_VB
a_DT
leaner_JJ
,_,
more_EMPH
resilient_JJ
Company_NN
,_,
and_ANDC
what_WP
we_FPP1
have_VPRT [SPAU]
now_TIME
is_VPRT [BEMA]
the_DT
right_JJ
structure_NN
and_CC
the_DT
right_JJ
team_NN
._.
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
01_CD
Shire_NN
plc_NN
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:53_CD
Page_NN
02_CD
plus_PIN
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:53_CD
Page_NN
03_CD
Were_VBD
seeing_VBG [PRIV]
the_DT
benets_NN
from_PIN
clever_JJ
acquisitions_NOMZ
and_CC
shrewd_JJ
partnerships_NN
,_,
and_ANDC
were_VBD
developing_VBG
whats_NN
acknowledged_VBD [PUBV]
to_TO
be_VB [BEMA]
one_CD
of_PIN
the_DT
richest_JJ
pipelines_NN
in_PIN
the_DT
specialty_NN
pharmaceutical_JJ
sector_NN
._.
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
03_CD
Shire_NN
plc_NN
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:53_CD
Page_NN
04_CD
Add_VB [PUBV]
to_PIN
that_DEMO
the_DT
professionalism_NN
of_PIN
our_FPP1
people_NN
,_,
a_DT
high-performing_JJ
portfolio_NN
of_PIN
profitable_JJ
drugs_NN
,_,
and_ANDC
an_DT
unrivaled_JJ
understanding_GER
of_PIN
the_DT
needs_NN
of_PIN
specialist_NN
physicians_NN
and_CC
their_TPP3
patients_NN
,_,
and_ANDC
it_PIT
all_QUAN
adds_VPRT [PUBV]
up_RP
to_PIN
a_DT
business_NOMZ
thats_VPRT
a_EMPH
lot_NULL
more_EMPH
than_PIN
the_DT
sum_NN
of_PIN
its_PIT
parts_NN
._.
04_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:53_CD
Page_NN
05_CD
add_VPRT [PUBV]
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:53_CD
Page_NN
06_CD
Financial_NN
highlights_VPRT
Revenue_NN
growth_NN
up_IN
Revenue_NN
$_$
million_CD
Revenue_NN
growth_NN
over_IN
the_DT
last_JJ
five_CD
years_NN
$_$
million_CD
2005_CD
1,599.3_CD
2005_CD
1,599.3_CD
2004_CD
1,363.2_CD
2004_CD
1,363.2_CD
2003_CD
1,211.6_CD
17_CD
%_NN
2002_CD
1,023.3_CD
2001_CD
845.1_CD
Sources_NN
of_PIN
revenue_NN
$_$
million_CD
Sources_NN
of_PIN
revenue_NN
%_NN
Revenue_NN
by_PIN
location_NOMZ
$_$
million_CD
1_CD
ADDERALL_NN
XR_NN
730.8_CD
1_CD
ADDERALL_NN
XR_NN
46_CD
2_CD
CARBATROL_NN
72.1_CD
2_CD
CARBATROL_NN
4_CD
1_CD
North_NN
America_NN
1,233.5_CD
9_CD
9_CD
8_CD
3_CD
PENTASA_NN
136.1_CD
8_CD
3_CD
PENTASA_NN
8_CD
2_CD
Rest_VPRT
of_PIN
the_DT
world_NN
365.8_CD
2_CD
4_CD
AGRYLIN_NN
XAGRID_NN
92.8_CD
4_CD
AGRYLIN_NN
XAGRID_NN
6_CD
Total_JJ
1,599.3_CD
5_CD
FOSRENOL_NN
53.5_CD
5_CD
FOSRENOL_NN
3_CD
6_CD
REPLAGAL_NN
41.3_CD
6_CD
REPLAGAL_NN
3_CD
7_CD
7_CD
1_CD
1_CD
7_CD
Other_JJ
201.1_CD
7_CD
Other_JJ
13_CD
8_CD
Royalty_NN
income_NN
242.9_CD
8_CD
Royalty_NN
income_NN
15_CD
6_CD
6_CD
9_CD
Licensing_GER
and_CC
9_CD
Licensing_GER
and_CC
5_CD
5_CD
1_CD
Development_NOMZ
Development_NOMZ
4_CD
4_CD
and_CC
other_JJ
28.7_CD
and_CC
other_JJ
2_CD
3_CD
2_CD
3_CD
2_CD
Total_JJ
1,599.3_CD
Total_JJ
100_CD
This_DEMP
represents_VPRT
REPLAGAL_NN
sales_NN
for_PIN
the_DT
five-month_JJ
period_NN
since_OSUB
the_DT
acquisition_NOMZ
of_PIN
TKT_NN
._.
06_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:53_CD
Page_NN
07_CD
Chairmans_NN
statement_NOMZ
Its_PIT
all_QUAN
adding_VBG [PUBV]
up_RP
for_PIN
Shire_NN
._.
Increasing_VBG
competition_NOMZ
from_PIN
generic_JJ
drugs_NN
2004_CD
:_:
$_$
1,363.2_CD
million_CD
._.
Although_CONC
there_EX
were_VBD
and_CC
patent_NN
expirations_NOMZ
present_JJ
another_DT
major_JJ
diluted_JJ
losses_NN
per_PIN
ordinary_JJ
share_NN
for_PIN
the_DT
year_NN
challenge_NN
to_PIN
the_DT
pharmaceutical_JJ
industry_NN
._.
of_PIN
82.1_CD
2004_CD
:_:
diluted_JJ
earnings_GER
per_PIN
share_NN
We_FPP1
are_VPRT
responding_VBG
by_PIN
focusing_VBG
R&D_NN
in_PIN
the_DT
of_PIN
53.3_CD
,_,
these_DEMP
included_VBD
the_DT
write-off_PIN
specialty_NN
area_NN
with_PIN
products_NN
for_PIN
smaller_JJ
of_PIN
$_$
673_CD
million_CD
of_PIN
in-process_JJ
R&D_NN
following_VBG [WZPRES]
populations_NOMZ
and_PHC
biologics_NN
as_RB
well_RB
as_IN
inthe_JJ
acquisition_NOMZ
of_PIN
TKT_NN
._.
Excluding_VBG [PRESP]
this_DEMO
write-off_PIN [STPR]
,_,
licensing_GER
or_CC
developing_VBG
drugs_NN
with_PIN
strong_JJ
earnings_GER
per_PIN
ordinary_JJ
share_NN
would_PRMD
have_VB [PEAS]
been_VBN [BEMA]
intellectual_JJ
property_NN
._.
Our_FPP1
success_NN
has_VPRT [PEAS]
been_VBN [BEMA]
51.8_CD
in_PIN
2005_CD
._.
built_VBN [PASTP]
on_PIN
innovative_JJ
products_NN
that_TSUB
focus_VPRT
on_PIN
areas_NN
of_PIN
unmet_JJ
medical_JJ
need_NN
and_CC
we_FPP1
will_PRMD
On_PIN
November_NN
25_CD
,_,
2005_CD
,_,
Shire_NN
plc_NN
,_,
a_DT
Company_NN
continue_VPRT
to_TO
pursue_VB
this_DEMO
proven_JJ
formula_NN
._.
incorporated_VBN [PASTP]
in_PIN
England_NN
and_PHC
Wales_NN
Shire_NN
,_,
became_VBD
the_DT
holding_VBG [PRIV]
Company_NN
of_PIN
Shire_NN
Dr_NN
James_NN
Cavanaugh_NN
In_PIN
todays_NN
market_NN
,_,
pharmaceutical_JJ
companies_NN
Pharmaceuticals_NN
Group_NN
plc_NN
SPG_NN
pursuant_JJ
to_PIN
Chairman_NN
need_VPRT
to_TO
look_VB
to_PIN
additional_JJ
partnering_GER
,_,
licensing_GER
,_,
a_DT
scheme_NN
of_PIN
arrangement_NOMZ
under_IN
Section_NOMZ
425_CD
mergers_NN
and_PHC
acquisitions_NOMZ
as_IN
ways_NN
to_TO
fill_VB
their_TPP3
of_PIN
the_DT
United_NN
Kingdom_NN
Companies_NN
Act_NN
1985_CD
product_NN
pipelines_NN
as_RB
well_RB
as_IN
to_TO
minimize_VB
the_DT
Scheme_NN
._.
As_CONJ
a_NULL
result_NULL
of_PIN
the_DT
Scheme_NN
,_,
SPG_NN
Shire_NN
made_VBD
considerable_JJ
progress_NN
in_PIN
challenges_NN
created_VBN [WZPAST]
by_PIN
the_DT
industrys_NN
recent_JJ
is_VPRT [BEMA]
now_TIME
a_DT
wholly-owned_JJ
subsidiary_NN
of_PIN
Shire_NN
._.
2005_CD
in_PIN
positioning_GER
itself_PIT
for_PIN
success_NN
in_PIN
a_DT
low_JJ
productivity_NOMZ
._.
Almost_DWNT
75_CD
%_NN
of_PIN
New_NN
Chemical_NN
global_JJ
pharmaceutical_JJ
industry_NN
that_TSUB
faces_VPRT
Entities_NOMZ
NCEs_NN
entering_VBG [WZPRES]
the_DT
market_NN
are_VPRT
New_NN
Board_NN
member_NN
unprecedented_JJ
challenges_NN
and_PHC
opportunities_NOMZ
specialty_NN
products_NN
and_CC
or_CC
biologics_NN
,_,
showing_VBG [PRIV] [THATD] [PRESP]
We_FPP1
are_VPRT
continuing_VBG
to_TO
strengthen_VB
our_FPP1
Board_NN
in_PIN
the_DT
coming_VBG
years_NN
._.
The_DT
challenges_NN
are_VPRT [BEMA]
multithat_PRED
the_DT
smaller_JJ
,_,
more_EMPH
nimble_JJ
biotech_JJ
model_NN
of_PIN
Directors_NN
with_PIN
the_DT
appointment_NOMZ
during_PIN
faceted_VBN
,_,
and_ANDC
therefore_CONJ
require_VB [SUAV]
a_DT
disciplined_JJ
has_VPRT [PEAS]
proved_VBN [PRIV]
particularly_RB
effective_JJ
to_PIN
date_NN
in_PIN
2005_CD
of_PIN
Patrick_NN
Langlois_NN
as_IN
a_DT
Non-executive_JJ
and_PHC
co-ordinated_JJ
response_NN
on_PIN
several_QUAN
fronts_NN
._.
Director_NN
and_PHC
member_NN
of_PIN
our_FPP1
Audit_NN
Committee_NN
._.
Mr_NN
Langlois_NN
,_,
who_WP
held_VBD [PRIV]
senior_JJ
positions_NOMZ
at_PIN
One_CD
challenge_NN
faced_VBN [WZPAST]
by_PIN
Shire_NN
during_PIN
2005_CD
Our_FPP1
acquisition_NOMZ
in_PIN
2005_CD
of_PIN
Transkaryotic_NN
Aventis_NN
S._NN
A._NN
and_CC
the_DT
Rhone-Poulenc_NN
Group_NN
,_,
was_VBD [BEMA]
the_DT
Canadian_JJ
government_NOMZ
decision_NN
to_PIN
Therapies_NN
Inc._NN
._.
TKT_NN
,_,
a_DT
US-based_JJ
brings_VPRT
additional_JJ
expertise_NN
to_PIN
our_FPP1
Board_NN
,_,
withdraw_VPRT
ADDERALL_NN
XR_NN
,_,
our_FPP1
medicine_NN
for_PIN
biopharmaceutical_JJ
company_NN
specializing_VBG [WZPRES]
including_VBG
a_DT
wealth_NN
of_PIN
experience_NN
in_PIN
financial_JJ
treating_VBG
Attention_NOMZ
Deficit_NN
and_PHC
Hyperactivity_NOMZ
in_PIN
therapies_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
rare_JJ
genetic_JJ
and_PHC
operational_JJ
management_NOMZ
within_PIN
the_DT
global_JJ
Disorder_NN
ADHD_NN
,_,
from_PIN
the_DT
Canadian_JJ
market_NN
._.
diseases_NN
caused_VBN [WZPAST]
by_PIN
protein_NN
deficiencies_NN
,_,
pharmaceutical_JJ
industry_NN
._.
Shires_NN
team_NN
demonstrated_VBD [PRIV]
incredible_JJ
fits_NN
this_DEMO
profile_NN
._.
The_DT
acquisition_NOMZ
significantly_RB
success_NN
by_PIN
reinstating_VBG
ADDERALL_NN
XR_NN
in_PIN
builds_VPRT
our_FPP1
pipeline_NN
while_OSUB
bringing_VBG
us_FPP1
a_DT
new_JJ
,_,
Positioned_VBN [PASTP]
for_PIN
growth_NN
Canada_NN
during_PIN
2005_CD
,_,
following_VBG [PRESP]
a_DT
review_NN
by_PIN
sustainable_JJ
area_NN
of_PIN
specialty_NN
pharmaceutical_JJ
Our_FPP1
industry_NN
offers_VPRT
significant_JJ
growth_NN
independent_JJ
experts_NN
._.
expertise_NN
in_PIN
a_DT
market_NN
where_RB
there_EX
are_VPRT
only_DWNT
opportunities_NOMZ
for_PIN
medium-sized_JJ
specialty_NN
a_DT
small_JJ
number_NN
of_PIN
players_NN
._.
We_FPP1
continue_VPRT
to_PIN
pharmaceutical_JJ
companies_NN
like_IN
Shire_NN
._.
The_DT
The_DT
traditional_JJ
investment_NOMZ
and_CC
actively_RB
look_VB
at_PIN
other_JJ
acquisition_NOMZ
opportunities_NOMZ
global_JJ
pharmaceuticals_NN
market_NN
is_VPRT [PASS]
forecast_VBN [PUBV]
commercialization_NOMZ
model_NN
of_PIN
the_DT
pharmaceutical_JJ
involving_VBG
companies_NN
with_PIN
good_JJ
products_NN
to_TO
fill_VB
to_TO
reach_VB
an_DT
annual_JJ
growth_NN
rate_NN
of_PIN
8.2_CD
%_NN
from_PIN
industry_NN
that_TSUB
hinges_VPRT
on_PIN
blockbuster_NN
brands_NN
our_FPP1
pipeline_NN
and_CC
pursue_VB
our_FPP1
growth_NN
strategy_NN
._.
2004_CD
2011_CD
and_CC
achieve_VB
$_$
967_CD
billion_CD
in_PIN
sales_NN
could_POMD
face_VB
considerable_JJ
challenges_NN
in_PIN
the_DT
in_PIN
2011_CD
._.
Such_JJ
expansion_NN
is_VPRT [PASS]
expected_VBN [PRIV]
,_,
however_CONJ
,_,
coming_VBG
years_NN
._.
This_DEMP
reaffirms_VPRT
the_DT
value_NN
of_PIN
We_FPP1
have_VPRT [PEAS]
strengthened_VBN
our_FPP1
European_JJ
focus_NN
to_TO
be_VB [PASS]
based_VBN
on_PIN
the_DT
ability_NOMZ
of_PIN
pharmaceutical_JJ
Shires_NN
strategy_NN
of_PIN
diversifying_VBG
our_FPP1
product_NN
and_CC
we_FPP1
also_RB
have_VPRT [PEAS]
established_VBN [PRIV]
a_DT
presence_NN
in_PIN
companies_NN
to_TO
adapt_VB
to_PIN
changes_NN
in_PIN
patient_JJ
portfolio_NN
with_PIN
a_DT
focus_NN
on_PIN
the_DT
development_NOMZ
emerging_VBG [WZPRES]
markets_NN
through_PIN
relationships_NN
with_PIN
population_NOMZ
,_,
and_ANDC
target_NN
diseases_NN
of_PIN
unmet_JJ
and_CC
marketing_GER
of_PIN
smaller_JJ
,_,
specialty_NN
products_NN
._.
We_FPP1
are_VPRT [SPAU] [PASS]
well_RB
positioned_VBN
to_TO
serve_VB
medical_JJ
need_NN
to_TO
maximize_VB
revenue_NN
potential_NN
._.
With_PIN
our_FPP1
operating_GER
model_NN
of_PIN
cross-functional_JJ
,_,
the_DT
growing_VBG
needs_NN
of_PIN
these_DEMO
markets_NN
._.
I_FPP1
am_VPRT [BEMA]
confident_PRED
that_THAC
we_FPP1
have_VPRT
the_DT
right_JJ
strategy_NN
global_JJ
teams_NN
responsible_JJ
for_PIN
each_QUAN
of_PIN
our_FPP1
and_CC
the_DT
right_JJ
people_NN
to_TO
be_VB [BEMA]
able_PRED
to_TO
benefit_VB
from_PIN
main_JJ
therapeutic_JJ
areas_NN
,_,
nimble_JJ
sales_NN
forces_NN
We_FPP1
are_VPRT
adapting_VBG
our_FPP1
development_NOMZ
and_PHC
sales_NN
this_DEMO
future_JJ
growth_NN
._.
dedicated_VBN
to_TO
building_VBG
relationships_NN
with_PIN
processes_NN
to_TO
support_VB
a_DT
diverse_JJ
product_NN
portfolio_NN
specialist_NN
physicians_NN
and_CC
their_TPP3
patients_NN
,_,
and_ANDC
global_JJ
markets_NN
,_,
to_TO
realize_VB [PRIV]
financial_JJ
gains_NN
and_CC
a_DT
deep_JJ
pipeline_NN
of_PIN
innovative_JJ
products_NN
and_CC
continued_VBN
growth_NN
._.
with_PIN
strong_JJ
patent_NN
protection_NOMZ
,_,
we_FPP1
are_VPRT [SPAU] [PASS]
best_RB
positioned_VBN
to_TO
respond_VB
to_TO
changing_VBG
2005_CD
results_NN
under_IN
USGAAP_NN
marketplace_NN
dynamics_NN
._.
Shires_NN
highly-focused_JJ
growth_NN
strategy_NN
continued_VBD
to_TO
produce_VB
superior_JJ
results_NN
in_PIN
2005_CD
._.
Dr_NN
James_NN
Cavanaugh_NN
Revenues_NN
were_VBD [BEMA]
up_RB
17_CD
%_NN
to_TO
$_$
1,599.3_CD
million_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
07_CD
Shire_NN
plc_NN
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:53_CD
Page_NN
08_CD
prep_NN
arati_NN
on_PIN
08_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:53_CD
Page_NN
09_CD
Chief_NN
Executives_NN
review_NN
Today_TIME
Shire_NN
has_VPRT
one_CD
of_PIN
the_DT
richest_JJ
product_NN
pipelines_NN
Matthew_NN
Emmens_NN
Chief_NN
Executive_NN
Officer_NN
in_PIN
the_DT
specialty_NN
pharmaceutical_JJ
industry_NN
._.
The_DT
year_NN
2005_CD
was_VBD [BEMA]
pivotal_PRED
for_PIN
Shire_NN
._.
With_PIN
a_DT
breakthrough_NN
acquisition_NOMZ
,_,
a_DT
key_JJ
collaboration_NOMZ
agreement_NOMZ
,_,
several_QUAN
product_NN
launches_NN
and_CC
continuing_VBG
advancement_NOMZ
of_PIN
our_FPP1
pipeline_NN
,_,
we_FPP1
have_VPRT [PEAS]
made_VBN
excellent_JJ
progress_NN
in_PIN
setting_VBG
the_DT
stage_NN
for_PIN
continued_JJ
growth_NN
._.
We_FPP1
are_VPRT
seeing_VBG [PRIV]
the_DT
results_NN
of_PIN
our_FPP1
focused_JJ
business_NOMZ
strategy_NN
through_PIN
a_DT
significant_JJ
increase_NN
in_PIN
the_DT
number_NN
of_PIN
late-stage_JJ
product_NN
candidates_NN
._.
Today_TIME
Shire_NN
has_VPRT
one_CD
of_PIN
the_DT
richest_JJ
product_NN
pipelines_NN
in_PIN
the_DT
specialty_NN
pharmaceutical_JJ
industry_NN
._.
Simultaneously_TIME
,_,
we_FPP1
have_VPRT [PEAS]
put_VBN
in_PIN
place_NN
a_DT
strengthened_JJ
organization_NOMZ
to_TO
deliver_VB
on_PIN
the_DT
opportunities_NOMZ
in_PIN
key_JJ
markets_NN
._.
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
09_CD
Shire_NN
plc_NN
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:53_CD
Page_NN
10_CD
Chief_NN
Executives_NN
review_NN
Our_FPP1
strong_JJ
competitive_JJ
position_NOMZ
is_VPRT [BEMA]
the_DT
result_NN
Pipeline_NN
successes_NN
as_IN
Shires_NN
authorized_VBD
generic_JJ
._.
Shire_NN
will_PRMD
of_PIN
the_DT
hard_JJ
work_NN
of_PIN
all_QUAN
2,400_CD
Shire_NN
employees_NN
._.
The_DT
year_NN
saw_VBD [PRIV]
a_DT
number_NN
of_PIN
other_JJ
exciting_JJ
receive_VPRT
royalties_NN
from_PIN
Impax_NN
on_PIN
these_DEMO
sales_NN
._.
We_FPP1
have_VPRT [PEAS]
made_VBN
good_JJ
on_PIN
our_FPP1
strategic_JJ
advances_NN
in_PIN
our_FPP1
pipeline_NN
:_:
This_DEMO
latest_JJ
development_NOMZ
is_VPRT [BEMA]
excellent_JJ
news_NN
for_PIN
commitment_NOMZ
to_TO
grow_VB
our_FPP1
underlying_VBG
business_NOMZ
Shire_NN
as_IN
it_PIT
removes_VPRT
some_QUAN
of_PIN
the_DT
uncertainty_NN
while_OSUB
expanding_VBG
our_FPP1
portfolio_NN
of_PIN
new_JJ
submission_NN
of_PIN
a_DT
NDA_NN
with_PIN
the_DT
FDA_NN
that_TSUB
surrounded_VBD
ADDERALL_NN
XR_NN
._.
We_FPP1
have_VPRT [PEAS]
continued_VBN
to_TO
evolve_VB
our_FPP1
for_PIN
MESAVANCE_NN
,_,
the_DT
first_JJ
once-daily_JJ
continues_VPRT
to_TO [SPIN]
vigorously_RB
defend_VB
its_PIT
intellectual_JJ
manufacturing_GER
capabilities_NOMZ
both_DT
in_PIN
small_JJ
mesalamine_NN
treatment_NOMZ
for_PIN
mild_JJ
to_PIN
moderate_JJ
property_NN
rights_NN
relating_VBG [WZPRES]
to_PIN
ADDERALL_NN
XR_NN
molecules_NN
and_PHC
proteins_NN
to_TO
mitigate_VB
supply_NN
ulcerative_JJ
colitis_NN
UC_NN
._.
In_CONJ
addition_NULL
,_,
we_FPP1
filed_VBD
in_PIN
the_DT
ongoing_JJ
patent_NN
litigations_NOMZ
with_PIN
Barr_NN
chain_NN
risk_NN
._.
this_DEMO
product_NN
with_PIN
Health_NN
Canada_NN
and_PHC
Laboratories_NN
Inc._NN
and_PHC
Teva_NN
Pharmaceuticals_NN
the_DT
European_JJ
authorities_NOMZ
during_PIN
the_DT
first_JJ
USA_NN
Inc._NN
._.
The_DT
acquisition_NOMZ
of_PIN
TKT_NN
in_PIN
July_NN
is_VPRT [BEMA]
an_DT
excellent_JJ
quarter_NN
of_PIN
2006_CD
:_:
strategic_JJ
fit_NN
and_CC
will_PRMD
bring_VB
significant_JJ
value_NN
Product_NN
launches_NN
in_PIN
2005_CD
to_PIN
the_DT
Company_NN
over_IN
time_NN
._.
It_PIT
broadens_VPRT
our_FPP1
submission_NN
of_PIN
an_DT
amended_VBN
NDA_NN
FOSRENOL_NN
,_,
for_PIN
the_DT
treatment_NOMZ
of_PIN
revenue_NN
base_NN
while_OSUB
building_VBG
our_FPP1
pipeline_NN
with_PIN
the_DT
FDA_NN
for_PIN
DAYTRANA_NN
,_,
the_DT
first_JJ
hyperphosphatemia_NN
in_PIN
end-stage_JJ
renal_JJ
in_PIN
the_DT
relatively_RB
low-risk_JJ
area_NN
of_PIN
Enzyme_NN
transdermal_JJ
patch_NN
for_PIN
the_DT
treatment_NOMZ
disease_NN
,_,
and_ANDC
Shires_NN
first_JJ
global_JJ
product_NN
,_,
Replacement_NOMZ
Therapy_NN
ERT_NN
._.
Historically_NN
,_,
of_PIN
ADHD_NN
an_DT
approval_NN
letter_NN
was_VBD [PASS]
received_VBN
was_VBD [SPAU] [PASS]
successfully_RB
launched_VBN
in_PIN
the_DT
US_FPP1
in_PIN
enzyme_NN
replacement_NOMZ
drugs_NN
have_VPRT [PEAS]
had_VBN
a_DT
high_JJ
in_PIN
April_NN
2006_CD
:_:
2005_CD
and_CC
performed_VBN
in_PIN
line_NN
with_PIN
its_PIT
major_JJ
success_NN
rate_NN
in_PIN
reaching_VBG
the_DT
market_NN
._.
Now_DPAR
competitor_NN
when_RB
launch_NN
periods_NN
are_VPRT [PASS]
called_VBN
Shire_NN
Human_NN
Genetic_NN
Therapies_NN
submission_NN
of_PIN
a_DT
NDA_NN
with_PIN
the_DT
FDA_NN
compared_VBN
._.
We_FPP1
also_RB
launched_VBD
FOSRENOL_NN
Shire_NN
HGT_NN
,_,
this_DEMO
dedicated_JJ
team_NN
is_VPRT
working_VBG
for_PIN
ELAPRASE_NN
,_,
as_RB
well_RB
as_IN
submission_NN
into_PIN
the_DT
first_JJ
four_CD
countries_NN
in_PIN
Europe_NN
and_CC
it_PIT
on_PIN
disease_NN
areas_NN
where_RB
there_EX
is_VPRT
high_JJ
unmet_JJ
of_PIN
a_DT
MAA_NN
in_PIN
Europe_NN
:_:
and_ANDC
will_PRMD
be_VB [PASS]
rolled_VBN
out_PIN
to_PIN
more_EMPH
European_JJ
countries_NN
medical_JJ
need_NN
._.
In_CONJ
addition_NULL
to_PIN
near-term_JJ
in_PIN
2006_CD
._.
In_CONJ
addition_NULL
,_,
we_FPP1
launched_VBD
higher_JJ
products_NN
,_,
it_PIT
provides_VPRT
Shire_NN
with_PIN
important_JJ
obtained_VBN
the_DT
reinstatement_NOMZ
of_PIN
dose_NN
formulations_NOMZ
in_PIN
the_DT
US_FPP1
._.
XAGRID_NN
,_,
our_FPP1
intellectual_JJ
property_NN
and_PHC
discovery_NN
ADDERALL_NN
XR_NN
in_PIN
Canada_NN
._.
treatment_NOMZ
for_PIN
a_DT
rare_JJ
platelet_NN
disorder_NN
known_VBN [PRIV]
capabilities_NOMZ
that_TSUB
will_PRMD
provide_VB
value_NN
over_IN
the_DT
as_IN
Essential_NN
Thrombocythemia_NN
ET_NN
,_,
was_VBD [BEMA]
very_AMP
long_JJ
term_NN
._.
Shire_NN
HGT_NN
already_RB
has_VPRT
one_CD
ADDERALL_NN
XR_NN
successfully_RB
launched_VBD
in_PIN
Europe_NN
,_,
achieving_VBG
approved_VBN
product_NN
in_PIN
Europe_NN
REPLAGAL_NN
for_PIN
ADDERALL_NN
XR_NN
,_,
our_FPP1
once-daily_JJ
treatment_NOMZ
sales_NN
of_PIN
$_$
46.8_CD
million_CD
in_PIN
2005_CD
._.
EQUETRO_NN
,_,
the_DT
treatment_NOMZ
of_PIN
Fabry_NN
Disease_NN
,_,
a_DT
lipid_JJ
storage_NN
for_PIN
ADHD_NN
,_,
continued_VBD
to_TO
perform_VB
extremely_AMP
the_DT
first_JJ
ever_RB
carbamazepine_JJ
treatment_NOMZ
disorder_NN
._.
At_PIN
the_DT
end_NN
of_PIN
2005_CD
,_,
we_FPP1
submitted_VBD [PUBV]
well_RB
during_PIN
the_DT
year_NN
,_,
reaching_VBG [PRESP]
an_DT
all-time_JJ
approved_VBN
for_PIN
manic_JJ
phase_NN
of_PIN
Bipolar_NN
Disorder_NN
,_,
a_DT
New_NN
Drug_NN
Application_NOMZ
NDA_NN
to_PIN
the_DT
Food_NN
high_JJ
market_NN
share_NN
of_PIN
26_CD
%_NN
in_PIN
the_DT
US_FPP1
._.
In_PIN
the_DT
was_VBD [PASS]
launched_VBN
in_PIN
the_DT
US_FPP1
._.
and_ANDC
Drug_NN
Administration_NOMZ
FDA_NN
for_PIN
idursulfase_NN
,_,
interest_NN
of_PIN
patient_JJ
safety_NN
,_,
during_PIN
2005_CD
we_FPP1
filed_VBD
the_DT
first_JJ
human_JJ
ERT_NN
treatment_NOMZ
for_PIN
Hunter_NN
a_DT
Citizen_NN
Petition_NOMZ
with_PIN
the_DT
FDA_NN
requesting_VBG [SUAV] [WZPRES]
Five_CD
launches_NN
in_PIN
2006_CD
and_CC
the_DT
first_JJ
half_DT
Syndrome_NN
,_,
under_IN
the_DT
trade_NN
name_NN
ELAPRASE_NN
,_,
that_THVC
they_TPP3
ask_VPRT [SUAV] [THATD]
companies_NN
seeking_VBG [WZPRES]
approval_NN
of_PIN
2007_CD
as_RB
well_RB
as_IN
submitting_VBG [PUBV]
Marketing_GER
Authorization_NOMZ
for_PIN
generic_JJ
ADDERALL_NN
XR_NN
or_CC
any_QUAN
follow-on_PIN
In_PIN
2006_CD
and_CC
during_PIN
the_DT
first_JJ
half_NN
of_PIN
2007_CD
,_,
Application_NOMZ
MAA_NN
in_PIN
Europe_NN
for_PIN
this_DEMO
product_NN
._.
of_PIN
ADDERALL_NN
XR_NN
to_TO
undertake_VB
more_EMPH
rigorous_JJ
we_FPP1
are_VPRT
planning_VBG
no_SYNE
fewer_JJ
than_PIN
five_CD
new_JJ
Our_FPP1
GA-GCB_JJ
compound_NN
for_PIN
Gaucher_NN
Disease_NN
bioequivalence_NN
testing_GER
or_CC
additional_JJ
clinical_JJ
product_NN
launches_NN
,_,
this_DEMP
is_VPRT [BEMA]
a_DT
record_NN
breaking_GER
will_PRMD
enter_VB
Phase_NN
3_CD
trials_NN
this_DEMO
year_NN
and_CC
there_EX
trials_NN
._.
This_DEMO
petition_NOMZ
is_VPRT
currently_RB
under_IN
review_NN
achievement_NOMZ
in_PIN
this_DEMO
industry_NN
._.
These_DEMP
will_PRMD
are_VPRT [BEMA]
several_QUAN
other_JJ
very_AMP
promising_JJ
compounds_NN
and_CC
to_PIN
date_NN
,_,
no_SYNE
approvals_NN
for_PIN
follow-on_PIN
require_VPRT [SUAV]
additional_JJ
spending_GER
on_PIN
advertising_GER
in_PIN
the_DT
pipeline_NN
._.
generic_JJ
versions_NN
of_PIN
ADDERALL_NN
XR_NN
have_VPRT [PEAS]
been_VBN
and_CC
promotion_NOMZ
,_,
and_ANDC
in_PIN
some_QUAN
cases_NN
additional_JJ
granted_VBN [SUAV]
._.
On_PIN
January_NN
19_CD
,_,
2006_CD
we_FPP1
announced_VBD [PUBV]
sales_NN
representatives_NN
._.
As_CONJ
a_NULL
result_NULL
,_,
our_FPP1
Selling_GER
,_,
Another_DT
major_JJ
milestone_NN
in_PIN
2005_CD
was_VBD [BEMA]
our_FPP1
that_DEMO
we_FPP1
settled_VBD
all_QUAN
pending_VBG
litigations_NOMZ
relating_VBG [WZPRES]
General_NN
and_PHC
Administration_NOMZ
SG&A_NN
costs_VPRT
collaboration_NOMZ
with_PIN
New_NN
River_NN
Pharmaceuticals_NN
to_PIN
ADDERALL_NN
XR_NN
with_PIN
Impax_NN
Laboratories_NN
are_VPRT [PASS]
expected_VBN [PRIV]
to_TO
rise_VB
in_PIN
order_NN
to_TO
support_VB
the_DT
New_NN
River_NN
to_TO
develop_VB
and_PHC
commercialize_VB
Inc._NN
._.
Impax_NN
._.
Impax_NN
confirmed_VBD [PUBV]
that_THVC
all_QUAN
Shire_NN
success_NN
of_PIN
these_DEMO
launches_NN
._.
NRP104_CD
is_VPRT [BEMA]
a_DT
very_AMP
promising_JJ
patents_NN
covering_VBG [WZPRES]
ADDERALL_NN
XR_NN
are_VPRT [BEMA]
valid_PRED
and_PHC
investigational_PRED
compound_NN
for_PIN
the_DT
treatment_NOMZ
enforceable_JJ
and_CC
that_THVC
their_TPP3
proposed_VBN [SUAV]
version_NN
of_PIN
of_PIN
ADHD_NN
,_,
an_DT
area_NN
of_PIN
leadership_NN
for_PIN
us_FPP1
._.
ADDERALL_NN
XR_NN
did_EMPH
infringe_VB
those_DEMO
patents_NN
._.
The_DT
New_NN
River_NN
made_VBD
excellent_JJ
progress_NN
during_PIN
agreement_NOMZ
states_NN
that_TOBJ
Impax_NN
will_PRMD
be_VB [PASS]
permitted_VBN
the_DT
year_NN
,_,
filing_VBG [PRESP]
a_DT
NDA_NN
for_PIN
NRP104_NN
with_PIN
the_DT
FDA_NN
to_TO
market_VB
their_TPP3
generic_JJ
version_NN
of_PIN
ADDERALL_NN
in_PIN
early_TIME
December_NN
and_CC
we_FPP1
are_VPRT
looking_VBG
forward_RB
XR_NN
no_RB
later_TIME
than_PIN
January_NN
1_CD
,_,
2010_CD
._.
In_PIN
certain_JJ
to_TO
launching_VBG
this_DEMO
product_NN
in_PIN
early_TIME
2007_CD
._.
situations_NOMZ
,_,
such_JJ
as_IN
the_DT
entry_NN
of_PIN
another_DT
generic_JJ
before_IN
2010_CD
,_,
Impax_NN
may_POMD
be_VB [PASS]
permitted_VBN
to_TO
market_VB
Shires_NN
ADDERALL_NN
XR_NN
in_PIN
the_DT
US_FPP1
10_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:53_CD
Page_NN
11_CD
We_FPP1
made_VBD
good_JJ
on_PIN
our_FPP1
strategic_JJ
commitment_NOMZ
to_TO
grow_VB
our_FPP1
underlying_VBG
business_NOMZ
while_OSUB
expanding_VBG
our_FPP1
portfolio_NN
of_PIN
new_JJ
products_NN
._.
What_WP
the_DT
analysts_NN
say_VPRT [PUBV]
In_PIN
February_NN
2006_CD
,_,
we_FPP1
submitted_VBD [PUBV]
a_DT
MAA_NN
welcome_JJ
to_PIN
them_TPP3
,_,
as_RB
well_RB
as_IN
to_TO
thank_VB
all_QUAN
for_PIN
MESAVANCE_NN
to_PIN
both_DT
European_JJ
and_CC
members_NN
of_PIN
our_FPP1
team_NN
around_PLACE
the_DT
world_NN
for_PIN
We_FPP1
believe_VPRT [PRIV] [THATD]
the_DT
Company_NN
has_VPRT
Canadian_JJ
Regulatory_NN
Agencies_NN
._.
During_PIN
2006_CD
their_TPP3
exceptional_JJ
efforts_NN
and_PHC
dedication_NOMZ
one_CD
of_PIN
the_DT
best_JJ
,_,
if_COND
not_XX0
the_DT
best_JJ
and_CC
the_DT
first_JJ
half_NN
of_PIN
2007_CD
we_FPP1
also_RB
expect_VPRT [PRIV]
to_TO
:_:
in_PIN
helping_VBG
us_FPP1
achieve_VB
our_FPP1
business_NOMZ
goals_NN
._.
pipelines_NN
,_,
in_PIN
the_DT
entire_JJ
sector_NN
as_IN
we_FPP1
project_VPRT
it_PIT
will_PRMD
launch_VB
at_PIN
launch_NN
MESAVANCE_NN
in_PIN
the_DT
US_FPP1
:_:
Shires_NN
transformation_NOMZ
least_JJ
seven_CD
new_JJ
products_NN
over_IN
A_DT
few_QUAN
years_NN
ago_RB
,_,
we_FPP1
imagined_VBD [PRIV]
a_DT
new_JJ
the_DT
next_JJ
three_CD
years_NN
._.
launch_NN
DYNEPO_NN
for_PIN
anemia_NN
in_PIN
Europe_NN
:_:
Shire_NN
._.
Since_OSUB
then_RB
weve_JJ
transformed_VBN
Shire_NN
Deutsche_NN
Bank_NN
to_TO
deepen_VB
our_FPP1
product_NN
pipeline_NN
,_,
enhance_VB
November_NN
3_CD
,_,
2005_CD
launch_NN
DAYTRANA_NN
in_PIN
the_DT
US_FPP1
:_:
our_FPP1
responsiveness_NOMZ
,_,
and_ANDC
capitalize_VB
on_PIN
opportunities_NOMZ
in_PIN
the_DT
global_JJ
specialty_NN
The_DT
closure_NN
of_PIN
the_DT
acquisition_NOMZ
launch_NN
NRP104_NN
in_PIN
the_DT
US_FPP1
:_:
pharmaceutical_JJ
market_NN
._.
We_FPP1
are_VPRT [PASS]
driven_VBN
of_PIN
TKT_NN
on_PIN
July_NN
27_CD
,_,
marks_VPRT
the_DT
by_PIN
a_DT
common_JJ
objective_NN
:_:
to_TO
make_VB
the_DT
most_EMPH
completion_NOMZ
of_PIN
the_DT
major_JJ
strategic_JJ
launch_NN
ELAPRASE_NN
in_PIN
the_DT
US_FPP1
and_PHC
Europe_NN
:_:
out_PIN
of_PIN
science_NN
and_PHC
technology_NN
to_TO
increase_VB
changes_NN
undertaken_VBN [WZPAST]
by_PIN
Shire_NN
since_OSUB
the_DT
number_NN
of_PIN
projects_NN
we_FPP1
are_VPRT
undertaking_VBG
the_DT
appointment_NOMZ
of_PIN
Matt_NN
Emmens_NN
file_NN
a_DT
NDA_NN
with_PIN
the_DT
FDA_NN
for_PIN
SPD465_NN
,_,
a_DT
so_OSUB
that_NULL
we_FPP1
can_POMD
help_VB
many_QUAN
more_EMPH
people_NN
as_IN
CEO_NN
in_PIN
2003_CD
._.
longer-acting_JJ
formulation_NOMZ
of_PIN
ADDERALL_NN
XR_NN
lead_NN
healthier_RB
,_,
less_JJ
impaired_JJ
lives_NN
._.
We_FPP1
are_VPRT
HSBC_NN
for_PIN
ADHD_NN
:_:
delivering_VBG [PRESP]
on_PIN
that_DEMO
goal_NN
,_,
and_ANDC
can_POMD
all_QUAN
be_VB [BEMA]
proud_JJ
September_NN
21_CD
,_,
2005_CD
of_PIN
our_FPP1
achievements_NOMZ
._.
file_NN
a_DT
NDA_NN
with_PIN
the_DT
FDA_NN
for_PIN
SPD503_NN
,_,
We_FPP1
believe_VPRT [PRIV]
that_THVC
the_DT
operational_JJ
a_DT
non-stimulant_JJ
treatment_NOMZ
for_PIN
ADHD_NN
:_:
Just_EMPH
imagine_VB [PRIV]
what_WP [WHCL]
we_FPP1
can_POMD
achieve_VB
in_PIN
performance_NN
of_PIN
the_DT
Company_NN
over_IN
the_DT
future_NN
._.
the_DT
next_JJ
12_CD
months_NN
will_PRMD
be_VB [BEMA]
critical_PRED
continue_VPRT
the_DT
rollout_NN
of_PIN
FOSRENOL_NN
for_PIN
the_DT
long-term_JJ
potential_NN
of_PIN
Shire_NN
._.
in_PIN
Europe_NN
:_:
and_ANDC
Morgan_NN
Stanley_NN
March_NN
29_CD
,_,
2006_CD
continue_VPRT
the_DT
launch_NN
of_PIN
FOSRENOL_NN
higher_JJ
strengths_NN
in_PIN
the_DT
US_FPP1
._.
Strengthened_VBN
management_NOMZ
team_NN
Matthew_NN
Emmens_NN
Shire_NN
continued_VBD
to_TO
build_VB
its_PIT
senior_JJ
management_NOMZ
team_NN
in_PIN
2005_CD
and_CC
we_FPP1
added_VBD [PUBV]
proven_VBN
talent_NN
across_PLACE
all_QUAN
areas_NN
of_PIN
the_DT
organization_NOMZ
and_CC
to_PIN
our_FPP1
leadership_NN
team_NN
._.
I_FPP1
am_VPRT [SPAU] [PASS]
particularly_RB
pleased_VBN
to_TO
welcome_VB
David_NN
Pendergast_NN
,_,
former_JJ
CEO_NN
of_PIN
TKT_NN
,_,
as_IN
Executive_NN
Vice_NN
President_NN
Shire_NN
HGT_NN
,_,
and_ANDC
Michael_NN
Cola_NN
,_,
formerly_TIME
President_NN
of_PIN
the_DT
Life_NN
Sciences_NN
division_NN
of_PIN
Safeguard_NN
Scientifics_NN
Inc._NN
as_IN
Executive_NN
Vice_NN
President_NN
for_PIN
Global_NN
Therapeutic_NN
Areas_NN
._.
Both_DT
bring_VPRT
a_DT
wealth_NN
of_PIN
experience_NN
in_PIN
the_DT
pharmaceutical_JJ
industry_NN
and_CC
are_VPRT [BEMA]
welcome_JJ
additions_NOMZ
to_PIN
our_FPP1
Executive_NN
Committee_NN
._.
With_PIN
the_DT
acquisition_NOMZ
of_PIN
TKT_NN
and_CC
the_DT
strengthening_GER
of_PIN
our_FPP1
organization_NOMZ
on_PIN
both_DT
sides_NN
of_PIN
the_DT
Atlantic_NN
,_,
we_FPP1
increased_VBD
our_FPP1
staff_NN
numbers_NN
by_PIN
570_CD
,_,
bringing_VBG [PRESP]
our_FPP1
total_JJ
All_QUAN
products_NN
in_PIN
development_NOMZ
and_PHC
registration_NOMZ
are_VPRT
staff_NN
numbers_NN
to_PIN
over_IN
2,400_CD
highly-skilled_JJ
subject_NN
to_PIN
regulatory_JJ
approvals_NN
._.
I_FPP1
would_PRMD
like_VB
to_TO
take_VB
this_DEMO
opportunity_NOMZ
to_TO
extend_VB
a_DT
warm_JJ
Source_NN
:_:
IMS_NN
Data_NN
2005_CD
._.
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
11_CD
Shire_NN
plc_NN
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:53_CD
Page_NN
12_CD
prod_VPRT
ucts_VPRT
12_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:53_CD
Page_NN
13_CD
Product_NN
portfolio_NN
Proven_NN
drugs_NN
,_,
profitable_JJ
position_NOMZ
._.
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
13_CD
Shire_NN
plc_NN
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:53_CD
Page_NN
14_CD
Product_NN
pipeline_NN
Rich_NN
,_,
deep_JJ
and_CC
coming_VBG
on_PIN
stream_NN
._.
Pipeline_NN
On_PIN
the_DT
market_NN
Central_NN
Nervous_NN
System_NN
CNS_NN
ADDERALL_NN
XR_NN
US_FPP1
CALCICHEW_NN
UK_NN
Ireland_NN
DAYTRANA_NN
approved_VBN [WZPAST]
by_PIN
FDA_NN
Mixed_NN
salts_NN
of_PIN
a_DT
single-entity_JJ
amphetamine_NN
Calcium_NN
carbonate_NN
adjunct_NN
in_PIN
Osteoporosis_NN
Methylphenidate_NN
transdermal_NN
system_NN
ADHD_NN
ADHD_NN
PROAMATINE_NN
AMATINE_NN
US_FPP1
ADDERALL_NN
US_FPP1
Midodrine_NN
hydrochloride_NN
NRP104_NN
in_PIN
Registration_NOMZ
US_FPP1
Mixed_NN
salts_NN
of_PIN
a_DT
single-entity_JJ
amphetamine_NN
Postural_NN
Hypotension_NN
Amphetamine_NN
ADHD_NN
ADHD_NN
Royalties_NN
SPD503_NN
Phase_NN
3_CD
US_FPP1
CARBATROL_NN
US_FPP1
3TC_NN
EPIVIR_NN
Worldwide_NN
Guanfacine_NN
ADHD_NN
Carbamazepine_NN
extended_VBD
release_NN
trademark_NN
of_PIN
GlaxoSmithKline_NN
GSK_NN
capsules_NN
Epilepsy_NN
lamivudine_NN
HIV_NN
SPD465_NN
Phase_NN
3_CD
US_FPP1
Mixed_NN
salts_NN
of_PIN
a_DT
single-entity_JJ
amphetamine_NN
EQUETRO_NN
US_FPP1
COMBIVIR_NN
Worldwide_NN
ADHD_NN
Carbamazepine_NN
extended_VBD
release_NN
trademark_NN
of_PIN
GSK_NN
capsules_NN
Bipolar_NN
1_CD
Disorder_NN
lamivudine_NN
HIV_NN
Gastro-Intestinal_NN
GI_NN
MESAVANCE_NN
in_PIN
Registration_NOMZ
EU_NN
US_FPP1
REMINYL_NN
REMINYL_NN
XL_NN
UK_NN
Ireland_NN
TRIZIVIR_NN
Worldwide_NN
5-ASA_NN
mesalamine_NN
UC_NN
Galantamine_NN
hydrobromide_NN
trademark_NN
of_PIN
GSK_NN
Alzheimers_NN
Disease_NN
lamivudine_NN
HIV_NN
Shire_NN
HGT_NN
1_CD
I2S_CD
ELAPRASE_NN
in_PIN
Registration_NOMZ
EU_NN
US_FPP1
PENTASA_NN
US_FPP1
ZEFFIX_NN
EPIVIR_NN
HBV_NN
HEPTOVIR_NN
Worldwide_NN
Idursulfase_NN
Hunter_NN
Syndrome_NN
5-ASA_NN
mesalamine_NN
UC_NN
trademark_NN
of_PIN
GSK_NN
lamivudine_NN
Hepatitis_NN
B_NN
infection_NOMZ
GA-GCB_NN
Phase_NN
3_CD
COLAZIDE_NN
UK_NN
EU_NN
US_FPP1
Gene-activated_VBD
Gaucher_NN
Disease_NN
Balsalazide_NN
UC_NN
REMINYL_NN
REMINYL_NN
XL_NN
RAZADYNE_NN
RAZADYNE_NN
ER_NN
Worldwide_NN
General_NN
Products_NN
REPLAGAL_NN
EU_NN
trademark_NN
of_PIN
Johnson_NN
&_CC
Johnson_NN
DYNEPO_NN
Manufacturing_GER
Registration_NOMZ
Agalsidase_NN
alfa_NN
Fabry_NN
Disease_NN
excluding_VBG [WZPRES]
UK_NN
and_PHC
Republic_NN
of_PIN
Ireland_NN
Erythropoietin_NN
EPO_NN
Anemia_NN
in_PIN
chronic_JJ
Galantamine_NN
hydrobromide_NN
renal_JJ
failure_NN
FOSRENOL_NN
EU_NN
US_FPP1
Alzheimers_NN
Disease_NN
Lanthanum_NN
carbonate_NN
Hyperphosphatemia_NN
All_QUAN
products_NN
in_PIN
development_NOMZ
and_PHC
registration_NOMZ
are_VPRT [BEMA]
subject_PRED
to_PIN
regulatory_JJ
approvals_NN
._.
XAGRID_NN
AGRYLIN_NN
EU_NN
US_FPP1
1_CD
Anagrelide_NN
hydrochloride_NN
This_DEMP
is_VPRT [BEMA]
not_XX0
a_DT
comprehensive_JJ
list_NN
of_PIN
Thrombocythemia_NN
trademarks_NN
for_PIN
this_DEMO
product_NN
as_IN
various_JJ
others_NN
are_VPRT [PASS]
used_VBN
in_PIN
smaller_JJ
markets_NN
._.
14_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:53_CD
Page_NN
15_CD
pipe_NN
line_NN
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
15_CD
Shire_NN
plc_NN
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:53_CD
Page_NN
16_CD
Operating_GER
review_NN
peo_NN
ple_NN
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:53_CD
Page_NN
17_CD
Shire_NN
has_VPRT
a_DT
can_POMD
do_VB
culture_NN
based_VBN [WZPAST]
on_PIN
an_DT
exceptional_JJ
level_NN
of_PIN
competence_NN
,_,
experience_NN
,_,
creativity_NOMZ
and_CC
above_PLACE
all_QUAN
,_,
energy_NN
._.
This_DEMP
is_VPRT
what_WP
makes_VPRT
us_FPP1
unique_JJ
and_CC
destined_VBD
for_PIN
success_NN
._.
Dr_NN
Eliseo_NN
Salinas_NN
Chief_NN
Scientific_NN
Officer_NN
and_PHC
Executive_NN
Vice_NN
President_NN
,_,
Global_NN
R&D_NN
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:53_CD
Page_NN
18_CD
Operating_GER
review_NN
01_CD
02_CD
03_CD
Shires_NN
winning_VBG [WZPRES]
formula_NN
Ms_NN
Deptula_NN
heads_VPRT
a_DT
team_NN
which_WDT [WHSUB]
is_VPRT [PASS]
based_VBN
both_DT
Over_IN
the_DT
past_JJ
24_CD
months_NN
,_,
Dr_NN
Salinas_NN
says_VPRT [PUBV]
,_,
Highly-skilled_JJ
and_PHC
dedicated_JJ
people_NN
,_,
working_VBG [PRESP]
in_PIN
the_DT
UK_NN
and_PHC
US_FPP1
and_CC
is_VPRT [PASS]
composed_VBN
of_PIN
highly_AMP
Shire_NN
has_VPRT [PEAS]
delivered_VBN
on_PIN
its_PIT
promises_NN
while_OSUB
together_RB
across_PLACE
functions_NOMZ
and_CC
on_PIN
a_DT
global_JJ
experienced_JJ
and_PHC
dedicated_JJ
professionals_NN
with_PIN
drastically_RB
transforming_VBG
the_DT
way_NN
it_PIT
operates_VPRT
basis_NN
,_,
to_TO
develop_VB
and_PHC
market_VB
specialty_NN
both_DT
scientific_JJ
and_CC
business_NOMZ
backgrounds_NN
._.
Management_NOMZ
has_VPRT [PEAS]
done_VBN
exactly_RB
pharmaceuticals_NN
that_TSUB
fill_VPRT
unmet_JJ
medical_JJ
needs_NN
._.
Business_NOMZ
development_NOMZ
efforts_NN
are_VPRT [PASS]
coordinated_VBN
what_WP
it_PIT
said_VBD [PUBV] [THATD]
it_PIT
would_PRMD
do_VB
:_:
divest_VB
non-core_JJ
throughout_PIN
the_DT
Company_NN
,_,
with_PIN
ideas_NN
and_PHC
businesses_NOMZ
to_TO
reinvest_VB
freed-up_JJ
resources_NN
in_PIN
These_DEMP
,_,
in_PIN
a_DT
nutshell_NN
,_,
are_VPRT [BEMA]
the_DT
qualities_NOMZ
that_TSUB
make_VPRT
contacts_NN
gained_VBD
from_PIN
individuals_NN
across_PLACE
the_DT
the_DT
core_NN
ones_NN
._.
In_PIN
R&D_NN
,_,
this_DEMP
has_VPRT [PEAS]
translated_VBN
into_PIN
Shire_NN
one_CD
of_PIN
the_DT
fastest_JJ
growing_VBG
specialty_NN
organization_NOMZ
._.
Shires_NN
interdisciplinary_JJ
structure_NN
applying_VBG [WZPRES]
additional_JJ
resources_NN
,_,
defining_VBG
new_JJ
companies_NN
in_PIN
todays_NN
pharmaceutical_JJ
industry_NN
._.
allows_VPRT [SUAV]
integrating_VBG
the_DT
specific_JJ
technical_JJ
and_CC
processes_VPRT
to_TO
increase_VB
efficiency_NN
and_PHC
reliability_NOMZ
,_,
scientific_JJ
input_NN
brought_VBN [WZPAST]
by_PIN
each_QUAN
function_NOMZ
into_PIN
and_CC
increasing_VBG
the_DT
ownership_NN
and_PHC
control_NN
of_PIN
Shire_NN
is_VPRT [BEMA]
a_DT
very_AMP
dynamic_JJ
organization_NOMZ
,_,
says_VPRT [PUBV]
a_DT
coherent_JJ
plan_NN
that_TSUB
helps_VPRT
meet_VB
long-term_JJ
our_FPP1
data_NN
while_OSUB
still_RB
relying_VBG
on_PIN
outside_PLACE
vendors_NN
._.
Barbara_NN
Deptula_NN
,_,
Shires_NN
Executive_NN
Vice_NN
corporate_JJ
objectives_NN
,_,
she_TPP3
notes_VPRT [PRIV]
._.
Its_PIT
like_IN
Dr_NN
Salinas_NN
notes_VPRT [PRIV]
that_THVC
Shire_NN
has_VPRT [PEAS]
decided_VBN [SUAV] [PRIV]
to_PIN
a_DT
small_JJ
start-up_JJ
entrepreneurial_JJ
company_NN
Replenishing_GER
Shires_NN
pipeline_NN
concentrate_NN
on_PIN
the_DT
core_NN
areas_NN
of_PIN
CNS_NN
,_,
GI_NN
and_CC
but_CC
has_VPRT
all_QUAN
the_DT
infrastructure_NN
,_,
support_NN
and_PHC
Shires_NN
Business_NOMZ
Development_NOMZ
team_NN
is_VPRT
firmly_RB
General_NN
Products_NN
GP_NN
such_JJ
as_IN
renal_JJ
therapies_NN
,_,
people_NN
of_PIN
a_DT
large_JJ
company_NN
._.
In_PIN
this_DEMO
kind_NN
committed_VBN
to_TO
expanding_VBG
and_CC
constantly_RB
each_QUAN
led_VBN
by_PIN
dedicated_JJ
Strategic_NN
Therapeutic_NN
of_PIN
environment_NOMZ
,_,
everyone_QUPR
can_POMD
contribute_VB
replenishing_VBG
Shires_NN
product_NN
pipeline_NN
._.
In_CONJ
addition_NULL
,_,
with_PIN
the_DT
to_PIN
the_DT
success_NN
of_PIN
the_DT
organization_NOMZ
,_,
which_WDT [SERE]
Accordingly_RB
,_,
it_PIT
is_VPRT [BEMA]
on_PIN
the_DT
lookout_NN
for_PIN
in-licensing_JJ
acquisition_NOMZ
of_PIN
TKT_NN
,_,
Shire_NN
has_VPRT
a_DT
new_JJ
biologics_NN
is_VPRT [BEMA]
very_AMP
appealing_PRED
to_PIN
me_FPP1
._.
opportunities_NOMZ
for_PIN
new_JJ
products_NN
essentially_RB
in_PIN
business_NOMZ
bringing_VBG [WZPRES]
exciting_JJ
new_JJ
products_NN
to_PIN
its_PIT
Phase_NN
2_CD
or_CC
3_CD
with_PIN
robust_JJ
intellectual_JJ
property_NN
portfolio_NN
._.
The_DT
Shire_NN
HGT_NN
business_NOMZ
is_VPRT [PASS]
managed_VBN
Shires_NN
adoption_NOMZ
of_PIN
a_DT
global_JJ
operating_GER
structure_NN
,_,
that_DEMP
offer_VPRT
a_DT
strategic_JJ
fit_NN
with_PIN
Shires_NN
current_JJ
by_PIN
Dr_NN
David_NN
Pendergast_NN
._.
Shire_NN
has_VPRT
very_AMP
with_PIN
cross-functional_JJ
teams_NN
dedicated_VBN [WZPAST]
to_PIN
business_NOMZ
and_CC
allow_VB [SUAV]
for_PIN
use_NN
of_PIN
the_DT
Companys_NN
interesting_JJ
compounds_NN
under_IN
development_NOMZ
developing_VBG [WZPRES]
and_PHC
marketing_VBG
products_NN
in_PIN
core_NN
expanding_VBG [WZPRES]
specialty_NN
sales_NN
force_NN
._.
We_FPP1
seek_VPRT
in_PIN
these_DEMO
areas_NN
and_CC
managing_VBG
the_DT
lifecycle_NN
therapeutic_JJ
areas_NN
,_,
gives_VPRT
it_PIT
a_DT
competitive_JJ
edge_NN
product-oriented_JJ
deals_NN
that_TSUB
would_PRMD
add_VB [PUBV]
value_NN
of_PIN
its_PIT
current_JJ
portfolio_NN
will_PRMD
be_VB [BEMA]
important_PRED
._.
in_PIN
todays_NN
complex_JJ
pharmaceutical_JJ
market_NN
,_,
to_PIN
a_DT
targeted_JJ
audience_NN
of_PIN
specialist_NN
physicians_NN
At_PIN
the_DT
same_JJ
time_NN
,_,
we_FPP1
are_VPRT [SPAU]
actively_RB
supporting_VBG
adds_VPRT [PUBV]
Dr_NN
Eliseo_NN
Salinas_NN
,_,
Chief_NN
Scientific_NN
Officer_NN
and_CC
their_TPP3
patients_NN
._.
There_EX
are_VPRT
literally_RB
thousands_NN
the_DT
search_NN
for_PIN
new_JJ
molecules_NN
,_,
including_VBG
and_CC
Executive_NN
Vice_NN
President_NN
,_,
Global_NN
R&D_NN
._.
of_PIN
opportunities_NOMZ
in_PIN
the_DT
market_NN
and_CC
its_PIT
some_QUAN
outside_PLACE
these_DEMO
areas_NN
on_PIN
an_DT
opportunistic_JJ
While_OSUB
drug_NN
development_NOMZ
is_VPRT [BEMA]
a_DT
global_JJ
task_NN
,_,
important_JJ
that_THAC
we_FPP1
maintain_VPRT [PUBV]
a_DT
focus_NN
and_PHC
basis_NN
as_OSUB
long_NULL
as_NULL
they_TPP3
meet_VPRT
our_FPP1
risk_NN
criteria_NN
._.
customers_NN
in_PIN
regional_JJ
markets_NN
can_POMD
be_VB [SPAU]
very_AMP
prioritize_VB
them_TPP3
,_,
says_VPRT [PUBV]
Ms_NN
Deptula_NN
._.
Her_TPP3
teams_NN
different_JJ
,_,
he_TPP3
notes_VPRT [PRIV]
._.
Our_FPP1
structure_NN
ensures_VPRT [SUAV] [PRIV] [THATD]
we_FPP1
biggest_JJ
transaction_NOMZ
to_PIN
date_NN
is_VPRT [BEMA]
the_DT
acquisition_NOMZ
Both_DT
Ms_NN
Deptula_NN
and_PHC
Dr_NN
Salinas_NN
say_VPRT [PUBV] [THATD]
Shires_NN
stay_VB
close_RB
to_PIN
our_FPP1
customers_NN
and_CC
understand_VB [PRIV]
of_PIN
US_FPP1
biopharmaceutical_JJ
company_NN
TKT_NN
._.
biggest_JJ
trump_NN
card_NN
is_VPRT [BEMA]
the_DT
quality_NOMZ
and_PHC
talent_NN
of_PIN
regional_JJ
specificities_NOMZ
,_,
with_PIN
their_TPP3
commercial_JJ
It_PIT
was_VBD [BEMA]
a_DT
very_AMP
exciting_JJ
process_NN
and_CC
a_DT
great_JJ
its_PIT
people_NN
,_,
who_WP
share_VPRT
a_DT
strong_JJ
entrepreneurial_JJ
and_PHC
economic_JJ
realities_NOMZ
,_,
allowing_VBG [SUAV] [PRESP]
for_PIN
a_DT
good_JJ
opportunity_NOMZ
for_PIN
Shire_NN
._.
It_PIT
allows_VPRT [SUAV]
us_FPP1
to_TO
move_VB [SUAV]
spirit_NN
and_CC
are_VPRT [SPAU] [PASS]
highly_AMP
motivated_VBN
._.
Shire_NN
has_VPRT
integration_NOMZ
of_PIN
basic_JJ
science_NN
and_CC
medical_JJ
needs_NN
._.
into_PIN
a_DT
new_JJ
direction_NOMZ
while_OSUB
still_RB
ticking_VBG
all_QUAN
our_FPP1
a_DT
can_POMD
do_VB
culture_NN
based_VBN [WZPAST]
on_PIN
an_DT
exceptional_JJ
strategic_JJ
boxes_NN
._.
level_NN
of_PIN
competence_NN
,_,
experience_NN
,_,
creativity_NOMZ
Ms_NN
Deptula_NN
,_,
a_DT
pharmacist_NN
and_PHC
MBA_NN
in_PIN
finance_NN
,_,
and_ANDC
above_PLACE
all_QUAN
,_,
energy_NN
._.
This_DEMP
is_VPRT
what_WP
makes_VPRT
has_VPRT
20_CD
years_NN
of_PIN
pharmaceutical_JJ
experience_NN
in_PIN
Dr_NN
Salinas_NN
,_,
a_DT
Psychiatrist_NN
with_PIN
a_DT
Masters_NN
us_FPP1
unique_JJ
and_CC
destined_VBD
for_PIN
success_NN
._.
Since_OSUB
Degree_NN
in_PIN
Pharmacology_NN
and_CC
15_CD
years_NN
joining_VBG [WZPRES]
Shire_NN
in_PIN
September_NN
2004_CD
,_,
she_TPP3
has_VPRT [PEAS]
been_VBN [BEMA]
of_PIN
industry_NN
experience_NN
,_,
says_VPRT [PUBV]
Shires_NN
model_NN
of_PIN
developing_VBG
a_DT
Company-wide_JJ
,_,
streamlined_JJ
searching_VBG
and_PHC
developing_VBG
lower-risk_JJ
products_NN
business_NOMZ
development_NOMZ
process_NN
._.
We_FPP1
are_VPRT [SPAU]
now_TIME
is_VPRT
what_WP
attracted_VBD
him_TPP3
to_TO
join_VB
the_DT
Company_NN
able_JJ
more_EMPH
effectively_RB
to_TO
identify_VB
,_,
evaluate_VB
in_PIN
2004_CD
._.
We_FPP1
are_VPRT
focusing_VBG
on_PIN
searching_VBG
and_CC
act_NN
on_PIN
product_NN
ideas_NN
and_PHC
opportunities_NOMZ
,_,
and_ANDC
developing_VBG
molecules_NN
intended_VBN [SUAV] [WZPAST]
for_PIN
the_DT
including_VBG
partnerships_NN
,_,
which_WDT [SERE]
will_PRMD
contribute_VB
specialist_NN
,_,
where_RB
the_DT
added_VBN [PUBV]
medical_JJ
value_NN
to_PIN
our_FPP1
growth_NN
._.
We_FPP1
can_POMD
react_VB
expeditiously_RB
of_PIN
the_DT
compound_NN
is_VPRT [BEMA]
more_EMPH
important_PRED
than_PIN
and_CC
with_PIN
an_DT
entrepreneurial_JJ
spirit_NN
._.
This_DEMO
approach_NN
is_VPRT [BEMA]
good_PRED
for_PIN
our_FPP1
business_NOMZ
and_CC
for_PIN
society_NN
as_IN
a_DT
whole_NN
._.
18_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:53_CD
Page_NN
19_CD
04_CD
05_CD
01_CD
Supporting_VBG
a_DT
global_JJ
vision_NN
FOSRENOL_NN
,_,
ELAPRASE_NN
and_PHC
MESAVANCE_NN
,_,
Shire_NN
is_VPRT [BEMA]
increasingly_RB
attractive_PRED
to_PIN
In_PIN
todays_NN
pharmaceutical_JJ
industry_NN
,_,
bringing_VBG
and_PHC
becoming_VBG
the_DT
best_JJ
specialty_NN
prospective_JJ
partners_NN
small_JJ
enough_RB
the_DT
right_JJ
products_NN
to_PIN
market_NN
in_PIN
a_DT
timely_JJ
pharmaceutical_JJ
Company_NN
in_PIN
the_DT
world_NN
with_PIN
to_TO
care_VB
,_,
large_JJ
enough_JJ
to_TO
deliver_VB
._.
manner_NN
is_VPRT [BEMA]
a_DT
critical_JJ
challenge_NN
,_,
requiring_VBG [SUAV]
expert_NN
the_DT
most_EMPH
dedicated_JJ
employees_NN
to_TO
achieve_VB
David_NN
Colpman_NN
knowledge_NN
of_PIN
complex_JJ
regulatory_JJ
requirements_NOMZ
this_DEMO
goal_NN
._.
Companies_NN
always_RB
like_VPRT
to_TO
talk_VB
Vice_NN
President_NN
,_,
Business_NOMZ
and_CC
a_DT
highly_AMP
focused_VBN
commercialization_NOMZ
about_IN
the_DT
future_NN
being_VBG [WZPRES] [BEMA]
bright_PRED
._.
Here_RB
,_,
we_FPP1
can_POMD
Development_NOMZ
strategy_NN
._.
For_PIN
a_DT
global_JJ
Company_NN
such_JJ
as_IN
Shire_NN
,_,
use_VPRT
that_DEMO
phrase_NN
with_PIN
absolute_JJ
conviction_NOMZ
._.
this_DEMO
challenge_NN
is_VPRT [BYPA]
heightened_VBN
by_PIN
the_DT
need_NN
02_CD
to_TO
gain_VB
new_JJ
product_NN
approvals_NN
from_PIN
dozens_NN
Our_FPP1
regulatory_JJ
experts_NN
on_PIN
both_DT
sides_NN
of_PIN
The_DT
TKT_NN
acquisition_NOMZ
was_VBD [BEMA]
a_DT
perfect_JJ
of_PIN
regulatory_JJ
bodies_NN
worldwide_NN
while_OSUB
managing_VBG
the_DT
Atlantic_NN
work_NN
closely_RB
with_PIN
all_QUAN
the_DT
STATs_NN
,_,
fit_VPRT
with_PIN
Shires_NN
strategy_NN
._.
Looking_VBG
hundreds_NN
of_PIN
existing_VBG
product_NN
licences_NN
and_CC
our_FPP1
R&D_NN
and_CC
manufacturing_VBG
colleagues_NN
forward_RB
,_,
we_FPP1
will_PRMD
continue_VB
to_TO
expand_VB
ensuring_VBG [SUAV] [PRIV]
all_QUAN
products_NN
efficiently_RB
reach_VPRT
their_TPP3
and_CC
worldwide_JJ
regulatory_JJ
agencies_NN
within_PIN
the_DT
specialty_NN
arena_NN
._.
to_TO
ensure_VB [SUAV] [PRIV]
the_DT
successful_JJ
registration_NOMZ
and_PHC
Suzanne_NN
Hare_NN
commercialization_NOMZ
of_PIN
Shires_NN
new_JJ
and_CC
existing_VBG
Senior_JJ
Corporate_JJ
Evaluations_NOMZ
At_PIN
Shire_NN
,_,
these_DEMO
vital_JJ
tasks_NN
are_VPRT [BYPA]
overseen_VBN
by_PIN
products_NN
,_,
explains_VPRT [PUBV]
Doug_NN
Hay_NN
,_,
Shires_NN
Senior_NN
Director_NN
STATs_NN
responsible_JJ
for_PIN
the_DT
Companys_NN
core_NN
Vice_NN
President_NN
,_,
Global_NN
Regulatory_NN
Affairs_NN
._.
businesses_NOMZ
:_:
CNS_NN
,_,
GI_NN
and_PHC
GP_NN
and_CC
a_DT
Global_JJ
Their_TPP3
role_NN
is_VPRT
proactively_RB
to_TO
identify_VB
and_PHC
address_VB
03_CD
Regulatory_NN
Affairs_NN
Group_NN
._.
regulatory_JJ
challenges_NN
to_TO
minimize_VB
potential_JJ
This_DEMP
is_VPRT [BEMA]
a_DT
time_NN
where_RB
the_DT
delays_NN
in_PIN
product_NN
approvals_NN
and_CC
optimize_VB
Company_NN
is_VPRT [BEMA]
set-up_PRED
for_PIN
future_JJ
Mike_NN
Cola_NN
,_,
Executive_NN
Vice_NN
President_NN
,_,
Global_NN
approved_VBD
labeling_VBG
._.
Therapeutic_JJ
Area_NN
,_,
says_VPRT [PUBV] [THATD]
his_TPP3
job_NN
is_VPRT
to_TO
build_VB
on_PIN
Arnaud_NN
Partiot_NN
this_DEMO
work_NN
by_PIN
leveraging_VBG
the_DT
Companys_NN
global_JJ
Building_GER
relationships_NN
and_PHC
trust_NN
Senior_JJ
Vice_NN
President_NN
,_,
Global_JJ
resources_NN
and_CC
developing_VBG
strategies_NN
to_TO
ensure_VB [SUAV] [PRIV]
Regulatory_NN
approvals_NN
have_VPRT [PEAS]
been_VBN [PASS]
complicated_VBN
Clinical_NN
Research_NN
and_PHC
Development_NOMZ
approved_VBD
products_NN
get_VB
to_PIN
the_DT
patients_NN
who_WP [WHOBJ]
in_PIN
recent_JJ
years_NN
by_PIN
increasing_VBG
agency_NN
scrutiny_NN
need_VPRT
them_TPP3
._.
The_DT
essence_NN
of_PIN
a_DT
great_JJ
company_NN
on_PIN
drug_NN
safety_NN
and_PHC
effectiveness_NOMZ
relative_JJ
04_CD
is_VPRT [BEMA]
a_DT
culture_NN
of_PIN
commitment_NOMZ
,_,
excellence_NN
to_PIN
standards_NN
of_PIN
care_NN
._.
With_PIN
regard_NN
to_PIN
safety_NN
,_,
Our_FPP1
regulatory_JJ
experts_NN
on_PIN
both_DT
and_CC
discipline_NN
._.
The_DT
aim_NN
is_VPRT
to_TO
focus_VB
on_PIN
your_SPP2
regulatory_JJ
agencies_NN
worldwide_NN
are_VPRT
seeking_VBG
sides_NN
of_PIN
the_DT
Atlantic_NN
work_NN
closely_RB
customers_NN
and_CC
provide_VB
them_TPP3
with_PIN
the_DT
greater_JJ
assurance_NN
that_TOBJ
a_DT
drug_NN
is_VPRT [PASS]
not_XX0
associated_VBN
with_PIN
all_QUAN
the_DT
STATs_NN
,_,
our_FPP1
R&D_NN
and_CC
best_JJ
products_NN
and_PHC
services_NN
in_PIN
the_DT
industry_NN
._.
with_PIN
adverse_JJ
events_NN
that_TSUB
may_POMD
not_XX0
be_VB [PASS]
detected_VBN
manufacturing_VBG
colleagues_NN
and_PHC
Physicians_NN
tell_VPRT
us_FPP1
what_WP
they_TPP3
need_VPRT
and_CC
our_FPP1
in_PIN
clinical_JJ
trials_NN
._.
In_CONJ
addition_NULL
,_,
many_QUAN
agencies_NN
worldwide_JJ
regulatory_JJ
agencies_NN
to_PIN
role_NN
is_VPRT
to_TO
come_VB
up_RP
with_PIN
the_DT
answers_NN
,_,
he_TPP3
says_VPRT [PUBV]
._.
are_VPRT
requiring_VBG [SUAV]
more_EMPH
definitive_JJ
data_NN
concerning_VBG [WZPRES]
ensure_VB [SUAV] [PRIV]
the_DT
successful_JJ
registration_NOMZ
To_TO
provide_VB
this_DEMO
level_NN
of_PIN
service_NN
the_DT
key_NN
a_DT
drugs_NN
effectiveness_NOMZ
in_CONJ
comparison_NULL
and_CC
commercialization_NOMZ
of_PIN
Shires_NN
is_VPRT
to_TO
build_VB
an_DT
effective_JJ
link_NN
between_PIN
product_NN
to_TO
approved_VBN
therapies_NN
._.
We_FPP1
work_VPRT
closely_RB
new_JJ
and_PHC
existing_JJ
products_NN
._.
development_NOMZ
and_PHC
marketing_GER
to_TO
ensure_VB [SUAV] [PRIV]
with_PIN
our_FPP1
R&D_NN
colleagues_NN
,_,
strategic_JJ
and_CC
Doug_NN
Hay_NN
successful_JJ
delivery_NN
._.
In_PIN
order_NN
to_TO
do_VB [PROD]
that_DEMO
you_SPP2
commercial_JJ
teams_NN
,_,
as_RB
well_RB
as_IN
manufacturing_GER
,_,
Senior_JJ
Vice_NN
President_NN
,_,
Global_NN
need_VPRT
to_PIN
further_JJ
strengthen_VB
the_DT
connection_NOMZ
to_TO
optimize_VB
development_NOMZ
programs_NN
and_CC
their_TPP3
Regulatory_NN
Affairs_NN
between_PIN
the_DT
Companys_NN
STATs_NN
and_CC
functional_JJ
documentation_NOMZ
for_PIN
each_QUAN
registration_NOMZ
dossier_NN
,_,
units_NN
,_,
building_VBG [PRESP]
a_DT
matrix_NN
that_TSUB
enables_VPRT
Shire_NN
says_VPRT [PUBV]
Dr_NN
Hay_NN
._.
Externally_RB
,_,
this_DEMP
requires_VPRT [SUAV]
more_EMPH
05_CD
people_NN
to_TO
work_VB
together_RB
toward_PIN
well-defined_JJ
frequent_JJ
communication_NOMZ
and_PHC
meetings_GER
We_FPP1
are_VPRT
building_VBG
a_DT
truly_RB
multiand_JJ
measurable_JJ
goals_NN
._.
with_PIN
regulatory_JJ
agencies_NN
and_CC
the_DT
building_GER
product_NN
,_,
multi-therapeutic_JJ
and_CC
of_PIN
stronger_JJ
professional_JJ
relationships_NN
,_,
global_JJ
organization_NOMZ
,_,
to_TO
become_VB
Aligning_VBG
the_DT
global_JJ
effort_NN
broader_JJ
respect_NN
and_PHC
trust_NN
._.
the_DT
best_JJ
specialty_NN
pharmaceutical_JJ
Mr_NN
Cola_NN
who_WP [WHSUB]
joined_VBD
Shire_NN
in_PIN
mid-2005_NN
with_PIN
company_NN
,_,
in_PIN
the_DT
world_NN
._.
a_DT
wealth_NN
of_PIN
pharmaceutical_JJ
industry_NN
and_PHC
Shire_NN
boasts_VPRT [PUBV]
a_DT
dedicated_JJ
,_,
experienced_JJ
and_CC
Mike_NN
Cola_NN
business_NOMZ
experience_NN
gained_VBD
at_PIN
companies_NN
talented_VBD
team_NN
of_PIN
regulatory_JJ
professionals_NN
Executive_NN
Vice_NN
President_NN
,_,
Global_NN
such_JJ
as_IN
AstraMerck_NN
,_,
AstraZeneca_NN
and_ANDC
who_WP
are_VPRT [BEMA]
highly_AMP
knowledgeable_PRED
about_IN
regional_JJ
Therapeutic_NN
Area_NN
Safeguard_NN
Scientifics_NN
,_,
says_VPRT [PUBV]
hes_NN
also_RB
very_AMP
regulatory_JJ
requirements_NOMZ
and_CC
accountable_JJ
excited_VBN
about_IN
the_DT
caliber_NN
of_PIN
Shires_NN
people_NN
._.
We_FPP1
have_VPRT
a_DT
regulatory_JJ
group_NN
with_PIN
the_DT
competence_NN
,_,
expertise_NN
and_PHC
Shire_NN
has_VPRT [SPAU] [PEAS]
already_RB
taken_VBN
many_QUAN
of_PIN
the_DT
capabilities_NOMZ
that_TSUB
are_VPRT
far_PLACE
beyond_IN
those_DEMO
normally_RB
steps_NN
necessary_JJ
to_TO
establish_VB [PRIV]
itself_PIT
as_IN
a_DT
truly_RB
expected_VBN [PRIV]
of_PIN
a_DT
company_NN
our_FPP1
size_NN
,_,
says_VPRT [PUBV]
Dr_NN
Hay_NN
._.
multi-product_NN
,_,
multi-therapeutic_JJ
,_,
global_JJ
organization_NOMZ
,_,
he_TPP3
notes_VPRT [PRIV]
._.
It_PIT
now_TIME
is_VPRT
moving_VBG [SUAV]
to_PIN
the_DT
next_JJ
tier_NN
,_,
perfecting_VBG [PRESP]
its_PIT
business_NOMZ
model_NN
,_,
introducing_VBG [PRESP]
truly_RB
global_JJ
products_NN
such_JJ
as_IN
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
19_CD
Shire_NN
plc_NN
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:53_CD
Page_NN
20_CD
Operating_GER
review_NN
General_NN
Products_NN
Our_FPP1
exible_JJ
organizational_JJ
structure_NN
and_PHC
ability_NOMZ
to_TO
focus_VB
around_PLACE
key_JJ
business_NOMZ
goals_NN
allows_VPRT [SUAV]
us_FPP1
to_TO
seize_VB
new_JJ
opportunities_NOMZ
faster_RB
than_PIN
anyone_QUPR
else_RB
._.
David_NN
Milton_NN
Senior_NN
Vice_NN
President_NN
and_PHC
head_NN
of_PIN
Shires_NN
GP_NN
STAT_NN
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:53_CD
Page_NN
21_CD
01_CD
02_CD
03_CD
01_CD
General_NN
Products_NN
GP_NN
Working_GER
closely_RB
with_PIN
Shires_NN
Business_NOMZ
Launching_GER
XAGRID_NN
in_PIN
Europe_NN
has_VPRT
While_OSUB
most_EMPH
of_PIN
the_DT
pharmaceutical_JJ
industry_NN
Development_NOMZ
team_NN
,_,
members_NN
of_PIN
the_DT
GP_NN
STAT_NN
been_VBN [BEMA]
great_PRED
and_CC
the_DT
future_NN
for_PIN
the_DT
is_VPRT
struggling_VBG
to_TO
find_VB [PRIV]
and_PHC
develop_VB
new_JJ
help_NN
to_TO
review_VB
thousands_NN
of_PIN
disease_NN
states_NN
and_CC
renal_JJ
portfolio_NN
is_VPRT [BEMA]
really_EMPH
exciting_PRED
._.
products_NN
to_TO
launch_VB
,_,
Shire_NN
is_VPRT
preparing_VBG
to_TO
assess_VB
their_TPP3
suitability_NOMZ
to_PIN
Shire_NN
and_PHC
importance_NN
Sally_NN
Gosden_NN
introduce_VB
a_DT
large_JJ
number_NN
of_PIN
new_JJ
and_PHC
exciting_JJ
to_PIN
specialist_NN
physicians_NN
._.
For_CONJ
example_NULL
,_,
it_PIT
played_VBD
Hospital_NN
Business_NOMZ
new_JJ
medicines_NN
over_IN
a_DT
relatively_RB
short_JJ
period_NN
a_DT
key_JJ
role_NN
in_PIN
identifying_VBG
TKT_NN
,_,
a_DT
US-based_JJ
of_PIN
time_NN
._.
According_VBG [PRESP]
to_PIN
David_NN
Milton_NN
,_,
Senior_NN
biopharmaceutical_JJ
company_NN
specializing_VBG [WZPRES]
in_PIN
02_CD
Vice_NN
President_NN
and_PHC
head_NN
of_PIN
Shires_NN
GP_NN
STAT_NN
,_,
therapeutics_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
rare_JJ
genetic_JJ
At_PIN
Shire_NN
we_FPP1
can_POMD
make_VB
a_DT
difference_NN
._.
this_DEMP
is_VPRT [BEMA]
the_DT
direct_JJ
result_NN
of_PIN
the_DT
Companys_NN
diseases_NN
caused_VBN [WZPAST]
by_PIN
protein_NN
deficiencies_NN
,_,
as_IN
a_DT
A_DT
difference_NN
to_PIN
patients_NN
,_,
to_PIN
doctors_NN
successful_JJ
strategy_NN
of_PIN
identifying_VBG
and_CC
strategic_JJ
acquisition_NOMZ
in_PIN
2005_CD
._.
This_DEMP
was_VBD [BEMA]
our_FPP1
first_JJ
with_PIN
medicines_NN
that_TSUB
are_VPRT [PASS]
needed_VBN
,_,
focusing_VBG [PRESP]
on_PIN
a_DT
number_NN
of_PIN
new_JJ
,_,
late_TIME
stage_NN
major_JJ
acquisition_NOMZ
since_OSUB
the_DT
introduction_NOMZ
of_PIN
the_DT
I_FPP1
really_EMPH
have_VPRT
the_DT
scope_NN
to_TO
make_VB
pipeline_NN
products_NN
._.
STAT_NN
operating_VBG [WZPRES]
model_NN
and_CC
represents_VPRT
a_DT
perfect_JJ
things_NN
happen_VB
._.
strategic_JJ
fit_NN
for_PIN
Shire_NN
,_,
says_VPRT [PUBV]
Mr_NN
Milton_NN
._.
TKTs_NN
Sheila_NN
Stranks_NN
Shires_NN
strategy_NN
of_PIN
focusing_VBG
on_PIN
the_DT
key_JJ
differentiated_JJ
products_NN
with_PIN
long_JJ
product_NN
life_NN
General_NN
Manager_NN
,_,
GP_NN
STAT_NN
pharmaceutical_JJ
markets_NN
of_PIN
North_NN
America_NN
cycles_NN
,_,
specialist_NN
prescribers_NN
and_CC
clear_JJ
unmet_JJ
and_PHC
top_JJ
five_CD
European_JJ
countries_NN
,_,
on_PIN
diseases_NN
medical_JJ
needs_NN
are_VPRT [BEMA]
highly_AMP
complementary_PRED
to_PIN
03_CD
treated_VBN
by_PIN
specialist_NN
physicians_NN
,_,
and_ANDC
on_PIN
a_DT
Shires_NN
business_NOMZ
and_CC
commercial_JJ
capabilities_NOMZ
._.
Our_FPP1
team_NN
is_VPRT [BEMA]
incredibly_RB
motivated_JJ
pipeline_NN
of_PIN
late_TIME
stage_NN
products_NN
,_,
has_VPRT [PEAS]
enabled_VBN
by_PIN
the_DT
future_NN
of_PIN
our_FPP1
UK_NN
business_NOMZ
._.
us_FPP1
to_TO
build_VB
a_DT
rapidly_RB
growing_VBG
business_NOMZ
with_PIN
Two_CD
global_JJ
product_NN
launches_NN
We_FPP1
are_VPRT [SPAU]
now_TIME
looking_VBG
forward_RB
an_DT
impressive_JJ
portfolio_NN
of_PIN
innovative_JJ
products_NN
,_,
2005_CD
also_RB
saw_VBD [PRIV]
the_DT
launch_NN
of_PIN
Shires_NN
first_RB
two_CD
to_PIN
the_DT
successful_JJ
launches_NN
he_TPP3
says_VPRT [PUBV]
._.
truly_RB
global_JJ
products_NN
:_:
FOSRENOL_NN
Shires_NN
new_JJ
of_PIN
FOSRENOL_NN
,_,
MESAVANCE_NN
phosphate_NN
binder_NN
that_TSUB
reduces_VPRT
elevated_JJ
blood_NN
and_PHC
DYNEPO_NN
._.
One_CD
of_PIN
the_DT
important_JJ
roles_NN
of_PIN
the_DT
GP_NN
STAT_NN
levels_NN
of_PIN
phosphate_NN
in_PIN
patients_NN
with_PIN
End-Stage_NN
John_NN
Freeman_NN
is_VPRT
to_TO
help_VB
identify_VB
,_,
search_NN
and_CC
support_VB
the_DT
Renal_NN
Disease_NN
ESRD_NN
,_,
in_PIN
the_DT
US_FPP1
,_,
and_ANDC
XAGRID_NN
Managing_VBG [WZPRES]
Director_NN
,_,
Commercial_NN
acquisition_NOMZ
of_PIN
new_JJ
products_NN
through_PIN
ina_NN
treatment_NOMZ
for_PIN
chronic_JJ
disorder_NN
of_PIN
bone_NN
licensing_GER
or_CC
merger_NN
&_CC
acquisition_NOMZ
in_PIN
new_JJ
marrow_NN
associated_VBN [WZPAST]
with_PIN
the_DT
increased_VBN
therapy_NN
areas_NN
that_TSUB
meet_VPRT
Shires_NN
strategy_NN
of_PIN
production_NOMZ
of_PIN
blood_NN
platelets_NN
,_,
in_PIN
Europe_NN
._.
targeting_VBG
specialist_JJ
diseases_NN
with_PIN
significant_JJ
unmet_JJ
medical_JJ
needs_NN
and_PHC
growth_NN
potential_NN
._.
Both_DT
these_DEMO
launches_NN
have_VPRT [PEAS]
been_VBN [BEMA]
successful_PRED
,_,
It_PIT
also_RB
works_VPRT
closely_RB
with_PIN
the_DT
Companys_NN
says_VPRT [PUBV]
Mr_NN
Milton_NN
._.
XAGRID_NN
is_VPRT
enjoying_VBG
good_JJ
Regulatory_NN
Affairs_NN
team_NN
to_TO
obtain_VB
global_JJ
market_NN
acceptance_NN
across_PLACE
Europe_NN
,_,
it_PIT
has_VPRT
registration_NOMZ
for_PIN
new_JJ
products_NN
,_,
manages_VPRT
some_QUAN
been_VBN [PASS]
designated_VBN
an_DT
orphan_JJ
medicinal_JJ
80_CD
products_NN
in_PIN
the_DT
GP_NN
portfolio_NN
and_CC
oversees_VPRT
product_NN
,_,
providing_VBG [PRESP]
it_PIT
with_PIN
up_RB
to_TO
ten_VB
years_NN
relationships_NN
with_PIN
partner_NN
organizations_NOMZ
such_JJ
market_NN
exclusivity_NOMZ
in_PIN
Europe_NN
._.
GSK_NN
markets_NN
Shires_NN
patented_VBD
3TC_NN
that_DEMO
over_IN
40,000_CD
patients_NN
suffer_VPRT
from_PIN
Essential_JJ
lamivudine_NN
,_,
which_WDT [SERE]
is_VPRT [BEMA]
a_DT
key_JJ
component_NN
in_PIN
Thrombocythemia_NN
across_PLACE
the_DT
EU_NN
,_,
where_RB
it_PIT
is_VPRT
FOSRENOL_NN
demonstrates_VPRT [PRIV]
reliable_JJ
most_EMPH
HIV_JJ
combination_NOMZ
treatment_NOMZ
regimes_VPRT
and_CC
currently_RB
the_DT
only_DWNT
approved_JJ
platelet-reducing_JJ
efficacy_NN
and_PHC
safety_NN
in_PIN
many_QUAN
wellis_NN
also_RB
used_VBD
to_TO
treat_VB
Chronic_NN
Hepatitis_NN
B._NN
treatment_NOMZ
across_PLACE
Europe_NN
._.
By_PIN
the_DT
end_NN
of_PIN
2005_CD
,_,
designed_VBN
clinical_JJ
trials_NN
,_,
with_PIN
the_DT
GSK_NN
pays_VPRT
a_DT
royalty_NN
on_PIN
sales_NN
of_PIN
3TC_CD
to_PIN
Shire_NN
._.
FOSRENOL_NN
had_VBD [PEAS]
captured_VBN
over_IN
8_CD
%_NN
of_PIN
new_JJ
added_VBN [PUBV]
benefit_NN
of_PIN
a_DT
lower_JJ
pill_NN
burden_NN
._.
US_FPP1
phosphate_NN
binder_NN
scrips_NN
and_CC
had_VBD [PEAS]
been_VBN [BEMA]
I_FPP1
believe_VPRT [PRIV]
that_THVC
FOSRENOL_NN
leads_VPRT
us_FPP1
The_DT
work_NN
of_PIN
the_DT
GP_NN
STAT_NN
is_VPRT [BEMA]
a_DT
major_JJ
approved_VBN
in_PIN
Europe_NN
,_,
where_RB
it_PIT
will_PRMD
be_VB [PASS]
rolled_VBN
closer_RB
to_PIN
the_DT
ideal_JJ
phosphate_NN
binder_NN
._.
contributor_NN
to_PIN
Shires_NN
future_NN
,_,
says_VPRT [PUBV]
Mr_NN
Milton_NN
,_,
out_PIN
in_PIN
2006_CD
._.
Dr_NN
Alastair_NN
Hutchison_NN
a_DT
biochemist_NN
and_PHC
MBA_NN
with_PIN
almost_DWNT
25_CD
years_NN
Manchester_NN
Institute_NN
of_PIN
Nephrology_NN
of_PIN
pharmaceutical_JJ
industry_NN
experience_NN
FOSRENOL_NN
,_,
the_DT
subject_NN
of_PIN
nine_CD
years_NN
&_CC
Transplantation_NOMZ
,_,
UK_NN
in_PIN
strategic_JJ
commercial_JJ
planning_GER
,_,
portfolio_NN
of_PIN
research_NN
and_PHC
development_NOMZ
,_,
clinical_JJ
studies_NN
prioritization_NOMZ
,_,
resource_NN
allocation_NOMZ
,_,
and_ANDC
business_NOMZ
and_CC
regulatory_JJ
reviews_NN
,_,
received_VBD
FDA_NN
development_NOMZ
._.
Our_FPP1
portfolio_NN
of_PIN
marketed_VBN
approval_NN
in_PIN
October_NN
2004_CD
,_,
six_CD
months_NN
after_IN
products_NN
around_PLACE
the_DT
world_NN
makes_VPRT
a_DT
critical_JJ
it_PIT
received_VBD
its_PIT
first_JJ
European_JJ
regulatory_JJ
contribution_NOMZ
to_PIN
the_DT
bottom_JJ
line_NN
and_CC
enables_VPRT
approval_NN
from_PIN
Sweden_NN
._.
FOSRENOL_NN
is_VPRT [BEMA]
the_DT
us_FPP1
to_TO
fund_VB
our_FPP1
ongoing_JJ
R&D_NN
,_,
infrastructure_NN
first_JJ
Shire_NN
compound_NN
taken_VBN [WZPAST]
from_PIN
the_DT
test_NN
tube_NN
and_PHC
business_NOMZ
development_NOMZ
activities_NOMZ
._.
to_PIN
approval_NN
and_CC
is_VPRT
strategically_RB
very_AMP
important_JJ
for_PIN
us_FPP1
,_,
says_VPRT [PUBV]
Mr_NN
Milton_NN
,_,
noting_VBG [PRIV]
that_THVC
the_DT
drug_NN
has_VPRT [PEAS]
been_VBN [PASS]
studied_VBN
more_EMPH
extensively_RB
than_PIN
any_QUAN
other_JJ
phosphate_NN
binder_NN
prior_RB
to_PIN
launch_NN
._.
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
21_CD
Shire_NN
plc_NN
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:53_CD
Page_NN
22_CD
Operating_GER
review_NN
General_NN
Products_NN
04_CD
05_CD
06_CD
04_CD
In_PIN
March_NN
2005_CD
,_,
regulatory_JJ
authorities_NOMZ
in_PIN
the_DT
He_TPP3
notes_VPRT [PRIV]
that_THVC
in_PIN
order_NN
for_PIN
Shire_NN
therapeutic_JJ
Interactions_NOMZ
with_PIN
enthusiastic_JJ
and_CC
EU_NN
granted_VBD [SUAV]
marketing_GER
authorization_NOMZ
for_PIN
teams_NN
to_TO
work_VB
together_RB
,_,
it_PIT
is_VPRT [BEMA]
important_PRED
that_THAC
experienced_JJ
people_NN
at_PIN
Shire_NN
make_VPRT
FOSRENOL_NN
in_PIN
16_CD
member_NN
states_NN
,_,
completing_VBG [PRESP]
they_TPP3
share_VPRT
a_DT
clear_JJ
and_PHC
common_JJ
vision_NN
._.
From_PIN
it_PIT
a_DT
stimulating_VBG
place_NN
to_TO
work_VB
._.
the_DT
first_JJ
step_NN
in_PIN
securing_VBG
marketing_GER
approval_NN
this_DEMO
foundation_NOMZ
a_DT
comprehensive_JJ
plan_NN
of_PIN
action_NOMZ
Prerak_NN
Mehta_NN
throughout_PIN
the_DT
remainder_NN
of_PIN
the_DT
EU_NN
._.
can_POMD
be_VB [PASS]
developed_VBN
,_,
with_PIN
individuals_NN
and_PHC
teams_NN
Medical_NN
Information_NOMZ
Associate_NN
assigned_VBN [WZPAST]
to_PIN
critical_JJ
activities_NOMZ
,_,
pulling_VBG [PRESP]
together_RB
Two_CD
additional_JJ
studies_NN
released_VBN [WZPAST]
in_PIN
2005_CD
further_RB
the_DT
best_JJ
talent_NN
within_PIN
the_DT
organization_NOMZ
._.
05_CD
confirmed_VBD [PUBV]
the_DT
safety_NN
and_PHC
efficacy_NN
profile_NN
of_PIN
In_PIN
this_DEMO
way_NN
,_,
it_PIT
is_VPRT [BEMA]
possible_PRED
to_TO
maximize_VB
fully_AMP
These_DEMP
are_VPRT [BEMA]
very_AMP
exciting_JJ
times_NN
for_PIN
FOSRENOL_NN
._.
Data_NN
presented_VBD
at_PIN
the_DT
National_NN
the_DT
talent_NN
within_PIN
our_FPP1
organization_NOMZ
,_,
irrespective_RB
Shire_NN
as_IN
we_FPP1
expand_VPRT
the_DT
portfolio_NN
Kidney_NN
Foundation_NOMZ
2005_CD
clinical_JJ
meeting_GER
in_PIN
of_PIN
function_NOMZ
,_,
department_NOMZ
or_CC
location_NOMZ
._.
Once_TIME
with_PIN
true_JJ
global_JJ
brands_NN
._.
Washington_NN
,_,
DC_NN
in_PIN
May_POMD
showed_VBD [PRIV]
that_THVC
in_PIN
vitro_NN
their_TPP3
goals_NN
have_VPRT [PEAS]
been_VBN [PASS]
accomplished_VBN
,_,
these_DEMO
Shirley_NN
Wakelin_NN
FOSRENOL_NN
binds_VPRT
phosphate_NN
across_PLACE
a_DT
broad_JJ
teams_NN
can_POMD
be_VB [PASS]
disbanded_VBN
and_CC
new_JJ
teams_NN
Director_NN
,_,
Renal_NN
Products_NN
,_,
GP_NN
STAT_NN
pH_NN
range_NN
with_PIN
higher_JJ
affinity_NOMZ
than_PIN
a_DT
competitor_NN
,_,
formed_VBN [PASTP]
as_RB
necessary_JJ
._.
Additional_JJ
clinical_JJ
06_CD
data_NN
presented_VBN [WZPAST]
at_PIN
the_DT
American_NN
Society_NN
Shires_NN
decision_NN
to_TO
consolidate_VB
its_PIT
business_NOMZ
Teamwork_NN
and_CC
effective_JJ
regulatory_JJ
of_PIN
Nephrology_NN
in_PIN
November_NN
showed_VBD [PRIV]
that_THVC
to_PIN
fewer_JJ
sites_NN
,_,
divest_VB
non-core_JJ
businesses_NOMZ
,_,
dialogue_NN
allows_VPRT [SUAV]
us_FPP1
to_TO
reach_VB
our_FPP1
non-calcium_JJ
FOSRENOL_NN
effectively_RB
maintains_VPRT [PUBV]
such_JJ
as_IN
vaccines_NN
,_,
and_ANDC
focus_VB
its_PIT
resources_NN
goals_NN
and_CC
achieve_VB
our_FPP1
ambitions_NOMZ
._.
reductions_NOMZ
in_PIN
mean_JJ
serum_NN
phosphorus_NN
levels_NN
on_PIN
the_DT
most_EMPH
important_JJ
products_NN
in_PIN
Venetta_NN
Lunn_NN
while_OSUB
demonstrating_VBG [PRIV]
safety_NN
and_PHC
tolerability_NOMZ
development_NOMZ
also_RB
gives_VPRT
it_PIT
a_DT
competitive_JJ
Senior_JJ
Director_NN
,_,
Regulatory_NN
Affairs_NN
in_PIN
ESRD_NN
patients_NN
for_PIN
up_RB
to_PIN
six_CD
years_NN
._.
advantage_NN
in_PIN
todays_NN
market_NN
,_,
Mr_NN
Milton_NN
notes_NN
._.
Most_EMPH
pharmaceutical_JJ
companies_NN
The_DT
GP_NN
STAT_NN
has_VPRT [SPAU] [PEAS]
also_RB
contributed_VBN
in_PIN
recent_JJ
have_VPRT [SPAU] [PEAS]
traditionally_RB
attempted_VBN
to_TO
do_VB [PROD]
everything_QUPR
years_NN
to_PIN
the_DT
launch_NN
of_PIN
several_QUAN
other_JJ
new_JJ
in-house_NN
,_,
from_PIN
basic_JJ
research_NN
through_PIN
products_NN
,_,
including_VBG
SOLARAZE_NN
,_,
a_DT
leading_VBG
development_NOMZ
,_,
manufacturing_GER
,_,
sales_NN
and_CC
topical_JJ
treatment_NOMZ
for_PIN
actinic_JJ
keratosis_NN
,_,
and_ANDC
marketing_GER
,_,
Shires_NN
strategy_NN
is_VPRT
to_TO
focus_VB
VANIQA_NN
,_,
a_DT
new_JJ
product_NN
designed_VBN
to_TO
slow_VB
only_DWNT
on_PIN
those_DEMO
areas_NN
of_PIN
critical_JJ
importance_NN
._.
unwanted_JJ
facial_JJ
hair_NN
growth_NN
in_PIN
women_NN
._.
In_PIN
late_TIME
By_PIN
out-sourcing_VBG
less_JJ
critical_JJ
items_NN
,_,
it_PIT
can_POMD
2006_CD
and_CC
in_PIN
the_DT
first_JJ
half_NN
of_PIN
2007_CD
,_,
it_PIT
also_RB
intends_VPRT [SUAV]
concentrate_NN
on_PIN
critical_JJ
business_NOMZ
issues_NN
to_TO
support_VB
the_DT
European_JJ
launch_NN
of_PIN
DYNEPO_NN
,_,
without_PIN
distraction_NOMZ
and_CC
have_VPRT
the_DT
ability_NOMZ
used_VBN [WZPAST]
for_PIN
the_DT
treatment_NOMZ
of_PIN
kidney_NN
diseaseto_NN
change_NN
direction_NOMZ
very_AMP
rapidly_RB
._.
related_JJ
anemia_NN
,_,
a_DT
product_NN
acquired_VBN [WZPAST]
from_PIN
Well_NN
for_PIN
me_FPP1
,_,
I_FPP1
take_VPRT
fewer_JJ
tablets_NN
TKTs_NN
portfolio_NN
._.
This_DEMO
strategy_NN
has_VPRT [SPAU] [PEAS]
clearly_RB
delivered_VBN
results_NN
over_IN
the_DT
past_JJ
couple_NN
of_PIN
years_NN
._.
We_FPP1
have_VPRT [PEAS]
developed_VBN
and_CC
the_DT
slightly_DWNT
sweet_JJ
taste_NN
and_CC
less_JJ
chalky_JJ
texture_NN
makes_VPRT
it_PIT
a_EMPH
lot_NULL
Remarkable_JJ
track_NN
record_NN
and_CC
launched_VBD
several_QUAN
new_JJ
products_NN
and_PHC
Mr_NN
Milton_NN
says_VPRT [PUBV]
Shires_NN
remarkable_JJ
track_NN
record_NN
achieved_VBD
impressive_JJ
sales_NN
growth_NN
while_OSUB
less_JJ
troublesome_JJ
to_TO
chew_VB
and_PHC
swallow_VB
._.
Three_CD
months_NN
later_TIME
,_,
in_PIN
bringing_VBG
new_JJ
products_NN
to_PIN
market_NN
has_VPRT [PEAS]
been_VBN [SPAU]
also_RB
building_VBG
a_DT
development_NOMZ
pipeline_NN
that_TSUB
enabled_VBD
by_PIN
its_PIT
nimble_JJ
organization_NOMZ
structure_NN
,_,
will_PRMD
continue_VB
to_TO
fuel_VB
Shires_NN
growth_NN
in_PIN
the_DT
my_FPP1
phosphorus_NN
levels_NN
are_VPRT [BEMA]
three_CD
points_NN
lower_JJ
._.
based_VBN
around_PLACE
the_DT
principle_NN
of_PIN
forming_VBG
flexible_JJ
,_,
next_JJ
decade_NN
._.
multi-functional_JJ
teams_NN
to_TO
achieve_VB
clear_JJ
Wayne_NN
Jones_NN
FOSRENOL_NN
patient_NN
business_NOMZ
goals_NN
,_,
and_ANDC
by_PIN
a_DT
corporate_JJ
culture_NN
Playing_VBG [WZPRES]
an_DT
important_JJ
role_NN
in_PIN
the_DT
search_NN
and_CC
that_THVC
champions_NN
creativity_NOMZ
and_PHC
innovation_NOMZ
._.
evaluation_NOMZ
of_PIN
new_JJ
business_NOMZ
opportunities_NOMZ
that_TSUB
could_POMD
contribute_VB
to_PIN
Shires_NN
future_JJ
portfolio_NN
Our_FPP1
flexible_JJ
organizational_JJ
structure_NN
and_PHC
ability_NOMZ
of_PIN
products_NN
gives_VPRT
Mr_NN
Milton_NN
the_DT
greatest_JJ
to_TO
focus_VB
around_PLACE
key_JJ
business_NOMZ
goals_NN
allows_VPRT [SUAV]
job_NN
satisfaction_NOMZ
._.
As_IN
a_DT
manager_NN
of_PIN
a_DT
rapidly_RB
us_FPP1
to_TO
seize_VB
new_JJ
opportunities_NOMZ
faster_RB
than_PIN
growing_VBG
business_NOMZ
,_,
my_FPP1
biggest_JJ
challenge_NN
anyone_QUPR
else_RB
,_,
he_TPP3
says_VPRT [PUBV]
._.
We_FPP1
are_VPRT [SPAU] [PASS]
also_RB
blessed_VBN
on_PIN
a_DT
daily_JJ
basis_NN
is_VPRT
balancing_VBG
the_DT
demands_NN
with_PIN
talented_JJ
,_,
experienced_JJ
and_CC
hardworking_VBG
for_PIN
investment_NOMZ
in_PIN
the_DT
future_NN
with_PIN
the_DT
need_NN
employees_NN
who_WP [WHSUB]
have_VPRT
a_DT
drive_NN
and_PHC
passion_NN
for_PIN
to_TO
maintain_VB [PUBV]
a_DT
healthy_JJ
P&L_NN
this_DEMO
however_CONJ
business_NOMZ
success_NN
._.
is_VPRT [BEMA]
a_DT
problem_NN
many_QUAN
other_JJ
industry_NN
executives_NN
would_PRMD
like_VB
to_TO
have_VB
._.
Data_NN
presented_VBD
May_POMD
5_CD
,_,
2005_CD
at_PIN
the_DT
National_NN
Study_NN
published_VBD
October_NN
24_CD
,_,
2005_CD
in_PIN
Nephron_NN
Kidney_NN
Foundation_NOMZ
NKF_NN
2005_CD
clinical_JJ
meeting_GER
Clinical_NN
Practice_NN
._.
Data_NN
presented_VBD
November_NN
12_CD
,_,
2005_CD
at_PIN
the_DT
annual_JJ
meeting_GER
of_PIN
the_DT
American_NN
Society_NN
of_PIN
Nephrology_NN
._.
22_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:53_CD
Page_NN
23_CD
Working_VBG
with_PIN
the_DT
FOSRENOL_NN
matrix_NN
teams_NN
delivering_VBG [WZPRES]
Shires_NN
first_JJ
global_JJ
launch_NN
is_VPRT [BEMA]
an_DT
exciting_JJ
challenge_NN
._.
Diana_NN
Stokes_NN
General_NN
Manager_NN
,_,
Renal_NN
Products_NN
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:53_CD
Page_NN
24_CD
Operating_GER
review_NN
Gastro-Intestinal_JJ
MESAVANCE_NN
could_POMD
be_VB [BEMA]
the_DT
most_EMPH
important_JJ
product_NN
for_PIN
mild_JJ
to_TO
moderately_RB
active_JJ
ulcerative_JJ
colitis_NN
launched_VBN [WZPAST]
in_PIN
more_EMPH
than_PIN
five_CD
years_NN
._.
Mike_NN
Yasick_NN
Senior_NN
Vice_NN
President_NN
,_,
GI_NN
Therapy_NN
Area_NN
Team_NN
Leader_NN
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:53_CD
Page_NN
25_CD
01_CD
02_CD
01_CD
Gastro-Intestinal_JJ
GI_NN
accountability_NOMZ
for_PIN
performance_NN
is_VPRT [PASS]
shared_VBN
In_PIN
the_DT
history_NN
of_PIN
Shire_NN
,_,
excellence_NN
Mike_NN
Yasick_NN
is_VPRT [BEMA]
unequivocal_PRED
about_IN
his_TPP3
role_NN
by_PIN
the_DT
markets_NN
,_,
functions_NOMZ
and_CC
the_DT
business_NOMZ
._.
I_FPP1
lead_VPRT
a_DT
diverse_JJ
This_DEMP
creates_VPRT
an_DT
environment_NOMZ
where_RB
ideas_NN
and_PHC
Excellence_NN
is_VPRT
what_WP
we_FPP1
are_VPRT [BEMA]
all_QUAN
about_RB
._.
group_NN
of_PIN
Shire_NN
team_NN
members_NN
whose_WPS [WHOBJ]
objective_JJ
initiatives_NN
can_POMD
be_VB [PASS]
challenged_VBN
and_PHC
tested_VBN
by_PIN
Jeff_NN
Kirby_NN
is_VPRT
to_TO
build_VB
our_FPP1
GI_NN
portfolio_NN
and_CC
successfully_RB
many_QUAN
experts_NN
._.
The_DT
result_NN
is_VPRT [BEMA]
a_DT
development_NOMZ
National_NN
Sales_NN
Director_NN
,_,
Specialty_NN
commercialize_VPRT
the_DT
GI_NN
products_NN
we_FPP1
have_VPRT
and_CC
and_CC
commercialization_NOMZ
process_NN
that_TSUB
optimizes_VPRT
Products_NN
optimize_VPRT
our_FPP1
marketed_VBN
products_NN
._.
We_FPP1
are_VPRT [BEMA]
the_DT
value_NN
of_PIN
our_FPP1
brands_NN
for_PIN
the_DT
Company_NN
helping_VBG [WZPRES]
to_TO
develop_VB
not_XX0
only_DWNT
global_JJ
products_NN
and_CC
the_DT
help_NN
that_TOBJ
we_FPP1
provide_VPRT
to_PIN
patients_NN
._.
02_CD
and_CC
strategy_NN
in_PIN
this_DEMO
promising_JJ
therapeutic_JJ
area_NN
,_,
The_DT
GI_NN
STAT_NN
has_VPRT
great_JJ
opportunities_NOMZ
but_CC
also_RB
ensuring_VBG [SUAV] [PRIV]
that_THVC
we_FPP1
have_VPRT
the_DT
optimal_JJ
The_DT
power_NN
of_PIN
teamwork_NN
ahead_PLACE
we_FPP1
are_VPRT [BEMA]
all_QUAN
part_NN
of_PIN
growing_VBG
financial_JJ
and_PHC
human_JJ
resources_NN
available_JJ
In_PIN
Mr_NN
Yasicks_NN
opinion_NN
,_,
strong_JJ
teamwork_NN
global_JJ
organization_NOMZ
and_CC
I_FPP1
look_VPRT
to_TO
implement_VB
our_FPP1
strategy_NN
._.
will_PRMD
be_VB [BEMA]
a_DT
key_JJ
success_NN
driver_NN
for_PIN
Shire_NN
moving_VBG [SUAV] [WZPRES]
forward_RB
to_PIN
the_DT
successful_JJ
European_JJ
forward_RB
._.
You_SPP2
get_VPRT
the_DT
most_EMPH
robust_JJ
analysis_NN
launch_NN
of_PIN
what_WP
will_PRMD
be_VB [BEMA]
an_DT
important_JJ
Mr_NN
Yasick_NN
is_VPRT [SPAU] [PASS]
particularly_RB
well_RB
qualified_VBN
for_PIN
and_CC
solutions_NOMZ
when_RB
people_NN
with_PIN
different_JJ
global_JJ
brand_NN
._.
the_DT
challenge_NN
,_,
with_PIN
20_CD
years_NN
of_PIN
experience_NN
perspectives_NN
work_VPRT
together_RB
._.
The_DT
role_NN
of_PIN
STAT_NN
Richard_NN
Jones_NN
in_PIN
the_DT
pharmaceuticals_NN
industry_NN
in_PIN
sales_NN
,_,
is_VPRT
to_TO
define_VB
the_DT
objectives_NN
,_,
set_VBN
metrics_NN
to_TO
track_VB
International_NN
Marketing_GER
Manager_NN
marketing_GER
,_,
new_JJ
product_NN
development_NOMZ
and_CC
and_CC
evaluate_VB
performance_NN
and_CC
to_TO
allow_VB [SUAV]
our_FPP1
commercialization_NOMZ
._.
He_TPP3
says_VPRT [PUBV] [THATD]
he_TPP3
was_VBD [PASS]
attracted_VBN
talented_JJ
teams_NN
to_TO
produce_VB
the_DT
outcomes_NN
03_CD
to_PIN
Shire_NN
because_CAUS
it_PIT
offered_VBD
the_DT
perfect_JJ
mix_NN
we_FPP1
need_VPRT
to_TO
achieve_VB
our_FPP1
goals_NN
._.
People_NN
want_VPRT
Its_PIT
exciting_JJ
to_TO
be_VB [BEMA]
a_DT
part_NN
of_PIN
Shires_NN
between_PIN
a_DT
solid_JJ
,_,
well-resourced_JJ
business_NOMZ
to_TO
work_VB
together_RB
when_RB
they_TPP3
can_POMD
see_VB [PRIV]
the_DT
high-performing_JJ
regulatory_JJ
team_NN
._.
typical_JJ
of_PIN
a_DT
big_JJ
pharmaceutical_JJ
company_NN
and_PHC
benefit_NN
of_PIN
their_TPP3
collaboration_NOMZ
and_ANDC
when_RB
they_TPP3
Tracy_NN
Rockney_NN
the_DT
entrepreneurial_JJ
environment_NOMZ
of_PIN
a_DT
start-up_NN
,_,
feel_VPRT [PRIV] [THATD]
their_TPP3
efforts_NN
are_VPRT [BYPA]
valued_VBN
by_PIN
the_DT
teams_NN
,_,
Senior_JJ
Director_NN
,_,
Regulatory_NN
Affairs_NN
with_PIN
a_DT
clear_JJ
mission_NN
to_TO
be_VB [BEMA]
a_DT
leading_VBG
specialist_NN
he_TPP3
adds_VPRT [PUBV]
._.
The_DT
real_JJ
motivation_NOMZ
for_PIN
teamwork_NN
04_CD
pharma_NN
company_NN
._.
The_DT
Companys_NN
employees_NN
comes_VPRT
from_PIN
a_DT
shared_VBN
vision_NN
of_PIN
the_DT
future_JJ
Shire_NN
has_VPRT
one_CD
of_PIN
the_DT
richest_JJ
portfolio_NN
are_VPRT [PASS]
accomplished_VBN
,_,
energetic_JJ
and_PHC
enthusiastic_JJ
._.
and_ANDC
from_PIN
creating_VBG
an_DT
environment_NOMZ
of_PIN
of_PIN
products_NN
in_PIN
the_DT
specialty_NN
arena_NN
It_PIT
is_VPRT [BYPA]
led_VBN
by_PIN
a_DT
new_JJ
management_NOMZ
team_NN
empowerment_NOMZ
._.
We_FPP1
have_VPRT
to_PIN
both_DT
trust_NN
and_CC
I_FPP1
am_VPRT
looking_VBG
forward_RB
to_TO
being_VBG [PASS]
composed_VBN
both_DT
of_PIN
people_NN
who_WP [WHSUB]
have_VPRT [PEAS]
built_VBN
Shire_NN
each_QUAN
other_JJ
and_CC
be_VB [BEMA]
willing_PRED
to_TO
challenge_VB
part_NN
of_PIN
making_VBG
it_PIT
a_DT
success_NN
._.
into_PIN
a_DT
billion_CD
dollar_NN
Company_NN
as_RB
well_RB
as_IN
people_NN
each_QUAN
other_JJ
to_TO
achieve_VB
the_DT
best_JJ
results_NN
._.
Ronald_NN
Diebold_NN
with_PIN
fresh_JJ
ideas_NN
and_CC
best_JJ
practices_NN
from_PIN
every_QUAN
North_NN
America_NN
,_,
Commercial_NN
model_NN
of_PIN
the_DT
pharmaceutical_JJ
industry_NN
._.
The_DT
GI_NN
STAT_NN
is_VPRT [PASS]
composed_VBN
of_PIN
a_DT
small_JJ
,_,
Development_NOMZ
Manager_NN
dedicated_VBD
group_NN
of_PIN
employees_NN
with_PIN
an_DT
Since_OSUB
taking_VBG
on_PIN
his_TPP3
new_JJ
position_NOMZ
in_PIN
2004_CD
,_,
average_NN
of_PIN
more_EMPH
than_PIN
20_CD
years_NN
of_PIN
experience_NN
Mr_NN
Yasick_NN
has_VPRT [PEAS]
been_VBN
focusing_VBG
on_PIN
implementing_VBG
in_PIN
the_DT
pharmaceutical_JJ
industry_NN
._.
For_CONJ
example_NULL
,_,
Shires_NN
new_JJ
global_JJ
operating_GER
model_NN
in_PIN
the_DT
GI_NN
the_DT
general_JJ
manager_NN
of_PIN
MESAVANCE_NN
,_,
Roger_NN
therapy_NN
area_NN
._.
The_DT
biggest_JJ
challenge_NN
has_VPRT [PEAS]
been_VBN
Adsett_NN
,_,
was_VBD [BEMA]
the_DT
US_FPP1
commercial_JJ
lead_NN
for_PIN
to_TO
put_VB
together_RB
complete_JJ
commercialization_NOMZ
the_DT
launch_NN
of_PIN
one_CD
of_PIN
the_DT
largest_JJ
GI_NN
brands_NN
in_PIN
plans_NN
that_TSUB
ensure_VPRT [SUAV] [PRIV] [THATD]
we_FPP1
have_VPRT
all_QUAN
the_DT
bases_NN
the_DT
world_NN
:_:
and_ANDC
the_DT
GI_NN
STATs_NN
Scientific_NN
Lead_JJ
,_,
covered_JJ
._.
When_RB
you_SPP2
consider_VPRT [PRIV]
the_DT
sweeping_JJ
Robyn_NN
Karlstadt_NN
,_,
is_VPRT [BEMA]
a_DT
certified_JJ
GI_NN
physician_NN
changes_NN
in_PIN
roles_NN
and_PHC
structure_NN
we_FPP1
have_VPRT [PEAS]
seen_VBN [PRIV]
who_WP
has_VPRT [PEAS]
authored_VBN
dozens_NN
of_PIN
papers_NN
and_CC
was_VBD [BEMA]
at_PIN
Shire_NN
in_PIN
the_DT
past_JJ
year_NN
,_,
combined_VBN [PASTP]
with_PIN
the_DT
a_DT
writer_NN
and_PHC
editor_NN
of_PIN
a_DT
GI_NN
section_NOMZ
in_PIN
a_DT
text_NN
challenges_NN
of_PIN
meeting_GER
launch_NN
objectives_NN
and_PHC
book_NN
._.
Dr_NN
Karlstadt_NN
was_VBD [BEMA]
also_RB
a_DT
key_JJ
member_NN
submitting_VBG [PUBV] [WZPRES]
a_DT
NDA_NN
for_PIN
our_FPP1
newest_JJ
product_NN
,_,
of_PIN
the_DT
launch_NN
team_NN
for_PIN
a_DT
multi-billion_JJ
dollar_NN
Shires_NN
commitment_NOMZ
to_TO
treating_VBG
IBD_NN
MESAVANCE_NN
,_,
you_SPP2
feel_VPRT [PRIV]
truly_RB
rewarded_VBN
with_PIN
GI_NN
brand_NN
._.
Our_FPP1
team_NN
knows_VPRT [PRIV]
what_WP [WHCL]
makes_VPRT
has_VPRT [SPAU] [PEAS]
already_RB
improved_VBN
many_QUAN
patients_NN
these_DEMO
achievements_NOMZ
!_.
successful_JJ
brands_NN
and_CC
has_VPRT
hands-on_PIN
lives_NN
._.
I_FPP1
have_VPRT [PEAS]
prescribed_VBN
PENTASA_NN
for_PIN
experience_NN
in_PIN
executing_VBG
those_DEMO
plans_NN
,_,
says_VPRT [PUBV]
many_QUAN
years_NN
and_CC
look_VB
forward_RB
to_PIN
the_DT
Mr_NN
Yasick_NN
says_VPRT [PUBV]
Shires_NN
GI_NN
team_NN
has_VPRT
a_DT
wellMr_NN
Yasick_NN
._.
Our_FPP1
collective_JJ
past_JJ
success_NN
approval_NN
of_PIN
MESAVANCE_NN
,_,
a_DT
product_NN
deserved_VBD
reputation_NOMZ
within_PIN
the_DT
Company_NN
is_VPRT [BEMA]
the_DT
best_JJ
reason_NN
to_TO
be_VB [BEMA]
confident_PRED
in_PIN
our_FPP1
that_DEMP
will_PRMD
in_PIN
my_FPP1
mind_NN
,_,
set_VBD
the_DT
standard_NN
as_IN
being_VBG [BEMA]
highly_AMP
collaborative_PRED
and_PHC
effective_PRED
._.
ability_NOMZ
to_TO
deliver_VB
in_PIN
the_DT
future_NN
._.
for_PIN
current_JJ
and_PHC
future_JJ
approved_VBN
The_DT
business_NOMZ
model_NN
relies_VPRT
on_PIN
people_NN
in_PIN
the_DT
medications_NOMZ
for_PIN
the_DT
treatment_NOMZ
functions_NOMZ
and_PHC
markets_NN
working_VBG [WZPRES]
together_RB
in_PIN
of_PIN
patients_NN
with_PIN
IBD_NN
._.
product_NN
strategy_NN
teams_NN
led_VBN [WZPAST]
by_PIN
product_NN
general_JJ
Dr_NN
Gary_NN
Lichtenstein_NN
,_,
MD_NN
managers_NN
and_CC
our_FPP1
team_NN
has_VPRT [PEAS]
embraced_VBN
this_DEMO
Director_NN
IBD_NN
Program_NN
Division_NN
style_NN
of_PIN
work_NN
._.
Shire_NN
is_VPRT [BEMA]
unique_PRED
in_PIN
that_DEMO
of_PIN
Gastroenterology_NN
,_,
University_NOMZ
of_PIN
Pennsylvania_NN
,_,
Philadelphia_NN
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
25_CD
Shire_NN
plc_NN
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:54_CD
Page_NN
26_CD
Operating_GER
review_NN
Gastro-Intestinal_NN
03_CD
04_CD
Strong_JJ
track_NN
record_NN
We_FPP1
are_VPRT [SPAU] [PASS]
very_AMP
excited_VBN
about_IN
the_DT
market_NN
mesalamine_NN
products_NN
,_,
only_DWNT
MESAVANCE_NN
The_DT
GI_NN
STAT_NN
will_PRMD
be_VB
building_VBG
on_PIN
Shires_NN
already_RB
potential_NN
of_PIN
this_DEMO
new_JJ
product_NN
and_CC
by_PIN
delivering_VBG
has_VPRT [PEAS]
been_VBN [SPAU] [PASS]
clinically_RB
proven_VBN
to_TO
do_VB [PROD]
that_DEMP
._.
strong_JJ
track_NN
record_NN
in_PIN
the_DT
GI_NN
therapeutic_JJ
area_NN
,_,
on_PIN
our_FPP1
promise_NN
to_TO
achieve_VB
these_DEMO
submissions_NN
,_,
With_PIN
PENTASA_NN
and_PHC
MESAVANCE_NN
,_,
Shire_NN
leveraging_VBG [WZPRES]
its_PIT
extensive_JJ
capabilities_NOMZ
,_,
resources_NN
says_VPRT [PUBV]
Mr_NN
Yasick_NN
._.
There_EX
are_VPRT
approximately_RB
a_DT
will_PRMD
have_VB
the_DT
only_DWNT
two_CD
products_NN
in_PIN
their_TPP3
class_NN
and_PHC
expertise_NN
to_TO
bring_VB
specialist_JJ
projects_NN
million_CD
patients_NN
worldwide_JJ
with_PIN
UC_NN
and_CC
more_EMPH
to_TO
demonstrate_VB [PRIV]
in_PIN
clinical_JJ
studies_NN
the_DT
ability_NOMZ
through_PIN
the_DT
development_NOMZ
and_PHC
registration_NOMZ
than_PIN
70_CD
%_NN
of_PIN
them_TPP3
are_VPRT
being_VBG [PASS]
treated_VBN
with_PIN
to_TO
control_VB
symptoms_NN
and_CC
induce_VB
remission_NN
phases_NN
in_PIN
the_DT
most_EMPH
effective_JJ
manner_NN
._.
MESAVANCE_NN
will_PRMD
be_VB [BEMA]
further_PRED
our_FPP1
sales_NN
and_PHC
marketing_GER
network_NN
targeting_VBG [WZPRES]
has_VPRT
a_DT
chance_NN
to_TO
be_VB [BEMA]
one_CD
of_PIN
the_DT
most_EMPH
important_JJ
differentiated_VBN
from_PIN
other_JJ
products_NN
in_PIN
the_DT
class_NN
GI_NN
physicians_NN
,_,
we_FPP1
have_VPRT [PEAS]
had_VBN
considerable_JJ
product_NN
launches_NN
in_PIN
mild_JJ
to_TO
moderately_RB
because_CAUS
Shire_NN
decided_VBD [SUAV] [PRIV]
to_TO
use_VB
the_DT
innovative_JJ
success_NN
in_PIN
the_DT
commercialization_NOMZ
phase_NN
,_,
severe_JJ
UC_NN
in_PIN
more_EMPH
than_PIN
five_CD
years_NN
._.
The_DT
entire_JJ
Phase_NN
3_CD
study_NN
design_NN
._.
Global_JJ
experts_NN
were_VBD
notes_NN
Mr_NN
Yasick_NN
._.
Company_NN
is_VPRT
behind_PLACE
MESAVANCE_NN
and_CC
we_FPP1
surprised_VBD
that_DEMO
we_FPP1
would_PRMD
be_VB [BEMA]
willing_PRED
to_TO
include_VB
will_PRMD
launch_VB
it_PIT
with_PIN
passion_NN
and_PHC
enthusiasm_NN
._.
the_DT
market_NN
leader_NN
as_IN
a_DT
reference_NN
arm_NN
,_,
and_ANDC
they_TPP3
Shire_VPRT
has_VPRT [PEAS]
established_VBN [PRIV]
itself_PIT
among_PIN
the_DT
market_NN
were_VBD [PASS]
impressed_VBN
with_PIN
the_DT
results_NN
of_PIN
the_DT
studies_NN
._.
leaders_NN
in_PIN
drug_NN
therapies_NN
for_PIN
UC_NN
._.
UC_NN
is_VPRT [BEMA]
a_DT
MESAVANCE_NN
utilizes_VPRT
a_DT
novel_NN
multimatrix_NN
chronic_NN
,_,
relapsing_VBG
type_NN
of_PIN
Inflammatory_NN
Bowel_NN
delivery_NN
system_NN
to_TO
provide_VB
the_DT
highest_JJ
strength_NN
Seizing_VBG [WZPRES]
opportunities_NOMZ
Disease_NN
IBD_NN
in_PIN
which_WDT [PIRE]
part_NN
,_,
or_CC
all_QUAN
,_,
of_PIN
the_DT
large_JJ
of_PIN
5-ASA_JJ
per_PIN
tablet_NN
of_PIN
any_QUAN
product_NN
available_JJ
._.
Shires_NN
GI_NN
STAT_NN
is_VPRT [SPAU]
actively_RB
evaluating_VBG
a_DT
variety_NN
intestine_JJ
becomes_VPRT
inflamed_VBN
and_CC
often_RB
With_PIN
this_DEMO
technology_NN
,_,
UC_NN
patients_NN
are_VPRT [BEMA]
able_PRED
to_PIN
of_PIN
GI_NN
licensing_GER
and_PHC
acquisition_NOMZ
opportunities_NOMZ
ulcerated_VBD
._.
Patients_NN
experience_VPRT
intermittent_JJ
treat_VB
their_TPP3
disease_NN
for_PIN
the_DT
first_JJ
time_NN
with_PIN
a_DT
once_TIME
to_TO
expand_VB
its_PIT
GI_NN
portfolio_NN
for_PIN
the_DT
treatment_NOMZ
attacks_NN
separated_VBN [WZPAST]
by_PIN
periods_NN
of_PIN
remission_NN
,_,
and_ANDC
daily_JJ
dose_NN
of_PIN
medicine_NN
._.
The_DT
unique_JJ
technology_NN
of_PIN
IBD_NN
and_CC
other_JJ
conditions_NOMZ
and_CC
contribute_VPRT
can_POMD
suffer_VB
diarrhoea_NN
,_,
bleeding_VBG
and_CC
abdominal_JJ
ensures_VPRT [SUAV] [PRIV]
continued_VBN
and_PHC
prolonged_VBN
exposure_NN
to_PIN
future_JJ
growth_NN
._.
IBD_NN
is_VPRT [PASS]
treated_VBN
with_PIN
several_QUAN
pain_NN
._.
The_DT
most_EMPH
frequently_RB
used_VBN
treatments_NOMZ
of_PIN
the_DT
colonic_JJ
mucosa_NN
to_PIN
the_DT
active_JJ
ingredient_NN
,_,
classes_NN
of_PIN
drugs_NN
,_,
explains_VPRT [PUBV]
Mr_NN
Yasick_NN
._.
The_DT
MMX_NN
MultiThese_NN
include_VPRT
anti-TNF_JJ
and_PHC
other_JJ
agents_NN
Matrix_NN
System_NN
which_WDT [WHSUB]
enables_VPRT
this_DEMP
was_VBD
that_DEMO
target_NN
pro-inflammatory_JJ
cytokines_NN
,_,
Shire_NN
has_VPRT
two_CD
marketed_VBN
products_NN
containing_VBG [WZPRES]
developed_VBN
by_PIN
Cosmo_NN
S._NN
p._NN
A_NN
and_CC
is_VPRT [BEMA]
a_DT
patented_JJ
immunosuppressives_NN
and_PHC
glucoticosteroids_NN
the_DT
mainstay_NN
treatment_NOMZ
for_PIN
IBD_NN
,_,
mesalamine_NN
technology_NN
licensed_VBD
from_PIN
Giuliani_NN
S._NN
p._NN
A._NN
that_TSUB
are_VPRT [PASS]
used_VBN
stepwise_NN
and_CC
in_PIN
combination_NOMZ
5-ASA_NN
:_:
PENTASA_NN
and_PHC
COLAZIDE_NN
._.
Shire_NN
has_VPRT
commercial_JJ
and_CC
to_TO
treat_VB
IBD_NN
._.
Given_VBN
our_FPP1
position_NOMZ
with_PIN
PENTASA_NN
,_,
delivers_VPRT
mesalamine_NN
throughout_PIN
the_DT
small_JJ
development_NOMZ
rights_NN
to_PIN
this_DEMO
technology_NN
in_PIN
the_DT
COLAZIDE_NN
and_PHC
MESAVANCE_NN
,_,
these_DEMP
would_PRMD
and_CC
large_JJ
bowel_NN
and_CC
is_VPRT [PASS]
marketed_VBN
in_PIN
the_DT
US_FPP1
US_FPP1
,_,
Canada_NN
,_,
the_DT
Pacific_NN
Rim_NN
and_PHC
Europe_NN
be_VB [BEMA]
great_JJ
additions_NOMZ
to_PIN
the_DT
Shire_NN
portfolio_NN
._.
in_PIN
250mg_CD
and_CC
500mg_CD
capsules_NN
and_CC
with_PIN
the_DT
exception_NOMZ
of_PIN
Italy_NN
where_RB
Giuliani_NN
In_CONJ
addition_NULL
,_,
we_FPP1
are_VPRT
looking_VBG
at_PIN
other_JJ
products_NN
COLAZIDE_NN
is_VPRT [BEMA]
an_DT
oral_JJ
mesalamine_NN
formulation_NOMZ
retains_VPRT
all_QUAN
rights_NN
._.
Our_FPP1
Phase_NN
3_CD
program_NN
was_VBD
which_WDT
GI_NN
physicians_NN
could_POMD
use_VB
to_TO
treat_VB
hepatic_JJ
for_PIN
the_DT
treatment_NOMZ
of_PIN
UC_NN
in_PIN
the_DT
UK_NN
._.
We_FPP1
worked_VBD
with_PIN
the_DT
FDA_NN
,_,
and_ANDC
disorders_NN
,_,
non-acid_JJ
esophageal_NN
disorders_NN
,_,
and_ANDC
COLAZIDE_NN
offer_VPRT
us_FPP1
a_DT
powerful_JJ
jumpstart_NN
a_DT
panel_NN
of_PIN
global_JJ
GI_NN
experts_NN
to_TO
create_VB
very_AMP
strict_JJ
pancreatic_JJ
insufficiency_NN
and_CC
the_DT
like_JJ
._.
for_PIN
our_FPP1
efforts_NN
to_TO
expand_VB
our_FPP1
relationship_NN
endpoints_NN
._.
Also_RB
,_,
in_PIN
one_CD
of_PIN
our_FPP1
Phase_NN
3_CD
studies_NN
,_,
with_PIN
GI_NN
specialists_NN
and_CC
serve_VB
the_DT
growing_VBG
we_FPP1
utilized_VBD
a_DT
reference_NN
arm_NN
containing_VBG [WZPRES]
By_PIN
extending_VBG
and_PHC
optimizing_VBG
new_JJ
uses_NN
for_PIN
needs_NN
of_PIN
their_TPP3
patients_NN
,_,
affirms_VPRT [PUBV]
Mr_NN
Yasick_NN
._.
Asacol_NN
,_,
the_DT
market_NN
leader_NN
,_,
at_PIN
its_PIT
indicated_JJ
Shires_NN
products_NN
through_PIN
the_DT
GI_NN
STAT_NN
,_,
both_DT
in_PIN
dose_NN
,_,
notes_VPRT [PRIV]
Mr_NN
Yasick_NN
._.
Both_DT
products_NN
existing_VBG [WZPRES]
and_CC
in_PIN
new_JJ
territories_NN
,_,
Shire_NN
intends_VPRT [SUAV]
to_PIN
MESAVANCE_NN
milestone_NN
showed_VBD [PRIV]
improvement_NOMZ
in_PIN
symptoms_NN
compared_VBN
build_VB
a_DT
truly_RB
global_JJ
franchise_NN
in_PIN
this_DEMO
promising_JJ
The_DT
GI_NN
STAT_NN
achieved_VBD
a_DT
major_JJ
milestone_NN
to_PIN
a_DT
placebo_NN
._.
However_CONJ
,_,
MESAVANCE_NN
showed_VBD [PRIV]
market_NN
segment_NOMZ
._.
We_FPP1
have_VPRT
a_DT
team_NN
of_PIN
talented_VBN
in_PIN
2005_CD
with_PIN
the_DT
filing_NN
of_PIN
a_DT
NDA_NN
to_PIN
the_DT
FDA_NN
significantly_RB
higher_JJ
rates_NN
of_PIN
disease_NN
remission_NN
people_NN
with_PIN
a_DT
track_NN
record_NN
of_PIN
success_NN
in_PIN
GI_NN
and_CC
for_PIN
MESAVANCE_NN
,_,
which_WDT [SERE]
would_PRMD
be_VB [BEMA]
the_DT
first_JJ
versus_PIN
a_DT
placebo_NN
while_OSUB
Asacol_NN
did_VBD
not_XX0
._.
in_PIN
launching_VBG
products_NN
to_PIN
GI_NN
specialists_NN
,_,
says_VPRT [PUBV]
available_JJ
once-daily_RB
mesalamine_JJ
treatment_NOMZ
Mr_NN
Yasick_NN
._.
We_FPP1
intend_VPRT [SUAV]
to_TO
make_VB
the_DT
most_EMPH
of_PIN
this_DEMO
for_PIN
active_JJ
,_,
mild-to-moderate_JJ
UC_NN
._.
MAAs_NN
IBD_NN
is_VPRT [BEMA]
a_DT
life-long_JJ
disease_NN
that_TSUB
requires_VPRT [SUAV]
opportunity_NOMZ
we_FPP1
have_VPRT
to_TO
create_VB
a_DT
new_JJ
standard_NN
for_PIN
MESAVANCE_NN
were_VBD [PASS]
submitted_VBN [PUBV]
during_PIN
the_DT
constant_JJ
treatment_NOMZ
._.
Failing_VBG
to_TO [SPIN]
adequately_RB
treat_VB
for_PIN
the_DT
pharmaceuticals_NN
industry_NN
._.
Through_PIN
first_JJ
quarter_NN
of_PIN
2006_CD
to_PIN
the_DT
EMEA_NN
and_CC
the_DT
IBD_NN
can_POMD
lead_VB
to_PIN
greater_JJ
numbers_NN
of_PIN
flare-ups_NN
,_,
excellent_JJ
execution_NOMZ
,_,
we_FPP1
intend_VPRT [SUAV]
to_TO
prove_VB [PRIV]
the_DT
Canadian_JJ
Regulatory_NN
Authorities_NOMZ
._.
This_DEMP
is_VPRT [BEMA]
the_DT
more_EMPH
resource_NN
utilization_NOMZ
greater_JJ
cost_NN
,_,
poor_JJ
value_NN
of_PIN
the_DT
specialist_NN
pharmaceuticals_NN
model_NN
._.
first_RB
simultaneous_JJ
global_JJ
regulatory_JJ
filing_NN
for_PIN
quality_NOMZ
of_PIN
life_NN
,_,
and_ANDC
greater_JJ
risk_NN
of_PIN
colorectal_JJ
Shire_NN
and_CC
it_PIT
represents_VPRT
a_DT
terrific_JJ
effort_NN
by_PIN
the_DT
cancer_NN
._.
MESAVANCE_NN
meets_VPRT
a_DT
need_NN
in_PIN
the_DT
R&D_NN
team_NN
and_CC
the_DT
Product_NN
Strategy_NN
Team_NN
market_NN
to_TO
improve_VB
compliance_NN
and_CC
reduce_VB
pill_NN
5-aminosalicylic_JJ
acid_NN
or_CC
known_VBN [PRIV]
as_IN
mesalamine_NN
or_CC
mesalazine_NN
._.
It_PIT
also_RB
raises_VPRT
the_DT
level_NN
of_PIN
performance_NN
of_PIN
this_DEMO
class_NN
of_PIN
drugs_NN
._.
Going_VBG
Asacol_NN
is_VPRT [BEMA]
a_DT
trade_NN
mark_NN
of_PIN
Proctor_NN
&_CC
Gamble_NN
._.
beyond_IN
simple_JJ
symptom_NN
relief_NN
to_TO
inducing_VBG
disease_NN
remission_NN
is_VPRT [BEMA]
a_DT
significant_JJ
advance_NN
Study_NN
presented_VBD
November_NN
1_CD
,_,
2005_CD
at_PIN
the_DT
70th_JJ
Annual_JJ
in_PIN
treating_VBG
UC_NN
._.
Among_PIN
the_DT
pH_NN
dependent_JJ
American_JJ
College_NN
of_PIN
Gastroenterology_NN
in_PIN
Honolulu_NN
,_,
Hawaii_NN
._.
26_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:54_CD
Page_NN
27_CD
I_FPP1
help_VPRT
underserved_VBD
patients_NN
in_PIN
markets_NN
that_TSUB
represent_VPRT
new_JJ
areas_NN
of_PIN
growth_NN
for_PIN
Shire_NN
._.
Lynda_NN
Berne_NN
Executive_NN
Director_NN
,_,
Gastroenterology_NN
Nephrology_NN
,_,
US_FPP1
Marketing_GER
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:54_CD
Page_NN
28_CD
Operating_GER
review_NN
We_FPP1
have_VPRT [PEAS]
congured_VBN
Central_NN
Nervous_NN
System_NN
ourselves_FPP1
along_IN
product_NN
lines_NN
with_PIN
the_DT
some_QUAN
of_PIN
the_DT
best_JJ
people_NN
in_PIN
the_DT
industry_NN
working_VBG [WZPRES]
together_RB
to_TO
drive_VB
our_FPP1
growth_NN
strategy_NN
._.
Tom_NN
Anderson_NN
Vice_NN
President_NN
and_PHC
Commercial_NN
Leader_NN
,_,
CNS_NN
STAT_NN
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:54_CD
Page_NN
29_CD
01_CD
02_CD
03_CD
01_CD
Central_NN
Nervous_NN
System_NN
CNS_NN
Shires_VPRT
CNS_NN
STAT_NN
has_VPRT
a_DT
solid_JJ
record_NN
of_PIN
I_FPP1
enjoy_VPRT
working_VBG
for_PIN
a_DT
Company_NN
Ask_NN
Tom_NN
Anderson_NN
and_PHC
Gerardo_NN
Torres_NN
why_RB
achievement_NOMZ
to_TO
build_VB
on_PIN [STPR]
,_,
including_VBG [PRESP]
several_QUAN
that_DEMO
consistently_RB
puts_VPRT
its_PIT
faith_NN
they_TPP3
believe_VPRT [PRIV] [THATD]
Shire_NN
has_VPRT
one_CD
of_PIN
the_DT
strongest_JJ
milestones_NN
in_PIN
2005_CD
:_:
and_ANDC
trust_NN
in_PIN
its_PIT
people_NN
._.
franchises_NN
in_PIN
the_DT
high_JJ
potential_JJ
CNS_NN
segment_NOMZ
David_NN
Chapman_NN
of_PIN
the_DT
global_JJ
pharmaceutical_JJ
market_NN
and_PHC
ADDERALL_NN
XR_NN
,_,
Shires_NN
patented_VBD
novel_JJ
General_NN
Manager_NN
,_,
Transdermal_NN
,_,
theyll_NN
give_VPRT
three_CD
simple_JJ
reasons_NN
:_:
the_DT
right_JJ
formulation_NOMZ
of_PIN
ADDERALL_NN
that_TSUB
provides_VPRT
CNS_NN
STAT_NN
people_NN
,_,
a_DT
great_JJ
portfolio_NN
of_PIN
products_NN
,_,
and_ANDC
all-day_JJ
treatment_NOMZ
for_PIN
ADHD_NN
with_PIN
one_CD
daily_RB
a_DT
clear_JJ
strategy_NN
for_PIN
future_JJ
growth_NN
._.
dose_NN
,_,
continued_VBD
to_TO
be_VB [BEMA]
the_DT
most_EMPH
prescribed_JJ
02_CD
ADHD_NN
treatment_NOMZ
in_PIN
the_DT
US_FPP1
,_,
with_PIN
over_IN
26_CD
%_NN
Shire_NN
has_VPRT
a_DT
wealth_NN
of_PIN
opportunities_NOMZ
._.
We_FPP1
have_VPRT [PEAS]
configured_VBN
ourselves_FPP1
along_IN
product_NN
share_NN
of_PIN
the_DT
prescription_NOMZ
ADHD_NN
market_NN
:_:
My_FPP1
teams_NN
information_NOMZ
helps_VPRT
lines_NN
with_PIN
the_DT
some_QUAN
of_PIN
the_DT
best_JJ
people_NN
in_PIN
the_DT
us_FPP1
choose_VB
the_DT
best_JJ
ones_NN
._.
industry_NN
working_VBG [WZPRES]
together_RB
to_TO
drive_VB
our_FPP1
growth_NN
the_DT
FDA_NN
approved_VBD
ADDERALL_NN
XR_NN
Matt_NN
Handel_NN
strategy_NN
,_,
says_VPRT [PUBV]
Mr_NN
Anderson_NN
,_,
Vice_NN
President_NN
as_IN
a_DT
treatment_NOMZ
for_PIN
adolescents_NN
aged_VBN
Senior_JJ
Director_NN
of_PIN
Business_NOMZ
and_PHC
Commercial_NN
leader_NN
of_PIN
Shires_NN
CNS_NN
STAT_NN
._.
1317_CD
with_PIN
ADHD_NN
,_,
offering_VBG
continuity_NOMZ
Analysis_NN
And_CC
we_FPP1
have_VPRT
a_DT
proven_JJ
strategy_NN
for_PIN
acquiring_VBG
in_PIN
the_DT
management_NOMZ
of_PIN
ADHD_NN
symptoms_NN
and_CC
developing_VBG
unique_JJ
products_NN
that_TSUB
will_PRMD
as_RB
children_NN
become_VPRT
older_JJ
:_:
03_CD
serve_VPRT
unmet_JJ
needs_NN
going_VBG [WZPRES]
forward_RB
._.
Shires_NN
can_POMD
do_VB
attitude_NN
is_VPRT [BEMA]
a_DT
study_NN
presented_VBN [WZPAST]
at_PIN
the_DT
US_FPP1
Psychiatric_NN
invigorating_VBG [WZPRES]
and_PHC
sets_VPRT
us_FPP1
up_RP
Shires_NN
CNS_NN
STAT_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
driving_VBG
and_CC
Mental_NN
Health_NN
Congress_NN
in_PIN
Las_NN
Vegas_NN
for_PIN
long-term_JJ
success_NN
._.
CNS-related_JJ
product_NN
and_PHC
project_NN
strategies_NN
._.
demonstrated_VBD [PRIV]
that_THVC
adults_NN
with_PIN
ADHD_NN
David_NN
Baker_NN
Its_PIT
priorities_NOMZ
include_VPRT
continuing_VBG
to_TO
build_VB
and_PHC
experienced_VBD
significant_JJ
long-term_JJ
ADHD_NN
Vice_NN
President_NN
,_,
ADHD_NN
Marketing_GER
strengthen_VB
Shires_NN
position_NOMZ
as_IN
the_DT
leading_VBG
symptom_NN
control_NN
when_RB
treated_VBN
with_PIN
onceADHD_NN
pharmaceutical_JJ
Company_NN
in_PIN
the_DT
US_FPP1
,_,
daily_JJ
ADDERALL_NN
XR_NN
:_:
while_OSUB
building_VBG
a_DT
value-added_JJ
pipeline_NN
in_PIN
CNS_NN
therapeutic_JJ
areas_NN
that_TSUB
are_VPRT
traditionally_RB
poorly_RB
Health_NN
Canada_NN
reinstated_VBD
marketing_GER
served_VBD
,_,
through_PIN
in-licensing_GER
and_CC
other_JJ
means_NN
._.
authorization_NOMZ
of_PIN
ADDERALL_NN
XR_NN
following_VBG [WZPRES]
a_DT
six-month_JJ
suspension_NN
after_IN
accepting_VBG [PRIV]
Today_TIME
,_,
Shire_NN
has_VPRT
one_CD
of_PIN
the_DT
best_JJ
portfolio_NN
recommendations_NOMZ
made_VBN [WZPAST]
by_PIN
a_DT
New_NN
of_PIN
marketed_VBN
and_CC
development_NOMZ
drugs_NN
in_PIN
the_DT
Drug_NN
Committee_NN
:_:
ADHD_NN
business_NOMZ
,_,
notes_VPRT [PRIV]
Mr_NN
Anderson_NN
,_,
who_WP
has_VPRT
20_CD
years_NN
of_PIN
industry_NN
experience_NN
and_CC
the_DT
FDA_NN
issued_VBD
an_DT
approvable_JJ
letter_NN
for_PIN
a_DT
strong_JJ
commercial_JJ
background_NN
._.
We_FPP1
intend_VPRT [SUAV]
DAYTRANA_NN
,_,
the_DT
first_JJ
non-oral_JJ
medication_NOMZ
to_TO
continue_VB
to_TO
be_VB [BEMA]
the_DT
No._NN
._.
1_CD
ADHD_NN
Company_NN
,_,
for_PIN
ADHD_NN
designed_VBN [WZPAST]
for_PIN
once-daily_JJ
use_NN
to_TO
building_VBG
on_PIN
the_DT
success_NN
of_PIN
ADDERALL_NN
XR_NN
treat_VB
ADHD_NN
in_PIN
children_NN
aged_VBN
612_CD
._.
Shire_NN
while_OSUB
introducing_VBG
multiple_JJ
new_JJ
products_NN
with_PIN
since_OSUB
received_VBN
FDA_NN
approval_NN
in_PIN
April_NN
2006_CD
unique_JJ
benefits_NN
to_PIN
patients_NN
._.
At_PIN
the_DT
same_JJ
time_NN
,_,
for_PIN
this_DEMO
product_NN
and_CC
is_VPRT
targeting_VBG
a_DT
launch_NN
we_FPP1
will_PRMD
make_VB
sure_JJ
our_FPP1
other_JJ
CNS_NN
products_NN
in_PIN
the_DT
US_FPP1
by_PIN
mid-2006_NN
:_:
are_VPRT [BEMA]
successful_PRED
and_CC
look_VB
at_PIN
adding_VBG [PUBV]
drugs_NN
for_PIN
other_JJ
diseases_NN
in_PIN
CNS_NN
where_RB
we_FPP1
a_DT
NDA_NN
was_VBD [PASS]
filed_VBN
with_PIN
the_DT
FDA_NN
for_PIN
the_DT
can_POMD
succeed_VB
with_PIN
the_DT
specialist_NN
model_NN
._.
investigational_JJ
compound_NN
NRP104_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
ADHD_NN
in_PIN
children_NN
aged_VBN
612_CD
._.
Wealth_NN
of_PIN
experience_NN
This_DEMP
cleared_VBD
the_DT
way_NN
for_PIN
Shire_NN
and_PHC
partner_NN
These_DEMO
efforts_NN
are_VPRT
being_VBG [BYPA]
supported_VBN
by_PIN
what_WP
New_NN
River_NN
to_TO
work_VB
toward_PIN
an_DT
approval_NN
and_PHC
Dr_NN
Torres_NN
describes_VPRT
as_IN
a_DT
unique_JJ
team_NN
with_PIN
subsequent_JJ
launch_NN
in_PIN
late_TIME
2006_CD
early_TIME
2007_CD
:_:
a_DT
wealth_NN
of_PIN
industry_NN
experience_NN
covering_VBG [WZPRES]
all_QUAN
and_CC
domains_NN
._.
Dr_NN
Torres_NN
is_VPRT [BEMA]
the_DT
Vice_NN
President_NN
and_PHC
Scientific_NN
Leader_NN
for_PIN
the_DT
CNS_NN
STAT_NN
._.
He_TPP3
says_VPRT [PUBV] [THATD]
Shire_NN
progressed_VBN [WZPAST]
with_PIN
plans_NN
to_TO
file_VB
NDAs_NN
the_DT
degree_NN
of_PIN
energy_NN
at_PIN
Shire_NN
is_VPRT [BEMA]
incredible_PRED
._.
with_PIN
the_DT
FDA_NN
for_PIN
SPD465_NN
,_,
a_DT
longer-acting_JJ
One_CD
of_PIN
my_FPP1
favorite_JJ
aspects_NN
of_PIN
this_DEMO
job_NN
formulation_NOMZ
of_PIN
ADDERALL_NN
XR_NN
,_,
and_ANDC
SPD503_NN
,_,
is_VPRT
brainstorming_VBG
with_PIN
groups_NN
of_PIN
such_JJ
bright_JJ
a_DT
non-stimulant_JJ
treatment_NOMZ
for_PIN
ADHD_NN
._.
people_NN
,_,
with_PIN
their_TPP3
wide-ranging_JJ
expertise_NN
and_CC
innovative_JJ
ideas_NN
._.
Study_NN
presented_VBD
November_NN
8_CD
,_,
2005_CD
at_PIN
the_DT
US_FPP1
Psychiatric_NN
and_PHC
Mental_NN
Health_NN
Congress_NN
in_PIN
Las_NN
Vegas_NN
,_,
NV_NN
._.
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
29_CD
Shire_NN
plc_NN
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:54_CD
Page_NN
30_CD
Operating_GER
review_NN
Central_NN
Nervous_NN
System_NN
04_CD
05_CD
06_CD
04_CD
The_DT
ADHD_NN
market_NN
has_VPRT [PEAS]
become_VBN
increasingly_RB
Cilag_NN
under_IN
the_DT
trade_NN
name_NN
REMINYL_NN
XR_NN
,_,
Shire_NN
has_VPRT
a_DT
tremendous_JJ
team_NN
competitive_JJ
,_,
notes_NN
Mr_NN
Anderson_NN
._.
Strong_JJ
with_PIN
the_DT
exception_NOMZ
of_PIN
the_DT
US_FPP1
where_RB
in_PIN
place_NN
and_CC
we_FPP1
can_POMD [SPAU]
now_TIME
see_VB [PRIV]
that_THVC
market_NN
growth_NN
over_IN
the_DT
last_JJ
few_QUAN
years_NN
has_VPRT
it_PIT
is_VPRT [PASS]
marketed_VBN
under_IN
the_DT
trade_NN
name_NN
the_DT
results_NN
of_PIN
years_NN
of_PIN
hard_JJ
work_NN
made_VBD
this_DEMO
a_DT
very_AMP
attractive_JJ
area_NN
for_PIN
drug_NN
RAZADYNE_NN
:_:
and_ANDC
are_VPRT
paying_VBG
off_PIN [STPR]
._.
companies_NN
,_,
and_ANDC
we_FPP1
now_TIME
have_VPRT
multiple_JJ
Simon_NN
Tulloch_NN
companies_NN
competing_VBG [WZPRES]
with_PIN
their_TPP3
products_NN
EQUETRO_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
Bipolar_NN
1_CD
Senior_JJ
Vice_NN
President_NN
,_,
CNS_NN
STAT_NN
for_PIN
the_DT
same_JJ
patients_NN
._.
In_PIN
this_DEMO
environment_NOMZ
,_,
Disorder_NN
,_,
was_VBD [PASS]
launched_VBN
in_PIN
the_DT
US_FPP1
in_PIN
April_NN
._.
new_JJ
products_NN
have_VPRT
to_TO
be_VB [BEMA]
clearly_RB
different_PRED
An_DT
efficacy_NN
study_NN
presented_VBN [WZPAST]
by_PIN
University_NOMZ
of_PIN
05_CD
from_PIN
what_WP
is_VPRT [BEMA]
out_PIN
there_RB
,_,
and_ANDC
this_DEMP
means_VPRT [PRIV] [THATD]
they_TPP3
North_NN
Carolina_NN
researchers_NN
presented_VBN [WZPAST]
at_PIN
the_DT
The_NN
General_NN
Manager_NN
position_NOMZ
at_PIN
must_NEMD
have_VB
important_JJ
efficacy_NN
and_PHC
safety_NN
US_FPP1
Psychiatric_NN
and_PHC
Mental_NN
Health_NN
Congress_NN
Shire_NN
is_VPRT [BEMA]
a_DT
great_JJ
opportunity_NOMZ
to_TO
lead_VB
benefits_NN
that_TOBJ
other_JJ
products_NN
do_VPRT
not_XX0
._.
in_PIN
Las_NN
Vegas_NN
in_PIN
November_NN
demonstrated_VBD [PRIV]
the_DT
functional_JJ
teams_NN
to_TO
drive_VB
better_JJ
that_THAC
EQUETRO_NN
significantly_RB
reduced_VBD
manic_JJ
decision-making_NN
and_PHC
results_NN
._.
Future_JJ
growth_NN
and_CC
mixed_JJ
symptoms_NN
for_PIN
patients_NN
and_PHC
Mark_NN
Charles_NN
Shires_NN
portfolio_NN
of_PIN
marketed_VBN
and_CC
development_NOMZ
was_VBD
generally_RB
well_RB
tolerated_JJ
._.
We_FPP1
believe_VPRT [PRIV]
CNS_NN
STAT_NN
,_,
General_NN
Manager_NN
drugs_NN
make_VPRT
it_PIT
very_AMP
well_RB
positioned_VBN
in_PIN
ADHD_NN
EQUETRO_NN
brings_VPRT
unique_JJ
benefits_NN
to_PIN
SPD503_CD
Dr_NN
Torres_NN
adds_VPRT [PUBV]
._.
Our_FPP1
vision_NN
is_VPRT
to_TO
have_VB
several_QUAN
patients_NN
and_CC
their_TPP3
families_NN
while_OSUB
offering_VBG
unique_JJ
products_NN
serving_VBG [WZPRES]
most_EMPH
if_COND
not_XX0
all_QUAN
types_NN
physicians_NN
a_DT
useful_JJ
option_NOMZ
in_PIN
the_DT
treatment_NOMZ
06_CD
of_PIN
ADHD_NN
patient_NN
._.
Our_FPP1
development_NOMZ
products_NN
of_PIN
manic_JJ
and_PHC
mixed_JJ
episodes_NN
in_PIN
bipolar_NN
Focused_VBN
,_,
cross-functional_JJ
product_NN
are_VPRT [BEMA]
all_QUAN
different_JJ
and_CC
serve_VB
different_JJ
patient_NN
disorders_NN
says_VPRT [PUBV]
Dr_NN
Torres_NN
._.
teams_NN
with_PIN
visionary_JJ
leadership_NN
needs_VPRT
on_PIN
a_DT
more_EMPH
individual_JJ
basis_NN
._.
DAYTRANA_NN
,_,
will_PRMD
drive_VB
Shires_NN
future_JJ
success_NN
._.
for_CONJ
example_NULL
,_,
will_PRMD
offer_VB
patients_NN
an_DT
alternative_JJ
Mr_NN
Anderson_NN
says_VPRT [PUBV]
the_DT
CNS_NN
STAT_NN
is_VPRT
refining_VBG
Michael_NN
Skoien_NN
route_NN
of_PIN
delivery_NN
for_PIN
methylphenidate_NN
no_SYNE
plans_NN
to_TO
make_VB
sure_JJ
Shire_NN
has_VPRT
the_DT
right_JJ
Vice_NN
President_NN
and_PHC
General_NN
pill_NN
swallowing_VBG [WZPRES]
but_CC
a_DT
transdermal_JJ
patch_NN
._.
marketing_GER
support_NN
,_,
geographic_JJ
spread_NN
and_PHC
Manager_NN
,_,
ADDERALL_NN
CNS_NN
STAT_NN
NRP104_NN
could_POMD
be_VB [BEMA]
better_PRED
than_PIN
current_JJ
product_NN
life_NN
cycle_NN
management_NOMZ
._.
It_PIT
is_VPRT
striving_VBG
amphetamine_NN
and_CC
other_JJ
products_NN
in_PIN
that_DEMO
it_PIT
to_TO
build_VB
a_DT
value-added_JJ
pipeline_NN
for_PIN
the_DT
CNS_NN
may_POMD
offer_VB
lower_JJ
diversion_NN
and_PHC
abuse_NN
potential_NN
._.
area_NN
by_PIN
looking_VBG
for_PIN
opportunities_NOMZ
to_PIN
in-license_JJ
Moreover_CONJ
,_,
we_FPP1
are_VPRT [BEMA]
always_RB
on_PIN
the_DT
lookout_NN
for_PIN
drugs_NN
already_RB
under_IN
development_NOMZ
._.
With_PIN
new_JJ
opportunities_NOMZ
and_CC
are_VPRT [BEMA]
clearly_RB
interested_PRED
our_FPP1
new_JJ
product_NN
focus_NN
and_CC
cross-functional_JJ
in_PIN
new_JJ
ADHD_NN
treatments_NOMZ
._.
organization_NOMZ
,_,
it_PIT
will_PRMD [SPAU]
now_TIME
be_VB [BEMA]
easier_PRED
to_TO
set_VB
parameters_NN
for_PIN
the_DT
types_NN
of_PIN
products_NN
we_FPP1
Shires_VPRT
other_JJ
drugs_NN
in_PIN
its_PIT
CNS_NN
portfolio_NN
also_RB
want_VPRT
to_TO
develop_VB
._.
We_FPP1
will_PRMD [SPAU]
also_RB
be_VB
taking_VBG
performed_VBN
well_RB
in_PIN
2005_CD
._.
a_DT
fresh_JJ
look_NN
at_PIN
other_JJ
disease_NN
states_NN
within_PIN
CNS_NN
where_RB
a_DT
specialist_NN
company_NN
such_JJ
as_IN
CARBATROL_NN
,_,
Shires_NN
extended-release_NN
ours_PRP
can_POMD
succeed_VB
with_PIN
a_DT
limited_JJ
sales_NN
force_NN
._.
formulation_NOMZ
of_PIN
carbamazepine_NN
for_PIN
the_DT
Shire_NN
has_VPRT
a_DT
longstanding_JJ
treatment_NOMZ
of_PIN
epilepsy_NN
,_,
continued_VBD
to_TO
hold_VB [PRIV]
Dr_NN
Torres_NN
adds_VPRT [PUBV]
that_THVC
Shires_NN
new_JJ
business_NOMZ
commitment_NOMZ
to_PIN
understanding_GER
and_CC
a_DT
significant_JJ
share_NN
of_PIN
the_DT
US_FPP1
prescription_NOMZ
model_NN
is_VPRT
ensuring_VBG [SUAV] [PRIV]
that_THVC
it_PIT
operates_VPRT
more_EMPH
addressing_VBG
the_DT
treatment_NOMZ
needs_VPRT
market_NN
in_PIN
its_PIT
category_NN
._.
CARBATROL_NN
consistently_RB
and_CC
makes_VPRT
the_DT
best_JJ
use_NN
of_PIN
its_PIT
of_PIN
children_NN
,_,
adolescents_NN
,_,
and_ANDC
continues_VPRT
to_TO
be_VB [BEMA]
an_DT
important_JJ
product_NN
resources_NN
._.
It_PIT
is_VPRT
allowing_VBG [SUAV]
for_PIN
better_JJ
alignment_NOMZ
adults_NN
with_PIN
ADHD_NN
._.
Their_TPP3
portfolio_NN
of_PIN
for_PIN
us_FPP1
notes_VPRT [PRIV]
Dr_NN
Torres_NN
:_:
between_PIN
our_FPP1
commercial_JJ
and_CC
R&D_NN
functions_NOMZ
._.
currently_RB
available_JJ
and_CC
medicationsIt_NN
is_VPRT [BEMA]
critically_RB
important_PRED
that_THAC
our_FPP1
marketing_GER
in-development_NOMZ
clearly_RB
signal_VB
their_TPP3
REMINYL_NN
XR_NN
,_,
a_DT
once-daily_JJ
treatment_NOMZ
plans_NN
are_VPRT [BEMA]
congruent_PRED
with_PIN
our_FPP1
plans_NN
for_PIN
intention_NOMZ
to_TO
continue_VB
being_VBG [BEMA]
a_DT
leader_NN
designed_VBN
to_TO
slow_VB
the_DT
progression_NN
of_PIN
the_DT
developing_VBG
new_JJ
products_NN
and_CC
this_DEMO
approach_NN
in_PIN
this_DEMO
field_NN
._.
symptoms_NN
of_PIN
Alzheimers_NN
Disease_NN
,_,
was_VBD
will_PRMD
help_VB
us_FPP1
get_VB
the_DT
right_JJ
products_NN
to_PIN
market_NN
Dr_NN
Timothy_NN
E._NN
Wilens_NN
launched_VBN [WZPAST]
by_PIN
Shire_NN
in_PIN
the_DT
United_NN
Kingdom_NN
in_PIN
a_DT
reasonable_JJ
time_NN
frame_NN
._.
Our_FPP1
ultimate_JJ
goal_NN
Associate_NN
Professor_NN
of_PIN
Psychiatry_NN
and_PHC
Ireland_NN
in_PIN
June_NN
._.
REMINYL_NN
is_VPRT [BEMA]
one_CD
of_PIN
the_DT
is_VPRT
to_TO
have_VB
a_DT
strong_JJ
portfolio_NN
of_PIN
global_JJ
products_NN
at_PIN
Harvard_NN
Medical_NN
School_NN
,_,
Boston_NN
,_,
main_JJ
products_NN
for_PIN
treating_VBG
mild-to-moderate_JJ
and_CC
we_FPP1
are_VPRT [BEMA]
well_RB
on_PIN
our_FPP1
way_NN
._.
Massachusetts_NN
dementia_NN
of_PIN
the_DT
Alzheimer_NN
type_NN
,_,
and_ANDC
is_VPRT [PASS]
Data_NN
presented_VBN
May_POMD
24_CD
,_,
2005_CD
at_PIN
the_DT
American_JJ
licensed_JJ
for_PIN
use_NN
in_PIN
more_EMPH
than_PIN
70_CD
countries_NN
._.
Psychiatric_NN
Association_NOMZ
in_PIN
Atlanta_NN
,_,
GA_NN
and_PHC
study_NN
Outside_PLACE
the_DT
UK_NN
and_PHC
Ireland_NN
,_,
this_DEMO
product_NN
is_VPRT [PASS]
presented_VBN
November_NN
8_CD
,_,
2005_CD
at_PIN
the_DT
US_FPP1
Psychiatric_NN
marketed_VBN [WZPAST]
by_PIN
Johnson_NN
&_CC
Johnson_NN
Janssen_NN
and_PHC
Mental_NN
Health_NN
Congress_NN
in_PIN
Las_NN
Vegas_NN
,_,
NV_NN
._.
30_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:54_CD
Page_NN
31_CD
Shire_NN
has_VPRT
one_CD
of_PIN
the_DT
best_JJ
portfolios_NN
of_PIN
marketed_VBN
and_CC
development_NOMZ
drugs_NN
in_PIN
the_DT
ADHD_NN
business_NOMZ
._.
Gerardo_NN
Torres_NN
Vice_NN
President_NN
and_PHC
Scientific_NN
Leader_NN
,_,
CNS_NN
STAT_NN
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:54_CD
Page_NN
32_CD
Operating_GER
review_NN
We_FPP1
have_VPRT [PEAS]
advanced_VBN
Human_NN
Genetic_NN
Therapies_NN
technologies_NN
and_CC
a_DT
clear_JJ
mission_NN
._.
David_NN
Pendergast_NN
Executive_NN
Vice_NN
President_NN
and_PHC
General_NN
Manager_NN
,_,
Shire_NN
HGT_NN
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:54_CD
Page_NN
33_CD
01_CD
02_CD
01_CD
Human_NN
Genetics_NN
Therapies_NN
Shire_NN
HGT_NN
High-potential_JJ
market_NN
We_FPP1
have_VPRT
unparalleled_JJ
technology_NN
Shires_VPRT
new_JJ
HGT_NN
team_NN
,_,
the_DT
former_JJ
TKT_NN
,_,
Dr_NN
Pendergast_NN
notes_VPRT [PRIV]
that_THVC
the_DT
evolution_NOMZ
of_PIN
the_DT
to_TO
develop_VB
treatment_NOMZ
for_PIN
genetic_JJ
specializes_VPRT
in_PIN
discovering_VBG [PRIV]
,_,
developing_VBG
biotechnology_NN
sciences_NN
has_VPRT [PEAS]
allowed_VBN [SUAV]
for_PIN
the_DT
diseases_NN
and_CC
I_FPP1
am_VPRT [BEMA]
very_AMP
proud_PRED
to_TO
and_CC
commercializing_VBG
protein_NN
therapeutics_NN
engineering_GER
of_PIN
proteins_NN
and_CC
producing_VBG
them_TPP3
be_VB
part_NN
of_PIN
the_DT
team_NN
that_DEMP
is_VPRT
making_VBG
primarily_RB
for_PIN
the_DT
treatment_NOMZ
of_PIN
genetic_JJ
diseases_NN
._.
Combined_VBN [PASTP]
with_PIN
the_DT
these_DEMO
therapies_NN
possible_JJ
!_.
This_DEMO
business_NOMZ
extends_VPRT
Shires_NN
reach_NN
by_PIN
discovery_NN
of_PIN
inherent_JJ
and_CC
engineered_VBN
means_NN
David_NN
Whiteman_NN
strengthening_VBG [WZPRES]
its_PIT
portfolio_NN
and_PHC
pipeline_NN
with_PIN
of_PIN
delivering_VBG
proteins_NN
to_PIN
cells_NN
throughout_PIN
the_DT
Principal_NN
Medical_NN
Director_NN
,_,
a_DT
range_NN
of_PIN
new_JJ
therapeutic_JJ
possibilities_NOMZ
body_NN
,_,
this_DEMP
provides_VPRT
great_JJ
potential_JJ
to_TO
address_VB
Shire_NN
HGT_NN
for_PIN
patients_NN
suffering_VBG [WZPRES]
with_PIN
genetic_JJ
diseases_NN
._.
a_DT
number_NN
of_PIN
serious_JJ
diseases_NN
previously_TIME
not_XX0
approachable_JJ
with_PIN
drug_NN
therapies_NN
._.
The_DT
number_NN
02_CD
By_PIN
adding_VBG [PUBV]
the_DT
proprietary_JJ
protein_NN
technologies_NN
of_PIN
these_DEMO
diseases_NN
is_VPRT [BEMA]
large_PRED
since_OSUB
there_EX
is_VPRT
the_DT
Im_NN
very_AMP
excited_JJ
about_IN
our_FPP1
of_PIN
TKT_NN
to_PIN
the_DT
proven_VBN
commercialization_NOMZ
knowpotential_NN
for_PIN
a_DT
single_JJ
gene_NN
mutation_NOMZ
to_TO
occur_VB
ability_NOMZ
to_TO [SPIN]
truly_RB
make_VB
a_DT
difference_NN
how_RB
of_PIN
Shire_NN
,_,
weve_JJ
generated_VBD
an_DT
entity_NOMZ
worth_NN
with_PIN
any_QUAN
birth_NN
and_CC
we_FPP1
have_VPRT [PEAS]
had_VBN
centuries_NN
in_PIN
patients_NN
lives_NN
._.
far_PLACE
more_EMPH
than_PIN
the_DT
sum_NN
of_PIN
its_PIT
parts_NN
,_,
says_VPRT [PUBV]
David_NN
of_PIN
evolution_NOMZ
for_PIN
these_DEMO
problems_NN
to_TO
develop_VB
._.
Andrew_NN
Komjathy_NN
Pendergast_NN
,_,
Shire_NN
HGTs_NN
Executive_NN
Vice_NN
At_PIN
this_DEMO
time_NN
protein_NN
replacement_NOMZ
therapy_NN
Vice_NN
President_NN
,_,
Commercial_NN
President_NN
and_PHC
General_NN
Manager_NN
._.
Together_RB
,_,
is_VPRT [BEMA]
often_RB
the_DT
only_DWNT
treatment_NOMZ
for_PIN
these_DEMO
patients_NN
._.
Operations_NOMZ
weve_NN
signalled_VBD
our_FPP1
intention_NOMZ
to_TO
continue_VB
growing_VBG
as_IN
market_NN
leaders_NN
in_PIN
serving_VBG
specialist_NN
Shire_NN
HGT_NN
employs_VPRT
slightly_DWNT
more_EMPH
than_PIN
500_CD
03_CD
physicians_NN
and_CC
their_TPP3
patients_NN
._.
individuals_NN
worldwide_JJ
and_CC
has_VPRT
a_DT
presence_NN
Breakthrough_NN
products_NN
and_CC
in_PIN
those_DEMO
countries_NN
which_WDT [WHSUB]
reimburse_VPRT
protein_NN
exceptional_JJ
staff_NN
make_VPRT
Shire_NN
TKT_NN
,_,
acquired_VBN [PASTP]
in_PIN
2005_CD
,_,
is_VPRT [BEMA]
an_DT
excellent_JJ
therapies_NN
for_PIN
genetic_JJ
diseases_NN
and_ANDC
where_RB
a_DT
great_JJ
place_NN
to_TO
work_VB
!_.
strategic_JJ
fit_NN
for_PIN
Shire_NN
,_,
adds_VPRT [PUBV]
Dr_NN
Pendergast_NN
,_,
patient_JJ
populations_NOMZ
warrant_VPRT
a_DT
presence_NN
._.
Jerry_NN
Justin_NN
former_JJ
executive_NN
vice_NN
president_NN
and_PHC
chief_NN
Based_VBN [WZPAST]
in_PIN
Cambridge_NN
,_,
Massachusetts_NN
the_DT
team_NN
Senior_JJ
Director_NN
Manufacturing_GER
operating_VBG [WZPRES]
officer_NN
of_PIN
TKT_NN
who_WP [WHSUB]
has_VPRT
33_CD
years_NN
is_VPRT [BEMA]
at_PIN
work_NN
on_PIN
a_DT
number_NN
of_PIN
exciting_JJ
scientific_JJ
Operations_NOMZ
,_,
Shire_NN
HGT_NN
of_PIN
pharmaceutical_JJ
industry_NN
experience_NN
._.
Both_DT
Shire_NN
and_PHC
TKT_NN
leverage_NN
relationships_NN
04_CD
with_PIN
highly_AMP
specialized_VBN
physicians_NN
and_CC
focus_VB
We_FPP1
use_VB
several_QUAN
technologies_NN
including_VBG [WZPRES]
gene_NN
We_FPP1
are_VPRT [PASS]
committed_VBN
to_TO
accelerating_VBG
on_PIN
the_DT
development_NOMZ
of_PIN
products_NN
that_TSUB
offer_VPRT
activation_NOMZ
,_,
fusion_NN
proteins_NN
,_,
and_ANDC
standard_JJ
the_DT
development_NOMZ
of_PIN
protein_NN
a_DT
strong_JJ
benefit-to-risk_NN
ratio_NN
._.
Both_DT
also_RB
care_VB
transfections_NOMZ
,_,
explains_VPRT [PUBV]
Dr_NN
Pendergast_NN
._.
enormously_AMP
for_PIN
the_DT
patients_NN
and_PHC
families_NN
that_TOBJ
Our_FPP1
approach_NN
for_PIN
glycoproteins_NN
is_VPRT
to_TO
use_VB
Yas_NN
Saotome_NN
are_VPRT [SPAU] [BYPA]
ultimately_RB
served_VBN
by_PIN
our_FPP1
product_NN
lines_NN
._.
human_JJ
cells_NN
either_CC
employing_VBG
gene_NN
activation_NOMZ
Senior_JJ
Director_NN
,_,
Cell_NN
culture_NN
or_CC
standard_JJ
methods_NN
._.
This_DEMO
approach_NN
yields_NN
Process_NN
Development_NOMZ
Shire_NN
HGT_NN
provides_VPRT
specific_JJ
disease_NN
area_NN
a_DT
truly_RB
human_JJ
molecule_NN
in_PIN
both_DT
the_DT
amino_JJ
acid_NN
expertise_NN
,_,
a_DT
high-quality_JJ
product_NN
portfolio_NN
sequence_NN
and_CC
the_DT
carbohydrate_NN
structure_NN
and_CC
a_DT
low-risk_JJ
,_,
well-balanced_JJ
development_NOMZ
thereby_RB
making_VBG
the_DT
therapy_NN
highly_AMP
active_JJ
and_CC
pipeline_NN
with_PIN
one_CD
marketed_VBN
product_NN
and_CC
less_JJ
immunogenic_JJ
._.
two_CD
attractive_JJ
late-stage_NN
products_NN
directed_VBD
at_PIN
genetic_JJ
diseases_NN
._.
In_CONJ
addition_NULL
,_,
protein_NN
Dr_NN
Pendergast_NN
notes_VPRT [PRIV]
that_THVC
genetic_JJ
disease_NN
replacement_NOMZ
therapy_NN
provides_VPRT
a_DT
good_JJ
platform_NN
research_NN
is_VPRT [BEMA]
less_RB
risky_PRED
than_PIN
traditional_JJ
for_PIN
further_JJ
expansion_NN
through_PIN
research_NN
and_CC
pharmaceutical_JJ
research_NN
._.
The_DT
diseases_NN
and_PHC
product_NN
in-licensing_GER
._.
Shire_NN
HGTs_NN
approach_VPRT
their_TPP3
causes_NN
are_VPRT [SPAU] [PASS]
well_RB
known_VBN [PRIV]
,_,
the_DT
treatment_NOMZ
to_PIN
product_NN
development_NOMZ
is_VPRT
to_TO
use_VB
protein_NN
path_NN
clear_JJ
,_,
and_ANDC
if_COND
we_FPP1
get_VPRT
good_JJ
animal_NN
model_NN
therapies_NN
to_TO
replace_VB
lost_VBN
biological_JJ
function_NOMZ
data_NN
,_,
the_DT
likelihood_NN
of_PIN
a_DT
late_TIME
stage_NN
project_NN
resulting_VBG [WZPRES]
from_PIN
a_DT
malfunctioning_GER
or_CC
missing_VBG
failure_NN
is_VPRT [BEMA]
low_PRED
._.
Hunter_NN
patients_NN
who_WP [WHSUB]
will_PRMD
receive_VB
gene_NN
in_PIN
affected_JJ
patients_NN
._.
It_PIT
does_VPRT
not_XX0
conduct_VB
ELAPRASE_NN
are_VPRT [PASS]
set_VBN
to_TO
have_VB
high-risk_JJ
discovery_NN
research_NN
and_PHC
protein_NN
a_DT
brighter_NN
future_NN
and_CC
I_FPP1
am_VPRT [BEMA]
glad_JJ
replacement_NOMZ
therapies_NN
generally_RB
benefit_VPRT
from_PIN
that_DEMO
I_FPP1
took_VBD
part_NN
in_PIN
the_DT
development_NOMZ
fast_RB
development_NOMZ
timelines_NN
._.
These_DEMO
drugs_NN
have_VPRT
of_PIN
this_DEMO
new_JJ
treatment_NOMZ
._.
a_DT
high_JJ
success_NN
rate_NN
in_PIN
reaching_VBG
the_DT
market_NN
Adam_NN
Cohen_NN
and_CC
normally_RB
benefit_NN
from_PIN
long_JJ
lifecycles_NN
Hunter_NN
Syndrome_NN
patient_NN
and_CC
once_TIME
marketed_VBN
due_JJ
to_PIN
orphan_JJ
drug_NN
status_NN
Elaprase_NN
clinical_JJ
trial_NN
participant_NN
._.
exclusivity_NOMZ
seven_CD
years_NN
in_PIN
the_DT
US_FPP1
and_CC
ten_CD
years_NN
in_PIN
the_DT
EU_NN
and_CC
robust_JJ
patent_NN
protection_NOMZ
._.
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
33_CD
Shire_NN
plc_NN
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:54_CD
Page_NN
34_CD
Operating_GER
review_NN
Human_NN
Genetic_NN
Therapies_NN
03_CD
04_CD
Shire_NN
HGT_NN
works_VPRT
on_PIN
genetic_JJ
diseases_NN
ELAPRASE_NN
:_:
An_DT
enzyme_NN
replacement_NOMZ
A_DT
focused_VBN
team_NN
with_PIN
serious_JJ
mortality_NOMZ
and_PHC
morbidity_NOMZ
effects_NN
therapy_NN
in_PIN
registration_NOMZ
since_OSUB
December_NN
Since_OSUB
the_DT
acquisition_NOMZ
of_PIN
TKT_NN
by_PIN
Shire_NN
on_PIN
patients_NN
that_TSUB
are_VPRT [BEMA]
amenable_PRED
to_PIN
protein_NN
2005_CD
for_PIN
the_DT
treatment_NOMZ
of_PIN
Hunter_NN
Syndrome_NN
._.
Dr_NN
Pendergast_NN
has_VPRT [PEAS]
overseen_VBN
a_DT
complex_JJ
replacement_NOMZ
therapy_NN
._.
One_CD
large_JJ
category_NN
is_VPRT [BEMA]
The_DT
product_NN
has_VPRT [PEAS]
gained_VBN
fast_JJ
track_NN
status_NN
transition_NOMZ
and_CC
built_VBD
a_DT
business_NOMZ
and_PHC
Lysosomal_NN
Storage_NN
Diseases_NN
LSDs_NN
resulting_VBG [WZPRES]
in_PIN
the_DT
US_FPP1
and_PHC
Shire_NN
hopes_VPRT [PRIV] [THATD]
it_PIT
will_PRMD
be_VB
management_NOMZ
team_NN
that_DEMP
is_VPRT [PASS]
focused_VBN
on_PIN
from_PIN
the_DT
bodys_NN
inability_NOMZ
to_TO
produce_VB
a_DT
specific_JJ
launched_VBN
in_PIN
mid-2006_NN
._.
Shire_NN
also_RB
submitted_VBD [PUBV]
protein_NN
therapies_NN
for_PIN
genetic_JJ
diseases_NN
and_PHC
enzyme_NN
designed_VBN
to_TO
metabolize_VB
different_JJ
a_DT
MAA_NN
to_PIN
the_DT
EMEA_NN
for_PIN
idursulfase_NN
and_CC
the_DT
is_VPRT [PASS]
organized_VBN
around_PLACE
four_CD
critical_JJ
business_NOMZ
waste_NN
products_NN
._.
These_DEMO
products_NN
build_VPRT
up_RP
subsequent_JJ
review_NN
is_VPRT [PASS]
expected_VBN [PRIV]
to_TO
take_VB
processes_NN
:_:
discovery_NN
,_,
development_NOMZ
,_,
in_PIN
the_DT
lysosomes_NN
of_PIN
cells_NN
over_IN
time_NN
resulting_VBG [WZPRES]
in_PIN
12_CD
months_NN
._.
Hunter_NN
Syndrome_NN
,_,
also_RB
known_VBN [PRIV]
supply_NN
and_PHC
sales_NN
._.
We_FPP1
are_VPRT [SPAU] [PASS]
well_RB
positioned_VBN
the_DT
engorgement_NOMZ
of_PIN
cell_NN
lysosomes_NN
,_,
cell_NN
stress_NN
as_IN
II_NN
MPS_NN
II_NN
for_PIN
success_NN
because_CAUS
we_FPP1
have_VPRT
a_DT
culture_NN
that_DEMP
and_CC
death_NN
followed_VBN [WZPAST]
by_PIN
tissue_NN
distress_NN
and_CC
is_VPRT [BEMA]
a_DT
rare_JJ
,_,
life_NN
threatening_JJ
genetic_JJ
disorder_NN
is_VPRT [BEMA]
very_AMP
committed_PRED
,_,
focused_VBD
,_,
team_NN
oriented_VBN
,_,
organ_NN
failure_NN
._.
LSDs_NN
can_POMD
interfere_VB
with_PIN
the_DT
caused_VBN
by_PIN
a_DT
lack_NN
of_PIN
the_DT
enzyme_NN
iduronateopen_NN
,_,
science_NN
based_VBN
and_CC
data_NN
driven_VBN
._.
central_JJ
nervous_JJ
system_NN
in_PIN
ways_NN
that_TSUB
can_POMD
often_RB
2-sulfatase_JJ
._.
Symptoms_NN
include_VPRT
hernias_NN
,_,
His_TPP3
favorite_JJ
parts_NN
of_PIN
the_DT
job_NN
are_VPRT
developing_VBG
have_VPRT
a_DT
distressing_JJ
physical_JJ
effect_NN
._.
Often_RB
named_VBN
frequent_JJ
ear_NN
infections_NOMZ
,_,
enlarged_JJ
livers_NN
and_PHC
therapies_NN
that_TSUB
help_VPRT
patients_NN
and_CC
working_VBG
with_PIN
for_PIN
the_DT
physician_NN
that_TSUB
first_RB
described_VBD
them_TPP3
spleens_VPRT
,_,
reduced_VBN
respiratory_JJ
capability_NOMZ
,_,
joint_JJ
bright_JJ
people_NN
to_TO
solve_VB
problems_NN
._.
Our_FPP1
team_NN
clinically_RB
,_,
these_DEMO
conditions_NOMZ
are_VPRT [PASS]
today_TIME
known_VBN [PRIV]
malformations_NOMZ
,_,
short_JJ
stature_NN
and_CC
cardiac_JJ
has_VPRT
a_DT
broad_JJ
range_NN
of_PIN
experiences_NN
and_CC
as_IN
Fabry_NN
Disease_NN
,_,
Hunter_NN
Syndrome_NN
,_,
problems_NN
._.
A_DT
number_NN
of_PIN
patients_NN
will_PRMD
also_RB
expertise_NN
from_PIN
very_AMP
large_JJ
pharma_NN
to_PIN
folks_NN
and_PHC
Gaucher_NN
Disease_NN
,_,
among_PIN
others_NN
._.
Shire_NN
suffer_VPRT
significant_JJ
CNS_NN
damage_NN
._.
The_DT
market_NN
that_TSUB
started_VBD
with_PIN
TKT_NN
over_IN
15_CD
years_NN
ago_RB
._.
HGT_NN
also_RB
has_VPRT
early_TIME
research_NN
programs_NN
is_VPRT [PASS]
estimated_VBN [PRIV]
at_PIN
$_$
300_CD
million_CD
worldwide_NN
:_:
and_ANDC
They_TPP3
all_QUAN
have_VPRT [PEAS]
proven_VBN
track_NN
records_NN
and_CC
the_DT
in_PIN
a_DT
number_NN
of_PIN
non-LSD_JJ
genetic_JJ
diseases_NN
._.
We_FPP1
have_VPRT
good_JJ
GA-GCB_NN
:_:
A_DT
gene_NN
activated_VBD
technologies_NN
and_CC
a_DT
clear_JJ
mission_NN
._.
A_DT
strong_JJ
pipeline_NN
glucocerebrosidase_NN
which_WDT
recently_TIME
Shire_NN
HGT_NN
has_VPRT
one_CD
approved_JJ
product_NN
and_CC
two_CD
completed_VBN
Phase_NN
2_CD
studies_NN
for_PIN
the_DT
Dr_NN
Pendergast_NN
says_VPRT [PUBV]
that_THVC
Shire_NN
will_PRMD
help_VB
Shire_NN
late-stage_JJ
clinical_JJ
development_NOMZ
candidates_NN
treatment_NOMZ
of_PIN
Gaucher_NN
Disease_NN
,_,
a_DT
genetic_JJ
HGT_NN
make_VPRT
the_DT
most_EMPH
out_PIN
of_PIN
its_PIT
science_NN
and_CC
with_PIN
rapid_JJ
development_NOMZ
time_NN
lines_NN
:_:
disorder_NN
caused_VBN [WZPAST]
by_PIN
deficiency_NN
of_PIN
the_DT
technology_NN
allowing_VBG [SUAV] [WZPRES]
an_DT
increase_NN
in_PIN
the_DT
number_NN
enzyme_NN
,_,
This_DEMO
deficiency_NN
causes_VPRT
a_DT
fatty_NN
of_PIN
projects_NN
it_PIT
can_POMD [SPAU]
now_TIME
undertake_VB
and_PHC
allowing_VBG [SUAV]
REPLAGAL_NN
:_:
an_DT
enzyme_NN
replacement_NOMZ
substance_NN
to_TO
accumulate_VB
in_PIN
certain_JJ
body_NN
all_QUAN
of_PIN
the_DT
fruits_NN
of_PIN
that_DEMO
research_NN
to_TO
be_VB [PASS]
marketed_VBN
therapy_NN
currently_RB
approved_VBN
and_PHC
marketed_VBN
tissues_NN
such_JJ
as_IN
the_DT
spleen_NN
,_,
liver_NN
,_,
and_ANDC
bone_NN
internally_RB
._.
Shires_NN
corporate_JJ
infrastructure_NN
,_,
to_TO
treat_VB
patients_NN
with_PIN
Fabry_NN
Disease_NN
LSD_NN
marrow_NN
._.
An_DT
individual_JJ
affected_VBN
by_PIN
Gaucher_NN
financial_JJ
support_NN
,_,
business_NOMZ
development_NOMZ
that_TSUB
affects_VPRT
810,000_CD
patients_NN
in_PIN
countries_NN
Disease_NN
might_POMD
exhibit_VB
one_CD
or_CC
several_QUAN
of_PIN
expertise_NN
and_PHC
ability_NOMZ
to_PIN
market_NN
products_NN
likely_JJ
to_TO
reimburse_VB
for_PIN
the_DT
treatment_NOMZ
._.
these_DEMO
symptoms_NN
:_:
enlarged_JJ
liver_NN
and_CC
or_CC
targeted_VBN
at_PIN
larger_JJ
patient_NN
populations_NOMZ
will_PRMD
Symptoms_NN
usually_RB
begin_VPRT
during_PIN
childhood_NN
spleen_NN
,_,
anemia_NN
,_,
fatigue_NN
,_,
easy_JJ
bruising_VBG
,_,
ensure_VB [SUAV] [PRIV]
that_THVC
Shire_NN
HGTs_NN
innovative_JJ
protein_NN
or_CC
adolescence_NN
and_CC
include_VPRT
burning_VBG
impaired_VBN
blood_NN
clotting_GER
,_,
bone_NN
pain_NN
,_,
and_ANDC
platform_NN
reaches_VPRT
the_DT
greatest_JJ
number_NN
sensations_NOMZ
in_PIN
the_DT
hands_NN
that_TSUB
get_VPRT
worse_JJ
fractures_NN
._.
The_DT
total_JJ
worldwide_JJ
estimated_VBN [PRIV]
of_PIN
patients_NN
in_PIN
the_DT
least_JJ
amount_NN
of_PIN
time_NN
and_CC
with_PIN
exercise_NN
and_CC
hot_JJ
weather_NN
and_CC
small_JJ
,_,
market_NN
is_VPRT [BEMA]
more_EMPH
than_PIN
$_$
840_CD
million_CD
._.
make_VB
a_DT
real_JJ
difference_NN
in_PIN
peoples_NN
lives_NN
._.
raised_VBN
reddish-purple_JJ
blemishes_NN
on_PIN
the_DT
skin_NN
._.
Lipid_JJ
storage_NN
may_POMD
lead_VB
to_TO
impaired_VBN
Shire_NN
HGTs_NN
key_JJ
products_NN
REPLAGAL_NN
,_,
arterial_JJ
circulation_NOMZ
and_CC
increased_VBD
risk_NN
ELAPRASE_NN
and_PHC
GA-GCB_NN
are_VPRT [PASS]
manufactured_VBN
of_PIN
heart_NN
attack_NN
or_CC
stroke_NN
._.
The_DT
heart_NN
may_POMD
through_PIN
a_DT
proprietary_JJ
process_NN
derived_VBN [WZPAST]
from_PIN
also_RB
become_VBN
enlarged_JJ
and_CC
the_DT
kidneys_NN
human_JJ
cell_NN
lines_NN
,_,
an_DT
advanced_JJ
technology_NN
often_RB
become_VPRT
progressively_RB
involved_VBN
compared_VBN
to_PIN
conventional_JJ
method_NN
of_PIN
using_VBG
resulting_VBG
in_PIN
ESRD_NN
._.
REPLAGAL_NN
is_VPRT [PASS]
approved_VBN
Chinese_JJ
hamster_NN
ovary_JJ
lines_NN
._.
Currently_RB
relying_VBG
in_PIN
34_CD
countries_NN
outside_PLACE
of_PIN
the_DT
US_FPP1
where_RB
on_PIN
a_DT
combination_NOMZ
of_PIN
internal_JJ
manufacturing_GER
ease_NN
of_PIN
administration_NOMZ
one_CD
fifth_NN
the_DT
and_CC
external_JJ
manufacturing_GER
filling_VBG [WZPRES]
partners_NN
volume_NN
infusion_NN
of_PIN
the_DT
competing_VBG
to_TO
produce_VB
its_PIT
products_NN
,_,
the_DT
unit_NN
is_VPRT [BEMA]
in_PIN
the_DT
product_NN
and_CC
a_DT
broader_JJ
label_NN
have_VPRT [PEAS]
helped_VBN
early_TIME
stages_NN
of_PIN
planning_VBG
for_PIN
expanded_VBN
to_TO
establish_VB [PRIV]
REPLAGALs_NN
competitive_JJ
manufacturing_GER
capability_NOMZ
._.
It_PIT
is_VPRT [PASS]
estimated_VBN [PRIV] [THATD]
the_DT
current_JJ
market_NN
is_VPRT
$_$
190_CD
million_CD
in_PIN
Western_NN
Europe_NN
:_:
34_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:54_CD
Page_NN
35_CD
We_FPP1
nd_VPRT
that_DEMO
nature_NN
is_VPRT [BEMA]
always_RB
surprising_PRED
us_FPP1
and_CC
these_DEMO
surprises_NN
are_VPRT [BEMA]
the_DT
essence_NN
of_PIN
discovery_NN
._.
Michael_NN
W._NN
Heartlein_NN
Vice_NN
President_NN
,_,
Research_NN
,_,
Shire_NN
HGT_NN
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:54_CD
Page_NN
36_CD
resp_NN
onsi_NN
ble_NN
36_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:54_CD
Page_NN
37_CD
Corporate_JJ
Responsibility_NOMZ
Our_FPP1
business_NOMZ
touches_NN
many_QUAN
peoples_NN
lives_NN
._.
Responsibility_NOMZ
in_PIN
pharmaceuticals_NN
Managing_VBG [WZPRES]
our_FPP1
products_NN
The_DT
supply_NN
chain_NN
There_EX
are_VPRT
few_QUAN
sectors_NN
that_TSUB
can_POMD
have_VB
so_EMPH
positive_JJ
This_DEMO
section_NOMZ
will_PRMD
explore_VB
how_RB
we_FPP1
address_VPRT
We_FPP1
made_VBN
particular_JJ
progress_NN
in_PIN
this_DEMO
area_NN
an_DT
impact_NN
on_PIN
society_NN
as_IN
pharmaceuticals_NN
._.
Our_FPP1
any_QUAN
specific_JJ
issues_NN
that_TSUB
occur_VPRT
in_PIN
relation_NOMZ
in_PIN
2005_CD
._.
Our_FPP1
new_JJ
global_JJ
procurement_NOMZ
ability_NOMZ
to_TO
treat_VB
,_,
prevent_VB
and_PHC
cure_VB
disease_NN
gives_VPRT
to_PIN
our_FPP1
drugs_NN
._.
Two_CD
examples_NN
from_PIN
2005_CD
are_VPRT
services_NN
group_NN
is_VPRT [SPAU]
now_TIME
implementing_VBG
us_FPP1
enormous_JJ
power_NN
for_PIN
good_JJ
,_,
but_CC
this_DEMP
brings_VPRT
the_DT
withdrawal_NN
of_PIN
ADDERALL_NN
XR_NN
in_PIN
Canada_NN
,_,
a_DT
Company-wide_JJ
procurement_NOMZ
process_NN
with_PIN
it_PIT
an_DT
enormous_JJ
responsibility_NOMZ
._.
So_RB
much_QUAN
so_RB
,_,
where_RB
we_FPP1
successfully_RB
addressed_VBD
questions_NOMZ
across_PLACE
all_QUAN
suppliers_NN
._.
This_DEMP
will_PRMD
allow_VB [SUAV]
us_FPP1
to_PIN
in_PIN
fact_NN
,_,
that_THVC
the_DT
whole_JJ
concept_NN
of_PIN
responsibility_NOMZ
raised_VBN [WZPAST]
by_PIN
Health_NN
Canada_NN
,_,
and_ANDC
REMINYL_NN
manage_VPRT
our_FPP1
relationships_NN
more_EMPH
effectively_RB
is_VPRT [BEMA]
inextricable_PRED
linked_VBN
to_PIN
the_DT
day-to-day_TIME
running_GER
in_PIN
the_DT
UK_NN
,_,
where_RB
a_DT
multi-faceted_JJ
campaign_NN
as_RB
well_RB
as_IN
to_TO
introduce_VB
social_JJ
and_CC
of_PIN
a_DT
pharmaceuticals_NN
business_NOMZ
like_IN
Shire_NN
._.
from_PIN
the_DT
medical_JJ
community_NOMZ
,_,
patients_NN
,_,
environmental_JJ
criteria_NN
for_PIN
suppliers_NN
,_,
politicians_NN
and_PHC
members_NN
of_PIN
the_DT
public_NN
may_POMD
and_CC
conduct_VB
compliance_NN
audits_NN
._.
This_DEMP
is_VPRT [BEMA]
one_CD
of_PIN
the_DT
reasons_NN
why_RB
we_FPP1
have_VPRT [SPAU]
now_TIME
help_VB
to_TO
retain_VB
National_NN
Health_NN
Service_NN
NHS_NN
decided_VBD [SUAV] [PRIV]
to_TO
move_VB [SUAV]
away_PLACE
from_PIN
using_VBG
the_DT
phrase_NN
funding_GER
for_PIN
treatment_NOMZ
for_PIN
Alzheimers_NN
Disease_NN
._.
Engaging_VBG [PRESP]
with_PIN
our_FPP1
people_NN
corporate_JJ
social_JJ
responsibility_NOMZ
,_,
in_PIN
favor_NN
of_PIN
the_DT
Our_FPP1
business_NOMZ
relies_VPRT
on_PIN
the_DT
enthusiasm_NN
,_,
much_QUAN
broader_JJ
term_NN
corporate_JJ
responsibility_NOMZ
Running_VBG [WZPRES]
Shire_NN
in_PIN
a_DT
responsible_JJ
way_NN
commitment_NOMZ
and_PHC
motivation_NOMZ
of_PIN
its_PIT
people_NN
CR_NN
._.
Talking_VBG [PRESP]
only_DWNT
about_IN
corporate_JJ
social_JJ
CR_NN
also_RB
extends_VPRT
to_PIN
the_DT
way_NN
Shire_NN
operates_VPRT
and_CC
the_DT
feedback_NN
we_FPP1
received_VBD
from_PIN
responsibility_NOMZ
can_POMD
suggest_VB [SUAV] [PUBV]
that_THVC
the_DT
external_JJ
as_IN
an_DT
organization_NOMZ
._.
Our_FPP1
CR_NN
Report_NN
will_PRMD
review_VB
:_:
employees_NN
during_PIN
2005_CD
was_VBD
particularly_RB
impact_NN
of_PIN
the_DT
business_NOMZ
is_VPRT [PASS]
limited_VBN
to_PIN
social_JJ
encouraging_JJ
._.
Acquiring_VBG
TKT_NN
was_VBD [BEMA]
a_DT
major_JJ
issues_NN
,_,
to_PIN
the_DT
exclusion_NN
of_PIN
wider_JJ
environmental_JJ
our_FPP1
environmental_JJ
performance_NN
:_:
event_NN
for_PIN
Shire_NN
in_PIN
2005_CD
and_CC
like_IN
any_QUAN
acquisition_NOMZ
and_CC
ethical_JJ
concerns_NN
:_:
and_ANDC
it_PIT
can_POMD [SPAU]
also_RB
imply_VB [PRIV] [THATD]
it_PIT
had_VBD
to_TO
be_VB [PASS]
managed_VBN
in_PIN
human_JJ
as_RB
well_RB
that_DEMP
this_DEMO
area_NN
is_VPRT [BEMA]
the_DT
preserve_VB
of_PIN
specialists_NN
,_,
health_NN
and_PHC
safety_NN
:_:
as_IN
commercial_JJ
terms_NN
._.
We_FPP1
quickly_RB
renamed_VBD
rather_RB
than_PIN
being_VBG [BEMA]
the_DT
responsibility_NOMZ
of_PIN
everyone_QUPR
the_DT
business_NOMZ
Shire_NN
HGT_NN
but_CC
made_VBD
few_QUAN
other_JJ
who_WP
works_VPRT
for_PIN
Shire_NN
._.
We_FPP1
wanted_VBD
our_FPP1
new_JJ
colleagues_NN
to_TO
feel_VB [PRIV]
part_NN
of_PIN
Shire_NN
as_RB
quickly_RB
as_IN
possible_JJ
,_,
This_DEMP
will_PRMD
be_VB [PASS]
reflected_VBN [PRIV]
in_PIN
Shires_NN
dedicated_VBD
the_DT
way_NN
we_FPP1
engage_VPRT
with_PIN
our_FPP1
people_NN
:_:
and_ANDC
and_CC
this_DEMP
involved_VBD
an_DT
intensive_JJ
program_NN
2005_CD
CR_NN
report_NN
,_,
which_WDT [SERE]
will_PRMD
concentrate_VB
of_PIN
communication_NOMZ
and_PHC
integration_NOMZ
,_,
including_VBG [PRESP]
on_PIN
the_DT
key_JJ
issues_NN
that_TOBJ
we_FPP1
face_VPRT
as_IN
a_DT
specialist_NN
our_FPP1
role_NN
in_PIN
the_DT
community_NOMZ
._.
a_DT
number_NN
of_PIN
high-profile_JJ
activities_NOMZ
in_PIN
the_DT
area_NN
pharmaceuticals_NN
business_NOMZ
._.
of_PIN
Cambridge_NN
,_,
Massachusetts_NN
where_RB
the_DT
Environmental_NN
performance_NN
main_JJ
office_NN
and_PHC
manufacturing_GER
site_NN
is_VPRT [PASS]
located_VBN
._.
The_DT
areas_NN
of_PIN
focus_NN
in_PIN
the_DT
2005_CD
CR_NN
report_NN
are_VPRT
:_:
We_FPP1
established_VBD [PRIV]
a_DT
new_JJ
environmental_JJ
As_CONJ
a_NULL
result_NULL
,_,
retention_NOMZ
of_PIN
these_DEMO
employees_NN
management_NOMZ
system_NN
in_PIN
2005_CD
,_,
which_WDT [SERE]
was_VBD
has_VPRT [PEAS]
been_VBN [BEMA]
very_AMP
high_PRED
over_IN
90_CD
%_NN
._.
Drug_NN
safety_NN
developed_VBN [WZPAST]
with_PIN
input_NN
from_PIN
both_DT
Deloitte_NN
and_CC
This_DEMP
will_PRMD
cover_VB
our_FPP1
policies_NN
and_PHC
practices_NN
the_DT
International_NN
Safety_NN
Council_NN
._.
We_FPP1
have_VPRT
new_JJ
Our_FPP1
role_NN
in_PIN
the_DT
community_NOMZ
in_PIN
relation_NOMZ
to_PIN
clinical_JJ
trials_NN
,_,
drug_NN
testing_GER
and_CC
environmental_JJ
performance_NN
targets_NN
for_PIN
2006_CD
,_,
We_FPP1
have_VPRT
an_DT
extensive_JJ
community_NOMZ
program_NN
,_,
quality_NOMZ
procedures_NN
,_,
and_ANDC
our_FPP1
commitment_NOMZ
covering_VBG [WZPRES]
matters_NN
such_JJ
as_IN
management_NOMZ
of_PIN
ranging_VBG
from_PIN
our_FPP1
support_NN
of_PIN
employee_NN
to_TO
publish_VB
research_NN
data_NN
._.
It_PIT
also_RB
includes_VPRT
waste_NN
,_,
reduction_NOMZ
of_PIN
CO_NN
emissions_NN
,_,
disposal_NN
volunteers_NN
to_TO
making_VBG
corporate_JJ
donations_NOMZ
2_CD
the_DT
ongoing_JJ
monitoring_GER
of_PIN
our_FPP1
products_NN
._.
of_PIN
hazardous_JJ
materials_NN
,_,
water_NN
and_PHC
energy_NN
to_PIN
organizations_NOMZ
working_VBG [WZPRES]
in_PIN
our_FPP1
own_JJ
conservation_NOMZ
and_PHC
reduction_NOMZ
of_PIN
use_NN
of_PIN
volatile_JJ
therapeutic_JJ
areas_NN
._.
We_FPP1
were_VBD [BEMA]
particularly_RB
proud_JJ
Responsible_JJ
marketing_GER
organic_JJ
chemicals_NN
or_CC
VOCs_NN
._.
of_PIN
the_DT
efforts_NN
our_FPP1
people_NN
made_VBN
to_TO
support_VB
This_DEMP
will_PRMD
address_VB
our_FPP1
approach_NN
to_TO
marketing_VBG
the_DT
victims_NN
of_PIN
the_DT
tsunami_NN
in_PIN
South-East_NN
Asia_NN
pharmaceutical_JJ
products_NN
,_,
how_RB
we_FPP1
train_VPRT
and_CC
Health_NN
and_PHC
safety_NN
and_PHC
Hurricane_NN
Katrina_NN
in_PIN
2005_CD
$_$
166,103_CD
manage_VB
our_FPP1
sales-force_NN
to_TO
ensure_VB [SUAV] [PRIV]
that_THVC
we_FPP1
We_FPP1
carried_VBD
out_PIN
a_DT
global_JJ
Environment_NOMZ
,_,
Health_NN
was_VBD [PASS]
raised_VBN
around_PLACE
the_DT
world_NN
,_,
which_WDT [SERE]
was_VBD
comply_VB
with_PIN
local_JJ
regulations_NOMZ
,_,
the_DT
highest_JJ
and_CC
Safety_NN
assessment_NOMZ
in_PIN
2004_CD
,_,
and_ANDC
will_PRMD
matched_VBN
by_PIN
the_DT
Company_NN
._.
ethical_JJ
standards_NN
and_PHC
codes_NN
of_PIN
practice_NN
._.
be_VB
repeating_VBG [PUBV]
this_DEMO
exercise_NN
in_PIN
2006_CD
._.
We_FPP1
have_VPRT
It_PIT
also_RB
explains_VPRT [PUBV]
our_FPP1
Medical_JJ
Legal_NN
Review_NN
a_DT
comprehensive_JJ
system_NN
for_PIN
identifying_VBG
and_CC
process_NN
,_,
which_WDT [SERE]
strives_VPRT
to_TO
ensure_VB [SUAV] [PRIV]
effective_JJ
addressing_VBG
possible_JJ
workplace_NN
risks_NN
,_,
with_PIN
the_DT
and_CC
accurate_JJ
communication_NOMZ
as_IN
part_NN
aim_NN
of_PIN
reducing_VBG
reportable_JJ
incidents_NN
by_PIN
50_CD
%_NN
._.
of_PIN
the_DT
production_NOMZ
of_PIN
our_FPP1
educational_JJ
and_PHC
promotional_JJ
materials_NN
._.
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
37_CD
Shire_NN
plc_NN
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:54_CD
Page_NN
38_CD
Corporate_JJ
Responsibility_NOMZ
Principles_NN
,_,
policies_NN
and_PHC
practices_NN
enterprise-wide_JJ
risk_NN
assessment_NOMZ
process_NN
of_PIN
which_WDT [PIRE]
this_DEMO
CR_NN
assessment_NOMZ
is_VPRT [BEMA]
a_DT
part_NN
._.
Identified_VBN
Accountability_NOMZ
risks_NN
are_VPRT [PASS]
reviewed_VBN
twice-yearly_JJ
by_PIN
the_DT
The_DT
Company_NN
attaches_VPRT
great_JJ
importance_NN
to_PIN
Executive_NN
Committee_NN
,_,
the_DT
Audit_NN
Committee_NN
social_JJ
and_PHC
environmental_JJ
issues_NN
and_CC
to_PIN
ethical_JJ
and_CC
the_DT
Board_NN
._.
Accordingly_RB
,_,
ultimate_JJ
responsibility_NOMZ
for_PIN
them_TPP3
is_VPRT [PASS]
taken_VBN
at_PIN
the_DT
highest_JJ
Training_GER
and_PHC
assessment_NOMZ
levels_NN
._.
The_DT
Board_NN
reviews_VPRT
the_DT
Companys_NN
In_PIN
keeping_VBG
with_PIN
our_FPP1
belief_NN
that_TOBJ
CR_NN
is_VPRT [BEMA]
an_DT
general_JJ
approach_NN
to_PIN
CR_NN
._.
Shires_NN
CR_NN
strategy_NN
integral_JJ
part_NN
of_PIN
our_FPP1
business_NOMZ
,_,
we_FPP1
seek_VPRT
to_PIN
New_NN
targets_NN
in_PIN
2006_CD
for_PIN
water_NN
and_CC
is_VPRT [BYPA]
implemented_VBN
by_PIN
our_FPP1
CR_NN
Committee_NN
._.
raise_NN
awareness_NOMZ
of_PIN
CR-related_JJ
issues_NN
in_PIN
our_FPP1
energy_NN
conservation_NOMZ
._.
This_DEMO
Committee_NN
is_VPRT [BYPA]
chaired_VBN
by_PIN
our_FPP1
Chief_NN
business-related_JJ
training_GER
._.
Specific_JJ
training_GER
Financial_NN
Officer_NN
,_,
who_WP
also_RB
takes_VPRT
responsibility_NOMZ
is_VPRT [PASS]
given_VBN
on_PIN
Shires_NN
code_NN
of_PIN
conduct_NN
and_CC
at_PIN
Board_NN
level_NN
for_PIN
CR_NN
._.
We_FPP1
made_VBD
a_DT
number_NN
for_PIN
those_DEMP
working_VBG
in_PIN
areas_NN
such_JJ
as_IN
sales_NN
of_PIN
changes_NN
to_TO
enchance_VB
the_DT
composition_NOMZ
and_PHC
marketing_GER
,_,
environmental_JJ
legislation_NOMZ
,_,
of_PIN
the_DT
Committee_NN
this_DEMO
year_NN
,_,
and_ANDC
now_TIME
have_VPRT
a_DT
and_CC
corporate_JJ
governance_NN
._.
good_JJ
balance_NN
of_PIN
senior_JJ
managers_NN
and_PHC
function_NOMZ
heads_NN
whose_WPS [WHOBJ]
roles_NN
have_VPRT
particular_JJ
relevance_NN
CR_NN
issues_NN
are_VPRT [PASS]
included_VBN
in_PIN
performance_NN
to_PIN
CR_NN
._.
Members_NN
of_PIN
the_DT
CR_NN
Committee_NN
include_VPRT
appraisals_NN
for_PIN
all_QUAN
senior_JJ
managers_NN
,_,
as_RB
well_RB
as_IN
Caroline_NN
West_NN
,_,
our_FPP1
new_JJ
Chief_NN
Compliance_NN
line_NN
managers_NN
with_PIN
functional_JJ
responsibilities_NOMZ
,_,
Officer_NN
,_,
Eliseo_NN
Salinas_NN
,_,
Chief_NN
Scientific_NN
Officer_NN
,_,
and_ANDC
those_DEMO
where_RB
CR_NN
issues_NN
have_VPRT
a_DT
direct_JJ
and_CC
David_NN
Pendergast_NN
,_,
who_WP
is_VPRT [BEMA]
the_DT
General_NN
impact_NN
on_PIN
their_TPP3
role_NN
._.
Manager_NN
of_PIN
our_FPP1
new_JJ
Shire_NN
HGT_NN
business_NOMZ
._.
Feedback_NN
from_PIN
employees_NN
in_PIN
2005_CD
Stakeholder_NN
engagement_NOMZ
was_VBD [BEMA]
particularly_RB
encouraging_PRED
._.
Objectives_NN
We_FPP1
put_VPRT
considerable_JJ
emphasis_NN
on_PIN
Shire_NN
sets_VPRT
corporate_JJ
objectives_NN
annually_RB
._.
maintaining_VBG [PUBV]
productive_JJ
relationships_NN
with_PIN
Achieving_VBG
our_FPP1
CR_NN
objectives_NN
is_VPRT [BEMA]
key_PRED
to_PIN
our_FPP1
all_QUAN
our_FPP1
key_JJ
stakeholders_NN
,_,
and_ANDC
the_DT
feedback_NN
overall_JJ
performance_NN
targets_NN
._.
Functional_NN
we_FPP1
receive_VPRT
from_PIN
them_TPP3
is_VPRT [PASS]
taken_VBN
into_PIN
account_NN
and_CC
individual_JJ
objectives_NN
are_VPRT [PASS]
aligned_VBN
with_PIN
in_PIN
developing_VBG
our_FPP1
CR_NN
policy_NN
,_,
CR_NN
strategy_NN
,_,
overall_JJ
corporate_JJ
objectives_NN
._.
In_PIN
this_DEMO
way_NN
our_FPP1
and_CC
CR_NN
performance_NN
targets_NN
._.
Stakeholder_NN
CR_NN
objectives_NN
permeate_VPRT
right_RB
through_PIN
the_DT
dialogue_NN
ranges_VPRT
from_PIN
meetings_GER
with_PIN
business_NOMZ
,_,
from_PIN
the_DT
Board_NN
to_PIN
every_QUAN
member_NN
institutional_JJ
shareholders_NN
conducted_VBN [WZPAST]
by_PIN
our_FPP1
of_PIN
staff_NN
._.
Chief_NN
Executive_NN
Officer_NN
and_PHC
Chief_NN
Financial_NN
Officer_NN
,_,
to_PIN
regular_JJ
interaction_NOMZ
with_PIN
regulators_NN
Our_FPP1
CR_NN
objectives_NN
are_VPRT [PASS]
formulated_VBN
and_PHC
agreed_VBN [SUAV] [PUBV]
and_CC
health_NN
providers_NN
such_JJ
as_IN
the_DT
FDA_NN
,_,
by_PIN
the_DT
CR_NN
Committee_NN
,_,
and_ANDC
monitored_VBD
at_PIN
Board_NN
the_DT
Medicines_NN
and_PHC
Healthcare_NN
Products_NN
level_NN
._.
They_TPP3
cover_VPRT
all_QUAN
the_DT
commercial_JJ
aspects_NN
Regulatory_NN
Agency_NN
and_PHC
National_NN
Institute_NN
for_PIN
of_PIN
our_FPP1
business_NOMZ
,_,
as_RB
well_RB
as_IN
the_DT
way_NN
in_PIN
which_WDT [PIRE]
Clinical_NN
Excellence_NN
NICE_NN
,_,
to_PIN
the_DT
relationships_NN
we_FPP1
operate_VPRT
as_IN
an_DT
organization_NOMZ
,_,
and_ANDC
include_VPRT
,_,
we_FPP1
have_VPRT
with_PIN
specialist_NN
physicians_NN
and_ANDC
for_CONJ
example_NULL
,_,
objectives_NN
relating_VBG [WZPRES]
to_PIN
clinical_JJ
patient_NN
groups_NN
,_,
such_JJ
as_IN
Children_NN
and_PHC
Adults_NN
trials_NN
,_,
product_NN
safety_NN
,_,
patient_JJ
education_NOMZ
,_,
with_PIN
Attention_NOMZ
Deficit_NN
Disorder_NN
CHADD_NN
,_,
ethical_JJ
selling_GER
,_,
procurement_NOMZ
,_,
and_ANDC
environmental_JJ
the_DT
Mucopolysaccharide_NN
MPS_NN
Society_NN
,_,
performance_NN
,_,
as_RB
well_RB
as_IN
people-related_JJ
issues_NN
the_DT
Alzheimers_NN
Society_NN
and_CC
the_DT
National_NN
such_JJ
as_IN
diversity_NOMZ
and_PHC
work-life_NN
balance_NN
._.
These_DEMO
objectives_NN
can_POMD
be_VB [PASS]
viewed_VBN
in_PIN
our_FPP1
CR_NN
report_NN
or_CC
on_PIN
our_FPP1
website_NN
._.
We_FPP1
also_RB
welcome_JJ
feedback_NN
from_PIN
anyone_QUPR
else_RB
with_PIN
an_DT
interest_NN
in_PIN
our_FPP1
business_NOMZ
,_,
and_ANDC
if_COND
you_SPP2
Risk_NN
management_NOMZ
have_VPRT
views_NN
or_CC
comments_NOMZ
you_SPP2
can_POMD
send_VB
them_TPP3
We_FPP1
undertook_VBD
a_DT
full_JJ
CR_NN
risk_NN
assessment_NOMZ
to_TO
cr@shire_VB
._.
com_NN
Main_NN
picture_NN
right_NN
:_:
in_PIN
2004_CD
,_,
and_ANDC
this_DEMP
was_VBD [PASS]
reviewed_VBN
in_PIN
depth_NN
and_CC
We_FPP1
were_VBD [BEMA]
joint_JJ
sponsors_NN
of_PIN
the_DT
re-affirmed_JJ
during_PIN
2005_CD
._.
Our_FPP1
CR_NN
Committee_NN
MPS_NN
Awareness_NOMZ
Day_NN
and_CC
took_VBD
members_NN
are_VPRT [BEMA]
responsible_PRED
for_PIN
ensuring_VBG [SUAV] [PRIV]
the_DT
CR_NN
part_NN
in_PIN
a_DT
ceremony_NN
to_TO
ring_VB
the_DT
bell_NN
risks_NN
are_VPRT [PASS]
assessed_VBN
and_PHC
revised_VBN
as_RB
necessary_JJ
at_PIN
NASDAQ_NN
._.
Shire_NN
engages_VPRT
in_PIN
an_DT
38_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:54_CD
Page_NN
39_CD
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:54_CD
Page_NN
40_CD
Board_NN
of_PIN
Directors_NN
01_CD
01_CD
Dr_NN
James_NN
Cavanaugh_NN
Dr_NN
James_NN
Cavanaugh_NN
68_CD
Chairman_NN
Dr_NN
James_NN
Cavanaugh_NN
has_VPRT [PEAS]
been_VBN [BEMA]
a_DT
member_NN
of_PIN
Shires_NN
Board_NN
since_OSUB
March_NN
24_CD
,_,
1997_CD
and_CC
02_CD
Chairman_NN
since_OSUB
May_POMD
11_CD
,_,
1999_CD
._.
He_TPP3
is_VPRT [BEMA]
a_DT
General_NN
Matthew_NN
Emmens_NN
Partner_NN
of_PIN
HealthCare_NN
Partners_NN
,_,
the_DT
General_NN
01_CD
02_CD
Chief_NN
Executive_NN
Officer_NN
Partner_NN
of_PIN
Healthcare_NN
Ventures_NN
,_,
a_DT
venture_NN
capital_NN
fund_NN
devoted_VBN [WZPAST]
to_PIN
healthcare_NN
,_,
Non_NN
-_:
03_CD
executive_NN
Chairman_NN
of_PIN
Diversa_NN
Corporation_NOMZ
Angus_NN
Russell_NN
and_CC
a_DT
Non-executive_JJ
Director_NN
of_PIN
MedImmune_NN
Chief_NN
Financial_NN
Officer_NN
Inc._NN
and_PHC
Advancis_NN
Pharmaceutical_NN
Corporation_NOMZ
._.
He_TPP3
is_VPRT [BEMA]
a_DT
former_JJ
President_NN
of_PIN
SmithKline_NN
&_CC
04_CD
French_JJ
Laboratories_NN
,_,
SmithKline_NN
Beecham_NN
Robin_NN
Buchanan_NN
Corporations_NOMZ
clinical_JJ
laboratory_NN
business_NOMZ
,_,
and_ANDC
Non-executive_JJ
Director_NN
Allergan_NN
International_NN
,_,
and_ANDC
served_VBD
as_IN
Deputy_NN
03_CD
04_CD
Assistant_NN
to_PIN
the_DT
US_FPP1
President_NN
on_PIN
the_DT
White_NN
05_CD
House_NN
Staff_NN
._.
Dr_NN
Cavanaugh_NN
is_VPRT
also_RB
Chairman_NN
The_NN
Hon_NN
James_NN
Grant_NN
of_PIN
Shires_NN
Nomination_NOMZ
Committee_NN
._.
Non-executive_JJ
Director_NN
02_CD
06_CD
Matthew_NN
Emmens_NN
54_CD
David_NN
Kappler_NN
Matthew_NN
Emmens_NN
has_VPRT [PEAS]
been_VBN
Shires_NN
Chief_NN
Non-executive_JJ
Director_NN
Executive_NN
Officer_NN
and_CC
a_DT
member_NN
of_PIN
the_DT
Board_NN
since_OSUB
March_NN
12_CD
,_,
2003_CD
._.
He_TPP3
began_VBD
his_TPP3
career_NN
05_CD
06_CD
07_CD
in_PIN
international_JJ
pharmaceuticals_NN
with_PIN
Merck_NN
Patrick_NN
Langlois_NN
&_CC
Co_NN
,_,
Inc._NN
in_PIN
1974_CD
,_,
where_RB
he_TPP3
held_VBD [PRIV]
a_DT
wide_JJ
Non-executive_JJ
Director_NN
range_NN
of_PIN
sales_NN
,_,
marketing_GER
and_CC
administrative_JJ
positions_NOMZ
._.
In_PIN
1992_CD
,_,
he_TPP3
helped_VBD
to_TO
establish_VB [PRIV]
08_CD
Astra_NN
Merck_NN
,_,
a_DT
joint_JJ
venture_NN
between_PIN
Merck_NN
Ronald_NN
Nordmann_NN
and_PHC
Astra_NN
AB_NN
of_PIN
Sweden_NN
,_,
becoming_VBG
President_NN
Non-executive_JJ
Director_NN
and_PHC
Chief_NN
Executive_NN
Officer_NN
._.
In_PIN
1999_CD
,_,
he_TPP3
joined_VBD
Merck_NN
KGaA_NN
and_CC
established_VBN [PRIV]
EMD_NN
09_CD
Pharmaceuticals_NN
,_,
the_DT
Companys_NN
US_FPP1
07_CD
08_CD
Barry_NN
Price_NN
prescription_NOMZ
pharmaceutical_JJ
business_NOMZ
._.
Non-executive_JJ
Director_NN
He_TPP3
was_VBD [SPAU] [PASS]
later_TIME
promoted_VBN
to_PIN
President_NN
of_PIN
Merck_NN
KGaAs_NN
global_JJ
prescription_NOMZ
business_NOMZ
,_,
based_VBN [PASTP]
in_PIN
Germany_NN
._.
Mr_NN
Emmens_NN
holds_VPRT [PRIV]
a_DT
degree_NN
in_PIN
Business_NOMZ
Management_NOMZ
from_PIN
Fairleigh_NN
Dickinson_NN
University_NOMZ
._.
He_TPP3
is_VPRT
also_RB
Chairman_NN
of_PIN
Shires_NN
Executive_NN
and_PHC
Portfolio_NN
Review_NN
Committees_NN
._.
09_CD
40_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:54_CD
Page_NN
41_CD
03_CD
06_CD
08_CD
Angus_NN
Russell_NN
50_CD
David_NN
Kappler_NN
58_CD
Ronald_NN
Nordmann_NN
64_CD
Angus_NN
Russell_NN
has_VPRT [PEAS]
been_VBN
Shires_NN
Chief_NN
David_NN
Kappler_NN
has_VPRT [PEAS]
been_VBN [BEMA]
a_DT
member_NN
of_PIN
Shires_NN
Ronald_NN
Nordmann_NN
has_VPRT [PEAS]
been_VBN [BEMA]
a_DT
member_NN
Financial_NN
Officer_NN
and_CC
a_DT
member_NN
of_PIN
the_DT
Board_NN
Board_NN
since_OSUB
April_NN
5_CD
,_,
2004_CD
._.
He_TPP3
is_VPRT [BEMA]
currently_RB
of_PIN
Shires_NN
Board_NN
since_OSUB
December_NN
23_CD
,_,
since_OSUB
December_NN
13_CD
,_,
1999_CD
._.
He_TPP3
also_RB
serves_VPRT
as_IN
also_RB
serving_VBG
as_IN
Non-executive_JJ
Chairman_NN
1999_CD
and_CC
previously_TIME
served_VBD
as_IN
a_DT
Nona_NN
non-executive_JJ
Director_NN
of_PIN
the_DT
City_NOMZ
of_PIN
London_NN
of_PIN
Premier_NN
Foods_NN
plc_NN
and_CC
as_IN
a_DT
Non-executive_JJ
executive_NN
Director_NN
of_PIN
Roberts_NN
Pharmaceutical_NN
Investment_NOMZ
Trust_NN
plc._NN
._.
Between_PIN
1980_CD
and_CC
Director_NN
of_PIN
Intercontinental_NN
Hotels_NN
Group_NN
plc_NN
Corporation_NOMZ
._.
He_TPP3
is_VPRT [BEMA]
also_RB
a_DT
Director_NN
of_PIN
1999_CD
,_,
Mr_NN
Russell_NN
held_VBD [PRIV]
a_DT
number_NN
of_PIN
positions_NOMZ
and_PHC
HMV_NN
Group_NN
plc._NN
._.
In_CONJ
addition_NULL
,_,
he_TPP3
was_VBD
Neurochem_NN
Inc._NN
and_PHC
Par_NN
Pharmaceutical_NN
of_PIN
increasing_VBG
responsibility_NOMZ
at_PIN
ICI_NN
,_,
Zeneca_NN
and_CC
a_DT
director_NN
of_PIN
Camelot_NN
Group_NN
plc_NN
from_PIN
1996_CD
-_:
Companies_NN
,_,
Inc._NN
._.
Mr_NN
Nordmann_NN
is_VPRT
CoAstraZeneca_NN
plc_NN
,_,
including_VBG
Vice_NN
President_NN
-_:
2002_CD
._.
Mr_NN
Kappler_NN
retired_VBD
from_PIN
Cadbury_NN
President_NN
of_PIN
Global_NN
Health_NN
Associates_NN
._.
Corporate_JJ
Finance_NN
at_PIN
AstraZeneca_NN
and_PHC
Group_NN
Schweppes_NN
plc_NN
in_PIN
April_NN
2004_CD
after_IN
serving_VBG
He_TPP3
has_VPRT [PEAS]
been_VBN [BEMA]
a_DT
financial_JJ
analyst_NN
in_PIN
healthcare_NN
Treasurer_NN
at_PIN
Zeneca_NN
._.
Mr_NN
Russell_NN
is_VPRT [BEMA]
a_DT
chartered_VBN
as_IN
Chief_NN
Financial_NN
Officer_NN
since_OSUB
1995_CD
._.
equities_NOMZ
since_OSUB
1971_CD
,_,
holding_VBG [PRIV]
senior_JJ
positions_NOMZ
accountant_NN
,_,
having_VBG [PEAS]
qualified_VBN
with_PIN
Coopers_NN
&_CC
He_TPP3
worked_VBD
for_PIN
the_DT
Cadbury_NN
Schweppes_NN
group_NN
with_PIN
Deerfield_NN
Management_NOMZ
,_,
PaineWebber_NN
,_,
Lybrand_NN
,_,
and_ANDC
a_DT
fellow_NN
of_PIN
the_DT
Association_NOMZ
of_PIN
between_PIN
1965_CD
and_CC
1984_CD
and_CC
rejoined_VBD
the_DT
Oppenheimer_NN
&_CC
Co._NN
._.
F_NN
Eberstadt_NN
&_CC
Co._NN
._.
Corporate_JJ
Treasurers_NN
._.
He_TPP3
is_VPRT [BEMA]
also_RB
a_DT
member_NN
of_PIN
Company_NN
in_PIN
1989_CD
following_VBG
its_PIT
acquisition_NOMZ
and_PHC
Warner-Chilcott_NN
Laboratories_NN
._.
He_TPP3
holds_VPRT [PRIV]
Shires_NN
Executive_NN
Committee_NN
and_CC
is_VPRT
Chairman_NN
of_PIN
Trebor_NN
Group_NN
,_,
where_RB
he_TPP3
was_VBD
Financial_NN
a_DT
bachelors_NN
degree_NN
from_PIN
Johns_NN
Hopkins_NN
of_PIN
the_DT
Corporate_JJ
Responsibility_NOMZ
Committee_NN
._.
Mr_NN
Kappler_NN
is_VPRT [BEMA]
a_DT
fellow_NN
of_PIN
the_DT
University_NOMZ
and_CC
an_DT
MBA_NN
from_PIN
Fairleigh_NN
Chartered_NN
Institute_NN
of_PIN
Management_NOMZ
Dickinson_NN
University_NOMZ
._.
Mr_NN
Nordmann_NN
is_VPRT [BEMA]
also_RB
04_CD
Accountants_NN
._.
He_TPP3
is_VPRT
also_RB
Chairman_NN
a_DT
member_NN
of_PIN
Shires_NN
Audit_NN
,_,
Nomination_NOMZ
Robin_NN
Buchanan_NN
53_CD
of_PIN
Shires_NN
Audit_NN
Committee_NN
._.
Robin_NN
Buchanan_NN
has_VPRT [PEAS]
been_VBN [BEMA]
a_DT
member_NN
of_PIN
Shires_NN
Board_NN
since_OSUB
July_NN
30_CD
,_,
2003_CD
._.
He_TPP3
also_RB
07_CD
09_CD
serves_VPRT
as_IN
a_DT
non-executive_JJ
director_NN
of_PIN
Liberty_NN
Patrick_NN
Langlois_NN
60_CD
Dr_NN
Barry_NN
Price_NN
62_CD
International_NN
plc._NN
._.
Mr_NN
Buchanan_NN
is_VPRT [BEMA]
Senior_JJ
Patrick_NN
Langlois_NN
has_VPRT [PEAS]
been_VBN [BEMA]
a_DT
member_NN
of_PIN
Dr_NN
Barry_NN
Price_NN
has_VPRT [PEAS]
been_VBN [BEMA]
a_DT
member_NN
Partner_NN
of_PIN
the_DT
UK_NN
operations_NOMZ
and_PHC
director_NN
Shires_NN
Board_NN
since_OSUB
November_NN
14_CD
,_,
2005_CD
._.
of_PIN
Shires_NN
Board_NN
since_OSUB
January_NN
16_CD
,_,
1996_CD
of_PIN
the_DT
global_JJ
business_NOMZ
consultants_NN
Bain_NN
&_CC
He_TPP3
is_VPRT [BEMA]
also_RB
a_DT
Non-executive_JJ
Director_NN
of_PIN
Coley_NN
and_CC
is_VPRT [BEMA]
the_DT
Companys_NN
senior_JJ
Non-executive_JJ
Company_NN
Inc._NN
and_CC
is_VPRT [BEMA]
a_DT
member_NN
of_PIN
that_DEMO
firms_NN
Pharmaceuticals_NN
Group_NN
,_,
Inc._NN
and_CC
was_VBD [BEMA]
a_DT
NonDirector_NN
._.
He_TPP3
also_RB
serves_VPRT
as_IN
Chairman_NN
of_PIN
worldwide_JJ
management_NOMZ
committee_NN
._.
He_TPP3
executive_JJ
Director_NN
of_PIN
Rhodia_NN
SA_NN
between_PIN
Antisoma_NN
plc_NN
and_PHC
Biowisdom_NN
Ltd._NN
._.
Dr_NN
Price_NN
previously_TIME
worked_VBD
for_PIN
American_NN
Express_NN
December_NN
2002_CD
and_CC
April_NN
2005_CD
._.
Mr_NN
Langlois_NN
worked_VBD
for_PIN
Glaxo_NN
for_PIN
28_CD
years_NN
,_,
where_RB
he_TPP3
International_NN
Banking_GER
Corporation_NOMZ
in_PIN
New_NN
previously_TIME
served_VBD
as_IN
Vice_NN
Chairman_NN
of_PIN
the_DT
held_VBN [PRIV]
positions_NOMZ
of_PIN
increasing_VBG
responsibility_NOMZ
York_NN
,_,
McKinsey_NN
&_CC
Company_NN
,_,
and_ANDC
Deloitte_NN
Management_NOMZ
Board_NN
of_PIN
Aventis_NN
S._NN
A._NN
Strasbourg_NN
,_,
with_PIN
the_DT
Companys_NN
research_NN
group_NN
._.
Dr_NN
Price_NN
&_CC
Touche_NN
,_,
where_RB
he_TPP3
qualified_VBD
as_IN
a_DT
chartered_JJ
having_VBG [PEAS]
been_VBN
Group_NN
Executive_NN
Vice_NN
President_NN
is_VPRT
also_RB
Chairman_NN
of_PIN
Shires_NN
Remuneration_NOMZ
accountant_NN
FCA_NN
._.
Mr_NN
Buchanan_NN
holds_VPRT [PRIV]
an_DT
and_CC
Chief_NN
Financial_NN
Officer_NN
for_PIN
several_QUAN
years_NN
._.
Committee_NN
and_CC
a_DT
member_NN
of_PIN
the_DT
Audit_NN
and_PHC
MBA_NN
with_PIN
Distinction_NOMZ
Baker_NN
Scholar_NN
from_PIN
He_TPP3
also_RB
spent_VBD
many_QUAN
years_NN
in_PIN
senior_JJ
financial_JJ
Nomination_NOMZ
Committees_NN
._.
He_TPP3
is_VPRT [BEMA]
also_RB
a_DT
roles_NN
with_PIN
the_DT
Rhone-Poulenc_NN
Group_NN
,_,
including_VBG
member_NN
of_PIN
Shires_NN
Remuneration_NOMZ
Committee_NN
._.
three_CD
years_NN
as_IN
a_DT
member_NN
of_PIN
the_DT
Executive_NN
Committee_NN
and_PHC
Chief_NN
Financial_NN
Officer_NN
._.
D._NN
in_PIN
Economics_NN
The_NN
Hon_NN
James_NN
Grant_NN
P._NN
C_NN
,_,
C._NN
M_NN
,_,
Q._NN
C_NN
68_CD
and_CC
a_DT
diploma_NN
in_PIN
banking_GER
studies_NN
._.
He_TPP3
is_VPRT [BEMA]
The_DT
Hon_NN
James_NN
Grant_NN
has_VPRT [PEAS]
been_VBN [BEMA]
a_DT
member_NN
also_RB
a_DT
member_NN
of_PIN
Shires_NN
Audit_NN
Committee_NN
._.
of_PIN
Shires_NN
Board_NN
since_OSUB
May_POMD
11_CD
,_,
2001_CD
and_CC
previously_TIME
served_VBD
as_IN
a_DT
Director_NN
of_PIN
BioChem_NN
Pharma_NN
Inc._NN
since_OSUB
1986_CD
._.
He_TPP3
also_RB
sits_VPRT
on_PIN
the_DT
boards_NN
of_PIN
two_CD
Canadian_JJ
public_JJ
corporations_NOMZ
and_CC
the_DT
boards_NN
of_PIN
a_DT
number_NN
of_PIN
other_JJ
private_JJ
corporations_NOMZ
and_CC
not-for-profit_JJ
foundations_NOMZ
and_PHC
councils_NN
._.
He_TPP3
is_VPRT [BEMA]
a_DT
partner_NN
and_PHC
Chair_NN
Emeritus_NN
with_PIN
the_DT
law_NN
firm_NN
Stikeman_NN
Elliott_NN
in_PIN
Montreal_NN
._.
Mr_NN
Grant_NN
holds_VPRT [PRIV]
degrees_NN
in_PIN
Arts_NN
and_PHC
Law_NN
from_PIN
McGill_NN
University_NOMZ
._.
He_TPP3
is_VPRT [BEMA]
also_RB
a_DT
member_NN
of_PIN
Shires_NN
Nomination_NOMZ
Committee_NN
._.
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
41_CD
Shire_NN
plc_NN
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:54_CD
Page_NN
42_CD
Executive_NN
Committee_NN
01_CD
08_CD
Matthew_NN
Emmens_NN
Tatjana_NN
May_POMD
Chief_NN
Executive_NN
Officer_NN
General_NN
Counsel_NN
,_,
Company_NN
and_PHC
Chairman_NN
of_PIN
the_DT
Secretary_NN
and_PHC
Executive_NN
Executive_NN
Committee_NN
Vice_NN
President_NN
Global_NN
Legal_NN
Affairs_NN
01_CD
02_CD
03_CD
02_CD
Angus_NN
Russell_NN
09_CD
Chief_NN
Financial_NN
Officer_NN
David_NN
Pendergast_NN
and_PHC
Executive_NN
Vice_NN
Executive_NN
Vice_NN
President_NN
President_NN
Global_NN
Finance_NN
and_PHC
General_NN
Manager_NN
,_,
Shire_NN
HGT_NN
03_CD
Mike_NN
Cola_NN
10_CD
Executive_NN
Vice_NN
President_NN
,_,
Dr_NN
Eliseo_NN
Salinas_NN
04_CD
05_CD
06_CD
Global_JJ
Therapeutic_NN
Areas_NN
Chief_NN
Scientific_NN
Officer_NN
and_PHC
Executive_NN
Vice_NN
President_NN
,_,
04_CD
Global_JJ
R&D_NN
Barbara_NN
Deptula_NN
Executive_NN
Vice_NN
President_NN
,_,
11_CD
Business_NOMZ
Development_NOMZ
Joseph_NN
Rus_NN
Executive_NN
Vice_NN
President_NN
05_CD
and_CC
General_NN
Manager_NN
,_,
Greg_NN
Flexter_NN
International_NN
07_CD
08_CD
09_CD
Executive_NN
Vice_NN
President_NN
and_PHC
General_NN
Manager_NN
,_,
North_NN
America_NN
06_CD
Anita_NN
Graham_NN
Executive_NN
Vice_NN
President_NN
,_,
Global_NN
Human_NN
Resources_NN
10_CD
11_CD
07_CD
John_NN
Lee_NN
Executive_NN
Vice_NN
President_NN
,_,
Global_NN
Supply_NN
Chain_NN
&_CC
Quality_NOMZ
42_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:54_CD
Page_NN
43_CD
01_CD
06_CD
10_CD
Matthew_NN
Emmens_NN
Anita_NN
Graham_NN
Dr_NN
Eliseo_NN
Salinas_NN
See_VB [PRIV]
page_NN
40_CD
._.
Anita_NN
Graham_NN
has_VPRT [PEAS]
been_VBN [BEMA]
with_PIN
Shire_NN
since_OSUB
Dr_NN
Eliseo_NN
Salinas_NN
has_VPRT [PEAS]
been_VBN [BEMA]
with_PIN
Shire_NN
since_OSUB
January_NN
2004_CD
._.
She_TPP3
was_VBD
previously_TIME
Vice_NN
June_NN
2004_CD
._.
He_TPP3
was_VBD
previously_TIME
Head_NN
of_PIN
Global_NN
02_CD
President_NN
of_PIN
Human_NN
Resources_NN
at_PIN
Cytyc_NN
Central_NN
Nervous_NN
Systems_NN
and_PHC
Vice_NN
President_NN
Angus_NN
Russell_NN
Corporation_NOMZ
._.
She_TPP3
also_RB
held_VBD [PRIV]
senior_JJ
HR_NN
for_PIN
Regional_NN
Clinical_NN
Research_NN
&_CC
Development_NOMZ
See_VB [PRIV]
page_NN
41_CD
._.
positions_NOMZ
at_PIN
Serono_NN
,_,
Inc._NN
and_PHC
Scudder_NN
at_PIN
Wyeth_NN
Research_NN
,_,
one_CD
of_PIN
the_DT
worlds_NN
leading_VBG [WZPRES]
Kemper_NN
Investments_NOMZ
,_,
Inc._NN
now_TIME
part_NN
pharmaceutical_JJ
companies_NN
._.
03_CD
of_PIN
Deutsche_NN
Bank_NN
and_CC
has_VPRT
extensive_JJ
Mike_NN
Cola_NN
experience_NN
in_PIN
all_QUAN
aspects_NN
of_PIN
HR_NN
,_,
both_DT
11_CD
Mike_NN
Cola_NN
has_VPRT [PEAS]
been_VBN [BEMA]
with_PIN
Shire_NN
since_OSUB
July_NN
in_PIN
Europe_NN
and_CC
the_DT
US_FPP1
._.
He_TPP3
was_VBD
previously_TIME
President_NN
of_PIN
the_DT
Joseph_NN
Rus_NN
has_VPRT [PEAS]
been_VBN [BEMA]
with_PIN
Shire_NN
since_OSUB
1999_CD
._.
life_NN
sciences_NN
division_NN
of_PIN
Safeguard_NN
Scientifics_NN
07_CD
Following_VBG
the_DT
merger_NN
of_PIN
Shire_NN
Pharmaceuticals_NN
Inc._NN
._.
Mr_NN
Cola_NN
also_RB
worked_VBD
for_PIN
AstraMerck_NN
John_NN
Lee_NN
and_PHC
BioChem_NN
Pharma_NN
in_PIN
May_POMD
2001_CD
,_,
he_TPP3
was_VBD
AstraZeneca_NN
and_CC
was_VBD [BEMA]
responsible_PRED
for_PIN
John_NN
Lee_NN
has_VPRT [PEAS]
been_VBN [BEMA]
with_PIN
Shire_NN
since_OSUB
April_NN
appointed_VBN
President_NN
and_PHC
Chief_NN
Executive_NN
developing_VBG [WZPRES]
AstraMercks_NN
product_NN
2000_CD
._.
He_TPP3
was_VBD
previously_TIME
Vice_NN
President_NN
,_,
Officer_NN
of_PIN
Shire_NN
BioChem_NN
Inc._NN
._.
He_TPP3
has_VPRT
more_EMPH
development_NOMZ
,_,
medical_JJ
affairs_NN
,_,
business_NOMZ
Operations_NOMZ
at_PIN
Schwarz_NN
Pharma_NN
,_,
and_ANDC
also_RB
than_PIN
25_CD
years_NN
of_PIN
experience_NN
in_PIN
the_DT
international_JJ
research_NN
,_,
licensing_GER
and_CC
pharmaceutical_JJ
worked_VBN
at_PIN
Central_NN
Pharmaceuticals_NN
,_,
The_DT
pharmaceutical_JJ
industry_NN
including_VBG [WZPRES]
European_JJ
business_NOMZ
._.
Vitarine_NN
Company_NN
now_TIME
Eon_NN
,_,
and_ANDC
Glenwood_NN
country_NN
management_NOMZ
._.
He_TPP3
has_VPRT
over_IN
31_CD
years_NN
of_PIN
04_CD
experience_NN
in_PIN
the_DT
pharmaceutical_JJ
industry_NN
._.
Barbara_NN
Deptula_NN
Barbara_NN
Deptula_NN
has_VPRT [PEAS]
been_VBN [BEMA]
with_PIN
Shire_NN
08_CD
since_OSUB
September_NN
2004_CD
._.
She_TPP3
was_VBD
previously_TIME
Tatjana_NN
May_POMD
President_NN
of_PIN
the_DT
biotechnology_NN
division_NN
Tatjana_NN
May_POMD
has_VPRT [PEAS]
been_VBN [BEMA]
with_PIN
Shire_NN
since_OSUB
May_POMD
of_PIN
Sicor_NN
Inc._NN
and_PHC
Senior_NN
Vice_NN
President_NN
for_PIN
2001_CD
._.
She_TPP3
was_VBD
previously_TIME
Assistant_NN
General_NN
commercial_JJ
and_CC
product_NN
development_NOMZ
at_PIN
Counsel_NN
at_PIN
the_DT
corporate_JJ
headquarters_NN
Coley_NN
Pharmaceutical_NN
Group_NN
._.
She_TPP3
also_RB
held_VBD [PRIV]
of_PIN
AstraZeneca_NN
plc_NN
and_CC
prior_RB
to_PIN
that_DEMO
she_TPP3
senior_JJ
management_NOMZ
positions_NOMZ
focused_VBD
worked_VBN
at_PIN
the_DT
law_NN
firm_NN
Slaughter_NN
and_PHC
May_POMD
._.
on_PIN
licensing_GER
and_PHC
business_NOMZ
development_NOMZ
at_PIN
US_FPP1
Bioscience_NN
,_,
Schering-Plough_NN
,_,
09_CD
American_NN
Cyanamid_NN
,_,
and_ANDC
Genetics_NN
Institute_NN
._.
Dr_NN
David_NN
Pendergast_NN
Dr_NN
David_NN
Pendergast_NN
has_VPRT [PEAS]
been_VBN [BEMA]
with_PIN
Shire_NN
since_OSUB
05_CD
July_NN
2005_CD
and_CC
was_VBD
previously_TIME
Chief_NN
Executive_NN
Greg_NN
Flexter_NN
Officer_NN
of_PIN
Transkaryotic_NN
Therapies_NN
Inc._NN
until_IN
Greg_NN
Flexter_NN
has_VPRT [PEAS]
been_VBN [BEMA]
with_PIN
Shire_NN
since_OSUB
its_PIT
acquisition_NOMZ
by_PIN
Shire_NN
._.
He_TPP3
was_VBD
previously_TIME
Vice_NN
President_NN
as_IN
Vice_NN
President_NN
of_PIN
Product_NN
Development_NOMZ
and_PHC
head_NN
of_PIN
the_DT
neuroscience_NN
business_NOMZ
and_PHC
Quality_NOMZ
at_PIN
Biogen_NN
,_,
Inc_NN
,_,
and_ANDC
held_VBD [PRIV]
senior_JJ
of_PIN
Novartis_NN
Pharmaceuticals_NN
,_,
responsible_JJ
for_PIN
positions_NOMZ
at_PIN
Fisons_NN
Ltd._NN
s_VPRT
Pharmaceutical_NN
US_FPP1
Marketing_GER
,_,
Sales_NN
and_PHC
Medical_NN
Research_NN
._.
Division_NN
and_CC
The_DT
Upjohn_NN
Company_NN
._.
He_TPP3
has_VPRT
Mr_NN
Flexter_NN
has_VPRT
more_EMPH
than_PIN
22_CD
years_NN
of_PIN
over_IN
30_CD
years_NN
of_PIN
pharmaceutical_JJ
and_CC
experience_NN
in_PIN
global_JJ
and_PHC
domestic_JJ
marketing_GER
,_,
biotechnology_NN
experience_NN
._.
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
43_CD
Shire_NN
plc_NN
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:54_CD
Page_NN
44_CD
perf_NN
orm_NN
ance_NN
44_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:54_CD
Page_NN
45_CD
Financial_NN
review_NN
For_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
,_,
total_JJ
revenues_NN
increased_VBN [WZPAST]
by_PIN
17_CD
%_NN
to_TO
$_$
1,599.3_CD
million_CD
compared_VBN
to_TO
$_$
1,363.2_CD
million_CD
in_PIN
2004_CD
._.
Angus_NN
Russell_NN
Chief_NN
Financial_NN
Officer_NN
The_NN
following_VBG [WZPRES]
discussion_NN
should_NEMD
be_VB [PASS]
read_VBN
in_PIN
conjunction_NOMZ
with_PIN
the_DT
Companys_NN
US_FPP1
GAAP_NN
consolidated_JJ
financial_JJ
statements_NOMZ
contained_VBN [WZPAST]
on_PIN
pages_NN
78127_CD
of_PIN
this_DEMO
annual_JJ
review_NN
._.
Results_NN
of_PIN
operations_NOMZ
For_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
,_,
the_DT
Companys_NN
total_NN
revenues_NN
increased_VBN [WZPAST]
by_PIN
17_CD
%_NN
to_TO
$_$
1,599.3_CD
million_CD
,_,
compared_VBN
to_TO
$_$
1,363.2_CD
million_CD
in_PIN
2004_CD
._.
Net_JJ
loss_NN
for_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
was_VBD
$_$
410.8_CD
million_CD
compared_VBN
to_PIN
net_JJ
income_NN
of_PIN
$_$
269_CD
million_CD
in_PIN
2004_CD
._.
The_DT
Companys_NN
net_JJ
loss_NN
for_PIN
2005_CD
was_VBD [BEMA]
primarily_RB
attributable_PRED
to_PIN
the_DT
in-process_JJ
R&D_NN
write-off_PIN
of_PIN
$_$
673_CD
million_CD
following_VBG
the_DT
acquisition_NOMZ
of_PIN
TKT_NN
._.
Total_JJ
revenues_NN
The_DT
following_JJ
table_NN
provides_VPRT
an_DT
analysis_NN
of_PIN
the_DT
Companys_NN
total_VPRT
revenues_NN
by_PIN
source_NN
:_:
2005_CD
2004_CD
Change_NN
Year_NN
to_PIN
December_NN
31_CD
,_,
$_$
million_CD
$_$
million_CD
%_NN
Product_NN
sales_NN
1,327.7_CD
1,112.5_CD
19_CD
Royalties_NN
242.9_CD
230.4_CD
5_CD
Licensing_GER
and_PHC
development_NOMZ
15.0_CD
13.4_CD
11_CD
Other_JJ
revenues_NN
13.7_CD
6.9_CD
Total_JJ
1,599.3_CD
1,363.2_CD
17_CD
All_QUAN
product_NN
sales_NN
are_VPRT [PASS]
reported_VBN [PUBV]
in_PIN
the_DT
Pharmaceutical_NN
Products_NN
segment_NOMZ
,_,
all_QUAN
royalties_NN
are_VPRT [PASS]
reported_VBN [PUBV]
in_PIN
the_DT
Royalty_NN
segment_NOMZ
._.
Product_NN
sales_NN
Product_NN
sales_NN
US_FPP1
prescription_NOMZ
2005_CD
2004_CD
growth_NN
growth_NN
Year_NN
to_PIN
December_NN
31_CD
,_,
$_$
million_CD
$_$
million_CD
%_NN
%_NN
CNS_NN
ADDERALL_NN
XR_NN
730.8_CD
606.7_CD
20_CD
12_CD
ADDERALL_NN
43.1_CD
34.5_CD
25_CD
CARBATROL_NN
72.1_CD
54.3_CD
33_CD
8_CD
GI_NN
PENTASA_NN
136.1_CD
115.0_CD
18_CD
6_CD
COLAZIDE_NN
8.6_CD
8.2_CD
5_CD
GP_NN
AGRYLIN_NN
and_PHC
XAGRID_NN
North_NN
America_NN
US_FPP1
and_PHC
Canada_NN
46.0_CD
119.1_CD
61_CD
48_CD
Rest_VPRT
of_PIN
the_DT
world_NN
46.8_CD
33.4_CD
40_CD
FOSRENOL_NN
53.5_CD
CALCICHEW_NN
38.7_CD
38.3_CD
1_CD
SOLARAZE_NN
12.5_CD
9.5_CD
32_CD
REMINYL_NN
REMINYL_NN
XL_NN
13.5_CD
10.8_CD
25_CD
LODINE_NN
12.6_CD
7.6_CD
66_CD
Shire_NN
HGT_NN
i_FPP1
REPLAGAL_NN
41.3_CD
Other_JJ
72.1_CD
75.1_CD
4_CD
Total_JJ
1,327.7_CD
1,112.5_CD
19_CD
i_FPP1
This_DEMP
represents_VPRT
REPLAGAL_NN
sales_NN
for_PIN
the_DT
five-month_JJ
period_NN
since_OSUB
the_DT
acquisition_NOMZ
of_PIN
TKT_NN
._.
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
45_CD
Shire_NN
plc_NN
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:54_CD
Page_NN
46_CD
Financial_NN
review_NN
The_DT
following_VBG
discussion_NN
includes_VPRT
references_NN
to_PIN
prescription_NOMZ
and_PHC
market_NN
On_PIN
February_NN
9_CD
,_,
2006_CD
,_,
a_DT
FDA_NN
Advisory_NN
Committee_NN
recommended_VBD [SUAV]
to_PIN
the_DT
share_NN
data_NN
for_PIN
key_JJ
products_NN
._.
The_DT
source_NN
of_PIN
this_DEMO
data_NN
is_VPRT
IMS_NN
Health_NN
,_,
FDA_NN
that_DEMO
risk_NN
information_NOMZ
about_IN
cardiovascular_JJ
events_NN
be_VB [PASS]
included_VBN
December_NN
2005_CD
._.
in_PIN
a_DT
black_JJ
box_NN
warning_VBG [PUBV] [WZPRES]
for_PIN
all_QUAN
stimulant_NN
medicines_NN
used_VBN
to_TO
treat_VB
ADHD_NN
._.
In_PIN
making_VBG
its_PIT
recommendation_NOMZ
,_,
the_DT
Advisory_NN
Committee_NN
recognized_VBD [PRIV]
During_PIN
2005_CD
,_,
the_DT
Company_NN
concluded_VBD [PRIV]
new_JJ
fee_NN
for_PIN
service_NN
agreements_NOMZ
that_TOBJ
the_DT
reported_VBN [PUBV]
incidence_NN
rates_NN
of_PIN
the_DT
rare_JJ
serious_JJ
cardiovascular_JJ
with_PIN
two_CD
of_PIN
its_PIT
three_CD
significant_JJ
wholesale_JJ
customers_NN
._.
These_DEMO
adverse_JJ
events_NN
that_TSUB
were_VBD [BYPA]
discussed_VBN
by_PIN
the_DT
Committee_NN
are_VPRT
generally_RB
agreements_NOMZ
,_,
which_WDT [SERE]
are_VPRT [BEMA]
commonplace_PRED
in_PIN
the_DT
pharmaceutical_JJ
industry_NN
,_,
within_PIN
the_DT
rates_NN
that_TSUB
would_PRMD
be_VB [PASS]
expected_VBN [PRIV]
from_PIN
the_DT
untreated_JJ
general_JJ
change_NN
the_DT
way_NN
wholesalers_NN
are_VPRT [PASS]
compensated_VBN
._.
ADDERALL_NN
XR_NN
and_PHC
ADDERALL_NN
already_RB
include_VPRT
a_DT
black_JJ
the_DT
wholesalers_NN
receive_VPRT
a_DT
distribution_NOMZ
fee_NN
from_PIN
pharmaceutical_JJ
box_NN
warning_GER
in_PIN
their_TPP3
labels_NN
for_PIN
safety_NN
concerns_NN
related_VBN
to_TO
amphetamine_VB
suppliers_NN
._.
These_DEMO
fee_NN
for_PIN
service_NN
agreements_NOMZ
eliminate_VB
wholesalers_NN
abuse_NN
or_CC
misuse_NN
and_CC
also_RB
warn_VB [PUBV]
of_PIN
the_DT
risk_NN
of_PIN
sudden_JJ
death_NN
in_PIN
patients_NN
incentives_NN
to_TO
acquire_VB
and_PHC
hold_VB [PRIV]
excess_JJ
inventories_NN
._.
The_DT
Company_NN
with_PIN
structural_JJ
cardiac_JJ
abnormalities_NOMZ
._.
Shire_NN
stands_VPRT
behind_PLACE
the_DT
current_JJ
believes_VPRT [PRIV] [THATD]
this_DEMP
will_PRMD
reduce_VB
the_DT
significant_JJ
impact_NN
of_PIN
wholesaler_NN
stocking_VBG [WZPRES]
labeling_VBG
and_PHC
believes_VPRT [PRIV]
that_THVC
further_JJ
action_NOMZ
is_VPRT [BEMA]
unwarranted_PRED
._.
and_ANDC
fide-stocking_JJ
on_PIN
its_PIT
product_NN
sales_NN
._.
Further_RB
,_,
the_DT
wholesalers_NN
will_PRMD
provide_VB
data_NN
regarding_VBG [WZPRES]
their_TPP3
inventories_NN
of_PIN
the_DT
Companys_NN
products_NN
it_PIT
In_PIN
January_NN
2006_CD
,_,
Shire_NN
settled_VBD
its_PIT
ADDERALL_NN
XR_NN
patent_NN
infringement_NOMZ
has_VPRT
on_PIN
hand_NN
._.
The_DT
Company_NN
is_VPRT
negotiating_VBG
a_DT
fees_NN
for_PIN
service_NN
agreement_NOMZ
lawsuits_NN
with_PIN
Impax_NN
._.
The_DT
litigations_NOMZ
involved_VBN
Shire_NN
US_FPP1
patents_NN
,_,
Nos._NN
._.
with_PIN
its_PIT
remaining_VBG
significant_JJ
wholesale_JJ
customer_NN
._.
Fees_NN
for_PIN
service_NN
6,322,819_CD
the_DT
819_CD
Patent_NN
,_,
6,605,300_CD
the_DT
300_CD
Patent_NN
and_CC
6,913,768_CD
are_VPRT [PASS]
treated_VBN
as_IN
a_DT
sales_NN
deduction_NOMZ
,_,
thus_CONJ
affecting_VBG
revenues_NN
rather_RB
than_PIN
the_DT
768_CD
Patent_NN
._.
As_IN
part_NN
of_PIN
the_DT
settlement_NOMZ
,_,
Impax_NN
has_VPRT [PEAS]
confirmed_VBN [PUBV]
that_THVC
its_PIT
cost_NN
of_PIN
sales_NN
._.
proposed_VBN [SUAV]
generic_JJ
ADDERALL_NN
XR_NN
product_NN
infringes_VPRT
Shires_NN
819_CD
,_,
300_CD
and_CC
768_CD
Patents_NN
and_CC
that_THVC
the_DT
three_CD
patents_NN
are_VPRT [BEMA]
valid_PRED
and_PHC
enforceable_PRED
._.
ADDERALL_NN
XR_NN
Under_IN
the_DT
terms_NN
of_PIN
the_DT
settlement_NOMZ
,_,
Impax_NN
will_PRMD
be_VB [PASS]
permitted_VBN
to_PIN
market_NN
US_FPP1
prescriptions_NOMZ
for_PIN
ADDERALL_NN
XR_NN
for_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
,_,
generic_JJ
versions_NN
of_PIN
ADDERALL_NN
XR_NN
in_PIN
the_DT
US_FPP1
no_RB
later_TIME
than_PIN
January_NN
1_CD
,_,
were_VBD [BEMA]
up_RB
12_CD
%_NN
._.
ADDERALL_NN
XR_NN
further_JJ
strengthened_VBD
its_PIT
position_NOMZ
as_IN
the_DT
2010_CD
,_,
and_ANDC
will_PRMD
pay_VB
Shire_NN
a_DT
royalty_NN
from_PIN
those_DEMO
sales_NN
._.
In_PIN
certain_JJ
situations_NOMZ
,_,
leading_VBG
brand_NN
in_PIN
the_DT
US_FPP1
ADHD_NN
market_NN
with_PIN
a_DT
1_CD
%_NN
increase_NN
in_PIN
market_NN
such_JJ
as_IN
the_DT
launch_NN
of_PIN
another_DT
generic_JJ
version_NN
of_PIN
ADDERALL_NN
XR_NN
,_,
Impax_NN
share_NN
to_PIN
an_DT
all_QUAN
time_NN
high_JJ
of_PIN
26_CD
%_NN
in_PIN
December_NN
2005_CD
December_NN
2004_CD
:_:
may_POMD
be_VB [PASS]
permitted_VBN
to_TO
enter_VB
the_DT
market_NN
as_IN
Shires_NN
authorized_VBD
generic_JJ
._.
In_CONJ
addition_NULL
,_,
the_DT
US_FPP1
ADHD_NN
market_NN
grew_VBD
5_CD
%_NN
overall_JJ
compared_VBN
to_PIN
the_DT
same_JJ
period_NN
in_PIN
2004_CD
._.
Shires_NN
ADDERALL_NN
XR_NN
patent_NN
infringement_NOMZ
lawsuits_NN
with_PIN
Barr_NN
continue_VPRT
._.
Shire_NN
is_VPRT
seeking_VBG
a_DT
ruling_NN
that_TSUB
Barrs_VPRT
Abbreviated_NN
New_NN
Drug_NN
Application_NOMZ
Product_NN
sales_NN
growth_NN
was_VBD [BEMA]
higher_PRED
than_PIN
prescription_NOMZ
growth_NN
for_PIN
the_DT
ANDA_NN
seeking_VBG [WZPRES]
permission_NN
to_TO
market_VB
its_PIT
generic_JJ
versions_NN
of_PIN
year_NN
due_JJ
mainly_RB
to_PIN
the_DT
impact_NN
of_PIN
price_NN
increases_NN
in_PIN
December_NN
2004_CD
ADDERALL_NN
XR_NN
infringes_VPRT
the_DT
819_CD
,_,
300_CD
and_CC
768_CD
Patents_NN
._.
Barrs_NN
and_PHC
August_NN
2005_CD
,_,
partially_DWNT
offset_VBN
by_PIN
a_DT
decrease_NN
in_PIN
pipeline_NN
inventory_NN
30-month_JJ
stay_NN
under_IN
the_DT
Hatch-Waxman_NN
Act_NN
expired_VBD
on_PIN
February_NN
18_CD
,_,
and_ANDC
higher_JJ
sales_NN
deductions_NOMZ
._.
Following_VBG [PRESP]
the_DT
expiry_NN
of_PIN
the_DT
30-month_JJ
stay_NN
,_,
the_DT
FDA_NN
may_POMD
approve_VB
Barrs_NN
ANDA_NN
._.
A_DT
final_JJ
pre-trial_JJ
conference_NN
in_PIN
the_DT
819_CD
and_CC
300_CD
Patent_NN
FDA_NN
approval_NN
of_PIN
the_DT
adolescent_JJ
indication_NOMZ
for_PIN
ADDERALL_NN
XR_NN
was_VBD [PASS]
cases_NN
took_VBD
place_NN
on_PIN
March_NN
10_CD
,_,
2006_CD
where_RB
the_DT
trial_NN
date_NN
was_VBD [PASS]
set_VBN
received_VBN
on_PIN
July_NN
22_CD
,_,
2005_CD
._.
for_PIN
October_NN
30_CD
,_,
2006_CD
._.
Shire_NN
is_VPRT
continuing_VBG
its_PIT
discussions_NN
with_PIN
Barr_NN
in_PIN
connection_NOMZ
with_PIN
these_DEMO
lawsuits_NN
and_CC
the_DT
discussions_NN
are_VPRT
progressing_VBG
._.
On_PIN
February_NN
12_CD
,_,
2005_CD
,_,
Shire_NN
announced_VBD [PUBV]
that_THVC
it_PIT
had_VBD [PEAS]
suspended_VBN
For_PIN
further_JJ
information_NOMZ
see_VPRT [PRIV]
Note_NN
21_CD
d_SYM
to_PIN
the_DT
Companys_NN
consolidated_JJ
sales_NN
of_PIN
ADDERALL_NN
XR_NN
in_PIN
Canada_NN
at_PIN
the_DT
request_NN
of_PIN
Health_NN
Canada_NN
._.
If_COND
the_DT
Company_NN
does_VPRT
not_XX0
prevail_VB
On_PIN
August_NN
24_CD
,_,
2005_CD
,_,
Shire_NN
announced_VBD [PUBV]
that_THVC
Health_NN
Canada_NN
would_PRMD
in_PIN
the_DT
lawsuits_NN
,_,
the_DT
Companys_NN
sales_NN
of_PIN
ADDERALL_NN
XR_NN
will_PRMD
decrease_VB
._.
reinstate_VB
the_DT
marketing_GER
authorization_NOMZ
of_PIN
ADDERALL_NN
XR_NN
in_PIN
Canada_NN
Any_QUAN
decrease_NN
in_PIN
the_DT
sales_NN
of_PIN
ADDERALL_NN
XR_NN
would_PRMD
significantly_RB
effective_JJ
August_NN
26_CD
,_,
2005_CD
._.
This_DEMO
reinstatement_NOMZ
follows_VPRT
the_DT
acceptance_NN
reduce_VB
revenues_NN
and_PHC
earnings_GER
._.
by_PIN
Health_NN
Canada_NN
of_PIN
the_DT
recommendations_NOMZ
from_PIN
the_DT
New_NN
Drug_NN
Committee_NN
,_,
which_WDT [SERE]
was_VBD [BYPA]
appointed_VBN
by_PIN
Health_NN
Canada_NN
at_PIN
Shires_NN
request_NN
CARBATROL_NN
to_TO
review_VB
the_DT
suspension_NN
of_PIN
ADDERALL_NN
XR_NN
in_PIN
Canada_NN
._.
US_FPP1
prescriptions_NOMZ
for_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
,_,
were_VBD [BEMA]
down_RB
8_CD
%_NN
compared_VBN [WZPAST]
to_PIN
the_DT
previous_JJ
year_NN
._.
This_DEMP
was_VBD [BEMA]
due_JJ
primarily_RB
to_TO
supply_VB
During_PIN
October_NN
2005_CD
,_,
Shire_NN
filed_VBD
a_DT
Citizen_NN
Petition_NOMZ
with_PIN
the_DT
FDA_NN
requesting_VBG [SUAV] [WZPRES]
constraints_NN
,_,
a_DT
4_CD
%_NN
decrease_NN
in_PIN
Shires_NN
market_NN
share_NN
of_PIN
the_DT
total_NN
that_TOBJ
the_DT
FDA_NN
require_VB [SUAV]
more_EMPH
rigorous_JJ
bioequivalence_NN
testing_GER
or_CC
additional_JJ
US_FPP1
extended_VBD
release_NN
carbamazepine_NN
prescription_NOMZ
market_NN
to_PIN
42_CD
%_NN
clinical_JJ
testing_GER
for_PIN
generic_JJ
or_CC
follow-on_PIN
drug_NN
products_NN
that_DEMO
reference_NN
in_PIN
December_NN
2005_CD
December_NN
2004_CD
:_:
46_CD
%_NN
and_CC
a_DT
5_CD
%_NN
decrease_NN
in_PIN
that_DEMO
ADDERALL_NN
XR_NN
before_IN
they_TPP3
can_POMD
be_VB [PASS]
approved_VBN
._.
Shire_NN
believes_VPRT [PRIV]
that_THVC
these_DEMO
market_NN
as_IN
a_DT
whole_NN
._.
The_DT
supply_NN
constraints_NN
have_VPRT [SPAU] [PEAS]
now_TIME
been_VBN [PASS]
resolved_VBN [SUAV]
._.
requested_VBN [SUAV] [THATD]
criteria_NN
will_PRMD
ensure_VB [SUAV] [PRIV]
that_THVC
generic_JJ
formulations_NOMZ
of_PIN
ADDERALL_NN
XR_NN
or_CC
follow-on_PIN
drug_NN
products_NN
will_PRMD
be_VB [BEMA]
clinically_RB
effective_PRED
and_PHC
safe_PRED
._.
In_PIN
January_NN
Product_NN
sales_NN
for_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
were_VBD [BEMA]
up_RB
33_CD
%_NN
2006_CD
,_,
Shire_NN
chose_VBD
to_TO
file_VB
a_DT
supplemental_JJ
amendment_NOMZ
to_PIN
its_PIT
original_JJ
Citizen_NN
compared_VBN [WZPAST]
to_PIN
the_DT
previous_JJ
year_NN
._.
The_DT
difference_NN
between_PIN
sales_NN
growth_NN
Petition_NOMZ
,_,
which_WDT [SERE]
included_VBD
additional_JJ
clinical_JJ
data_NN
in_PIN
support_NN
of_PIN
the_DT
original_JJ
and_CC
the_DT
lower_JJ
level_NN
of_PIN
prescriptions_NOMZ
is_VPRT [BEMA]
due_PRED
to_PIN
price_NN
increases_NN
in_PIN
August_NN
filing_NN
._.
The_DT
FDA_NN
has_VPRT
six_CD
months_NN
to_TO
respond_VB
to_PIN
Shires_NN
petition_NOMZ
and_ANDC
while_OSUB
this_DEMO
2004_CD
and_CC
October_NN
2005_CD
and_CC
to_TO
lower_VB
sales_NN
deductions_NOMZ
than_PIN
in_PIN
2004_CD
._.
petition_NOMZ
is_VPRT
under_IN
review_NN
it_PIT
will_PRMD
not_XX0
grant_VB [SUAV]
final_JJ
approval_NN
of_PIN
generic_JJ
or_CC
follow-on_PIN
drug_NN
products_NN
referencing_VBG [WZPRES]
ADDERALL_NN
XR_NN
._.
Patent_NN
litigation_NOMZ
proceedings_GER
with_PIN
Nostrum_NN
and_PHC
Corepharma_NN
relating_VBG [WZPRES]
to_PIN
CARBATROL_NN
are_VPRT [BEMA]
in_PIN
progress_NN
._.
For_PIN
details_NN
,_,
please_VB
see_VB [PRIV] [THATD]
the_DT
litigation_NOMZ
update_VB
on_PIN
page_NN
111_CD
._.
46_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:54_CD
Page_NN
47_CD
PENTASA_NN
US_FPP1
prescriptions_NOMZ
for_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
were_VBD [BEMA]
up_RB
6_CD
%_NN
compared_VBN [WZPAST]
to_PIN
the_DT
previous_JJ
year_NN
._.
The_DT
increase_NN
was_VBD [BEMA]
due_PRED
to_PIN
the_DT
success_NN
of_PIN
the_DT
co-promotional_JJ
agreement_NOMZ
with_PIN
Solvay_NN
Pharmaceuticals_NN
Inc._NN
the_DT
impact_NN
of_PIN
the_DT
500mg_JJ
dosage_NN
form_NN
launched_VBN [WZPAST]
in_PIN
the_DT
third_JJ
quarter_NN
of_PIN
2004_CD
and_CC
a_DT
2_CD
%_NN
increase_NN
in_PIN
the_DT
total_JJ
US_FPP1
oral_JJ
mesalamine_NN
prescription_NOMZ
market_NN
._.
Product_NN
sales_NN
for_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
were_VBD [BEMA]
up_RB
18_CD
%_NN
,_,
compared_VBN [PASTP]
to_PIN
the_DT
previous_JJ
year_NN
._.
The_DT
difference_NN
between_PIN
sales_NN
growth_NN
and_PHC
prescription_NOMZ
growth_NN
is_VPRT [BEMA]
due_PRED
to_PIN
the_DT
impact_NN
of_PIN
the_DT
September_NN
2004_CD
price_NN
increase_NN
and_CC
a_DT
normalization_NOMZ
of_PIN
pipeline_NN
inventories_NN
compared_VBN [WZPAST]
to_PIN
lower_JJ
levels_NN
in_PIN
2004_CD
._.
PENTASA_NN
had_VBD
an_DT
18_CD
%_NN
share_NN
of_PIN
the_DT
total_JJ
US_FPP1
oral_JJ
mesalamine_NN
prescription_NOMZ
market_NN
in_PIN
December_NN
2005_CD
December_NN
2004_CD
:_:
18_CD
%_NN
._.
AGRYLIN_NN
XAGRID_NN
AGRYLIN_NN
XAGRID_NN
sales_NN
worldwide_NN
for_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
were_VBD
$_$
92.8_CD
million_CD
,_,
down_RB
39_CD
%_NN
compared_VBN [WZPAST]
to_PIN
the_DT
previous_JJ
year_NN
2004_CD
:_:
$_$
152.5_CD
million_CD
._.
North_PLACE
American_JJ
sales_NN
were_VBD
$_$
46_CD
million_CD
,_,
down_RB
61_CD
%_NN
compared_VBN [WZPAST]
to_PIN
the_DT
previous_JJ
year_NN
2004_CD
:_:
$_$
119.1_CD
million_CD
._.
This_DEMO
reduction_NOMZ
was_VBD [PASS]
expected_VBN [PRIV]
following_VBG
the_DT
approval_NN
of_PIN
generic_JJ
versions_NN
of_PIN
AGRYLIN_NN
in_PIN
the_DT
US_FPP1
market_NN
in_PIN
April_NN
2005_CD
._.
Rest_VB
of_PIN
the_DT
World_NN
sales_NN
all_QUAN
sales_NN
outside_PLACE
North_NN
America_NN
were_VBD
$_$
46.8_CD
million_CD
,_,
up_RB
40_CD
%_NN
,_,
compared_VBN [PASTP]
to_PIN
the_DT
previous_JJ
year_NN
2004_CD
:_:
$_$
33.4_CD
million_CD
._.
This_DEMP
was_VBD [BEMA]
primarily_RB
due_PRED
to_PIN
the_DT
successful_JJ
launch_NN
of_PIN
XAGRID_NN
in_PIN
the_DT
UK_NN
,_,
Germany_NN
and_PHC
France_NN
in_PIN
the_DT
first_JJ
quarter_NN
of_PIN
2005_CD
and_CC
Spain_NN
in_PIN
the_DT
third_JJ
quarter_NN
of_PIN
2005_CD
._.
In_PIN
accordance_NN
with_PIN
current_JJ
orphan_JJ
drug_NN
legislation_NOMZ
in_PIN
the_DT
EU_NN
,_,
XAGRID_NN
will_PRMD
have_VB
up_RP
to_TO
ten_VB
years_NN
of_PIN
marketing_GER
exclusivity_NOMZ
in_PIN
the_DT
EU_NN
._.
FOSRENOL_NN
FOSRENOL_NN
was_VBD [PASS]
launched_VBN
in_PIN
the_DT
US_FPP1
in_PIN
January_NN
2005_CD
._.
Product_NN
sales_NN
for_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
were_VBD
$_$
53.5_CD
million_CD
,_,
with_PIN
US_FPP1
prescriptions_NOMZ
for_PIN
the_DT
year_NN
totalling_VBG [WZPRES]
137,000_CD
._.
FOSRENOL_NN
had_VBD
an_DT
8_CD
%_NN
share_NN
of_PIN
the_DT
total_JJ
US_FPP1
phosphate_NN
binding_JJ
market_NN
in_PIN
December_NN
2005_CD
._.
On_PIN
November_NN
28_CD
,_,
2005_CD
the_DT
FDA_NN
approved_VBD
new_JJ
,_,
higher-dose_JJ
formulations_NOMZ
of_PIN
FOSRENOL_NN
._.
New_NN
,_,
higher-dose_JJ
strengths_NN
of_PIN
750mg_NN
and_CC
1,000_CD
mg_NN
were_VBD [PASS]
shipped_VBN
to_PIN
wholesalers_NN
in_PIN
the_DT
US_FPP1
in_PIN
December_NN
2005_CD
._.
Higher-dose_JJ
strengths_NN
should_NEMD
help_VB
to_TO
reduce_VB
the_DT
number_NN
of_PIN
pills_NN
that_TSUB
end-stage_VPRT
renal_JJ
disease_NN
patients_NN
need_VPRT
to_TO
take_VB
to_TO
achieve_VB
target_NN
phosphorus_NN
levels_NN
._.
Product_NN
sales_NN
in_PIN
Q4_NN
2005_CD
were_VBD
$_$
29_CD
million_CD
compared_VBN
with_PIN
$_$
9.7_CD
million_CD
in_PIN
Q3_CD
2005_CD
._.
The_DT
variance_NN
relates_VPRT
primarily_RB
to_TO
increased_VBN
pipeline_NN
inventory_NN
sales_NN
to_PIN
wholesalers_NN
of_PIN
the_DT
new_JJ
higher-dose_JJ
formulation_NOMZ
during_PIN
December_NN
._.
FOSRENOL_NN
was_VBD [PASS]
launched_VBN
in_PIN
Austria_NN
in_PIN
December_NN
2005_CD
._.
Shire_NN
continues_VPRT
its_PIT
discussions_NN
relating_VBG [WZPRES]
to_PIN
FOSRENOL_NN
with_PIN
regulatory_JJ
authorities_NOMZ
and_PHC
reimbursement_NOMZ
agencies_NN
across_PLACE
Europe_NN
and_CC
other_JJ
regions_NN
and_CC
further_JJ
launches_NN
are_VPRT [PASS]
expected_VBN [PRIV]
in_PIN
European_JJ
markets_NN
over_IN
the_DT
next_JJ
few_QUAN
months_NN
,_,
subject_JJ
to_TO
obtaining_VBG
national_JJ
approvals_NN
and_CC
concluding_VBG [PRIV]
pricing_GER
and_PHC
reimbursement_NOMZ
negotiations_NOMZ
._.
REPLAGAL_NN
REPLAGAL_NN
was_VBD [BYPA]
acquired_VBN
by_PIN
Shire_NN
as_IN
part_NN
of_PIN
the_DT
TKT_NN
acquisition_NOMZ
,_,
which_WDT [SERE]
completed_VBD
on_PIN
July_NN
27_CD
,_,
2005_CD
._.
Product_NN
sales_NN
for_PIN
the_DT
period_NN
since_OSUB
acquisition_NOMZ
were_VBD
$_$
41.3_CD
million_CD
._.
The_DT
majority_NOMZ
of_PIN
REPLAGAL_NN
sales_NN
are_VPRT [BEMA]
in_PIN
Europe_NN
._.
Total_JJ
sales_NN
for_PIN
the_DT
full_JJ
year_NN
,_,
including_VBG
pre-acquisition_JJ
sales_NN
,_,
were_VBD
$_$
94.6_CD
million_CD
2004_CD
:_:
$_$
77.4_CD
million_CD
._.
The_DT
increase_NN
in_PIN
sales_NN
including_VBG [WZPRES]
pre-acquisition_JJ
sales_NN
is_VPRT [BEMA]
primarily_RB
due_PRED
to_PIN
greater_JJ
European_JJ
coverage_NN
by_PIN
an_DT
increased_VBN
number_NN
of_PIN
sales_NN
representatives_NN
._.
Foreign_JJ
exchange_NN
effect_NN
As_IN
many_QUAN
of_PIN
the_DT
Companys_NN
sales_NN
revenues_NN
are_VPRT [PASS]
earned_VBN
in_PIN
currencies_NN
other_JJ
than_PIN
US_FPP1
Dollars_NN
primarily_RB
Canadian_JJ
Dollars_NN
,_,
Pounds_NN
Sterling_GER
,_,
Swedish_NN
Krona_NN
and_PHC
Euros_NN
,_,
revenue_NN
growth_NN
reported_VBD [PUBV]
in_PIN
US_FPP1
Dollars_NN
includes_VPRT
the_DT
impact_NN
of_PIN
translating_VBG
the_DT
sales_NN
made_VBN [WZPAST]
in_PIN
a_DT
local_JJ
currency_NN
into_PIN
US_FPP1
Dollars_NN
._.
With_PIN
the_DT
US_FPP1
Dollar_NN
strengthening_VBG [WZPRES]
against_PIN
these_DEMO
currencies_NN
over_IN
the_DT
last_JJ
12_CD
months_NN
,_,
the_DT
translation_NOMZ
of_PIN
sales_NN
made_VBN [WZPAST]
in_PIN
these_DEMO
currencies_NN
into_PIN
US_FPP1
Dollars_NN
has_VPRT [PEAS]
impacted_VBN
on_PIN
the_DT
reported_VBN [PUBV]
growth_NN
rates_NN
._.
The_DT
table_NN
below_PLACE
shows_NN
the_DT
effect_NN
of_PIN
foreign_JJ
exchange_NN
translations_NOMZ
on_PIN
the_DT
revenue_NN
growth_NN
of_PIN
the_DT
key_JJ
affected_JJ
products_NN
as_RB
well_RB
as_IN
the_DT
underlying_VBG
performance_NN
of_PIN
key_JJ
products_NN
in_PIN
their_TPP3
local_JJ
currency_NN
:_:
2005_CD
sales_NN
Impact_NN
of_PIN
2005_CD
sales_NN
in_PIN
growth_NN
in_PIN
translation_NOMZ
2005_CD
sales_NN
US_FPP1
Dollars_NN
local_JJ
to_PIN
US_FPP1
growth_NN
in_PIN
Year_NN
to_PIN
December_NN
31_CD
,_,
$_$
million_CD
currency_NN
Dollars_NN
US_FPP1
Dollars_NN
AGRYLIN_NN
sales_NN
in_PIN
Canadian_JJ
Dollars_NN
5.3_CD
49_CD
%_NN
4_CD
%_NN
45_CD
%_NN
AGRYLIN_NN
XAGRID_NN
sales_NN
in_PIN
Euros_NN
28.3_CD
41_CD
%_NN
41_CD
%_NN
AGRYLIN_NN
XAGRID_NN
sales_NN
in_PIN
Pounds_NN
Sterling_GER
18.9_CD
11_CD
%_NN
1_CD
%_NN
10_CD
%_NN
CALCICHEW_NN
sales_NN
in_PIN
Pounds_NN
Sterling_GER
35.0_CD
1_CD
%_NN
1_CD
%_NN
REMINYL_NN
and_PHC
REMINYL_NN
XL_NN
sales_NN
in_PIN
Pounds_NN
Sterling_GER
11.8_CD
27_CD
%_NN
1_CD
%_NN
26_CD
%_NN
Revenue_NN
growth_NN
analysis_NN
does_VPRT
not_XX0
include_VB
sales_NN
of_PIN
:_:
ADDERALL_NN
XR_NN
in_PIN
Canadian_NN
Dollars_NN
due_JJ
to_PIN
the_DT
fact_NN
that_TOBJ
sales_NN
of_PIN
ADDERALL_NN
XR_NN
in_PIN
Canada_NN
were_VBD [PASS]
suspended_VBN
for_PIN
most_EMPH
of_PIN
2005_CD
:_:
and_ANDC
REPLAGAL_NN
sales_NN
of_PIN
$_$
41.3_CD
million_CD
in_PIN
Euros_NN
and_PHC
Swedish_NN
Krona_NN
._.
There_EX
is_VPRT
no_SYNE
comparative_JJ
data_NN
for_PIN
REPLAGAL_NN
as_IN
it_PIT
was_VBD [PASS]
acquired_VBN
with_PIN
TKT_NN
in_PIN
July_NN
2005_CD
._.
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
47_CD
Shire_NN
plc_NN
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:54_CD
Page_NN
48_CD
Financial_NN
review_NN
Royalties_NN
Royalty_NN
revenue_NN
increased_VBD
5_CD
%_NN
to_TO
$_$
242.9_CD
million_CD
for_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
,_,
2004_CD
:_:
$_$
230.4_CD
million_CD
primarily_RB
as_CONJ
a_NULL
result_NULL
of_PIN
strong_JJ
sales_NN
growth_NN
._.
This_DEMP
was_VBD [BEMA]
due_PRED
to_PIN
the_DT
continued_JJ
growth_NN
in_PIN
the_DT
nucleoside_NN
analog_NN
market_NN
for_PIN
HIV_NN
and_CC
a_DT
small_JJ
positive_JJ
impact_NN
of_PIN
foreign_JJ
exchange_NN
movements_NOMZ
._.
Shire_NN
receives_VPRT
royalties_NN
from_PIN
GSK_NN
on_PIN
worldwide_JJ
3TC_NN
sales_NN
._.
GSKs_NN
worldwide_JJ
sales_NN
of_PIN
3TC_NN
for_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
,_,
were_VBD
$_$
1,211_CD
million_CD
,_,
an_DT
increase_NN
of_PIN
2_CD
%_NN
compared_VBN [WZPAST]
to_PIN
prior_JJ
year_NN
2004_CD
:_:
$_$
1,184_CD
million_CD
._.
ZEFFIX_NN
Royalties_NN
from_PIN
sales_NN
of_PIN
ZEFFIX_NN
for_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
,_,
were_VBD
$_$
30.5_CD
million_CD
,_,
an_DT
increase_NN
of_PIN
11_CD
%_NN
compared_VBN [WZPAST]
to_PIN
2004_CD
$_$
27.4_CD
million_CD
,_,
due_JJ
to_PIN
strong_JJ
growth_NN
in_PIN
the_DT
Japanese_JJ
market_NN
and_CC
a_DT
small_JJ
positive_JJ
impact_NN
of_PIN
foreign_JJ
exchange_NN
movements_NOMZ
._.
Shire_NN
receives_VPRT
royalties_NN
from_PIN
GSK_NN
on_PIN
worldwide_JJ
ZEFFIX_NN
sales_NN
._.
GSKs_NN
worldwide_JJ
sales_NN
of_PIN
ZEFFIX_NN
for_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
,_,
were_VBD
$_$
266_CD
million_CD
,_,
an_DT
increase_NN
of_PIN
11_CD
%_NN
compared_VBN [WZPAST]
to_PIN
prior_JJ
year_NN
2004_CD
:_:
$_$
240_CD
million_CD
._.
Other_JJ
Other_JJ
royalties_NN
are_VPRT [BEMA]
primarily_RB
in_PIN
respect_NN
of_PIN
REMINYL_NN
and_PHC
REMINYL_NN
XL_NN
now_TIME
marketed_VBD
as_IN
RAZADYNE_NN
and_PHC
RAZADYNE_NN
ER_NN
in_PIN
the_DT
US_FPP1
,_,
a_DT
product_NN
marketed_VBN
worldwide_NN
by_PIN
Janssen_NN
Pharmaceutical_NN
N._NN
V._NN
Janssen_NN
,_,
an_DT
affiliate_NN
of_PIN
Johnson_NN
&_CC
Johnson_NN
,_,
with_PIN
the_DT
exception_NOMZ
of_PIN
the_DT
UK_NN
and_CC
the_DT
Republic_NN
of_PIN
Ireland_NN
where_RB
Shire_NN
acquired_VBD
the_DT
exclusive_JJ
marketing_GER
rights_NN
from_PIN
May_POMD
2004_CD
._.
Sales_NN
of_PIN
the_DT
REMINYL_NN
RAZADYNE_NN
range_NN
,_,
for_PIN
the_DT
symptomatic_JJ
treatment_NOMZ
of_PIN
mild_JJ
to_TO
moderately_RB
severe_JJ
dementia_NN
of_PIN
the_DT
Alzheimers_NN
type_NN
,_,
are_VPRT
growing_VBG
well_RB
in_PIN
the_DT
Alzheimers_NN
market_NN
._.
On_PIN
April_NN
11_CD
,_,
2005_CD
,_,
Ortho-McNeil_NN
Neurologics_NN
Inc._NN
._.
Janssens_NN
US_FPP1
affiliate_NN
company_NN
announced_VBD [PUBV]
that_THVC
REMINYL_NN
would_PRMD
be_VB [PASS]
marketed_VBN
in_PIN
the_DT
US_FPP1
under_IN
the_DT
new_JJ
product_NN
name_NN
of_PIN
RAZADYNE_NN
._.
Subsequently_TIME
,_,
in_PIN
the_DT
US_FPP1
,_,
REMINYL_NN
XL_NN
was_VBD [PASS]
launched_VBN
as_IN
RAZADYNE_NN
ER_NN
._.
Ortho-McNeil_NN
Neurologics_NN
Inc._NN
worked_VBD
closely_RB
with_PIN
the_DT
FDA_NN
on_PIN
a_DT
name_NN
change_NN
following_VBG [WZPRES]
dispensing_JJ
errors_NN
in_PIN
the_DT
US_FPP1
between_PIN
REMINYL_NN
and_CC
the_DT
Type_NN
2_CD
diabetes_NN
mellitus_NN
drug_NN
known_VBN [PRIV]
as_IN
AMARYL_NN
._.
Shire_NN
is_VPRT [BEMA]
only_DWNT
aware_PRED
of_PIN
one_CD
similar_JJ
dispensing_GER
error_NN
outside_PLACE
the_DT
US_FPP1
._.
On_PIN
March_NN
1_CD
,_,
2005_CD
,_,
NICE_NN
in_PIN
England_NN
and_PHC
Wales_NN
issued_VBD
an_DT
Appraisal_NN
Consultation_NOMZ
Document_NOMZ
ACD_NN
._.
This_DEMO
document_NOMZ
included_VBD
a_DT
recommendation_NOMZ
that_TOBJ
all_QUAN
existing_VBG
approved_VBN
products_NN
for_PIN
the_DT
symptomatic_JJ
treatment_NOMZ
of_PIN
mild-to-moderate_JJ
Alzheimers_NN
Disease_NN
in_PIN
England_NN
and_PHC
Wales_NN
should_NEMD [SPAU]
no_RB
longer_RB
be_VB [BYPA]
reimbursed_VBN
by_PIN
the_DT
National_NN
Health_NN
Service_NN
NHS_NN
when_RB
used_VBN
in_PIN
the_DT
treatment_NOMZ
of_PIN
new_JJ
patients_NN
._.
The_DT
recommendation_NOMZ
potentially_RB
affected_VBD
sales_NN
of_PIN
REMINYL_NN
and_CC
of_PIN
REMINYL_NN
XL_NN
in_PIN
England_NN
and_PHC
Wales_NN
._.
An_DT
amended_VBN
ACD_NN
was_VBD [BYPA]
issued_VBN
by_PIN
NICE_NN
on_PIN
January_NN
23_CD
,_,
2006_CD
._.
The_DT
new_JJ
ACD_NN
recommends_VPRT [SUAV]
that_THVC
REMINYL_NN
and_PHC
REMINYL_NN
XL_NN
,_,
together_RB
with_PIN
other_JJ
drugs_NN
in_PIN
the_DT
same_JJ
class_NN
,_,
be_VB [BYPA]
reimbursed_VBN
by_PIN
the_DT
NHS_NN
when_RB
used_VBN
for_PIN
the_DT
treatment_NOMZ
of_PIN
either_DT
i_FPP1
patients_NN
with_PIN
existing_VBG
Alzheimers_NN
Disease_NN
already_RB
being_VBG [PASS]
treated_VBN
with_PIN
one_CD
of_PIN
these_DEMO
drugs_NN
:_:
or_CC
ii_FW
newly_RB
diagnosed_VBN
patients_NN
once_TIME
their_TPP3
disease_NN
has_VPRT [PEAS]
progressed_VBN
to_PIN
a_DT
moderate_JJ
stage_NN
._.
Therefore_CONJ
the_DT
current_JJ
recommendation_NOMZ
excludes_VPRT
the_DT
reimbursement_NOMZ
of_PIN
treatment_NOMZ
for_PIN
patients_NN
presenting_VBG [WZPRES]
with_PIN
mild_JJ
symptoms_NN
of_PIN
Alzheimers_NN
Disease_NN
for_PIN
which_WDT [PIRE]
REMINYL_NN
and_PHC
REMINYL_NN
XL_NN
are_VPRT [PASS]
approved_VBN
._.
A_DT
final_JJ
appraisal_NN
document_NOMZ
is_VPRT [PASS]
expected_VBN [PRIV]
from_PIN
NICE_NN
in_PIN
July_NN
2006_CD
._.
Cost_NN
of_PIN
product_NN
sales_NN
For_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
,_,
the_DT
cost_NN
of_PIN
product_NN
sales_NN
amounted_VBD
to_PIN
16_CD
%_NN
of_PIN
product_NN
sales_NN
2004_CD
:_:
13_CD
%_NN
._.
The_DT
decrease_NN
in_PIN
gross_JJ
margin_NN
is_VPRT [BEMA]
primarily_RB
due_PRED
to_PIN
the_DT
addition_NOMZ
of_PIN
REPLAGAL_NN
to_PIN
Shires_NN
product_NN
portfolio_NN
following_VBG [WZPRES]
the_DT
acquisition_NOMZ
of_PIN
TKT_NN
._.
REPLAGALs_NN
cost_NN
of_PIN
product_NN
sales_NN
relates_VPRT
entirely_AMP
to_PIN
the_DT
acquired_VBN
inventories_NN
,_,
which_WDT [SERE]
in_PIN
accordance_NN
with_PIN
US_FPP1
Generally_RB
Accepted_JJ
Accounting_GER
Principles_NN
GAAP_NN
,_,
have_VPRT [PEAS]
been_VBN [PASS]
accounted_VBN
for_PIN
at_PIN
fair_JJ
value_NN
,_,
estimated_VBN [PRIV]
to_TO
be_VB [BEMA]
97_CD
%_NN
of_PIN
the_DT
expected_VBN [PRIV]
sales_NN
price_NN
of_PIN
REPLAGAL_NN
._.
Accordingly_RB
,_,
little_JJ
or_CC
no_SYNE
margin_NN
will_PRMD
be_VB [PASS]
reflected_VBN [PRIV]
for_PIN
REPLAGAL_NN
sales_NN
until_IN
all_QUAN
acquired_VBN
finished_VBN
goods_NN
have_VPRT [PEAS]
been_VBN [PASS]
sold_VBN
anticipated_VBN [PRIV]
Q3_NN
2006_CD
._.
For_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
the_DT
cost_NN
of_PIN
product_NN
sales_NN
for_PIN
REPLAGAL_NN
includes_VPRT
a_DT
$_$
41.9_CD
million_CD
adjustment_NOMZ
in_PIN
respect_NN
of_PIN
the_DT
acquired_VBN
inventory_NN
of_PIN
which_WDT [PIRE]
$_$
39.8_CD
million_CD
related_VBN
to_PIN
sales_NN
of_PIN
acquired_VBN
finished_VBN
goods_NN
and_CC
$_$
2.1_CD
million_CD
was_VBD [BEMA]
a_DT
write-off_PIN
of_PIN
damaged_JJ
work-in-process_NN
._.
In_PIN
2005_CD
,_,
this_DEMO
fair_JJ
value_NN
adjustment_NOMZ
increased_VBD
Shires_NN
cost_NN
of_PIN
product_NN
sales_NN
by_PIN
3_CD
%_NN
._.
48_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:54_CD
Page_NN
49_CD
R&D_NN
R&D_NN
expenditure_NN
increased_VBD
from_PIN
$_$
196.3_CD
million_CD
in_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
to_TO
$_$
336.2_CD
million_CD
in_PIN
2005_CD
._.
Expressed_VBN
as_IN
a_DT
percentage_NN
of_PIN
total_JJ
revenues_NN
,_,
R&D_NN
expenditure_NN
was_VBD [BEMA]
21_CD
%_NN
for_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
2004_CD
:_:
14_CD
%_NN
._.
The_DT
increase_NN
was_VBD [BEMA]
primarily_RB
due_PRED
to_TO
:_:
the_DT
initial_JJ
payment_NOMZ
to_PIN
New_NN
River_NN
of_PIN
$_$
50_CD
million_CD
for_PIN
in-licensing_JJ
NRP104_NN
,_,
which_WDT [SERE]
has_VPRT [PEAS]
been_VBN [PASS]
expensed_VBN
in_PIN
accordance_NN
with_PIN
the_DT
Companys_NN
accounting_GER
policy_NN
:_:
and_ANDC
the_DT
addition_NOMZ
of_PIN
two_CD
significant_JJ
R&D_NN
projects_NN
following_VBG [WZPRES]
the_DT
acquisition_NOMZ
of_PIN
TKT_NN
ELAPRASE_NN
and_PHC
GA-GCB_NN
._.
The_DT
New_NN
River_NN
payment_NOMZ
and_CC
the_DT
R&D_NN
expenditure_NN
on_PIN
ELAPRASE_NN
and_PHC
GA-GCB_NN
represented_VBD
5_CD
%_NN
of_PIN
R&D_NN
expenditure_NN
as_IN
a_DT
percentage_NN
of_PIN
revenues_NN
._.
Shires_NN
pipeline_NN
is_VPRT [SPAU] [PASS]
now_TIME
well_RB
advanced_VBN
with_PIN
seven_CD
projects_NN
in_PIN
late-stage_JJ
development_NOMZ
or_CC
registration_NOMZ
._.
Selling_VBG
,_,
general_JJ
and_PHC
administrative_JJ
SG&A_NN
expenses_NN
Total_JJ
SG&A_NN
costs_NN
increased_VBD
from_PIN
$_$
516.6_CD
million_CD
in_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
,_,
to_TO
$_$
705.6_CD
million_CD
in_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
,_,
an_DT
increase_NN
of_PIN
37_CD
%_NN
._.
As_IN
a_DT
percentage_NN
of_PIN
product_NN
sales_NN
,_,
SG&A_NN
expenses_NN
were_VBD [BEMA]
53_CD
%_NN
2004_CD
:_:
46_CD
%_NN
._.
2005_CD
2004_CD
Change_NN
Year_NN
to_PIN
December_NN
31_CD
,_,
$_$
million_CD
$_$
million_CD
%_NN
Sales_NN
costs_VPRT
181.8_CD
141.5_CD
28_CD
Marketing_GER
costs_NN
252.2_CD
175.9_CD
43_CD
Other_JJ
SG&A_NN
costs_NN
197.2_CD
140.7_CD
40_CD
631.2_CD
458.1_CD
38_CD
i_FPP1
Depreciation_NOMZ
and_PHC
amortization_NOMZ
74.4_CD
58.5_CD
27_CD
Total_JJ
SG&A_NN
costs_NN
705.6_CD
516.6_CD
37_CD
i_FPP1
Excludes_NN
depreciation_NOMZ
from_PIN
manufacturing_VBG
plants_NN
of_PIN
$_$
3.5_CD
million_CD
2004_CD
:_:
$_$
2.7_CD
million_CD
which_WDT
is_VPRT [PASS]
included_VBN
in_PIN
cost_NN
of_PIN
product_NN
sales_NN
._.
SG&A_NN
expenses_NN
increased_VBD
from_PIN
$_$
458.1_CD
million_CD
in_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
,_,
to_TO
$_$
631.2_CD
million_CD
in_PIN
2005_CD
,_,
an_DT
increase_NN
of_PIN
38_CD
%_NN
._.
As_IN
a_DT
percentage_NN
of_PIN
product_NN
sales_NN
,_,
these_DEMO
expenses_NN
were_VBD [BEMA]
48_CD
%_NN
2004_CD
:_:
41_CD
%_NN
._.
This_DEMO
increase_NN
was_VBD [PASS]
expected_VBN [PRIV]
,_,
with_PIN
additional_JJ
costs_NN
attributable_JJ
to_PIN
four_CD
product_NN
launches_NN
during_PIN
2005_CD
,_,
together_RB
with_PIN
incremental_JJ
costs_NN
in_PIN
2005_CD
associated_VBN
with_PIN
the_DT
new_JJ
FOSRENOL_NN
and_PHC
EQUETRO_NN
sales_NN
forces_NN
,_,
patent_NN
litigation_NOMZ
and_PHC
infrastructure_NN
,_,
$_$
24.5_CD
million_CD
of_PIN
SG&A_NN
costs_NN
related_VBN [WZPAST]
to_PIN
the_DT
acquired_VBN
TKT_NN
business_NOMZ
and_CC
$_$
4.5_CD
million_CD
related_VBN
to_PIN
the_DT
set_VBN
up_IN
of_PIN
the_DT
new_JJ
listed_VBN
holding_VBG [PRIV]
company_NN
for_PIN
the_DT
Shire_NN
Group_NN
._.
The_DT
depreciation_NOMZ
charge_NN
for_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
,_,
was_VBD
$_$
29.2_CD
million_CD
2004_CD
:_:
$_$
19.8_CD
million_CD
,_,
which_WDT [SERE]
in_PIN
2005_CD
included_VBD
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
write-downs_NN
of_PIN
$_$
6.5_CD
million_CD
2004_CD
:_:
$_$
1.6_CD
million_CD
._.
Amortization_NOMZ
charges_NN
,_,
including_VBG [PRESP]
the_DT
amortization_NOMZ
on_PIN
acquired_VBN
products_NN
,_,
were_VBD
$_$
45.2_CD
million_CD
for_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
2004_CD
:_:
$_$
38.7_CD
million_CD
._.
Intangible_JJ
asset_NN
impairments_VPRT
The_DT
charge_NN
for_PIN
intangible_JJ
asset_NN
impairments_NOMZ
for_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
was_VBD
$_$
5.6_CD
million_CD
2004_CD
:_:
$_$
13.5_CD
million_CD
._.
The_DT
approval_NN
of_PIN
generic_JJ
versions_NN
of_PIN
AGRYLIN_NN
in_PIN
April_NN
2005_CD
and_CC
the_DT
decision_NN
not_XX0
to_TO
support_VB
and_PHC
promote_VB
certain_JJ
non-core_JJ
products_NN
going_VBG [WZPRES]
forward_RB
resulted_VBD
in_PIN
changes_NN
to_PIN
the_DT
estimate_NN
of_PIN
the_DT
Companys_NN
future_JJ
cash_NN
flows_NN
and_CC
,_,
as_CONJ
a_NULL
result_NULL
,_,
impairments_NOMZ
were_VBD [PASS]
required_VBN [SUAV]
in_PIN
both_DT
2005_CD
and_CC
2004_CD
._.
Reorganization_NOMZ
costs_NN
2005_CD
2004_CD
Year_NN
to_PIN
December_NN
31_CD
,_,
$_$
million_CD
$_$
million_CD
Employee_NN
severance_NN
1.6_CD
20.0_CD
Relocation_NOMZ
costs_VPRT
13.8_CD
Write-off_PIN
of_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
1.2_CD
Consultancy_NN
costs_NN
0.5_CD
2.9_CD
Duplicate_NN
facilities_NOMZ
7.2_CD
5.1_CD
Information_NOMZ
technology_NN
costs_VPRT
2.1_CD
Other_JJ
costs_NN
3.4_CD
9.3_CD
48.5_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
49_CD
Shire_NN
plc_NN
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:54_CD
Page_NN
50_CD
Financial_NN
review_NN
As_IN
previously_TIME
disclosed_VBN [PUBV]
,_,
the_DT
Company_NN
began_VBD
a_DT
consolidation_NOMZ
of_PIN
its_PIT
North_PLACE
American_JJ
sites_NN
in_PIN
2004_CD
,_,
with_PIN
the_DT
aim_NN
of_PIN
decreasing_VBG
the_DT
number_NN
of_PIN
sites_NN
from_PIN
16_CD
to_PIN
four_CD
,_,
including_VBG [PRESP]
the_DT
opening_GER
of_PIN
a_DT
new_JJ
US_FPP1
headquarters_NN
office_NN
in_PIN
Wayne_NN
,_,
Pennsylvania_NN
._.
The_DT
Company_NN
recorded_VBN
costs_NN
of_PIN
$_$
9.3_CD
million_CD
in_PIN
2005_CD
and_CC
$_$
48.5_CD
million_CD
in_PIN
2004_CD
primarily_RB
associated_VBN
with_PIN
:_:
severance_NN
costs_NN
relating_VBG [WZPRES]
to_PIN
137_CD
employees_NN
:_:
retention_NOMZ
payments_NOMZ
to_PIN
key_JJ
employees_NN
:_:
relocation_NOMZ
costs_NN
relating_VBG [WZPRES]
to_PIN
85_CD
employees_NN
who_WP [WHSUB]
relocated_VBD
to_PIN
Wayne_NN
,_,
Pennsylvania_NN
:_:
costs_NN
of_PIN
duplicate_VPRT
facilities_NOMZ
including_VBG [WZPRES]
lease_NN
exit_NN
costs_NN
:_:
and_ANDC
other_JJ
incremental_JJ
costs_NN
associated_VBN [WZPAST]
with_PIN
the_DT
site_NN
closures_NN
,_,
such_JJ
as_IN
legal_JJ
,_,
consultancy_NN
,_,
the_DT
write-down_NN
of_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
and_PHC
information_NOMZ
technology_NN
costs_NN
._.
Following_VBG [PRESP]
the_DT
closure_NN
of_PIN
the_DT
Newport_NN
site_NN
in_PIN
July_NN
2005_CD
,_,
the_DT
site_NN
consolidation_NOMZ
is_VPRT [BEMA]
now_TIME
complete_PRED
and_CC
no_SYNE
further_JJ
reorganization_NOMZ
costs_NN
are_VPRT [PASS]
expected_VBN [PRIV]
._.
Integration_NOMZ
costs_NN
For_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
,_,
the_DT
Company_NN
incurred_VBN
$_$
9.7_CD
million_CD
of_PIN
costs_NN
associated_VBN [WZPAST]
with_PIN
the_DT
integration_NOMZ
of_PIN
the_DT
TKT_NN
business_NOMZ
into_PIN
the_DT
Shire_NN
Group_NN
2004_CD
:_:
$_$
nil_JJ
._.
This_DEMP
included_VBD
retention_NOMZ
payments_NOMZ
for_PIN
key_JJ
staff_NN
of_PIN
$_$
7_CD
million_CD
,_,
information_NOMZ
technology_NN
costs_NN
of_PIN
$_$
1_CD
million_CD
and_CC
other_JJ
costs_NN
of_PIN
$_$
1.7_CD
million_CD
._.
In-process_JJ
R&D_NN
write-off_PIN
During_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
,_,
as_IN
required_VBN [SUAV]
by_PIN
Financial_NN
Accounting_GER
Standards_NN
Board_NN
Interpretation_NOMZ
No._NN
._.
4_CD
,_,
Applicability_NOMZ
of_PIN
FASB_NN
Statement_NOMZ
No._NN
._.
2_CD
to_PIN
Business_NOMZ
Combinations_NOMZ
Accounted_NN
for_PIN
by_PIN
the_DT
Purchase_NN
Method_NN
FIN_NN
4_CD
,_,
the_DT
Company_NN
wrote-off_PIN
the_DT
portion_NOMZ
of_PIN
the_DT
TKT_NN
purchase_NN
price_NN
allocated_VBN [WZPAST]
to_PIN
in-process_JJ
research_NN
and_PHC
development_NOMZ
of_PIN
$_$
673_CD
million_CD
._.
This_DEMO
amount_NN
represents_VPRT
the_DT
value_NN
of_PIN
those_DEMO
intangible_JJ
assets_NN
acquired_VBN
as_IN
part_NN
of_PIN
the_DT
TKT_NN
acquisition_NOMZ
,_,
which_WDT [SERE]
at_PIN
the_DT
time_NN
of_PIN
acquisition_NOMZ
had_VBD [PEAS]
not_XX0
been_VBN [BYPA]
approved_VBN
by_PIN
the_DT
FDA_NN
or_CC
other_JJ
regulatory_JJ
authorities_NOMZ
,_,
including_VBG
ELAPRASE_NN
and_PHC
GA-GCB_NN
._.
For_PIN
the_DT
determination_NOMZ
of_PIN
the_DT
fair_JJ
value_NN
of_PIN
in-process_JJ
research_NN
and_PHC
development_NOMZ
see_VPRT [PRIV]
Note_NN
4_CD
to_PIN
the_DT
Companys_NN
consolidated_JJ
financial_JJ
statements_NOMZ
on_PIN
page_NN
95_CD
._.
Interest_NN
income_NN
For_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
the_DT
Company_NN
received_VBD
interest_NN
income_NN
of_PIN
$_$
35.3_CD
million_CD
2004_CD
:_:
$_$
21.9_CD
million_CD
._.
The_DT
increase_NN
compared_VBN [WZPAST]
to_PIN
2004_CD
is_VPRT [BEMA]
due_PRED
to_PIN
higher_JJ
interest_NN
rates_NN
on_PIN
the_DT
Companys_NN
US_FPP1
cash_NN
deposits_NN
which_WDT [WHSUB]
were_VBD [SPAU] [BYPA]
partially_DWNT
offset_VBN
by_PIN
the_DT
interest_NN
foregone_JJ
by_PIN
the_DT
Company_NN
on_PIN
the_DT
net_JJ
payments_NOMZ
of_PIN
$_$
1.1_CD
billion_CD
made_VBN
to_PIN
date_NN
in_PIN
respect_NN
of_PIN
the_DT
acquisition_NOMZ
of_PIN
TKT_NN
._.
Interest_NN
expense_NN
For_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
the_DT
Company_NN
incurred_VBN
interest_NN
expense_NN
of_PIN
$_$
12_CD
million_CD
2004_CD
:_:
$_$
12.3_CD
million_CD
._.
In_PIN
2005_CD
,_,
this_DEMO
expense_NN
included_VBD
a_DT
$_$
7.7_CD
million_CD
provision_NN
for_PIN
interest_NN
,_,
which_WDT [SERE]
may_POMD
be_VB [BYPA]
awarded_VBN
by_PIN
the_DT
court_NN
in_PIN
respect_NN
of_PIN
amounts_NN
due_JJ
to_PIN
former_JJ
holders_NN
of_PIN
approximately_RB
11.3_CD
million_CD
shares_NN
of_PIN
TKT_NN
common_JJ
stock_NN
who_WP [WHSUB]
have_VPRT [PEAS]
submitted_VBN [PUBV]
written_VBN [PUBV]
demands_NN
for_PIN
appraisal_NN
of_PIN
these_DEMO
shares_NN
see_VPRT [PRIV]
Note_NN
27_CD
to_PIN
the_DT
Companys_NN
consolidated_JJ
financial_JJ
statements_NOMZ
on_PIN
page_NN
120_CD
._.
In_CONJ
addition_NULL
,_,
interest_NN
expense_NN
includes_VPRT
$_$
1.2_CD
million_CD
,_,
relating_VBG [PRESP]
to_PIN
the_DT
costs_NN
of_PIN
a_DT
bridging_VBG
loan_NN
to_TO
finance_VB
the_DT
TKT_NN
acquisition_NOMZ
and_CC
other_JJ
interest_NN
related_VBN
expenses_NN
of_PIN
$_$
3.1_CD
million_CD
._.
In_PIN
2004_CD
,_,
interest_NN
expense_NN
included_VBD
the_DT
write-off_PIN
of_PIN
$_$
7.4_CD
million_CD
of_PIN
deferred_JJ
debt_NN
acquisition_NOMZ
costs_NN
arising_VBG [WZPRES]
on_PIN
the_DT
issue_NN
of_PIN
convertible_JJ
loan_NN
notes_NN
in_PIN
August_NN
2001_CD
._.
The_DT
write-off_PIN
was_VBD [PASS]
required_VBN [SUAV]
as_IN
a_DT
significant_JJ
portion_NOMZ
of_PIN
the_DT
convertible_JJ
loan_NN
notes_NN
were_VBD [PASS]
redeemed_VBN
._.
The_DT
$_$
7.4_CD
million_CD
represented_VBD
the_DT
balance_NN
of_PIN
these_DEMO
fees_NN
at_PIN
the_DT
date_NN
of_PIN
redemption_NOMZ
in_PIN
August_NN
2004_CD
._.
In_CONJ
addition_NULL
,_,
interest_NN
expense_NN
included_VBD
a_DT
$_$
4.2_CD
million_CD
interest_NN
charge_NN
incurred_VBN [WZPAST]
prior_RB
to_PIN
the_DT
redemption_NOMZ
and_CC
$_$
0.1_CD
million_CD
of_PIN
other_JJ
interest-related_JJ
expenses_NN
._.
Other_JJ
income_NN
expense_NN
,_,
net_JJ
2005_CD
2004_CD
Year_NN
to_PIN
December_NN
31_CD
,_,
$_$
million_CD
$_$
million_CD
Investment_NOMZ
income_NN
8.3_CD
18.9_CD
Write-down_NN
of_PIN
non-current_JJ
asset_NN
investments_NOMZ
2.0_CD
15.4_CD
Gain_NN
on_PIN
sale_NN
of_PIN
drug_NN
formulation_NOMZ
business_NOMZ
3.6_CD
Foreign_NN
exchange_NN
and_CC
other_JJ
0.3_CD
Total_JJ
9.9_CD
3.8_CD
50_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:54_CD
Page_NN
51_CD
An_DT
important_JJ
part_NN
of_PIN
Shires_NN
business_NOMZ
strategy_NN
is_VPRT
to_TO
protect_VB
its_PIT
products_NN
For_PIN
further_JJ
details_NN
see_VPRT [PRIV]
Note_NN
26_CD
and_CC
Note_VB [PRIV]
6_CD
to_PIN
the_DT
Companys_NN
consolidated_JJ
financial_JJ
statements_NOMZ
on_PIN
pages_NN
120_CD
and_CC
97_CD
._.
and_ANDC
technologies_NN
through_PIN
the_DT
use_NN
of_PIN
patents_NN
,_,
proprietary_JJ
technologies_NN
and_PHC
trademarks_NN
,_,
to_PIN
the_DT
extent_NN
available_JJ
._.
The_DT
Company_NN
intends_VPRT [SUAV]
The_DT
write-down_NN
in_PIN
investments_NOMZ
in_PIN
2005_CD
and_CC
2004_CD
resulted_VBD
from_PIN
events_NN
to_TO
defend_VB
its_PIT
intellectual_JJ
property_NN
and_ANDC
as_CONJ
a_NULL
result_NULL
may_POMD
need_VB
cash_NN
for_PIN
funding_VBG
litigation_NOMZ
expenses_NN
incurred_VBN
._.
and_ANDC
circumstances_NN
that_TSUB
indicated_VBD [PRIV]
there_EX
was_VBD
an_DT
other-than-temporary_JJ
impairment_NOMZ
of_PIN
investments_NOMZ
and_CC
,_,
accordingly_RB
,_,
management_NOMZ
recorded_VBD
The_DT
Company_NN
ordinarily_RB
finances_VPRT
its_PIT
activities_NOMZ
through_PIN
cash_NN
generated_VBD
an_DT
impairment_NOMZ
based_VBN [WZPAST]
on_PIN
its_PIT
assessment_NOMZ
of_PIN
fair_JJ
value_NN
._.
Further_JJ
details_NN
are_VPRT [PASS]
disclosed_VBN [PUBV]
in_PIN
Note_NN
11_CD
to_PIN
the_DT
Companys_NN
consolidated_JJ
financial_JJ
from_PIN
operating_VBG
activities_NOMZ
,_,
private_JJ
and_PHC
public_JJ
offerings_GER
of_PIN
equity_NOMZ
and_PHC
debt_NN
securities_NOMZ
and_CC
the_DT
proceeds_NN
of_PIN
asset_NN
or_CC
investment_NOMZ
disposals_NN
._.
Multicurrency_NN
Revolving_GER
Facilities_NOMZ
Agreement_NOMZ
Investment_NOMZ
income_NN
for_PIN
2005_CD
included_VBD
a_DT
$_$
3.9_CD
million_CD
realized_VBD [PRIV]
gain_NN
on_PIN
the_DT
sale_NN
of_PIN
a_DT
portfolio_NN
investment_NOMZ
2004_CD
:_:
$_$
14.8_CD
million_CD
._.
In_PIN
connection_NOMZ
with_PIN
the_DT
acquisition_NOMZ
of_PIN
TKT_NN
,_,
Shire_NN
and_CC
certain_JJ
members_NN
of_PIN
the_DT
Shire_NN
Group_NN
entered_VBD
into_PIN
a_DT
Multicurrency_NN
Revolving_GER
Facilities_NOMZ
Income_NN
taxes_NN
Agreement_NOMZ
the_DT
Facilities_NOMZ
Agreement_NOMZ
with_PIN
ABN_NN
AMRO_NN
Bank_NN
N._NN
V._NN
Barclays_NN
Capital_NN
,_,
Citigroup_NN
Global_NN
Markets_NN
Limited_NN
,_,
HSBC_NN
Bank_NN
plc_NN
The_DT
Companys_NN
effective_JJ
tax_NN
rate_NN
for_PIN
2005_CD
was_VBD [BEMA]
negative_PRED
29_CD
%_NN
a_DT
tax_NN
charge_NN
of_PIN
$_$
92.1_CD
million_CD
on_PIN
losses_NN
from_PIN
continuing_VBG
operations_NOMZ
and_CC
The_DT
Royal_NN
Bank_NN
of_PIN
Scotland_NN
plc_VPRT
the_DT
Lenders_NN
on_PIN
June_NN
15_CD
,_,
2005_CD
._.
The_DT
Facilities_NOMZ
Agreement_NOMZ
comprises_VPRT
two_CD
credit_NN
facilities_NOMZ
:_:
i_FPP1
a_DT
committed_VBN
before_IN
income_NN
taxes_NN
and_PHC
equity_NOMZ
method_NN
investees_NN
of_PIN
$_$
320.9_CD
million_CD
._.
The_DT
significant_JJ
difference_NN
from_PIN
the_DT
prior-year_JJ
effective_JJ
tax_NN
rate_NN
multicurrency_NN
three-year_JJ
revolving_JJ
loan_NN
facility_NOMZ
in_PIN
an_DT
aggregate_JJ
amount_NN
of_PIN
$_$
500_CD
million_CD
Facility_NOMZ
A_DT
and_CC
ii_FW
a_DT
committed_JJ
364_CD
day_NN
revolving_JJ
loan_NN
of_PIN
28_CD
%_NN
is_VPRT [BEMA]
due_PRED
to_PIN
the_DT
in-process_JJ
research_NN
and_PHC
development_NOMZ
write-off_PIN
of_PIN
$_$
673_CD
million_CD
,_,
which_WDT [SERE]
is_VPRT
not_XX0
tax_NN
deductible_JJ
._.
facility_NOMZ
in_PIN
an_DT
aggregate_JJ
amount_NN
of_PIN
$_$
300_CD
million_CD
Facility_NOMZ
B_NN
and_CC
together_RB
with_PIN
Facility_NOMZ
A_DT
,_,
the_DT
Facilities_NOMZ
._.
Shire_NN
has_VPRT [PEAS]
agreed_VBN [SUAV] [PUBV]
to_TO
act_VB
as_IN
guarantor_NN
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
,_,
the_DT
Company_NN
had_VBD [PEAS]
deferred_VBN
tax_NN
assets_NN
for_PIN
any_QUAN
of_PIN
its_PIT
subsidiaries_NN
that_TSUB
borrow_VPRT
under_IN
the_DT
Facilities_NOMZ
Agreement_NOMZ
._.
net_NN
of_PIN
valuation_NOMZ
allowances_NN
of_PIN
$_$
116.2_CD
million_CD
2004_CD
:_:
$_$
78.1_CD
million_CD
._.
The_DT
increase_NN
in_PIN
deferred_JJ
tax_NN
is_VPRT [BEMA]
primarily_RB
attributable_PRED
to_PIN
the_DT
acquisition_NOMZ
Facility_NOMZ
A_DT
may_POMD
be_VB [PASS]
used_VBN
for_PIN
general_JJ
corporate_JJ
purposes_NN
,_,
including_VBG
financing_VBG
the_DT
purchase_NN
price_NN
and_CC
other_JJ
costs_NN
with_PIN
respect_NN
to_PIN
the_DT
of_PIN
TKT_NN
that_TSUB
resulted_VBD
in_PIN
a_DT
net_JJ
deferred_VBN
tax_NN
asset_NN
of_PIN
$_$
60.4_CD
million_CD
being_VBG [PASS]
recorded_VBN
in_PIN
the_DT
opening_GER
day_NN
balance_NN
sheet_NN
,_,
although_CONC
part_NN
of_PIN
the_DT
asset_NN
acquisition_NOMZ
of_PIN
TKT_NN
including_VBG [WZPRES]
refinancing_GER
TKTs_NN
existing_VBG [WZPRES]
indebtedness_NOMZ
._.
Facility_NOMZ
B_NN
may_POMD
be_VB [PASS]
used_VBN
only_DWNT
for_PIN
financing_VBG
certain_JJ
milestone_NN
payments_NOMZ
was_VBD [SPAU] [PASS]
subsequently_TIME
realized_VBN [PRIV]
in_PIN
the_DT
post_NN
acquisition_NOMZ
period_NN
._.
Realization_NOMZ
of_PIN
deferred_JJ
tax_NN
assets_NN
is_VPRT [BEMA]
dependent_PRED
upon_PIN
generating_VBG
sufficient_JJ
taxable_JJ
due_JJ
under_IN
the_DT
agreement_NOMZ
between_PIN
Shire_NN
,_,
and_ANDC
inter_VB
alia_NN
,_,
New_NN
River_NN
Pharmaceuticals_NN
Inc._NN
._.
New_NN
River_NN
,_,
dated_VBN
January_NN
31_CD
,_,
2005_CD
._.
income_NN
to_TO
utilize_VB
such_JJ
assets_NN
._.
Although_CONC
realization_NOMZ
of_PIN
these_DEMO
assets_NN
is_VPRT [PASS]
not_XX0
assured_VBN
,_,
it_PIT
is_VPRT [BEMA]
more_EMPH
likely_PRED
than_PIN
not_XX0
that_DEMO
the_DT
amount_NN
recognized_VBN [PRIV]
Facility_NOMZ
A_DT
terminates_NN
on_PIN
June_NN
15_CD
,_,
2008_CD
,_,
and_ANDC
Facility_NOMZ
B_NN
terminates_VPRT
on_PIN
will_PRMD
be_VB [PASS]
realized_VBN [PRIV]
._.
See_VB [PRIV]
Note_VB [PRIV]
29_CD
to_PIN
the_DT
Companys_NN
consolidated_JJ
financial_JJ
statements_NOMZ
on_PIN
page_NN
121_CD
for_PIN
expiry_NN
dates_NN
of_PIN
these_DEMO
tax_NN
losses_NN
._.
At_PIN
Shires_NN
request_NN
,_,
the_DT
Lenders_NN
may_POMD
agree_VB [SUAV] [PUBV]
to_PIN
successive_JJ
annual_JJ
extensions_NN
of_PIN
Facility_NOMZ
B_NN
,_,
but_CC
not_XX0
beyond_IN
the_DT
maturity_NOMZ
date_NN
of_PIN
Equity_NOMZ
in_PIN
earnings_GER
losses_NN
of_PIN
equity_NOMZ
method_NN
investees_VPRT
Facility_NOMZ
A._NN
Alternatively_CONJ
,_,
Shire_NN
has_VPRT
the_DT
right_NN
to_TO
draw_VB
Facility_NOMZ
B_NN
or_CC
convert_VB
existing_VBG
loans_NN
under_IN
Facility_NOMZ
B_NN
into_PIN
a_DT
term_NN
loan_NN
with_PIN
the_DT
same_JJ
maturity_NOMZ
Net_JJ
losses_NN
of_PIN
$_$
1_CD
million_CD
were_VBD [PASS]
recorded_VBN
for_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
2004_CD
:_:
net_JJ
earnings_GER
of_PIN
$_$
2.5_CD
million_CD
._.
This_DEMP
comprised_VBN
earnings_GER
date_NN
as_IN
Facility_NOMZ
A._NN
The_NN
availability_NOMZ
of_PIN
loans_NN
under_IN
each_QUAN
of_PIN
the_DT
Facilities_NOMZ
is_VPRT [BEMA]
subject_PRED
to_PIN
customary_JJ
conditions_NOMZ
,_,
including_VBG [PRESP]
the_DT
absence_NN
of_PIN
of_PIN
$_$
5.3_CD
million_CD
from_PIN
the_DT
50_CD
%_NN
share_NN
of_PIN
the_DT
antiviral_JJ
commercialization_NOMZ
partnership_NN
with_PIN
GSK_NN
in_PIN
Canada_NN
2004_CD
:_:
$_$
4.4_CD
million_CD
,_,
offset_VBN [PASTP]
by_PIN
the_DT
any_QUAN
defaults_NN
thereunder_RB
and_CC
the_DT
accuracy_NN
in_PIN
all_QUAN
material_NN
respects_VPRT
of_PIN
Shires_NN
representations_NOMZ
and_PHC
warranties_NN
contained_VBD
therein_RB
._.
Companys_NN
share_NN
of_PIN
losses_NN
in_PIN
the_DT
GeneChem_NN
and_PHC
EGS_NN
Healthcare_NN
Funds_NN
of_PIN
$_$
6.3_CD
million_CD
2004_CD
:_:
$_$
1.9_CD
million_CD
._.
The_DT
Facilities_NOMZ
include_VPRT
representations_NOMZ
and_PHC
warranties_NN
,_,
covenants_NN
and_CC
Discontinued_VBN
operations_NOMZ
events_NN
of_PIN
default_NN
,_,
including_VBG
requirements_NOMZ
that_TSUB
Shires_VPRT
ratio_NN
of_PIN
Net_JJ
Debt_NN
to_PIN
EBITDA_NN
as_IN
defined_VBN
in_PIN
the_DT
Facilities_NOMZ
Agreement_NOMZ
not_XX0
exceed_VB
3.0_CD
to_PIN
1_CD
During_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
gains_NN
on_PIN
disposition_NOMZ
of_PIN
the_DT
discontinued_VBN
operations_NOMZ
totaled_VBD
$_$
3.1_CD
million_CD
._.
This_DEMP
resulted_VBD
from_PIN
the_DT
and_CC
that_THVC
the_DT
ratio_NN
of_PIN
EBITDA_NN
to_PIN
Net_JJ
Interest_NN
be_VB [BEMA]
not_XX0
less_PRED
than_PIN
4.0_CD
to_PIN
1_CD
,_,
both_DT
in_PIN
respect_NN
of_PIN
the_DT
most_EMPH
recently_TIME
ended_VBN
fiscal_JJ
year_NN
,_,
and_ANDC
limitations_NOMZ
finalization_NOMZ
of_PIN
the_DT
working_VBG
capital_NN
agreement_NOMZ
with_PIN
ID_NN
Biomedical_NN
Inc._NN
._.
IDB_NN
,_,
which_WDT [SERE]
was_VBD
part_NN
of_PIN
the_DT
sale_NN
of_PIN
Shires_NN
vaccines_NN
business_NOMZ
to_PIN
on_PIN
the_DT
creation_NOMZ
of_PIN
liens_NN
,_,
disposal_NN
of_PIN
assets_NN
,_,
incurrence_NN
of_PIN
indebtedness_NOMZ
,_,
making_VBG [PRESP]
of_PIN
loans_NN
and_CC
giving_VBG
of_PIN
guarantees_NN
._.
As_CONJ
a_NULL
result_NULL
,_,
a_DT
disputed_VBN
amount_NN
,_,
which_WDT [SERE]
had_VBD [SPAU] [PEAS]
previously_TIME
been_VBN [PASS]
provided_VBN
for_PIN [STPR]
,_,
was_VBD [PASS]
received_VBN
and_CC
the_DT
corresponding_JJ
provision_NN
Interest_NN
on_PIN
loans_NN
under_IN
the_DT
Facilities_NOMZ
will_PRMD
be_VB [BEMA]
payable_PRED
on_PIN
the_DT
last_JJ
day_NN
was_VBD [PASS]
released_VBN
._.
of_PIN
each_QUAN
interest_NN
period_NN
,_,
which_WDT [SERE]
period_NN
may_POMD
be_VB [BEMA]
one_CD
,_,
two_CD
,_,
three_CD
or_CC
six_CD
months_NN
at_PIN
the_DT
election_NOMZ
of_PIN
Shire_NN
or_CC
as_IN
otherwise_CONJ
agreed_VBN [SUAV] [PUBV]
with_PIN
the_DT
Liquidity_NOMZ
and_PHC
capital_NN
resources_NN
General_NN
Lenders_NN
._.
The_DT
interest_NN
rate_NN
on_PIN
each_QUAN
loan_NN
for_PIN
each_QUAN
interest_NN
period_NN
is_VPRT [BEMA]
the_DT
percentage_NN
rate_NN
per_PIN
annum_NN
,_,
which_WDT [SERE]
is_VPRT [BEMA]
the_DT
aggregate_NN
of_PIN
the_DT
applicable_JJ
The_DT
Companys_NN
funding_GER
requirements_NOMZ
depend_VPRT
on_PIN
a_DT
number_NN
of_PIN
factors_NN
,_,
including_VBG [PRESP]
its_PIT
development_NOMZ
programs_NN
:_:
corporate_JJ
,_,
business_NOMZ
and_PHC
product_NN
margin_NN
ranging_VBG [WZPRES]
from_PIN
0.35_CD
to_PIN
0.65_CD
%_NN
per_PIN
annum_NN
,_,
depending_VBG [PRESP]
on_PIN
the_DT
ratio_NN
of_PIN
Net_JJ
Debt_NN
to_PIN
EBITDA_NN
,_,
LIBOR_NN
,_,
and_ANDC
mandatory_JJ
cost_NN
,_,
if_COND
any_QUAN
acquisitions_NOMZ
:_:
the_DT
level_NN
of_PIN
resources_NN
required_VBN [SUAV] [WZPAST]
for_PIN
the_DT
expansion_NN
of_PIN
manufacturing_GER
and_PHC
marketing_GER
capabilities_NOMZ
as_IN
the_DT
product_NN
base_NN
expands_VPRT
:_:
as_IN
calculated_VBN [PRIV]
in_PIN
accordance_NN
with_PIN
Schedule_NN
5_CD
of_PIN
the_DT
Facilities_NOMZ
Agreement_NOMZ
._.
Shire_NN
shall_PRMD [SPAU]
also_RB
pay_VB
fees_NN
equal_JJ
to_PIN
35_CD
%_NN
per_PIN
annum_NN
of_PIN
the_DT
increases_NN
in_PIN
accounts_NN
receivable_JJ
and_CC
inventory_NN
which_WDT [WHSUB]
may_POMD
arise_VB
as_IN
sales_NN
levels_NN
increase_NN
:_:
competitive_JJ
and_PHC
technological_JJ
developments_NOMZ
:_:
applicable_JJ
margin_NN
on_PIN
available_JJ
commitments_NOMZ
under_IN
Facility_NOMZ
A_DT
for_PIN
the_DT
availability_NOMZ
period_NN
applicable_JJ
to_PIN
Facility_NOMZ
A_DT
and_CC
20_CD
per_PIN
cent_NN
per_PIN
annum_NN
the_DT
timing_NN
and_PHC
cost_NN
of_PIN
obtaining_VBG
required_JJ
regulatory_JJ
approvals_NN
for_PIN
new_JJ
products_NN
:_:
the_DT
timing_NN
and_PHC
quantum_NN
of_PIN
milestone_NN
payments_NOMZ
of_PIN
the_DT
applicable_JJ
margin_NN
on_PIN
available_JJ
commitments_NOMZ
under_IN
Facility_NOMZ
B_NN
for_PIN
the_DT
availability_NOMZ
period_NN
applicable_JJ
to_PIN
Facility_NOMZ
B_NN
in_PIN
respect_NN
of_PIN
the_DT
on_PIN
collaborative_JJ
projects_NN
:_:
the_DT
timing_NN
of_PIN
and_CC
quantum_NN
of_PIN
tax_NN
and_PHC
dividend_NN
payments_NOMZ
:_:
the_DT
timing_NN
and_PHC
quantum_NN
of_PIN
purchases_NN
of_PIN
Shire_NN
period_NN
prior_RB
to_PIN
January_NN
1_CD
,_,
2007_CD
,_,
and_ANDC
30_CD
%_NN
per_PIN
annum_NN
of_PIN
the_DT
applicable_JJ
margin_NN
thereafter_RB
._.
Interest_NN
on_PIN
overdue_JJ
amounts_NN
under_IN
the_DT
Facilities_NOMZ
shares_NN
in_PIN
the_DT
market_NN
to_TO
satisfy_VB
option_NOMZ
exercises_NN
and_CC
the_DT
continuing_VBG
cash_NN
generated_VBD
from_PIN
sales_NN
of_PIN
Shires_NN
key_JJ
products_NN
._.
will_PRMD
accrue_VB
at_PIN
a_DT
rate_NN
,_,
which_WDT [SERE]
is_VPRT [BEMA]
one_CD
percent_NN
higher_JJ
than_PIN
the_DT
rates_NN
otherwise_CONJ
applicable_JJ
to_PIN
the_DT
loans_NN
under_IN
the_DT
Facilities_NOMZ
._.
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
51_CD
Shire_NN
plc_NN
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:54_CD
Page_NN
52_CD
Financial_NN
review_NN
Upon_PIN
a_DT
change_NN
of_PIN
control_NN
of_PIN
Shire_NN
or_CC
upon_PIN
the_DT
occurrence_NN
of_PIN
an_DT
event_NN
of_PIN
default_NN
and_CC
the_DT
expiration_NOMZ
of_PIN
any_QUAN
applicable_JJ
cure_NN
period_NN
,_,
the_DT
total_JJ
commitments_NOMZ
under_IN
the_DT
Facilities_NOMZ
may_POMD
be_VB [PASS]
canceled_VBN
,_,
all_QUAN
or_CC
part_NN
of_PIN
the_DT
loans_NN
,_,
together_RB
with_PIN
accrued_VBN
interest_NN
and_CC
all_QUAN
other_JJ
amounts_NN
accrued_VBN
or_CC
outstanding_JJ
may_POMD
be_VB [BEMA]
immediately_TIME
due_PRED
and_PHC
payable_PRED
and_CC
all_QUAN
or_CC
part_NN
of_PIN
the_DT
loans_NN
may_POMD
become_VB
payable_JJ
on_PIN
demand_NN
._.
Events_NN
of_PIN
default_NN
under_IN
the_DT
Facilities_NOMZ
include_VPRT
:_:
i_FPP1
non-payment_NOMZ
of_PIN
any_QUAN
amounts_NN
due_JJ
under_IN
the_DT
Facilities_NOMZ
,_,
ii_FW
failure_NN
to_TO
satisfy_VB
any_QUAN
financial_JJ
covenants_NN
,_,
iii_FW
material_NN
misrepresentation_NOMZ
in_PIN
any_QUAN
of_PIN
the_DT
finance_NN
documents_NOMZ
,_,
iv_NN
failure_NN
to_TO
pay_VB
,_,
or_CC
certain_JJ
other_JJ
defaults_NN
under_IN
other_JJ
financial_JJ
indebtedness_NOMZ
,_,
v_FW
certain_JJ
insolvency_NN
events_NN
or_CC
proceedings_GER
,_,
vi_FW
material_NN
adverse_JJ
changes_NN
in_PIN
the_DT
business_NOMZ
,_,
operations_NOMZ
,_,
assets_NN
or_CC
financial_JJ
condition_NOMZ
of_PIN
the_DT
Group_NN
,_,
vii_FW
certain_JJ
ERISA_NN
breaches_NN
which_WDT [WHSUB]
would_PRMD
have_VB
a_DT
material_NN
adverse_JJ
effect_NN
,_,
viii_FW
change_NN
of_PIN
control_NN
of_PIN
a_DT
subsidiary_NN
of_PIN
Shire_NN
that_DEMP
is_VPRT [BEMA]
a_DT
party_NN
to_PIN
the_DT
Facilities_NOMZ
Agreement_NOMZ
,_,
or_CC
ix_VB
if_COND
it_PIT
becomes_VPRT
illegal_JJ
for_PIN
Shire_NN
or_CC
any_QUAN
of_PIN
its_PIT
subsidiaries_NN
that_TSUB
are_VPRT
parties_NN
to_PIN
the_DT
Facility_NOMZ
Agreement_NOMZ
to_TO
perform_VB
their_TPP3
obligations_NOMZ
or_CC
they_TPP3
repudiate_VPRT
the_DT
Facilities_NOMZ
Agreement_NOMZ
or_CC
any_QUAN
Finance_NN
Document_NOMZ
as_IN
defined_VBN
in_PIN
the_DT
Facilities_NOMZ
Agreement_NOMZ
._.
The_DT
Facilities_NOMZ
Agreement_NOMZ
is_VPRT [BYPA]
governed_VBN
by_PIN
English_NN
law_NN
._.
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
,_,
the_DT
Company_NN
had_VBD
not_XX0
drawn-down_JJ
on_PIN
these_DEMO
facilities_NOMZ
._.
Shire_NN
anticipates_VPRT [PRIV]
that_THVC
its_PIT
operating_GER
cash_NN
flow_NN
together_RB
with_PIN
available_JJ
cash_NN
,_,
cash_NN
equivalents_NN
and_CC
short-term_JJ
investments_NOMZ
and_CC
the_DT
above_PLACE
mentioned_VBN [PUBV]
debt_NN
facility_NOMZ
will_PRMD
be_VB [BEMA]
sufficient_PRED
to_TO
meet_VB
its_PIT
anticipated_JJ
future_NN
operating_GER
expenses_NN
,_,
outstanding_JJ
costs_NN
related_VBN [WZPAST]
to_PIN
the_DT
acquisition_NOMZ
of_PIN
TKT_NN
,_,
capital_NN
expenditures_NN
,_,
dividends_NN
,_,
share_NN
repurchases_NN
and_PHC
debt_NN
service_NN
and_PHC
lease_NN
obligations_NOMZ
as_IN
they_TPP3
become_VPRT
due_JJ
over_IN
the_DT
next_JJ
12_CD
months_NN
._.
If_COND
the_DT
Company_NN
decides_VPRT [SUAV] [PRIV]
to_TO
acquire_VB
other_JJ
businesses_NOMZ
,_,
it_PIT
expects_VPRT [PRIV]
to_TO
fund_VB
these_DEMO
acquisitions_NOMZ
from_PIN
existing_VBG
cash_NN
resources_NN
,_,
the_DT
debt_NN
facility_NOMZ
discussed_VBN
above_PLACE
and_CC
possibly_RB
through_PIN
new_JJ
borrowings_GER
and_CC
or_CC
the_DT
issue_NN
of_PIN
new_JJ
equity_NOMZ
if_COND
necessary_JJ
._.
Sources_NN
and_PHC
uses_NN
of_PIN
cash_NN
The_DT
following_VBG
table_NN
provides_VPRT
an_DT
analysis_NN
of_PIN
the_DT
Companys_NN
gross_JJ
and_PHC
net_JJ
cash_NN
funds_NN
as_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
and_CC
2004_CD
:_:
2005_CD
2004_CD
Change_NN
December_NN
31_CD
,_,
$_$
000_CD
$_$
000_CD
%_NN
Cash_NN
and_PHC
cash_NN
equivalents_NN
656,456_CD
1,111,477_CD
41_CD
%_NN
Short-term_JJ
investments_NOMZ
6,947_CD
324,411_CD
98_CD
%_NN
Gross_NN
cash_NN
funds_NN
663,403_CD
1,435,888_CD
54_CD
%_NN
Total_JJ
debt_NN
116_CD
116_CD
Net_JJ
cash_NN
funds_NN
663,287_CD
1,435,772_CD
54_CD
%_NN
Cash_NN
flow_NN
activity_NOMZ
Net_JJ
cash_NN
provided_VBN [WZPAST]
by_PIN
operating_VBG
activities_NOMZ
for_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
was_VBD
$_$
381.1_CD
million_CD
,_,
a_DT
decrease_NN
of_PIN
$_$
107.6_CD
million_CD
compared_VBN
to_PIN
the_DT
previous_JJ
year_NN
._.
The_DT
reduction_NOMZ
in_PIN
cash_NN
generation_NOMZ
is_VPRT [BEMA]
primarily_RB
due_PRED
to_PIN
the_DT
operating_GER
losses_NN
of_PIN
the_DT
acquired_VBN
TKT_NN
business_NOMZ
,_,
the_DT
$_$
50_CD
million_CD
payment_NOMZ
to_PIN
New_NN
River_NN
and_CC
the_DT
timing_NN
of_PIN
working_VBG
capital_NN
payments_NOMZ
._.
Net_JJ
cash_NN
used_VBN [WZPAST]
in_PIN
investing_VBG
activities_NOMZ
was_VBD
$_$
836.4_CD
million_CD
in_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
._.
Decreases_NN
in_PIN
short-term_JJ
investments_NOMZ
of_PIN
$_$
366.7_CD
million_CD
along_IN
with_PIN
proceeds_NN
of_PIN
$_$
60_CD
million_CD
from_PIN
the_DT
redemption_NOMZ
by_PIN
IDB_NN
of_PIN
its_PIT
subscription_NOMZ
receipts_NN
and_CC
the_DT
receipt_NN
from_PIN
IDB_NN
of_PIN
additional_JJ
proceeds_NN
from_PIN
the_DT
sale_NN
of_PIN
the_DT
vaccines_NN
business_NOMZ
of_PIN
$_$
32.2_CD
million_CD
,_,
offset_VBN
cash_NN
paid_VBN [WZPAST]
on_PIN
the_DT
purchase_NN
of_PIN
TKT_NN
net_NN
of_PIN
cash_NN
and_PHC
cash_NN
equivalents_NN
acquired_VBN [WZPAST]
of_PIN
$_$
1,151.5_CD
million_CD
,_,
loans_NN
made_VBN [WZPAST]
to_PIN
IDB_NN
of_PIN
$_$
43.2_CD
million_CD
see_VPRT [PRIV]
Note_NN
6_CD
to_PIN
the_DT
Companys_NN
consolidated_JJ
financial_JJ
statements_NOMZ
on_PIN
page_NN
97_CD
,_,
capital_NN
expenditure_NN
on_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
of_PIN
$_$
86.2_CD
million_CD
and_CC
intangible_JJ
assets_NN
of_PIN
$_$
20.5_CD
million_CD
._.
Capital_NN
expenditure_NN
on_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
included_VBD
$_$
23.3_CD
million_CD
leasehold_NN
building_GER
improvements_NOMZ
,_,
$_$
16.3_CD
million_CD
on_PIN
computer_NN
equipment_NOMZ
and_CC
$_$
3.1_CD
million_CD
on_PIN
furniture_NN
and_PHC
fittings_GER
for_PIN
the_DT
new_JJ
Shire_NN
US_FPP1
headquarters_NN
at_PIN
Wayne_NN
,_,
Pennsylvania_NN
,_,
$_$
10.6_CD
million_CD
on_PIN
IT_PIT
projects_NN
,_,
$_$
5.4_CD
million_CD
on_PIN
the_DT
expansion_NN
and_PHC
refurbishment_NOMZ
at_PIN
the_DT
Basingstoke_NN
Head_NN
Office_NN
,_,
$_$
3.2_CD
million_CD
of_PIN
plant_NN
equipment_NOMZ
and_CC
$_$
15.9_CD
million_CD
on_PIN
the_DT
expansion_NN
and_PHC
modification_NOMZ
at_PIN
Shire_NN
US_FPP1
Manufacturing_GER
Inc._NN
in_PIN
the_DT
US_FPP1
._.
Capital_NN
expenditure_NN
on_PIN
intangible_JJ
assets_NN
included_VBD
the_DT
final_JJ
payment_NOMZ
for_PIN
the_DT
acquisition_NOMZ
of_PIN
the_DT
exclusive_JJ
commercialization_NOMZ
rights_NN
to_PIN
REMINYL_NN
in_PIN
the_DT
UK_NN
and_PHC
Republic_NN
of_PIN
Ireland_NN
._.
Net_JJ
cash_NN
provided_VBN [WZPAST]
by_PIN
financing_VBG
activities_NOMZ
was_VBD
$_$
9.6_CD
million_CD
for_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
._.
This_DEMP
was_VBD [BEMA]
primarily_RB
due_PRED
to_PIN
inflows_NN
of_PIN
$_$
37.1_CD
million_CD
from_PIN
the_DT
exercise_NN
of_PIN
employee_NN
stock_NN
options_NOMZ
being_VBG [WZPRES] [BYPA]
offset_VBN
by_PIN
the_DT
dividend_NN
payments_NOMZ
of_PIN
$_$
28.5_CD
million_CD
in_PIN
respect_NN
of_PIN
the_DT
six_CD
months_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
and_CC
the_DT
six_CD
months_NN
to_PIN
June_NN
30_CD
,_,
2005_CD
._.
The_DT
total_JJ
cash_NN
consideration_NOMZ
for_PIN
the_DT
acquisition_NOMZ
of_PIN
TKT_NN
is_VPRT [PASS]
expected_VBN [PRIV]
to_TO
be_VB
approximately_RB
$_$
1.6_CD
billion_CD
,_,
subject_JJ
to_TO
change_VB
as_RB
may_POMD
be_VB [BYPA]
required_VBN [SUAV]
by_PIN
the_DT
appraisal_NN
rights_NN
process_NN
._.
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
,_,
shareholders_NN
owning_VBG [WZPRES]
approximately_RB
24.8_CD
million_CD
TKT_NN
shares_NN
had_VBD [PEAS]
accepted_VBN [PRIV]
the_DT
offer_NN
and_CC
$_$
916.9_CD
million_CD
had_VBD [PEAS]
been_VBN [PASS]
paid_VBN
to_PIN
them_TPP3
,_,
$_$
83.9_CD
million_CD
was_VBD [PASS]
paid_VBN
in_PIN
connection_NOMZ
with_PIN
TKT_NN
stock_NN
options_NOMZ
and_CC
$_$
170.1_CD
million_CD
in_PIN
connection_NOMZ
with_PIN
convertible_JJ
notes_NN
,_,
outstanding_JJ
at_PIN
the_DT
date_NN
of_PIN
acquisition_NOMZ
._.
Following_VBG [PRESP]
the_DT
exercise_NN
of_PIN
appraisal_NN
rights_NN
by_PIN
former_JJ
holders_NN
of_PIN
approximately_RB
11.3_CD
million_CD
shares_NN
of_PIN
TKT_NN
common_JJ
stock_NN
,_,
the_DT
remaining_VBG
$_$
419.9_CD
million_CD
,_,
together_RB
with_PIN
any_QUAN
interest_NN
that_TOBJ
the_DT
Court_NN
may_POMD
award_NN
,_,
will_PRMD
be_VB [PASS]
paid_VBN
to_PIN
them_TPP3
subject_JJ
to_PIN
the_DT
appraisal_NN
process_NN
outlined_VBN [WZPAST]
in_PIN
Note_NN
27_CD
to_PIN
the_DT
Companys_NN
consolidated_JJ
financial_JJ
statements_NOMZ
on_PIN
page_NN
120_CD
._.
For_PIN
every_QUAN
$_$
1_CD
increase_NN
decrease_NN
in_PIN
the_DT
merger_NN
consideration_NOMZ
applicable_JJ
to_PIN
those_DEMO
TKT_NN
shareholders_NN
who_WP [WHSUB]
have_VPRT [PEAS]
asserted_VBN [PUBV]
appraisal_NN
rights_NN
,_,
the_DT
total_JJ
estimated_JJ
purchase_NN
price_NN
would_PRMD
increase_VB
decrease_NN
by_PIN
approximately_RB
$_$
11.3_CD
million_CD
._.
52_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:54_CD
Page_NN
53_CD
As_CONJ
a_NULL
result_NULL
of_PIN
the_DT
acquisition_NOMZ
of_PIN
TKT_NN
,_,
cash_NN
balances_NN
have_VPRT [PEAS]
been_VBN [SPAU] [PASS]
significantly_RB
reduced_VBN
._.
Interest_NN
receivable_NN
has_VPRT [PEAS]
increased_VBN
as_IN
increases_NN
in_PIN
US_FPP1
interest_NN
rates_NN
have_VPRT
more_EMPH
than_PIN
offset_VB
the_DT
impact_NN
of_PIN
the_DT
reduced_JJ
cash_NN
balances_NN
._.
The_DT
average_JJ
cash_NN
balances_NN
pre-acquisition_JJ
and_CC
post-acquisition_NOMZ
of_PIN
TKT_NN
for_PIN
2005_CD
were_VBD
$_$
1.5_CD
billion_CD
and_CC
$_$
0.6_CD
billion_CD
respectively_RB
._.
Outstanding_JJ
letters_NN
of_PIN
credit_NN
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
,_,
the_DT
Company_NN
had_VBD
irrevocable_JJ
standby_JJ
letters_NN
of_PIN
credit_NN
with_PIN
Barclays_NN
Bank_NN
plc_NN
in_PIN
the_DT
amount_NN
of_PIN
$_$
15_CD
million_CD
providing_VBG
security_NOMZ
on_PIN
the_DT
recoverability_NOMZ
of_PIN
insurance_NN
claims_NN
and_PHC
Bank_NN
of_PIN
America_NN
in_PIN
the_DT
amount_NN
of_PIN
$_$
7.9_CD
million_CD
,_,
providing_VBG
security_NOMZ
on_PIN
the_DT
payment_NOMZ
of_PIN
lease_NN
obligations_NOMZ
._.
Cash_NN
requirements_NOMZ
Aggregate_NN
contractual_JJ
obligations_NOMZ
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
the_DT
Companys_NN
contractual_JJ
obligations_NOMZ
were_VBD
as_IN
follows_VPRT
:_:
Payments_NOMZ
due_JJ
by_PIN
period_NN
Less_RB
than_PIN
More_EMPH
than_PIN
Total_JJ
1_CD
year_NN
13_CD
years_NN
35_CD
years_NN
5_CD
years_NN
Contractual_JJ
obligations_NOMZ
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
Long-term_JJ
debt_NN
116_CD
116_CD
i_FPP1
Operating_VBG
leases_NN
165,599_CD
26,110_CD
51,457_CD
38,016_CD
50,016_CD
ii_FW
Purchase_NN
obligations_NOMZ
81,401_CD
69,733_CD
11,668_CD
Other_JJ
long-term_JJ
liabilities_NOMZ
iii_FW
reflected_VBN [PRIV]
on_PIN
the_DT
balance_NN
sheet_NN
491,244_CD
461,029_CD
30,187_CD
28_CD
Total_JJ
Notes_NN
i_FPP1
The_DT
Company_NN
leases_VPRT
certain_JJ
properties_NN
,_,
motor_NN
vehicles_NN
and_PHC
equipment_NOMZ
under_IN
operating_VBG
leases_NN
expiring_VBG [WZPRES]
through_PIN
2025_CD
._.
During_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
the_DT
Company_NN
signed_VBD
a_DT
20-year_JJ
operating_GER
lease_NN
on_PIN
a_DT
property_NN
in_PIN
the_DT
Republic_NN
of_PIN
Ireland_NN
and_CC
acquired_VBD
certain_JJ
operating_VBG
leases_NN
with_PIN
its_PIT
acquisition_NOMZ
of_PIN
TKT_NN
._.
ii_FW
Purchase_NN
obligations_NOMZ
include_VPRT
agreements_NOMZ
to_TO
purchase_VB
goods_NN
or_CC
services_NN
that_TSUB
are_VPRT [BEMA]
enforceable_PRED
and_CC
legally_RB
binding_JJ
and_CC
that_DEMP
specify_VB
all_QUAN
significant_JJ
terms_NN
,_,
including_VBG
open_JJ
purchase_NN
orders_NN
._.
Shire_NN
expects_VPRT [PRIV]
to_TO
fund_VB
the_DT
following_VBG
commitments_NOMZ
with_PIN
cash_NN
flows_NN
from_PIN
operations_NOMZ
:_:
Clinical_JJ
testing_GER
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
,_,
the_DT
Company_NN
had_VBD [PEAS]
committed_VBN
to_TO
pay_VB
approximately_RB
$_$
16.3_CD
million_CD
to_TO
contract_VB
vendors_NN
for_PIN
administering_VBG
and_PHC
executing_VBG
clinical_JJ
trials_NN
._.
The_DT
timing_NN
of_PIN
payments_NOMZ
is_VPRT
not_XX0
reasonably_RB
certain_PRED
as_IN
payments_NOMZ
are_VPRT [BEMA]
dependent_PRED
upon_PIN
actual_JJ
services_NN
performed_VBN [WZPAST]
by_PIN
the_DT
organizations_NOMZ
as_IN
determined_VBN [SUAV] [PRIV]
by_PIN
patient_JJ
enrolment_NOMZ
levels_NN
and_CC
related_JJ
activities_NOMZ
._.
However_CONJ
,_,
the_DT
Company_NN
currently_RB
expects_VPRT [PRIV]
to_TO
pay_VB
$_$
13.2_CD
million_CD
for_PIN
these_DEMO
commitments_NOMZ
throughout_PIN
2006_CD
as_IN
ongoing_JJ
trials_NN
are_VPRT [PASS]
completed_VBN
and_CC
the_DT
remainder_NN
in_PIN
2007_CD
._.
Contract_NN
manufacturing_GER
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
the_DT
Company_NN
had_VBD [PEAS]
committed_VBN
to_TO
pay_VB
approximately_RB
$_$
23.1_CD
million_CD
in_PIN
respect_NN
of_PIN
contract_NN
manufacturing_GER
over_IN
the_DT
next_JJ
12_CD
months_NN
._.
Interests_NN
in_PIN
companies_NN
and_PHC
partnerships_NN
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
,_,
the_DT
Company_NN
had_VBD
outstanding_JJ
commitments_NOMZ
to_TO
subscribe_VB
for_PIN
interests_NN
in_PIN
companies_NN
and_PHC
partnerships_NN
for_PIN
amounts_NN
totalling_VBG [WZPRES]
$_$
25.2_CD
million_CD
2004_CD
:_:
$_$
22_CD
million_CD
of_PIN
which_WDT [PIRE]
$_$
9.9_CD
million_CD
is_VPRT [PASS]
committed_VBN
in_PIN
2006_CD
and_CC
a_DT
further_JJ
$_$
2.9_CD
million_CD
could_POMD
be_VB [BEMA]
payable_PRED
in_PIN
2006_CD
,_,
depending_VBG [PRESP]
on_PIN
the_DT
timing_NN
of_PIN
capital_NN
calls_NN
._.
Manufacturing_GER
facilities_NOMZ
At_PIN
December_NN
31_CD
,_,
2005_CD
the_DT
Company_NN
had_VBD [PEAS]
committed_VBN
a_DT
total_NN
of_PIN
$_$
6.1_CD
million_CD
to_PIN
the_DT
expansion_NN
and_PHC
modification_NOMZ
of_PIN
its_PIT
manufacturing_GER
facilities_NOMZ
at_PIN
Owings_NN
Mills_NN
,_,
Maryland_NN
and_PHC
Cambridge_NN
,_,
Massachusetts_NN
._.
Of_PIN
this_DEMO
total_NN
,_,
$_$
3.2_CD
million_CD
is_VPRT
to_TO
facilitate_VB
the_DT
production_NOMZ
and_PHC
packaging_GER
of_PIN
additional_JJ
strategic_JJ
products_NN
and_CC
$_$
2.9_CD
million_CD
is_VPRT [BEMA]
for_PIN
the_DT
design_NN
and_PHC
construction_NOMZ
of_PIN
a_DT
technology_NN
center_NN
at_PIN
Owings_NN
Mills_NN
._.
All_QUAN
costs_NN
are_VPRT [PASS]
expected_VBN [PRIV]
to_TO
be_VB [PASS]
incurred_VBN
in_PIN
2006_CD
._.
Basingstoke_NN
,_,
UK_NN
expansion_NN
The_DT
Company_NN
is_VPRT [BEMA]
in_PIN
the_DT
process_NN
of_PIN
expanding_VBG
its_PIT
UK_NN
headquarters_NN
at_PIN
Basingstoke_NN
,_,
UK_NN
._.
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
,_,
the_DT
Company_NN
had_VBD
an_DT
outstanding_JJ
commitment_NOMZ
of_PIN
$_$
4.5_CD
million_CD
,_,
which_WDT [SERE]
is_VPRT [PASS]
expected_VBN [PRIV]
to_TO
be_VB [PASS]
incurred_VBN
in_PIN
2006_CD
._.
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
53_CD
Shire_NN
plc_NN
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:54_CD
Page_NN
54_CD
Financial_NN
review_NN
iii_FW
Other_JJ
liabilities_NOMZ
reflected_VBN [PRIV] [WZPAST]
on_PIN
the_DT
balance_NN
sheet_NN
include_VPRT
:_:
Off-balance_JJ
sheet_NN
arrangements_NOMZ
There_EX
are_VPRT
no_SYNE
off-balance_JJ
sheet_NN
arrangements_NOMZ
that_TSUB
have_VPRT
,_,
or_CC
are_VPRT
TKT_NN
shareholders_NN
asserting_VBG [PUBV] [WZPRES]
appraisal_NN
rights_NN
reasonably_RB
likely_JJ
to_TO
have_VB
,_,
a_DT
current_JJ
or_CC
future_JJ
effect_NN
on_PIN
the_DT
Companys_NN
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
,_,
appraisal_NN
rights_NN
had_VBD [PEAS]
been_VBN [PASS]
asserted_VBN [PUBV]
in_PIN
financial_JJ
condition_NOMZ
,_,
revenues_NN
or_CC
expenses_NN
,_,
results_NN
of_PIN
operations_NOMZ
,_,
respect_NN
of_PIN
approximately_RB
11.3_CD
million_CD
shares_NN
of_PIN
TKT_NN
common_JJ
stock_NN
._.
liquidity_NOMZ
,_,
capital_NN
expenditures_NN
or_CC
capital_NN
resources_NN
that_TSUB
are_VPRT [BEMA]
material_PRED
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
,_,
the_DT
Company_NN
recorded_VBD
a_DT
liability_NOMZ
of_PIN
to_PIN
investors_NN
._.
$_$
419.9_CD
million_CD
based_VBN
on_PIN
the_DT
merger_NN
consideration_NOMZ
of_PIN
$_$
37_CD
per_PIN
share_NN
for_PIN
the_DT
11.3_CD
million_CD
shares_NN
outstanding_JJ
at_PIN
that_DEMO
time_NN
plus_PIN
a_DT
provision_NN
Foreign_JJ
currency_NN
fluctuations_NOMZ
for_PIN
interest_NN
of_PIN
$_$
7.7_CD
million_CD
that_DEMP
may_POMD
be_VB [BYPA]
awarded_VBN
by_PIN
the_DT
court_NN
see_VB [PRIV]
Note_VB [PRIV]
A_DT
number_NN
of_PIN
operating_VBG
units_NN
in_PIN
the_DT
Group_NN
have_VPRT
functional_JJ
currencies_NN
26_CD
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
on_PIN
page_NN
120_CD
._.
Until_IN
such_JJ
other_JJ
than_PIN
the_DT
US_FPP1
Dollar_NN
._.
As_IN
such_JJ
,_,
the_DT
consolidated_JJ
financial_JJ
results_NN
time_NN
as_IN
the_DT
appraisal_NN
process_NN
is_VPRT [BEMA]
complete_PRED
the_DT
Company_NN
is_VPRT [BEMA]
unable_PRED
are_VPRT [BEMA]
subject_PRED
to_PIN
fluctuations_NOMZ
in_PIN
exchange_NN
rates_NN
,_,
particularly_RB
those_DEMO
between_PIN
to_TO
determine_VB [SUAV] [PRIV]
the_DT
extent_NN
of_PIN
its_PIT
liability_NOMZ
._.
For_PIN
every_QUAN
$_$
1_CD
increase_NN
decrease_NN
the_DT
US_FPP1
Dollar_NN
,_,
Canadian_NN
Dollar_NN
,_,
Pound_NN
Sterling_GER
,_,
Euro_NN
and_PHC
Swedish_NN
in_PIN
the_DT
merger_NN
consideration_NOMZ
applicable_JJ
to_PIN
those_DEMO
TKT_NN
shareholders_NN
Krona_NN
._.
The_DT
accumulated_VBN
foreign_JJ
currency_NN
translation_NOMZ
differences_NN
who_WP [WHSUB]
have_VPRT [PEAS]
asserted_VBN [PUBV]
appraisal_NN
rights_NN
,_,
the_DT
total_JJ
estimated_JJ
purchase_NN
of_PIN
$_$
62.2_CD
million_CD
are_VPRT [PASS]
reported_VBN [PUBV]
within_PIN
accumulated_VBN
other_JJ
comprehensive_JJ
price_NN
would_PRMD
increase_VB
decrease_NN
by_PIN
approximately_RB
$_$
11.3_CD
million_CD
._.
income_NN
in_PIN
the_DT
consolidated_JJ
balance_NN
sheet_NN
and_CC
$_$
1.4_CD
million_CD
expense_NN
is_VPRT [PASS]
reported_VBN [PUBV]
in_PIN
other_JJ
income_NN
on_PIN
the_DT
consolidated_JJ
income_NN
statement_NOMZ
._.
The_DT
contractual_JJ
obligations_NOMZ
table_NN
above_PLACE
does_VPRT
not_XX0
include_VB
payments_NOMZ
yet_RB
to_TO
fall_VB
due_JJ
upon_PIN
the_DT
occurrence_NN
of_PIN
certain_JJ
milestones_NN
and_CC
other_JJ
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
,_,
the_DT
Company_NN
had_VBD
five_CD
outstanding_JJ
forward_RB
contractual_JJ
commitments_NOMZ
._.
The_DT
most_EMPH
significant_JJ
payments_NOMZ
are_VPRT [BEMA]
foreign_JJ
exchange_NN
contracts_NN
with_PIN
a_DT
total_JJ
principal_JJ
amount_NN
equivalent_NN
as_IN
follows_VPRT
:_:
to_TO
$_$
206_CD
million_CD
to_TO
manage_VB
the_DT
currency_NN
risk_NN
associated_VBN [WZPAST]
with_PIN
certain_JJ
inter-company_JJ
loans_NN
._.
DAYTRANA_NN
In_PIN
connection_NOMZ
with_PIN
the_DT
Companys_NN
acquisition_NOMZ
in_PIN
2003_CD
from_PIN
Noven_NN
Concentration_NOMZ
of_PIN
credit_NN
risk_NN
of_PIN
the_DT
worldwide_JJ
sales_NN
and_PHC
marketing_GER
rights_NN
to_PIN
DAYTRANA_NN
,_,
Shire_NN
The_NN
Companys_NN
revenues_NN
from_PIN
product_NN
sales_NN
are_VPRT [SPAU] [PASS]
mainly_RB
derived_VBN
from_PIN
has_VPRT
an_DT
obligation_NOMZ
to_TO
make_VB
certain_JJ
payments_NOMZ
on_PIN
the_DT
achievement_NOMZ
of_PIN
the_DT
agreements_NOMZ
with_PIN
major_JJ
pharmaceutical_JJ
companies_NN
and_PHC
relationships_NN
following_VBG [WZPRES]
milestones_NN
:_:
$_$
50_CD
million_CD
upon_PIN
FDA_NN
approval_NN
of_PIN
the_DT
product_NN
,_,
with_PIN
pharmaceutical_JJ
wholesale_JJ
distributors_NN
and_CC
retail_JJ
pharmacy_NN
chains_NN
._.
which_WDT [SERE]
will_PRMD
be_VB [PASS]
capitalized_VBN
and_PHC
amortized_VBN
over_IN
its_PIT
useful_JJ
economic_JJ
life_NN
:_:
Such_JJ
clients_NN
typically_RB
have_VPRT
significant_JJ
cash_NN
resources_NN
and_CC
as_IN
such_JJ
and_CC
up_RB
to_TO
$_$
75_CD
million_CD
,_,
linked_VBN [PASTP]
to_PIN
future_JJ
sales_NN
performance_NN
._.
An_DT
approvable_JJ
the_DT
risk_NN
is_VPRT [PASS]
considered_VBN [PRIV]
minimal_JJ
._.
The_DT
Company_NN
has_VPRT [PEAS]
taken_VBN
positive_JJ
steps_NN
letter_NN
was_VBD [PASS]
received_VBN
from_PIN
the_DT
FDA_NN
on_PIN
December_NN
23_CD
,_,
2005_CD
._.
Final_JJ
to_TO
manage_VB
any_QUAN
credit_NN
risk_NN
associated_VBN [WZPAST]
with_PIN
these_DEMO
transactions_NOMZ
._.
Shire_NN
regulatory_JJ
approval_NN
was_VBD [PASS]
received_VBN
from_PIN
the_DT
FDA_NN
on_PIN
April_NN
6_CD
,_,
2006_CD
._.
operates_VPRT
clearly_RB
defined_VBN
credit_NN
evaluation_NOMZ
procedures_NN
._.
For_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
,_,
there_EX
were_VBD
three_CD
customers_NN
in_PIN
the_DT
US_FPP1
who_WP [WHSUB]
NRP104_VPRT
accounted_VBN
for_PIN
69_CD
%_NN
of_PIN
the_DT
Companys_NN
total_VPRT
revenues_NN
._.
In_PIN
connection_NOMZ
with_PIN
the_DT
Companys_NN
collaboration_NOMZ
with_PIN
New_NN
River_NN
to_TO
commercialize_VB
NRP104_NN
,_,
the_DT
Company_NN
has_VPRT
an_DT
obligation_NOMZ
to_TO
make_VB
certain_JJ
Financial_NN
instruments_NOMZ
that_TSUB
potentially_RB
expose_VB
Shire_NN
to_PIN
concentrations_NOMZ
payments_NOMZ
on_PIN
the_DT
achievement_NOMZ
of_PIN
the_DT
following_VBG
milestones_NN
:_:
$_$
50_CD
million_CD
of_PIN
credit_NN
risk_NN
consist_VPRT
primarily_RB
of_PIN
short-term_JJ
cash_NN
investments_NOMZ
and_CC
upon_PIN
the_DT
FDAs_NN
acceptance_NN
of_PIN
filing_NN
of_PIN
the_DT
NDA_NN
:_:
up_RP
to_TO
$_$
300_CD
million_CD
trade_NN
accounts_NN
receivable_JJ
._.
Excess_JJ
cash_NN
is_VPRT [PASS]
invested_VBN
in_PIN
short-term_JJ
following_VBG
the_DT
first_JJ
commercial_JJ
sale_NN
of_PIN
the_DT
product_NN
,_,
depending_VBG [PRESP]
on_PIN
the_DT
money_NN
market_NN
instruments_NOMZ
,_,
including_VBG
bank_NN
and_PHC
building_GER
society_NN
term_NN
characteristics_NN
of_PIN
the_DT
approved_VBN
product_NN
labeling_VBG [WZPRES]
:_:
$_$
100_CD
million_CD
on_PIN
deposits_NN
,_,
commercial_JJ
paper_NN
and_CC
other_JJ
debt_NN
securities_NOMZ
from_PIN
a_DT
variety_NN
achieving_VBG [WZPRES]
a_DT
significant_JJ
sales_NN
target_NN
:_:
and_ANDC
$_$
5_CD
million_CD
following_VBG
the_DT
first_JJ
of_PIN
companies_NN
with_PIN
strong_JJ
credit_NN
ratings_GER
._.
These_DEMO
investments_NOMZ
typically_RB
commercial_JJ
sale_NN
in_PIN
certain_JJ
specified_VBN
EU_NN
markets_NN
._.
An_DT
upfront_JJ
payment_NOMZ
bear_NN
minimal_JJ
risk_NN
._.
of_PIN
$_$
50_CD
million_CD
was_VBD [PASS]
expensed_VBN
as_IN
an_DT
R&D_NN
cost_NN
during_PIN
the_DT
first_JJ
quarter_NN
of_PIN
2005_CD
._.
The_DT
NDA_NN
for_PIN
NRP104_NN
was_VBD [PASS]
filed_VBN
on_PIN
December_NN
6_CD
,_,
2005_CD
and_CC
Inflation_NOMZ
accepted_VBN [PRIV] [WZPAST]
for_PIN
review_NN
by_PIN
the_DT
FDA_NN
on_PIN
January_NN
26_CD
,_,
2006_CD
,_,
triggering_VBG [PRESP]
the_DT
Although_CONC
at_PIN
reduced_JJ
levels_NN
in_PIN
recent_JJ
years_NN
,_,
inflation_NOMZ
continues_VPRT
to_TO
apply_VB
$_$
50_CD
million_CD
milestone_NN
payment_NOMZ
,_,
which_WDT [SERE]
has_VPRT [SPAU] [PEAS]
now_TIME
been_VBN [PASS]
paid_VBN
._.
upward_RB
pressure_NN
on_PIN
the_DT
cost_NN
of_PIN
goods_NN
and_PHC
services_NN
which_WDT [WHSUB]
are_VPRT [PASS]
used_VBN
in_PIN
the_DT
business_NOMZ
._.
However_CONJ
,_,
the_DT
Company_NN
believes_VPRT [PRIV]
that_THVC
the_DT
net_JJ
effect_NN
of_PIN
FOSRENOL_NN
patent_NN
rights_NN
inflation_NOMZ
on_PIN
its_PIT
operations_NOMZ
has_VPRT [PEAS]
been_VBN [BEMA]
minimal_PRED
during_PIN
the_DT
past_JJ
three_CD
years_NN
._.
In_PIN
connection_NOMZ
with_PIN
the_DT
Companys_NN
purchase_NN
of_PIN
the_DT
global_JJ
patents_NN
for_PIN
FOSRENOL_NN
from_PIN
AnorMED_NN
Inc._NN
in_PIN
2004_CD
,_,
the_DT
Company_NN
has_VPRT
outstanding_JJ
Treasury_NN
policies_NN
and_PHC
organization_NOMZ
commitments_NOMZ
to_TO
pay_VB
AnorMED_NN
Inc._NN
$_$
6_CD
million_CD
when_RB
FOSRENOL_NN
The_DT
Companys_NN
principal_JJ
treasury_NN
operations_NOMZ
are_VPRT [BYPA]
co-ordinated_VBN
by_PIN
is_VPRT [PASS]
approved_VBN
in_PIN
certain_JJ
European_JJ
countries_NN
and_CC
$_$
6_CD
million_CD
upon_PIN
receipt_NN
its_PIT
corporate_JJ
treasury_NN
function_NOMZ
,_,
which_WDT [SERE]
is_VPRT [PASS]
based_VBN
in_PIN
the_DT
UK_NN
._.
All_QUAN
treasury_NN
of_PIN
regulatory_JJ
approval_NN
in_PIN
Japan_NN
._.
operations_NOMZ
are_VPRT [PASS]
conducted_VBN
within_PIN
a_DT
framework_NN
of_PIN
policies_NN
and_PHC
procedures_NN
approved_VBN [WZPAST]
by_PIN
the_DT
Board_NN
._.
As_IN
a_DT
matter_NN
of_PIN
policy_NN
,_,
the_DT
Other_JJ
R&D_NN
commitments_NOMZ
Company_NN
does_VPRT
not_XX0
undertake_VB
speculative_JJ
transactions_NOMZ
that_TSUB
would_PRMD
As_RB
at_PIN
December_NN
31_CD
,_,
2005_CD
,_,
the_DT
Company_NN
had_VBD
commitments_NOMZ
of_PIN
increase_NN
its_PIT
currency_NN
or_CC
interest_NN
rate_NN
exposure_NN
._.
$_$
18_CD
million_CD
on_PIN
achievement_NOMZ
of_PIN
specified_VBN
milestones_NN
from_PIN
products_NN
under_IN
development_NOMZ
in_PIN
licensed_VBN
from_PIN
third_JJ
parties_NN
of_PIN
which_WDT [PIRE]
$_$
6.6_CD
million_CD
is_VPRT [PASS]
committed_VBN
to_TO
be_VB [PASS]
paid_VBN
in_PIN
2006_CD
._.
54_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Review_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:54_CD
Page_NN
55_CD
As_IN
a_DT
matter_NN
of_PIN
English_JJ
law_NN
,_,
Shire_NN
may_POMD
pay_VB
dividends_NN
only_DWNT
out_PIN
of_PIN
its_PIT
The_NN
Board_NN
reviews_VPRT
and_PHC
agrees_VPRT [SUAV] [PUBV]
policies_NN
for_PIN
managing_VBG
the_DT
risks_NN
and_CC
they_TPP3
are_VPRT [PASS]
summarized_VBN
below_PLACE
:_:
distributable_JJ
profits_NN
,_,
which_WDT [SERE]
are_VPRT [BEMA]
the_DT
accumulated_VBN
realized_VBD [PRIV]
profits_NN
under_IN
generally_RB
accepted_VBN [PRIV]
accounting_GER
principles_NN
in_PIN
the_DT
United_NN
Kingdom_NN
Interest_NN
rate_NN
risk_NN
including_VBG [WZPRES]
reserves_NN
arising_VBG [WZPRES]
from_PIN
a_DT
reduction_NOMZ
of_PIN
share_NN
capital_NN
,_,
of_PIN
Shire_NN
plc_NN
and_CC
not_XX0
the_DT
consolidated_JJ
Group_NN
,_,
so_RB
far_PLACE
as_IN
not_XX0
previously_TIME
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
,_,
the_DT
Company_NN
has_VPRT
no_SYNE
material_NN
debt_NN
outstanding_JJ
._.
Therefore_CONJ
the_DT
Companys_NN
interest_NN
charge_NN
on_PIN
its_PIT
debt_NN
utilized_VBN [WZPAST]
by_PIN
distribution_NOMZ
or_CC
capitalization_NOMZ
,_,
less_JJ
accumulated_VBN
realized_VBN [PRIV]
losses_NN
,_,
so_RB
far_PLACE
as_IN
not_XX0
previously_TIME
written_VBN [PUBV]
off_PIN
in_PIN
a_DT
reduction_NOMZ
or_CC
obligations_NOMZ
is_VPRT [BEMA]
low_PRED
and_ANDC
consequently_CONJ
the_DT
Companys_NN
interest_NN
expense_NN
charge_NN
has_VPRT [PEAS]
limited_VBN
exposure_NN
to_PIN
interest_NN
rate_NN
movements_NOMZ
._.
The_DT
Company_NN
reorganization_NOMZ
of_PIN
capital_NN
duly_RB
made_VBD
._.
is_VPRT [PASS]
exposed_VBN
to_PIN
movements_NOMZ
in_PIN
interest_NN
rates_NN
affecting_VBG [WZPRES]
interest_NN
income_NN
._.
This_DEMO
exposure_NN
is_VPRT [BEMA]
primarily_RB
to_PIN
US_FPP1
Dollar_NN
interest_NN
rates_NN
._.
As_IN
the_DT
Company_NN
On_PIN
November_NN
28_CD
,_,
2005_CD
,_,
the_DT
High_NN
Court_NN
of_PIN
Justice_NN
in_PIN
England_NN
and_PHC
Wales_NN
approved_VBD
a_DT
reduction_NOMZ
of_PIN
Shires_NN
share_NN
capital_NN
to_TO
take_VB
effect_NN
on_PIN
maintains_VPRT [PUBV]
all_QUAN
of_PIN
its_PIT
investments_NOMZ
on_PIN
a_DT
short-term_JJ
basis_NN
for_PIN
liquidity_NOMZ
purposes_NN
this_DEMO
risk_NN
is_VPRT [PASS]
not_XX0
actively_RB
managed_VBN
._.
November_NN
29_CD
,_,
2005_CD
,_,
when_RB
the_DT
nominal_JJ
value_NN
of_PIN
each_QUAN
Shire_NN
ordinary_JJ
share_NN
was_VBD [PASS]
reduced_VBN
from_PIN
3.50_CD
to_PIN
0.05_CD
._.
This_DEMO
reduction_NOMZ
increased_VBD
the_DT
In_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
,_,
the_DT
average_JJ
interest_NN
rate_NN
received_VBD
distributable_JJ
reserves_NN
available_JJ
to_TO
Shire_VB
to_TO
approximately_RB
$_$
2.95_CD
billion_CD
,_,
which_WDT [SERE]
the_DT
Directors_NN
of_PIN
Shire_NN
can_POMD
utilize_VB
for_PIN
future_JJ
dividend_NN
payments_NOMZ
on_PIN
cash_NN
and_CC
liquid_JJ
investments_NOMZ
was_VBD [BEMA]
approximately_RB
2.90_CD
%_NN
per_PIN
annum_NN
._.
The_DT
largest_JJ
proportion_NOMZ
of_PIN
investments_NOMZ
was_VBD [BEMA]
in_PIN
US_FPP1
Dollar_NN
money_NN
market_NN
at_PIN
their_TPP3
discretion_NOMZ
._.
As_CONJ
a_NULL
result_NULL
of_PIN
this_DEMO
capital_NN
reduction_NOMZ
,_,
as_RB
at_PIN
December_NN
31_CD
,_,
2005_CD
,_,
Shire_NN
had_VBD
distributable_JJ
profits_NN
of_PIN
$_$
2,946_CD
million_CD
._.
Future_JJ
dividend_NN
policy_NN
will_PRMD
Foreign_NN
exchange_NN
risk_NN
The_DT
Company_NN
is_VPRT [PASS]
exposed_VBN
to_PIN
movements_NOMZ
in_PIN
foreign_JJ
exchange_NN
rates_NN
be_VB [BEMA]
dependent_PRED
upon_PIN
distributable_JJ
profits_NN
,_,
financial_JJ
condition_NOMZ
,_,
the_DT
terms_NN
of_PIN
any_QUAN
then_RB
existing_VBG
debt_NN
facilities_NOMZ
and_CC
other_JJ
relevant_JJ
factors_NN
existing_VBG [WZPRES]
against_PIN
the_DT
US_FPP1
Dollar_NN
for_PIN
trading_VBG
transactions_NOMZ
and_CC
the_DT
translation_NOMZ
of_PIN
net_JJ
assets_NN
,_,
liabilities_NOMZ
and_PHC
earnings_GER
of_PIN
non-US_FPP1
subsidiaries_NN
._.
trading_GER
currencies_NN
of_PIN
the_DT
Company_NN
are_VPRT [BEMA]
the_DT
US_FPP1
Dollar_NN
,_,
the_DT
Canadian_JJ
Dollar_NN
,_,
Pounds_NN
Sterling_GER
,_,
the_DT
Euro_NN
and_PHC
Swedish_NN
Krona_NN
._.
The_DT
consolidated_JJ
financial_JJ
statements_NOMZ
of_PIN
foreign_JJ
entities_NOMZ
are_VPRT [PASS]
translated_VBN
using_VBG
the_DT
accounting_GER
policies_NN
described_VBN [WZPAST]
in_PIN
Note_NN
3_CD
to_PIN
the_DT
Companys_NN
consolidated_JJ
financial_JJ
statements_NOMZ
on_PIN
page_NN
86_CD
._.
Angus_NN
Russell_NN
The_NN
exposure_NN
to_PIN
foreign_JJ
exchange_NN
risk_NN
is_VPRT [PASS]
managed_VBN
and_PHC
monitored_VBN
by_PIN
the_DT
treasury_NN
function_NOMZ
._.
Exposures_NN
are_VPRT [SPAU] [PASS]
generally_RB
managed_VBN
through_PIN
natural_JJ
hedging_GER
via_PIN
the_DT
currency_NN
denomination_NOMZ
of_PIN
cash_NN
balances_NN
._.
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
the_DT
Company_NN
had_VBD
five_CD
outstanding_JJ
forward_RB
foreign_JJ
exchange_NN
contracts_NN
with_PIN
a_DT
total_JJ
principal_JJ
amount_NN
of_PIN
$_$
206_CD
million_CD
equivalent_JJ
to_TO
manage_VB
the_DT
currency_NN
risk_NN
associated_VBN [WZPAST]
with_PIN
certain_JJ
inter-company_JJ
loans_NN
._.
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
there_EX
were_VBD
net_JJ
unrealized_JJ
gains_NN
of_PIN
$_$
2.6_CD
million_CD
on_PIN
these_DEMO
contracts_NN
._.
Market_NN
risk_NN
of_PIN
investments_NOMZ
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
,_,
the_DT
Company_NN
has_VPRT
$_$
50.2_CD
million_CD
of_PIN
investments_NOMZ
comprising_VBG [WZPRES]
equity_NOMZ
investment_NOMZ
funds_NN
,_,
private_JJ
companies_NN
and_CC
publicly-quoted_JJ
equities_NOMZ
._.
The_DT
public-quoted_JJ
companies_NN
are_VPRT [PASS]
exposed_VBN
to_PIN
market_NN
risk_NN
._.
No_SYNE
financial_JJ
instruments_NOMZ
or_CC
derivatives_NN
have_VPRT [PEAS]
been_VBN [PASS]
employed_VBN
to_TO
hedge_VB
this_DEMO
risk_NN
._.
Dividend_NN
policy_NN
An_DT
interim_JJ
dividend_NN
for_PIN
the_DT
first_JJ
half_NN
of_PIN
2005_CD
of_PIN
1.8246_CD
1.0475_CD
p_NN
per_PIN
ordinary_JJ
share_NN
equivalent_NN
to_PIN
5.4738_CD
per_PIN
ADS_NN
and_CC
6.7629_CD
Canadian_JJ
per_PIN
exchangeable_JJ
share_NN
was_VBD [PASS]
paid_VBN
in_PIN
October_NN
2005_CD
._.
The_DT
Board_NN
has_VPRT [PEAS]
resolved_VBN [SUAV]
to_TO
pay_VB
a_DT
second_JJ
interim_JJ
dividend_NN
of_PIN
4.419_CD
2.5356_CD
p_NN
per_PIN
ordinary_JJ
share_NN
equivalent_NN
to_PIN
13.257_CD
per_PIN
ADS_NN
and_CC
15.2217_CD
Canadian_JJ
per_PIN
exchangeable_JJ
share_NN
for_PIN
the_DT
six_CD
months_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
._.
This_DEMP
is_VPRT [BEMA]
consistent_PRED
with_PIN
Shires_NN
stated_VBD [PUBV]
policy_NN
of_PIN
paying_VBG
a_DT
dividend_NN
semi-annually_RB
,_,
set_VBN [PASTP]
in_PIN
US_FPP1
cents_NN
per_PIN
share_NN
ADS_NN
,_,
with_PIN
the_DT
first_JJ
interim_JJ
payment_NOMZ
in_PIN
each_QUAN
year_NN
being_VBG [WZPRES] [PASS]
maintained_VBN [PUBV]
at_PIN
a_DT
consistent_JJ
level_NN
._.
Any_QUAN
growth_NN
will_PRMD
come_VB
through_PIN
increasing_VBG
the_DT
second_JJ
interim_JJ
dividend_NN
in_PIN
a_DT
financial_JJ
year_NN
._.
Shire_NN
intends_VPRT [SUAV]
to_TO
pursue_VB
a_DT
progressive_JJ
dividend_NN
policy_NN
._.
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
55_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:56_CD
Page_NN
56_CD
Nomination_NOMZ
Committee_NN
report_NN
Directors_NN
remuneration_JJ
report_NN
The_DT
members_NN
of_PIN
the_DT
Nomination_NOMZ
Committee_NN
as_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
Introduction_NOMZ
were_VBD
Dr_NN
James_NN
Cavanaugh_NN
Chairman_NN
,_,
Mr_NN
Ronald_NN
Nordmann_NN
,_,
The_DT
This_DEMO
report_NN
has_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
in_PIN
accordance_NN
with_PIN
Schedule_NN
7A_NN
Hon_NN
James_NN
Grant_NN
and_PHC
Dr_NN
Barry_NN
Price_NN
._.
A_DT
majority_NOMZ
of_PIN
the_DT
Committee_NN
has_VPRT
to_PIN
the_DT
Companies_NN
Act_NN
1985_CD
and_CC
complies_VPRT
with_PIN
the_DT
Combined_NN
Code_NN
been_VBN [BYPA]
determined_VBN [SUAV] [PRIV]
by_PIN
Shires_NN
Board_NN
to_TO
be_VB [BEMA]
Independent_JJ
Non-executive_JJ
on_PIN
Corporate_JJ
Governance_NN
._.
The_DT
report_NN
also_RB
meets_VPRT
the_DT
relevant_JJ
Directors_NN
for_PIN
the_DT
purposes_NN
of_PIN
the_DT
Combined_NN
Code_NN
._.
Dr_NN
James_NN
requirements_NOMZ
of_PIN
the_DT
Listing_GER
Rules_NN
of_PIN
the_DT
Financial_NN
Services_NN
Authority_NOMZ
Cavanaugh_NN
is_VPRT [BEMA]
the_DT
Chairman_NN
of_PIN
the_DT
Company_NN
and_CC
in_PIN
this_DEMO
capacity_NOMZ
and_CC
describes_VPRT
how_RB
the_DT
Board_NN
has_VPRT [PEAS]
applied_VBN
the_DT
principles_NN
relating_VBG [WZPRES]
to_TO
is_VPRT [PASS]
not_XX0
considered_VBN [PRIV]
to_TO
be_VB [BEMA]
independent_PRED
under_IN
the_DT
Combined_NN
Code_NN
._.
Directors_NN
remuneration_NOMZ
under_IN
the_DT
Directors_NN
Remuneration_NOMZ
Report_NN
Regulations_NOMZ
2002_CD
._.
As_IN
required_VBN [SUAV]
by_PIN
the_DT
Act_NN
,_,
a_DT
resolution_NOMZ
to_TO
approve_VB
the_DT
The_DT
Nomination_NOMZ
Committee_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
identifying_VBG
and_CC
report_NN
will_PRMD
be_VB [PASS]
proposed_VBN [SUAV]
at_PIN
the_DT
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
of_PIN
the_DT
Company_NN
nominating_GER
,_,
for_PIN
the_DT
approval_NN
of_PIN
the_DT
Board_NN
,_,
candidates_NN
for_PIN
the_DT
Board_NN
._.
at_PIN
which_WDT [PIRE]
the_DT
financial_JJ
statements_NOMZ
will_PRMD
be_VB [PASS]
approved_VBN
._.
The_DT
Act_NN
requires_VPRT [SUAV]
The_DT
Terms_NN
of_PIN
Reference_NN
of_PIN
the_DT
Nomination_NOMZ
Committee_NN
require_VPRT [SUAV]
it_PIT
,_,
before_IN
the_DT
auditors_NN
to_TO
report_VB [PUBV]
to_PIN
the_DT
Companys_NN
members_NN
on_PIN
certain_JJ
parts_NN
of_PIN
any_QUAN
appointment_NOMZ
is_VPRT [PASS]
made_VBN
,_,
to_TO
evaluate_VB
the_DT
balance_NN
of_PIN
skills_NN
,_,
knowledge_NN
the_DT
Directors_NN
remuneration_NOMZ
report_NN
and_CC
to_PIN
state_NN
whether_IN
in_PIN
their_TPP3
opinion_NN
and_PHC
experience_NN
on_PIN
the_DT
Board_NN
and_CC
,_,
in_PIN
light_NN
of_PIN
this_DEMO
evaluation_NOMZ
,_,
to_TO
identify_VB
these_DEMO
parts_NN
of_PIN
the_DT
report_NN
have_VPRT [PEAS]
been_VBN [SPAU] [PASS]
properly_RB
prepared_VBN
in_PIN
accordance_NN
the_DT
capabilities_NOMZ
required_VBN [SUAV] [WZPAST]
for_PIN
a_DT
particular_JJ
appointment_NOMZ
._.
The_DT
Committee_NN
with_PIN
the_DT
Companies_NN
Act_NN
1985_CD
._.
The_DT
report_NN
has_VPRT [SPAU] [PEAS]
therefore_CONJ
been_VBN [PASS]
divided_VBN
utilizes_VPRT
the_DT
services_NN
of_PIN
professional_JJ
search_NN
agencies_NN
specializing_VBG [WZPRES]
in_PIN
the_DT
into_PIN
separate_JJ
sections_NOMZ
for_PIN
audited_JJ
and_PHC
unaudited_JJ
information_NOMZ
._.
recruitment_NOMZ
of_PIN
high_JJ
calibre_NN
candidates_NN
._.
The_DT
Committee_NN
is_VPRT [PASS]
required_VBN [SUAV]
to_TO
consider_VB [PRIV]
candidates_NN
from_PIN
a_DT
wide_JJ
range_NN
of_PIN
backgrounds_NN
,_,
on_PIN
merit_NN
and_CC
Unaudited_JJ
information_NOMZ
against_PIN
objective_JJ
criteria_NN
._.
It_PIT
is_VPRT [SPAU] [PASS]
also_RB
required_VBN [SUAV]
to_TO
ensure_VB [SUAV] [PRIV]
that_THVC
candidates_NN
Dear_RB
Shareholder_NN
,_,
have_VPRT
sufficient_JJ
time_NN
to_TO
devote_VB
to_PIN
the_DT
position_NOMZ
._.
The_DT
Committee_NN
also_RB
Directors_NN
remuneration_NOMZ
monitors_VPRT
succession_NN
planning_GER
to_PIN
the_DT
Board_NN
and_CC
oversees_VPRT
succession_NN
During_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
the_DT
Remuneration_NOMZ
Committee_NN
planning_VBG [WZPRES]
for_PIN
senior_JJ
management_NOMZ
._.
continued_VBD
its_PIT
work_NN
,_,
on_PIN
behalf_NN
of_PIN
the_DT
Board_NN
,_,
on_PIN
Directors_NN
remuneration_NOMZ
._.
During_PIN
2005_CD
,_,
the_DT
Committee_NN
made_VBD
recommendations_NOMZ
to_PIN
the_DT
Board_NN
on_PIN
the_DT
appointment_NOMZ
of_PIN
Mr_NN
Patrick_NN
Langlois_NN
and_CC
the_DT
reappointment_NOMZ
During_PIN
the_DT
past_JJ
two_CD
years_NN
,_,
the_DT
Company_NN
has_VPRT [PEAS]
implemented_VBN
a_DT
business_NOMZ
of_PIN
Mr_NN
Nordmann_NN
._.
strategy_NN
and_PHC
model_NN
focused_VBD
on_PIN
identifying_VBG
,_,
developing_VBG
and_PHC
marketing_VBG
pharmaceuticals_NN
in_PIN
targeted_JJ
therapeutic_JJ
areas_NN
for_PIN
diseases_NN
treated_VBN
New_NN
Non-executive_JJ
Directors_NN
receive_VPRT
a_DT
customized_VBN
induction_NOMZ
process_NN
by_PIN
specialist_NN
physicians_NN
._.
Moving_VBG [SUAV] [PRESP]
to_PIN
this_DEMO
model_NN
has_VPRT [PEAS]
required_VBN [SUAV] [THATD]
the_DT
sale_NN
taking_VBG [WZPRES]
account_NN
of_PIN
their_TPP3
particular_JJ
experience_NN
and_PHC
backgrounds_NN
._.
of_PIN
non-core_JJ
businesses_NOMZ
and_PHC
site_NN
consolidation_NOMZ
,_,
as_RB
well_RB
as_IN
a_DT
major_JJ
internal_JJ
This_DEMO
process_NN
includes_VPRT
meetings_GER
with_PIN
senior_JJ
management_NOMZ
._.
reorganization_NOMZ
to_TO [SPIN]
fully_AMP
integrate_VB
and_PHC
align_VB
key_JJ
functions_NOMZ
and_PHC
staff_NN
on_PIN
a_DT
global_JJ
,_,
therapy_NN
area_NN
and_PHC
market_NN
basis_NN
._.
As_IN
part_NN
of_PIN
the_DT
reorganization_NOMZ
,_,
The_DT
Committee_NN
met_VBD
three_CD
times_NN
during_PIN
2005_CD
._.
All_QUAN
members_NN
were_VBD [BEMA]
present_PRED
the_DT
Company_NN
has_VPRT [PEAS]
established_VBN [PRIV]
a_DT
new_JJ
US_FPP1
headquarters_NN
office_NN
in_PIN
Wayne_NN
,_,
at_PIN
the_DT
meetings_GER
._.
Pennsylvania_NN
where_RB
the_DT
majority_NOMZ
of_PIN
our_FPP1
senior_JJ
executives_NN
are_VPRT [PASS]
based_VBN
._.
In_CONJ
addition_NULL
,_,
the_DT
Company_NN
has_VPRT [SPAU] [PEAS]
recently_TIME
completed_VBN
the_DT
acquisition_NOMZ
of_PIN
TKT_NN
,_,
which_WDT [SERE]
is_VPRT [PASS]
based_VBN
in_PIN
Cambridge_NN
,_,
Massachusetts_NN
._.
The_DT
Company_NN
operates_VPRT
in_PIN
a_DT
competitive_JJ
multinational_JJ
environment_NOMZ
._.
In_PIN
2005_CD
,_,
approximately_RB
90_CD
%_NN
of_PIN
the_DT
Companys_NN
revenues_NN
were_VBD [PASS]
generated_VBN
and_CC
80_CD
%_NN
of_PIN
its_PIT
employees_NN
were_VBD [PASS]
based_VBN
outside_PLACE
the_DT
UK_NN
._.
Indeed_RB
most_EMPH
Dr_JJ
James_NN
Cavanaugh_NN
of_PIN
the_DT
Companys_NN
revenues_NN
are_VPRT [PASS]
generated_VBN
in_PIN
the_DT
US_FPP1
and_CC
the_DT
majority_NOMZ
Chairman_NN
of_PIN
the_DT
Nomination_NOMZ
Committee_NN
of_PIN
its_PIT
employees_NN
and_CC
most_EMPH
of_PIN
its_PIT
senior_JJ
executives_NN
are_VPRT [PASS]
based_VBN
in_PIN
the_DT
US_FPP1
._.
The_DT
importance_NN
of_PIN
our_FPP1
US_FPP1
business_NOMZ
to_PIN
the_DT
continuing_VBG
growth_NN
of_PIN
your_SPP2
Company_NN
,_,
coupled_VBN [PASTP]
with_PIN
the_DT
fact_NN
that_TOBJ
most_EMPH
of_PIN
our_FPP1
senior_JJ
executives_NN
are_VPRT [PASS]
based_VBN
in_PIN
the_DT
US_FPP1
,_,
presents_VPRT
the_DT
Committee_NN
with_PIN
particular_JJ
challenges_NN
._.
Key_NN
elements_NOMZ
of_PIN
our_FPP1
remuneration_NOMZ
package_NN
,_,
including_VBG
long-term_JJ
incentive_NN
arrangements_NOMZ
,_,
have_VPRT [PEAS]
been_VBN [BEMA]
in_PIN
place_NN
for_PIN
five_CD
years_NN
or_CC
more_EMPH
and_CC
,_,
over_IN
this_DEMO
time_NN
,_,
the_DT
Company_NN
has_VPRT [PEAS]
grown_VBN
and_PHC
changed_VBN
significantly_RB
._.
As_CONJ
a_NULL
result_NULL
of_PIN
both_DT
the_DT
growth_NN
and_PHC
development_NOMZ
of_PIN
the_DT
Company_NN
and_CC
the_DT
competitive_JJ
operating_GER
environment_NOMZ
,_,
the_DT
Committee_NN
reviewed_VBN
senior_JJ
executive_NN
remuneration_NOMZ
during_PIN
2005_CD
and_CC
conducted_VBD
a_DT
competitive_JJ
benchmarking_GER
study_NN
._.
On_PIN
the_DT
basis_NN
of_PIN [STPR]
,_,
and_ANDC
consistent_JJ
with_PIN [STPR]
,_,
data_NN
from_PIN
the_DT
study_NN
,_,
the_DT
Committee_NN
modified_VBD
the_DT
remuneration_NOMZ
policy_NN
and_CC
proposed_VBD [SUAV]
a_DT
number_NN
of_PIN
changes_NN
to_TO
remuneration_VB
including_VBG
the_DT
introduction_NOMZ
of_PIN
a_DT
new_JJ
share_NN
plan_NN
to_TO
replace_VB
Shires_NN
existing_VBG [WZPRES]
plans_NN
and_PHC
amendments_NOMZ
to_PIN
the_DT
annual_JJ
incentive_NN
plan_NN
._.
The_DT
Committee_NN
conducted_VBD
a_DT
consultation_NOMZ
process_NN
with_PIN
major_JJ
shareholders_NN
regarding_VBG [WZPRES]
the_DT
proposed_JJ
programs_NN
and_CC
made_VBN
changes_NN
to_PIN
its_PIT
proposals_NN
consistent_JJ
with_PIN
shareholder_NN
feedback_NN
._.
These_DEMP
are_VPRT [PASS]
described_VBN
within_PIN
this_DEMO
report_NN
._.
The_DT
Remuneration_NOMZ
Committee_NN
is_VPRT [PASS]
committed_VBN
to_PIN
a_DT
continuing_VBG
dialogue_NN
with_PIN
shareholders_NN
and_CC
we_FPP1
take_VPRT
account_NN
of_PIN
your_SPP2
views_NN
._.
We_FPP1
hope_VPRT [PRIV] [THATD]
that_DEMP
this_DEMO
report_NN
provides_VPRT
helpful_JJ
context_NN
and_PHC
explanation_NOMZ
about_IN
the_DT
policies_NN
and_CC
practical_JJ
considerations_NOMZ
that_TSUB
influence_VPRT
our_FPP1
decisions_NN
._.
Dr_NN
Barry_NN
Price_NN
Chairman_NN
of_PIN
the_DT
Remuneration_NOMZ
Committee_NN
56_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:56_CD
Page_NN
57_CD
Directors_NN
remuneration_JJ
report_NN
The_DT
Remuneration_NOMZ
Committee_NN
share-based_JJ
compensation_NOMZ
is_VPRT [BEMA]
a_DT
key_JJ
element_NOMZ
of_PIN
the_DT
Companys_NN
The_DT
Remuneration_NOMZ
Committee_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
all_QUAN
elements_NOMZ
of_PIN
the_DT
remuneration_NOMZ
policy_NN
as_IN
it_PIT
aligns_VPRT
the_DT
interests_NN
of_PIN
the_DT
Companys_NN
executive_NN
Directors_NN
remuneration_NOMZ
,_,
as_RB
well_RB
as_IN
their_TPP3
performance_NN
executives_NN
with_PIN
the_DT
interests_NN
of_PIN
its_PIT
shareholders_NN
._.
of_PIN
compensation_NOMZ
also_RB
utilizes_VPRT
a_DT
blended_JJ
US_FPP1
UK_NN
market_NN
comparison_NN
to_TO
determine_VB [SUAV] [PRIV]
face_NN
value_NN
of_PIN
awards_NN
to_PIN
executive_JJ
Directors_NN
:_:
The_DT
constitution_NOMZ
of_PIN
the_DT
Committee_NN
was_VBD [PASS]
reviewed_VBN
in_PIN
2004_CD
and_CC
changes_NN
were_VBD [PASS]
made_VBN
to_TO
ensure_VB [SUAV] [PRIV]
compliance_NN
with_PIN
the_DT
Combined_NN
Code_NN
._.
The_DT
benefits_NN
programs_NN
are_VPRT [BEMA]
locally_PLACE
competitive_PRED
and_CC
provide_VB
for_PIN
the_DT
Company_NN
considers_VPRT [PRIV]
all_QUAN
members_NN
of_PIN
the_DT
Committee_NN
to_TO
be_VB [BEMA]
independent_PRED
._.
welfare_NN
and_PHC
well-being_NN [BEMA]
of_PIN
our_FPP1
employees_NN
and_CC
their_TPP3
families_NN
:_:
The_DT
Chief_NN
Executive_NN
Officer_NN
and_CC
the_DT
Chief_NN
Financial_NN
Officer_NN
attend_VB
the_DT
Committee_NN
currently_RB
aims_VPRT
for_PIN
variable_JJ
compensation_NOMZ
meetings_GER
of_PIN
the_DT
Committee_NN
at_PIN
its_PIT
invitation_NOMZ
,_,
but_CC
neither_SYNE
is_VPRT [PASS]
involved_VBN
to_TO
represent_VB
over_IN
two-thirds_NN
of_PIN
total_JJ
remuneration_NOMZ
:_:
and_ANDC
in_PIN
any_QUAN
decisions_NN
relating_VBG [WZPRES]
to_PIN
their_TPP3
own_JJ
remuneration_NOMZ
._.
the_DT
Committee_NN
believes_VPRT [PRIV]
that_THVC
executive_NN
Directors_NN
should_NEMD
be_VB [BEMA]
The_DT
members_NN
of_PIN
the_DT
Remuneration_NOMZ
Committee_NN
during_PIN
2005_CD
were_VBD
:_:
encouraged_VBD
to_TO
own_VB
shares_NN
in_PIN
the_DT
Company_NN
in_PIN
order_NN
to_TO
ensure_VB [SUAV] [PRIV]
the_DT
alignment_NOMZ
of_PIN
their_TPP3
interests_NN
with_PIN
those_DEMO
of_PIN
the_DT
Companys_NN
Dr_NN
Barry_NN
Price_NN
,_,
the_DT
Senior_JJ
Independent_NN
Director_NN
of_PIN
the_DT
Company_NN
shareholders_NN
._.
Share_NN
ownership_NN
guidelines_NN
became_VBD
effective_JJ
and_CC
Chairman_NN
of_PIN
the_DT
Committee_NN
:_:
in_PIN
2006_CD
._.
Mr_NN
Robin_NN
Buchanan_NN
,_,
an_DT
Independent_NN
Non-executive_JJ
Director_NN
:_:
and_ANDC
The_DT
remuneration_NOMZ
package_NN
The_DT
main_JJ
elements_NOMZ
of_PIN
the_DT
remuneration_NOMZ
package_NN
for_PIN
executive_NN
Mr_NN
Ronald_NN
Nordmann_NN
,_,
an_DT
Independent_NN
Non-executive_JJ
Director_NN
._.
Directors_NN
and_CC
senior_JJ
management_NOMZ
are_VPRT
:_:
Details_NN
of_PIN
the_DT
number_NN
of_PIN
Committee_NN
meetings_GER
in_PIN
2005_CD
and_CC
the_DT
1_CD
Base_NN
salary_NN
attendance_NN
at_PIN
those_DEMO
meetings_GER
is_VPRT [PASS]
set_VBN
out_PIN
in_PIN
the_DT
section_NOMZ
headed_VBD
Corporate_JJ
Governance_NN
Statements_NOMZ
._.
2_CD
Annual_JJ
Incentive_NN
Plan_NN
a_DT
Cash_NN
component_NN
The_DT
Remuneration_NOMZ
Committee_NN
was_VBD [SPAU] [PASS]
materially_RB
assisted_VBN
in_PIN
2005_CD
by_PIN
Mrs_NN
b_NN
Share_NN
component_NN
Anita_NN
Graham_NN
,_,
EVP_NN
Global_NN
Human_NN
Resources_NN
._.
The_DT
following_VBG
external_JJ
advisers_NN
were_VBD [BYPA]
appointed_VBN
by_PIN
and_CC
materially_RB
assisted_VBD
the_DT
Committee_NN
:_:
3_CD
Long-term_JJ
Incentives_NN
c_NN
Share_NN
options_NOMZ
Towers_NN
Perrin_NN
who_WP [WHSUB]
provided_VBD
advice_NN
in_PIN
relation_NOMZ
to_PIN
executive_JJ
Directors_NN
d_SYM
Long-term_JJ
Incentive_NN
Plan_NN
remuneration_NOMZ
and_CC
the_DT
design_NN
and_PHC
operation_NOMZ
of_PIN
the_DT
Companys_NN
share_NN
e_SYM
Portfolio_NN
Share_NN
Plan_NN
incentive_NN
schemes_NN
:_:
4_CD
Pension_NN
and_CC
other_JJ
benefits_NN
Deloitte_NN
&_CC
Touche_NN
LLP_NN
who_WP [WHSUB]
also_RB
provided_VBD
audit_NN
and_PHC
tax_NN
services_NN
to_PIN
the_DT
Company_NN
who_WP [WHSUB]
provided_VBD
data_NN
and_PHC
advice_NN
on_PIN
the_DT
design_NN
and_CC
The_DT
share_NN
component_NN
under_IN
the_DT
Annual_JJ
Incentive_NN
Plan_NN
,_,
and_ANDC
the_DT
operation_NOMZ
of_PIN
the_DT
Companys_NN
incentive_NN
schemes_NN
:_:
and_ANDC
Portfolio_NN
Share_NN
Plan_NN
,_,
were_VBD [PASS]
introduced_VBN
as_CONJ
a_NULL
result_NULL
of_PIN
the_DT
remuneration_NOMZ
review_NN
in_PIN
2005_CD
._.
The_DT
2005_CD
annual_JJ
incentive_NN
therefore_CONJ
did_VBD
not_XX0
contain_VB
a_DT
Slaughter_NN
and_PHC
May_POMD
,_,
who_WP
provided_VBD
general_JJ
legal_JJ
advice_NN
to_PIN
the_DT
share_NN
component_NN
._.
Going_VBG [PRESP]
forward_RB
,_,
the_DT
Portfolio_NN
Share_NN
Plan_NN
will_PRMD
replace_VB
Company_NN
._.
the_DT
previous_JJ
Share_NN
Option_NOMZ
and_CC
Long-term_JJ
Incentive_NN
Plans_NN
,_,
and_ANDC
no_SYNE
further_JJ
awards_NN
will_PRMD
be_VB [PASS]
made_VBN
under_IN
these_DEMO
plans_NN
._.
Executive_NN
remuneration_NOMZ
policy_NN
The_DT
Remuneration_NOMZ
Committee_NN
considers_VPRT [PRIV]
that_THVC
an_DT
effective_JJ
remuneration_NOMZ
1_CD
Salary_JJ
policy_NN
,_,
aligned_VBN [PASTP]
to_PIN
the_DT
Companys_NN
business_NOMZ
needs_NN
,_,
is_VPRT [BEMA]
important_PRED
to_PIN
the_DT
The_DT
Remuneration_NOMZ
Committee_NN
reviews_VPRT
salaries_NN
annually_RB
._.
It_PIT
directly_RB
impacts_VPRT
the_DT
Companys_NN
ability_NOMZ
to_TO
recruit_VB
,_,
and_ANDC
early_TIME
2005_CD
the_DT
Committee_NN
undertook_VBD
a_DT
competitive_JJ
review_NN
of_PIN
the_DT
retain_VB
and_PHC
motivate_VB
high_JJ
caliber_NN
executives_NN
who_WP [WHSUB]
deliver_VPRT
sustained_VBN
Companys_NN
executive_NN
remuneration_NOMZ
programs_NN
and_PHC
practices_NN
,_,
including_VBG
value_NN
to_PIN
shareholders_NN
and_CC
build_VB
the_DT
Company_NN
for_PIN
long-term_JJ
success_NN
._.
base_NN
salary_NN
benchmarks_NN
and_PHC
levels_NN
._.
Based_VBN [PASTP]
on_PIN
the_DT
competitive_JJ
analysis_NN
the_DT
Committee_NN
determined_VBD [SUAV] [PRIV]
that_THVC
the_DT
correct_JJ
comparator_NN
group_NN
is_VPRT [BEMA]
a_DT
blend_VB
The_DT
Remuneration_NOMZ
Committee_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
developing_VBG
,_,
reviewing_VBG [PRESP]
of_PIN
US_FPP1
and_PHC
UK_NN
companies_NN
with_PIN
sector_NN
,_,
size_NN
,_,
complexity_NOMZ
and_CC
international_JJ
and_CC
overseeing_VBG
the_DT
implementation_NOMZ
of_PIN
the_DT
Companys_NN
compensation_NOMZ
characteristics_NN
similar_JJ
to_PIN
those_DEMO
of_PIN
the_DT
Company_NN
._.
Where_RB
appropriate_JJ
,_,
and_ANDC
benefits_NN
policy_NN
._.
The_DT
Remuneration_NOMZ
Committee_NN
regularly_RB
monitors_VPRT
the_DT
competitive_JJ
review_NN
included_VBD
a_DT
detailed_JJ
analysis_NN
to_TO
align_VB
these_DEMO
the_DT
effectiveness_NOMZ
of_PIN
the_DT
policy_NN
and_CC
reviews_VPRT
this_DEMO
policy_NN
based_VBN [WZPAST]
on_PIN
characteristics_NN
to_PIN
best_JJ
represent_VPRT
the_DT
Companys_NN
operating_VBG [WZPRES]
position_NOMZ
._.
independent_JJ
analysis_NN
and_PHC
advice_NN
,_,
an_DT
understanding_GER
of_PIN
the_DT
business_NOMZ
drivers_NN
and_CC
competitive_JJ
environment_NOMZ
in_PIN
which_WDT [PIRE]
the_DT
Company_NN
operates_VPRT
As_IN
part_NN
of_PIN
its_PIT
normal_JJ
annual_JJ
salary_NN
review_NN
process_NN
,_,
the_DT
Committee_NN
and_CC
ongoing_JJ
dialogue_NN
with_PIN
shareholders_NN
._.
conducts_VPRT
a_DT
review_NN
of_PIN
a_DT
range_NN
of_PIN
factors_NN
such_JJ
as_IN
competitive_JJ
market_NN
data_NN
provided_VBN [WZPAST]
by_PIN
independent_JJ
external_JJ
consultants_NN
,_,
US_FPP1
and_PHC
UK_NN
The_DT
Companys_NN
executive_NN
compensation_NOMZ
and_PHC
benefits_NN
policy_NN
market_NN
conditions_NOMZ
,_,
performance-related_JJ
pay_NN
increases_NN
across_PLACE
the_DT
is_VPRT [PASS]
based_VBN
on_PIN
the_DT
following_VBG
principles_NN
:_:
Company_NN
and_CC
individual_JJ
skills_NN
,_,
performance_NN
and_PHC
results_NN
achieved_VBN
._.
The_DT
Remuneration_NOMZ
Committees_NN
policy_NN
is_VPRT [BEMA]
for_PIN
salary_NN
to_TO
be_VB [PASS]
targeted_VBN
base_NN
pay_NN
is_VPRT [PASS]
market_NN
driven_VBN
utilizing_VBG
a_DT
blended_JJ
US_FPP1
UK_NN
market_NN
at_PIN
or_CC
around_PLACE
the_DT
median_NN
of_PIN
the_DT
blend_VB
of_PIN
US_FPP1
UK_NN
comparators_NN
,_,
with_PIN
comparison_NN
,_,
and_ANDC
is_VPRT [PASS]
targeted_VBN
at_PIN
or_CC
around_PLACE
the_DT
median_NN
relative_JJ
appropriate_JJ
differentiation_NOMZ
based_VBN [WZPAST]
upon_PIN
skills_NN
and_PHC
experience_NN
as_RB
well_RB
to_PIN
the_DT
comparison_NN
:_:
as_IN
individual_JJ
performance_NN
._.
Based_VBN [PASTP]
on_PIN
this_DEMO
review_NN
,_,
salaries_NN
for_PIN
the_DT
Chief_NN
Executive_NN
Officer_NN
and_PHC
Chief_NN
Financial_NN
Officer_NN
were_VBD [PASS]
increased_VBN
the_DT
Annual_JJ
Incentive_NN
Plan_NN
is_VPRT [BEMA]
performance-based_PRED
and_CC
is_VPRT [PASS]
linked_VBN
to_PIN
5_CD
%_NN
and_CC
4_CD
%_NN
effective_JJ
January_NN
1_CD
,_,
2006_CD
,_,
respectively_RB
,_,
to_TO
$_$
1,103,017_CD
the_DT
achievement_NOMZ
of_PIN
an_DT
appropriate_JJ
mix_NN
of_PIN
corporate_JJ
and_PHC
individual_JJ
denominated_VBN
in_PIN
$_$
and_ANDC
372,120_CD
$_$
677,630_CD
equivalent_JJ
based_VBN
performance_NN
targets_NN
._.
The_DT
Annual_JJ
Incentive_NN
Plan_NN
allows_VPRT [SUAV]
the_DT
Company_NN
on_PIN
the_DT
average_JJ
exchange_NN
rates_NN
prevailing_VBG [WZPRES]
in_PIN
2005_CD
._.
These_DEMO
increases_NN
to_TO
measure_VB
and_PHC
reward_VB
progress_NN
against_PIN
its_PIT
strategic_JJ
goals_NN
and_CC
are_VPRT [BEMA]
in_PIN
line_NN
with_PIN
increases_NN
provided_VBN [WZPAST]
to_PIN
the_DT
Companys_NN
employees_NN
._.
is_VPRT [SPAU] [PASS]
closely_RB
tied_VBN
to_PIN
delivery_NN
of_PIN
sustained_JJ
shareholder_NN
value_NN
:_:
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
57_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:56_CD
Page_NN
58_CD
Directors_NN
remuneration_JJ
report_NN
2_CD
Annual_JJ
Incentive_NN
Plan_NN
Target_NN
Maximum_NN
Weighting_GER
of_PIN
target_NN
incentive_NN
incentive_NN
incentive_NN
objectives_NN
Shire_NN
operates_VPRT
an_DT
Annual_JJ
Incentive_NN
Plan_NN
which_WDT [WHSUB]
rewards_VPRT
executive_NN
as_IN
a_DT
%_NN
as_IN
a_DT
%_NN
Director_NN
performance_NN
dependent_JJ
on_PIN
achievement_NOMZ
of_PIN
pre-defined_JJ
Board_NN
of_PIN
salary_NN
of_PIN
salary_NN
Corporate_JJ
Individual_NN
approved_VBD
corporate_JJ
objectives_NN
and_PHC
Committee_NN
approved_VBD
individual_JJ
Mr_NN
Matthew_NN
Emmens_NN
objectives_NN
._.
The_DT
Company_NN
implemented_VBD
the_DT
Balanced_NN
Scorecard_NN
to_TO
set_VB
Chief_NN
Executive_NN
Officer_NN
65_CD
%_NN
115_CD
%_NN
80_CD
%_NN
20_CD
%_NN
corporate_JJ
objectives_NN
in_PIN
2005_CD
._.
The_DT
Scorecard_NN
organizes_VPRT
corporate_JJ
objectives_NN
into_PIN
all_QUAN
areas_NN
that_TSUB
drive_VPRT
the_DT
success_NN
of_PIN
the_DT
business_NOMZ
:_:
financial_JJ
,_,
Mr_NN
Angus_NN
Russell_NN
products_NN
and_PHC
markets_NN
,_,
people_NN
and_PHC
capabilities_NOMZ
,_,
and_ANDC
operational_JJ
Chief_NN
Financial_NN
Officer_NN
55_CD
%_NN
100_CD
%_NN
70_CD
%_NN
30_CD
%_NN
effectiveness_NOMZ
._.
The_DT
incentive_NN
payments_NOMZ
awarded_VBD
to_PIN
each_QUAN
executive_NN
Director_NN
for_PIN
2005_CD
At_PIN
the_DT
start_NN
of_PIN
the_DT
year_NN
corporate_JJ
objectives_NN
are_VPRT [BYPA]
set_VBN
by_PIN
the_DT
Board_NN
for_PIN
reflect_VPRT [PRIV]
the_DT
corporate_JJ
and_PHC
individual_JJ
achievements_NOMZ
and_CC
amounted_VBD
to_PIN
each_QUAN
area_NN
of_PIN
the_DT
Scorecard_NN
._.
These_DEMO
objectives_NN
apply_VPRT
to_PIN
all_QUAN
employees_NN
115_CD
%_NN
of_PIN
salary_NN
for_PIN
Mr_NN
Emmens_NN
and_CC
70_CD
%_NN
of_PIN
salary_NN
for_PIN
Mr_NN
Russell_NN
._.
participating_VBG [PRESP]
in_PIN
the_DT
Companys_NN
Annual_JJ
Incentive_NN
Plan_NN
and_CC
include_VPRT
a_DT
description_NOMZ
of_PIN
the_DT
objective_NN
and_CC
key_JJ
performance_NN
indicators_NN
KPI_NN
,_,
These_DEMO
incentive_NN
awards_NN
are_VPRT [BEMA]
consistent_PRED
with_PIN
the_DT
overall_JJ
performance_NN
including_VBG [WZPRES]
targets_NN
and_PHC
deadlines_NN
._.
Awards_NN
under_IN
the_DT
Plan_NN
are_VPRT [PASS]
made_VBN
only_DWNT
of_PIN
the_DT
Company_NN
in_PIN
2005_CD
,_,
which_WDT [SERE]
included_VBD
:_:
when_RB
exacting_VBG
levels_NN
of_PIN
performance_NN
specified_VBN [WZPAST]
by_PIN
the_DT
KPI_NN
have_VPRT [PEAS]
been_VBN [PASS]
achieved_VBN
._.
Objectives_NN
measured_VBN [WZPAST]
by_PIN
the_DT
Companys_NN
financial_JJ
revenue_NN
growth_NN
of_PIN
17_CD
%_NN
:_:
performance_NN
are_VPRT [PASS]
assessed_VBN
on_PIN
the_DT
Companys_NN
results_NN
,_,
as_IN
reported_VBN [PUBV]
in_PIN
the_DT
Companys_NN
Form_NN
10-K_NN
under_IN
US_FPP1
GAAP_NN
._.
the_DT
acquisition_NOMZ
of_PIN
TKT_NN
:_:
The_DT
detailed_JJ
objectives_NN
and_PHC
performance_NN
standards_NN
contain_VPRT
the_DT
in-licensing_JJ
acquisition_NOMZ
co-promotion_NOMZ
of_PIN
four_CD
new_JJ
products_NN
commercially_RB
sensitive_JJ
information_NOMZ
and_ANDC
therefore_CONJ
are_VPRT [PASS]
not_XX0
detailed_VBN
here_RB
._.
NRP104_CD
,_,
ELAPRASE_NN
,_,
DYNEPO_NN
,_,
GA-GCB_NN
:_:
However_CONJ
,_,
some_QUAN
of_PIN
the_DT
objectives_NN
are_VPRT [PASS]
summarized_VBN
below_PLACE
according_VBG
to_PIN
the_DT
four_CD
Scorecard_NN
areas_NN
for_PIN
2005_CD
:_:
the_DT
launch_NN
of_PIN
four_CD
new_JJ
products_NN
FOSRENOL_NN
,_,
EQUETRO_NN
,_,
XAGRID_NN
,_,
PENTASA_NN
500mg_CD
:_:
1_CD
Financial_NN
a_DT
Growth_NN
in_PIN
revenue_NN
and_CC
net_JJ
income_NN
:_:
highly_AMP
successful_JJ
achievement_NOMZ
of_PIN
R&D_NN
milestones_NN
including_VBG [WZPRES]
the_DT
filing_NN
b_NN
Revenue_NN
growth_NN
tied_VBN [WZPAST]
to_PIN
the_DT
acquisition_NOMZ
of_PIN
new_JJ
products_NN
:_:
of_PIN
MESAVANCE_NN
and_PHC
ELAPRASE_NN
in_PIN
the_DT
US_FPP1
and_CC
the_DT
reinstatement_NOMZ
b_NN
M&A_NN
and_PHC
divestiture_NN
targets_NN
._.
of_PIN
ADDERALL_NN
XR_NN
in_PIN
Canada_NN
:_:
and_ANDC
2_CD
Products_NN
markets_VPRT
the_DT
highly_AMP
successful_JJ
implementation_NOMZ
of_PIN
other_JJ
Scorecard_NN
objectives_NN
a_DT
Product_NN
launches_NN
:_:
focused_VBN [PASTP]
on_PIN
the_DT
continuing_VBG
growth_NN
of_PIN
the_DT
Company_NN
._.
b_NN
Key_NN
R&D_NN
milestones_NN
such_JJ
as_IN
submissions_NN
and_PHC
approvals_NN
:_:
b_NN
Product_NN
pipeline_NN
growth_NN
progression_NN
and_CC
in-licensing_JJ
acquisition_NOMZ
._.
Changes_NN
to_PIN
the_DT
Annual_JJ
Incentive_NN
Plan_NN
for_PIN
2006_CD
following_VBG
the_DT
remuneration_NOMZ
review_NN
and_CC
subsequent_JJ
consultation_NOMZ
with_PIN
shareholders_NN
3_CD
People_NN
and_PHC
capabilities_NOMZ
As_IN
part_NN
of_PIN
the_DT
remuneration_NOMZ
review_NN
and_CC
following_VBG
consultation_NOMZ
with_PIN
a_DT
Development_NOMZ
of_PIN
capabilities_NOMZ
in_PIN
areas_NN
of_PIN
core_NN
competence_NN
:_:
the_DT
Companys_NN
major_JJ
shareholders_NN
and_PHC
investor_NN
bodies_NN
including_VBG [WZPRES]
b_NN
The_DT
staffing_GER
and_PHC
development_NOMZ
of_PIN
our_FPP1
people_NN
:_:
operationalizing_VBG [PRESP]
the_DT
ABI_NN
and_PHC
RREV_NN
,_,
the_DT
Committee_NN
proposed_VBD [SUAV]
some_QUAN
changes_NN
to_PIN
the_DT
new_JJ
US_FPP1
headquarters_NN
._.
4_CD
Operational_JJ
effectiveness_NOMZ
As_IN
described_VBN
in_PIN
last_JJ
years_NN
remuneration_JJ
report_NN
,_,
in_PIN
2005_CD
,_,
the_DT
Company_NN
a_DT
Global_JJ
product_NN
development_NOMZ
targets_NN
:_:
ceased_VBD
the_DT
matching_JJ
share_NN
portion_NOMZ
of_PIN
the_DT
Plan_NN
by_PIN
discontinuing_VBG
the_DT
b_NN
Risk_NN
management_NOMZ
,_,
compliance_NN
initiatives_NN
and_CC
operational_JJ
Deferred_NN
Bonus_NN
Plan_NN
._.
For_PIN
the_DT
financial_JJ
year_NN
2006_CD
,_,
a_DT
restricted_JJ
share_NN
excellence_NN
targets_NN
._.
element_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
added_VBN [PUBV]
to_PIN
the_DT
Plan_NN
,_,
so_IN
the_DT
Plan_NN
effectively_RB
has_VPRT
two_CD
components_NN
:_:
a_DT
cash_NN
component_NN
and_CC
a_DT
share_NN
component_NN
._.
Personal_JJ
objectives_NN
are_VPRT [SPAU] [PASS]
also_RB
set_VBN
at_PIN
the_DT
beginning_GER
of_PIN
the_DT
year_NN
and_CC
are_VPRT [PASS]
aligned_VBN
with_PIN
individual_JJ
accountabilities_NOMZ
for_PIN
the_DT
development_NOMZ
and_CC
The_DT
target_NN
cash_NN
incentive_NN
for_PIN
the_DT
Chief_NN
Executive_NN
Officer_NN
and_CC
the_DT
Chief_NN
execution_NOMZ
of_PIN
plans_NN
to_TO
achieve_VB
corporate_JJ
objectives_NN
in_PIN
the_DT
current_JJ
year_NN
Financial_NN
Officer_NN
remain_VPRT
respectively_RB
at_PIN
the_DT
2005_CD
levels_NN
of_PIN
65_CD
%_NN
and_CC
55_CD
%_NN
and_CC
build_VB
for_PIN
the_DT
future_JJ
success_NN
of_PIN
the_DT
Company_NN
._.
of_PIN
salary_NN
and_CC
the_DT
maximum_NN
cash_NN
incentive_NN
amounts_NN
remain_VPRT
respectively_RB
115_CD
%_NN
and_CC
100_CD
%_NN
of_PIN
salary_NN
._.
The_DT
Remuneration_NOMZ
Committee_NN
assesses_VPRT
performance_NN
against_PIN
objectives_NN
in_PIN
the_DT
first_JJ
quarter_NN
of_PIN
the_DT
following_JJ
year_NN
._.
Through_PIN
2005_CD
,_,
the_DT
annual_JJ
incentive_NN
is_VPRT [BEMA]
payable_PRED
in_PIN
cash_NN
and_CC
is_VPRT [BEMA]
not_XX0
pensionable_PRED
._.
The_DT
target_NN
incentive_NN
is_VPRT [PASS]
paid_VBN
where_RB
executive_JJ
Directors_NN
have_VPRT [SPAU] [PEAS]
fully_AMP
achieved_VBN
their_TPP3
individual_JJ
objectives_NN
and_CC
the_DT
corporate_JJ
objectives_NN
have_VPRT [PEAS]
been_VBN [PASS]
met_VBN
in_PIN
full_JJ
._.
The_DT
maximum_NN
incentive_NN
is_VPRT [PASS]
paid_VBN
when_RB
the_DT
Remuneration_NOMZ
Committee_NN
determines_VPRT [SUAV] [PRIV]
that_THVC
individual_JJ
and_CC
or_CC
corporate_JJ
performance_NN
has_VPRT [PEAS]
been_VBN [BEMA]
exceptional_PRED
._.
Maximum_NN
incentive_NN
payments_NOMZ
for_PIN
2005_CD
were_VBD [PASS]
capped_VBN
at_PIN
115_CD
%_NN
of_PIN
salary_NN
for_PIN
the_DT
Chief_NN
Executive_NN
Officer_NN
and_CC
100_CD
%_NN
of_PIN
salary_NN
for_PIN
the_DT
Chief_NN
Financial_NN
Officer_NN
._.
58_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:56_CD
Page_NN
59_CD
Directors_NN
remuneration_JJ
report_NN
The_DT
new_JJ
restricted_JJ
share_NN
element_NOMZ
will_PRMD
be_VB [PASS]
set_VBN
as_IN
follows_VPRT
:_:
for_PIN
the_DT
Chief_NN
The_NN
2000_CD
Executive_NN
Share_NN
Option_NOMZ
Scheme_NN
,_,
which_WDT [SERE]
was_VBD [BYPA]
approved_VBN
by_PIN
Executive_NN
Officer_NN
,_,
the_DT
target_NN
restricted_VBN
share_NN
element_NOMZ
is_VPRT [BEMA]
20_CD
%_NN
and_CC
the_DT
shareholders_NN
in_PIN
2000_CD
,_,
contained_VBD
an_DT
unlimited_JJ
retesting_GER
feature_NN
from_PIN
the_DT
maximum_NN
restricted_VBN
share_NN
element_NOMZ
is_VPRT [BEMA]
65_CD
%_NN
._.
For_PIN
the_DT
Chief_NN
Financial_NN
date_NN
of_PIN
grant_NN
._.
The_DT
Remuneration_NOMZ
Committee_NN
decided_VBD [SUAV] [PRIV]
,_,
after_IN
consultation_NOMZ
Officer_NN
,_,
the_DT
target_NN
restricted_VBN
share_NN
element_NOMZ
is_VPRT [BEMA]
15_CD
%_NN
and_CC
the_DT
maximum_NN
with_PIN
some_QUAN
of_PIN
the_DT
Companys_NN
major_JJ
institutional_JJ
shareholders_NN
in_PIN
2003_CD
,_,
restricted_VBN
share_NN
element_NOMZ
is_VPRT [BEMA]
55_CD
%_NN
._.
Awards_NN
of_PIN
restricted_JJ
shares_NN
will_PRMD
be_VB
that_DEMO
for_PIN
options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
scheme_NN
from_PIN
2004_CD
onwards_NN
,_,
the_DT
made_VBN
in_PIN
the_DT
same_JJ
manner_NN
as_IN
awards_NN
of_PIN
cash_NN
under_IN
the_DT
Plan_NN
,_,
utilizing_VBG
performance_NN
condition_NOMZ
should_NEMD
be_VB [PASS]
retested_VBN
once_TIME
only_DWNT
,_,
five_CD
years_NN
after_IN
the_DT
the_DT
same_JJ
operational_JJ
objectives_NN
and_PHC
measures_NN
per_PIN
Companys_NN
grant_NN
and_CC
then_RB
only_DWNT
where_RB
Shires_NN
EPS_NN
growth_NN
has_VPRT [PEAS]
not_XX0
met_VBN
the_DT
minimum_NN
Balanced_JJ
Scorecard_NN
and_CC
individual_JJ
objectives_NN
._.
The_DT
levels_NN
of_PIN
target_NN
and_PHC
level_NN
of_PIN
performance_NN
over_IN
the_DT
first_JJ
three_CD
years_NN
._.
The_DT
level_NN
of_PIN
EPS_NN
growth_NN
maximum_NN
restricted_VBN
shares_NN
have_VPRT [PEAS]
been_VBN [PASS]
set_VBN
to_TO
be_VB [BEMA]
competitive_PRED
in_PIN
both_DT
over_IN
the_DT
five-year_JJ
period_NN
needs_VPRT
to_TO
be_VB [BEMA]
commensurately_RB
higher_PRED
to_TO
meet_VB
the_DT
UK_NN
and_PHC
US_FPP1
and_CC
to_TO
enable_VB
Shire_NN
to_TO
operate_VB
a_DT
common_JJ
framework_NN
for_PIN
the_DT
retest_NN
._.
the_DT
senior_JJ
executive_NN
team_NN
irrespective_RB
of_PIN
location_NOMZ
._.
The_DT
restricted_JJ
share_NN
element_NOMZ
is_VPRT [PASS]
earned_VBN
at_PIN
the_DT
same_JJ
time_NN
as_IN
the_DT
cash_NN
portion_NOMZ
of_PIN
the_DT
incentive_NN
,_,
The_DT
new_JJ
Portfolio_NN
Share_NN
Plan_NN
does_VPRT
not_XX0
allow_VB [SUAV]
re-testing_JJ
._.
but_CC
is_VPRT [PASS]
deferred_VBN
for_PIN
three_CD
years_NN
._.
As_IN
discussed_VBN
with_PIN
the_DT
Companys_NN
major_JJ
shareholders_NN
and_PHC
investor_NN
bodies_NN
,_,
this_DEMO
restricted_JJ
share_NN
element_NOMZ
is_VPRT [PASS]
taken_VBN
The_DT
table_NN
below_PLACE
sets_NN
out_PIN
the_DT
share_NN
options_NOMZ
that_TSUB
were_VBD [PASS]
granted_VBN [SUAV]
to_PIN
into_PIN
account_NN
for_PIN
the_DT
purposes_NN
of_PIN
determining_VBG [SUAV] [PRIV]
competitive_JJ
levels_NN
of_PIN
executive_NN
Directors_NN
during_PIN
2005_CD
._.
share-based_JJ
and_PHC
total_JJ
compensation_NOMZ
._.
The_DT
table_NN
below_PLACE
compares_VPRT
the_DT
Number_NN
of_PIN
previous_JJ
and_CC
the_DT
new_JJ
Annual_JJ
Incentive_NN
Plan_NN
structure_NN
._.
Executive_NN
Director_NN
and_CC
ordinary_JJ
Exercise_NN
share_NN
option_NOMZ
scheme_NN
Date_NN
of_PIN
grant_NN
Shares_NN
Price_NN
New_NN
Annual_JJ
Incentive_NN
Plan_NN
Mr_NN
Matthew_NN
Emmens_NN
Previous_JJ
Annual_JJ
Incentive_NN
Plan_NN
cash_NN
plus_PIN
2000_CD
Executive_NN
Scheme_NN
May_POMD
2005_CD
295,000_CD
5.585_CD
cash_NN
only_DWNT
restricted_JJ
shares_NN
Mr_NN
Angus_NN
Russell_NN
Target_NN
Maximum_NN
Target_NN
Maximum_NN
2000_CD
Executive_NN
Scheme_NN
May_POMD
2005_CD
195,000_CD
5.585_CD
incentive_NN
incentive_NN
incentive_NN
incentive_NN
as_IN
a_DT
%_NN
as_IN
a_DT
%_NN
as_IN
a_DT
%_NN
as_IN
a_DT
%_NN
of_PIN
salary_NN
of_PIN
salary_NN
of_PIN
salary_NN
of_PIN
salary_NN
Details_NN
of_PIN
the_DT
Companys_NN
share_NN
option_NOMZ
schemes_NN
are_VPRT [PASS]
set_VBN
out_PIN
in_PIN
Note_NN
31_CD
Mr_NN
Matthew_NN
Emmens_NN
65_CD
%_NN
cash_NN
115_CD
%_NN
cash_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
._.
Performance_NN
conditions_NOMZ
Chief_NN
Executive_NN
Officer_NN
65_CD
%_NN
115_CD
%_NN
20_CD
%_NN
shares_NN
65_CD
%_NN
shares_NN
attaching_VBG [WZPRES]
to_PIN
previous_JJ
executive_NN
option_NOMZ
grants_NN
are_VPRT [PASS]
detailed_VBN
in_PIN
the_DT
audited_JJ
section_NOMZ
of_PIN
this_DEMO
Report_NN
._.
Mr_NN
Angus_NN
Russell_NN
55_CD
%_NN
cash_NN
100_CD
%_NN
cash_NN
Chief_NN
Financial_NN
Officer_NN
55_CD
%_NN
100_CD
%_NN
15_CD
%_NN
shares_NN
55_CD
%_NN
shares_NN
b_NN
Long-term_JJ
Incentive_NN
Plan_NN
The_NN
Long-term_JJ
Incentive_NN
Plan_NN
LTIP_NN
was_VBD [PASS]
adopted_VBN
at_PIN
the_DT
Companys_NN
3_CD
Long-term_JJ
Incentives_NN
1998_CD
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
and_PHC
amended_VBN
in_PIN
2000_CD
._.
Under_IN
the_DT
LTIP_NN
,_,
a_DT
Share_NN
options_NOMZ
the_DT
Remuneration_NOMZ
Committee_NN
has_VPRT
discretion_NOMZ
to_TO
make_VB
awards_NN
of_PIN
shares_NN
During_PIN
2005_CD
,_,
discretionary_JJ
grants_NN
of_PIN
share_NN
options_NOMZ
under_IN
the_DT
subject_NN
to_PIN
a_DT
maximum_NN
of_PIN
100_CD
%_NN
of_PIN
salary_NN
a_DT
year_NN
._.
Companys_NN
2000_CD
Executive_NN
Share_NN
Option_NOMZ
Scheme_NN
were_VBD [PASS]
made_VBN
to_PIN
executive_JJ
Directors_NN
to_TO
align_VB
their_TPP3
interests_NN
with_PIN
those_DEMO
of_PIN
shareholders_NN
The_DT
performance_NN
condition_NOMZ
attached_VBN [WZPAST]
to_PIN
the_DT
vesting_GER
of_PIN
awards_NN
under_IN
and_CC
to_TO
promote_VB
sustained_VBN
long-term_JJ
Company_NN
performance_NN
._.
The_DT
face_NN
the_DT
LTIP_NN
is_VPRT
Shires_NN
Total_NN
Shareholder_NN
Return_NN
TSR_NN
relative_JJ
to_PIN
the_DT
value_NN
of_PIN
annual_JJ
option_NOMZ
grants_NN
under_IN
the_DT
Scheme_NN
was_VBD [PASS]
capped_VBN
at_PIN
three_CD
FTSE_NN
100_CD
Index_NN
over_IN
a_DT
three-year_JJ
period_NN
._.
The_DT
Committee_NN
considers_VPRT [PRIV]
times_NN
salary_NN
._.
In_PIN
order_NN
for_PIN
options_NOMZ
to_PIN
vest_NN
,_,
stretching_VBG
performance_NN
targets_NN
that_DEMP
this_DEMO
measure_NN
is_VPRT [BEMA]
a_DT
reliable_JJ
and_PHC
appropriate_JJ
measure_NN
of_PIN
the_DT
must_NEMD
be_VB [PASS]
met_VBN
._.
For_PIN
2005_CD
grants_NN
,_,
the_DT
performance_NN
target_NN
is_VPRT [PASS]
based_VBN
on_PIN
real_JJ
Companys_NN
performance_NN
and_CC
that_THVC
the_DT
FTSE_NN
100_CD
is_VPRT [BEMA]
an_DT
appropriate_JJ
growth_NN
in_PIN
diluted_JJ
Earnings_GER
Per_PIN
Share_NN
EPS_NN
as_IN
reported_VBN [PUBV]
under_IN
US_FPP1
GAAP_NN
benchmark_NN
given_VBN
that_DEMO
the_DT
Company_NN
is_VPRT [BEMA]
a_DT
member_NN
of_PIN
the_DT
Index_NN
._.
adjusted_VBN
to_TO
ensure_VB [SUAV] [PRIV]
a_DT
consistent_JJ
basis_NN
of_PIN
measurement_NOMZ
,_,
as_IN
approved_VBN
by_PIN
the_DT
Remuneration_NOMZ
Committee_NN
,_,
including_VBG [PRESP]
the_DT
add_VB [PUBV]
back_RB
of_PIN
significant_JJ
Under_IN
the_DT
LTIP_NN
:_:
one_CD
time_NN
items_NN
._.
all_QUAN
shares_NN
vest_NN
if_COND
Shires_NN
TSR_NN
is_VPRT [BEMA]
in_PIN
the_DT
top_JJ
10_CD
%_NN
of_PIN
the_DT
FTSE_NN
100_CD
:_:
The_DT
earnings_GER
per_PIN
share_NN
based_VBN
measure_NN
was_VBD [PASS]
introduced_VBN
in_PIN
2002_CD
following_VBG
consultation_NOMZ
with_PIN
major_JJ
institutional_JJ
shareholders_NN
and_CC
,_,
during_PIN
the_DT
course_NN
20_CD
%_NN
of_PIN
the_DT
shares_NN
vest_NN
if_COND
Shires_NN
TSR_NN
is_VPRT [BEMA]
at_PIN
the_DT
median_NN
of_PIN
the_DT
FTSE_NN
of_PIN
the_DT
consultation_NOMZ
process_NN
,_,
the_DT
performance_NN
test_NN
for_PIN
executive_NN
Directors_NN
100_CD
,_,
with_PIN
vesting_VBG
between_PIN
these_DEMO
points_NN
on_PIN
a_DT
linear_JJ
basis_NN
:_:
and_ANDC
options_NOMZ
was_VBD [PASS]
toughened_VBN
compared_VBN
to_PIN
that_DEMO
for_PIN
other_JJ
employees_NN
._.
no_SYNE
shares_NN
vest_NN
if_COND
Shires_NN
TSR_NN
is_VPRT
below_PLACE
the_DT
median_NN
of_PIN
the_DT
FTSE_NN
100_CD
._.
The_DT
minimum_JJ
performance_NN
required_VBN [SUAV] [WZPAST]
in_PIN
order_NN
for_PIN
executive_NN
Directors_NN
options_NOMZ
to_PIN
vest_NN
is_VPRT
that_DEMO
Shires_NN
EPS_NN
grows_VPRT
by_PIN
15_CD
%_NN
in_PIN
excess_NN
of_PIN
the_DT
Retail_NN
The_NN
Remuneration_NOMZ
Committee_NN
determines_VPRT [SUAV] [PRIV]
whether_IN [WHCL]
and_CC
to_TO
what_WP
extent_NN
Price_NN
Index_NN
RPI_NN
or_CC
5_CD
%_NN
on_PIN
average_NN
a_DT
year_NN
in_PIN
the_DT
three_CD
years_NN
following_VBG [WZPRES]
the_DT
performance_NN
condition_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
met_VBN
on_PIN
the_DT
basis_NN
of_PIN
data_NN
provided_VBD
the_DT
date_NN
of_PIN
grant_NN
._.
In_PIN
the_DT
case_NN
of_PIN
an_DT
annual_JJ
grant_NN
of_PIN
options_NOMZ
worth_JJ
three_CD
by_PIN
an_DT
independent_JJ
third_JJ
party_NN
._.
To_PIN
date_NN
,_,
all_QUAN
awards_NN
made_VBN
under_IN
the_DT
times_NN
salary_NN
,_,
Shires_NN
EPS_NN
must_NEMD
grow_VB
by_PIN
21_CD
%_NN
in_PIN
excess_NN
of_PIN
RPI_NN
or_CC
on_PIN
LTIP_NN
have_VPRT [PEAS]
been_VBN [PASS]
made_VBN
as_IN
a_DT
conditional_JJ
allocation_NOMZ
,_,
thereby_RB
allowing_VBG [SUAV]
,_,
average_JJ
7_CD
%_NN
a_DT
year_NN
in_PIN
the_DT
three_CD
years_NN
following_VBG [WZPRES]
the_DT
date_NN
of_PIN
grant_NN
for_PIN
all_QUAN
at_PIN
the_DT
Remuneration_NOMZ
Committees_NN
discretion_NOMZ
,_,
for_PIN
a_DT
cash_NN
equivalent_NN
the_DT
options_NOMZ
to_PIN
vest_NN
._.
to_TO
be_VB [PASS]
paid_VBN
on_PIN
maturity_NOMZ
of_PIN
the_DT
award_NN
._.
Whilst_OSUB
the_DT
performance_NN
period_NN
is_VPRT [PASS]
measured_VBN
over_IN
three_CD
years_NN
,_,
an_DT
award_NN
is_VPRT [SPAU] [PASS]
normally_RB
transferred_VBN
after_IN
Options_NOMZ
with_PIN
a_DT
value_NN
the_DT
fourth_JJ
anniversary_NN
of_PIN
grant_NN
,_,
to_PIN
the_DT
extent_NN
the_DT
performance_NN
condition_NOMZ
on_PIN
grant_NN
as_IN
a_DT
%_NN
of_PIN
salary_NN
Three-year_JJ
EPS_NN
growth_NN
has_VPRT [PEAS]
been_VBN [PASS]
met_VBN
._.
Up_IN
to_PIN
100_CD
%_NN
RPI_NN
plus_PIN
15_CD
%_NN
for_PIN
executive_NN
Directors_NN
RPI_NN
plus_PIN
9_CD
%_NN
for_PIN
all_QUAN
other_JJ
employees_NN
101_CD
%_NN
to_PIN
200_CD
%_NN
RPI_NN
plus_PIN
15_CD
%_NN
201_CD
%_NN
to_PIN
300_CD
%_NN
RPI_NN
plus_PIN
21_CD
%_NN
The_DT
Portfolio_NN
Share_NN
Plan_NN
has_VPRT [PEAS]
replaced_VBN
both_DT
the_DT
2000_CD
Executive_NN
Over_IN
301_CD
%_NN
of_PIN
salary_NN
RPI_NN
plus_PIN
27_CD
%_NN
Share_NN
Option_NOMZ
Scheme_NN
and_CC
the_DT
Long-term_JJ
Incentive_NN
Plan_NN
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
59_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:56_CD
Page_NN
60_CD
Directors_NN
remuneration_JJ
report_NN
Directors_NN
were_VBD [PASS]
granted_VBN [SUAV]
awards_NN
under_IN
the_DT
LTIP_NN
in_PIN
2005_CD
as_IN
a_DT
conditional_JJ
for_PIN
the_DT
Chief_NN
Executive_NN
Officer_NN
,_,
equivalent_JJ
to_TO
approximately_RB
four_CD
allocation_NOMZ
as_IN
defined_VBN
in_PIN
the_DT
LTIP_NN
,_,
as_IN
follows_VPRT
:_:
times_NN
base_NN
salary_NN
in_PIN
SARs_NN
and_CC
three_CD
times_NN
base_JJ
salary_NN
in_PIN
PSPs_NN
:_:
and_ANDC
Earliest_JJ
date_NN
for_PIN
the_DT
Chief_NN
Financial_NN
Officer_NN
,_,
equivalent_JJ
to_TO
approximately_RB
on_PIN
which_WDT [PIRE]
2.2_CD
times_NN
base_JJ
salary_NN
in_PIN
SARs_NN
and_CC
1.6_CD
times_NN
base_JJ
salary_NN
in_PIN
PSPs_NN
._.
Value_NN
of_PIN
an_DT
award_NN
conditional_JJ
Total_NN
can_POMD
be_VB
award_NN
at_PIN
number_NN
of_PIN
transferred_VBN
Performance_NN
criteria_NN
Date_NN
of_PIN
grant_NN
date_NN
ordinary_JJ
to_PIN
a_DT
Awards_NN
under_IN
the_DT
Plan_NN
will_PRMD
normally_RB
vest_NN
on_PIN
the_DT
third_JJ
anniversary_NN
i_FPP1
award_NN
$_$
shares_NN
Director_NN
of_PIN
the_DT
date_NN
of_PIN
grant_NN
._.
In_PIN
the_DT
case_NN
of_PIN
executive_NN
Directors_NN
,_,
awards_NN
will_PRMD
only_DWNT
vest_NN
if_COND
the_DT
Committee_NN
determines_VPRT [SUAV] [PRIV]
that_THVC
the_DT
performance_NN
Mr_NN
Matthew_NN
Emmens_NN
May_POMD
2005_CD
1,024,504_CD
97,468_CD
May_POMD
2009_CD
conditions_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
satisfied_VBN
and_CC
that_DEMP
,_,
in_PIN
the_DT
opinion_NN
of_PIN
the_DT
Mr_NN
Angus_NN
Russell_NN
May_POMD
2005_CD
664,486_CD
63,217_CD
May_POMD
2009_CD
Committee_NN
,_,
the_DT
underlying_VBG
performance_NN
of_PIN
the_DT
Company_NN
is_VPRT [BEMA]
sufficient_PRED
to_TO
justify_VB
the_DT
vesting_GER
of_PIN
the_DT
award_NN
._.
i_FPP1
Translated_VBN
from_PIN
into_PIN
$_$
at_PIN
the_DT
average_JJ
exchange_NN
rate_NN
during_PIN
May_POMD
2005_CD
._.
Performance_NN
criteria_NN
will_PRMD
be_VB [PASS]
based_VBN
on_PIN
relative_JJ
Total_JJ
Shareholder_NN
Return_NN
TSR_NN
measured_VBN [WZPAST]
against_PIN
two_CD
comparator_NN
groups_NN
._.
Vesting_VBG [PRESP]
of_PIN
one-third_JJ
c_NN
The_DT
New_NN
Portfolio_NN
Share_NN
Plan_NN
of_PIN
an_DT
Award_NN
will_PRMD
depend_VB
upon_PIN
the_DT
Companys_NN
performance_NN
relative_JJ
to_PIN
the_DT
TSR_NN
performance_NN
of_PIN
FTSE_NN
100_CD
constituents_NN
,_,
excluding_VBG
financial_JJ
As_IN
part_NN
of_PIN
the_DT
remuneration_NOMZ
review_NN
,_,
the_DT
Committee_NN
proposed_VBD [SUAV]
a_DT
number_NN
of_PIN
changes_NN
to_TO
existing_VBG
equity_NOMZ
plans_NN
._.
Following_VBG
consultation_NOMZ
with_PIN
the_DT
institutions_NOMZ
._.
The_DT
vesting_GER
of_PIN
the_DT
remaining_VBG
two-thirds_NN
of_PIN
an_DT
Award_NN
will_PRMD
depend_VB
upon_PIN
the_DT
Companys_NN
performance_NN
relative_JJ
to_PIN
the_DT
Companys_NN
major_JJ
shareholders_NN
and_PHC
investor_NN
bodies_NN
including_VBG [WZPRES]
the_DT
ABI_NN
and_PHC
RREV_NN
the_DT
Committee_NN
made_VBD
changes_NN
to_PIN
its_PIT
initial_JJ
proposals_NN
TSR_NN
performance_NN
of_PIN
a_DT
group_NN
of_PIN
international_JJ
companies_NN
from_PIN
the_DT
pharmaceutical_JJ
sector_NN
see_VPRT [PRIV]
below_PLACE
._.
Vesting_VBG
will_PRMD
be_VB
as_IN
follows_VPRT
:_:
consistent_JJ
with_PIN
shareholder_NN
feedback_NN
and_CC
submitted_VBD [PUBV]
the_DT
new_JJ
Plan_NN
for_PIN
shareholder_NN
vote_NN
in_PIN
October_NN
2005_CD
._.
The_DT
Plan_NN
was_VBD [BYPA]
approved_VBN
by_PIN
performance_NN
below_PLACE
the_DT
median_NN
versus_PIN
the_DT
comparator_NN
companies_NN
an_DT
overwhelming_JJ
majority_NOMZ
of_PIN
shareholders_NN
._.
This_DEMO
new_JJ
Plan_NN
,_,
The_DT
Portfolio_NN
Share_NN
Plan_NN
the_DT
Plan_NN
,_,
was_VBD [BYPA]
adopted_VBN
by_PIN
the_DT
Companys_NN
shareholders_NN
and_CC
the_DT
FTSE_NN
1000_CD
%_NN
vesting_GER
:_:
on_PIN
October_NN
28_CD
,_,
2005_CD
._.
This_DEMO
Plan_NN
replaces_VPRT
the_DT
2000_CD
Executive_NN
Share_NN
Option_NOMZ
Scheme_NN
and_CC
the_DT
Long-term_JJ
Incentive_NN
Plan_NN
._.
The_DT
Company_NN
will_PRMD
performance_NN
at_PIN
median_JJ
versus_PIN
the_DT
comparator_NN
companies_NN
and_CC
the_DT
1_CD
FTSE_NN
10033_CD
3_CD
%_NN
vesting_GER
:_:
and_ANDC
make_VB
no_SYNE
further_JJ
awards_NN
to_PIN
executive_JJ
Directors_NN
or_CC
any_QUAN
other_JJ
employee_NN
under_IN
the_DT
previous_JJ
plans_NN
._.
performance_NN
between_PIN
median_NN
and_CC
upper_JJ
quartile_NN
versus_PIN
the_DT
The_DT
purpose_NN
of_PIN
the_DT
Plan_NN
is_VPRT
to_TO
enable_VB
the_DT
Company_NN
to_TO
motivate_VB
comparator_NN
companies_NN
and_CC
the_DT
FTSE_NN
100_CD
straight-line_JJ
vesting_GER
1_CD
from_PIN
33_CD
3_CD
%_NN
to_PIN
100_CD
%_NN
for_PIN
at_PIN
or_CC
above_PLACE
upper_JJ
quartile_JJ
performance_NN
._.
and_ANDC
reward_VB
its_PIT
workforce_NN
by_PIN
reference_NN
to_TO
share_VB
price_NN
performance_NN
,_,
and_ANDC
to_TO
link_VB
the_DT
interests_NN
of_PIN
participants_NN
with_PIN
those_DEMO
of_PIN
our_FPP1
shareholders_NN
._.
The_DT
comparator_NN
group_NN
of_PIN
international_JJ
companies_NN
from_PIN
the_DT
The_DT
Plan_NN
is_VPRT [PASS]
designed_VBN
to_TO
align_VB
the_DT
interests_NN
of_PIN
selected_VBN
employees_NN
of_PIN
the_DT
Company_NN
with_PIN
long-term_JJ
value_NN
creation_NOMZ
for_PIN
shareholders_NN
._.
Participation_NOMZ
pharmaceutical_JJ
sector_NN
will_PRMD [SPAU]
initially_TIME
include_VB
the_DT
following_JJ
companies_NN
:_:
in_PIN
the_DT
Plan_NN
is_VPRT [BEMA]
discretionary_PRED
._.
Under_IN
the_DT
Plan_NN
,_,
awards_NN
granted_VBN [SUAV] [WZPAST]
to_PIN
executive_JJ
Directors_NN
will_PRMD
be_VB [BEMA]
subject_PRED
to_PIN
a_DT
performance_NN
target_NN
,_,
which_WDT [SERE]
must_NEMD
,_,
in_PIN
normal_JJ
Allergan_NN
,_,
Altana_NN
,_,
Biovail_NN
,_,
Cephalon_NN
,_,
Forest_NN
Labs_NN
,_,
King_NN
,_,
Kos_NN
,_,
Lundbeck_NN
,_,
Medicis_NN
,_,
Novo_NN
Nordisk_NN
,_,
Schering_GER
AG_NN
,_,
Sepracor_NN
,_,
Serono_NN
,_,
UCB_NN
,_,
circumstances_NN
,_,
be_VB [PASS]
met_VBN
before_IN
the_DT
award_NN
vests_NN
._.
Performance_NN
targets_NN
will_PRMD [SPAU]
normally_RB
be_VB [PASS]
measured_VBN
over_IN
a_DT
period_NN
of_PIN
not_XX0
less_JJ
than_PIN
three_CD
years_NN
._.
Special_JJ
rules_NN
apply_VPRT
in_PIN
the_DT
event_NN
of_PIN
the_DT
participants_NN
employment_NOMZ
terminating_VBG [WZPRES]
early_TIME
or_CC
on_PIN
a_DT
change_NN
of_PIN
control_NN
of_PIN
the_DT
Company_NN
._.
The_DT
Committee_NN
has_VPRT
the_DT
discretion_NOMZ
to_TO
amend_VB
this_DEMO
group_NN
of_PIN
companies_NN
to_TO
ensure_VB [SUAV] [PRIV]
that_THVC
the_DT
group_NN
stays_VPRT
both_DT
relevant_JJ
and_CC
representative_NN
:_:
The_DT
Plan_NN
is_VPRT [PASS]
split_VBN
into_PIN
two_CD
parts_NN
,_,
which_WDT [SERE]
can_POMD
be_VB [PASS]
operated_VBN
separately_RB
._.
however_CONJ
,_,
the_DT
change_NN
must_NEMD
not_XX0
have_VB
the_DT
effect_NN
of_PIN
making_VBG
the_DT
performance_NN
criteria_NN
either_CC
materially_RB
easier_JJ
or_CC
materially_RB
more_EMPH
difficult_JJ
Under_IN
Part_NN
A_NN
of_PIN
the_DT
Plan_NN
,_,
Stock_NN
Appreciation_NOMZ
Right_NN
SAR_NN
Awards_NN
to_TO
achieve_VB
,_,
in_PIN
the_DT
opinion_NN
of_PIN
the_DT
Committee_NN
,_,
than_PIN
it_PIT
was_VBD
or_CC
they_TPP3
were_VBD
immediately_TIME
before_IN
the_DT
circumstance_NN
in_PIN
question_NOMZ
._.
A_DT
SAR_NN
Award_NN
is_VPRT [BEMA]
the_DT
right_NN
to_TO
receive_VB
shares_NN
or_CC
ADSs_NN
in_PIN
the_DT
Company_NN
linked_VBN [WZPAST]
to_PIN
the_DT
increase_NN
in_PIN
value_NN
of_PIN
a_DT
specified_VBN
number_NN
TSR_NN
performance_NN
will_PRMD
be_VB [PASS]
measured_VBN
using_VBG
an_DT
averaging_GER
period_NN
of_PIN
of_PIN
shares_NN
over_IN
a_DT
period_NN
between_PIN
three_CD
and_CC
five_CD
years_NN
from_PIN
the_DT
date_NN
of_PIN
grant_NN
and_CC
,_,
in_PIN
the_DT
case_NN
of_PIN
executive_NN
Directors_NN
,_,
subject_JJ
to_PIN
the_DT
three_CD
months_NN
._.
In_CONJ
addition_NULL
,_,
the_DT
Committee_NN
will_PRMD
have_VB
regard_NN
to_PIN
the_DT
same_JJ
calculation_NOMZ
using_VBG [WZPRES]
an_DT
averaging_GER
period_NN
of_PIN
six_CD
months_NN
as_IN
part_NN
of_PIN
a_DT
fairness_NOMZ
satisfaction_NOMZ
of_PIN
performance_NN
targets_NN
._.
SAR_NN
Awards_NN
will_PRMD
normally_RB
vest_NN
three_CD
years_NN
after_IN
the_DT
date_NN
of_PIN
grant_NN
,_,
subject_JJ
to_PIN
the_DT
satisfaction_NOMZ
of_PIN
review_NN
to_TO
ensure_VB [SUAV] [PRIV] [THATD]
that_DEMP
vesting_VBG
properly_RB
reflects_VPRT [PRIV]
underlying_VBG
performance_NN
._.
performance_NN
targets_NN
in_PIN
the_DT
case_NN
of_PIN
executive_NN
Directors_NN
,_,
and_ANDC
can_POMD
be_VB [PASS]
exercised_VBN
up_RP
until_IN
the_DT
fifth_JJ
anniversary_NN
of_PIN
the_DT
date_NN
of_PIN
grant_NN
._.
If_COND
the_DT
performance_NN
conditions_NOMZ
are_VPRT [PASS]
not_XX0
met_VBN
,_,
awards_NN
will_PRMD
lapse_NN
._.
Under_IN
Part_NN
B_NN
of_PIN
the_DT
Plan_NN
,_,
Performance_NN
Share_NN
PSP_NN
Awards_NN
can_POMD
d_SYM
The_DT
implementation_NOMZ
of_PIN
share_NN
ownership_NN
guidelines_NN
The_DT
Remuneration_NOMZ
Committee_NN
believes_VPRT [PRIV]
that_THVC
executive_NN
Directors_NN
and_CC
be_VB [PASS]
granted_VBN [SUAV]
._.
A_DT
PSP_NN
Award_NN
is_VPRT [BEMA]
the_DT
right_NN
to_TO
receive_VB
a_DT
specified_VBN
number_NN
of_PIN
shares_NN
or_CC
ADSs_NN
three_CD
years_NN
from_PIN
the_DT
date_NN
of_PIN
grant_NN
._.
In_PIN
the_DT
case_NN
certain_JJ
other_JJ
members_NN
of_PIN
senior_JJ
management_NOMZ
should_NEMD
be_VB [PASS]
encouraged_VBN
to_TO
own_VB
shares_NN
in_PIN
the_DT
Company_NN
in_PIN
order_NN
to_TO
ensure_VB [SUAV] [PRIV]
the_DT
alignment_NOMZ
of_PIN
their_TPP3
of_PIN
executive_NN
Directors_NN
,_,
performance_NN
targets_NN
must_NEMD
be_VB [PASS]
satisfied_VBN
before_IN
a_DT
PSP_NN
Award_NN
vests_NN
._.
Upon_PIN
vesting_VBG
of_PIN
the_DT
PSP_NN
Award_NN
,_,
shares_NN
interests_NN
with_PIN
those_DEMO
of_PIN
the_DT
Companys_NN
shareholders_NN
._.
The_DT
Committee_NN
discussed_VBD
this_DEMO
matter_NN
with_PIN
shareholders_NN
during_PIN
its_PIT
consultation_NOMZ
process_NN
will_PRMD
be_VB [PASS]
released_VBN
to_PIN
the_DT
participant_NN
automatically_RB
without_PIN
any_QUAN
action_NOMZ
on_PIN
the_DT
part_NN
of_PIN
the_DT
participant_NN
._.
in_PIN
2005_CD
,_,
and_ANDC
has_VPRT [PEAS]
developed_VBN
share_NN
ownership_NN
guidelines_NN
which_WDT [WHSUB]
came_VBD
into_PIN
effect_NN
in_PIN
2006_CD
._.
The_DT
Plan_NN
contains_VPRT
individual_JJ
grant_NN
limits_NN
set_VBN [WZPAST]
at_PIN
six_CD
times_NN
base_JJ
salary_NN
for_PIN
SAR_NN
awards_NN
in_PIN
any_QUAN
one_CD
year_NN
and_CC
four_CD
times_NN
base_JJ
salary_NN
for_PIN
PSP_NN
awards_NN
in_PIN
any_QUAN
one_CD
year_NN
._.
It_PIT
is_VPRT [BEMA]
the_DT
Companys_NN
intention_NOMZ
for_PIN
awards_NN
granted_VBN [SUAV]
under_IN
the_DT
Plan_NN
to_PIN
executive_JJ
Directors_NN
to_TO
be_VB [PASS]
comprised_VBN
of_PIN
either_DT
or_CC
both_DT
a_DT
SAR_NN
Award_NN
and_CC
a_DT
PSP_NN
Award_NN
._.
For_PIN
2006_CD
,_,
it_PIT
is_VPRT [BEMA]
the_DT
Companys_NN
intention_NOMZ
to_TO
provide_VB
grants_NN
to_PIN
the_DT
Chief_NN
Executive_NN
Officer_NN
and_PHC
Chief_NN
Financial_NN
Officer_NN
with_PIN
face_NN
values_NN
calculated_VBN [PRIV] [WZPAST]
by_PIN
reference_NN
to_PIN
the_DT
average_JJ
share_NN
price_NN
over_IN
the_DT
prior_JJ
12-month_JJ
calendar_NN
period_NN
as_IN
follows_VPRT
:_:
60_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:56_CD
Page_NN
61_CD
Directors_NN
remuneration_JJ
report_NN
The_DT
Executive_NN
Share_NN
Ownership_NN
Guidelines_NN
are_VPRT [BYPA]
administered_VBN
by_PIN
the_DT
Service_NN
contracts_NN
Remuneration_NOMZ
Committee_NN
and_CC
are_VPRT [PASS]
based_VBN
on_PIN
the_DT
following_VBG
principles_NN
:_:
The_DT
Remuneration_NOMZ
Committee_NN
continues_VPRT
to_TO
believe_VB [PRIV]
that_THVC
executive_JJ
Directors_NN
service_NN
contracts_NN
should_NEMD
be_VB [BEMA]
for_PIN
a_DT
rolling_JJ
term_NN
and_CC
,_,
for_PIN
UK_NN
the_DT
Committee_NN
believes_VPRT [PRIV]
that_THVC
share_NN
ownership_NN
is_VPRT [BEMA]
an_DT
important_JJ
contracts_NN
,_,
incorporate_VB
notice_NN
periods_NN
of_PIN
12_CD
months_NN
._.
The_DT
Committee_NN
element_NOMZ
of_PIN
an_DT
executives_NN
role_NN
in_PIN
running_VBG
the_DT
Company_NN
and_CC
also_RB
believes_VPRT [PRIV]
that_THVC
the_DT
Company_NN
should_NEMD
retain_VB
the_DT
right_NN
to_TO
make_VB
a_DT
represents_VPRT
both_DT
a_DT
commitment_NOMZ
by_PIN
the_DT
executive_NN
as_RB
well_RB
as_IN
an_DT
payment_NOMZ
in_PIN
lieu_NN
of_PIN
notice_NN
to_PIN
a_DT
Director_NN
._.
The_DT
contracts_NN
contain_VPRT
obligations_NOMZ
alignment_NOMZ
of_PIN
the_DT
executives_NN
interests_NN
with_PIN
those_DEMO
of_PIN
shareholders_NN
:_:
on_PIN
the_DT
executive_NN
Directors_NN
in_PIN
respect_NN
of_PIN
intellectual_JJ
property_NN
,_,
together_RB
with_PIN
post-termination_JJ
restrictions_NOMZ
._.
The_DT
Committees_NN
view_VPRT
is_VPRT
that_DEMP
,_,
the_DT
Committee_NN
believes_VPRT [PRIV]
that_THVC
share_NN
ownership_NN
by_PIN
executives_NN
should_NEMD
in_PIN
the_DT
event_NN
of_PIN
early_TIME
termination_NOMZ
,_,
executive_NN
Directors_NN
should_NEMD
be_VB [PASS]
treated_VBN
be_VB [SPAU] [PASS]
strongly_AMP
encouraged_VBN
,_,
but_CC
not_XX0
mandated_VBN
:_:
fairly_RB
but_CC
paid_VBD
no_SYNE
more_EMPH
than_PIN
is_VPRT [BEMA]
necessary_PRED
._.
Moreover_CONJ
,_,
there_EX
should_NEMD
be_VB
no_SYNE
element_NOMZ
of_PIN
reward_NN
for_PIN
failure_NN
._.
the_DT
Committee_NN
understands_VPRT [PRIV] [THATD]
that_DEMP
,_,
depending_VBG [PRESP]
on_PIN
personal_JJ
and_PHC
other_JJ
circumstances_NN
,_,
an_DT
executive_NN
may_POMD
not_XX0
be_VB [BEMA]
able_PRED
to_TO
achieve_VB
the_DT
desired_VBN [SUAV]
The_DT
executive_NN
Directors_NN
contracts_NN
of_PIN
employment_NOMZ
,_,
which_WDT [SERE]
were_VBD [PASS]
revised_VBN
level_NN
of_PIN
share_NN
ownership_NN
:_:
following_VBG
consultation_NOMZ
with_PIN
some_QUAN
of_PIN
the_DT
Companys_NN
major_JJ
shareholders_NN
in_PIN
2003_CD
,_,
are_VPRT [PASS]
dated_VBN
March_NN
10_CD
,_,
2004_CD
in_PIN
the_DT
case_NN
of_PIN
Mr_NN
Russell_NN
and_CC
the_DT
Committee_NN
believes_VPRT [PRIV]
that_THVC
executives_NN
should_NEMD
understand_VB [PRIV]
the_DT
March_NN
12_CD
,_,
2004_CD
in_PIN
the_DT
case_NN
of_PIN
Mr_NN
Emmens_NN
._.
Both_DT
agreements_NOMZ
were_VBD
importance_NN
of_PIN
share_NN
ownership_NN
in_PIN
the_DT
stewardship_NN
of_PIN
the_DT
Company_NN
,_,
revised_VBN [PASTP]
on_PIN
November_NN
21_CD
,_,
2005_CD
to_TO
provide_VB
for_PIN
Shire_NN
plc_NN
being_VBG [WZPRES]
and_CC
both_DT
appropriate_JJ
time_NN
and_PHC
latitude_NN
will_PRMD
be_VB [PASS]
provided_VBN
to_PIN
executives_NN
established_VBN [PRIV]
as_IN
the_DT
new_JJ
holding_VBG [PRIV]
company_NN
for_PIN
the_DT
Shire_NN
Group_NN
._.
to_TO
achieve_VB
desired_VBN [SUAV]
share_NN
ownership_NN
levels_NN
,_,
where_RB
possible_JJ
:_:
and_ANDC
Mr_NN
Russells_NN
contract_NN
requires_VPRT [SUAV]
him_TPP3
to_TO
give_VB
the_DT
Company_NN
12_CD
months_NN
notice_NN
and_CC
expires_VPRT
on_PIN
him_TPP3
reaching_VBG
65_CD
._.
Mr_NN
Emmens_NN
contract_NN
requires_VPRT [SUAV]
share_NN
ownership_NN
levels_NN
will_PRMD
be_VB [PASS]
reviewed_VBN
annually_RB
for_PIN
each_QUAN
executive_NN
._.
him_TPP3
to_TO
give_VB
the_DT
Company_NN
six_CD
months_NN
notice_NN
and_CC
no_SYNE
age_NN
is_VPRT [PASS]
specified_VBN
for_PIN
retirement_NOMZ
._.
The_DT
Company_NN
is_VPRT [PASS]
required_VBN [SUAV]
to_TO
give_VB
Mr_NN
Russell_NN
12_CD
months_NN
Executives_NN
are_VPRT [PASS]
encouraged_VBN
,_,
within_PIN
a_DT
five-year_JJ
period_NN
following_VBG [WZPRES]
the_DT
notice_NN
of_PIN
termination_NOMZ
,_,
other_JJ
than_PIN
if_COND
termination_NOMZ
is_VPRT [BEMA]
for_PIN
cause_NN
,_,
whereas_OSUB
later_TIME
of_PIN
either_CC
the_DT
initiation_NOMZ
of_PIN
these_DEMO
guidelines_NN
,_,
or_CC
their_TPP3
appointment_NOMZ
it_PIT
is_VPRT [PASS]
not_XX0
obliged_VBN
to_TO
give_VB
Mr_NN
Emmens_NN
any_QUAN
notice_NN
._.
If_COND
Mr_NN
Emmens_NN
contract_NN
or_CC
election_NOMZ
,_,
to_TO
attain_VB
and_PHC
hold_VB [PRIV]
an_DT
investment_NOMZ
position_NOMZ
no_SYNE
less_JJ
than_PIN
the_DT
is_VPRT [PASS]
terminated_VBN
without_PIN
cause_NN
the_DT
Company_NN
is_VPRT [PASS]
required_VBN [SUAV]
to_TO
pay_VB
him_TPP3
one_CD
multiples_NN
of_PIN
base_NN
salary_NN
set_VBN [WZPAST]
forth_RB
below_PLACE
._.
years_NN
salary_NN
and_CC
the_DT
cash_NN
equivalent_NN
of_PIN
one_CD
years_NN
pension_NN
,_,
car_NN
and_CC
other_JJ
contractual_JJ
benefits_NN
._.
The_DT
following_VBG
are_VPRT [BEMA]
the_DT
guideline_NN
share_NN
ownership_NN
levels_NN
for_PIN
the_DT
executive_NN
Directors_NN
:_:
In_PIN
the_DT
event_NN
of_PIN
termination_NOMZ
of_PIN
employment_NOMZ
within_PIN
twelve_CD
months_NN
of_PIN
a_DT
change_NN
of_PIN
control_NN
,_,
the_DT
amount_NN
payable_JJ
in_PIN
respect_NN
of_PIN
each_QUAN
Chief_NN
Executive_NN
:_:
2_CD
x_SYM
Base_NN
Salary_NN
of_PIN
Mr_NN
Emmens_NN
and_PHC
Mr_NN
Russell_NN
is_VPRT [BEMA]
one_CD
years_NN
salary_NN
and_CC
the_DT
cash_NN
equivalent_NN
of_PIN
one_CD
years_NN
pension_NN
,_,
car_NN
and_CC
other_JJ
contractual_JJ
benefits_NN
._.
Chief_NN
Financial_NN
Officer_NN
:_:
1.5_CD
x_SYM
Base_NN
Salary_NN
Any_QUAN
incentive_NN
payable_JJ
is_VPRT [BEMA]
at_PIN
the_DT
discretion_NOMZ
of_PIN
the_DT
Remuneration_NOMZ
Committee_NN
and_CC
is_VPRT [PASS]
capped_VBN
at_PIN
the_DT
contractual_JJ
maximum_NN
incentive_NN
._.
All_QUAN
shares_NN
beneficially_RB
owned_VBN
by_PIN
an_DT
executive_NN
excluding_VBG [WZPRES]
unexercised_JJ
vested_JJ
Stock_NN
Options_NOMZ
or_CC
SARs_NN
count_VPRT
towards_PIN
achieving_VBG
these_DEMO
guidelines_NN
._.
The_DT
amount_NN
of_PIN
incentive_NN
payable_JJ
upon_PIN
termination_NOMZ
of_PIN
employment_NOMZ
in_PIN
any_QUAN
other_JJ
circumstances_NN
,_,
other_JJ
than_PIN
for_PIN
cause_NN
,_,
is_VPRT [BEMA]
at_PIN
the_DT
discretion_NOMZ
The_DT
Remuneration_NOMZ
Committee_NN
will_PRMD
review_VB
share_NN
ownership_NN
levels_NN
for_PIN
of_PIN
the_DT
Remuneration_NOMZ
Committee_NN
and_CC
is_VPRT [PASS]
capped_VBN
at_PIN
the_DT
contractual_JJ
each_QUAN
executive_NN
on_PIN
an_DT
annual_JJ
basis_NN
._.
The_DT
Committee_NN
will_PRMD
discuss_VB
with_PIN
each_QUAN
target_NN
incentive_NN
._.
executive_JJ
Director_NN
their_TPP3
plans_NN
for_PIN
share_NN
ownership_NN
on_PIN
a_DT
regular_JJ
basis_NN
:_:
the_DT
Chief_NN
Executive_NN
Officer_NN
will_PRMD
discuss_VB
with_PIN
each_QUAN
of_PIN
the_DT
remaining_VBG
executives_NN
Non-executive_JJ
Directors_NN
and_CC
the_DT
Chairman_NN
their_TPP3
plans_NN
for_PIN
share_NN
ownership_NN
on_PIN
a_DT
regular_JJ
basis_NN
._.
Each_QUAN
Non-executive_JJ
Director_NN
is_VPRT [PASS]
paid_VBN
a_DT
fee_NN
for_PIN
serving_VBG
as_IN
a_DT
Director_NN
and_CC
additional_JJ
fees_NN
are_VPRT [PASS]
paid_VBN
for_PIN
membership_NN
or_CC
chairmanship_NN
of_PIN
the_DT
4_CD
Pension_NN
and_CC
other_JJ
benefits_NN
Audit_NN
,_,
Remuneration_NOMZ
and_PHC
Nomination_NOMZ
Committees_NN
._.
The_DT
Chairman_NN
The_NN
Companys_NN
policy_NN
is_VPRT
to_TO
ensure_VB [SUAV] [PRIV]
that_THVC
pension_NN
benefits_NN
are_VPRT [BEMA]
competitive_PRED
of_PIN
the_DT
Company_NN
receives_VPRT
an_DT
inclusive_JJ
fee_NN
._.
Fees_NN
are_VPRT [BYPA]
determined_VBN [SUAV] [PRIV]
by_PIN
the_DT
in_PIN
the_DT
markets_NN
in_PIN
which_WDT [PIRE]
Shire_NN
operates_VPRT
._.
Shire_NN
contributes_VPRT
30_CD
%_NN
of_PIN
the_DT
Chief_NN
Board_NN
,_,
with_PIN
the_DT
exception_NOMZ
of_PIN
the_DT
Chairmans_NN
fee_NN
which_WDT [WHSUB]
is_VPRT [PASS]
determined_VBN [SUAV] [PRIV]
Executive_NN
Officers_NN
annual_JJ
salary_NN
to_PIN
a_DT
Supplemental_NN
Employee_NN
Retirement_NOMZ
by_PIN
the_DT
Remuneration_NOMZ
Committee_NN
and_CC
confirmed_VBN [PUBV]
by_PIN
the_DT
Board_NN
._.
Plan_NN
SERP_NN
and_CC
401_CD
k_NN
Plan_NN
in_PIN
the_DT
US_FPP1
._.
The_DT
SERP_NN
is_VPRT [BEMA]
an_DT
unfunded_JJ
defined_VBN
Fees_NN
are_VPRT [PASS]
benchmarked_VBN
against_PIN
Non-executive_JJ
Director_NN
fees_NN
of_PIN
benefit_NN
scheme_NN
:_:
the_DT
benefits_NN
are_VPRT [BEMA]
payable_PRED
to_PIN
certain_JJ
senior_JJ
US_FPP1
employees_NN
comparable_JJ
companies_NN
._.
The_DT
fees_NN
paid_VBN [WZPAST]
to_PIN
Non-executive_JJ
Directors_NN
as_IN
lump_NN
sums_NN
on_PIN
leaving_VBG
the_DT
Groups_NN
employment_NOMZ
or_CC
earlier_TIME
due_JJ
to_PIN
death_NN
,_,
are_VPRT [BEMA]
not_XX0
performance-related_PRED
._.
Details_NN
of_PIN
fees_NN
paid_VBN [WZPAST]
to_PIN
the_DT
Chairman_NN
and_PHC
disability_NOMZ
or_CC
termination_NOMZ
._.
The_DT
amount_NN
of_PIN
benefit_NN
is_VPRT [PASS]
based_VBN
on_PIN
the_DT
value_NN
of_PIN
Non-executive_JJ
Directors_NN
in_PIN
2005_CD
are_VPRT [PASS]
set_VBN
out_PIN
in_PIN
the_DT
table_NN
on_PIN
page_NN
62_CD
._.
notional_JJ
contributions_NOMZ
adjusted_VBN [WZPAST]
for_PIN
earned_VBN
investment_NOMZ
returns_NN
as_IN
if_COND
they_TPP3
were_VBD [PASS]
invested_VBN
in_PIN
investments_NOMZ
of_PIN
the_DT
employees_NN
choice_NN
._.
The_DT
Non-executive_JJ
Directors_NN
are_VPRT [BEMA]
not_XX0
eligible_PRED
to_TO
join_VB
the_DT
Companys_NN
pension_NN
scheme_NN
._.
In_PIN
the_DT
UK_NN
,_,
Shire_NN
operates_VPRT
a_DT
defined_VBN
contribution_NOMZ
scheme_NN
._.
The_DT
Company_NN
contributes_VPRT
25_CD
%_NN
of_PIN
salary_NN
for_PIN
the_DT
Chief_NN
Financial_NN
Officer_NN
to_PIN
pension_NN
Non-executive_JJ
Directors_NN
do_VPRT
not_XX0
participate_VB
in_PIN
any_QUAN
of_PIN
the_DT
Company_NN
benefits_NN
._.
The_DT
implications_NOMZ
of_PIN
the_DT
forthcoming_JJ
UK_NN
pension_NN
tax_NN
reforms_NN
,_,
share_NN
schemes_NN
or_CC
other_JJ
employee_NN
benefit_NN
schemes_NN
and_CC
no_SYNE
options_NOMZ
which_WDT [WHSUB]
become_VPRT
effective_JJ
in_PIN
2006_CD
,_,
will_PRMD
be_VB [PASS]
considered_VBN [PRIV]
during_PIN
the_DT
course_NN
have_VPRT [PEAS]
been_VBN [PASS]
granted_VBN [SUAV]
to_PIN
Non-executive_JJ
Directors_NN
in_PIN
their_TPP3
capacity_NOMZ
as_IN
of_PIN
the_DT
year_NN
and_CC
the_DT
Committee_NN
will_PRMD
agree_VB [SUAV] [PUBV]
any_QUAN
policy_NN
changes_NN
necessary_JJ
Non-executive_JJ
Directors_NN
of_PIN
Shire_NN
._.
On_PIN
the_DT
merger_NN
of_PIN
Shire_NN
with_PIN
BioChem_NN
in_PIN
respect_NN
of_PIN
the_DT
pension_NN
arrangements_NOMZ
of_PIN
the_DT
Chief_NN
Financial_NN
Officer_NN
Pharma_NN
Inc._NN
in_PIN
2001_CD
,_,
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
to_PIN
The_DT
Hon_NN
James_NN
Grant_NN
and_CC
other_JJ
UK_NN
executives_NN
._.
in_PIN
replacement_NOMZ
for_PIN
Mr_NN
Grants_NN
BioChem_NN
Pharma_NN
options_NOMZ
._.
The_DT
grant_NN
of_PIN
these_DEMO
replacement_NOMZ
options_NOMZ
and_CC
the_DT
original_JJ
BioChem_NN
Pharma_NN
option_NOMZ
In_CONJ
addition_NULL
to_PIN
salary_NN
,_,
the_DT
executive_NN
Directors_NN
receive_VPRT
certain_JJ
benefits_NN
grant_NN
were_VBD [PASS]
made_VBN
on_PIN
the_DT
same_JJ
terms_NN
as_IN
applied_VBN
to_PIN
other_JJ
employees_NN
in_PIN
kind_NN
,_,
principally_RB
a_DT
car_NN
or_CC
car_NN
allowance_NN
,_,
life_NN
insurance_NN
,_,
private_JJ
medical_JJ
at_PIN
the_DT
time_NN
,_,
including_VBG
that_DEMO
these_DEMO
options_NOMZ
are_VPRT [BEMA]
not_XX0
subject_PRED
to_PIN
any_QUAN
insurance_NN
and_CC
dental_JJ
cover_NN
._.
These_DEMO
benefits_NN
are_VPRT [BEMA]
not_XX0
pensionable_PRED
._.
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
61_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
62_CD
Directors_NN
remuneration_JJ
report_NN
Non-executive_JJ
Directors_NN
are_VPRT [PASS]
appointed_VBN
ordinarily_RB
for_PIN
a_DT
term_NN
of_PIN
two_CD
The_DT
three-year_JJ
graph_NN
tracks_VPRT
the_DT
TSR_NN
performance_NN
since_OSUB
the_DT
Company_NN
years_NN
,_,
subject_JJ
to_PIN
shareholder_NN
approval_NN
._.
Non-executive_JJ
Directors_NN
who_WP [WHSUB]
started_VBD
to_TO
implement_VB
its_PIT
new_JJ
strategic_JJ
plan_NN
under_IN
new_JJ
management_NOMZ
._.
have_VB [PEAS]
served_VBN
on_PIN
the_DT
Board_NN
for_PIN
nine_CD
years_NN
or_CC
more_EMPH
are_VPRT [PASS]
appointed_VBN
for_PIN
one_CD
year_NN
terms_NN
and_CC
,_,
in_PIN
accordance_NN
with_PIN
the_DT
Combined_NN
Code_NN
on_PIN
Corporate_NN
Three-year_JJ
historical_JJ
TSR_NN
performance_NN
._.
Change_NN
in_PIN
Governance_NN
,_,
are_VPRT [BEMA]
subject_PRED
to_PIN
annual_JJ
re-election_NOMZ
by_PIN
shareholders_NN
._.
value_NN
of_PIN
a_DT
hypothetical_JJ
100_CD
holding_GER
over_IN
three_CD
years_NN
._.
Re-appointment_NOMZ
of_PIN
Non-executive_JJ
Directors_NN
following_VBG [WZPRES]
the_DT
expiry_NN
200_CD
of_PIN
their_TPP3
term_NN
of_PIN
appointment_NOMZ
is_VPRT [BEMA]
subject_PRED
to_PIN
Board_NN
approval_NN
._.
180_CD
Details_NN
of_PIN
the_DT
unexpired_JJ
terms_NN
of_PIN
the_DT
letters_NN
of_PIN
appointment_NOMZ
and_PHC
notice_NN
160_CD
periods_NN
are_VPRT
as_IN
follows_VPRT
:_:
140_CD
Date_NN
of_PIN
Date_NN
of_PIN
Notice_NN
120_CD
Director_NN
appointment_NOMZ
term_NN
expiry_JJ
period_NN
100_CD
Dr_NN
James_NN
Cavanaugh_NN
24.03.05_CD
23.03.07_CD
3_CD
months_NN
80_CD
Dr_NN
Barry_NN
Price_NN
25.01.06_CD
24.01.07_CD
3_CD
months_NN
60_CD
The_DT
Hon_NN
James_NN
Grant_NN
11.05.05_CD
10.05.07_CD
3_CD
months_NN
40_CD
Mr_NN
Ronald_NN
Nordmann_NN
23.12.05_CD
22.12.06_CD
3_CD
months_NN
20_CD
Mr_NN
Robin_NN
Buchanan_NN
30.07.05_CD
29.07.07_CD
3_CD
months_NN
0_CD
Mr_NN
David_NN
Kappler_NN
06.04.04_CD
05.04.06_CD
3_CD
months_NN
31.12.02_CD
31.12.03_CD
31.12.04_CD
31.12.05_CD
Mr_NN
Patrick_NN
Langlois_NN
11.11.05_CD
10.11.07_CD
3_CD
months_NN
Shire_NN
TSR_NN
Ex-financials_NN
FTSE_NN
100_CD
TSR_NN
The_DT
fee_NN
policy_NN
structure_NN
for_PIN
Non-executive_JJ
Directors_NN
,_,
effective_JJ
January_NN
1_CD
,_,
Comparator_NN
group_NN
TSR_NN
2006_CD
,_,
is_VPRT [PASS]
presented_VBN
in_PIN
the_DT
table_NN
below_PLACE
._.
Change_NN
in_PIN
i_FPP1
2006_CD
Board_NN
membership_NN
annual_JJ
basic_JJ
fees_NN
value_NN
of_PIN
a_DT
hypothetical_JJ
100_CD
holding_GER
over_IN
five_CD
years_NN
._.
Chairman_NN
of_PIN
the_DT
Board_NN
inclusive_NN
of_PIN
all_QUAN
Committees_NN
409,725_CD
160_CD
Senior_JJ
Non-executive_JJ
Director_NN
inclusive_NN
of_PIN
NED_NN
fee_NN
81,945_CD
Non-executive_JJ
Director_NN
72,840_CD
140_CD
Committee_NN
membership_NN
fees_NN
120_CD
Audit_NN
Committee_NN
chair_NN
36,420_CD
Remuneration_NOMZ
Committee_NN
chair_NN
22,763_CD
100_CD
Nomination_NOMZ
Committee_NN
chair_NN
22,763_CD
Audit_NN
Committee_NN
member_NN
18,210_CD
80_CD
Remuneration_NOMZ
Committee_NN
member_NN
13,658_CD
Nomination_NOMZ
Committee_NN
member_NN
9,105_CD
60_CD
40_CD
i_FPP1
Denominated_VBN
in_PIN
sterling_GER
and_CC
translated_VBN
into_PIN
$_$
at_PIN
the_DT
average_JJ
exchange_NN
rate_NN
prevailing_VBG [WZPRES]
in_PIN
2005_CD
._.
20_CD
Related_VBN
party_NN
transactions_NOMZ
0_CD
Details_NN
of_PIN
transactions_NOMZ
relating_VBG [WZPRES]
to_PIN
Dr_NN
James_NN
Cavanaugh_NN
,_,
The_DT
Hon_NN
31.12.00_CD
31.12.01_CD
31.12.02_CD
31.12.03_CD
31.12.04_CD
31.12.05_CD
James_NN
Grant_NN
,_,
who_WP
is_VPRT [BEMA]
a_DT
partner_NN
of_PIN
a_DT
Canadian_JJ
law_NN
firm_NN
with_PIN
which_WDT [PIRE]
the_DT
Company_NN
incurred_VBN
professional_JJ
fees_NN
during_PIN
the_DT
year_NN
and_CC
with_PIN
Shire_NN
TSR_NN
Ex-financials_NN
FTSE_NN
100_CD
TSR_NN
Dr_NN
Francesco_NN
Bellini_NN
,_,
a_DT
former_JJ
Non-executive_JJ
Director_NN
,_,
are_VPRT [PASS]
given_VBN
Comparator_NN
group_NN
TSR_NN
in_PIN
the_DT
Directors_NN
report_VPRT [PUBV]
on_PIN
page_NN
114_CD
._.
Performance_NN
graph_NN
Other_JJ
remuneration_NOMZ
The_DT
graphs_NN
below_PLACE
set_VBN
out_PIN
the_DT
Total_JJ
Shareholder_NN
Return_NN
TSR_NN
for_PIN
the_DT
The_DT
Company_NN
believes_VPRT [PRIV]
there_EX
are_VPRT
benefits_NN
to_PIN
executive_JJ
Directors_NN
three_CD
and_CC
five_CD
years_NN
ending_VBG [WZPRES]
December_NN
31_CD
,_,
2005_CD
._.
The_DT
graphs_NN
compare_VPRT
participation_NOMZ
at_PIN
the_DT
Board_NN
level_NN
at_PIN
other_JJ
companies_NN
,_,
including_VBG
crossthe_NN
performance_NN
of_PIN
a_DT
hypothetical_JJ
100_CD
holding_GER
of_PIN
the_DT
Companys_NN
industry_NN
and_PHC
cross-company_NN
exposure_NN
and_CC
the_DT
added_VBN [PUBV]
perspective_NN
shares_NN
with_PIN
that_DEMO
of_PIN
a_DT
holding_GER
of_PIN
shares_NN
in_PIN
the_DT
FTSE_NN
100_CD
index_NN
excluding_VBG [WZPRES]
of_PIN
outside_PLACE
views_NN
._.
It_PIT
is_VPRT [BEMA]
therefore_CONJ
the_DT
Companys_NN
policy_NN
to_TO
allow_VB [SUAV]
executive_JJ
financial_JJ
institutions_NOMZ
and_CC
with_PIN
a_DT
holding_GER
in_PIN
a_DT
group_NN
comprised_VBD
of_PIN
the_DT
Directors_NN
to_TO
take_VB
up_RP
Non-executive_JJ
positions_NOMZ
at_PIN
other_JJ
companies_NN
and_CC
following_VBG
pharma_JJ
companies_NN
:_:
Novo_NN
Nordisk_NN
,_,
Schering_GER
AG_NN
,_,
Serono_NN
,_,
retain_VPRT
associated_VBN
earnings_GER
as_OSUB
long_NULL
as_NULL
such_JJ
appointments_NOMZ
are_VPRT
expressly_RB
Altana_NN
,_,
UCB_NN
,_,
Lundbeck_NN
,_,
Forest_NN
Labs_NN
,_,
Allergan_NN
,_,
Sepracor_NN
,_,
Cephalon_NN
,_,
permitted_VBN [PASTP]
by_PIN
the_DT
Board_NN
of_PIN
Directors_NN
._.
Mr_NN
Emmens_NN
was_VBD [PASS]
appointed_VBN
Watson_NN
,_,
Biovail_NN
,_,
King_NN
,_,
Valeant_NN
,_,
Medicis_NN
and_PHC
Kos_NN
._.
This_DEMO
comparator_NN
as_IN
a_DT
Non-executive_JJ
Director_NN
of_PIN
Vertex_NN
Pharmaceuticals_NN
Inc_NN
during_PIN
2004_CD
._.
group_NN
is_VPRT [BEMA]
a_DT
blend_VB
of_PIN
US_FPP1
and_PHC
UK_NN
companies_NN
with_PIN
sector_NN
,_,
size_NN
,_,
complexity_NOMZ
In_PIN
this_DEMO
capacity_NOMZ
he_TPP3
was_VBD [PASS]
paid_VBN
$_$
37,917_CD
in_PIN
2005_CD
,_,
which_WDT [SERE]
he_TPP3
will_PRMD
retain_VB
._.
and_ANDC
international_JJ
characteristics_NN
similar_JJ
to_PIN
those_DEMO
of_PIN
the_DT
Company_NN
._.
These_DEMO
comparisons_NN
will_PRMD [SPAU]
also_RB
be_VB [PASS]
used_VBN
to_TO
determine_VB [SUAV] [PRIV]
achievement_NOMZ
Mr_NN
Russell_NN
is_VPRT [BEMA]
a_DT
Non-executive_JJ
Director_NN
of_PIN
The_NN
City_NOMZ
of_PIN
London_NN
of_PIN
performance_NN
conditions_NOMZ
relating_VBG [WZPRES]
to_PIN
the_DT
Annual_JJ
Incentive_NN
Plan_NN
and_PHC
Investment_NOMZ
Trust_NN
plc_NN
and_CC
its_PIT
associated_VBN
companies_NN
,_,
The_DT
City_NOMZ
of_PIN
London_NN
Portfolio_NN
Share_NN
Plan_NN
._.
European_NN
Trust_NN
Limited_NN
,_,
The_NN
City_NOMZ
of_PIN
London_NN
Investments_NOMZ
Limited_NN
and_PHC
The_NN
City_NOMZ
of_PIN
London_NN
Finance_NN
Company_NN
Limited_NN
._.
In_PIN
this_DEMO
capacity_NOMZ
,_,
he_TPP3
was_VBD [PASS]
paid_VBN
17,500_CD
$_$
31,868_CD
equivalent_NN
in_PIN
2005_CD
,_,
which_WDT [SERE]
he_TPP3
will_PRMD
retain_VB
._.
62_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
Value_NN
of_PIN
hypothetical_JJ
100_CD
holding_VBG [PRIV]
Value_NN
of_PIN
hypothetical_JJ
100_CD
holding_VBG [PRIV]
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
63_CD
Directors_NN
remuneration_JJ
report_NN
Audited_VBN
information_NOMZ
Aggregate_NN
Directors_NN
remuneration_VPRT
The_DT
total_JJ
amounts_NN
for_PIN
Directors_NN
remuneration_NOMZ
were_VBD
as_IN
follows_VPRT
:_:
2005_CD
2004_CD
$_$
000_CD
$_$
000_CD
Emoluments_NOMZ
4,289_CD
4,751_CD
Money_NN
purchase_NN
pension_NN
contributions_NOMZ
488_CD
450_CD
Gains_NN
on_PIN
exercise_NN
of_PIN
share_NN
options_NOMZ
194_CD
216_CD
Amounts_NN
receivable_JJ
under_IN
long-term_JJ
incentive_NN
schemes_NN
159_CD
Compensation_NOMZ
for_PIN
loss_NN
of_PIN
office_NN
4,971_CD
5,576_CD
Directors_NN
emoluments_VPRT
Cash_NN
Non-cash_JJ
benefits_NN
benefits_NN
Total_JJ
Total_JJ
Salary_NN
Incentive_NN
Fees_NN
in_PIN
kind_NN
in_PIN
kind_NN
2005_CD
2004_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
Executive_NN
i_FPP1
v_FW
Mr_NN
Matthew_NN
Emmens_NN
1,049_CD
1,208_CD
29_CD
2,286_CD
2,601_CD
ii_FW
Mr_NN
Angus_NN
Russell_NN
652_CD
415_CD
26_CD
10_CD
1,103_CD
1,126_CD
ii_FW
vi_FW
Dr_FW
Wilson_NN
Totten_NN
469_CD
Total_JJ
executive_NN
1,701_CD
1,623_CD
55_CD
10_CD
3,389_CD
4,196_CD
Non-executive_JJ
i_FPP1
Dr_FW
James_NN
Cavanaugh_NN
364 364 137_CD
iii_FW
Dr_FW
Barry_NN
Price_NN
132 132 110_CD
i_FPP1
The_DT
Hon_NN
James_NN
Grant_NN
82_CD
82_CD
73_CD
i_FPP1
Mr_NN
Ronald_NN
Nordmann_NN
114_CD
114_CD
99_CD
iii_NN
Mr_NN
Robin_NN
Buchanan_NN
87_CD
87_CD
73_CD
iii_NN
Mr_NN
David_NN
Kappler_NN
109_CD
109_CD
63_CD
iv_NN
vii_FW
Mr_NN
Patrick_NN
Langlois_NN
12_CD
12_CD
Total_JJ
Non-executive_JJ
900 900 555_CD
Total_JJ
1,701_CD
1,623_CD
900_CD
55_CD
10_CD
4,289_CD
4,751_CD
Notes_NN
i_FPP1
Paid_NN
in_PIN
$_$
._.
ii_FW
Salary_FW
and_CC
benefits_NN
in_PIN
kind_NN
paid_VBN [WZPAST]
in_PIN
Sterling_GER
and_CC
translated_VBN
into_PIN
$_$
at_PIN
the_DT
average_JJ
exchange_NN
rates_NN
for_PIN
the_DT
year_NN
._.
Incentive_JJ
payable_JJ
in_PIN
Sterling_GER
and_CC
translated_VBN
at_PIN
the_DT
exchange_NN
rate_NN
at_PIN
end_NN
February_NN
2006_CD
._.
iii_FW
Fees_NN
paid_VBN [WZPAST]
in_PIN
Sterling_GER
and_CC
translated_VBN
into_PIN
$_$
at_PIN
the_DT
average_JJ
exchange_NN
rates_NN
for_PIN
the_DT
year_NN
._.
iv_NN
Paid_VBN [WZPAST]
in_PIN
Euros_NN
and_CC
translated_VBN
into_PIN
$_$
at_PIN
the_DT
average_JJ
exchange_NN
rate_NN
for_PIN
the_DT
service_NN
period_NN
._.
v_FW
The_DT
Company_NN
underwent_VBD
a_DT
major_JJ
internal_JJ
reorganization_NOMZ
in_PIN
2004_CD
,_,
which_WDT [SERE]
resulted_VBD
in_PIN
the_DT
Company_NN
selecting_VBG [WZPRES]
Philadelphia_NN
as_IN
its_PIT
US_FPP1
corporate_JJ
headquarters_NN
._.
Mr_NN
Emmens_NN
was_VBD [PASS]
paid_VBN
$_$
770,000_CD
in_PIN
connection_NOMZ
with_PIN
costs_NN
associated_VBN [WZPAST]
with_PIN
his_TPP3
relocation_NOMZ
to_PIN
the_DT
Philadelphia_NN
area_NN
._.
vi_FW
Dr_FW
Totten_FW
stepped_VBD
down_RP
as_IN
a_DT
Director_NN
of_PIN
the_DT
Company_NN
on_PIN
May_POMD
25_CD
,_,
2004_CD
._.
vii_FW
Mr_NN
Langlois_NN
was_VBD [PASS]
appointed_VBN
a_DT
Non-executive_JJ
Director_NN
on_PIN
November_NN
11_CD
,_,
2005_CD
._.
Cash_NN
benefits_NN
in_PIN
kind_NN
represent_VPRT
expense_NN
allowances_NN
including_VBG [WZPRES]
dental_JJ
costs_NN
._.
Non-cash_JJ
benefits_NN
in_PIN
kind_NN
consist_VPRT
of_PIN
private_JJ
medical_JJ
insurance_NN
._.
Details_NN
of_PIN
the_DT
exercise_NN
of_PIN
share_NN
options_NOMZ
are_VPRT [PASS]
disclosed_VBN [PUBV]
on_PIN
page_NN
64_CD
._.
Non-executive_JJ
Director_NN
remuneration_NOMZ
is_VPRT [BEMA]
to_PIN
from_PIN
the_DT
date_NN
of_PIN
resignation_NOMZ
appointment_NOMZ
._.
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
63_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
64_CD
Directors_NN
remuneration_JJ
report_NN
Directors_NN
pension_NN
entitlements_NOMZ
The_DT
following_JJ
Directors_NN
are_VPRT
members_NN
of_PIN
money_NN
purchase_NN
schemes_NN
._.
Contributions_NOMZ
made_VBN [WZPAST]
by_PIN
the_DT
Company_NN
not_XX0
included_VBD
in_PIN
emoluments_NOMZ
above_PLACE
in_PIN
respect_NN
of_PIN
2005_CD
were_VBD
as_IN
follows_VPRT
:_:
2005_CD
2004_CD
Name_NN
of_PIN
Director_NN
$_$
000_CD
$_$
000_CD
Mr_NN
Matthew_NN
Emmens_NN
323_CD
227_CD
i_FPP1
Mr_NN
Angus_NN
Russell_NN
165_CD
157_CD
Dr_NN
Wilson_NN
Totten_NN
stepped_VBD
down_RP
as_IN
a_DT
Director_NN
on_PIN
May_POMD
25_CD
,_,
2004 66 488 450_CD
i_FPP1
At_PIN
Mr_NN
Russells_NN
request_NN
the_DT
Company_NN
deferred_VBN
$_$
59,000_CD
of_PIN
pension_NN
contributions_NOMZ
earned_VBN [WZPAST]
in_PIN
2005_CD
,_,
to_TO
be_VB [PASS]
paid_VBN
in_PIN
2006_CD
._.
Directors_NN
shareholdings_GER
Directors_NN
who_WP [WHSUB]
held_VBD [PRIV]
office_NN
at_PIN
the_DT
end_NN
of_PIN
the_DT
year_NN
had_VBD
interests_NN
in_PIN
the_DT
share_NN
capital_NN
of_PIN
the_DT
Company_NN
as_IN
follows_VPRT
all_QUAN
interests_NN
are_VPRT [BEMA]
beneficial_PRED
:_:
2005_CD
2004_CD
Number_NN
of_PIN
Number_NN
of_PIN
Name_NN
of_PIN
Director_NN
ordinary_JJ
shares_NN
ordinary_JJ
shares_NN
Dr_NN
James_NN
Cavanaugh_NN
412,849_CD
412,849_CD
Mr_NN
Matthew_NN
Emmens_NN
18,938_CD
Mr_NN
Angus_NN
Russell_NN
1,882_CD
Dr_NN
Barry_NN
Price_NN
31,350_CD
31,350_CD
The_DT
Hon_NN
James_NN
Grant_NN
68,269_CD
36,410_CD
Mr_NN
Ronald_NN
Nordmann_NN
46,966_CD
46,966_CD
Mr_NN
Robin_NN
Buchanan_NN
7,500_CD
Mr_NN
David_NN
Kappler_NN
5,000_CD
5,000_CD
Mr_NN
Patrick_NN
Langlois_NN
Directors_NN
share_VPRT
options_NOMZ
Aggregate_JJ
emoluments_NOMZ
disclosed_VBN [PUBV]
above_PLACE
do_VPRT
not_XX0
include_VB
any_QUAN
amounts_NN
for_PIN
the_DT
value_NN
of_PIN
options_NOMZ
to_TO
acquire_VB
ordinary_JJ
shares_NN
in_PIN
the_DT
Company_NN
granted_VBN [SUAV]
to_TO
or_CC
held_VBN [PRIV]
by_PIN
the_DT
Directors_NN
._.
Directors_NN
and_PHC
employees_NN
have_VPRT [PEAS]
been_VBN [PASS]
granted_VBN [SUAV]
options_NOMZ
over_IN
ordinary_JJ
shares_NN
under_IN
the_DT
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
2000_CD
Executive_NN
Share_NN
Option_NOMZ
Scheme_NN
Parts_NN
A_NN
and_PHC
B_NN
2000_CD
Executive_NN
Scheme_NN
,_,
the_DT
Shire_NN
Holdings_GER
Limited_NN
Share_NN
Option_NOMZ
Scheme_NN
SHL_NN
Scheme_NN
,_,
the_DT
Pharmavene_NN
1991_CD
Stock_NN
Option_NOMZ
Plan_NN
SLI_NN
Plan_NN
,_,
the_DT
Shire_NN
Pharmaceuticals_NN
Executive_NN
Share_NN
Option_NOMZ
Scheme_NN
Parts_NN
A_NN
and_PHC
B_NN
Executive_NN
Scheme_NN
,_,
the_DT
Shire_NN
Pharmaceuticals_NN
Sharesave_NN
Scheme_NN
Sharesave_NN
Scheme_NN
,_,
the_DT
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Employee_NN
Stock_NN
Purchase_NN
Plan_NN
Stock_NN
Purchase_NN
Plan_NN
,_,
the_DT
Roberts_NN
Stock_NN
Option_NOMZ
Plan_NN
Roberts_NN
Plan_NN
and_CC
the_DT
BioChem_NN
Stock_NN
Option_NOMZ
Plan_NN
BioChem_NN
Plan_NN
._.
Details_NN
of_PIN
options_NOMZ
exercised_VBN [WZPAST]
during_PIN
the_DT
year_NN
with_PIN
prior-year_JJ
comparatives_NN
are_VPRT
as_IN
follows_VPRT
:_:
Gains_NN
on_PIN
Gains_NN
on_PIN
Exercise_NN
Market_NN
price_NN
at_PIN
exercise_NN
exercise_NN
Number_NN
of_PIN
price_NN
exercise_NN
date_NN
2005_CD
2004_CD
Director_NN
Scheme_NN
options_NOMZ
$_$
000_CD
$_$
000_CD
The_DT
Hon_NN
James_NN
Grant_NN
BioChem_NN
Plan_NN
31,859_CD
1.2400_CD
4.9950_CD
216_CD
31,859_CD
2.5000_CD
5.5850_CD
176 176 216_CD
Mr_NN
Matthew_NN
Emmens_NN
Stock_NN
Purchase_NN
Plan_NN
1,928_CD
4.0900_CD
7.2000_CD
11_CD
Mr_NN
Angus_NN
Russell_NN
Sharesave_NN
Plan_NN
1,882_CD
5.020_CD
7.0400_CD
7_CD
64_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
65_CD
Directors_NN
remuneration_JJ
report_NN
Details_NN
of_PIN
options_NOMZ
exercised_VBN
after_IN
ceasing_VBG
to_TO
be_VB [BEMA]
a_DT
Director_NN
are_VPRT
as_IN
follows_VPRT
:_:
Gains_NN
on_PIN
Gains_NN
on_PIN
Exercise_NN
Market_NN
price_NN
at_PIN
exercise_NN
exercise_NN
Number_NN
of_PIN
price_NN
exercise_NN
date_NN
2005_CD
2004_CD
Director_NN
Scheme_NN
options_NOMZ
$_$
000_CD
$_$
000_CD
Dr_NN
Wilson_NN
Totten_NN
Executive_NN
Scheme_NN
B_NN
141,138_CD
3.3850_CD
5.2000_CD
469_CD
301,775_CD
3.3800_CD
5.1592_CD
984_CD
8,862_CD
3.3850_CD
6.3500_CD
47_CD
25,000_CD
4.7050_CD
6.3500_CD
75_CD
2000_CD
Executive_NN
Scheme_NN
B_NN
122,368_CD
5.0650_CD
6.3500_CD
286_CD
203,612_CD
5.2600_CD
6.3500_CD
404_CD
812_CD
1,453_CD
i_FPP1
Mr_NN
Rolf_NN
Stahel_NN
Executive_NN
Scheme_NN
B_NN
81,918_CD
3.3850_CD
6.4200_CD
476_CD
i_FPP1
On_PIN
November_NN
23_CD
,_,
2005_CD
a_DT
gross_JJ
payment_NOMZ
of_PIN
$_$
482,103_CD
paid_VBN
in_PIN
Sterling_GER
and_CC
translated_VBN
into_PIN
$_$
at_PIN
the_DT
average_JJ
exchange_NN
rate_NN
in_PIN
November_NN
2005_CD
was_VBD [PASS]
made_VBN
to_PIN
Mr_NN
Rolf_NN
Stahel_NN
in_PIN
connection_NOMZ
with_PIN
a_DT
share_NN
option_NOMZ
that_TSUB
was_VBD [SPAU] [PASS]
inadvertently_RB
allowed_VBN [SUAV]
to_PIN
lapse_NN
._.
The_DT
option_NOMZ
was_VBD [PASS]
granted_VBN [SUAV]
on_PIN
March_NN
4_CD
,_,
2002_CD
over_IN
209,211_CD
shares_NN
with_PIN
an_DT
exercise_NN
price_NN
of_PIN
5.065_CD
per_PIN
share_NN
._.
The_DT
payment_NOMZ
,_,
which_WDT [SERE]
was_VBD [BEMA]
subject_PRED
to_PIN
tax_NN
and_CC
non-pensionable_JJ
,_,
was_VBD [PASS]
intended_VBN [SUAV]
to_TO
put_VB
Mr_NN
Stahel_NN
in_PIN
the_DT
same_JJ
position_NOMZ
as_IN
if_COND
he_TPP3
had_VBD [PEAS]
exercised_VBN
the_DT
option_NOMZ
and_CC
subsequently_TIME
sold_VBD
the_DT
shares_NN
on_PIN
the_DT
day_NN
on_PIN
which_WDT [PIRE]
he_TPP3
notified_VBD
the_DT
Company_NN
of_PIN
his_TPP3
desire_NN
to_TO
exercise_VB
the_DT
option_NOMZ
._.
Following_VBG [PRESP]
the_DT
implementation_NOMZ
of_PIN
the_DT
Scheme_NN
of_PIN
Arrangement_NOMZ
,_,
on_PIN
November_NN
25_CD
,_,
2005_CD
,_,
all_QUAN
existing_VBG
options_NOMZ
to_TO
acquire_VB
ordinary_JJ
shares_NN
in_PIN
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Old_NN
Options_NOMZ
were_VBD [PASS]
swapped_VBN
for_PIN
new_JJ
equivalent_JJ
options_NOMZ
to_TO
acquire_VB
ordinary_JJ
shares_NN
in_PIN
Shire_NN
plc_NN
New_NN
Options_NOMZ
._.
Any_QUAN
performance_NN
conditions_NOMZ
attached_VBN [WZPAST]
to_PIN
the_DT
Old_NN
Options_NOMZ
continue_VPRT
to_TO
apply_VB
to_PIN
the_DT
New_NN
Options_NOMZ
._.
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
65_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
66_CD
Directors_NN
remuneration_JJ
report_NN
Notes_NN
i_FPP1
Options_NOMZ
granted_VBN [SUAV]
under_IN
this_DEMO
scheme_NN
are_VPRT [BEMA]
subject_PRED
to_PIN
performance_NN
criteria_NN
and_CC
can_POMD
not_XX0
be_VB [PASS]
exercised_VBN
in_PIN
full_JJ
,_,
unless_COND
Shires_NN
ordinary_JJ
share_NN
price_NN
increases_NN
at_PIN
a_DT
compound_NN
rate_NN
of_PIN
at_PIN
least_JJ
20.5_CD
%_NN
per_PIN
annum_NN
over_IN
a_DT
minimum_JJ
three-year_JJ
measurement_NOMZ
period_NN
._.
If_COND
Shires_NN
share_NN
price_NN
increases_NN
at_PIN
a_DT
compound_NN
rate_NN
of_PIN
14.5_CD
%_NN
per_PIN
annum_NN
over_IN
a_DT
minimum_JJ
three-year_JJ
measurement_NOMZ
period_NN
,_,
60_CD
%_NN
of_PIN
the_DT
options_NOMZ
may_POMD
be_VB [PASS]
exercised_VBN
._.
If_COND
these_DEMO
conditions_NOMZ
are_VPRT [PASS]
not_XX0
met_VBN
after_IN
the_DT
initial_JJ
three_CD
years_NN
,_,
they_TPP3
are_VPRT [SPAU] [PASS]
thereafter_RB
tested_VBN
quarterly_JJ
by_PIN
reference_NN
to_TO
share_VB
price_NN
growth_NN
over_IN
the_DT
extended_JJ
period_NN
._.
If_COND
the_DT
share_NN
price_NN
does_VPRT
not_XX0
meet_VB
these_DEMO
conditions_NOMZ
at_PIN
any_QUAN
time_NN
,_,
none_INPR
of_PIN
the_DT
options_NOMZ
granted_VBN [SUAV]
become_VBN
exercisable_JJ
._.
On_PIN
February_NN
28_CD
,_,
2000_CD
,_,
the_DT
Remuneration_NOMZ
Committee_NN
of_PIN
the_DT
Board_NN
exercised_VBD
its_PIT
powers_NN
to_TO
amend_VB
the_DT
terms_NN
of_PIN
the_DT
Executive_NN
Share_NN
Option_NOMZ
Scheme_NN
so_RB
as_IN
to_TO
include_VB
a_DT
cliff_NN
vesting_VBG [WZPRES]
provision_NN
._.
It_PIT
is_VPRT [PASS]
intended_VBN [SUAV]
that_THVC
no_SYNE
further_JJ
options_NOMZ
will_PRMD
be_VB [PASS]
granted_VBN [SUAV]
under_IN
the_DT
Executive_NN
Scheme_NN
._.
ii_FW
Options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
Sharesave_NN
Scheme_NN
are_VPRT [PASS]
granted_VBN [SUAV]
with_PIN
an_DT
exercise_NN
price_NN
equal_JJ
to_PIN
80_CD
%_NN
of_PIN
the_DT
mid-market_JJ
price_NN
on_PIN
the_DT
day_NN
before_IN
invitations_NOMZ
are_VPRT [PASS]
issued_VBN
to_PIN
employees_NN
._.
Employees_NN
may_POMD
enter_VB
into_PIN
three_CD
or_CC
five-year_JJ
savings_GER
contracts_NN
._.
iii_FW
Options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
2000_CD
Executive_NN
Scheme_NN
are_VPRT [BEMA]
exercisable_JJ
subject_NN
to_PIN
certain_JJ
performance_NN
criteria_NN
._.
In_PIN
respect_NN
of_PIN
any_QUAN
option_NOMZ
granted_VBN [SUAV] [WZPAST]
prior_RB
to_PIN
August_NN
2002_CD
,_,
if_COND
Shires_NN
ordinary_JJ
share_NN
price_NN
increases_NN
at_PIN
a_DT
compound_NN
rate_NN
of_PIN
at_PIN
least_JJ
20.5_CD
%_NN
per_PIN
annum_NN
over_IN
a_DT
minimum_JJ
three-year_JJ
measurement_NOMZ
period_NN
,_,
the_DT
option_NOMZ
becomes_VPRT
exercisable_JJ
in_PIN
full_JJ
._.
If_COND
it_PIT
increases_VPRT
by_PIN
at_PIN
least_JJ
14.5_CD
%_NN
per_PIN
annum_NN
over_IN
the_DT
same_JJ
three-year_JJ
period_NN
,_,
60_CD
%_NN
of_PIN
the_DT
options_NOMZ
granted_VBN [SUAV]
become_VBN
exercisable_JJ
._.
If_COND
these_DEMO
conditions_NOMZ
are_VPRT [PASS]
not_XX0
met_VBN
after_IN
the_DT
initial_JJ
three-year_JJ
measurement_NOMZ
period_NN
,_,
they_TPP3
will_PRMD [SPAU]
thereafter_RB
be_VB [PASS]
tested_VBN
quarterly_JJ
by_PIN
reference_NN
to_TO
compound_VB
annual_JJ
share_NN
price_NN
growth_NN
over_IN
an_DT
extended_JJ
period_NN
._.
The_DT
performance_NN
criteria_NN
were_VBD [PASS]
reviewed_VBN
in_PIN
2002_CD
to_TO
ensure_VB [SUAV] [PRIV] [THATD]
the_DT
criteria_NN
reflected_VBD [PRIV]
the_DT
market_NN
in_PIN
which_WDT [PIRE]
Shire_NN
operates_VPRT
._.
Given_VBN
Shires_NN
development_NOMZ
,_,
it_PIT
was_VBD [PASS]
considered_VBN [PRIV]
appropriate_JJ
that_THAC
an_DT
EPS-based_JJ
measure_NN
should_NEMD
be_VB [PASS]
adopted_VBN
in_PIN
place_NN
of_PIN
share_NN
price_NN
growth_NN
targets_NN
._.
The_DT
performance_NN
criteria_NN
are_VPRT [PASS]
based_VBN
on_PIN
real_JJ
growth_NN
in_PIN
the_DT
diluted_JJ
earnings_GER
per_PIN
share_NN
reported_VBN [PUBV] [WZPAST]
in_PIN
the_DT
Companys_NN
Form_NN
10-K_NN
under_IN
US_FPP1
GAAP_NN
,_,
adjusted_VBN
to_TO
ensure_VB [SUAV] [PRIV]
a_DT
consistent_JJ
basis_NN
of_PIN
measurement_NOMZ
,_,
as_IN
approved_VBN
by_PIN
the_DT
Remuneration_NOMZ
Committee_NN
,_,
including_VBG [PRESP]
the_DT
add_VB [PUBV]
back_RB
of_PIN
significant_JJ
one-time_JJ
items_NN
option_NOMZ
EPS_NN
._.
Therefore_CONJ
,_,
the_DT
performance_NN
criteria_NN
were_VBD [PASS]
amended_VBN
so_OSUB
that_NULL
an_DT
option_NOMZ
would_PRMD
become_VB
exercisable_JJ
in_PIN
full_JJ
if_COND
Shires_NN
option_NOMZ
EPS_NN
growth_NN
over_IN
a_DT
three-year_JJ
period_NN
from_PIN
the_DT
date_NN
of_PIN
award_NN
exceeds_VPRT
the_DT
UK_NN
Retail_NN
Prices_NN
Index_NN
RPI_NN
for_PIN
the_DT
following_VBG
tranches_NN
of_PIN
grants_NN
:_:
Options_NOMZ
with_PIN
a_DT
grant_NN
value_NN
of_PIN
up_RB
to_PIN
100_CD
%_NN
of_PIN
salary_NN
RPI_NN
plus_PIN
9_CD
%_NN
Directors_NN
,_,
RPI_NN
plus_PIN
15_CD
%_NN
Between_PIN
101_CD
%_NN
and_CC
200_CD
%_NN
of_PIN
salary_NN
RPI_NN
plus_PIN
15_CD
%_NN
Between_PIN
201_CD
%_NN
and_CC
300_CD
%_NN
of_PIN
salary_NN
RPI_NN
plus_PIN
21_CD
%_NN
Over_IN
301_CD
%_NN
of_PIN
salary_NN
RPI_NN
plus_PIN
27_CD
%_NN
The_DT
new_JJ
EPS_NN
performance_NN
criteria_NN
apply_VPRT
to_PIN
options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
2000_CD
Executive_NN
Scheme_NN
from_PIN
August_NN
2002_CD
._.
After_IN
consultation_NOMZ
with_PIN
certain_JJ
of_PIN
its_PIT
institutional_JJ
shareholders_NN
,_,
the_DT
Company_NN
has_VPRT [PEAS]
decided_VBN [SUAV] [PRIV]
that_THVC
for_PIN
options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
scheme_NN
from_PIN
2004_CD
onwards_NN
,_,
the_DT
retest_NN
of_PIN
the_DT
performance_NN
condition_NOMZ
if_COND
Shires_NN
option_NOMZ
EPS_NN
growth_NN
has_VPRT [PEAS]
fallen_VBN
short_JJ
of_PIN
the_DT
minimum_JJ
annual_JJ
average_JJ
percentage_NN
increase_NN
over_IN
the_DT
three-year_JJ
period_NN
from_PIN
grant_NN
,_,
has_VPRT [PEAS]
been_VBN [PASS]
changed_VBN
._.
The_DT
performance_NN
condition_NOMZ
will_PRMD
be_VB [PASS]
retested_VBN
once_TIME
only_DWNT
,_,
at_PIN
five_CD
years_NN
after_IN
the_DT
grant_NN
._.
Hence_CONJ
the_DT
level_NN
of_PIN
option_NOMZ
EPS_NN
growth_NN
in_PIN
the_DT
next_JJ
two_CD
years_NN
needs_VPRT
to_TO
be_VB [BEMA]
consequentially_RB
higher_PRED
to_TO
meet_VB
the_DT
test_NN
._.
Six_CD
weeks_NN
prior_RB
to_PIN
the_DT
expiration_NOMZ
date_NN
,_,
any_QUAN
options_NOMZ
that_TSUB
have_VPRT
not_XX0
become_VB
exercisable_JJ
at_PIN
an_DT
earlier_TIME
date_NN
,_,
automatically_RB
vest_NN
without_PIN
reference_NN
to_PIN
the_DT
performance_NN
criteria_NN
._.
It_PIT
is_VPRT [PASS]
intended_VBN [SUAV]
that_THVC
no_SYNE
further_JJ
options_NOMZ
will_PRMD
be_VB [PASS]
granted_VBN [SUAV]
under_IN
the_DT
2000_CD
Executive_NN
Scheme_NN
._.
iv_NN
Following_VBG [WZPRES]
the_DT
acquisition_NOMZ
of_PIN
BioChem_NN
Pharma_NN
Inc._NN
on_PIN
May_POMD
11_CD
,_,
2001_CD
,_,
the_DT
BioChem_NN
Stock_NN
Option_NOMZ
Plan_NN
was_VBD [PASS]
amended_VBN
such_OSUB
that_NULL
options_NOMZ
over_IN
BioChem_NN
Pharma_NN
Inc._NN
s_VPRT [BEMA]
common_JJ
stock_NN
became_VBD
options_NOMZ
over_IN
ordinary_JJ
shares_NN
of_PIN
Shire_NN
._.
All_QUAN
BioChem_NN
Pharma_NN
Inc._NN
options_NOMZ
,_,
which_WDT [SERE]
were_VBD
not_XX0
already_RB
exercisable_PRED
,_,
vested_JJ
and_CC
became_VBD
exercisable_JJ
as_CONJ
a_NULL
result_NULL
of_PIN
the_DT
acquisition_NOMZ
._.
It_PIT
is_VPRT [PASS]
intended_VBN [SUAV]
that_THVC
no_SYNE
further_JJ
options_NOMZ
will_PRMD
be_VB [PASS]
granted_VBN [SUAV]
under_IN
the_DT
BioChem_NN
Stock_NN
Option_NOMZ
Plan_NN
._.
v_FW
Under_IN
the_DT
Stock_NN
Purchase_NN
Plan_NN
,_,
options_NOMZ
are_VPRT [PASS]
granted_VBN [SUAV]
with_PIN
an_DT
exercise_NN
price_NN
equal_JJ
to_PIN
85_CD
%_NN
of_PIN
the_DT
fair_JJ
market_NN
value_NN
of_PIN
a_DT
share_NN
on_PIN
the_DT
enrolment_NOMZ
date_NN
the_DT
first_JJ
day_NN
of_PIN
the_DT
offering_GER
period_NN
or_CC
the_DT
exercise_NN
date_NN
the_DT
last_JJ
day_NN
of_PIN
the_DT
offering_GER
period_NN
,_,
whichever_WDT
is_VPRT [BEMA]
the_DT
lower_JJ
._.
The_DT
offering_GER
period_NN
is_VPRT [BEMA]
for_PIN
27_CD
months_NN
._.
The_DT
market_NN
price_NN
of_PIN
the_DT
ordinary_JJ
shares_NN
at_PIN
December_NN
31_CD
,_,
2005_CD
was_VBD [BEMA]
7.44_CD
and_CC
the_DT
range_NN
during_PIN
the_DT
year_NN
was_VBD [BEMA]
5.39_CD
to_PIN
7.53_CD
._.
Long-term_JJ
Incentive_NN
Plan_NN
LTIP_NN
The_NN
following_VBG [WZPRES]
award_NN
,_,
granted_VBN [SUAV]
under_IN
the_DT
Long-term_JJ
Incentive_NN
Plan_NN
lapsed_VBD
during_PIN
the_DT
year_NN
2005_CD
and_CC
no_SYNE
payment_NOMZ
was_VBD [PASS]
made_VBN
under_IN
it_PIT
as_IN
the_DT
performance_NN
criteria_NN
was_VBD [PASS]
not_XX0
met_VBN
at_PIN
the_DT
maturity_NOMZ
date_NN
:_:
Actual_NN
Initial_JJ
award_NN
performanceDate_NN
of_PIN
Director_NN
Date_NN
of_PIN
award_NN
made_VBN
related_JJ
award_NN
maturity_NOMZ
i_FPP1
Mr_NN
Angus_NN
Russell_NN
05.06.01_CD
11,535_CD
06.06.05_CD
i_FPP1
The_DT
performance_NN
criteria_NN
attaching_VBG [WZPRES]
to_PIN
awards_NN
made_VBN
under_IN
the_DT
Long-term_JJ
Incentive_NN
Plan_NN
are_VPRT [PASS]
detailed_VBN
on_PIN
page_NN
59_CD
._.
Performance_NN
conditions_NOMZ
attaching_VBG [WZPRES]
to_PIN
awards_NN
made_VBN
under_IN
the_DT
Long-term_JJ
Incentive_NN
Plan_NN
are_VPRT [PASS]
detailed_VBN
on_PIN
page_NN
59_CD
._.
Following_VBG [PRESP]
the_DT
implementation_NOMZ
of_PIN
the_DT
Scheme_NN
of_PIN
Arrangement_NOMZ
,_,
on_PIN
November_NN
25_CD
,_,
2005_CD
,_,
all_QUAN
awards_NN
over_IN
ordinary_JJ
shares_NN
in_PIN
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
Old_NN
Awards_NN
were_VBD [PASS]
swapped_VBN
for_PIN
new_JJ
equivalent_JJ
awards_NN
over_IN
ordinary_JJ
shares_NN
in_PIN
Shire_NN
plc_NN
New_NN
Awards_NN
._.
Any_QUAN
performance_NN
conditions_NOMZ
attached_VBN [WZPAST]
to_PIN
the_DT
Old_NN
Awards_NN
continue_VPRT
to_TO
apply_VB
to_PIN
the_DT
New_NN
Awards_NN
._.
Portfolio_NN
Share_NN
Plan_NN
PSP_NN
The_NN
Shire_NN
plc_NN
PSP_NN
was_VBD [PASS]
adopted_VBN
at_PIN
the_DT
Companys_NN
Extraordinary_JJ
General_NN
Meeting_VBG [WZPRES]
held_VBN [PRIV]
on_PIN
October_NN
28_CD
,_,
2005_CD
._.
No_SYNE
awards_NN
,_,
under_IN
the_DT
PSP_NN
,_,
were_VBD [PASS]
made_VBN
to_PIN
executive_JJ
Directors_NN
in_PIN
2005_CD
._.
Approval_NN
This_DEMO
report_NN
was_VBD [BYPA]
approved_VBN
by_PIN
the_DT
Board_NN
of_PIN
Directors_NN
on_PIN
February_NN
22_CD
,_,
2006_CD
and_CC
signed_VBN
on_PIN
its_PIT
behalf_NN
by_PIN
:_:
Dr_NN
Barry_NN
Price_NN
Chairman_NN
of_PIN
the_DT
Remuneration_NOMZ
Committee_NN
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
67_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
68_CD
Audit_NN
Committee_NN
report_NN
Membership_NN
review_NN
at_PIN
least_JJ
annually_RB
the_DT
effectiveness_NOMZ
of_PIN
the_DT
Companys_NN
internal_JJ
The_DT
members_NN
of_PIN
the_DT
Committee_NN
as_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
were_VBD
control_NN
system_NN
in_PIN
the_DT
overall_JJ
context_NN
of_PIN
the_DT
Companys_NN
risk_NN
David_NN
Kappler_NN
Chairman_NN
,_,
Barry_NN
Price_NN
,_,
Ronald_NN
Nordmann_NN
and_PHC
Patrick_NN
management_NOMZ
system_NN
:_:
Langlois_NN
._.
Mr_NN
Kappler_NN
,_,
Dr_NN
Price_NN
and_PHC
Mr_NN
Nordmann_NN
served_VBD
as_IN
members_NN
of_PIN
the_DT
Committee_NN
throughout_PIN
2005_CD
and_CC
Mr_NN
Langlois_NN
became_VBD
a_DT
member_NN
oversee_VPRT
the_DT
Companys_NN
anti-fraud_JJ
programs_NN
and_PHC
controls_NN
of_PIN
the_DT
Committee_NN
upon_PIN
his_TPP3
appointment_NOMZ
to_PIN
the_DT
Board_NN
in_PIN
November_NN
and_CC
to_TO
oversee_VB
the_DT
investigation_NOMZ
and_PHC
remediation_NOMZ
of_PIN
any_QUAN
alleged_JJ
2005_CD
._.
Each_QUAN
of_PIN
the_DT
members_NN
of_PIN
the_DT
Committee_NN
has_VPRT [PEAS]
been_VBN [PASS]
determined_VBN [SUAV] [PRIV]
or_CC
suspected_VBN [PRIV]
fraud_NN
:_:
by_PIN
Shires_NN
Board_NN
to_TO
be_VB [BEMA]
an_DT
Independent_JJ
Non-executive_JJ
Director_NN
for_PIN
the_DT
purposes_NN
of_PIN
The_DT
UK_NN
Combined_NN
Code_NN
on_PIN
Corporate_NN
Governance_NN
monitor_NN
and_CC
review_VB
the_DT
internal_JJ
operational_JJ
audit_NN
program_NN
,_,
the_DT
Combined_NN
Code_NN
._.
Each_QUAN
member_NN
also_RB
satisfies_VPRT
the_DT
NASDAQ_NN
consider_VB [PRIV]
the_DT
findings_GER
of_PIN
internal_JJ
operational_JJ
audit_NN
reviews_NN
and_PHC
rules_NN
regarding_VBG [WZPRES]
the_DT
independence_NN
of_PIN
members_NN
of_PIN
the_DT
Audit_NN
Committee_NN
._.
managements_NOMZ
response_NN
to_PIN
them_TPP3
:_:
and_ANDC
Mr_NN
David_NN
Kappler_NN
chairs_VPRT
the_DT
Committee_NN
._.
The_DT
Board_NN
is_VPRT [PASS]
satisfied_VBN
that_DEMO
review_NN
compliance_NN
with_PIN
treasury_NN
policy_NN
._.
Mr_NN
Kappler_NN
,_,
in_PIN
his_TPP3
capacity_NOMZ
as_IN
Chairman_NN
of_PIN
the_DT
Committee_NN
,_,
has_VPRT
recent_JJ
and_PHC
relevant_JJ
financial_JJ
experience_NN
._.
The_DT
Board_NN
has_VPRT [PEAS]
determined_VBN [SUAV] [PRIV]
that_THVC
The_DT
Committee_NN
reports_NN
to_PIN
the_DT
Board_NN
on_PIN
any_QUAN
matter_NN
on_PIN
which_WDT [PIRE]
Mr_NN
Kappler_NN
is_VPRT [BEMA]
the_DT
Committees_NN
financial_JJ
expert_NN
for_PIN
the_DT
purposes_NN
of_PIN
the_DT
it_PIT
considers_VPRT [PRIV]
that_THVC
action_NOMZ
is_VPRT [PASS]
required_VBN [SUAV]
and_PHC
makes_VPRT
recommendations_NOMZ
Sarbanes-Oxley_NN
Act_NN
2002_CD
._.
Mr_NN
Kappler_NN
was_VBD [BEMA]
a_DT
Director_NN
of_PIN
Camelot_NN
for_PIN
steps_NN
to_TO
be_VB [PASS]
taken_VBN
._.
The_DT
Terms_NN
of_PIN
Reference_NN
of_PIN
the_DT
Committee_NN
Group_NN
plc_NN
from_PIN
1996_CD
to_PIN
2002_CD
and_CC
he_TPP3
serves_VPRT
as_IN
a_DT
Non-executive_JJ
Director_NN
give_VPRT
it_PIT
authority_NOMZ
to_TO
investigate_VB
any_QUAN
activity_NOMZ
within_PIN
its_PIT
Terms_NN
of_PIN
Reference_NN
at_PIN
HMV_NN
Group_NN
plc_NN
and_PHC
Intercontinental_NN
Hotels_NN
Group_NN
plc._NN
._.
Additionally_RB
,_,
and_ANDC
to_TO
be_VB [BEMA]
responsible_PRED
for_PIN
the_DT
resolution_NOMZ
of_PIN
disagreements_NOMZ
between_PIN
he_TPP3
is_VPRT [BEMA]
Non-executive_JJ
Chairman_NN
at_PIN
Premier_NN
Foods_NN
plc._NN
._.
Mr_NN
Kappler_NN
management_NOMZ
and_CC
the_DT
auditor_NN
regarding_VBG [WZPRES]
the_DT
Companys_NN
financial_JJ
is_VPRT [BEMA]
a_DT
fellow_NN
of_PIN
the_DT
Chartered_NN
Institute_NN
of_PIN
Management_NOMZ
Accountants_NN
._.
The_DT
Committee_NN
is_VPRT [SPAU] [PASS]
also_RB
authorized_VBN
to_TO
seek_VB
any_QUAN
information_NOMZ
it_PIT
requires_VPRT [SUAV]
from_PIN
any_QUAN
employee_NN
of_PIN
the_DT
Company_NN
in_PIN
order_NN
to_TO
perform_VB
The_DT
members_NN
of_PIN
the_DT
Committee_NN
are_VPRT [PASS]
chosen_VBN
from_PIN
amongst_PIN
the_DT
its_PIT
duties_NN
and_CC
to_TO
call_VB
any_QUAN
employee_NN
to_TO
be_VB [PASS]
questioned_VBN
at_PIN
a_DT
meeting_GER
Non-executive_JJ
Directors_NN
of_PIN
the_DT
Company_NN
who_WP [WHSUB]
are_VPRT [BEMA]
independent_PRED
for_PIN
the_DT
of_PIN
the_DT
Committee_NN
._.
purposes_NN
of_PIN
the_DT
Combined_NN
Code_NN
and_CC
the_DT
NASDAQ_NN
rules_NN
and_CC
are_VPRT [PASS]
selected_VBN
on_PIN
the_DT
basis_NN
of_PIN
their_TPP3
knowledge_NN
and_PHC
experience_NN
of_PIN
financial_JJ
matters_NN
and_CC
The_DT
Committee_NN
met_VBD
on_PIN
six_CD
occasions_NN
in_PIN
2005_CD
._.
Each_QUAN
meeting_GER
was_VBD [BEMA]
financial_JJ
reporting_GER
._.
Committee_NN
members_NN
hold_VPRT [PRIV]
office_NN
for_PIN
an_DT
initial_JJ
period_NN
attended_VBN [WZPAST]
by_PIN
all_QUAN
members_NN
of_PIN
the_DT
Committee_NN
._.
At_PIN
the_DT
invitation_NOMZ
of_PIN
the_DT
of_PIN
two_CD
years_NN
,_,
subject_JJ
to_TO
continuing_VBG
as_IN
a_DT
Director_NN
of_PIN
the_DT
Company_NN
._.
Chairman_NN
,_,
the_DT
Chief_NN
Executive_NN
Officer_NN
,_,
the_DT
Chief_NN
Financial_NN
Officer_NN
Thereafter_RB
,_,
they_TPP3
may_POMD
hold_VB [PRIV]
office_NN
for_PIN
such_JJ
duration_NOMZ
as_IN
determined_VBN [SUAV] [PRIV]
by_PIN
the_DT
and_CC
the_DT
Group_NN
Financial_NN
Controller_NN
attended_VBD
all_QUAN
of_PIN
the_DT
Committees_NN
Board_NN
._.
Details_NN
of_PIN
the_DT
fees_NN
paid_VBN [WZPAST]
to_PIN
members_NN
of_PIN
the_DT
Committee_NN
are_VPRT [PASS]
set_VBN
meetings_GER
in_PIN
2005_CD
._.
In_CONJ
addition_NULL
,_,
at_PIN
the_DT
invitation_NOMZ
of_PIN
the_DT
Chairman_NN
,_,
the_DT
out_PIN
in_PIN
the_DT
Directors_NN
remuneration_NOMZ
report_NN
on_PIN
page_NN
62_CD
._.
Chief_NN
Risk_NN
Officer_NN
and_PHC
Head_NN
of_PIN
Internal_NN
Audit_NN
attended_VBD
each_QUAN
of_PIN
the_DT
four_CD
quarterly_JJ
meetings_GER
at_PIN
which_WDT [PIRE]
risk_NN
management_NOMZ
systems_NN
and_CC
internal_JJ
Role_NN
of_PIN
Committee_NN
audit_NN
programs_NN
were_VBD [PASS]
reviewed_VBN
._.
The_DT
Terms_NN
of_PIN
Reference_NN
of_PIN
the_DT
Committee_NN
have_VPRT [PEAS]
been_VBN [BYPA]
approved_VBN
by_PIN
the_DT
Board_NN
and_CC
are_VPRT [BEMA]
available_PRED
for_PIN
review_NN
on_PIN
Shires_NN
website_NN
._.
The_DT
key_JJ
In_PIN
accordance_NN
with_PIN
its_PIT
Terms_NN
of_PIN
Reference_NN
,_,
the_DT
Committee_NN
held_VBD [PRIV]
a_DT
functions_NOMZ
of_PIN
the_DT
Committee_NN
under_IN
its_PIT
Terms_NN
of_PIN
Reference_NN
are_VPRT
to_TO
:_:
number_NN
of_PIN
private_JJ
meetings_GER
with_PIN
the_DT
lead_NN
partner_NN
from_PIN
the_DT
Companys_NN
external_JJ
auditors_NN
and_CC
the_DT
Companys_NN
Chief_NN
Internal_NN
Auditor_NN
during_PIN
monitor_NN
the_DT
integrity_NOMZ
of_PIN
the_DT
financial_JJ
statements_NOMZ
of_PIN
the_DT
Company_NN
,_,
the_DT
course_NN
of_PIN
the_DT
year_NN
without_PIN
any_QUAN
Executive_NN
member_NN
of_PIN
the_DT
Board_NN
including_VBG [WZPRES]
its_PIT
annual_JJ
and_PHC
quarterly_JJ
reports_NN
,_,
preliminary_JJ
results_NN
in_PIN
attendance_NN
._.
The_DT
purpose_NN
of_PIN
these_DEMO
meetings_GER
was_VBD
to_TO
facilitate_VB
free_JJ
announcements_NOMZ
and_CC
any_QUAN
other_JJ
corporate_JJ
announcement_NOMZ
relating_VBG [WZPRES]
and_CC
open_JJ
discussions_NN
between_PIN
the_DT
Audit_NN
Committee_NN
members_NN
and_CC
to_PIN
the_DT
Companys_NN
financial_JJ
performance_NN
:_:
the_DT
Chief_NN
Internal_NN
Auditor_NN
and_CC
the_DT
external_JJ
lead_NN
audit_NN
partner_NN
separately_RB
from_PIN
the_DT
main_JJ
sessions_NN
of_PIN
the_DT
Audit_NN
Committee_NN
which_WDT [WHSUB]
were_VBD [PASS]
attended_VBN
ensure_VB [SUAV] [PRIV]
clarity_NOMZ
of_PIN
disclosure_NN
in_PIN
financial_JJ
reporting_GER
and_CC
the_DT
presentation_NOMZ
by_PIN
the_DT
Chief_NN
Financial_NN
Officer_NN
and_CC
the_DT
Group_NN
Financial_NN
Controller_NN
._.
of_PIN
a_DT
balanced_JJ
and_PHC
understandable_JJ
assessment_NOMZ
of_PIN
the_DT
Companys_NN
financial_JJ
position_NOMZ
:_:
Approval_NN
of_PIN
audit_NN
and_CC
non-audit_JJ
services_NN
provided_VBN [WZPAST]
by_PIN
auditor_NN
The_DT
Committee_NN
has_VPRT [PEAS]
adopted_VBN
formal_JJ
policies_NN
and_PHC
procedures_NN
in_PIN
relation_NOMZ
have_VPRT
the_DT
primary_JJ
responsibility_NOMZ
for_PIN
making_VBG
a_DT
recommendation_NOMZ
to_PIN
the_DT
provision_NN
of_PIN
audit_NN
and_CC
non-audit_JJ
services_NN
by_PIN
the_DT
external_JJ
auditor_NN
,_,
to_TO
be_VB [PASS]
put_VBN
to_PIN
shareholders_NN
for_PIN
approval_NN
at_PIN
the_DT
Annual_JJ
General_NN
which_WDT [WHSUB]
were_VBD [SPAU] [PASS]
most_EMPH
recently_TIME
revised_VBN
in_PIN
February_NN
2006_CD
._.
The_DT
principal_JJ
Meeting_VBG
in_PIN
relation_NOMZ
to_PIN
the_DT
appointment_NOMZ
,_,
re-appointment_NOMZ
,_,
removal_NN
purpose_NN
of_PIN
these_DEMO
policies_NN
and_PHC
procedures_NN
is_VPRT
to_TO
ensure_VB [SUAV] [PRIV]
that_THVC
the_DT
and_CC
remuneration_NOMZ
of_PIN
the_DT
external_JJ
auditor_NN
and_CC
to_TO
assess_VB
,_,
at_PIN
least_JJ
independence_NN
of_PIN
the_DT
external_JJ
auditor_NN
is_VPRT [PASS]
not_XX0
impaired_VBN
._.
annually_RB
,_,
the_DT
objectivity_NOMZ
and_PHC
independence_NN
of_PIN
the_DT
external_JJ
auditor_NN
:_:
The_DT
Sarbanes-Oxley_NN
Act_NN
2002_CD
and_CC
accordingly_RB
the_DT
Committees_NN
policy_NN
review_NN
and_CC
discuss_VB
issues_NN
and_PHC
recommendations_NOMZ
arising_VBG [WZPRES]
from_PIN
prohibits_VPRT
the_DT
provision_NN
of_PIN
certain_JJ
non-audit_JJ
services_NN
to_PIN
the_DT
Company_NN
the_DT
external_JJ
audit_NN
,_,
and_ANDC
any_QUAN
matters_NN
the_DT
external_JJ
auditor_NN
may_POMD
wish_VB
by_PIN
the_DT
external_JJ
auditor_NN
,_,
including_VBG
:_:
to_TO
discuss_VB
:_:
bookkeeping_GER
or_CC
other_JJ
services_NN
related_VBN [WZPAST]
to_PIN
the_DT
accounting_GER
records_NN
set_VBN
and_PHC
apply_VB
a_DT
formal_JJ
policy_NN
in_PIN
relation_NOMZ
to_PIN
the_DT
provision_NN
of_PIN
non-audit_JJ
or_CC
financial_JJ
statements_NOMZ
of_PIN
the_DT
Company_NN
:_:
services_NN
by_PIN
the_DT
external_JJ
auditor_NN
with_PIN
a_DT
view_NN
to_TO
preserving_VBG
the_DT
external_JJ
auditors_NN
independence_NN
and_PHC
objectivity_NOMZ
:_:
design_NN
and_PHC
implementation_NOMZ
of_PIN
financial_JJ
information_NOMZ
systems_NN
:_:
establish_VB [PRIV]
procedures_NN
for_PIN
the_DT
receipt_NN
,_,
retention_NOMZ
and_PHC
treatment_NOMZ
appraisal_NN
or_CC
valuation_NOMZ
services_NN
,_,
fairness_NOMZ
opinions_NN
or_CC
contributionof_NN
complaints_NN
received_VBN [WZPAST]
by_PIN
the_DT
Company_NN
regarding_VBG [WZPRES]
accounting_GER
,_,
in-kind_JJ
reports_NN
:_:
and_ANDC
internal_JJ
accounting_GER
controls_NN
or_CC
auditing_GER
matters_NN
:_:
actuarial_JJ
or_CC
internal_JJ
audit_NN
outsourcing_VBG [WZPRES]
services_NN
._.
68_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
69_CD
Audit_NN
Committee_NN
report_NN
Other_JJ
types_NN
of_PIN
audit_NN
and_CC
non-audit_JJ
services_NN
may_POMD
be_VB [PASS]
performed_VBN
2_CD
Internal_NN
financial_JJ
control_NN
and_PHC
risk_NN
management_NOMZ
systems_NN
by_PIN
the_DT
external_JJ
auditor_NN
if_COND
the_DT
work_NN
is_VPRT [BEMA]
either_DT
specifically_RB
pre-approved_JJ
the_DT
Companys_NN
risk_NN
management_NOMZ
strategy_NN
,_,
its_PIT
internal_JJ
audit_NN
strategy_NN
,_,
by_PIN
the_DT
Committee_NN
or_CC
the_DT
work_NN
falls_VPRT
within_PIN
the_DT
Committees_NN
schedule_VPRT
its_PIT
plan_NN
and_PHC
progress_NN
in_PIN
complying_VBG
with_PIN
Section_NOMZ
404_CD
of_PIN
the_DT
of_PIN
pre-approved_JJ
services_NN
._.
The_DT
Committees_NN
pre-approval_JJ
policy_NN
covers_VPRT
Sarbanes-Oxley_NN
Act_NN
2002_CD
and_CC
the_DT
effectiveness_NOMZ
of_PIN
the_DT
Companys_NN
three_CD
categories_NN
of_PIN
work_NN
audit_NN
services_NN
,_,
audit-related_JJ
services_NN
and_PHC
tax_NN
system_NN
of_PIN
internal_JJ
control_NN
during_PIN
the_DT
year_NN
:_:
services_NN
._.
If_COND
the_DT
proposed_VBN [SUAV]
services_NN
to_TO
be_VB [BYPA]
provided_VBN
by_PIN
the_DT
external_JJ
auditor_NN
fall_NN
within_PIN
a_DT
category_NN
of_PIN
pre-approved_JJ
services_NN
,_,
they_TPP3
may_POMD
be_VB [PASS]
provided_VBN
revisions_NN
to_PIN
the_DT
policy_NN
for_PIN
the_DT
management_NOMZ
of_PIN
treasury_NN
were_VBD [BEMA]
by_PIN
the_DT
auditor_NN
without_PIN
being_VBG [SPAU] [BYPA]
specifically_RB
approved_VBN
by_PIN
the_DT
Committee_NN
,_,
reviewed_VBN
and_PHC
recommended_VBN [SUAV]
for_PIN
approval_NN
to_PIN
the_DT
Board_NN
:_:
provided_VBD
that_DEMO
management_NOMZ
does_VPRT
not_XX0
need_VB
to_TO
exercise_VB
any_QUAN
discretion_NOMZ
in_PIN
determining_VBG [SUAV] [PRIV]
whether_IN [WHCL]
a_DT
proposed_JJ
service_NN
falls_VPRT
within_PIN
one_CD
of_PIN
the_DT
quarterly_JJ
reports_NN
on_PIN
treasury_NN
investments_NOMZ
and_PHC
compliance_NN
pre-approved_JJ
categories_NN
._.
In_PIN
all_QUAN
cases_NN
,_,
the_DT
Committee_NN
is_VPRT [PASS]
notified_VBN
with_PIN
treasury_NN
policy_NN
were_VBD [PASS]
discussed_VBN
:_:
of_PIN
any_QUAN
pre-approved_JJ
service_NN
that_DEMP
is_VPRT [BYPA]
provided_VBN
by_PIN
the_DT
auditor_NN
._.
approval_NN
of_PIN
the_DT
insurance_NN
renewal_NN
program_NN
for_PIN
2005_CD
6_CD
:_:
Any_QUAN
service_NN
proposed_VBN [SUAV]
to_TO
be_VB [BYPA]
provided_VBN
by_PIN
the_DT
auditor_NN
which_WDT [WHSUB]
is_VPRT [BEMA]
not_XX0
a_DT
pre-approved_JJ
service_NN
must_NEMD
be_VB [PASS]
approved_VBN
in_PIN
advance_NN
by_PIN
the_DT
Committee_NN
,_,
monitoring_GER
of_PIN
the_DT
Groups_NN
whistle-blowing_JJ
and_CC
fraud_NN
policies_NN
:_:
and_ANDC
which_WDT
will_PRMD
consider_VB [PRIV]
whether_IN [WHCL]
the_DT
independence_NN
,_,
skills_NN
and_PHC
experience_NN
of_PIN
the_DT
auditor_NN
make_VB
it_PIT
a_DT
suitable_JJ
supplier_NN
of_PIN
the_DT
proposed_JJ
service_NN
._.
the_DT
Companys_NN
internal_JJ
controls_NN
over_IN
financial_JJ
reporting_GER
._.
Committee_NN
activities_NOMZ
3_CD
External_NN
auditor_NN
During_PIN
2005_CD
,_,
the_DT
business_NOMZ
discussed_VBN [WZPAST]
by_PIN
the_DT
Committee_NN
included_VBD
The_DT
Committee_NN
reviewed_VBD
the_DT
performance_NN
of_PIN
the_DT
external_JJ
auditor_NN
the_DT
following_GER
:_:
following_VBG [PRESP]
the_DT
completion_NOMZ
of_PIN
the_DT
2004_CD
audit_NN
process_NN
,_,
which_WDT [SERE]
resulted_VBD
in_PIN
the_DT
Committee_NN
resolving_VBG [SUAV] [WZPRES]
to_TO
recommend_VB [SUAV]
that_THVC
the_DT
Company_NN
submit_VB [PUBV]
1_CD
Financial_NN
statements_NOMZ
a_DT
resolution_NOMZ
to_PIN
the_DT
2005_CD
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
to_TO
re-appoint_VB
Deloitte_NN
the_DT
financial_JJ
disclosures_NN
contained_VBN [WZPAST]
in_PIN
the_DT
Companys_NN
quarterly_JJ
&_CC
Touche_NN
LLP_NN
as_IN
the_DT
Companys_NN
external_JJ
auditor_NN
._.
At_PIN
forthcoming_JJ
results_NN
announcements_NOMZ
:_:
meetings_GER
in_PIN
2006_CD
,_,
the_DT
Committee_NN
will_PRMD
conduct_VB
a_DT
formal_JJ
review_NN
of_PIN
the_DT
performance_NN
of_PIN
the_DT
external_JJ
auditor_NN
and_CC
the_DT
effectiveness_NOMZ
of_PIN
the_DT
audit_NN
various_JJ
accounting_GER
matters_NN
,_,
including_VBG [PRESP]
the_DT
application_NOMZ
of_PIN
the_DT
process_NN
in_PIN
connection_NOMZ
with_PIN
the_DT
2005_CD
financial_JJ
year_NN
audit_NN
._.
Companys_NN
critical_JJ
accounting_GER
policies_NN
and_CC
new_JJ
accounting_GER
standards_NN
in_PIN
the_DT
context_NN
of_PIN
the_DT
financial_JJ
disclosures_NN
,_,
including_VBG [PRESP]
the_DT
Throughout_PIN
the_DT
year_NN
,_,
the_DT
Committee_NN
has_VPRT [PEAS]
kept_VBN
the_DT
objectivity_NOMZ
and_PHC
acquisition_NOMZ
of_PIN
TKT_NN
,_,
the_DT
impact_NN
of_PIN
the_DT
Health_NN
Canada_NN
suspension_NN
independence_NN
of_PIN
the_DT
external_JJ
auditor_NN
under_IN
review_NN
and_CC
has_VPRT [PEAS]
obtained_VBN
of_PIN
ADDERALL_NN
XR_NN
,_,
the_DT
impact_NN
of_PIN
fair_JJ
value_NN
accounting_GER
for_PIN
sharereports_NN
from_PIN
the_DT
Companys_NN
external_JJ
auditor_NN
describing_VBG [WZPRES]
all_QUAN
relationships_NN
based_VBN
compensation_NOMZ
and_CC
new_JJ
Inventory_NN
Management_NOMZ
Agreements_NOMZ
between_PIN
the_DT
auditor_NN
and_CC
the_DT
Company_NN
._.
The_DT
Committee_NN
has_VPRT [PEAS]
remained_VBN
with_PIN
key_JJ
US_FPP1
wholesalers_NN
:_:
satisfied_JJ
that_THAC
neither_SYNE
the_DT
level_NN
of_PIN
non-audit_JJ
services_NN
nor_SYNE
the_DT
nature_NN
of_PIN
the_DT
work_NN
performed_VBN [WZPAST]
by_PIN
the_DT
external_JJ
auditors_NN
has_VPRT
in_PIN
any_QUAN
way_NN
impaired_VBN
their_TPP3
a_DT
review_NN
of_PIN
the_DT
Companys_NN
preparations_NOMZ
for_PIN
the_DT
adoption_NOMZ
in_PIN
2005_CD
objectivity_NOMZ
and_PHC
independence_NN
._.
Details_NN
of_PIN
the_DT
fees_NN
paid_VBN [WZPAST]
to_PIN
the_DT
external_JJ
of_PIN
International_NN
Financial_NN
Reporting_GER
Standards_NN
IFRS_NN
,_,
including_VBG [PRESP]
the_DT
auditors_NN
are_VPRT [PASS]
disclosed_VBN [PUBV]
in_PIN
Note_NN
7_CD
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
._.
approval_NN
of_PIN
the_DT
Companys_NN
accounting_GER
policies_NN
under_IN
IFRS_NN
._.
The_DT
Audit_NN
Committee_NN
reviewed_VBD
and_PHC
approved_VBD
the_DT
Companys_NN
publication_NOMZ
in_PIN
September_NN
2005_CD
of_PIN
its_PIT
half-yearly_JJ
financial_JJ
statements_NOMZ
and_CC
full-year_JJ
comparative_JJ
financial_JJ
statements_NOMZ
for_PIN
2004_CD
,_,
as_IN
prepared_VBN
in_PIN
accordance_NN
with_PIN
IFRS_NN
:_:
and_ANDC
quarterly_JJ
reports_NN
from_PIN
the_DT
external_JJ
auditors_NN
were_VBD [BYPA]
received_VBN
by_PIN
the_DT
David_NN
Kappler_NN
Committee_NN
and_CC
discussed_VBN
._.
The_DT
reports_NN
addressed_VBD
the_DT
following_VBG
Chairman_NN
of_PIN
the_DT
Audit_NN
Committee_NN
key_JJ
areas_NN
:_:
auditor_NN
responsibility_NOMZ
and_PHC
independence_NN
:_:
significant_JJ
accounting_GER
estimates_NN
and_PHC
judgements_NOMZ
made_VBN [WZPAST]
by_PIN
management_NOMZ
:_:
audit_NN
adjustments_NOMZ
proposed_VBN [SUAV]
and_ANDC
whether_IN
they_TPP3
were_VBD [BYPA]
corrected_VBN
by_PIN
management_NOMZ
:_:
and_ANDC
significant_JJ
accounting_GER
policies_NN
and_CC
unusual_JJ
transactions_NOMZ
._.
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
69_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
70_CD
Corporate_JJ
governance_NN
statements_NOMZ
The_DT
Company_NN
is_VPRT [PASS]
committed_VBN
to_PIN
high_JJ
standards_NN
Independence_NN
of_PIN
Directors_NN
of_PIN
corporate_JJ
governance_NN
The_DT
Board_NN
considers_VPRT [PRIV]
Dr_NN
Barry_NN
Price_NN
,_,
Mr_NN
Ronald_NN
Nordmann_NN
,_,
The_DT
Hon_NN
The_NN
Board_NN
is_VPRT [PASS]
committed_VBN
to_PIN
high_JJ
standards_NN
of_PIN
corporate_JJ
governance_NN
James_NN
Grant_NN
,_,
Mr_NN
Robin_NN
Buchanan_NN
,_,
Mr_NN
David_NN
Kappler_NN
and_PHC
Mr_NN
Patrick_NN
and_CC
supports_VPRT
the_DT
provisions_NN
and_PHC
principles_NN
set_VBN [WZPAST]
out_PIN
in_PIN
The_DT
Combined_VBN
Langlois_NN
to_TO
be_VB [BEMA]
Independent_JJ
Non-executive_JJ
Directors_NN
._.
The_DT
Board_NN
Code_NN
on_PIN
Corporate_NN
Governance_NN
issued_VBN [WZPAST]
by_PIN
the_DT
UK_NN
Financial_NN
Reporting_GER
views_VPRT
each_QUAN
of_PIN
these_DEMO
Non-executive_JJ
Directors_NN
to_TO
be_VB [BEMA]
independent_JJ
Council_NN
in_PIN
July_NN
2003_CD
the_DT
Combined_NN
Code_NN
._.
of_PIN
management_NOMZ
,_,
independent_JJ
in_PIN
judgement_NOMZ
and_PHC
character_NN
and_CC
free_JJ
from_PIN
any_QUAN
business_NOMZ
or_CC
other_JJ
relationship_NN
which_WDT [WHSUB]
could_POMD [SPAU]
materially_RB
interfere_VB
Statement_NOMZ
of_PIN
compliance_NN
with_PIN
the_DT
Combined_NN
Code_NN
with_PIN
the_DT
exercise_NN
of_PIN
their_TPP3
independent_JJ
judgement_NOMZ
._.
Throughout_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
the_DT
Company_NN
has_VPRT
,_,
in_PIN
the_DT
Directors_NN
opinion_NN
,_,
complied_VBN [PASTP]
with_PIN
the_DT
provisions_NN
set_VBN [WZPAST]
out_PIN
The_DT
Board_NN
has_VPRT [PEAS]
taken_VBN
into_PIN
consideration_NOMZ
that_TOBJ
The_DT
Hon_NN
James_NN
Grant_NN
in_PIN
Section_NOMZ
1_CD
of_PIN
the_DT
Combined_NN
Code_NN
._.
is_VPRT [BEMA]
a_DT
partner_NN
of_PIN
Stikeman_NN
Elliot_NN
,_,
a_DT
Canadian_JJ
law_NN
firm_NN
which_WDT [WHOBJ]
,_,
from_PIN
time_NN
to_PIN
time_NN
,_,
provides_VPRT
legal_JJ
advice_NN
to_PIN
the_DT
Shire_NN
Group_NN
._.
The_DT
Board_NN
considers_VPRT [PRIV]
The_NN
Board_NN
Mr_NN
Grant_NN
to_TO
be_VB [BEMA]
independent_PRED
notwithstanding_CONJ
his_TPP3
position_NOMZ
as_IN
he_TPP3
is_VPRT [BEMA]
The_DT
Board_NN
comprises_VPRT
the_DT
Chairman_NN
,_,
two_CD
Executive_NN
and_CC
six_CD
not_XX0
involved_VBN
in_PIN
the_DT
provision_NN
of_PIN
legal_JJ
advice_NN
to_PIN
the_DT
Shire_NN
Group_NN
and_CC
Non-executive_JJ
Directors_NN
and_CC
meets_VPRT
at_PIN
least_JJ
six_CD
times_NN
a_DT
year_NN
._.
is_VPRT [PASS]
not_XX0
engaged_VBN
in_PIN
marketing_VBG
the_DT
services_NN
of_PIN
Stikeman_NN
Elliott_NN
to_PIN
the_DT
The_DT
Non-executive_JJ
Directors_NN
bring_VPRT
judgement_NOMZ
which_WDT [WHSUB]
is_VPRT [BEMA]
independent_JJ
Shire_NN
Group_NN
._.
Stikeman_NN
Elliott_NN
is_VPRT [BEMA]
one_CD
of_PIN
a_DT
range_NN
of_PIN
legal_JJ
and_PHC
other_JJ
of_PIN
management_NOMZ
to_PIN
Board_NN
deliberations_NOMZ
._.
The_DT
executive_NN
Directors_NN
professional_JJ
advisors_NN
engaged_VBN [WZPAST]
by_PIN
the_DT
Shire_NN
Group_NN
from_PIN
time_NN
to_PIN
time_NN
._.
have_VB
responsibility_NOMZ
for_PIN
day-to-day_TIME
business_NOMZ
operations_NOMZ
._.
Accordingly_RB
,_,
the_DT
Board_NN
does_VPRT
not_XX0
consider_VB [PRIV]
the_DT
relationship_NN
between_PIN
the_DT
Shire_NN
Group_NN
and_PHC
Stikeman_NN
Elliott_NN
to_TO
be_VB [BEMA]
material_PRED
and_CC
the_DT
fact_NN
that_TOBJ
The_NN
Board_NN
has_VPRT
overall_JJ
responsibility_NOMZ
for_PIN
managing_VBG
the_DT
Company_NN
and_PHC
Mr_NN
Grant_NN
is_VPRT [BEMA]
a_DT
partner_NN
at_PIN
that_DEMO
firm_NN
does_VPRT
not_XX0
,_,
in_PIN
the_DT
Boards_NN
assessment_NOMZ
,_,
its_PIT
strategic_JJ
direction_NOMZ
and_CC
seeks_VPRT
to_TO
provide_VB
effective_JJ
leadership_NN
and_CC
affect_VB
his_TPP3
independence_NN
._.
Mr_NN
Grant_NN
was_VBD [BEMA]
a_DT
Board_NN
member_NN
of_PIN
BioChem_NN
the_DT
control_NN
required_VBN [SUAV] [WZPAST]
for_PIN
a_DT
listed_VBN
company_NN
._.
The_DT
Board_NN
discharges_VPRT
those_DEMO
Pharma_NN
Inc._NN
prior_RB
to_PIN
its_PIT
merger_NN
with_PIN
Shire_NN
in_PIN
2001_CD
._.
Mr_NN
Grant_NN
has_VPRT
responsibilities_NOMZ
through_PIN
regularly_RB
scheduled_VBN
meetings_GER
._.
The_DT
Board_NN
an_DT
extensive_JJ
knowledge_NN
of_PIN
Shires_NN
business_NOMZ
and_CC
he_TPP3
brings_VPRT
valued_VBN
has_VPRT [SPAU] [PEAS]
formally_RB
reserved_VBN
specific_JJ
matters_NN
to_PIN
itself_PIT
for_PIN
determination_NOMZ
which_WDT [WHSUB]
expertize_VPRT
to_PIN
the_DT
Board_NN
._.
include_VPRT
strategic_JJ
issues_NN
,_,
budgeting_GER
,_,
changes_NN
in_PIN
share_NN
capital_NN
,_,
approval_NN
of_PIN
the_DT
Companys_NN
financial_JJ
statements_NOMZ
and_PHC
entry_NN
into_PIN
material_NN
contracts_NN
._.
The_DT
Board_NN
,_,
when_RB
making_VBG
its_PIT
determination_NOMZ
on_PIN
the_DT
independence_NN
Matters_NN
not_XX0
formally_RB
reserved_VBN
to_PIN
the_DT
Board_NN
are_VPRT [PASS]
delegated_VBN
to_PIN
the_DT
of_PIN
Dr_NN
Price_NN
,_,
gave_VBD
particular_JJ
consideration_NOMZ
to_PIN
the_DT
fact_NN
that_TOBJ
Dr_NN
Price_NN
has_VPRT
Executive_NN
Committee_NN
and_CC
to_PIN
various_JJ
other_JJ
Board_NN
committees_NN
whose_WPS [WHSUB]
been_VBN [BEMA]
a_DT
serving_VBG
member_NN
of_PIN
the_DT
Board_NN
for_PIN
ten_CD
years_NN
,_,
that_THVC
the_DT
Combined_VBN
functions_NOMZ
are_VPRT [PASS]
described_VBN
below_PLACE
._.
Code_NN
suggests_VPRT [SUAV] [PUBV]
that_THVC
length_NN
of_PIN
service_NN
of_PIN
nine_CD
years_NN
or_CC
more_EMPH
is_VPRT [BEMA]
relevant_PRED
to_PIN
a_DT
determination_NOMZ
of_PIN
independence_NN
and_CC
that_DEMO
re-appointment_JJ
should_NEMD
The_DT
Board_NN
reviews_VPRT
the_DT
Companys_NN
internal_JJ
controls_NN
and_PHC
risk_NN
be_VB [BEMA]
subject_PRED
to_PIN
rigorous_JJ
review_NN
._.
The_DT
Board_NN
was_VBD [BEMA]
also_RB
mindful_PRED
of_PIN
the_DT
need_NN
management_NOMZ
policies_NN
and_CC
approves_VPRT
its_PIT
Code_NN
of_PIN
Ethics_NN
._.
The_DT
Board_NN
to_TO
ensure_VB [SUAV] [PRIV]
progressive_JJ
refreshening_GER
of_PIN
the_DT
Board_NN
._.
In_PIN
this_DEMO
regard_NN
the_DT
approves_VPRT
major_JJ
investment_NOMZ
and_CC
contractual_JJ
decisions_NN
which_WDT [WHSUB]
exceed_VPRT
Board_NN
took_VBD
into_PIN
account_NN
that_DEMO
there_EX
have_VPRT [PEAS]
been_VBN
substantial_JJ
changes_NN
defined_VBN
thresholds_NN
._.
It_PIT
also_RB
monitors_VPRT
and_PHC
evaluates_VPRT
the_DT
performance_NN
to_PIN
the_DT
Board_NN
membership_NN
in_PIN
recent_JJ
years_NN
,_,
including_VBG [PRESP]
the_DT
appointments_NOMZ
of_PIN
the_DT
Shire_NN
Group_NN
as_IN
a_DT
whole_NN
,_,
through_PIN
engaging_VBG
with_PIN
the_DT
of_PIN
Mr_NN
Buchanan_NN
and_PHC
Mr_NN
Emmens_NN
in_PIN
2003_CD
,_,
Mr_NN
Kappler_NN
in_PIN
2004_CD
and_CC
Chief_NN
Executive_NN
Officer_NN
,_,
Chief_NN
Financial_NN
Officer_NN
and_PHC
members_NN
Mr_NN
Langlois_NN
in_PIN
2005_CD
._.
Having_VBG [PEAS]
considered_VBN [PRIV]
the_DT
issue_NN
,_,
the_DT
Board_NN
has_VPRT
of_PIN
the_DT
Executive_NN
Committee_NN
,_,
as_IN
appropriate_JJ
._.
no_SYNE
hesitation_NOMZ
in_PIN
asking_VBG [SUAV]
Dr_NN
Price_NN
to_TO
remain_VB
on_PIN
the_DT
Board_NN
._.
Dr_NN
Prices_NN
commitment_NOMZ
to_PIN
the_DT
Company_NN
is_VPRT [BEMA]
undiminished_PRED
and_CC
his_TPP3
performance_NN
The_DT
Board_NN
members_NN
receive_VPRT
detailed_VBN
information_NOMZ
from_PIN
executive_NN
continues_VPRT
to_TO
be_VB [BEMA]
effective_PRED
._.
In_PIN
accordance_NN
with_PIN
the_DT
Combined_NN
Code_NN
,_,
Directors_NN
,_,
the_DT
Company_NN
Secretary_NN
,_,
members_NN
of_PIN
the_DT
Executive_NN
Dr_NN
Prices_NN
re-appointment_JJ
to_PIN
the_DT
Board_NN
is_VPRT [BEMA]
for_PIN
a_DT
one-year_JJ
term_NN
._.
Committee_NN
and_CC
other_JJ
senior_JJ
managers_NN
to_TO
enable_VB
them_TPP3
to_TO
discharge_VB
His_TPP3
re-appointment_NOMZ
will_PRMD
be_VB [BEMA]
subject_PRED
to_PIN
shareholder_NN
approval_NN
at_PIN
the_DT
their_TPP3
responsibilities_NOMZ
efficiently_RB
and_PHC
effectively_RB
._.
All_QUAN
Directors_NN
have_VPRT
2006_CD
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
._.
access_NN
to_PIN
the_DT
advice_NN
and_PHC
guidance_NN
of_PIN
the_DT
Company_NN
Secretary_NN
and_CC
are_VPRT [PASS]
encouraged_VBN
to_TO
seek_VB
independent_JJ
advice_NN
at_PIN
the_DT
Companys_NN
Throughout_PIN
2005_CD
and_CC
up_RB
to_PIN
the_DT
date_NN
of_PIN
publication_NOMZ
of_PIN
this_DEMO
report_NN
,_,
expense_NN
,_,
where_RB
they_TPP3
feel_VPRT [PRIV] [THATD]
it_PIT
is_VPRT [BEMA]
appropriate_PRED
._.
The_DT
Board_NN
is_VPRT [BEMA]
of_PIN
the_DT
opinion_NN
at_PIN
least_JJ
half_PDT
the_DT
Board_NN
,_,
excluding_VBG [PRESP]
the_DT
Chairman_NN
,_,
comprised_VBD
that_DEMO
each_QUAN
of_PIN
its_PIT
members_NN
has_VPRT
the_DT
knowledge_NN
,_,
aptitude_NN
and_PHC
experience_NN
Non-executive_JJ
Directors_NN
determined_VBN [SUAV] [PRIV] [WZPAST]
by_PIN
the_DT
Board_NN
to_TO
be_VB [BEMA]
independent_PRED
._.
to_TO
perform_VB
the_DT
functions_NOMZ
required_VBN [SUAV] [WZPAST]
of_PIN
a_DT
director_NN
of_PIN
a_DT
listed_VBN
company_NN
._.
Board_NN
and_PHC
Committee_NN
changes_NN
Biographical_NN
details_NN
of_PIN
the_DT
members_NN
of_PIN
the_DT
Board_NN
are_VPRT [PASS]
shown_VBN [PRIV]
on_PIN
pages_NN
Mr_NN
Patrick_NN
Langlois_NN
joined_VBD
the_DT
Board_NN
as_IN
a_DT
Non-executive_JJ
Director_NN
4041_CD
._.
and_ANDC
a_DT
member_NN
of_PIN
the_DT
Audit_NN
Committee_NN
on_PIN
November_NN
11_CD
,_,
2005_CD
._.
70_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
71_CD
Corporate_JJ
governance_NN
statements_NOMZ
Board_NN
meetings_GER
Senior_JJ
Non-executive_JJ
Director_NN
During_PIN
2005_CD
,_,
there_EX
were_VBD
13_CD
Board_NN
meetings_GER
of_PIN
which_WDT [PIRE]
seven_CD
were_VBD
faceDr_NN
Barry_NN
Price_NN
is_VPRT [BEMA]
the_DT
Senior_JJ
Independent_NN
Non-executive_JJ
Director_NN
._.
to-face_JJ
meetings_GER
and_CC
six_CD
held_VBN [PRIV]
by_PIN
telephone_NN
._.
Board_NN
meetings_GER
are_VPRT
well_RB
Dr_NN
Price_NN
is_VPRT [BEMA]
the_DT
Companys_NN
longest-serving_JJ
Director_NN
and_CC
as_IN
such_JJ
he_TPP3
attended_VBD
._.
The_DT
record_NN
of_PIN
attendance_NN
by_PIN
Directors_NN
at_PIN
Board_NN
meetings_GER
has_VPRT
significant_JJ
knowledge_NN
of_PIN
Shire_NN
and_CC
its_PIT
business_NOMZ
._.
Dr_NN
Prices_NN
in-depth_JJ
is_VPRT [PASS]
set_VBN
out_PIN
below_PLACE
:_:
knowledge_NN
of_PIN
Shire_NN
and_CC
the_DT
pharmaceutical_JJ
industry_NN
generally_RB
is_VPRT [BEMA]
acknowledged_PRED
and_CC
utilized_VBN
by_PIN
the_DT
Board_NN
._.
Dr_NN
Price_NN
chairs_VPRT
meetings_GER
held_VBD [PRIV]
Number_NN
of_PIN
by_PIN
the_DT
Non-executive_JJ
Directors_NN
during_PIN
the_DT
year_NN
in_PIN
the_DT
absence_NN
of_PIN
the_DT
meetings_GER
Out_PIN
of_PIN
Attendance_NN
executive_NN
Directors_NN
and_CC
the_DT
Chairman_NN
._.
Dr_NN
Price_NN
is_VPRT [BEMA]
available_PRED
,_,
as_IN
required_VBN [SUAV]
,_,
Directors_NN
attended_VBD
possible_JJ
%_NN
for_PIN
consultation_NOMZ
with_PIN
major_JJ
shareholders_NN
on_PIN
any_QUAN
matter_NN
of_PIN
concern_NN
._.
James_NN
Cavanaugh_NN
Chairman_NN
13_CD
13_CD
100_CD
Supply_NN
of_PIN
information_NOMZ
The_DT
executive_NN
Directors_NN
and_CC
the_DT
Company_NN
Secretary_NN
are_VPRT [BEMA]
responsible_JJ
Matthew_NN
Emmens_NN
for_PIN
ensuring_VBG [SUAV] [PRIV] [THATD]
that_DEMP
detailed_VBN
information_NOMZ
is_VPRT [PASS]
provided_VBN
to_PIN
Board_NN
members_NN
Chief_NN
Executive_NN
Officer_NN
13_CD
13_CD
100_CD
in_PIN
advance_NN
of_PIN
any_QUAN
scheduled_VBN
Board_NN
meeting_GER
._.
Before_IN
decisions_NN
are_VPRT
Angus_NN
Russell_NN
made_VBD
,_,
consideration_NOMZ
is_VPRT [PASS]
given_VBN
to_PIN
the_DT
adequacy_NN
of_PIN
information_NOMZ
available_JJ
Chief_NN
Financial_NN
Officer_NN
13_CD
13_CD
100_CD
to_PIN
the_DT
Board_NN
and_CC
,_,
if_COND
necessary_JJ
,_,
decisions_NN
are_VPRT [PASS]
deferred_VBN
if_COND
further_JJ
information_NOMZ
is_VPRT [PASS]
required_VBN [SUAV]
._.
The_DT
Company_NN
Secretary_NN
,_,
Ms_NN
Tatjana_NN
May_POMD
,_,
Barry_NN
Price_NN
is_VPRT
also_RB
secretary_NN
to_PIN
all_QUAN
of_PIN
the_DT
Board_NN
committees_NN
._.
Senior_JJ
Non-executive_JJ
Director_NN
12_CD
13_CD
92_CD
The_DT
Hon_NN
James_NN
Grant_NN
Appointment_NOMZ
and_PHC
re-election_NOMZ
of_PIN
Directors_NN
Non-executive_JJ
Director_NN
12_CD
13_CD
92_CD
The_DT
Board_NN
has_VPRT
authority_NOMZ
to_TO
appoint_VB
any_QUAN
person_NN
to_TO
be_VB [BEMA]
a_DT
Director_NN
._.
Any_QUAN
Director_NN
so_EMPH
appointed_JJ
must_NEMD
retire_VB
and_PHC
submit_VB [PUBV]
himself_TPP3
for_PIN
election_NOMZ
Ronald_NN
Nordmann_NN
at_PIN
the_DT
next_JJ
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
._.
Non-executive_JJ
Director_NN
13_CD
13_CD
100_CD
Robin_NN
Buchanan_NN
Non-executive_JJ
Directors_NN
are_VPRT [PASS]
appointed_VBN
ordinarily_RB
for_PIN
a_DT
term_NN
of_PIN
two_CD
Non-executive_JJ
Director_NN
13_CD
13_CD
100_CD
years_NN
,_,
subject_JJ
to_PIN
shareholder_NN
approval_NN
._.
Non-executive_JJ
Directors_NN
who_WP [WHSUB]
have_VPRT [PEAS]
served_VBN
on_PIN
the_DT
Board_NN
for_PIN
nine_CD
years_NN
or_CC
more_EMPH
are_VPRT [PASS]
appointed_VBN
David_NN
Kappler_NN
for_PIN
one_CD
year_NN
terms_NN
and_CC
,_,
in_PIN
accordance_NN
with_PIN
the_DT
Combined_NN
Code_NN
Non-executive_JJ
Director_NN
13_CD
13_CD
100_CD
on_PIN
Corporate_JJ
Governance_NN
,_,
are_VPRT [BEMA]
subject_PRED
to_PIN
annual_JJ
re-election_NOMZ
by_PIN
Patrick_NN
Langlois_NN
shareholders_NN
._.
Re-appointment_NOMZ
of_PIN
Non-executive_JJ
Directors_NN
following_VBG [WZPRES]
Non-executive_JJ
Director_NN
the_DT
expiry_NN
of_PIN
their_TPP3
term_NN
of_PIN
appointment_NOMZ
is_VPRT [BEMA]
subject_PRED
to_PIN
Board_NN
approval_NN
._.
appointed_VBN
November_NN
11_CD
,_,
2005_CD
1_CD
1_CD
100_CD
At_PIN
every_QUAN
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
a_DT
minimum_NN
of_PIN
one-third_NN
of_PIN
the_DT
Directors_NN
must_NEMD
retire_VB
from_PIN
office_NN
and_CC
may_POMD
offer_VB
themselves_TPP3
for_PIN
reThe_NN
Chairman_NN
and_CC
the_DT
Non-executive_JJ
Directors_NN
met_VBD
during_PIN
the_DT
year_NN
election_NOMZ
by_PIN
shareholders_NN
._.
Accordingly_RB
,_,
no_SYNE
Director_NN
should_NEMD
serve_VB
without_PIN
the_DT
executive_NN
Directors_NN
being_VBG [WZPRES] [BEMA]
present_PRED
._.
for_PIN
more_EMPH
than_PIN
three_CD
years_NN
without_PIN
being_VBG [BEMA]
subject_PRED
to_PIN
re-election_NOMZ
._.
Chairman_NN
and_PHC
Chief_NN
Executive_NN
Officer_NN
All_QUAN
of_PIN
the_DT
current_JJ
Directors_NN
of_PIN
Shire_NN
plc_NN
were_VBD [BYPA]
appointed_VBN
by_PIN
the_DT
Board_NN
as_IN
The_DT
offices_NN
of_PIN
Chairman_NN
and_PHC
Chief_NN
Executive_NN
Officer_NN
are_VPRT [PASS]
held_VBN [PRIV]
separately_RB
._.
a_DT
result_NN
of_PIN
the_DT
scheme_NN
of_PIN
arrangement_NOMZ
implemented_VBN [WZPAST]
on_PIN
November_NN
25_CD
,_,
The_DT
Chairman_NN
,_,
Dr_NN
James_NN
Cavanaugh_NN
,_,
is_VPRT [BEMA]
responsible_PRED
for_PIN
the_DT
conduct_NN
2005_CD
,_,
whereby_OSUB
Shire_NN
plc_NN
was_VBD [PASS]
established_VBN [PRIV]
as_IN
the_DT
new_JJ
UK_NN
listed_VBN
holding_GER
of_PIN
the_DT
Board_NN
and_CC
ensures_VPRT [SUAV] [PRIV]
that_THVC
Board_NN
discussions_NN
are_VPRT [PASS]
conducted_VBN
in_PIN
Company_NN
for_PIN
the_DT
Shire_NN
Group_NN
in_PIN
place_NN
of_PIN
Shire_NN
Pharmaceuticals_NN
Group_NN
such_EMPH
a_NULL
way_NN
that_TOBJ
all_QUAN
views_NN
are_VPRT [PASS]
taken_VBN
into_PIN
account_NN
,_,
so_OSUB
that_NULL
no_SYNE
individual_JJ
plc_NN
Scheme_NN
._.
As_CONJ
a_NULL
result_NULL
of_PIN
the_DT
implementation_NOMZ
of_PIN
the_DT
Scheme_NN
,_,
all_QUAN
Director_NN
or_CC
small_JJ
group_NN
of_PIN
Directors_NN
dominates_VPRT
proceedings_GER
._.
The_DT
Chief_NN
of_PIN
the_DT
Directors_NN
of_PIN
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
became_VBD
Directors_NN
Executive_NN
Officer_NN
has_VPRT
the_DT
overall_JJ
responsibility_NOMZ
for_PIN
running_VBG
the_DT
business_NOMZ
of_PIN
Shire_NN
plc_NN
but_CC
were_VBD [BYPA]
appointed_VBN
by_PIN
the_DT
Board_NN
rather_RB
than_PIN
shareholders_NN
._.
on_PIN
a_DT
day-to-day_TIME
basis_NN
and_CC
chairs_VPRT
the_DT
Executive_NN
Committee_NN
._.
Accordingly_RB
,_,
at_PIN
the_DT
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
to_TO
be_VB [PASS]
held_VBN [PRIV]
in_PIN
2006_CD
,_,
all_QUAN
of_PIN
the_DT
Directors_NN
will_PRMD
retire_VB
and_PHC
offer_VB
themselves_TPP3
for_PIN
re-election_NOMZ
._.
The_DT
roles_NN
and_PHC
responsibilities_NOMZ
of_PIN
the_DT
Chairman_NN
and_CC
the_DT
Chief_NN
Executive_NN
Officer_NN
are_VPRT [SPAU] [PASS]
clearly_RB
defined_VBN
,_,
separate_JJ
and_CC
have_VPRT [PEAS]
been_VBN [BYPA]
approved_VBN
by_PIN
Further_JJ
information_NOMZ
concerning_VBG [WZPRES]
all_QUAN
the_DT
Directors_NN
standing_VBG [WZPRES]
for_PIN
re-election_NOMZ
the_DT
Board_NN
._.
at_PIN
the_DT
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
,_,
including_VBG [PRESP]
their_TPP3
biographies_NN
,_,
will_PRMD
be_VB [PASS]
included_VBN
in_PIN
the_DT
Notice_NN
of_PIN
Meeting_VBG
to_PIN
Shareholders_NN
._.
The_DT
terms_NN
of_PIN
appointment_NOMZ
of_PIN
each_QUAN
of_PIN
the_DT
Non-executive_JJ
Directors_NN
and_CC
the_DT
service_NN
contracts_NN
of_PIN
the_DT
executive_NN
Directors_NN
will_PRMD
be_VB [PASS]
made_VBN
available_JJ
for_PIN
inspection_NOMZ
at_PIN
the_DT
Companys_NN
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
in_PIN
2006_CD
._.
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
71_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
72_CD
Corporate_JJ
governance_NN
statements_NOMZ
Board_NN
performance_NN
evaluation_NOMZ
3_CD
Nomination_NOMZ
Committee_NN
The_NN
Company_NN
conducted_VBD
evaluations_NOMZ
of_PIN
the_DT
performance_NN
of_PIN
the_DT
Board_NN
,_,
The_DT
Nomination_NOMZ
Committee_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
identifying_VBG
and_CC
its_PIT
committees_NN
and_CC
its_PIT
Directors_NN
in_PIN
2005_CD
._.
The_DT
2005_CD
evaluations_NOMZ
were_VBD [BEMA]
nominating_PRED
,_,
for_PIN
the_DT
approval_NN
of_PIN
the_DT
Board_NN
,_,
candidates_NN
for_PIN
the_DT
Board_NN
._.
The_DT
undertaken_VBN
by_PIN
way_NN
of_PIN
questionnaires_NN
prepared_VBN [WZPAST]
by_PIN
the_DT
Chairman_NN
and_PHC
Committee_NN
also_RB
ensures_VPRT [SUAV] [PRIV]
adequate_JJ
succession_NN
planning_GER
for_PIN
the_DT
Board_NN
the_DT
Company_NN
Secretary_NN
._.
The_DT
reviews_NN
covered_VBD
a_DT
wide_JJ
range_NN
of_PIN
matters_NN
and_CC
senior_JJ
management_NOMZ
._.
This_DEMO
Committee_NN
meets_VPRT
as_IN
required_VBN [SUAV]
and_CC
in_PIN
2005_CD
including_VBG
adequacy_NN
of_PIN
the_DT
composition_NOMZ
of_PIN
the_DT
Board_NN
and_CC
its_PIT
Committees_NN
,_,
was_VBD [BYPA]
chaired_VBN
by_PIN
Dr_NN
James_NN
Cavanaugh_NN
._.
Mr_NN
Ronald_NN
Nordmann_NN
,_,
The_DT
Hon_NN
performance_NN
of_PIN
Directors_NN
and_CC
the_DT
adequacy_NN
of_PIN
information_NOMZ
provided_VBN
._.
James_NN
Grant_NN
and_PHC
Dr_NN
Barry_NN
Price_NN
also_RB
served_VBD
on_PIN
this_DEMO
Committee_NN
in_PIN
2005_CD
._.
Responses_NN
were_VBD [PASS]
aggregated_VBN
on_PIN
a_DT
non-attributed_JJ
basis_NN
and_CC
circulated_VBN
All_QUAN
members_NN
participated_VBD
in_PIN
all_QUAN
discussions_NN
of_PIN
this_DEMO
Committee_NN
in_PIN
2005_CD
._.
to_PIN
each_QUAN
Board_NN
and_PHC
Committee_NN
member_NN
._.
The_DT
responses_NN
then_RB
formed_VBD
the_DT
basis_NN
of_PIN
a_DT
discussion_NN
between_PIN
the_DT
relevant_JJ
members_NN
of_PIN
the_DT
Board_NN
The_DT
Nomination_NOMZ
Committee_NN
retains_VPRT
the_DT
services_NN
of_PIN
executive_JJ
search_NN
or_CC
Committee_NN
with_PIN [STPR]
,_,
respectively_RB
,_,
the_DT
Chairman_NN
and_CC
the_DT
Committee_NN
consultants_NN
to_TO
assist_VB
it_PIT
in_PIN
the_DT
identification_NOMZ
and_PHC
nomination_NOMZ
of_PIN
new_JJ
Chairman_NN
._.
A_DT
number_NN
of_PIN
minor_JJ
improvements_NOMZ
to_TO
operating_VBG
procedures_NN
Board_NN
candidates_NN
._.
For_PIN
further_JJ
information_NOMZ
about_IN
the_DT
Nomination_NOMZ
Committee_NN
,_,
its_PIT
Committees_NN
of_PIN
the_DT
Board_NN
membership_NN
and_PHC
activities_NOMZ
for_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
The_DT
Board_NN
has_VPRT [PEAS]
established_VBN [PRIV]
the_DT
Audit_NN
Committee_NN
,_,
the_DT
Remuneration_NOMZ
please_VB
refer_VPRT
to_PIN
the_DT
Nomination_NOMZ
Committee_NN
report_NN
on_PIN
page_NN
56_CD
._.
Committee_NN
,_,
the_DT
Nomination_NOMZ
Committee_NN
and_CC
the_DT
Executive_NN
Committee_NN
._.
Each_QUAN
committee_NN
has_VPRT
its_PIT
own_JJ
written_VBN [PUBV]
terms_NN
of_PIN
reference_NN
which_WDT [WHSUB]
have_VPRT
4_CD
Executive_NN
Committee_NN
been_VBN [BYPA]
approved_VBN
by_PIN
the_DT
Board_NN
._.
The_DT
Terms_NN
of_PIN
Reference_NN
of_PIN
the_DT
Audit_NN
,_,
The_NN
Board_NN
has_VPRT [PEAS]
delegated_VBN
the_DT
day-to-day_TIME
management_NOMZ
of_PIN
the_DT
Company_NN
Nomination_NOMZ
and_PHC
Remuneration_NOMZ
Committees_NN
are_VPRT [BEMA]
available_PRED
on_PIN
the_DT
to_PIN
the_DT
Executive_NN
Committee_NN
,_,
which_WDT [SERE]
operates_VPRT
within_PIN
clear_JJ
and_PHC
formal_JJ
Companys_NN
website_NN
._.
Details_NN
of_PIN
each_QUAN
committee_NN
are_VPRT
as_IN
follows_VPRT
:_:
parameters_NN
._.
The_DT
Executive_NN
Committee_NN
meets_VPRT
at_PIN
least_JJ
11_CD
times_NN
per_PIN
year_NN
._.
The_DT
Chief_NN
Executive_NN
is_VPRT [BEMA]
the_DT
Chairman_NN
1_CD
Audit_NN
Committee_NN
of_PIN
the_DT
Executive_NN
Committee_NN
,_,
which_WDT [SERE]
on_PIN
December_NN
31_CD
,_,
2005_CD
consisted_VBD
The_DT
Audit_NN
Committee_NN
has_VPRT [PEAS]
been_VBN [PASS]
established_VBN [PRIV]
for_PIN
the_DT
purpose_NN
of_PIN
of_PIN
11_CD
Executive_NN
Vice_NN
Presidents_NN
including_VBG [WZPRES]
the_DT
two_CD
executive_NN
Directors_NN
._.
overseeing_VBG [PRESP]
the_DT
accounting_GER
and_CC
financial_JJ
reporting_GER
processes_NN
of_PIN
the_DT
The_NN
Executive_NN
Committee_NN
reports_VPRT [PUBV]
to_TO
and_CC
seeks_VPRT
guidance_NN
from_PIN
the_DT
Company_NN
,_,
the_DT
audit_NN
of_PIN
its_PIT
financial_JJ
statements_NOMZ
and_CC
the_DT
Companys_NN
Board_NN
on_PIN
a_DT
regular_JJ
basis_NN
._.
It_PIT
meets_VPRT
at_PIN
least_JJ
four_CD
times_NN
a_DT
year_NN
._.
The_DT
members_NN
of_PIN
the_DT
Audit_NN
Committee_NN
are_VPRT [BEMA]
all_QUAN
Independent_NN
Non-executive_JJ
The_DT
Members_NN
of_PIN
the_DT
Executive_NN
Committee_NN
as_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
Directors_NN
._.
For_PIN
further_JJ
information_NOMZ
about_IN
the_DT
Audit_NN
Committee_NN
,_,
its_PIT
were_VBD
Matthew_NN
Emmens_NN
Chief_NN
Executive_NN
Officer_NN
,_,
Angus_NN
Russell_NN
membership_NN
and_PHC
activities_NOMZ
for_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
,_,
Chief_NN
Financial_NN
Officer_NN
and_PHC
Executive_NN
Vice_NN
President_NN
of_PIN
Global_NN
Finance_NN
,_,
please_VB
refer_VPRT
to_PIN
the_DT
Audit_NN
Committee_NN
report_NN
on_PIN
pages_NN
6869_CD
._.
Tatjana_NN
May_POMD
General_NN
Counsel_NN
,_,
Executive_NN
Vice_NN
President_NN
of_PIN
Global_NN
Legal_NN
Affairs_NN
and_PHC
Company_NN
Secretary_NN
,_,
Anita_NN
Graham_NN
Executive_NN
Vice_NN
2_CD
Remuneration_NOMZ
Committee_NN
President_NN
Global_NN
Human_NN
Resources_NN
,_,
Eliseo_NN
Salinas_NN
Executive_NN
Vice_NN
The_NN
Remuneration_NOMZ
Committee_NN
determines_VPRT [SUAV] [PRIV]
on_PIN
behalf_NN
of_PIN
the_DT
Board_NN
President_NN
of_PIN
Global_NN
R&D_NN
,_,
Greg_NN
Flexter_NN
Executive_NN
Vice_NN
President_NN
the_DT
remuneration_NOMZ
policy_NN
for_PIN
the_DT
executive_NN
Directors_NN
and_CC
other_JJ
senior_JJ
and_CC
General_NN
Manager_NN
,_,
North_NN
America_NN
,_,
Joseph_NN
Rus_NN
Executive_NN
Vice_NN
executives_NN
and_CC
the_DT
fixing_VBG
of_PIN
the_DT
terms_NN
of_PIN
employment_NOMZ
of_PIN
the_DT
executive_NN
President_NN
and_PHC
General_NN
Manager_NN
,_,
International_NN
,_,
Barbara_NN
Deptula_NN
Directors_NN
._.
The_DT
remuneration_NOMZ
of_PIN
the_DT
Non-executive_JJ
Directors_NN
is_VPRT
Executive_NN
Vice_NN
President_NN
of_PIN
Business_NOMZ
Development_NOMZ
,_,
John_NN
Lee_NN
determined_VBN [SUAV] [PRIV] [WZPAST]
by_PIN
the_DT
Board_NN
._.
The_DT
remuneration_NOMZ
of_PIN
the_DT
executive_NN
Directors_NN
Executive_NN
Vice_NN
President_NN
of_PIN
Supply_NN
Chain_NN
and_PHC
Quality_NOMZ
,_,
Mike_NN
Cola_NN
and_CC
the_DT
Chairman_NN
is_VPRT [BYPA]
determined_VBN [SUAV] [PRIV]
by_PIN
the_DT
Remuneration_NOMZ
Committee_NN
._.
Executive_NN
Vice_NN
President_NN
of_PIN
Global_NN
Business_NOMZ
Units_NN
and_PHC
David_NN
The_NN
remuneration_NOMZ
of_PIN
the_DT
members_NN
of_PIN
the_DT
Executive_NN
Committee_NN
,_,
other_JJ
Pendergast_NN
Executive_NN
Vice_NN
President_NN
of_PIN
Human_NN
Genetic_NN
Therapies_NN
._.
than_PIN
the_DT
executive_NN
Directors_NN
,_,
is_VPRT [BYPA]
determined_VBN [SUAV] [PRIV]
by_PIN
the_DT
Chief_NN
Executive_NN
Officer_NN
following_VBG [WZPRES]
discussion_NN
with_PIN
the_DT
Remuneration_NOMZ
Committee_NN
._.
The_DT
Executive_NN
Committee_NN
normally_RB
meets_VPRT
once_TIME
a_DT
month_NN
to_TO
deliberate_VB
The_DT
members_NN
of_PIN
the_DT
Remuneration_NOMZ
Committee_NN
are_VPRT [BEMA]
all_QUAN
Independent_NN
on_PIN
major_JJ
business_NOMZ
issues_NN
._.
It_PIT
also_RB
considers_VPRT [PRIV]
those_DEMO
matters_NN
that_TSUB
are_VPRT [BEMA]
of_PIN
Non-executive_JJ
Directors_NN
._.
a_DT
size_NN
and_PHC
significance_NN
as_IN
to_TO
require_VB [SUAV]
referral_NN
to_PIN
the_DT
Board_NN
before_IN
such_JJ
matters_NN
are_VPRT [PASS]
referred_VBN
to_PIN
the_DT
Board_NN
for_PIN
final_JJ
consideration_NOMZ
and_PHC
decision_NN
._.
The_DT
Remuneration_NOMZ
Committee_NN
engages_VPRT
external_JJ
consultants_NN
to_TO
advise_VB
on_PIN
aspects_NN
of_PIN
remuneration_NOMZ
,_,
as_IN
it_PIT
considers_VPRT [PRIV]
necessary_JJ
._.
Directors_NN
remuneration_VPRT
The_DT
Companys_NN
remuneration_NOMZ
policy_NN
is_VPRT [PASS]
described_VBN
in_PIN
the_DT
Directors_NN
The_DT
Remuneration_NOMZ
Committee_NN
met_VBD
on_PIN
seven_CD
occasions_NN
in_PIN
2005_CD
._.
remuneration_NOMZ
report_NN
on_PIN
pages_NN
5667_CD
._.
The_DT
report_NN
details_NN
the_DT
level_NN
Dr_NN
Barry_NN
Price_NN
chaired_VBD
the_DT
Remuneration_NOMZ
Committee_NN
throughout_PIN
the_DT
of_PIN
remuneration_NOMZ
for_PIN
Directors_NN
and_CC
the_DT
basis_NN
upon_PIN
which_WDT [PIRE]
executive_JJ
year_NN
and_PHC
Mr_NN
Robin_NN
Buchanan_NN
and_PHC
Mr_NN
Ronald_NN
Nordmann_NN
were_VBD
members_NN
remuneration_NOMZ
is_VPRT [PASS]
determined_VBN [SUAV] [PRIV]
._.
All_QUAN
members_NN
attended_VBD
all_QUAN
meetings_GER
._.
For_PIN
further_JJ
information_NOMZ
about_IN
the_DT
Remuneration_NOMZ
Committee_NN
,_,
its_PIT
membership_NN
and_PHC
activities_NOMZ
for_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
,_,
please_VB
refer_VPRT
to_PIN
the_DT
Directors_NN
remuneration_NOMZ
report_NN
on_PIN
pages_NN
5667_CD
._.
72_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
73_CD
Corporate_JJ
governance_NN
statements_NOMZ
Relations_NOMZ
with_PIN
shareholders_NN
The_DT
Board_NN
receives_VPRT
advice_NN
and_PHC
information_NOMZ
from_PIN
the_DT
Corporate_JJ
The_DT
Company_NN
is_VPRT [PASS]
committed_VBN
to_TO
maintaining_VBG [PUBV]
constructive_JJ
relationships_NN
Responsibility_NOMZ
Committee_NN
CR_NN
Committee_NN
to_TO
make_VB
this_DEMO
assessment_NOMZ
._.
The_DT
CR_NN
Committee_NN
,_,
which_WDT [SERE]
is_VPRT [BYPA]
chaired_VBN
by_PIN
the_DT
Chief_NN
Financial_NN
Officer_NN
,_,
meets_VPRT
three_CD
times_NN
a_DT
year_NN
and_CC
is_VPRT [BEMA]
responsible_PRED
for_PIN
setting_VBG
the_DT
policies_NN
The_DT
Company_NN
announces_VPRT [PUBV]
its_PIT
financial_JJ
results_NN
quarterly_RB
._.
The_DT
Chief_NN
and_PHC
procedures_NN
that_TSUB
manage_VPRT
SEE_VB [PRIV]
issues_NN
,_,
risks_NN
and_PHC
opportunities_NOMZ
._.
Executive_NN
Officer_NN
and_PHC
Chief_NN
Financial_NN
Officer_NN
give_VPRT
presentations_NOMZ
SEE_VB [PRIV] [THATD]
risks_NN
are_VPRT [PASS]
managed_VBN
within_PIN
the_DT
overall_JJ
framework_NN
of_PIN
risk_NN
on_PIN
the_DT
results_NN
each_QUAN
quarter_NN
by_PIN
teleconference_NN
for_PIN
institutional_JJ
investors_NN
,_,
management_NOMZ
,_,
explained_VBD [PUBV]
below_PLACE
under_IN
the_DT
heading_VBG
internal_JJ
control_NN
._.
The_DT
full-year_JJ
results_NN
under_IN
US_FPP1
GAAP_NN
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
Companys_NN
Annual_JJ
Review_NN
,_,
along_IN
with_PIN
a_DT
summary_NN
This_DEMO
year_NN
the_DT
Company_NN
has_VPRT [SPAU] [PEAS]
again_TIME
decided_VBN [SUAV] [PRIV]
to_TO
produce_VB
a_DT
stand-alone_JJ
financial_JJ
statement_NOMZ
of_PIN
the_DT
Companys_NN
results_NN
under_IN
International_NN
report_NN
on_PIN
Corporate_JJ
Responsibility_NOMZ
._.
This_DEMP
is_VPRT [BEMA]
available_PRED
on_PIN
request_NN
or_CC
Financial_JJ
Reporting_GER
Standards_NN
IFRS_NN
._.
Full_NN
IFRS_NN
results_NN
are_VPRT [PASS]
included_VBN
from_PIN
the_DT
Shire_NN
website_NN
._.
in_PIN
the_DT
Companys_NN
Annual_JJ
Report_NN
._.
As_IN
the_DT
Company_NN
has_VPRT [PEAS]
securities_NOMZ
listed_VBN [WZPAST]
on_PIN
NASDAQ_NN
in_PIN
the_DT
US_FPP1
,_,
the_DT
Company_NN
also_RB
files_VPRT
quarterly_JJ
reports_NN
on_PIN
Code_NN
of_PIN
Ethics_NN
Form_NN
10-Q_NN
and_CC
an_DT
annual_JJ
report_NN
on_PIN
Form_NN
10-K_NN
with_PIN
the_DT
US_FPP1
Securities_NOMZ
The_DT
Company_NN
is_VPRT [PASS]
committed_VBN
to_PIN
the_DT
maintenance_NN
of_PIN
high_JJ
ethical_JJ
and_CC
Exchange_NN
Commission_NN
SEC_NN
._.
standards_NN
in_PIN
its_PIT
dealings_GER
with_PIN
all_QUAN
persons_NN
with_PIN
whom_WP [PIRE]
it_PIT
is_VPRT [PASS]
involved_VBN
._.
The_DT
Companys_NN
Code_NN
of_PIN
Ethics_NN
applies_VPRT
to_PIN
all_QUAN
Directors_NN
and_CC
The_DT
Chief_NN
Executive_NN
Officer_NN
and_CC
the_DT
Chief_NN
Financial_NN
Officer_NN
,_,
supported_VBD
employees_NN
and_CC
is_VPRT [BEMA]
available_PRED
for_PIN
review_NN
on_PIN
the_DT
Companys_NN
website_NN
._.
by_PIN
other_JJ
senior_JJ
executives_NN
,_,
also_RB
arrange_VPRT [SUAV]
individual_JJ
and_CC
group_NN
meetings_GER
with_PIN
major_JJ
shareholders_NN
throughout_PIN
the_DT
year_NN
to_TO
discuss_VB
the_DT
Companys_NN
Dividends_NN
strategy_NN
and_PHC
performance_NN
and_CC
to_TO
understand_VB [PRIV]
the_DT
views_NN
of_PIN
major_JJ
The_DT
Company_NN
commenced_VBD
the_DT
payment_NOMZ
of_PIN
a_DT
semi-annual_JJ
dividend_NN
shareholders_NN
,_,
which_WDT [SERE]
are_VPRT [SPAU] [PASS]
then_RB
communicated_VBN
to_PIN
the_DT
Board_NN
as_IN
a_DT
whole_NN
._.
in_PIN
2004_CD
with_PIN
the_DT
aim_NN
to_TO
grow_VB
the_DT
total_JJ
dividend_NN
paid_VBN [WZPAST]
for_PIN
each_QUAN
year_NN
The_DT
Chairman_NN
and_CC
the_DT
Senior_JJ
Independent_NN
Non-executive_JJ
Director_NN
progressively_RB
._.
As_CONJ
a_NULL
result_NULL
of_PIN
the_DT
adoption_NOMZ
of_PIN
this_DEMO
dividend_NN
policy_NN
,_,
are_VPRT [BEMA]
available_JJ
also_RB
to_TO
meet_VB
with_PIN
major_JJ
shareholders_NN
._.
the_DT
Company_NN
intends_VPRT [SUAV]
to_TO
declare_VB [PUBV]
interim_JJ
dividends_NN
twice_RB
per_PIN
year_NN
,_,
with_PIN
the_DT
first_JJ
payment_NOMZ
made_VBN
around_PLACE
September_NN
October_NN
,_,
following_VBG [PRESP]
The_DT
Companys_NN
website_NN
at_PIN
www_NN
._.
com_NN
provides_VPRT
information_NOMZ
determination_NOMZ
of_PIN
first-half_JJ
results_NN
,_,
and_ANDC
the_DT
second_JJ
payment_NOMZ
around_PLACE
about_IN
the_DT
Company_NN
and_CC
its_PIT
business_NOMZ
and_CC
is_VPRT [SPAU] [PASS]
regularly_RB
updated_VBN
._.
April_NN
May_POMD
of_PIN
each_QUAN
year_NN
,_,
following_VBG
finalization_NOMZ
of_PIN
the_DT
full-year_JJ
results_NN
._.
The_DT
Companys_NN
Investor_NN
Relations_NOMZ
department_NOMZ
acts_VPRT
as_IN
a_DT
contact_NN
The_DT
Company_NN
does_VPRT
not_XX0
intend_VB [SUAV]
to_TO
put_VB
a_DT
resolution_NOMZ
to_PIN
shareholders_NN
to_TO
point_VB
for_PIN
investors_NN
throughout_PIN
the_DT
year_NN
._.
approve_VB
a_DT
final_JJ
dividend_NN
at_PIN
the_DT
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
which_WDT
is_VPRT [PASS]
held_VBN [PRIV]
in_PIN
June_NN
each_QUAN
year_NN
because_CAUS
if_COND
the_DT
Company_NN
was_VBD
to_TO
delay_VB
payment_NOMZ
The_DT
Company_NN
holds_VPRT [PRIV] [THATD]
its_PIT
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
in_PIN
London_NN
._.
At_PIN
the_DT
of_PIN
the_DT
second-half_JJ
final_JJ
dividend_NN
,_,
by_PIN
seeking_VBG
shareholder_NN
approval_NN
for_PIN
annual_JJ
meeting_GER
,_,
a_DT
business_NOMZ
presentation_NOMZ
is_VPRT [PASS]
made_VBN
to_PIN
shareholders_NN
the_DT
payment_NOMZ
at_PIN
the_DT
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
,_,
the_DT
Company_NN
would_PRMD
not_XX0
and_CC
shareholders_NN
are_VPRT [PASS]
given_VBN
the_DT
opportunity_NOMZ
to_TO
ask_VB [SUAV]
questions_NOMZ
of_PIN
the_DT
be_VB [BEMA]
able_PRED
to_TO
maintain_VB [PUBV]
an_DT
even_JJ
payment_NOMZ
cycle_NN
at_PIN
approximately_RB
six-month_JJ
Directors_NN
._.
The_DT
Directors_NN
also_RB
make_VPRT
themselves_TPP3
available_JJ
informally_RB
intervals_NN
unless_COND
first-half_JJ
dividend_NN
payments_NOMZ
were_VBD [SPAU] [PASS]
also_RB
delayed_VBN
._.
This_DEMP
is_VPRT
after_IN
the_DT
meeting_GER
to_TO
answer_VB
questions_NOMZ
from_PIN
shareholders_NN
._.
beneficial_JJ
for_PIN
the_DT
Company_NN
,_,
both_DT
from_PIN
a_DT
cash_NN
flow_NN
planning_GER
and_CC
from_PIN
an_DT
accounting_GER
perspective_NN
and_CC
is_VPRT [BEMA]
beneficial_PRED
for_PIN
shareholders_NN
as_IN
dividends_NN
Balanced_JJ
and_PHC
timely_JJ
assessment_NOMZ
of_PIN
positions_NOMZ
and_PHC
prospects_NN
are_VPRT [PASS]
paid_VBN
promptly_RB
and_CC
a_DT
smooth_JJ
payment_NOMZ
cycle_NN
is_VPRT [PASS]
maintained_VBN [PUBV]
._.
The_DT
Company_NN
strives_VPRT
to_TO
give_VB
timely_JJ
assessments_NOMZ
of_PIN
matters_NN
that_TSUB
impact_VPRT
on_PIN
its_PIT
business_NOMZ
and_CC
financial_JJ
position_NOMZ
and_CC
to_TO
present_VB
scientific_JJ
Donations_NOMZ
to_PIN
Political_NN
Organizations_NOMZ
and_PHC
EU_NN
Political_NN
Expenditure_NN
and_CC
other_JJ
information_NOMZ
in_PIN
a_DT
balanced_JJ
way_NN
._.
At_PIN
the_DT
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
in_PIN
June_NN
2005_CD
,_,
shareholders_NN
authorized_VBD
the_DT
Company_NN
to_TO
make_VB
donations_NOMZ
to_PIN
EU_NN
Political_NN
Organizations_NOMZ
and_PHC
Corporate_NN
Responsibility_NOMZ
CR_NN
to_TO
incur_VB
EU_NN
Political_NN
Expenditure_NN
,_,
under_IN
the_DT
provisions_NN
of_PIN
the_DT
Political_NN
The_NN
Company_NN
recognizes_VPRT [PRIV]
the_DT
impact_NN
that_TOBJ
its_PIT
business_NOMZ
may_POMD
have_VB
on_PIN
Parties_NN
,_,
Elections_NOMZ
and_PHC
Referendums_NN
Act_NN
2000_CD
,_,
of_PIN
up_RB
to_PIN
25,000_CD
,_,
people_NN
and_CC
the_DT
environment_NOMZ
as_RB
well_RB
as_IN
the_DT
wider_JJ
implications_NOMZ
of_PIN
its_PIT
equivalent_JJ
to_TO
$_$
45,525_CD
at_PIN
average_JJ
2005_CD
exchange_NN
rates_NN
respectively_RB
,_,
operations_NOMZ
on_PIN
the_DT
general_JJ
community_NOMZ
._.
The_DT
Company_NN
therefore_CONJ
attaches_VPRT
each_QUAN
year_NN
._.
Although_CONC
the_DT
Company_NN
does_VPRT
not_XX0
make_VB
and_PHC
does_VPRT
not_XX0
intend_VB [SUAV]
great_JJ
importance_NN
to_PIN
social_JJ
and_PHC
environmental_JJ
issues_NN
and_CC
to_PIN
ethical_JJ
to_TO
make_VB
payments_NOMZ
or_CC
donations_NOMZ
to_PIN
EU_NN
political_JJ
parties_NN
,_,
within_PIN
the_DT
business_NOMZ
practices_NN
._.
Accordingly_RB
,_,
ultimate_JJ
responsibility_NOMZ
for_PIN
them_TPP3
is_VPRT [BEMA]
normal_JJ
meaning_GER
of_PIN
that_DEMO
expression_NN
,_,
the_DT
definition_NOMZ
in_PIN
the_DT
legislation_NOMZ
taken_VBN [WZPAST]
at_PIN
the_DT
highest_JJ
levels_NN
._.
The_DT
Board_NN
reviews_VPRT
the_DT
Companys_NN
general_NN
of_PIN
EU_NN
Political_NN
Organization_NOMZ
is_VPRT [BEMA]
wide_PRED
._.
It_PIT
can_POMD
extend_VB
to_PIN
bodies_NN
which_WDT [WHSUB]
approach_VPRT
to_PIN
corporate_JJ
responsibility_NOMZ
._.
The_DT
Board_NN
also_RB
reviews_VPRT
the_DT
the_DT
Company_NN
might_POMD
wish_VB
to_TO
support_VB
including_VBG
those_DEMO
concerned_JJ
specific_JJ
business_NOMZ
risks_NN
related_VBN [WZPAST]
to_PIN
Social_NN
,_,
Environmental_NN
and_PHC
Ethical_NN
with_PIN
policy_NN
review_NN
and_PHC
law_NN
reform_NN
._.
The_DT
Company_NN
made_VBD
no_SYNE
donations_NOMZ
SEE_VPRT [PRIV]
matters_NN
annually_RB
._.
to_PIN
either_DT
EU_NN
or_CC
non-EU_NN
Political_NN
Organizations_NOMZ
during_PIN
2005_CD
._.
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
73_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
74_CD
Corporate_JJ
governance_NN
statements_NOMZ
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
2006_CD
On_PIN
behalf_NN
of_PIN
the_DT
Board_NN
,_,
the_DT
Audit_NN
Committee_NN
has_VPRT
the_DT
responsibility_NOMZ
for_PIN
The_DT
2006_CD
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
will_PRMD
be_VB [PASS]
held_VBN [PRIV]
on_PIN
Wednesday_NN
,_,
June_NN
21_CD
,_,
reviewing_VBG [PRESP]
the_DT
effectiveness_NOMZ
of_PIN
the_DT
system_NN
of_PIN
internal_JJ
financial_JJ
controls_NN
2006_CD
._.
The_DT
business_NOMZ
to_TO
be_VB [PASS]
transacted_VBN
at_PIN
the_DT
meeting_GER
will_PRMD
include_VB
:_:
and_ANDC
the_DT
audit_NN
process_NN
._.
The_DT
Audit_NN
Committee_NN
has_VPRT
independent_JJ
access_NN
to_PIN
the_DT
auditor_NN
throughout_PIN
the_DT
year_NN
in_CONJ
addition_NULL
to_PIN
presentations_NOMZ
from_PIN
the_DT
receiving_VBG
the_DT
Companys_NN
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
auditor_NN
on_PIN
a_DT
quarterly_JJ
basis_NN
._.
Any_QUAN
significant_JJ
findings_GER
or_CC
identified_VBN
risks_NN
2005_CD
,_,
together_RB
with_PIN
the_DT
Directors_NN
Report_NN
,_,
Remuneration_NOMZ
Report_NN
are_VPRT [SPAU] [PASS]
closely_RB
examined_VBN
and_PHC
are_VPRT [PASS]
reported_VBN [PUBV]
to_PIN
the_DT
Board_NN
with_PIN
and_CC
the_DT
Auditors_NN
Report_VPRT [PUBV]
on_PIN
those_DEMO
accounts_NN
and_CC
the_DT
auditable_JJ
part_NN
recommendations_NOMZ
for_PIN
action_NOMZ
._.
of_PIN
the_DT
Remuneration_NOMZ
Report_NN
:_:
The_DT
Company_NN
has_VPRT [PEAS]
established_VBN [PRIV]
a_DT
Disclosure_NN
Committee_NN
,_,
which_WDT [SERE]
approving_VBG
the_DT
2005_CD
Directors_NN
remuneration_JJ
report_NN
:_:
is_VPRT [BYPA]
chaired_VBN
by_PIN
the_DT
Chief_NN
Financial_NN
Officer_NN
._.
Its_PIT
membership_NN
includes_VPRT
senior_JJ
managers_NN
from_PIN
the_DT
legal_JJ
,_,
finance_NN
and_PHC
risk_NN
departments_NOMZ
._.
electing_VBG [PRESP]
each_QUAN
of_PIN
Dr_NN
James_NN
Cavanaugh_NN
,_,
Mr_NN
Matthew_NN
Emmens_NN
,_,
Its_PIT
responsibilities_NOMZ
include_VPRT
ensuring_VBG [SUAV] [PRIV]
that_THVC
information_NOMZ
disclosed_VBD [PUBV]
Mr_NN
Angus_NN
Russell_NN
,_,
Mr_NN
Robin_NN
Buchanan_NN
,_,
The_DT
Hon_NN
James_NN
Grant_NN
,_,
to_PIN
investors_NN
in_PIN
the_DT
Companys_NN
periodic_JJ
financial_JJ
reports_NN
is_VPRT [PASS]
recorded_VBN
,_,
Mr_NN
David_NN
Kappler_NN
,_,
Mr_NN
Ronald_NN
Nordmann_NN
,_,
Dr_NN
Barry_NN
Price_NN
and_CC
summarized_VBN
and_PHC
reported_VBN [PUBV]
accurately_RB
._.
Mr_NN
Patrick_NN
Langlois_NN
to_PIN
the_DT
Board_NN
:_:
Following_VBG [PRESP]
the_DT
enactment_NOMZ
of_PIN
the_DT
Sarbanes-Oxley_NN
Act_NN
2002_CD
in_PIN
the_DT
re-appointing_JJ
Deloitte_NN
&_CC
Touche_NN
LLP_NN
as_IN
auditors_NN
and_CC
authorizing_VBG
United_NN
States_NN
,_,
the_DT
Chief_NN
Executive_NN
Officer_NN
and_CC
the_DT
Chief_NN
Financial_NN
the_DT
Audit_NN
Committee_NN
to_TO
approve_VB
their_TPP3
remuneration_NOMZ
:_:
Officer_NN
are_VPRT [PASS]
required_VBN [SUAV]
to_TO
complete_VB
formal_JJ
certifications_NOMZ
,_,
which_WDT [SERE]
confirm_VPRT [PUBV]
,_,
inter_VPRT
alia_NN
,_,
that_DEMP
:_:
giving_VBG [PRESP]
the_DT
Directors_NN
the_DT
authority_NOMZ
to_TO
disapply_VB
pre-emption_JJ
rights_NN
when_RB
allotting_VBG
new_JJ
shares_NN
in_PIN
certain_JJ
circumstances_NN
:_:
the_DT
annual_JJ
report_NN
on_PIN
Form_NN
10-K_NN
in_PIN
the_DT
United_NN
States_NN
does_VPRT
not_XX0
contain_VB
any_QUAN
material_NN
misstatements_NOMZ
or_CC
omissions_NN
:_:
giving_VBG
authority_NOMZ
to_PIN
the_DT
Company_NN
to_TO
make_VB
limited_JJ
donations_NOMZ
to_PIN
EU_NN
political_JJ
organizations_NOMZ
and_CC
to_TO
incur_VB
limited_JJ
EU_NN
political_JJ
financial_JJ
information_NOMZ
reported_VBN [PUBV] [WZPAST]
in_PIN
Form_NN
10-K_JJ
fairly_RB
presents_VPRT
the_DT
financial_JJ
expenditure_NN
:_:
and_ANDC
condition_NOMZ
,_,
results_NN
of_PIN
operations_NOMZ
and_PHC
cash_NN
flows_NN
of_PIN
the_DT
Company_NN
:_:
authorizing_VBG [PRESP]
the_DT
Company_NN
to_TO
make_VB
market_NN
purchases_NN
of_PIN
up_IN
the_DT
Chief_NN
Executive_NN
Officer_NN
and_CC
the_DT
Chief_NN
Financial_NN
Officer_NN
are_VPRT [BEMA]
to_PIN
10_CD
%_NN
of_PIN
the_DT
Companys_NN
issued_VBD
share_NN
capital_NN
._.
responsible_JJ
for_PIN
determining_VBG [SUAV] [PRIV]
and_PHC
maintaining_VBG [PUBV]
disclosure_NN
controls_NN
and_PHC
procedures_NN
for_PIN
the_DT
purposes_NN
of_PIN
financial_JJ
reporting_GER
in_PIN
the_DT
United_NN
States_NN
:_:
Financial_NN
disclosure_NN
,_,
internal_JJ
control_NN
and_CC
the_DT
role_NN
of_PIN
the_DT
auditors_NN
The_DT
Board_NN
has_VPRT
,_,
through_PIN
the_DT
Audit_NN
Committee_NN
,_,
established_VBD [PRIV]
formal_JJ
the_DT
Chief_NN
Executive_NN
Officer_NN
and_CC
the_DT
Chief_NN
Financial_NN
Officer_NN
and_CC
transparent_JJ
arrangements_NOMZ
for_PIN
financial_JJ
reporting_GER
,_,
internal_JJ
control_NN
have_VPRT [PEAS]
evaluated_VBN
the_DT
effectiveness_NOMZ
of_PIN
those_DEMO
disclosure_NN
controls_NN
and_CC
external_JJ
auditing_GER
._.
The_DT
Audit_NN
Committees_NN
terms_NN
of_PIN
reference_NN
extend_VPRT
and_CC
procedures_NN
:_:
to_PIN
the_DT
Companys_NN
risk_NN
management_NOMZ
activities_NOMZ
as_IN
a_DT
whole_JJ
and_CC
not_XX0
just_EMPH
the_DT
financial_JJ
aspects_NN
of_PIN
internal_JJ
control_NN
._.
the_DT
Chief_NN
Executive_NN
Officer_NN
and_CC
the_DT
Chief_NN
Financial_NN
Officer_NN
have_VPRT [PEAS]
indicated_VBN [PRIV]
in_PIN
Form_NN
10-K_JJ
whether_IN
there_EX
were_VBD
any_QUAN
significant_JJ
changes_NN
All_QUAN
employees_NN
can_POMD
raise_VB
any_QUAN
concerns_NN
in_PIN
any_QUAN
of_PIN
these_DEMO
areas_NN
with_PIN
in_PIN
the_DT
Companys_NN
internal_JJ
control_NN
over_IN
financial_JJ
reporting_GER
:_:
and_ANDC
the_DT
Chairman_NN
of_PIN
the_DT
Audit_NN
Committee_NN
in_PIN
the_DT
strictest_JJ
confidence_NN
._.
The_DT
Company_NN
operates_VPRT
a_DT
Global_JJ
Compliance_NN
Helpline_NN
,_,
which_WDT [SERE]
provides_VPRT
based_VBN
on_PIN
the_DT
evaluation_NOMZ
of_PIN
the_DT
Chief_NN
Executive_NN
Officer_NN
and_CC
the_DT
a_DT
confidential_JJ
means_NN
through_PIN
which_WDT [PIRE]
all_QUAN
employees_NN
are_VPRT [BEMA]
able_PRED
to_TO
report_VB [PUBV]
Chief_NN
Financial_NN
Officer_NN
,_,
all_QUAN
significant_JJ
deficiencies_NN
and_PHC
material_NN
concerns_NN
relating_VBG [WZPRES]
to_PIN
financial_JJ
disclosure_NN
,_,
internal_JJ
control_NN
and_CC
other_JJ
weaknesses_NOMZ
in_PIN
the_DT
design_NN
or_CC
operation_NOMZ
of_PIN
internal_JJ
control_NN
over_IN
compliance_NN
issues_NN
in_PIN
good_JJ
faith_NN
without_PIN
fear_NN
of_PIN
discrimination_NOMZ
or_CC
reprisal_NN
._.
financial_JJ
reporting_GER
which_WDT [WHSUB]
are_VPRT [BEMA]
reasonably_RB
likely_PRED
to_TO
affect_VB
adversely_RB
the_DT
Companys_NN
ability_NOMZ
to_PIN
record_NN
,_,
process_NN
,_,
summarize_VB
and_PHC
report_VB [PUBV] [THATD]
1_CD
Financial_NN
reporting_VBG [PUBV] [THATD] [WZPRES]
financial_JJ
information_NOMZ
included_VBD
in_PIN
Form_NN
10-K_NN
have_VPRT [PEAS]
been_VBN [PASS]
disclosed_VBN [PUBV] [THATD]
The_DT
Board_NN
has_VPRT
ultimate_JJ
responsibility_NOMZ
for_PIN
the_DT
preparation_NOMZ
of_PIN
accounts_NN
to_PIN
the_DT
Companys_NN
auditors_NN
._.
and_ANDC
for_PIN
the_DT
monitoring_GER
of_PIN
systems_NN
of_PIN
internal_JJ
financial_JJ
control_NN
._.
The_DT
Board_NN
strives_VPRT
to_TO
present_VB
a_DT
balanced_JJ
and_PHC
understandable_JJ
assessment_NOMZ
The_DT
Chief_NN
Executive_NN
Officer_NN
and_CC
the_DT
Chief_NN
Financial_NN
Officer_NN
have_VPRT
of_PIN
the_DT
Companys_NN
position_NOMZ
and_CC
its_PIT
prospects_NN
and_PHC
endeavors_NN
to_TO
present_VB
completed_VBN
these_DEMO
certifications_NOMZ
and_CC
they_TPP3
have_VPRT [PEAS]
been_VBN [PASS]
filed_VBN
with_PIN
the_DT
SEC_NN
scientific_JJ
and_PHC
other_JJ
information_NOMZ
in_PIN
a_DT
balanced_JJ
way_NN
._.
The_DT
Company_NN
in_PIN
the_DT
United_NN
States_NN
as_IN
part_NN
of_PIN
the_DT
Companys_NN
annual_JJ
report_NN
in_PIN
the_DT
publishes_VPRT
quarterly_JJ
financial_JJ
reports_NN
so_OSUB
that_NULL
its_PIT
shareholders_NN
can_POMD
United_NN
States_NN
on_PIN
Form_NN
10-K_NN
._.
monitor_NN
the_DT
Companys_NN
financial_JJ
position_NOMZ
regularly_RB
._.
74_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
75_CD
Corporate_JJ
governance_NN
statements_NOMZ
2_CD
Risk_NN
management_NOMZ
,_,
compliance_NN
and_CC
internal_JJ
control_NN
iv_VBD
a_DT
range_NN
of_PIN
corporate_JJ
policies_NN
and_PHC
procedures_NN
have_VPRT [PEAS]
been_VBN [BEMA]
The_DT
Board_NN
,_,
in_PIN
accordance_NN
with_PIN
the_DT
Turnbull_NN
Guidance_NN
on_PIN
internal_JJ
implemented_VBN
:_:
control_NN
,_,
recognizes_VPRT [PRIV]
its_PIT
overall_JJ
responsibility_NOMZ
to_TO
maintain_VB [PUBV]
a_DT
sound_JJ
system_NN
of_PIN
internal_JJ
control_NN
to_TO
safeguard_VB
shareholders_NN
investments_NOMZ
and_CC
the_DT
v_NN
the_DT
internal_JJ
audit_NN
department_NOMZ
,_,
overseen_VBN [PASTP]
by_PIN
the_DT
Vice_NN
President_NN
Companys_NN
assets_NN
and_CC
to_TO [SPIN]
regularly_RB
review_VB
its_PIT
effectiveness_NOMZ
._.
Whilst_OSUB
the_DT
Internal_NN
Audit_NN
,_,
carries_VPRT
out_PIN
regular_JJ
reviews_NN
of_PIN
control_NN
activities_NOMZ
and_PHC
Board_NN
acknowledges_VPRT [PUBV]
its_PIT
responsibility_NOMZ
for_PIN
the_DT
system_NN
of_PIN
internal_JJ
control_NN
,_,
reports_NN
findings_GER
to_PIN
management_NOMZ
:_:
and_ANDC
there_EX
are_VPRT
limitations_NOMZ
in_PIN
any_QUAN
system_NN
of_PIN
internal_JJ
control_NN
and_CC
accordingly_RB
even_RB
the_DT
most_EMPH
effective_JJ
system_NN
can_POMD
provide_VB
only_DWNT
reasonable_JJ
and_CC
not_XX0
vi_VB
the_DT
Audit_NN
Committee_NN
considers_VPRT [PRIV]
the_DT
major_JJ
findings_GER
of_PIN
any_QUAN
internal_JJ
absolute_JJ
assurance_NN
._.
Such_EMPH
a_NULL
system_NN
is_VPRT [PASS]
designed_VBN
to_TO
manage_VB
rather_RB
than_PIN
investigations_NOMZ
and_PHC
managements_NOMZ
response_NN
to_PIN
them_TPP3
._.
The_DT
Audit_NN
eliminate_VB
the_DT
risk_NN
of_PIN
failure_NN
to_TO
achieve_VB
business_NOMZ
objectives_NN
and_CC
can_POMD
Committee_NN
reports_NN
annually_RB
to_PIN
the_DT
Board_NN
on_PIN
the_DT
effectiveness_NOMZ
of_PIN
the_DT
provide_VPRT
only_DWNT
reasonable_JJ
and_CC
not_XX0
absolute_JJ
assurance_NN
against_PIN
material_NN
Companys_NN
control_VPRT
environment_NOMZ
._.
Effective_JJ
identification_NOMZ
,_,
assessment_NOMZ
and_PHC
management_NOMZ
of_PIN
risks_NN
The_DT
Board_NN
has_VPRT [PEAS]
reviewed_VBN
both_DT
the_DT
key_JJ
risks_NN
faced_VBN [WZPAST]
by_PIN
the_DT
Company_NN
and_CC
The_DT
management_NOMZ
of_PIN
business_NOMZ
risk_NN
is_VPRT [BEMA]
essential_PRED
for_PIN
ensuring_VBG [SUAV] [PRIV]
that_THVC
the_DT
the_DT
effectiveness_NOMZ
of_PIN
the_DT
Companys_NN
internal_JJ
control_NN
systems_NN
in_PIN
2005_CD
._.
Company_NN
creates_VPRT
and_PHC
preserves_VPRT
shareholder_NN
value_NN
._.
Accordingly_RB
,_,
Outside_PLACE
of_PIN
its_PIT
review_NN
,_,
the_DT
Board_NN
delegates_NN
responsibility_NOMZ
to_PIN
the_DT
Audit_NN
the_DT
Company_NN
has_VPRT
an_DT
ongoing_JJ
process_NN
for_PIN
identifying_VBG
,_,
evaluating_VBG
and_CC
Committee_NN
for_PIN
more_EMPH
regular_JJ
review_NN
of_PIN
both_DT
key_JJ
risks_NN
and_CC
internal_JJ
managing_VBG
the_DT
significant_JJ
risks_NN
that_TOBJ
it_PIT
faces_VPRT
._.
This_DEMO
process_NN
has_VPRT [PEAS]
been_VBN
controls_NN
and_CC
for_PIN
monitoring_VBG
the_DT
activities_NOMZ
of_PIN
the_DT
internal_JJ
audit_NN
function_NOMZ
._.
in_PIN
operation_NOMZ
throughout_PIN
the_DT
period_NN
under_IN
review_NN
and_CC
up_RB
to_PIN
the_DT
date_NN
The_DT
Audit_NN
Committee_NN
has_VPRT [PEAS]
kept_VBN
these_DEMO
areas_NN
under_IN
review_NN
in_PIN
2005_CD
._.
of_PIN
the_DT
signing_GER
of_PIN
the_DT
accounts_NN
._.
All_QUAN
risks_NN
are_VPRT [PASS]
recorded_VBN
on_PIN
a_DT
corporate_JJ
risk_NN
schedule_NN
which_WDT [WHSUB]
allocates_VPRT
specific_JJ
responsibility_NOMZ
to_PIN
members_NN
The_DT
Company_NN
has_VPRT
risk_NN
management_NOMZ
,_,
compliance_NN
and_CC
internal_JJ
audit_NN
of_PIN
the_DT
Executive_NN
Committee_NN
._.
This_DEMO
schedule_NN
has_VPRT [PEAS]
been_VBN [PASS]
reviewed_VBN
functions_NOMZ
._.
A_DT
Chief_NN
Compliance_NN
Officer_NN
was_VBD [PASS]
appointed_VBN
in_PIN
2005_CD
and_CC
the_DT
by_PIN
the_DT
Audit_NN
Committee_NN
during_PIN
2005_CD
._.
role_NN
of_PIN
Chief_NN
Risk_NN
Officer_NN
combined_VBN [WZPAST]
with_PIN
it_PIT
._.
The_DT
role_NN
of_PIN
Chief_NN
Compliance_NN
and_PHC
Risk_NN
Officer_NN
and_CC
the_DT
role_NN
of_PIN
Director_NN
of_PIN
Internal_NN
Audit_NN
,_,
which_WDT [SERE]
Effective_NN
internal_JJ
control_NN
procedures_NN
are_VPRT [BEMA]
separate_PRED
,_,
report_NN
to_PIN
the_DT
Chief_NN
Executive_NN
Officer_NN
and_PHC
Chief_NN
Financial_NN
The_NN
Company_NN
has_VPRT
a_DT
system_NN
of_PIN
control_NN
procedures_NN
._.
Compliance_NN
with_PIN
Officer_NN
,_,
respectively_RB
,_,
but_CC
each_QUAN
have_VPRT
direct_JJ
access_NN
to_PIN
the_DT
Chairman_NN
,_,
these_DEMO
procedures_NN
is_VPRT [PASS]
monitored_VBN
through_PIN
a_DT
system_NN
of_PIN
internal_JJ
review_NN
and_CC
the_DT
Chairman_NN
of_PIN
the_DT
Audit_NN
Committee_NN
and_CC
the_DT
other_JJ
members_NN
of_PIN
the_DT
regular_JJ
reports_NN
on_PIN
financial_JJ
performance_NN
._.
Any_QUAN
significant_JJ
issues_NN
arising_VBG [WZPRES]
Audit_NN
Committee_NN
._.
They_TPP3
also_RB
both_DT
attend_VB
and_PHC
present_VB
regularly_RB
at_PIN
Audit_NN
are_VPRT [PASS]
reported_VBN [PUBV]
to_PIN
the_DT
Audit_NN
Committee_NN
._.
During_PIN
2005_CD
,_,
the_DT
Company_NN
has_VPRT
Committee_NN
meetings_GER
._.
made_VBD
a_DT
significant_JJ
investment_NOMZ
in_PIN
its_PIT
internal_JJ
financial_JJ
control_NN
procedures_NN
as_IN
part_NN
of_PIN
its_PIT
compliance_NN
with_PIN
s404_CD
Sarbanes-Oxley_NN
Act_NN
requirements_NOMZ
._.
The_DT
Companys_NN
risk_NN
management_NOMZ
,_,
compliance_NN
and_CC
internal_JJ
audit_NN
This_DEMP
has_VPRT [PEAS]
included_VBN
the_DT
review_NN
,_,
documentation_NOMZ
and_PHC
testing_GER
of_PIN
all_QUAN
key_JJ
strategy_NN
is_VPRT [PASS]
based_VBN
on_PIN
a_DT
risk_NN
and_PHC
control_NN
framework_NN
containing_VBG [WZPRES]
the_DT
internal_JJ
financial_JJ
controls_NN
._.
The_DT
conclusion_NN
of_PIN
this_DEMO
exercise_NN
is_VPRT
that_DEMP
following_VBG
key_JJ
elements_NOMZ
:_:
the_DT
Company_NN
had_VBD
an_DT
effective_JJ
system_NN
of_PIN
internal_JJ
controls_NN
over_IN
its_PIT
US_FPP1
GAAP_NN
Form_NN
10-K_JJ
financial_JJ
reporting_GER
at_PIN
December_NN
31_CD
,_,
2005_CD
._.
an_DT
effective_JJ
control_NN
environment_NOMZ
:_:
Effective_JJ
internal_JJ
audit_NN
an_DT
effective_JJ
process_NN
to_TO
identify_VB
,_,
assess_VB
and_PHC
manage_VB
risks_NN
:_:
The_DT
internal_JJ
review_NN
of_PIN
the_DT
Companys_NN
control_VPRT
procedures_NN
and_PHC
compliance_NN
with_PIN
them_TPP3
is_VPRT [SPAU] [PASS]
mostly_RB
undertaken_VBN
through_PIN
internal_JJ
audit_NN
._.
The_DT
effective_JJ
internal_JJ
control_NN
procedures_NN
:_:
and_ANDC
Audit_NN
Committee_NN
monitors_VPRT
and_PHC
reviews_VPRT
the_DT
internal_JJ
audit_NN
program_NN
,_,
considers_VPRT [PRIV]
the_DT
findings_GER
of_PIN
internal_JJ
audit_NN
reviews_NN
and_PHC
managements_NOMZ
effective_JJ
internal_JJ
audit_NN
._.
response_NN
to_PIN
them_TPP3
,_,
and_ANDC
ensures_VPRT [SUAV] [PRIV]
efficient_JJ
co-ordination_NOMZ
between_PIN
the_DT
Companys_NN
internal_JJ
and_PHC
external_JJ
auditors_NN
._.
The_DT
Companys_NN
internal_JJ
audit_NN
Effective_JJ
control_NN
environment_NOMZ
function_NOMZ
,_,
comprizing_VBG [PRESP]
a_DT
mixture_NN
of_PIN
internal_JJ
and_PHC
out-sourced_JJ
resource_NN
,_,
The_DT
key_JJ
elements_NOMZ
of_PIN
the_DT
Companys_NN
control_VPRT
environment_NOMZ
are_VPRT
as_IN
follows_VPRT
:_:
was_VBD [BEMA]
operational_PRED
throughout_PIN
2005_CD
._.
The_DT
Audit_NN
Committee_NN
,_,
which_WDT [SERE]
is_VPRT [BEMA]
responsible_PRED
for_PIN
monitoring_VBG
the_DT
activity_NOMZ
of_PIN
the_DT
internal_JJ
audit_NN
function_NOMZ
,_,
i_FPP1
the_DT
Board_NN
has_VPRT
overall_JJ
responsibility_NOMZ
to_TO
maintain_VB [PUBV] [THATD]
the_DT
internal_JJ
control_NN
has_VPRT [PEAS]
reviewed_VBN
the_DT
effectiveness_NOMZ
of_PIN
the_DT
internal_JJ
audit_NN
during_PIN
2005_CD
._.
system_NN
and_CC
has_VPRT [PEAS]
delegated_VBN
certain_JJ
responsibilities_NOMZ
to_PIN
the_DT
Executive_NN
Committee_NN
and_CC
or_CC
the_DT
Audit_NN
Committee_NN
:_:
3_CD
External_NN
auditing_GER
The_DT
Audit_NN
Committee_NN
has_VPRT
the_DT
primary_JJ
responsibility_NOMZ
for_PIN
determining_VBG [SUAV] [PRIV]
ii_FW
a_DT
framework_NN
of_PIN
Corporate_JJ
Values_NN
and_CC
a_DT
Code_NN
of_PIN
Ethics_NN
which_WDT [WHSUB]
sets_VPRT
the_DT
remuneration_NOMZ
of_PIN [STPR]
,_,
and_ANDC
overseeing_VBG
the_DT
work_NN
of_PIN [STPR]
,_,
any_QUAN
accounting_GER
firm_NN
appropriate_JJ
standards_NN
of_PIN
ethical_JJ
behavior_NN
are_VPRT [BEMA]
operational_PRED
throughout_PIN
engaged_VBN
to_TO
conduct_VB
the_DT
external_JJ
audit_NN
._.
The_DT
Audit_NN
Committee_NN
assesses_VPRT
the_DT
Group_NN
:_:
at_PIN
least_JJ
annually_RB
the_DT
objectivity_NOMZ
and_PHC
independence_NN
of_PIN
the_DT
external_JJ
auditor_NN
taking_VBG [WZPRES]
into_PIN
account_NN
relevant_JJ
regulatory_JJ
requirements_NOMZ
._.
iii_FW
the_DT
internal_JJ
structure_NN
of_PIN
the_DT
organization_NOMZ
is_VPRT [SPAU] [PASS]
well_RB
documented_VBN
with_PIN
The_DT
Audit_NN
Committee_NN
reviews_VPRT
and_PHC
approves_VPRT
the_DT
annual_JJ
external_JJ
audit_NN
clear_JJ
reporting_GER
lines_NN
and_CC
clear_JJ
limits_NN
of_PIN
authority_NOMZ
for_PIN
different_JJ
matters_NN
:_:
plan_NN
each_QUAN
year_NN
and_CC
ensures_VPRT [SUAV] [PRIV] [THATD]
it_PIT
is_VPRT [BEMA]
consistent_PRED
with_PIN
the_DT
scope_NN
of_PIN
the_DT
auditors_NN
engagement_NOMZ
._.
The_DT
Audit_NN
Committee_NN
also_RB
considers_VPRT [PRIV]
whether_IN [WHCL]
the_DT
skills_NN
and_PHC
experience_NN
of_PIN
the_DT
external_JJ
audit_NN
firm_NN
make_VPRT
it_PIT
a_DT
suitable_JJ
supplier_NN
of_PIN
non-audit_JJ
services_NN
._.
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
75_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
76_CD
Corporate_JJ
governance_NN
statements_NOMZ
The_DT
Audit_NN
Committee_NN
has_VPRT [PEAS]
set_VBN
and_PHC
applies_VPRT
a_DT
formal_JJ
policy_NN
in_PIN
relation_NOMZ
The_DT
Companys_NN
management_NOMZ
assessed_VBD
the_DT
effectiveness_NOMZ
of_PIN
the_DT
to_PIN
the_DT
provision_NN
of_PIN
non-audit_JJ
services_NN
by_PIN
the_DT
external_JJ
auditor_NN
specifying_VBG [WZPRES]
Companys_NN
internal_JJ
control_NN
over_IN
financial_JJ
reporting_GER
for_PIN
the_DT
purposes_NN
of_PIN
the_DT
types_NN
of_PIN
non-audit_JJ
work_NN
:_:
the_DT
Companys_NN
Annual_JJ
Report_NN
on_PIN
Form_NN
10-K_NN
as_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
,_,
which_WDT [SERE]
was_VBD [PASS]
filed_VBN
with_PIN
the_DT
US_FPP1
Securities_NOMZ
and_PHC
Exchange_NN
Commission_NN
i_FPP1
for_PIN
which_WDT [PIRE]
the_DT
external_JJ
auditors_NN
are_VPRT [PASS]
excluded_VBN
:_:
on_PIN
March_NN
1_CD
,_,
2006_CD
._.
In_PIN
making_VBG
this_DEMO
assessment_NOMZ
,_,
the_DT
Companys_NN
management_NOMZ
used_VBD
the_DT
criteria_NN
set_VBN [WZPAST]
forth_RB
by_PIN
the_DT
Committee_NN
ii_NN
for_PIN
which_WDT [PIRE]
the_DT
external_JJ
auditors_NN
can_POMD
be_VB [PASS]
engaged_VBN
without_PIN
referral_NN
of_PIN
Sponsoring_VBG
Organizations_NOMZ
of_PIN
the_DT
Treadway_NN
Commission_NN
COSO_NN
to_PIN
the_DT
Committee_NN
:_:
and_ANDC
in_PIN
Internal_NN
Control-Integrated_NN
Framework_NN
._.
iii_NN
for_PIN
which_WDT [PIRE]
a_DT
case-by-case_JJ
decision_NN
is_VPRT [BEMA]
necessary_PRED
,_,
with_PIN
a_DT
view_NN
Based_VBN [WZPAST]
on_PIN
its_PIT
assessment_NOMZ
,_,
management_NOMZ
believes_VPRT [PRIV] [THATD]
that_DEMP
,_,
as_IN
of_PIN
to_TO
preserving_VBG
the_DT
auditors_NN
independence_NN
and_PHC
objectivity_NOMZ
._.
The_DT
Audit_NN
December_NN
31_CD
,_,
2005_CD
,_,
the_DT
Companys_NN
internal_JJ
control_NN
over_IN
financial_JJ
Committee_NN
also_RB
considers_VPRT [PRIV] [THATD]
the_DT
fees_NN
paid_VBN [WZPAST]
to_PIN
the_DT
external_JJ
auditors_NN
reporting_VBG [PUBV] [WZPRES]
is_VPRT [BEMA]
effective_PRED
based_VBN
on_PIN
those_DEMO
criteria_NN
._.
and_ANDC
whether_IN
the_DT
fee_NN
levels_NN
for_PIN
non-audit_JJ
services_NN
,_,
individually_RB
and_CC
in_PIN
aggregate_JJ
,_,
relative_JJ
to_PIN
the_DT
audit_NN
fee_NN
are_VPRT [BEMA]
appropriate_PRED
to_TO
enable_VB
Deloitte_NN
&_CC
Touche_NN
LLP_NN
,_,
an_DT
independent_JJ
registered_JJ
public_JJ
accounting_GER
a_DT
proper_JJ
audit_NN
to_TO
be_VB [PASS]
conducted_VBN
._.
firm_NN
,_,
has_VPRT [PEAS]
issued_VBN
an_DT
audit_NN
report_NN
on_PIN
managements_NOMZ
assessment_NOMZ
of_PIN
the_DT
Companys_NN
internal_JJ
control_NN
over_IN
its_PIT
Form_NN
10-K_NN
US_FPP1
GAAP_NN
financial_JJ
Going_VBG
concern_NN
basis_NN
reporting_GER
._.
The_DT
Auditors_NN
Report_NN
appears_VPRT [SMP]
on_PIN
pages_NN
F-2_NN
and_PHC
F-3_NN
After_IN
making_VBG
enquiries_NN
,_,
the_DT
Directors_NN
have_VPRT [PEAS]
formed_VBN
a_DT
judgement_NOMZ
,_,
at_PIN
the_DT
of_PIN
the_DT
Companys_NN
Annual_JJ
Report_NN
in_PIN
the_DT
United_NN
States_NN
on_PIN
Form_NN
10-K_NN
._.
time_NN
of_PIN
approving_VBG
the_DT
financial_JJ
statements_NOMZ
,_,
that_THVC
there_EX
is_VPRT
a_DT
reasonable_JJ
expectation_NOMZ
that_TOBJ
the_DT
Group_NN
has_VPRT
adequate_JJ
resources_NN
to_TO
continue_VB
in_PIN
Changes_NN
in_PIN
internal_JJ
control_NN
over_IN
financial_JJ
reporting_GER
operational_JJ
existence_NN
for_PIN
the_DT
foreseeable_JJ
future_NN
._.
For_PIN
this_DEMO
reason_NN
the_DT
In_PIN
2004_CD
,_,
the_DT
Company_NN
commenced_VBD
the_DT
implementation_NOMZ
of_PIN
a_DT
new_JJ
Directors_NN
continue_VPRT
to_TO
adopt_VB
the_DT
going_VBG
concern_NN
basis_NN
in_PIN
preparing_VBG
the_DT
integrated_VBN
information_NOMZ
system_NN
covering_VBG [WZPRES]
financial_JJ
processes_NN
,_,
production_NOMZ
,_,
financial_JJ
statements_NOMZ
._.
Further_JJ
implementations_NOMZ
were_VBD [PASS]
made_VBN
in_PIN
the_DT
fourth_JJ
quarter_NN
of_PIN
2005_CD
and_CC
more_EMPH
are_VPRT [PASS]
planned_VBN
for_PIN
2006_CD
and_CC
2007_CD
._.
Disclosure_NN
controls_NN
and_PHC
procedures_NN
The_DT
implementations_NOMZ
have_VPRT [PEAS]
involved_VBN
changes_NN
in_PIN
the_DT
Companys_NN
The_NN
Company_NN
,_,
under_IN
the_DT
supervision_NN
and_CC
with_PIN
the_DT
participation_NOMZ
of_PIN
the_DT
information_NOMZ
systems_NN
that_TSUB
included_VBD
aspects_NN
of_PIN
the_DT
Companys_NN
internal_JJ
Companys_NN
management_NOMZ
,_,
including_VBG [PRESP]
the_DT
Chief_NN
Executive_NN
Officer_NN
and_CC
the_DT
control_NN
over_IN
financial_JJ
reporting_GER
and_ANDC
therefore_CONJ
changes_NN
to_PIN
the_DT
Companys_NN
Chief_NN
Financial_NN
Officer_NN
,_,
has_VPRT [PEAS]
performed_VBN
an_DT
evaluation_NOMZ
of_PIN
the_DT
effectiveness_NOMZ
internal_JJ
control_NN
over_IN
financial_JJ
reporting_GER
._.
The_DT
Company_NN
has_VPRT [PEAS]
reviewed_VBN
of_PIN
the_DT
Companys_NN
disclosure_NN
controls_NN
and_PHC
procedures_NN
,_,
in_PIN
relation_NOMZ
each_QUAN
system_NN
as_IN
it_PIT
is_VPRT
being_VBG [PASS]
implemented_VBN
and_CC
the_DT
controls_NN
affected_VBN [WZPAST]
by_PIN
to_PIN
its_PIT
Form_NN
10-K_NN
US_FPP1
GAAP_NN
reporting_GER
,_,
as_RB
at_PIN
December_NN
31_CD
,_,
2005_CD
._.
the_DT
implementation_NOMZ
of_PIN
the_DT
new_JJ
systems_NN
and_CC
made_VBN
appropriate_JJ
changes_NN
The_DT
Companys_NN
management_NOMZ
necessarily_RB
applied_VBD
its_PIT
judgement_NOMZ
to_PIN
affected_JJ
internal_JJ
controls_NN
as_IN
it_PIT
implemented_VBD
the_DT
new_JJ
systems_NN
._.
in_PIN
assessing_VBG
the_DT
costs_NN
and_PHC
benefits_NN
of_PIN
such_JJ
controls_NN
and_PHC
procedures_NN
,_,
Management_NOMZ
believes_VPRT [PRIV]
that_THVC
the_DT
controls_NN
as_IN
modified_VBN
are_VPRT [BEMA]
appropriate_PRED
which_WDT
by_PIN
their_TPP3
nature_NN
can_POMD
provide_VB
only_DWNT
reasonable_JJ
assurance_NN
regarding_VBG [WZPRES]
and_PHC
functioning_VBG
effectively_RB
._.
Based_VBN [PASTP]
on_PIN
this_DEMO
evaluation_NOMZ
,_,
the_DT
Companys_NN
Chief_NN
Executive_NN
Officer_NN
and_PHC
Chief_NN
Financial_NN
Officer_NN
During_PIN
the_DT
period_NN
covered_VBN [WZPAST]
by_PIN
this_DEMO
Annual_JJ
Review_NN
,_,
the_DT
Company_NN
concluded_VBD [PRIV]
that_THVC
the_DT
Companys_NN
disclosure_NN
controls_NN
and_PHC
procedures_NN
are_VPRT [PASS]
concluded_VBN [PRIV]
the_DT
acquisition_NOMZ
of_PIN
TKT_NN
._.
Significant_JJ
material_NN
weaknesses_NOMZ
effective_JJ
at_PIN
a_DT
reasonable_JJ
level_NN
of_PIN
assurance_NN
for_PIN
gathering_GER
,_,
analyzing_VBG [PRESP]
in_PIN
TKTs_NN
internal_JJ
control_NN
over_IN
financial_JJ
reporting_GER
were_VBD [PASS]
identified_VBN
with_PIN
and_CC
disclosing_VBG [PUBV]
the_DT
information_NOMZ
that_TOBJ
the_DT
Company_NN
is_VPRT [PASS]
required_VBN [SUAV]
to_TO
respect_VB
to_PIN
its_PIT
sales_NN
and_PHC
marketing_GER
subsidiary_NN
,_,
TKT_NN
Europe_NN
A._NN
B._NN
disclose_VB [PUBV]
in_PIN
the_DT
reports_NN
it_PIT
files_VPRT
under_IN
the_DT
US_FPP1
Securities_NOMZ
Exchange_NN
Act_NN
formerly_TIME
TKT_NN
Europe-5S_NN
A._NN
B._NN
,_,
or_CC
TKT_NN
Europe_NN
,_,
as_RB
at_PIN
December_NN
31_CD
,_,
of_PIN
1934_CD
,_,
within_PIN
the_DT
time_NN
periods_NN
specified_VBN [WZPAST]
in_PIN
the_DT
rules_NN
and_PHC
forms_NN
of_PIN
the_DT
2004_CD
,_,
as_IN
described_VBN
in_PIN
TKTs_NN
Annual_JJ
Report_NN
on_PIN
Form_NN
10-K_NN
for_PIN
2004_CD
._.
US_FPP1
Securities_NOMZ
and_PHC
Exchange_NN
Commission_NN
._.
The_DT
Company_NN
undertook_VBD
a_DT
review_NN
of_PIN
these_DEMO
material_NN
weaknesses_NOMZ
following_VBG [WZPRES]
completion_NOMZ
of_PIN
the_DT
Companys_NN
acquisition_NOMZ
of_PIN
TKT_NN
and_CC
has_VPRT
Managements_NOMZ
report_NN
on_PIN
internal_JJ
control_NN
over_IN
financial_JJ
reporting_GER
undertaken_VBN
appropriate_JJ
remediation_NOMZ
activities_NOMZ
._.
Management_NOMZ
believes_VPRT [PRIV]
The_DT
Companys_NN
management_NOMZ
is_VPRT [BEMA]
responsible_PRED
for_PIN
establishing_VBG [PRIV]
and_CC
that_THVC
the_DT
controls_NN
as_IN
modified_VBN
are_VPRT [BEMA]
appropriate_PRED
and_CC
functioning_VBG
effectively_RB
._.
maintaining_VBG [PUBV]
adequate_JJ
internal_JJ
control_NN
over_IN
financial_JJ
reporting_GER
as_IN
defined_VBN
in_PIN
Rule_NN
13_CD
a_DT
to_PIN
15_CD
f_SYM
or_CC
15_CD
d_SYM
-15_CD
f_SYM
promulgated_VBN
under_IN
the_DT
US_FPP1
Securities_NOMZ
Exchange_NN
Act_NN
of_PIN
1934_CD
._.
Because_CAUS
of_PIN
its_PIT
inherent_JJ
limitations_NOMZ
,_,
internal_JJ
control_NN
over_IN
financial_JJ
reporting_GER
may_POMD
not_XX0
prevent_VB
or_CC
detect_VB
misstatements_NOMZ
._.
Projections_NOMZ
of_PIN
any_QUAN
evaluation_NOMZ
of_PIN
effectiveness_NOMZ
to_PIN
future_JJ
periods_NN
are_VPRT [BEMA]
subject_PRED
to_PIN
the_DT
risk_NN
that_TOBJ
controls_NN
may_POMD
become_VB
inadequate_JJ
because_CAUS
of_PIN
changes_NN
in_PIN
conditions_NOMZ
,_,
or_CC
that_THVC
the_DT
degree_NN
of_PIN
compliance_NN
with_PIN
the_DT
policies_NN
or_CC
procedures_NN
may_POMD
deteriorate_VB
._.
76_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
77_CD
Report_NN
of_PIN
independent_JJ
registered_JJ
public_JJ
accounting_GER
rm_NN
To_PIN
the_DT
Board_NN
of_PIN
Directors_NN
and_PHC
Stockholders_NN
of_PIN
Shire_NN
plc_NN
,_,
Because_CAUS
of_PIN
the_DT
inherent_JJ
limitations_NOMZ
of_PIN
internal_JJ
control_NN
over_IN
financial_JJ
Basingstoke_NN
,_,
England_NN
reporting_GER
,_,
including_VBG [PRESP]
the_DT
possibility_NOMZ
of_PIN
collusion_NN
or_CC
improper_JJ
management_NOMZ
We_FPP1
have_VPRT [PEAS]
audited_VBN
the_DT
accompanying_VBG
consolidated_JJ
balance_NN
sheets_NN
override_NN
of_PIN
controls_NN
,_,
material_NN
misstatements_NOMZ
due_JJ
to_PIN
error_NN
or_CC
fraud_NN
may_POMD
of_PIN
Shire_NN
plc_NN
and_PHC
subsidiaries_NN
the_DT
Company_NN
as_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
not_XX0
be_VB [PASS]
prevented_VBN
or_CC
detected_VBN
on_PIN
a_DT
timely_JJ
basis_NN
._.
Also_RB
,_,
projections_NOMZ
of_PIN
any_QUAN
and_CC
2004_CD
,_,
and_ANDC
the_DT
related_JJ
consolidated_JJ
statements_NOMZ
of_PIN
operations_NOMZ
,_,
evaluation_NOMZ
of_PIN
the_DT
effectiveness_NOMZ
of_PIN
the_DT
internal_JJ
control_NN
over_IN
financial_JJ
stockholders_NN
equity_NOMZ
,_,
comprehensive_JJ
income_NN
,_,
and_ANDC
cash_NN
flows_NN
reporting_VBG [PUBV] [WZPRES]
to_PIN
future_JJ
periods_NN
are_VPRT [BEMA]
subject_PRED
to_PIN
the_DT
risk_NN
that_TOBJ
the_DT
controls_NN
may_POMD
for_PIN
each_QUAN
of_PIN
the_DT
three_CD
years_NN
in_PIN
the_DT
period_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
._.
become_VBN
inadequate_JJ
because_CAUS
of_PIN
changes_NN
in_PIN
conditions_NOMZ
,_,
or_CC
that_THVC
the_DT
We_FPP1
also_RB
have_VPRT [PEAS]
audited_VBN
managements_NOMZ
assessment_NOMZ
,_,
included_VBD
in_PIN
the_DT
degree_NN
of_PIN
compliance_NN
with_PIN
the_DT
policies_NN
or_CC
procedures_NN
may_POMD
deteriorate_VB
._.
accompanying_VBG
Management_NOMZ
Report_NN
on_PIN
Internal_NN
Controls_NN
Over_NN
Financial_NN
Reporting_GER
,_,
that_THVC
the_DT
Company_NN
maintained_VBD [PUBV]
effective_JJ
internal_JJ
control_NN
In_PIN
our_FPP1
opinion_NN
,_,
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
referred_VBD
to_PIN
above_PLACE
over_IN
financial_JJ
reporting_GER
as_IN
of_PIN
December_NN
31_CD
,_,
2005_CD
,_,
based_VBN [PASTP]
on_PIN
criteria_NN
present_JJ
fairly_RB
,_,
in_PIN
all_QUAN
material_NN
respects_VPRT
,_,
the_DT
financial_JJ
position_NOMZ
of_PIN
the_DT
established_VBN [PRIV]
in_PIN
Internal_NN
Control_NN
Integrated_NN
Framework_NN
issued_VBN [WZPAST]
by_PIN
the_DT
Company_NN
as_IN
of_PIN
December_NN
31_CD
,_,
2005_CD
and_CC
2004_CD
,_,
and_ANDC
the_DT
results_NN
of_PIN
its_PIT
Committee_NN
of_PIN
Sponsoring_GER
Organizations_NOMZ
of_PIN
the_DT
Treadway_NN
Commission_NN
._.
operations_NOMZ
and_CC
its_PIT
cash_NN
flows_VPRT
for_PIN
each_QUAN
of_PIN
the_DT
three_CD
years_NN
in_PIN
the_DT
period_NN
The_DT
Companys_NN
management_NOMZ
is_VPRT [BEMA]
responsible_PRED
for_PIN
these_DEMO
financial_JJ
ended_VBN
December_NN
31_CD
,_,
2005_CD
,_,
in_PIN
conformity_NOMZ
with_PIN
accounting_GER
principles_NN
statements_NOMZ
and_CC
the_DT
financial_JJ
statement_NOMZ
schedule_NN
,_,
for_PIN
maintaining_VBG [PUBV]
generally_RB
accepted_VBN [PRIV]
in_PIN
the_DT
United_NN
States_NN
of_PIN
America_NN
._.
Also_RB
,_,
in_PIN
our_FPP1
opinion_NN
,_,
effective_JJ
internal_JJ
control_NN
over_IN
financial_JJ
reporting_GER
,_,
and_ANDC
for_PIN
its_PIT
assessment_NOMZ
such_JJ
financial_JJ
statement_NOMZ
schedule_NN
,_,
when_RB
considered_VBN [PRIV]
in_PIN
relation_NOMZ
to_PIN
the_DT
of_PIN
the_DT
effectiveness_NOMZ
of_PIN
internal_JJ
control_NN
over_IN
financial_JJ
reporting_GER
._.
Our_FPP1
basic_JJ
consolidated_JJ
financial_JJ
statements_NOMZ
taken_VBN
as_IN
a_DT
whole_NN
,_,
presents_VPRT
responsibility_NOMZ
is_VPRT
to_TO
express_VB
an_DT
opinion_NN
on_PIN
these_DEMO
financial_JJ
statements_NOMZ
fairly_RB
,_,
in_PIN
all_QUAN
material_NN
respects_VPRT
,_,
the_DT
information_NOMZ
set_VBN [WZPAST]
forth_RB
therein_RB
._.
Also_RB
,_,
in_PIN
and_CC
the_DT
financial_JJ
statement_NOMZ
schedule_NN
,_,
an_DT
opinion_NN
on_PIN
managements_NOMZ
our_FPP1
opinion_NN
,_,
managements_NOMZ
assessment_NOMZ
that_TOBJ
the_DT
Company_NN
maintained_VBD [PUBV]
assessment_NOMZ
,_,
and_ANDC
an_DT
opinion_NN
on_PIN
the_DT
effectiveness_NOMZ
of_PIN
the_DT
Companys_NN
effective_JJ
internal_JJ
control_NN
over_IN
financial_JJ
reporting_GER
as_IN
of_PIN
December_NN
31_CD
,_,
internal_JJ
control_NN
over_IN
financial_JJ
reporting_GER
based_VBN [WZPAST]
on_PIN
our_FPP1
audits_NN
._.
2005_CD
,_,
is_VPRT [SPAU] [PASS]
fairly_RB
stated_VBN [PUBV]
,_,
in_PIN
all_QUAN
material_NN
respects_VPRT
,_,
based_VBN [PASTP]
on_PIN
the_DT
criteria_NN
established_VBN [PRIV] [WZPAST]
in_PIN
Internal_NN
Control_NN
Integrated_NN
Framework_NN
issued_VBN [WZPAST]
by_PIN
the_DT
We_FPP1
conducted_VBD
our_FPP1
audits_NN
in_PIN
accordance_NN
with_PIN
the_DT
standards_NN
Committee_NN
of_PIN
Sponsoring_GER
Organizations_NOMZ
of_PIN
the_DT
Treadway_NN
Commission_NN
._.
of_PIN
the_DT
Public_NN
Company_NN
Accounting_GER
Oversight_NN
Board_NN
United_NN
States_NN
._.
Furthermore_CONJ
,_,
in_PIN
our_FPP1
opinion_NN
,_,
the_DT
Company_NN
maintained_VBD [PUBV]
,_,
in_PIN
all_QUAN
material_NN
Those_DEMO
standards_NN
require_VPRT [SUAV]
that_THVC
we_FPP1
plan_VPRT
and_PHC
perform_VPRT
the_DT
audit_NN
to_TO
obtain_VB
respects_NN
,_,
effective_JJ
internal_JJ
control_NN
over_IN
financial_JJ
reporting_GER
as_IN
of_PIN
reasonable_JJ
assurance_NN
about_IN
whether_IN
the_DT
financial_JJ
statements_NOMZ
are_VPRT [BEMA]
free_JJ
December_NN
31_CD
,_,
2005_CD
,_,
based_VBN [PASTP]
on_PIN
the_DT
criteria_NN
established_VBN [PRIV] [WZPAST]
in_PIN
Internal_NN
Control_NN
of_PIN
material_NN
misstatement_NOMZ
and_ANDC
whether_IN
effective_JJ
internal_JJ
control_NN
over_IN
Integrated_NN
Framework_NN
issued_VBN [WZPAST]
by_PIN
the_DT
Committee_NN
of_PIN
Sponsoring_VBG
financial_JJ
reporting_GER
was_VBD [PASS]
maintained_VBN [PUBV]
in_PIN
all_QUAN
material_NN
respects_VPRT
._.
Our_FPP1
audit_NN
Organizations_NOMZ
of_PIN
the_DT
Treadway_NN
Commission_NN
._.
of_PIN
financial_JJ
statements_NOMZ
included_VBD
examining_VBG
,_,
on_PIN
a_DT
test_NN
basis_NN
,_,
evidence_NN
supporting_VBG [WZPRES]
the_DT
amounts_NN
and_PHC
disclosures_NN
in_PIN
the_DT
financial_JJ
statements_NOMZ
,_,
Deloitte_NN
&_CC
Touche_NN
LLP_NN
assessing_VBG [WZPRES]
the_DT
accounting_GER
principles_NN
used_VBN
and_CC
significant_JJ
estimates_NN
Reading_VBG [WZPRES]
,_,
England_NN
made_VBN [WZPAST]
by_PIN
management_NOMZ
,_,
and_ANDC
evaluating_VBG
the_DT
overall_JJ
financial_JJ
statement_NOMZ
March_NN
1_CD
,_,
2006_CD
presentation_NOMZ
._.
Our_FPP1
audit_NN
of_PIN
internal_JJ
control_NN
over_IN
financial_JJ
reporting_GER
included_VBD
obtaining_VBG
an_DT
understanding_GER
of_PIN
internal_JJ
control_NN
over_IN
financial_JJ
reporting_GER
,_,
evaluating_VBG
managements_NOMZ
assessment_NOMZ
,_,
testing_GER
and_CC
evaluating_VBG
the_DT
design_NN
and_CC
operating_VBG
effectiveness_NOMZ
of_PIN
internal_JJ
control_NN
,_,
and_ANDC
performing_VBG
such_JJ
other_JJ
procedures_NN
as_IN
we_FPP1
considered_VBD [PRIV]
necessary_JJ
in_PIN
the_DT
circumstances_NN
._.
We_FPP1
believe_VPRT [PRIV]
that_THVC
our_FPP1
audits_NN
provide_VB
a_DT
reasonable_JJ
basis_NN
for_PIN
our_FPP1
opinions_NN
._.
A_DT
companys_NN
internal_JJ
control_NN
over_IN
financial_JJ
reporting_GER
is_VPRT [BEMA]
a_DT
process_NN
designed_VBN [WZPAST]
by_PIN [STPR]
,_,
or_CC
under_IN
the_DT
supervision_NN
of_PIN [STPR]
,_,
the_DT
companys_NN
principal_JJ
executive_NN
and_CC
principal_JJ
financial_JJ
officers_NN
,_,
or_CC
persons_NN
performing_VBG [WZPRES]
similar_JJ
functions_NOMZ
,_,
and_ANDC
effected_VBN
by_PIN
the_DT
companys_NN
board_NN
of_PIN
directors_NN
,_,
management_NOMZ
,_,
and_ANDC
other_JJ
personnel_NN
to_TO
provide_VB
reasonable_JJ
assurance_NN
regarding_VBG [WZPRES]
the_DT
reliability_NOMZ
of_PIN
financial_JJ
reporting_GER
and_CC
the_DT
preparation_NOMZ
of_PIN
financial_JJ
statements_NOMZ
for_PIN
external_JJ
purposes_NN
in_PIN
accordance_NN
with_PIN
generally_RB
accepted_VBN [PRIV]
accounting_GER
principles_NN
._.
A_DT
companys_NN
internal_JJ
control_NN
over_IN
financial_JJ
reporting_GER
includes_VPRT
those_DEMO
policies_NN
and_PHC
procedures_NN
that_TOBJ
1_CD
pertain_NN
to_PIN
the_DT
maintenance_NN
of_PIN
records_NN
that_DEMP
,_,
in_PIN
reasonable_JJ
detail_NN
,_,
accurately_RB
and_PHC
fairly_RB
reflect_VPRT [PRIV]
the_DT
transactions_NOMZ
and_PHC
dispositions_NOMZ
of_PIN
the_DT
assets_NN
of_PIN
the_DT
company_NN
:_:
2_CD
provide_VPRT
reasonable_JJ
assurance_NN
that_TOBJ
transactions_NOMZ
are_VPRT [PASS]
recorded_VBN
as_RB
necessary_JJ
to_TO
permit_VB
preparation_NOMZ
of_PIN
financial_JJ
statements_NOMZ
in_PIN
accordance_NN
with_PIN
generally_RB
accepted_VBN [PRIV]
accounting_GER
principles_NN
and_CC
that_THVC
receipts_NN
and_PHC
expenditures_NN
of_PIN
the_DT
company_NN
are_VPRT
being_VBG [PASS]
made_VBN
only_DWNT
in_PIN
accordance_NN
with_PIN
authorizations_NOMZ
of_PIN
management_NOMZ
and_PHC
directors_NN
of_PIN
the_DT
company_NN
:_:
and_ANDC
3_CD
provide_VPRT
reasonable_JJ
assurance_NN
regarding_VBG [WZPRES]
prevention_NOMZ
or_CC
timely_JJ
detection_NOMZ
of_PIN
unauthorized_JJ
acquisition_NOMZ
,_,
use_NN
,_,
or_CC
disposition_NOMZ
of_PIN
the_DT
companys_NN
assets_NN
that_TSUB
could_POMD
have_VB
a_DT
material_NN
effect_NN
on_PIN
the_DT
financial_JJ
statements_NOMZ
._.
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
77_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
78_CD
Consolidated_NN
balance_NN
sheets_NN
In_PIN
thousands_NN
of_PIN
US_FPP1
Dollars_NN
,_,
except_PIN
share_NN
data_NN
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2005_CD
2004_CD
Notes_NN
$_$
000_CD
$_$
000_CD
Assets_NN
Current_JJ
assets_NN
:_:
Cash_NN
and_PHC
cash_NN
equivalents_NN
656,456_CD
1,111,477_CD
Restricted_VBN
cash_NN
30,568_CD
21,627_CD
Short-term_JJ
investments_NOMZ
10_CD
6,947_CD
324,411_CD
Accounts_NN
receivable_NN
,_,
net_JJ
7_CD
329,924_CD
222,546_CD
Inventories_NN
8_CD
136,057_CD
41,230_CD
Deferred_JJ
tax_NN
asset_NN
29_CD
54,186_CD
70,387_CD
Prepaid_NN
expenses_NN
and_CC
other_JJ
current_JJ
assets_NN
9_CD
98,084_CD
137,271_CD
Total_JJ
current_JJ
assets_NN
1,312,222_CD
1,928,949_CD
Investments_NOMZ
11_CD
50,162_CD
63,267_CD
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
,_,
net_JJ
12_CD
233,999_CD
131,351_CD
Goodwill_NN
13_CD
367,652_CD
235,396_CD
Other_JJ
intangible_JJ
assets_NN
,_,
net_JJ
14_CD
729,304_CD
309,297_CD
Deferred_JJ
tax_NN
asset_NN
29_CD
61,994_CD
7,724_CD
Other_JJ
non-current_JJ
assets_NN
15_CD
42,907_CD
38,895_CD
Total_JJ
assets_NN
2,798,240_CD
2,714,879_CD
Liabilities_NOMZ
and_PHC
shareholders_NN
equity_NOMZ
Current_JJ
liabilities_NOMZ
:_:
Loan_NN
facility_NOMZ
to_PIN
ID_NN
Biomedical_NN
,_,
Inc._NN
43,162_CD
Accounts_NN
payable_JJ
and_CC
accrued_VBN
expenses_NN
16_CD
431,819_CD
311,231_CD
Liability_NOMZ
to_TO
dissenting_VBG
shareholders_NN
4_CD
427,609_CD
Other_JJ
current_JJ
liabilities_NOMZ
17_CD
105,993_CD
77,558_CD
Total_JJ
current_JJ
liabilities_NOMZ
965,421_CD
431,951_CD
Long-term_JJ
debt_NN
,_,
excluding_VBG
current_JJ
installments_NOMZ
116_CD
116_CD
Other_JJ
non-current_JJ
liabilities_NOMZ
19_CD
43,437_CD
32,159_CD
Total_JJ
liabilities_NOMZ
1,008,974_CD
464,226_CD
Commitments_NOMZ
and_PHC
contingencies_NN
21_CD
Shareholders_NN
equity_NOMZ
:_:
Common_JJ
stock_NN
of_PIN
5p_JJ
par_JJ
value_NN
:_:
18,333,006,420_CD
shares_NN
authorized_VBN
:_:
and_ANDC
495,733,782_CD
shares_NN
issued_VBN
and_CC
outstanding_JJ
2004_CD
:_:
800,000,000_CD
shares_NN
authorized_VBN
:_:
and_ANDC
484,916,034_CD
shares_NN
issued_VBN
and_CC
outstanding_JJ
2_CD
42,728_CD
41,796_CD
Exchangeable_JJ
shares_NN
:_:
2,187,793_CD
shares_NN
issued_VBN
and_CC
outstanding_JJ
2004_CD
:_:
4,226,476_CD
101,248_CD
195,830_CD
Treasury_NN
stock_NN
22_CD
2,813_CD
264_CD
Additional_JJ
paid-in_PIN
capital_NN
1,205,257_CD
1,070,675_CD
Accumulated_VBN
other_JJ
comprehensive_JJ
income_NN
71,472_CD
131,939_CD
Retained_VBN
earnings_GER
371,374_CD
810,677_CD
Total_JJ
shareholders_NN
equity_NOMZ
1,789,266_CD
2,250,653_CD
Total_JJ
liabilities_NOMZ
and_PHC
shareholders_NN
equity_NOMZ
2,798,240_CD
2,714,879_CD
The_DT
accompanying_JJ
notes_NN
are_VPRT [BEMA]
an_DT
integral_JJ
part_NN
of_PIN
these_DEMO
consolidated_JJ
financial_JJ
statements_NOMZ
._.
78_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
79_CD
Consolidated_NN
statements_NOMZ
of_PIN
operations_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
Dollars_NN
,_,
except_PIN
share_NN
data_NN
2005 2004 2003_CD
Year_NN
to_PIN
December_NN
31_CD
,_,
Notes_NN
$_$
000_CD
$_$
000_CD
$_$
000_CD
Revenues_NN
:_:
Product_NN
sales_NN
1,327,660_CD
1,112,457_CD
1,004,307_CD
Royalties_NN
242,910_CD
230,364_CD
203,573_CD
Licensing_GER
and_PHC
development_NOMZ
15,002_CD
13,479_CD
3,677_CD
Other_JJ
revenues_NN
13,744_CD
6,907_CD
13_CD
Total_JJ
revenues_NN
1,599,316_CD
1,363,207_CD
1,211,570_CD
Costs_NN
and_PHC
expenses_NN
:_:
Cost_NN
of_PIN
product_NN
sales_NN
213,964_CD
141,909_CD
143,160_CD
Research_NN
and_PHC
development_NOMZ
336,217_CD
196,265_CD
187,677_CD
Selling_GER
,_,
general_JJ
and_PHC
administrative_JJ
705,559_CD
516,645_CD
409,717_CD
Intangible_JJ
asset_NN
impairment_NOMZ
14_CD
5,632_CD
13,477_CD
27,489_CD
Reorganization_NOMZ
costs_NN
6_CD
9,335_CD
48,469_CD
23,940_CD
Integration_NOMZ
costs_NN
5_CD
9,716_CD
In-process_JJ
R&D_NN
write-off_PIN
4_CD
673,000_CD
Total_JJ
operating_GER
expenses_NN
1,953,423_CD
916,765_CD
791,983_CD
Operating_GER
loss_NN
income_NN
354,107_CD
446,442_CD
419,587_CD
Interest_NN
income_NN
35,300_CD
21,901_CD
16,856_CD
Interest_NN
expense_NN
27_CD
12,023_CD
12,294_CD
9,451_CD
Other_JJ
income_NN
expense_NN
,_,
net_JJ
26_CD
9,945_CD
3,845_CD
20,645_CD
Total_JJ
other_JJ
income_NN
expense_NN
,_,
net_JJ
33,222_CD
13,452_CD
13,240_CD
Loss_NN
income_NN
from_PIN
continuing_VBG
operations_NOMZ
before_IN
income_NN
taxes_NN
,_,
equity_NOMZ
in_PIN
losses_NN
earnings_GER
of_PIN
equity_NOMZ
method_NN
investees_NN
and_CC
discontinued_VBN
operations_NOMZ
320,885_CD
459,894_CD
406,347_CD
Income_NN
taxes_NN
29_CD
92,083_CD
129,103_CD
107,353_CD
Equity_NOMZ
in_PIN
losses_NN
earnings_GER
of_PIN
equity_NOMZ
method_NN
investees_VPRT
30_CD
1,000_CD
2,508_CD
1,057_CD
Loss_NN
income_NN
from_PIN
continuing_VBG
operations_NOMZ
413,968_CD
333,299_CD
297,937_CD
Loss_NN
from_PIN
discontinued_VBN
operations_NOMZ
net_NN
of_PIN
income_NN
tax_NN
expense_NN
of_PIN
$_$
nil_CD
,_,
$_$
nil_JJ
and_CC
$_$
nil_JJ
respectively_RB
6_CD
20,135_CD
21,886_CD
Gain_NN
loss_NN
on_PIN
disposition_NOMZ
of_PIN
discontinued_VBN
operations_NOMZ
net_NN
of_PIN
income_NN
tax_NN
expense_NN
of_PIN
$_$
nil_CD
,_,
$_$
nil_JJ
and_CC
$_$
nil_JJ
respectively_RB
6_CD
3,125_CD
44,157_CD
Net_JJ
loss_NN
income_NN
410,843_CD
269,007_CD
276,051_CD
Earnings_GER
per_PIN
share_NN
basic_JJ
24_CD
Loss_NN
income_NN
from_PIN
continuing_VBG
operations_NOMZ
82.7_CD
67.2_CD
59.8_CD
Loss_NN
from_PIN
discontinued_VBN
operations_NOMZ
4.1_CD
4.4_CD
Gain_NN
loss_NN
on_PIN
disposition_NOMZ
of_PIN
discontinued_VBN
operations_NOMZ
0.6_CD
8.9_CD
82.1_CD
54.2_CD
55.4_CD
Earnings_GER
per_PIN
share_NN
diluted_VBN
24_CD
Loss_NN
income_NN
from_PIN
continuing_VBG
operations_NOMZ
82.7_CD
65.9_CD
58.4_CD
Loss_NN
from_PIN
discontinued_VBN
operations_NOMZ
4.0_CD
4.2_CD
Gain_NN
loss_NN
on_PIN
disposition_NOMZ
of_PIN
discontinued_VBN
operations_NOMZ
0.6_CD
8.6_CD
82.1_CD
53.3_CD
54.2_CD
Weighted_VBN
average_JJ
number_NN
of_PIN
shares_NN
:_:
Basic_JJ
500,243,137_CD
496,306,604_CD
498,212,826_CD
Diluted_NN
500,243,137_CD
511,267,432_CD
518,967,395_CD
The_DT
accompanying_JJ
notes_NN
are_VPRT [BEMA]
an_DT
integral_JJ
part_NN
of_PIN
these_DEMO
consolidated_JJ
financial_JJ
statements_NOMZ
._.
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
79_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
80_CD
Consolidated_NN
statements_NOMZ
of_PIN
changes_NN
in_PIN
shareholders_NN
equity_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
Dollars_NN
,_,
except_PIN
share_NN
data_NN
Accumulated_VBN
other_JJ
Common_JJ
Exchangeable_JJ
comprestock_NN
shares_NN
Additionalhensive_NN
Total_NN
Common_NN
number_NN
Exchangeable_JJ
number_NN
Treasury_NN
paid-in_PIN
income_NN
Retained_VBN
shareholders_NN
stock_NN
shares_NN
shares_NN
shares_NN
stock_NN
capital_NN
losses_NN
earnings_GER
equity_NOMZ
$_$
000_CD
000s_CD
$_$
000_CD
000s_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
As_IN
at_PIN
December_NN
31_CD
,_,
2002_CD
40,051_CD
484,344_CD
272,523_CD
5,874_CD
1,027,499_CD
41,431_CD
274,524_CD
1,573,166_CD
Effect_NN
of_PIN
Scheme_NN
i_FPP1
of_PIN
Arrangement_NOMZ
2,882,142_CD
2,882,142_CD
i_FPP1
Effect_NN
of_PIN
capital_NN
reduction_NOMZ
2,880,447_CD
2,880,447_CD
Net_JJ
income_NN
276,051276,051_CD
Foreign_JJ
currency_NN
translation_NOMZ
114,116_CD
114,116_CD
Redemption_NOMZ
of_PIN
common_JJ
stock_NN
654_CD
7,593_CD
51,738_CD
52,392_CD
Exchange_NN
of_PIN
exchangeable_JJ
shares_NN
9_CD
104_CD
1,856_CD
34_CD
1,847_CD
Options_NOMZ
exercised_VBN
90_CD
1,040_CD
5,105_CD
5,195_CD
Stock_NN
option_NOMZ
compensation_NOMZ
and_PHC
warrants_NN
24_CD
24_CD
Tax_NN
benefit_NN
associated_VBN [WZPAST]
with_PIN
exercise_NN
of_PIN
stock_NN
options_NOMZ
692_CD
692_CD
Unrealized_JJ
holding_VBG [PRIV]
gain_NN
on_PIN
available-for-sale_JJ
investments_NOMZ
6,322_CD
6,322_CD
As_IN
at_PIN
December_NN
31_CD
,_,
2003_CD
41,191_CD
477,895_CD
270,667_CD
5,840_CD
981,686_CD
79,007_CD
550,575_CD
1,923,126_CD
Net_JJ
income_NN
269,007269,007_CD
Foreign_JJ
currency_NN
translation_NOMZ
46,801_CD
46,801_CD
Exchange_NN
of_PIN
exchangeable_JJ
shares_NN
417_CD
4,839_CD
74,837_CD
1,614_CD
74,420_CD
Options_NOMZ
exercised_VBN
181_CD
2,09813,23513,416_CD
Stock_NN
option_NOMZ
compensation_NOMZ
and_PHC
warrants_NN
216_CD
216_CD
Tax_NN
benefit_NN
associated_VBN [WZPAST]
with_PIN
exercise_NN
of_PIN
stock_NN
options_NOMZ
354_CD
354_CD
New_NN
shares_NN
issued_VBD
7_CD
84 764 771_CD
Treasury_NN
stock_NN
51,286_CD
shares_NN
264_CD
264_CD
Unrealized_JJ
holding_VBG [PRIV]
gain_NN
on_PIN
available-for-sale_JJ
securities_NOMZ
27,011_CD
27,011_CD
Realized_VBN [PRIV]
gain_NN
on_PIN
available-for-sale_JJ
securities_NOMZ
20,880_CD
20,880_CD
Dividends_NN
8,905_CD
8,905_CD
As_IN
at_PIN
December_NN
31_CD
,_,
2004_CD
41,796_CD
484,916_CD
195,830_CD
4,226_CD
264_CD
1,070,675_CD
131,939_CD
810,677_CD
2,250,653_CD
Net_JJ
loss_NN
410,843_CD
410,843_CD
Foreign_JJ
currency_NN
translation_NOMZ
55,976_CD
55,976_CD
Exchange_NN
of_PIN
exchangeable_JJ
shares_NN
527_CD
6,116_CD
94,582_CD
2,038_CD
94,055_CD
Options_NOMZ
exercised_VBN
405_CD
4,70236,70837,113_CD
Stock_NN
option_NOMZ
compensation_NOMZ
and_PHC
warrants_NN
392_CD
392_CD
Tax_NN
benefit_NN
associated_VBN [WZPAST]
with_PIN
exercise_NN
of_PIN
stock_NN
options_NOMZ
3,427_CD
3,427_CD
Treasury_NN
stock_NN
242,302_CD
shares_NN
2,549_CD
2,549_CD
Unrealized_JJ
holding_VBG [PRIV]
loss_NN
on_PIN
available-for-sale_JJ
securities_NOMZ
1,018_CD
1,018_CD
Realized_VBN [PRIV]
gain_NN
on_PIN
available-for-sale_JJ
securities_NOMZ
3,473_CD
3,473_CD
Dividends_NN
28,460_CD
28,460_CD
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
42,728_CD
495,734_CD
101,248_CD
2,188_CD
2,813_CD
1,205,257_CD
71,472_CD
371,374_CD
1,789,266_CD
i_FPP1
Net_JJ
increase_NN
to_PIN
common_JJ
stock_NN
is_VPRT
$_$
1.7_CD
million_CD
._.
The_DT
accompanying_JJ
notes_NN
are_VPRT [BEMA]
an_DT
integral_JJ
part_NN
of_PIN
these_DEMO
consolidated_JJ
financial_JJ
statements_NOMZ
._.
Dividends_NN
per_PIN
share_NN
During_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
the_DT
Company_NN
declared_VBD [PUBV] [THATD]
dividends_NN
totaling_VBG [WZPRES]
5.6746_CD
per_PIN
ordinary_JJ
share_NN
,_,
equivalent_JJ
to_PIN
17.02_CD
per_PIN
American_JJ
Depositary_NN
Share_NN
,_,
and_ANDC
21.09_CD
Canadian_JJ
per_PIN
exchangeable_JJ
share_NN
._.
Treasury_NN
stock_NN
191,016_CD
shares_NN
were_VBD [PASS]
purchased_VBN
during_PIN
2005_CD
at_PIN
a_DT
cost_NN
to_PIN
the_DT
Company_NN
of_PIN
$_$
2.5_CD
million_CD
._.
80_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
81_CD
Consolidated_NN
statements_NOMZ
of_PIN
comprehensive_JJ
income_NN
In_PIN
thousands_NN
of_PIN
US_FPP1
Dollars_NN
2005 2004 2003_CD
Year_NN
to_PIN
December_NN
31_CD
,_,
$_$
000_CD
$_$
000_CD
$_$
000_CD
Net_JJ
loss_NN
income_NN
410,843_CD
269,007_CD
276,051_CD
Other_JJ
comprehensive_JJ
income_NN
:_:
Foreign_JJ
currency_NN
translation_NOMZ
55,976_CD
46,801_CD
114,116_CD
Unrealized_JJ
holding_VBG [PRIV]
loss_NN
gain_NN
on_PIN
available-for-sale_JJ
securities_NOMZ
1,018_CD
27,011_CD
6,322_CD
Realized_VBN [PRIV]
gain_NN
on_PIN
available-for-sale_JJ
securities_NOMZ
3,473_CD
20,880_CD
Comprehensive_JJ
loss_NN
income_NN
471,310_CD
321,939_CD
396,489_CD
The_DT
components_NN
of_PIN
accumulated_VBN
other_JJ
comprehensive_JJ
income_NN
as_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
and_CC
2004_CD
are_VPRT
as_IN
follows_VPRT
:_:
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2005_CD
2004_CD
$_$
000_CD
$_$
000_CD
Foreign_JJ
currency_NN
translation_NOMZ
62,246_CD
118,222_CD
Unrealized_JJ
holding_GER
gains_NN
on_PIN
available-for-sale_JJ
securities_NOMZ
9,226_CD
13,717_CD
Accumulated_VBN
other_JJ
comprehensive_JJ
income_NN
71,472_CD
131,939_CD
There_EX
are_VPRT
no_SYNE
material_NN
tax_NN
effects_NN
related_VBN [WZPAST]
to_PIN
the_DT
items_NN
included_VBD
above_PLACE
._.
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
81_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
82_CD
Consolidated_NN
statements_NOMZ
of_PIN
cash_NN
flows_NN
In_PIN
thousands_NN
of_PIN
US_FPP1
Dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
Revised_VBN
Revised_VBN
2005 2004 2003_CD
Year_NN
to_PIN
December_NN
31_CD
,_,
Notes_NN
$_$
000_CD
$_$
000_CD
$_$
000_CD
Cash_NN
flows_VPRT
from_PIN
activities_NOMZ
:_:
Net_JJ
loss_NN
income_NN
from_PIN
continuing_VBG
operations_NOMZ
413,968_CD
333,299_CD
297,937_CD
Adjustments_NOMZ
to_TO
reconcile_VB
net_JJ
income_NN
to_PIN
net_JJ
cash_NN
provided_VBN [WZPAST]
by_PIN
operating_VBG
activities_NOMZ
:_:
Depreciation_NOMZ
and_PHC
amortization_NOMZ
:_:
Cost_NN
of_PIN
product_NN
sales_NN
3,483_CD
2,740_CD
2,550_CD
SG&A_NN
67,977_CD
58,513_CD
35,642_CD
Stock_NN
option_NOMZ
compensation_NOMZ
392_CD
216_CD
24_CD
In-process_NN
R&D_NN
write-off_PIN
673,000_CD
Write_VPRT [PUBV]
down_IN
of_PIN
long-term_JJ
assets_NN
14,064_CD
29,317_CD
59,820_CD
Gain_NN
on_PIN
sale_NN
of_PIN
long-term_JJ
assets_NN
3,854_CD
15,268_CD
169_CD
Gain_NN
on_PIN
sale_NN
of_PIN
drug_NN
formulation_NOMZ
business_NOMZ
6_CD
3,561_CD
Movement_NOMZ
in_PIN
deferred_JJ
taxes_NN
22,295_CD
14,979_CD
22,193_CD
Equity_NOMZ
in_PIN
losses_NN
earnings_GER
of_PIN
equity_NOMZ
method_NN
investees_VPRT
1,000_CD
2,508_CD
1,057_CD
Other_JJ
1,468_CD
Changes_NN
in_PIN
operating_VBG
assets_NN
and_PHC
liabilities_NOMZ
,_,
net_NN
of_PIN
acquisitions_NOMZ
:_:
Increase_VB
in_PIN
accounts_NN
receivable_JJ
79,885_CD
28,066_CD
45,408_CD
Increase_VPRT
in_PIN
sales_NN
deduction_NOMZ
accrual_NN
18,616_CD
50,746_CD
20,357_CD
Decrease_NN
in_PIN
inventory_NN
8,582_CD
2,185_CD
6,261_CD
Increase_VPRT
decrease_NN
in_PIN
prepayments_NOMZ
and_CC
other_JJ
current_JJ
assets_NN
40,111_CD
2,509_CD
11,765_CD
Increase_VPRT
in_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
held_VBN [PRIV] [WZPAST]
for_PIN
sale_NN
12,470_CD
Increase_VPRT
decrease_NN
in_PIN
other_JJ
assets_NN
731_CD
13,520_CD
291_CD
Increase_VPRT
decrease_NN
in_PIN
accounts_NN
and_PHC
notes_NN
payable_JJ
and_PHC
other_JJ
liabilities_NOMZ
122,949_CD
76,793_CD
890_CD
Decrease_NN
increase_NN
in_PIN
deferred_JJ
revenue_NN
13,520_CD
6,151_CD
19,372_CD
Returns_NN
on_PIN
investments_NOMZ
4,710_CD
4,043_CD
2,289_CD
Cash_NN
flows_NN
used_VBN [WZPAST]
in_PIN
discontinued_VBN
operations_NOMZ
362_CD
30,525_CD
24,131_CD
A_DT
Net_JJ
cash_NN
provided_VBN [WZPAST]
by_PIN
operating_VBG
activities_NOMZ
381,076_CD
488,686_CD
354,934_CD
Cash_NN
flows_VPRT
from_PIN
investing_VBG
activities_NOMZ
:_:
Movement_NOMZ
in_PIN
short-term_JJ
investments_NOMZ
366,731_CD
20,282_CD
11,997_CD
Movements_NOMZ
in_PIN
restricted_JJ
cash_NN
768_CD
24,847_CD
5,531_CD
Purchase_NN
of_PIN
subsidiary_NN
undertaking_GER
1,114,048_CD
Expenses_NN
of_PIN
acquisition_NOMZ
37,491_CD
Purchase_NN
of_PIN
long-term_JJ
investments_NOMZ
7,700_CD
6,124_CD
5,643_CD
Purchase_NN
of_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
86,239_CD
57,603_CD
44,681_CD
Purchase_NN
of_PIN
intangible_JJ
assets_NN
20,491_CD
30,209_CD
47,049_CD
Proceeds_NN
from_PIN
sale_NN
of_PIN
long-term_JJ
investments_NOMZ
10,135_CD
26,733_CD
1,000_CD
Proceeds_NN
from_PIN
sale_NN
of_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
116_CD
3,527_CD
1,262_CD
Proceeds_NN
from_PIN
sale_NN
of_PIN
intangible_JJ
assets_NN
3,701_CD
Proceeds_NN
from_PIN
sale_NN
of_PIN
assets_NN
held_VBN [PRIV] [WZPAST]
for_PIN
sale_NN
11,289_CD
Proceeds_NN
from_PIN
sale_NN
of_PIN
drug_NN
formulation_NOMZ
business_NOMZ
557_CD
Returns_NN
of_PIN
investments_NOMZ
3,774_CD
1,450_CD
Loans_NN
made_VBN [WZPAST]
to_PIN
ID_NN
Biomedical_NN
Corporation_NOMZ
IDB_NN
43,162_CD
56,838_CD
Deferred_JJ
proceeds_NN
from_PIN
sale_NN
of_PIN
the_DT
vaccines_NN
business_NOMZ
92,236_CD
34,912_CD
Cash_NN
flows_NN
used_VBN [WZPAST]
in_PIN
discontinued_VBN
operations_NOMZ
12,715_CD
7,484_CD
B_NN
Net_JJ
cash_NN
used_VBN [WZPAST]
in_PIN
investing_VBG
activities_NOMZ
836,350_CD
77,312_CD
85,067_CD
82_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
83_CD
Consolidated_NN
statements_NOMZ
of_PIN
cash_NN
flows_NN
continued_VBD
In_PIN
thousands_NN
of_PIN
US_FPP1
Dollars_NN
Revised_VBD
Revised_VBN
2005 2004 2003_CD
Year_NN
to_PIN
December_NN
31_CD
,_,
$_$
000_CD
$_$
000_CD
$_$
000_CD
Cash_NN
flows_VPRT
from_PIN
financing_VBG
activities_NOMZ
:_:
Redemption_NOMZ
of_PIN
2_CD
%_NN
convertible_JJ
loan_NN
notes_NN
370,109_CD
29,775_CD
Repayment_NOMZ
of_PIN
long-term_JJ
debt_NN
,_,
capital_NN
leases_NN
and_PHC
notes_NN
6,079_CD
231_CD
Proceeds_NN
from_PIN
exercise_NN
of_PIN
options_NOMZ
37,113_CD
13,416_CD
5,195_CD
Proceeds_NN
from_PIN
issue_NN
of_PIN
common_JJ
stock_NN
,_,
net_JJ
771_CD
Tax_NN
benefit_NN
of_PIN
stock_NN
option_NOMZ
compensation_NOMZ
,_,
charged_VBN [PASTP]
directly_RB
to_PIN
reserves_NN
3,427_CD
354_CD
692_CD
Payments_NOMZ
for_PIN
redemption_NOMZ
of_PIN
common_JJ
stock_NN
52,392_CD
Payments_NOMZ
to_TO
acquire_VB
treasury_NN
stock_NN
2,480_CD
264_CD
Payment_NOMZ
of_PIN
dividend_NN
28,460_CD
8,905_CD
Cash_NN
flows_NN
used_VBN [WZPAST]
in_PIN
discontinued_VBN
operations_NOMZ
706_CD
C_NN
Net_JJ
cash_NN
provided_VBN [WZPAST]
by_PIN
used_VBN
in_PIN
financing_GER
activities_NOMZ
9,600_CD
370,816_CD
77,217_CD
Effect_NN
of_PIN
foreign_JJ
exchange_NN
rate_NN
changes_NN
on_PIN
cash_NN
and_PHC
cash_NN
equivalents_NN
9,347_CD
7,567_CD
25,133_CD
Effect_NN
of_PIN
foreign_JJ
exchange_NN
rate_NN
changes_NN
on_PIN
discontinued_VBN
operations_NOMZ
10_CD
111_CD
D_NN
Net_JJ
effect_NN
of_PIN
foreign_JJ
exchange_NN
rate_NN
changes_NN
9,347_CD
7,557_CD
25,244_CD
A_DT
B_NN
C_NN
D_NN
Net_JJ
decrease_NN
increase_NN
in_PIN
cash_NN
and_PHC
cash_NN
equivalents_NN
455,021_CD
48,115_CD
217,894_CD
Cash_NN
flows_NN
used_VBN [WZPAST]
in_PIN
discontinued_VBN
operations_NOMZ
327_CD
Cash_NN
and_PHC
cash_NN
equivalents_NN
at_PIN
beginning_GER
of_PIN
period_NN
1,111,477_CD
1,063,362_CD
845,141_CD
Cash_NN
and_PHC
cash_NN
equivalents_NN
at_PIN
end_NN
of_PIN
period_NN
656,456_CD
1,111,477_CD
1,063,362_CD
Supplemental_NN
information_NOMZ
associated_VBN [WZPAST]
with_PIN
continuing_VBG
operations_NOMZ
:_:
Revised_VBN
Revised_VBN
2005 2004 2003_CD
Year_NN
to_PIN
December_NN
31_CD
,_,
$_$
000_CD
$_$
000_CD
$_$
000_CD
Interest_NN
paid_VBN
4,334_CD
4,849_CD
7,716_CD
Income_NN
taxes_NN
paid_VBD
54,096_CD
123,510_CD
118,527_CD
Non_NN
cash_NN
activities_NOMZ
:_:
Proceeds_NN
from_PIN
sale_NN
of_PIN
drug_NN
formulation_NOMZ
business_NOMZ
:_:
Equity_NOMZ
in_PIN
Supernus_NN
Pharmaceuticals_NN
Inc._NN
3,900_CD
Proceeds_NN
from_PIN
sale_NN
of_PIN
a_DT
business_NOMZ
:_:
4,931,864_CD
shares_NN
of_PIN
IDB_NN
60,000_CD
Escrow_NN
funds_NN
30,000_CD
The_DT
accompanying_JJ
notes_NN
are_VPRT [BEMA]
an_DT
integral_JJ
part_NN
of_PIN
these_DEMO
consolidated_JJ
financial_JJ
statements_NOMZ
._.
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
83_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
84_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
Dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
1_CD
Description_NOMZ
of_PIN
operations_NOMZ
Shire_NN
plcs_VPRT
Shire_NN
and_CC
its_PIT
subsidiaries_NN
,_,
collectively_RB
referred_VBD
to_PIN
as_IN
the_DT
Company_NN
or_CC
the_DT
Group_NN
,_,
strategic_JJ
goal_NN
is_VPRT
to_TO
become_VB
the_DT
leading_VBG
specialty_NN
pharmaceutical_JJ
company_NN
that_TSUB
focuses_VPRT
on_PIN
meeting_VBG
the_DT
needs_NN
of_PIN
the_DT
specialist_NN
physician_NN
._.
Shires_NN
therapeutic_JJ
focus_NN
is_VPRT [BEMA]
on_PIN
Central_NN
Nervous_NN
System_NN
CNS_NN
,_,
Gastro-Intestinal_NN
GI_NN
,_,
Human_NN
Genetic_NN
Therapies_NN
Shire_NN
HGT_NN
and_PHC
General_NN
Products_NN
GP_NN
._.
The_DT
structure_NN
is_VPRT [BEMA]
sufficiently_RB
flexible_PRED
to_TO
allow_VB [SUAV]
Shire_NN
to_TO
target_VB
new_JJ
therapeutic_JJ
areas_NN
to_PIN
the_DT
extent_NN
opportunities_NOMZ
arise_VPRT
through_PIN
acquisitions_NOMZ
._.
Shire_NN
believes_VPRT [PRIV]
that_THVC
a_DT
carefully_RB
selected_VBN
portfolio_NN
of_PIN
products_NN
with_PIN
strategically_RB
aligned_VBN
and_CC
relatively_RB
small-scale_JJ
sales_NN
forces_NN
will_PRMD
deliver_VB
strong_JJ
results_NN
._.
Shires_NN
focused_VBD
strategy_NN
is_VPRT
to_TO
develop_VB
and_CC
market_NN
products_NN
for_PIN
specialty_NN
physicians_NN
._.
Shires_NN
in-licensing_GER
,_,
merger_NN
and_PHC
acquisition_NOMZ
efforts_NN
are_VPRT [PASS]
focused_VBN
on_PIN
products_NN
in_PIN
niche_NN
markets_NN
with_PIN
strong_JJ
intellectual_JJ
property_NN
protection_NOMZ
either_RB
in_PIN
the_DT
US_FPP1
or_CC
Europe_NN
._.
Consistent_JJ
with_PIN
this_DEMO
strategy_NN
the_DT
Company_NN
completed_VBD
the_DT
acquisition_NOMZ
of_PIN
Transkaryotic_NN
Therapies_NN
Inc._NN
._.
TKT_NN
on_PIN
July_NN
27_CD
,_,
2005_CD
._.
This_DEMO
acquisition_NOMZ
added_VBD [PUBV]
Shire_NN
HGT_NN
to_PIN
the_DT
Groups_NN
existing_VBG [WZPRES]
business_NOMZ
,_,
which_WDT [SERE]
is_VPRT [BEMA]
complementary_PRED
to_TO
,_,
and_ANDC
consistent_JJ
with_PIN [STPR]
,_,
the_DT
Companys_NN
stated_VBD [PUBV]
strategy_NN
of_PIN
meeting_VBG
the_DT
needs_NN
of_PIN
the_DT
specialist_NN
physician_NN
using_VBG [WZPRES]
small-scale_JJ
sales_NN
forces_NN
._.
TKT_NN
was_VBD [PASS]
renamed_VBN
Shire_NN
Human_NN
Genetic_NN
Therapies_NN
with_PIN
effect_NN
from_PIN
January_NN
17_CD
,_,
2006_CD
._.
2_CD
Change_NN
in_PIN
reporting_VBG [PUBV]
entity_NOMZ
On_PIN
November_NN
25_CD
,_,
2005_CD
,_,
Shire_NN
plc_NN
,_,
a_DT
public_JJ
limited_JJ
Company_NN
incorporated_VBN [WZPAST]
in_PIN
England_NN
and_PHC
Wales_NN
,_,
became_VBD
the_DT
holding_VBG [PRIV]
company_NN
of_PIN
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
SPG_NN
pursuant_JJ
to_PIN
a_DT
Scheme_NN
of_PIN
Arrangement_NOMZ
under_IN
Section_NOMZ
425_CD
of_PIN
the_DT
UK_NN
Companies_NN
Act_NN
1985_CD
that_DEMP
was_VBD [BYPA]
approved_VBN
by_PIN
the_DT
High_NN
Court_NN
of_PIN
Justice_NN
in_PIN
England_NN
and_PHC
Wales_NN
and_CC
the_DT
shareholders_NN
of_PIN
SPG_NN
the_DT
Scheme_NN
of_PIN
Arrangement_NOMZ
._.
Pursuant_JJ
to_PIN
the_DT
Scheme_NN
of_PIN
Arrangement_NOMZ
,_,
ordinary_JJ
shares_NN
,_,
each_QUAN
having_VBG
a_DT
nominal_JJ
value_NN
of_PIN
3.50_CD
,_,
of_PIN
Shire_NN
Shire_NN
Ordinary_NN
Shares_NN
were_VBD [PASS]
exchanged_VBN
for_PIN
ordinary_JJ
shares_NN
,_,
each_QUAN
having_VBG
a_DT
nominal_JJ
value_NN
of_PIN
0.05_CD
of_PIN
SPG_NN
SPG_NN
Ordinary_NN
Shares_NN
,_,
on_PIN
a_DT
one-for-one_JJ
basis_NN
._.
As_CONJ
a_NULL
result_NULL
of_PIN
the_DT
Scheme_NN
of_PIN
Arrangement_NOMZ
,_,
SPG_NN
is_VPRT [BEMA]
now_TIME
a_DT
wholly-owned_JJ
subsidiary_NN
of_PIN
Shire_NN
and_CC
has_VPRT [PEAS]
been_VBN [PASS]
re-registered_VBN
as_IN
a_DT
private_JJ
Company_NN
under_IN
the_DT
name_NN
Shire_NN
Pharmaceuticals_NN
Group_NN
Limited_NN
._.
The_DT
Shire_NN
Ordinary_NN
Shares_NN
carry_VPRT
substantially_RB
the_DT
same_JJ
rights_NN
as_IN
did_VBD [PROD]
the_DT
SPG_NN
Ordinary_NN
Shares_NN
._.
The_DT
Scheme_NN
of_PIN
Arrangement_NOMZ
did_VBD
not_XX0
involve_VB
any_QUAN
payment_NOMZ
for_PIN
the_DT
new_JJ
Shire_NN
Ordinary_NN
Shares_NN
._.
Shires_NN
Board_NN
of_PIN
Directors_NN
,_,
management_NOMZ
and_CC
corporate_JJ
governance_NN
arrangements_NOMZ
immediately_TIME
following_VBG
the_DT
Scheme_NN
of_PIN
Arrangement_NOMZ
were_VBD [BEMA]
the_DT
same_JJ
as_IN
SPG_NN
immediately_TIME
before_IN
the_DT
Scheme_NN
of_PIN
Arrangement_NOMZ
became_VBD
effective_JJ
._.
The_DT
consolidated_JJ
assets_NN
and_PHC
liabilities_NOMZ
of_PIN
Shire_NN
immediately_TIME
after_IN
the_DT
Scheme_NN
of_PIN
Arrangement_NOMZ
were_VBD [BEMA]
the_DT
same_JJ
as_IN
the_DT
consolidated_JJ
assets_NN
and_PHC
liabilities_NOMZ
of_PIN
SPG_NN
immediately_TIME
prior_RB
thereto_RB
._.
The_DT
SPG_NN
Ordinary_NN
Shares_NN
underlying_VBG [WZPRES]
the_DT
SPG_NN
American_NN
Depositary_NN
Shares_NN
the_DT
SPG_NN
ADSs_NN
,_,
each_QUAN
representing_VBG
three_CD
SPG_NN
Ordinary_NN
Shares_NN
,_,
participated_VBD
in_PIN
the_DT
Scheme_NN
of_PIN
Arrangement_NOMZ
like_IN
all_QUAN
other_JJ
SPG_NN
Ordinary_NN
Shares_NN
._.
The_DT
Scheme_NN
of_PIN
Arrangement_NOMZ
did_VBD
not_XX0
involve_VB
any_QUAN
payment_NOMZ
for_PIN
the_DT
new_JJ
Shire_NN
ADSs_NN
,_,
which_WDT [SERE]
represent_VPRT
three_CD
ordinary_JJ
shares_NN
of_PIN
Shire_NN
._.
Shire_NN
was_VBD [PASS]
incorporated_VBN
on_PIN
June_NN
27_CD
,_,
2005_CD
._.
Prior_RB
to_PIN
November_NN
25_CD
,_,
2005_CD
Shire_NN
had_VBD [PEAS]
not_XX0
commenced_VBN
trading_GER
or_CC
made_VBN
any_QUAN
profits_NN
or_CC
trading_GER
losses_NN
._.
On_PIN
November_NN
28_CD
,_,
2005_CD
,_,
the_DT
High_NN
Court_NN
of_PIN
Justice_NN
in_PIN
England_NN
and_PHC
Wales_NN
approved_VBD
a_DT
reduction_NOMZ
of_PIN
Shires_NN
share_NN
capital_NN
to_TO
take_VB
effect_NN
on_PIN
November_NN
29_CD
,_,
2005_CD
,_,
when_RB
the_DT
nominal_JJ
value_NN
of_PIN
each_QUAN
Shire_NN
ordinary_JJ
share_NN
was_VBD [PASS]
reduced_VBN
from_PIN
3.50_CD
to_PIN
0.05_CD
._.
This_DEMO
reduction_NOMZ
increased_VBD
the_DT
distributable_JJ
reserves_NN
potentially_RB
available_JJ
to_TO
Shire_VB
to_TO
approximately_RB
$_$
2.95_CD
billion_CD
,_,
which_WDT [SERE]
the_DT
Directors_NN
of_PIN
Shire_NN
can_POMD
utilize_VB
for_PIN
future_JJ
dividend_NN
payments_NOMZ
at_PIN
their_TPP3
discretion_NOMZ
._.
In_PIN
accordance_NN
with_PIN
Statement_NOMZ
of_PIN
Financial_NN
Accounting_GER
Standards_NN
SFAS_NN
No._NN
._.
141_CD
Accounting_GER
for_PIN
Business_NOMZ
Combinations_NOMZ
,_,
the_DT
corporate_JJ
restructuring_GER
is_VPRT [PASS]
accounted_VBN
for_PIN
as_IN
a_DT
reorganization_NOMZ
of_PIN
entities_NOMZ
under_IN
common_JJ
control_NN
._.
Accordingly_RB
,_,
the_DT
historical_JJ
financial_JJ
statements_NOMZ
prior_RB
to_PIN
the_DT
reorganization_NOMZ
are_VPRT [PASS]
labeled_VBN
as_IN
those_DEMO
of_PIN
Shire_NN
,_,
but_CC
continue_VPRT
to_TO
represent_VB
the_DT
operations_NOMZ
of_PIN
SPG_NN
._.
For_PIN
periods_NN
prior_RB
to_PIN
the_DT
corporate_JJ
restructuring_GER
,_,
the_DT
equity_NOMZ
of_PIN
Shire_NN
represents_VPRT
the_DT
historical_JJ
equity_NOMZ
of_PIN
SPG_NN
,_,
restated_VBN
to_TO
reflect_VB [PRIV]
the_DT
nominal_JJ
value_NN
of_PIN
shares_NN
received_VBN [WZPAST]
in_PIN
the_DT
Scheme_NN
of_PIN
Arrangement_NOMZ
as_IN
adjusted_VBN
by_PIN
the_DT
reduction_NOMZ
of_PIN
capital_NN
._.
The_DT
difference_NN
in_PIN
the_DT
nominal_JJ
value_NN
of_PIN
shares_NN
before_IN
and_CC
after_IN
the_DT
restatement_NOMZ
relates_VPRT
to_PIN
the_DT
effect_NN
of_PIN
foreign_JJ
exchange_NN
movements_NOMZ
and_CC
the_DT
offset_VBN
is_VPRT [PASS]
recorded_VBN
in_PIN
additional_JJ
paid-in_PIN
capital_NN
._.
Earnings_GER
per_PIN
share_NN
are_VPRT [BEMA]
unaffected_PRED
by_PIN
the_DT
reorganization_NOMZ
._.
All_QUAN
SPG_NN
stock_NN
options_NOMZ
granted_VBN [SUAV] [WZPAST]
to_PIN
Directors_NN
and_PHC
employees_NN
under_IN
stock_NN
option_NOMZ
plans_NN
that_TSUB
were_VBD [BEMA]
in_PIN
existence_NN
immediately_TIME
prior_RB
to_PIN
the_DT
Scheme_NN
of_PIN
Arrangement_NOMZ
were_VBD [BEMA]
exchangeable_PRED
for_PIN
stock_NN
options_NOMZ
in_PIN
Shire_NN
on_PIN
a_DT
one-for-one_JJ
basis_NN
with_PIN
no_SYNE
change_NN
in_PIN
any_QUAN
of_PIN
the_DT
terms_NN
or_CC
conditions_NOMZ
._.
The_DT
number_NN
of_PIN
stock_NN
options_NOMZ
for_PIN
which_WDT [PIRE]
this_DEMO
exchange_NN
did_VBD
not_XX0
take_VB
place_NN
was_VBD
not_XX0
material_NN
._.
For_PIN
presented_VBN
periods_NN
prior_RB
to_PIN
the_DT
2005_CD
corporate_JJ
restructuring_GER
,_,
the_DT
equity_NOMZ
of_PIN
Shire_NN
represents_VPRT
the_DT
historical_JJ
equity_NOMZ
of_PIN
SPG_NN
,_,
restated_VBN
to_TO
reflect_VB [PRIV]
the_DT
change_NN
in_PIN
nominal_JJ
value_NN
of_PIN
shares_NN
resulting_VBG [WZPRES]
from_PIN
the_DT
corporate_JJ
restructuring_GER
._.
The_DT
increase_NN
in_PIN
the_DT
value_NN
of_PIN
common_JJ
stock_NN
at_PIN
December_NN
31_CD
,_,
2002_CD
of_PIN
$_$
1.7_CD
million_CD
to_TO
$_$
41.7_CD
million_CD
on_PIN
restatement_NOMZ
is_VPRT [BEMA]
due_PRED
to_PIN
differences_NN
between_PIN
the_DT
historic_JJ
exchange_NN
rates_NN
used_VBN
to_TO
convert_VB
SPGs_NN
Sterling_GER
denominated_VBD
nominal_JJ
share_NN
capital_NN
into_PIN
US_FPP1
Dollars_NN
,_,
and_ANDC
the_DT
exchange_NN
rate_NN
at_PIN
the_DT
time_NN
of_PIN
the_DT
corporate_JJ
restructuring_GER
._.
The_DT
offset_VBN
is_VPRT [PASS]
recorded_VBN
in_PIN
additional_JJ
paid-in_PIN
capital_NN
._.
84_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
85_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
Dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
3_CD
Summary_NN
of_PIN
significant_JJ
accounting_GER
policies_NN
a_DT
Basis_NN
of_PIN
preparation_NOMZ
The_DT
accompanying_VBG
consolidated_JJ
financial_JJ
statements_NOMZ
include_VPRT
the_DT
accounts_NN
of_PIN
Shire_NN
and_CC
all_QUAN
of_PIN
its_PIT
subsidiary_NN
undertakings_GER
after_IN
elimination_NOMZ
of_PIN
intercompany_NN
accounts_NN
and_PHC
transactions_NOMZ
._.
b_NN
Use_NN
of_PIN
estimates_NN
in_PIN
consolidated_JJ
financial_JJ
statements_NOMZ
The_DT
preparation_NOMZ
of_PIN
consolidated_JJ
financial_JJ
statements_NOMZ
,_,
in_PIN
conformity_NOMZ
with_PIN
US_FPP1
generally_RB
accepted_VBD [PRIV]
accounting_GER
principles_NN
GAAP_NN
and_PHC
Securities_NOMZ
Exchange_NN
Commission_NN
SEC_NN
regulations_NOMZ
,_,
requires_VPRT [SUAV]
management_NOMZ
to_TO
make_VB
estimates_NN
and_PHC
assumptions_NOMZ
that_TSUB
affect_VPRT
the_DT
reported_VBN [PUBV]
amounts_NN
of_PIN
assets_NN
and_PHC
liabilities_NOMZ
,_,
disclosure_NN
of_PIN
contingent_JJ
assets_NN
and_PHC
liabilities_NOMZ
at_PIN
the_DT
date_NN
of_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
and_CC
reported_VBD [PUBV]
amounts_NN
of_PIN
revenues_NN
and_PHC
expenses_NN
during_PIN
the_DT
reporting_GER
period_NN
._.
Actual_JJ
results_NN
could_POMD
differ_VB
from_PIN
those_DEMO
estimates_NN
._.
Estimates_NN
and_PHC
assumptions_NOMZ
are_VPRT [SPAU] [PASS]
primarily_RB
made_VBN
in_PIN
relation_NOMZ
to_PIN
provisions_NN
for_PIN
sales_NN
deductions_NOMZ
,_,
valuation_NOMZ
of_PIN
intangible_JJ
assets_NN
and_CC
fixed_VBN
asset_NN
investments_NOMZ
,_,
contingent_JJ
liabilities_NOMZ
,_,
the_DT
valuation_NOMZ
of_PIN
tax_NN
assets_NN
and_PHC
liabilities_NOMZ
,_,
the_DT
valuation_NOMZ
of_PIN
in-process_JJ
research_NN
and_PHC
development_NOMZ
and_PHC
inventory_NN
acquired_VBN [WZPAST]
with_PIN
TKT_NN
and_CC
the_DT
amount_NN
payable_JJ
to_PIN
former_JJ
holders_NN
of_PIN
TKT_NN
common_JJ
stock_NN
of_PIN
approximately_RB
11.3_CD
million_CD
shares_NN
who_WP [WHSUB]
have_VPRT [PEAS]
submitted_VBN [PUBV]
written_VBN [PUBV]
demands_NN
for_PIN
appraisal_NN
of_PIN
these_DEMO
shares_NN
in_PIN
relation_NOMZ
to_PIN
the_DT
Companys_NN
acquisition_NOMZ
of_PIN
TKT_NN
on_PIN
July_NN
27_CD
,_,
2005_CD
._.
c_NN
Revenue_NN
recognition_NOMZ
The_DT
Company_NN
recognizes_VPRT [PRIV]
revenue_NN
when_RB
:_:
there_EX
is_VPRT
persuasive_JJ
evidence_NN
of_PIN
an_DT
agreement_NOMZ
or_CC
arrangement_NOMZ
:_:
delivery_NN
of_PIN
products_NN
has_VPRT [PEAS]
occurred_VBN
or_CC
services_NN
have_VPRT [PEAS]
been_VBN [PASS]
rendered_VBN
:_:
the_DT
sellers_NN
price_NN
to_PIN
the_DT
buyer_NN
is_VPRT [PASS]
fixed_VBN
or_CC
determinable_JJ
:_:
and_ANDC
collectability_NOMZ
is_VPRT [SPAU] [PASS]
reasonably_RB
assured_VBN
._.
The_DT
Companys_NN
principal_JJ
revenue_NN
streams_NN
and_CC
their_TPP3
respective_JJ
accounting_GER
treatments_NOMZ
are_VPRT [PASS]
discussed_VBN
below_PLACE
:_:
i_FPP1
Product_NN
sales_NN
Revenue_NN
for_PIN
the_DT
sales_NN
of_PIN
products_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
upon_PIN
shipment_NOMZ
to_PIN
customers_NN
or_CC
at_PIN
the_DT
time_NN
of_PIN
delivery_NN
depending_VBG [WZPRES]
on_PIN
the_DT
terms_NN
of_PIN
sale_NN
._.
Provisions_NN
for_PIN
rebates_NN
,_,
product_NN
returns_NN
and_PHC
discounts_NN
to_PIN
customers_NN
are_VPRT [PASS]
provided_VBN
for_PIN
as_IN
reductions_NOMZ
to_PIN
revenue_NN
in_PIN
the_DT
same_JJ
period_NN
as_IN
the_DT
related_JJ
sales_NN
are_VPRT [PASS]
recorded_VBN
._.
The_DT
Company_NN
monitors_NN
and_CC
tracks_VPRT
the_DT
amount_NN
of_PIN
sales_NN
deductions_NOMZ
based_VBN [WZPAST]
on_PIN
historical_JJ
experience_NN
to_TO
estimate_VB [PRIV]
the_DT
amount_NN
of_PIN
reduction_NOMZ
to_PIN
revenue_NN
._.
ii_FW
Licensing_GER
and_PHC
development_NOMZ
fees_NN
Licensing_VBG [WZPRES]
and_CC
development_NOMZ
fees_NN
represent_VPRT
revenues_NN
derived_VBN [WZPAST]
from_PIN
product_NN
out-licensing_JJ
agreements_NOMZ
and_CC
from_PIN
contract_NN
research_NN
and_PHC
development_NOMZ
agreements_NOMZ
._.
Initial_JJ
license_NN
fees_NN
received_VBN [WZPAST]
in_PIN
connection_NOMZ
with_PIN
product_NN
out-licensing_JJ
agreements_NOMZ
,_,
even_RB
where_RB
such_JJ
fees_NN
are_VPRT [BEMA]
non-refundable_PRED
and_CC
not_XX0
creditable_JJ
against_PIN
future_JJ
royalty_NN
payments_NOMZ
,_,
are_VPRT [PASS]
deferred_VBN
and_PHC
recognized_VBN [PRIV]
over_IN
the_DT
period_NN
of_PIN
the_DT
license_NN
term_NN
,_,
or_CC
the_DT
period_NN
of_PIN
the_DT
associated_VBN
collaborative_JJ
assistance_NN
._.
In_PIN
circumstances_NN
where_RB
initial_JJ
license_NN
fees_NN
are_VPRT [BEMA]
not_XX0
for_PIN
a_DT
defined_VBN
period_NN
,_,
revenues_NN
are_VPRT [PASS]
deferred_VBN
and_PHC
recognized_VBN [PRIV]
over_IN
the_DT
period_NN
to_PIN
the_DT
expiration_NOMZ
of_PIN
the_DT
relevant_JJ
patent_NN
to_PIN
which_WDT [PIRE]
the_DT
license_NN
relates_VPRT
._.
Revenue_NN
from_PIN
contract_NN
research_NN
and_PHC
development_NOMZ
agreements_NOMZ
is_VPRT [PASS]
recognized_VBN [PRIV]
as_IN
the_DT
services_NN
are_VPRT [PASS]
performed_VBN
._.
iii_FW
Royalty_NN
income_NN
Royalty_NN
income_NN
relating_VBG [WZPRES]
to_PIN
licensed_JJ
technology_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
when_RB [WHCL]
the_DT
licensee_NN
sells_VPRT
the_DT
underlying_JJ
product_NN
._.
The_DT
Company_NN
receives_VPRT
sales_NN
information_NOMZ
from_PIN
the_DT
licensee_NN
on_PIN
a_DT
monthly_JJ
basis_NN
._.
For_PIN
any_QUAN
period_NN
that_TOBJ
the_DT
information_NOMZ
is_VPRT [BEMA]
not_XX0
available_PRED
,_,
the_DT
Company_NN
estimates_VPRT [PRIV]
sales_NN
amounts_NN
based_VBN [WZPAST]
on_PIN
the_DT
historical_JJ
product_NN
information_NOMZ
._.
Where_RB
applicable_JJ
,_,
all_QUAN
revenues_NN
are_VPRT [PASS]
stated_VBN [PUBV]
net_NN
of_PIN
value_NN
added_VBD [PUBV]
tax_NN
and_CC
similar_JJ
taxes_NN
,_,
and_ANDC
trade_NN
discounts_NN
._.
No_SYNE
revenue_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
for_PIN
consideration_NOMZ
,_,
the_DT
value_NN
or_CC
receipt_NN
of_PIN
which_WDT [PIRE]
is_VPRT [BEMA]
dependent_PRED
on_PIN
future_JJ
events_NN
,_,
future_JJ
performance_NN
,_,
or_CC
refund_NN
obligations_NOMZ
._.
iv_NN
Milestones_NN
During_PIN
the_DT
term_NN
of_PIN
certain_JJ
research_NN
and_PHC
development_NOMZ
agreements_NOMZ
and_PHC
licensing_GER
agreements_NOMZ
,_,
the_DT
Company_NN
receives_VPRT
non-refundable_JJ
milestones_NN
as_IN
certain_JJ
technical_JJ
targets_NN
are_VPRT [PASS]
achieved_VBN
._.
Revenues_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
on_PIN
achievement_NOMZ
of_PIN
such_JJ
milestones_NN
._.
The_DT
Company_NN
also_RB
receives_VPRT
non-refundable_JJ
clinical_JJ
milestones_NN
when_RB
certain_JJ
targets_NN
are_VPRT [PASS]
achieved_VBN
during_PIN
the_DT
clinical_JJ
phases_NN
of_PIN
development_NOMZ
,_,
such_JJ
as_IN
the_DT
submission_NN
of_PIN
clinical_JJ
data_NN
to_PIN
a_DT
regulatory_JJ
authority_NOMZ
._.
These_DEMO
clinical_JJ
milestones_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
when_RB [WHCL]
receivable_JJ
i._NN
e._NN
on_PIN
completion_NOMZ
of_PIN
the_DT
relevant_JJ
phase_NN
._.
If_COND
milestone_NN
payments_NOMZ
are_VPRT [BEMA]
creditable_PRED
against_PIN
future_JJ
royalty_NN
payments_NOMZ
,_,
the_DT
milestones_NN
are_VPRT [PASS]
deferred_VBN
and_PHC
released_VBN
over_IN
the_DT
period_NN
in_PIN
which_WDT [PIRE]
the_DT
royalties_NN
are_VPRT [PASS]
anticipated_VBN [PRIV]
to_TO
be_VB [PASS]
paid_VBN
._.
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
85_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
86_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
Dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
3_CD
Summary_NN
of_PIN
significant_JJ
accounting_GER
policies_NN
continued_VBD
d_SYM
Sales_NN
deductions_NOMZ
i_FPP1
Rebates_NN
Rebates_NN
primarily_RB
consist_VPRT
of_PIN
statutory_JJ
rebates_NN
to_PIN
state_NN
Medicaid_NN
agencies_NN
and_CC
contractual_JJ
rebates_NN
with_PIN
health-maintenance_NN
organizations_NOMZ
._.
These_DEMO
rebates_NN
are_VPRT [PASS]
based_VBN
on_PIN
price_NN
differentials_NN
between_PIN
a_DT
base_NN
price_NN
and_CC
the_DT
selling_GER
price_NN
._.
As_CONJ
a_NULL
result_NULL
,_,
rebates_NN
generally_RB
increase_VB
as_IN
a_DT
percentage_NN
of_PIN
the_DT
selling_GER
price_NN
over_IN
the_DT
life_NN
of_PIN
the_DT
product_NN
as_IN
prices_NN
increase_NN
._.
Provisions_NN
for_PIN
rebates_NN
are_VPRT [PASS]
recorded_VBN
as_IN
reductions_NOMZ
to_PIN
revenue_NN
in_PIN
the_DT
same_JJ
period_NN
as_IN
the_DT
related_JJ
sales_NN
,_,
with_PIN
estimates_NN
of_PIN
future_JJ
utilization_NOMZ
derived_VBN [WZPAST]
from_PIN
historical_JJ
trends_NN
._.
ii_FW
Returns_NN
The_DT
Company_NN
estimates_VPRT [PRIV]
the_DT
proportion_NOMZ
of_PIN
recorded_JJ
revenue_NN
that_TSUB
will_PRMD
result_VB
in_PIN
a_DT
return_NN
,_,
based_VBN [PASTP]
on_PIN
historical_JJ
trends_NN
and_ANDC
when_RB
applicable_JJ
,_,
specific_JJ
factors_NN
affecting_VBG [WZPRES]
certain_JJ
products_NN
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
The_DT
accrual_NN
is_VPRT [PASS]
recorded_VBN
as_IN
a_DT
reduction_NOMZ
to_PIN
revenue_NN
in_PIN
the_DT
same_JJ
period_NN
as_IN
the_DT
related_JJ
sales_NN
are_VPRT [PASS]
recorded_VBN
._.
iii_FW
Coupons_NN
The_DT
Company_NN
uses_VPRT
coupons_NN
as_IN
a_DT
form_NN
of_PIN
sales_NN
incentive_NN
._.
An_DT
accrual_NN
is_VPRT [PASS]
established_VBN [PRIV]
based_VBN
on_PIN
the_DT
Companys_NN
expectation_NOMZ
of_PIN
the_DT
level_NN
of_PIN
coupon_NN
redemption_NOMZ
,_,
using_VBG
historical_JJ
trends_NN
._.
iv_FW
Discounts_NN
The_DT
Company_NN
offers_VPRT
cash_NN
discounts_NN
to_PIN
customers_NN
for_PIN
the_DT
early_TIME
payment_NOMZ
of_PIN
receivables_NN
._.
Those_DEMO
discounts_NN
are_VPRT [PASS]
recorded_VBN
as_IN
reductions_NOMZ
to_PIN
revenue_NN
and_PHC
accounts_NN
receivable_NN
in_PIN
the_DT
same_JJ
period_NN
that_TOBJ
the_DT
related_JJ
sale_NN
is_VPRT [PASS]
recorded_VBN
._.
v_FW
Wholesaler_NN
chargebacks_VPRT
The_DT
Company_NN
has_VPRT
contractual_JJ
agreements_NOMZ
whereby_OSUB
it_PIT
supplies_VPRT
certain_JJ
products_NN
to_PIN
third_JJ
parties_NN
at_PIN
predetermined_VBN
prices_NN
._.
Wholesalers_NN
acting_VBG [WZPRES]
as_IN
intermediaries_NN
in_PIN
these_DEMO
transactions_NOMZ
are_VPRT [BYPA]
reimbursed_VBN
by_PIN
the_DT
Company_NN
if_COND
the_DT
predetermined_VBN
prices_NN
are_VPRT [BEMA]
less_PRED
than_PIN
the_DT
prices_NN
paid_VBN [WZPAST]
by_PIN
the_DT
wholesaler_NN
to_PIN
the_DT
Company_NN
._.
Accruals_NN
for_PIN
wholesaler_NN
chargebacks_NN
,_,
which_WDT [SERE]
are_VPRT [PASS]
based_VBN
on_PIN
historical_JJ
trends_NN
,_,
are_VPRT [PASS]
recorded_VBN
as_IN
reductions_NOMZ
to_PIN
revenue_NN
in_PIN
the_DT
same_JJ
period_NN
as_IN
the_DT
related_JJ
sales_NN
are_VPRT [PASS]
recorded_VBN
._.
e_LS
Cost_NN
of_PIN
product_NN
sales_NN
Cost_NN
of_PIN
sales_NN
includes_VPRT
both_DT
the_DT
cost_NN
of_PIN
purchasing_VBG
finished_JJ
product_NN
for_PIN
sale_NN
,_,
together_RB
with_PIN
the_DT
cost_NN
of_PIN
raw_JJ
materials_NN
and_CC
manufacturing_VBG
for_PIN
those_DEMO
products_NN
that_TSUB
are_VPRT [BYPA]
manufactured_VBN
by_PIN
the_DT
Company_NN
._.
Royalties_NN
that_TSUB
are_VPRT [BEMA]
payable_PRED
on_PIN
those_DEMO
products_NN
that_TOBJ
the_DT
Company_NN
does_VPRT
not_XX0
own_VB
the_DT
rights_NN
to_TO
are_VB [SPAU] [PASS]
also_RB
included_VBN
in_PIN
cost_NN
of_PIN
sales_NN
._.
f_LS
Leased_VBN
assets_NN
The_DT
costs_NN
of_PIN
operating_VBG
leases_NN
are_VPRT [PASS]
charged_VBN
to_PIN
operations_NOMZ
on_PIN
a_DT
straight-line_JJ
basis_NN
over_IN
the_DT
lease_NN
term_NN
,_,
even_RB
if_COND
rental_JJ
payments_NOMZ
are_VPRT [PASS]
not_XX0
made_VBN
on_PIN
such_EMPH
a_NULL
basis_NN
._.
Assets_NN
acquired_VBN
under_IN
capital_NN
leases_NN
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
balance_NN
sheet_NN
as_IN
tangible_JJ
fixed_JJ
assets_NN
and_CC
are_VPRT [PASS]
depreciated_VBN
over_IN
the_DT
shorter_JJ
of_PIN
the_DT
period_NN
of_PIN
the_DT
lease_NN
or_CC
their_TPP3
useful_JJ
lives_NN
._.
The_DT
capital_NN
elements_NOMZ
of_PIN
future_JJ
lease_NN
payments_NOMZ
are_VPRT [PASS]
recorded_VBN
as_IN
liabilities_NOMZ
,_,
while_OSUB
the_DT
interest_NN
element_NOMZ
is_VPRT [PASS]
charged_VBN
to_PIN
operations_NOMZ
over_IN
the_DT
period_NN
of_PIN
the_DT
lease_NN
to_TO
produce_VB
a_DT
level_NN
yield_NN
on_PIN
the_DT
balance_NN
of_PIN
the_DT
capital_NN
lease_NN
obligation_NOMZ
._.
g_NN
Advertising_GER
expense_NN
The_DT
Company_NN
expenses_NN
the_DT
cost_NN
of_PIN
advertising_GER
as_IN
incurred_VBN
._.
Advertising_GER
costs_NN
amounted_VBD
to_TO
$_$
62.3_CD
million_CD
,_,
$_$
47.6_CD
million_CD
,_,
and_ANDC
$_$
40.7_CD
million_CD
for_PIN
the_DT
years_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
,_,
2004_CD
and_CC
2003_CD
respectively_RB
._.
h_NN
Valuation_NOMZ
and_PHC
impairment_NOMZ
of_PIN
long-lived_JJ
assets_NN
other_JJ
than_PIN
goodwill_NN
and_PHC
investments_NOMZ
The_DT
Company_NN
evaluates_VPRT
the_DT
carrying_VBG
value_NN
of_PIN
long-lived_JJ
assets_NN
other_JJ
than_PIN
goodwill_NN
and_PHC
investments_NOMZ
for_PIN
impairment_NOMZ
whenever_RB
events_NN
or_CC
changes_NN
in_PIN
circumstances_NN
indicate_VPRT [PRIV]
that_THVC
the_DT
carrying_VBG
amounts_NN
of_PIN
the_DT
assets_NN
may_POMD
not_XX0
be_VB [BEMA]
recoverable_PRED
._.
When_RB
such_EMPH
a_NULL
determination_NOMZ
is_VPRT [PASS]
made_VBN
,_,
managements_NOMZ
estimate_NN
of_PIN
undiscounted_JJ
cash_NN
flows_VPRT
to_TO
be_VB [BYPA]
generated_VBN
by_PIN
the_DT
assets_NN
is_VPRT [PASS]
compared_VBN
to_PIN
the_DT
carrying_VBG
value_NN
of_PIN
the_DT
assets_NN
to_TO
determine_VB [SUAV] [PRIV]
whether_IN [WHCL]
an_DT
impairment_NOMZ
has_VPRT [PEAS]
occurred_VBN
._.
If_COND
an_DT
impairment_NOMZ
is_VPRT [PASS]
indicated_VBN [PRIV]
,_,
the_DT
amount_NN
of_PIN
the_DT
impairment_NOMZ
recognized_VBN [PRIV] [WZPAST]
in_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
is_VPRT [BYPA]
determined_VBN [SUAV] [PRIV]
by_PIN
estimating_VBG [PRIV]
the_DT
fair_JJ
value_NN
of_PIN
the_DT
assets_NN
and_CC
recording_VBG
a_DT
loss_NN
for_PIN
the_DT
amount_NN
that_TOBJ
the_DT
carrying_VBG
value_NN
exceeds_VPRT
the_DT
estimated_VBN [PRIV]
fair_JJ
value_NN
._.
This_DEMO
fair_JJ
value_NN
is_VPRT [SPAU] [PASS]
usually_RB
determined_VBN [SUAV] [PRIV]
based_VBN
on_PIN
estimated_VBN [PRIV]
discounted_JJ
cash_NN
flows_NN
._.
i_FPP1
Finance_NN
costs_NN
of_PIN
debt_NN
Finance_NN
costs_NN
of_PIN
debt_NN
are_VPRT [PASS]
recorded_VBN
as_IN
a_DT
deferred_JJ
asset_NN
and_CC
amortized_VBN
to_PIN
the_DT
statement_NOMZ
of_PIN
operations_NOMZ
over_IN
the_DT
term_NN
of_PIN
the_DT
debt_NN
,_,
using_VBG [PRESP]
the_DT
effective_JJ
interest_NN
rate_NN
method_NN
._.
Deferred_JJ
financing_GER
costs_NN
relating_VBG [WZPRES]
to_PIN
debt_NN
extinguishments_NOMZ
are_VPRT [PASS]
written_VBN [PUBV]
off_PIN
and_CC
reflected_VBN [PRIV]
in_PIN
interest_NN
expense_NN
in_PIN
the_DT
consolidated_JJ
statements_NOMZ
of_PIN
operations_NOMZ
._.
j_NN
Foreign_NN
currency_NN
Monetary_NN
assets_NN
and_PHC
liabilities_NOMZ
in_PIN
foreign_JJ
currencies_NN
are_VPRT [PASS]
translated_VBN
into_PIN
the_DT
relevant_JJ
functional_JJ
currency_NN
at_PIN
the_DT
rate_NN
of_PIN
exchange_NN
ruling_NN
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
Transactions_NOMZ
in_PIN
foreign_JJ
currencies_NN
are_VPRT [PASS]
translated_VBN
into_PIN
the_DT
relevant_JJ
functional_JJ
currency_NN
at_PIN
the_DT
rate_NN
of_PIN
exchange_NN
ruling_NN
at_PIN
the_DT
date_NN
of_PIN
the_DT
transaction_NOMZ
._.
Transaction_NOMZ
gains_NN
and_PHC
losses_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
arriving_VBG
at_PIN
operating_VBG
net_JJ
loss_NN
income_NN
._.
The_DT
results_NN
of_PIN
overseas_PLACE
operations_NOMZ
,_,
whose_WPS
functional_JJ
currency_NN
is_VPRT
not_XX0
US_FPP1
Dollars_NN
,_,
are_VPRT [PASS]
translated_VBN
at_PIN
the_DT
average_JJ
monthly_JJ
rates_NN
of_PIN
exchange_NN
during_PIN
the_DT
period_NN
and_CC
their_TPP3
balance_NN
sheets_NN
at_PIN
the_DT
rates_NN
ruling_VBG [SUAV] [WZPRES]
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
The_DT
cumulative_JJ
effect_NN
of_PIN
exchange_NN
rate_NN
movements_NOMZ
is_VPRT [PASS]
included_VBN
in_PIN
a_DT
separate_JJ
component_NN
of_PIN
other_JJ
comprehensive_JJ
income_NN
._.
86_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
87_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
Dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
3_CD
Summary_NN
of_PIN
significant_JJ
accounting_GER
policies_NN
continued_VBD
Foreign_JJ
currency_NN
exchange_NN
transaction_NOMZ
gains_NN
and_PHC
losses_NN
on_PIN
an_DT
after-tax_JJ
basis_NN
included_VBD
in_PIN
consolidated_JJ
net_JJ
income_NN
in_PIN
the_DT
years_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
,_,
2004_CD
,_,
and_ANDC
2003_CD
,_,
amounted_VBD
to_PIN
a_DT
$_$
1.4_CD
million_CD
loss_NN
,_,
$_$
2.5_CD
million_CD
loss_NN
and_CC
$_$
6.7_CD
million_CD
loss_NN
,_,
respectively_RB
._.
k_NN
Income_NN
taxes_NN
The_DT
Company_NN
provides_VPRT
for_PIN
income_NN
taxes_NN
in_PIN
accordance_NN
with_PIN
SFAS_NN
No._NN
._.
Deferred_JJ
tax_NN
assets_NN
and_PHC
liabilities_NOMZ
are_VPRT [PASS]
provided_VBN
for_PIN
differences_NN
between_PIN
the_DT
carrying_VBG
amounts_NN
of_PIN
assets_NN
and_PHC
liabilities_NOMZ
in_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
and_CC
the_DT
tax_NN
bases_NN
of_PIN
assets_NN
and_PHC
liabilities_NOMZ
that_TSUB
will_PRMD
result_VB
in_PIN
future_JJ
taxable_JJ
or_CC
deductible_JJ
amounts_NN
._.
The_DT
deferred_JJ
tax_NN
assets_NN
and_PHC
liabilities_NOMZ
are_VPRT [PASS]
measured_VBN
using_VBG
the_DT
enacted_VBN
tax_NN
laws_NN
and_PHC
rates_NN
applicable_JJ
to_PIN
the_DT
periods_NN
in_PIN
which_WDT [PIRE]
the_DT
differences_NN
are_VPRT [PASS]
expected_VBN [PRIV]
to_TO
affect_VB
taxable_JJ
income_NN
._.
Income_NN
tax_NN
expense_NN
is_VPRT [PASS]
computed_VBN
as_IN
the_DT
tax_NN
payable_JJ
or_CC
refundable_JJ
for_PIN
the_DT
period_NN
,_,
plus_PIN
or_CC
minus_PIN
the_DT
change_NN
during_PIN
the_DT
period_NN
in_PIN
deferred_JJ
tax_NN
assets_NN
and_PHC
liabilities_NOMZ
._.
Deferred_JJ
tax_NN
assets_NN
are_VPRT [BYPA]
reduced_VBN
by_PIN
a_DT
valuation_NOMZ
allowance_NN
when_RB
,_,
in_PIN
the_DT
opinion_NN
of_PIN
management_NOMZ
,_,
it_PIT
is_VPRT [BEMA]
more_EMPH
likely_PRED
than_PIN
not_XX0
that_DEMO
some_QUAN
portion_NOMZ
or_CC
all_QUAN
of_PIN
the_DT
deferred_JJ
tax_NN
assets_NN
will_PRMD
not_XX0
be_VB [PASS]
realized_VBN [PRIV]
._.
l_NN
Earnings_GER
per_PIN
share_NN
Earnings_GER
per_PIN
share_NN
is_VPRT [PASS]
computed_VBN
in_PIN
accordance_NN
with_PIN
SFAS_NN
No._NN
._.
Basic_JJ
earnings_GER
per_PIN
share_NN
is_VPRT [PASS]
based_VBN
upon_PIN
net_JJ
income_NN
loss_NN
available_JJ
to_PIN
ordinary_JJ
shareholders_NN
divided_VBN [WZPAST]
by_PIN
the_DT
weighted_JJ
average_JJ
number_NN
of_PIN
ordinary_JJ
shares_NN
outstanding_JJ
during_PIN
the_DT
period_NN
._.
Diluted_JJ
earnings_GER
per_PIN
share_NN
is_VPRT [PASS]
based_VBN
upon_PIN
net_JJ
income_NN
loss_NN
available_JJ
to_PIN
ordinary_JJ
shareholders_NN
adjusted_VBN [WZPAST]
for_PIN
the_DT
impact_NN
on_PIN
interest_NN
expense_NN
of_PIN
including_VBG
convertible_JJ
debt_NN
in_PIN
ordinary_JJ
share_NN
equivalents_NN
on_PIN
an_DT
if_COND
converted_VBN
basis_NN
divided_VBN [WZPAST]
by_PIN
the_DT
weighted_JJ
average_JJ
number_NN
of_PIN
ordinary_JJ
share_NN
equivalents_NN
outstanding_JJ
during_PIN
the_DT
period_NN
,_,
adjusted_VBN [PASTP]
for_PIN
the_DT
effect_NN
of_PIN
all_QUAN
dilutive_JJ
potential_JJ
ordinary_JJ
shares_NN
that_TSUB
were_VBD [BEMA]
outstanding_PRED
during_PIN
the_DT
year_NN
._.
Such_JJ
potentially_RB
dilutive_JJ
shares_NN
are_VPRT [PASS]
excluded_VBN
when_RB
the_DT
effect_NN
would_PRMD
be_VB
to_TO
increase_VB
earnings_GER
per_PIN
share_NN
or_CC
reduce_VB
a_DT
loss_NN
per_PIN
share_NN
._.
m_VB
Employee_NN
stock_NN
plans_VPRT
The_DT
Company_NN
accounts_NN
for_PIN
its_PIT
stock_NN
options_NOMZ
using_VBG [WZPRES]
the_DT
intrinsic-value_JJ
method_NN
prescribed_VBN [WZPAST]
in_PIN
Accounting_GER
Principles_NN
Board_NN
Opinion_NN
No._NN
._.
25_CD
,_,
Accounting_GER
for_PIN
Stock_NN
Issued_NN
to_PIN
Employees_NN
APB_NN
No._NN
._.
Accordingly_RB
,_,
compensation_NOMZ
cost_NN
of_PIN
stock_NN
options_NOMZ
is_VPRT [PASS]
measured_VBN
as_IN
the_DT
excess_NN
,_,
if_COND
any_QUAN
,_,
of_PIN
the_DT
quoted_VBN
market_NN
price_NN
of_PIN
Shires_NN
ordinary_JJ
shares_NN
at_PIN
the_DT
measurement_NOMZ
date_NN
over_IN
the_DT
option_NOMZ
exercise_NN
price_NN
and_CC
is_VPRT [PASS]
charged_VBN
to_PIN
operations_NOMZ
over_IN
the_DT
vesting_JJ
period_NN
._.
For_PIN
plans_NN
where_RB
the_DT
measurement_NOMZ
date_NN
occurs_VPRT
after_IN
the_DT
grant_NN
date_NN
,_,
referred_VBD
to_PIN
as_IN
variable_JJ
plans_NN
,_,
compensation_NOMZ
cost_NN
is_VPRT [BEMA]
re-measured_PRED
on_PIN
the_DT
basis_NN
of_PIN
the_DT
current_JJ
market_NN
value_NN
of_PIN
Shires_NN
ordinary_JJ
shares_NN
at_PIN
the_DT
end_NN
of_PIN
each_QUAN
reporting_GER
period_NN
._.
The_DT
Company_NN
recognizes_VPRT [PRIV]
compensation_NOMZ
expense_NN
for_PIN
variable_JJ
plans_NN
with_PIN
performance_NN
conditions_NOMZ
if_COND
achievement_NOMZ
of_PIN
those_DEMO
conditions_NOMZ
becomes_VPRT
probable_JJ
._.
123_CD
,_,
Accounting_GER
for_PIN
Stock_NN
Based_VBD
Compensation_NOMZ
SFAS_NN
No._NN
._.
123_CD
,_,
the_DT
Company_NN
has_VPRT [PEAS]
included_VBN
in_PIN
these_DEMO
financial_JJ
statements_NOMZ
the_DT
required_JJ
pro-forma_FW
disclosures_NN
as_IN
if_COND
the_DT
fair_JJ
value_NN
method_NN
of_PIN
accounting_GER
had_VBD [PEAS]
been_VBN [PASS]
applied_VBN
._.
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
,_,
the_DT
Company_NN
had_VBD
seven_CD
stock-based_JJ
employee_NN
compensation_NOMZ
plans_NN
,_,
which_WDT [SERE]
are_VPRT [PASS]
described_VBN
more_EMPH
fully_AMP
in_PIN
Note_NN
31_CD
._.
The_DT
following_VBG
table_NN
illustrates_VPRT
the_DT
effect_NN
on_PIN
net_JJ
income_NN
and_PHC
earnings_GER
per_PIN
share_NN
if_COND
the_DT
Company_NN
had_VBD [PEAS]
applied_VBN
the_DT
fair_JJ
value_NN
recognition_NOMZ
provisions_NN
of_PIN
SFAS_NN
No._NN
._.
2005 2004 2003_CD
Year_NN
to_PIN
December_NN
31_CD
,_,
$_$
000_CD
$_$
000_CD
$_$
000_CD
Net_JJ
loss_NN
income_NN
,_,
as_IN
reported_VBN [PUBV]
410,843_CD
269,007_CD
276,051_CD
Add_VB [PUBV]
:_:
Stock-based_JJ
employee_NN
compensation_NOMZ
charge_NN
credit_NN
included_VBN [WZPAST]
in_PIN
reported_JJ
net_JJ
income_NN
,_,
net_NN
of_PIN
related_JJ
tax_NN
effects_NN
392_CD
216_CD
24_CD
Deduct_NN
:_:
Total_JJ
stock-based_JJ
employee_NN
compensation_NOMZ
expense_NN
determined_VBN [SUAV] [PRIV]
under_IN
a_DT
fair_JJ
value_NN
based_VBN
method_NN
for_PIN
all_QUAN
awards_NN
,_,
net_NN
of_PIN
related_JJ
tax_NN
effects_NN
25,982_CD
32,966_CD
31,956_CD
Pro_PIN
forma_FW
net_JJ
loss_NN
income_NN
436,433_CD
236,257_CD
244,071_CD
2005 2004 2003_CD
Year_NN
to_PIN
December_NN
31_CD
,_,
Earnings_GER
per_PIN
share_NN
As_IN
reported_VBN [PUBV]
basic_JJ
82.1_CD
54.2_CD
55.4_CD
As_IN
reported_VBN [PUBV]
diluted_VBN
82.1_CD
53.3_CD
54.2_CD
Pro-forma_JJ
basic_JJ
87.2_CD
47.6_CD
49.0_CD
Pro-forma_JJ
diluted_VBN
87.2_CD
46.9_CD
48.0_CD
The_DT
fair_JJ
value_NN
of_PIN
the_DT
share-based_JJ
payment_NOMZ
used_VBN
to_TO
compute_VB
pro-forma_FW
net_JJ
loss_NN
income_NN
and_CC
per_PIN
share_NN
disclosures_NN
represents_VPRT
the_DT
estimated_VBN [PRIV]
present_JJ
value_NN
at_PIN
grant_NN
date_NN
using_VBG [WZPRES]
the_DT
Black-Scholes_NN
option-pricing_GER
model_NN
with_PIN
the_DT
following_VBG
weighted_JJ
average_JJ
assumptions_NOMZ
:_:
Year_NN
to_PIN
December_NN
31_CD
,_,
2005 2004 2003_CD
Risk-free_JJ
interest_NN
rate_NN
3.93_CD
4.59_CD
%_NN
2.46_CD
4.19_CD
%_NN
1.89_CD
3.40_CD
%_NN
Expected_VBN [PRIV]
dividend_NN
yield_NN
0.6_CD
%_NN
0_CD
%_NN
:_:
0.6_CD
%_NN
0_CD
%_NN
Weighted_JJ
average_NN
expected_VBN [PRIV]
life_NN
6.5_CD
years_NN
6.8_CD
years_NN
4.9_CD
years_NN
Weighted_JJ
average_NN
expected_VBN [PRIV]
volatility_NOMZ
47.7_CD
%_NN
48.5_CD
%_NN
60.0_CD
%_NN
From_PIN
January_NN
1_CD
,_,
2006_CD
the_DT
Company_NN
will_PRMD
apply_VB
SFAS_NN
No._NN
._.
123_CD
revised_VBN
2004_CD
,_,
Share-Based_NN
Payment_NOMZ
SFAS_NN
No._NN
._.
123R_CD
issued_VBN
by_PIN
the_DT
Financial_NN
Accounting_GER
Standards_NN
Board_NN
FASB_NN
in_PIN
December_NN
2004_CD
._.
See_VB [PRIV]
Note_NN
3_CD
x_SYM
iii_FW
for_PIN
details_NN
._.
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
87_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
88_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
Dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
3_CD
Summary_NN
of_PIN
significant_JJ
accounting_GER
policies_NN
continued_VBD
n_JJ
Cash_NN
and_PHC
cash_NN
equivalents_NN
Cash_NN
and_PHC
cash_NN
equivalents_NN
are_VPRT [PASS]
defined_VBN
as_IN
short-term_JJ
highly_AMP
liquid_JJ
investments_NOMZ
with_PIN
original_JJ
maturities_NOMZ
of_PIN
90_CD
days_NN
or_CC
less_JJ
._.
o_NN
Short-term_JJ
investments_NOMZ
Short-term_JJ
investments_NOMZ
consist_VPRT
of_PIN
commercial_JJ
paper_NN
and_CC
institutional_JJ
and_CC
managed_VBD
cash_NN
funds_NN
._.
In_PIN
accordance_NN
with_PIN
SFAS_NN
No._NN
._.
115_CD
,_,
Accounting_GER
for_PIN
Certain_NN
Investments_NOMZ
in_PIN
Debt_NN
and_PHC
Equity_NOMZ
Securities_NOMZ
SFAS_NN
No._NN
._.
115_CD
,_,
and_ANDC
based_VBN
on_PIN
the_DT
Companys_NN
intentions_NOMZ
regarding_VBG [WZPRES]
these_DEMO
instruments_NOMZ
,_,
the_DT
Company_NN
has_VPRT [PEAS]
classified_VBN
all_QUAN
short-term_JJ
investments_NOMZ
held_VBN [PRIV] [WZPAST]
at_PIN
December_NN
31_CD
,_,
2005_CD
as_IN
available-for-sale_JJ
._.
Accordingly_RB
,_,
the_DT
Company_NN
records_NN
these_DEMO
investments_NOMZ
at_PIN
their_TPP3
fair_JJ
values_NN
with_PIN
unrealized_JJ
gains_NN
and_PHC
losses_NN
included_VBD
in_PIN
the_DT
consolidated_JJ
statements_NOMZ
of_PIN
comprehensive_JJ
income_NN
,_,
net_NN
of_PIN
any_QUAN
related_JJ
tax_NN
effect_NN
._.
Realized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
and_PHC
declines_NN
in_PIN
value_NN
judged_VBN [PRIV]
to_TO
be_VB [BEMA]
other-than-temporary_PRED
on_PIN
available-for-sale_JJ
securities_NOMZ
are_VPRT [PASS]
included_VBN
in_PIN
other_JJ
income_NN
expense_NN
,_,
net_JJ
see_VPRT [PRIV]
Note_NN
26_CD
._.
Institutional_JJ
and_CC
managed_VBD
cash_NN
funds_NN
are_VPRT [BEMA]
short-term_JJ
money_NN
market_NN
instruments_NOMZ
,_,
including_VBG
bank_NN
and_PHC
building_GER
society_NN
term_NN
deposits_NN
and_CC
other_JJ
debt_NN
securities_NOMZ
from_PIN
a_DT
variety_NN
of_PIN
companies_NN
with_PIN
strong_JJ
credit_NN
ratings_GER
._.
p_NN
Financial_NN
instruments_NOMZ
derivatives_NN
The_DT
Company_NN
uses_VPRT
derivative_JJ
financial_JJ
instruments_NOMZ
to_TO
manage_VB
its_PIT
exposure_NN
to_PIN
foreign_JJ
exchange_NN
risk_NN
associated_VBN [WZPAST]
with_PIN
intercompany_NN
loan_NN
arrangements_NOMZ
._.
These_DEMO
instruments_NOMZ
consist_VPRT
of_PIN
forward_RB
foreign_JJ
exchange_NN
contracts_NN
and_CC
foreign_JJ
exchange_NN
swaps_NN
._.
The_DT
Company_NN
does_VPRT
not_XX0
adopt_VB
hedge_JJ
accounting_GER
treatment_NOMZ
for_PIN
these_DEMO
instruments_NOMZ
and_PHC
movements_NOMZ
in_PIN
their_TPP3
fair_JJ
values_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
statement_NOMZ
of_PIN
operations_NOMZ
._.
The_DT
fair_JJ
values_NN
of_PIN
these_DEMO
instruments_NOMZ
are_VPRT [PASS]
included_VBN
on_PIN
the_DT
balance_NN
sheet_NN
in_PIN
current_JJ
assets_NN
liabilities_NOMZ
._.
q_NN
Inventories_NN
Inventories_NN
are_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
the_DT
lower_JJ
of_PIN
cost_NN
including_VBG [WZPRES]
manufacturing_GER
overheads_NN
,_,
where_RB
appropriate_JJ
or_CC
net_JJ
realizable_JJ
value_NN
._.
Cost_NN
incurred_VBN [WZPAST]
in_PIN
bringing_VBG
each_QUAN
product_NN
to_PIN
its_PIT
present_JJ
location_NOMZ
and_PHC
condition_NOMZ
is_VPRT [PASS]
based_VBN
on_PIN
purchase_NN
costs_NN
calculated_VBN [PRIV] [WZPAST]
on_PIN
a_DT
first-in_PIN [STPR]
,_,
first-out_PIN
basis_NN
,_,
including_VBG
transport_NN
._.
Net_JJ
realizable_JJ
value_NN
is_VPRT [PASS]
based_VBN
on_PIN
estimated_VBN [PRIV]
normal_JJ
selling_GER
price_NN
less_RB
further_JJ
costs_NN
expected_VBN [PRIV]
to_TO
be_VB [PASS]
incurred_VBN
to_PIN
completion_NOMZ
and_PHC
disposal_NN
._.
r_NN
Assets_NN
held_VBN [PRIV] [WZPAST]
for_PIN
sale_NN
An_DT
asset_NN
is_VPRT [PASS]
classified_VBN
as_IN
held_VBN [PRIV]
for_PIN
sale_NN
when_RB
,_,
amongst_PIN
other_JJ
things_NN
,_,
the_DT
Company_NN
has_VPRT [PEAS]
committed_VBN
to_PIN
a_DT
plan_NN
of_PIN
disposition_NOMZ
,_,
the_DT
asset_NN
is_VPRT [BEMA]
available_PRED
for_PIN
immediate_JJ
sale_NN
,_,
and_ANDC
the_DT
plan_NN
is_VPRT [PASS]
not_XX0
expected_VBN [PRIV]
to_TO
change_VB
significantly_RB
._.
s_PRP
Investments_NOMZ
The_DT
Company_NN
has_VPRT
certain_JJ
investments_NOMZ
in_PIN
pharmaceutical_JJ
and_CC
biotechnology_NN
companies_NN
._.
Investments_NOMZ
are_VPRT [PASS]
accounted_VBN
for_PIN
using_VBG
the_DT
equity_NOMZ
method_NN
of_PIN
accounting_GER
if_COND
the_DT
investment_NOMZ
gives_VPRT
the_DT
Company_NN
the_DT
ability_NOMZ
to_TO
exercise_VB
significant_JJ
influence_NN
,_,
but_CC
not_XX0
control_VB
over_RP
,_,
the_DT
investee_NN
._.
Significant_JJ
influence_NN
is_VPRT [SPAU] [PASS]
generally_RB
deemed_VBN [PRIV]
to_TO
exist_VB
if_COND
the_DT
Company_NN
has_VPRT
an_DT
ownership_NN
interest_NN
in_PIN
the_DT
voting_NN
stock_NN
of_PIN
the_DT
investee_NN
between_PIN
20_CD
%_NN
and_CC
50_CD
%_NN
,_,
although_CONC
other_JJ
factors_NN
,_,
such_JJ
as_IN
representation_NOMZ
on_PIN
the_DT
investees_NN
Board_NN
of_PIN
Directors_NN
and_CC
the_DT
impact_NN
of_PIN
commercial_JJ
arrangements_NOMZ
,_,
are_VPRT [PASS]
considered_VBN [PRIV]
in_PIN
determining_VBG [SUAV] [PRIV]
whether_IN [WHCL]
the_DT
equity_NOMZ
method_NN
of_PIN
accounting_GER
is_VPRT [BEMA]
appropriate_PRED
._.
Under_IN
the_DT
equity_NOMZ
method_NN
of_PIN
accounting_GER
,_,
the_DT
Company_NN
records_NN
its_PIT
investments_NOMZ
in_PIN
equity-method_JJ
investees_NN
in_PIN
the_DT
consolidated_JJ
balance_NN
sheet_NN
as_IN
investments_NOMZ
and_CC
its_PIT
share_NN
of_PIN
the_DT
investees_NN
earnings_GER
or_CC
losses_NN
together_RB
with_PIN
other-than-temporary_JJ
impairments_NOMZ
in_PIN
value_NN
as_IN
equity_NOMZ
in_PIN
earnings_GER
losses_NN
of_PIN
equity_NOMZ
method_NN
investees_NN
in_PIN
the_DT
consolidated_JJ
statement_NOMZ
of_PIN
operations_NOMZ
._.
All_QUAN
other_JJ
equity_NOMZ
investments_NOMZ
,_,
which_WDT [SERE]
consist_VPRT
of_PIN
investments_NOMZ
for_PIN
which_WDT [PIRE]
the_DT
Company_NN
does_VPRT
not_XX0
have_VB
the_DT
ability_NOMZ
to_TO
exercise_VB
significant_JJ
influence_NN
,_,
are_VPRT [PASS]
accounted_VBN
for_PIN
under_IN
the_DT
cost_NN
method_NN
or_CC
at_PIN
fair_JJ
value_NN
._.
Investments_NOMZ
in_PIN
private_JJ
companies_NN
are_VPRT [PASS]
carried_VBN
at_PIN
cost_NN
,_,
less_JJ
provisions_NN
for_PIN
other-than-temporary_JJ
impairment_NOMZ
in_PIN
value_NN
._.
For_PIN
public_JJ
companies_NN
that_TSUB
have_VPRT
readily_RB
determinable_JJ
fair_JJ
values_NN
,_,
the_DT
Company_NN
classifies_VPRT
its_PIT
equity_NOMZ
investments_NOMZ
as_IN
availablefor-sale_JJ
and_CC
,_,
accordingly_RB
,_,
records_NN
these_DEMO
investments_NOMZ
at_PIN
their_TPP3
fair_JJ
values_NN
with_PIN
unrealized_JJ
gains_NN
and_PHC
losses_NN
included_VBD
in_PIN
the_DT
consolidated_JJ
statements_NOMZ
of_PIN
comprehensive_JJ
income_NN
,_,
net_NN
of_PIN
any_QUAN
related_JJ
tax_NN
effect_NN
._.
The_DT
cost_NN
of_PIN
securities_NOMZ
sold_VBN [WZPAST]
is_VPRT [PASS]
based_VBN
on_PIN
the_DT
specific_JJ
identification_NOMZ
method_NN
._.
Interest_NN
and_PHC
dividends_NN
on_PIN
securities_NOMZ
classified_VBN
as_IN
available-for-sale_NN
are_VPRT [PASS]
included_VBN
as_IN
interest_NN
income_NN
._.
t_NN
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
is_VPRT [PASS]
shown_VBN [PRIV]
at_PIN
cost_NN
,_,
less_JJ
accumulated_VBN
depreciation_NOMZ
and_CC
any_QUAN
impairment_NOMZ
._.
The_DT
cost_NN
of_PIN
significant_JJ
assets_NN
includes_VPRT
capitalized_JJ
interest_NN
incurred_VBN [WZPAST]
during_PIN
the_DT
construction_NOMZ
period_NN
._.
Depreciation_NOMZ
is_VPRT [PASS]
provided_VBN
on_PIN
a_DT
straight-line_JJ
basis_NN
at_PIN
rates_NN
calculated_VBN [PRIV] [WZPAST]
to_PIN
write-off_PIN
the_DT
cost_NN
less_JJ
estimated_VBN [PRIV]
residual_JJ
value_NN
of_PIN
each_QUAN
asset_NN
over_IN
its_PIT
estimated_VBN [PRIV]
useful_JJ
life_NN
as_IN
follows_VPRT
:_:
Buildings_GER
2050_CD
years_NN
Office_NN
furniture_NN
,_,
fittings_GER
and_PHC
equipment_NOMZ
310_CD
years_NN
Warehouse_NN
,_,
laboratory_NN
and_PHC
manufacturing_GER
equipment_NOMZ
310_CD
years_NN
The_DT
cost_NN
of_PIN
land_NN
is_VPRT [PASS]
not_XX0
depreciated_VBN
._.
Expenditures_NN
for_PIN
maintenance_NN
and_PHC
repairs_NN
are_VPRT [PASS]
charged_VBN
to_PIN
operations_NOMZ
as_IN
incurred_VBN
._.
The_DT
costs_NN
of_PIN
major_JJ
renewals_NN
and_PHC
improvements_NOMZ
are_VPRT [PASS]
capitalized_VBN
._.
At_PIN
the_DT
time_NN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
is_VPRT [PASS]
retired_VBN
or_CC
otherwise_CONJ
disposed_JJ
of_PIN [STPR]
,_,
the_DT
cost_NN
and_CC
accumulated_VBN
depreciation_NOMZ
are_VPRT [PASS]
eliminated_VBN
from_PIN
the_DT
asset_NN
and_CC
accumulated_VBN
depreciation_NOMZ
accounts_NN
._.
The_DT
profit_NN
or_CC
loss_NN
on_PIN
such_JJ
disposition_NOMZ
is_VPRT [PASS]
reflected_VBN [PRIV]
in_PIN
operating_VBG
loss_NN
income_NN
._.
88_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
89_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
Dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
3_CD
Summary_NN
of_PIN
significant_JJ
accounting_GER
policies_NN
continued_VBD
u_JJ
Goodwill_NN
and_CC
other_JJ
intangible_JJ
assets_NN
i_FPP1
Goodwill_NN
In_PIN
a_DT
business_NOMZ
combination_NOMZ
,_,
goodwill_NN
represents_VPRT
the_DT
excess_NN
of_PIN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
consideration_NOMZ
given_VBN
over_IN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
identifiable_JJ
assets_NN
and_PHC
liabilities_NOMZ
acquired_VBN
._.
Goodwill_NN
is_VPRT [PASS]
not_XX0
amortized_VBN
to_PIN
operations_NOMZ
,_,
but_CC
instead_CONJ
is_VPRT [PASS]
reviewed_VBN
for_PIN
impairment_NOMZ
,_,
at_PIN
least_JJ
annually_RB
or_CC
whenever_RB
events_NN
or_CC
changes_NN
in_PIN
circumstances_NN
indicate_VPRT [PRIV]
that_THVC
the_DT
carrying_VBG
value_NN
may_POMD
not_XX0
be_VB [BEMA]
recoverable_PRED
._.
Some_QUAN
factors_NN
the_DT
Company_NN
considers_VPRT [PRIV]
important_JJ
which_WDT
could_POMD
trigger_VB
an_DT
impairment_NOMZ
review_NN
include_VPRT
the_DT
following_GER
:_:
i_FPP1
significant_JJ
underperformance_NN
of_PIN
a_DT
reporting_VBG [PUBV]
unit_NN
relative_JJ
to_TO
expected_VBN [PRIV]
historical_JJ
or_CC
projected_VBN
future_JJ
operating_GER
results_NN
:_:
ii_FW
significant_JJ
changes_NN
in_PIN
the_DT
manner_NN
of_PIN
the_DT
Companys_NN
use_NN
of_PIN
acquired_VBN
assets_NN
or_CC
the_DT
strategy_NN
for_PIN
the_DT
overall_JJ
business_NOMZ
:_:
and_ANDC
iii_FW
significant_JJ
negative_JJ
industry_NN
or_CC
economic_JJ
trends_NN
._.
142_CD
,_,
Goodwill_NN
and_CC
Other_JJ
Intangible_NN
Assets_NN
,_,
goodwill_NN
is_VPRT [PASS]
reviewed_VBN
for_PIN
impairment_NOMZ
by_PIN
comparing_VBG
the_DT
carrying_VBG
value_NN
of_PIN
each_QUAN
reporting_VBG [PUBV]
units_NN
net_JJ
assets_NN
including_VBG [WZPRES]
allocated_VBN
goodwill_NN
to_PIN
the_DT
fair_JJ
value_NN
of_PIN
those_DEMO
net_JJ
assets_NN
._.
If_COND
the_DT
reporting_VBG [PUBV] [THATD]
units_NN
carrying_VBG [WZPRES]
amount_NN
is_VPRT [BEMA]
greater_PRED
than_PIN
its_PIT
fair_JJ
value_NN
,_,
then_RB
a_DT
second_JJ
step_NN
is_VPRT [PASS]
performed_VBN
whereby_OSUB
the_DT
portion_NOMZ
of_PIN
the_DT
fair_JJ
value_NN
that_TSUB
relates_VPRT
to_PIN
the_DT
reporting_VBG [PUBV]
units_NN
goodwill_NN
is_VPRT [PASS]
compared_VBN
to_PIN
the_DT
carrying_VBG
value_NN
of_PIN
that_DEMO
goodwill_NN
._.
The_DT
Company_NN
recognizes_VPRT [PRIV]
a_DT
goodwill_NN
impairment_NOMZ
charge_NN
for_PIN
the_DT
amount_NN
the_DT
carrying_VBG
value_NN
of_PIN
goodwill_NN
exceeds_VPRT
the_DT
fair_JJ
value_NN
._.
The_DT
Company_NN
has_VPRT [PEAS]
determined_VBN [SUAV] [PRIV]
that_THVC
there_EX
are_VPRT
no_SYNE
impairment_NOMZ
losses_NN
for_PIN
any_QUAN
of_PIN
the_DT
reporting_GER
periods_NN
covered_VBN [WZPAST]
by_PIN
these_DEMO
financial_JJ
statements_NOMZ
._.
ii_FW
Other_JJ
intangible_JJ
assets_NN
Other_JJ
intangible_JJ
assets_NN
,_,
which_WDT [SERE]
comprise_VPRT
intellectual_JJ
property_NN
including_VBG [WZPRES]
trademarks_NN
for_PIN
products_NN
with_PIN
a_DT
defined_VBN
revenue_NN
stream_NN
namely_CONJ
commercial_JJ
products_NN
or_CC
rights_NN
to_PIN
products_NN
awaiting_VBG [WZPRES]
final_JJ
regulatory_JJ
approval_NN
,_,
are_VPRT [PASS]
recorded_VBN
at_PIN
cost_NN
and_CC
amortized_VBN
over_IN
the_DT
estimated_VBN [PRIV]
useful_JJ
life_NN
of_PIN
the_DT
related_JJ
product_NN
,_,
which_WDT [SERE]
ranges_VPRT
from_PIN
535_CD
years_NN
weighted_VBN
average_JJ
16_CD
years_NN
._.
Intellectual_NN
property_NN
with_PIN
no_DT
defined_VBN
revenue_NN
stream_NN
,_,
where_RB
the_DT
related_JJ
product_NN
has_VPRT [PEAS]
not_XX0
yet_RB
completed_VBN
the_DT
necessary_JJ
approval_NN
process_NN
,_,
is_VPRT [PASS]
written_VBN [PUBV]
off_PIN
to_PIN
operations_NOMZ
on_PIN
acquisition_NOMZ
._.
The_DT
following_VBG
factors_NN
are_VPRT [PASS]
considered_VBN [PRIV]
in_PIN
estimating_VBG [PRIV]
useful_JJ
lives_NN
._.
Where_RB
an_DT
intangible_JJ
asset_NN
is_VPRT [BEMA]
a_DT
composite_NN
of_PIN
a_DT
number_NN
of_PIN
factors_NN
,_,
the_DT
period_NN
of_PIN
amortization_NOMZ
is_VPRT [PASS]
determined_VBN [SUAV] [PRIV]
from_PIN
considering_VBG [PRIV]
these_DEMO
factors_NN
together_RB
:_:
expected_VBN [PRIV]
use_NN
of_PIN
the_DT
asset_NN
:_:
regulatory_JJ
,_,
legal_JJ
or_CC
contractual_JJ
provisions_NN
,_,
including_VBG [PRESP]
the_DT
regulatory_JJ
approval_NN
and_PHC
review_NN
process_NN
,_,
patent_NN
issues_NN
and_PHC
actions_NOMZ
by_PIN
government_NOMZ
agencies_NN
:_:
the_DT
effects_NN
of_PIN
obsolescence_NN
,_,
changes_NN
in_PIN
demand_NN
,_,
competing_VBG
products_NN
and_CC
other_JJ
economic_JJ
factors_NN
,_,
including_VBG [PRESP]
the_DT
stability_NOMZ
of_PIN
the_DT
market_NN
,_,
known_VBN [PRIV]
technological_JJ
advances_NN
,_,
development_NOMZ
of_PIN
competing_VBG
drugs_NN
that_TSUB
are_VPRT [BEMA]
more_EMPH
effective_JJ
clinically_RB
or_CC
economically_RB
:_:
and_ANDC
actions_NOMZ
of_PIN
competitors_NN
,_,
suppliers_NN
,_,
regulatory_JJ
agencies_NN
or_CC
others_NN
that_TSUB
may_POMD
eliminate_VB
current_JJ
competitive_JJ
advantages_NN
._.
v_FW
Non-monetary_JJ
transactions_NOMZ
The_DT
Company_NN
enters_VPRT
into_PIN
certain_JJ
non-monetary_JJ
transactions_NOMZ
that_TSUB
involve_VPRT
either_CC
the_DT
granting_VBG [SUAV]
of_PIN
a_DT
license_NN
over_IN
the_DT
Companys_NN
patents_NN
or_CC
the_DT
disposal_NN
of_PIN
an_DT
asset_NN
or_CC
group_NN
of_PIN
assets_NN
in_PIN
exchange_NN
for_PIN
a_DT
nonmonetary_JJ
asset_NN
,_,
usually_RB
equity_NOMZ
._.
The_DT
Company_NN
accounts_NN
for_PIN
these_DEMO
transactions_NOMZ
at_PIN
fair_JJ
value_NN
where_RB
the_DT
Company_NN
is_VPRT [BEMA]
able_PRED
to_TO
determine_VB [SUAV] [PRIV]
the_DT
fair_JJ
value_NN
within_PIN
reasonable_JJ
limits_NN
._.
To_PIN
the_DT
extent_NN
that_TOBJ
the_DT
Company_NN
concludes_VPRT [PRIV]
that_THVC
it_PIT
is_VPRT [BEMA]
unable_PRED
to_TO
determine_VB [SUAV] [PRIV]
the_DT
fair_JJ
value_NN
of_PIN
a_DT
transaction_NOMZ
,_,
that_DEMO
transaction_NOMZ
is_VPRT [PASS]
accounted_VBN
for_PIN
at_PIN
the_DT
recorded_JJ
amounts_NN
of_PIN
the_DT
assets_NN
exchanged_VBD
._.
Management_NOMZ
is_VPRT [PASS]
required_VBN [SUAV]
to_TO
exercise_VB
its_PIT
judgment_NOMZ
in_PIN
determining_VBG [SUAV] [PRIV]
whether_IN [WHCL]
or_CC
not_XX0
the_DT
fair_JJ
value_NN
of_PIN
the_DT
asset_NN
received_VBD
or_CC
that_DEMP
given_VBN
up_RP
can_POMD
be_VB [PASS]
determined_VBN [SUAV] [PRIV]
._.
w_VB
Reclassifications_NOMZ
Certain_NN
amounts_VPRT
reported_VBN [PUBV]
in_PIN
previous_JJ
years_NN
have_VPRT [PEAS]
been_VBN [PASS]
reclassified_VBN
to_TO
conform_VB
to_PIN
the_DT
2005_CD
presentation_NOMZ
._.
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
89_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
90_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
Dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
3_CD
Summary_NN
of_PIN
significant_JJ
accounting_GER
policies_NN
continued_VBD
x_SYM
New_NN
accounting_GER
pronouncements_NOMZ
i_FPP1
Adopted_VBN
in_PIN
the_DT
current_JJ
year_NN
:_:
EITF_NN
03-13_CD
In_PIN
November_NN
2004_CD
,_,
the_DT
Emerging_VBG
Issues_NN
Task_NN
Force_NN
EITF_NN
reached_VBD
a_DT
consensus_NN
on_PIN
EITF_NN
03-13_CD
,_,
Applying_VBG [PRESP]
the_DT
Conditions_NOMZ
in_PIN
Paragraph_NN
42_CD
of_PIN
SFAS_NN
144_CD
,_,
Accounting_GER
for_PIN
the_DT
Impairment_NOMZ
or_CC
Disposal_NN
of_PIN
Long-Lived_NN
Assets_NN
,_,
in_PIN
Determining_VBG [SUAV] [PRIV]
Whether_NN [WHCL]
to_PIN
Report_NN
Discontinued_NN
Operations_NOMZ
EITF_NN
03-13_CD
._.
The_DT
purpose_NN
of_PIN
the_DT
EITF_NN
is_VPRT
to_TO
clarify_VB
when_RB
a_DT
disposition_NOMZ
should_NEMD
be_VB [PASS]
classified_VBN
as_IN
a_DT
discontinued_VBN
operation_NOMZ
caused_VBN [WZPAST]
by_PIN
the_DT
contravening_VBG
wording_GER
of_PIN
paragraph_NN
42_CD
of_PIN
SFAS_NN
No._NN
._.
144_CD
,_,
Accounting_GER
for_PIN
the_DT
Impairment_NOMZ
or_CC
Disposal_NN
of_PIN
Long-Lived_NN
Assets_NN
SFAS_NN
No._NN
._.
The_DT
EITF_NN
reached_VBD
a_DT
consensus_NN
that_DEMO
classification_NOMZ
of_PIN
a_DT
disposed_JJ
component_NN
as_IN
a_DT
discontinued_VBN
operation_NOMZ
is_VPRT [BEMA]
appropriate_JJ
only_DWNT
if_COND
the_DT
ongoing_JJ
entity_NOMZ
:_:
has_VPRT
no_DT
continuing_VBG
direct_JJ
cash_NN
flows_VPRT
a_DT
term_NN
EITF_NN
03-13_CD
introduces_VPRT
to_TO
interpret_VB
paragraph_NN
42_CD
a_DT
:_:
and_ANDC
does_VPRT
not_XX0
retain_VB
an_DT
interest_NN
,_,
contract_NN
,_,
or_CC
other_JJ
arrangement_NOMZ
sufficient_JJ
to_TO
enable_VB
it_PIT
to_TO
exert_VB
significant_JJ
influence_NN
over_IN
the_DT
disposed_JJ
components_NN
operating_VBG [WZPRES]
and_CC
financial_JJ
policies_NN
after_IN
the_DT
disposal_NN
transaction_NOMZ
an_DT
interpretation_NOMZ
of_PIN
paragraph_NN
42_CD
b._NN
EITF_NN
03-13_CD
should_NEMD
be_VB [PASS]
applied_VBN
to_PIN
components_NN
that_TSUB
are_VPRT [PASS]
disposed_VBN
of_PIN
or_CC
classified_VBN
as_IN
held_VBN [PRIV]
for_PIN
sale_NN
in_PIN
periods_NN
beginning_VBG [WZPRES]
after_IN
December_NN
15_CD
,_,
2004_CD
._.
Previously_TIME
reported_VBN [PUBV]
operating_GER
results_NN
within_PIN
an_DT
enterprises_NN
fiscal_JJ
year_NN
that_TSUB
includes_VPRT
the_DT
ratification_NOMZ
date_NN
may_POMD
be_VB [PASS]
reclassified_VBN
to_TO
reflect_VB [PRIV]
the_DT
consensus_NN
._.
The_DT
adoption_NOMZ
of_PIN
EITF_NN
03-13_CD
has_VPRT [PEAS]
had_VBN
no_SYNE
impact_NN
on_PIN
the_DT
Companys_NN
reporting_GER
of_PIN
discontinued_VBN
operations_NOMZ
as_IN
the_DT
Company_NN
has_VPRT [PEAS]
not_XX0
disposed_VBN
of_PIN
any_QUAN
operations_NOMZ
in_PIN
the_DT
period_NN
to_PIN
which_WDT [PIRE]
this_DEMO
guidance_NN
has_VPRT [PEAS]
been_VBN [BEMA]
relevant_PRED
._.
EITF_NN
05-06_CD
In_PIN
June_NN
2005_CD
the_DT
EITF_NN
reached_VBD
consensus_NN
on_PIN
Issue_NN
05-6_CD
,_,
Determining_VBG [SUAV] [PRIV] [PRESP]
the_DT
Amortization_NOMZ
Period_NN
for_PIN
Leasehold_NN
Improvements_NOMZ
Purchased_NN
after_IN
Lease_NN
Inception_NOMZ
or_CC
Acquired_VBN
in_PIN
a_DT
Business_NOMZ
Combination_NOMZ
EITF_NN
05-6_CD
._.
EITF_NN
05-6_CD
requires_VPRT [SUAV]
leasehold_NN
improvements_NOMZ
acquired_VBN [WZPAST]
in_PIN
a_DT
business_NOMZ
combination_NOMZ
to_TO
be_VB [PASS]
amortized_VBN
over_IN
the_DT
shorter_JJ
of_PIN
the_DT
useful_JJ
life_NN
of_PIN
the_DT
assets_NN
or_CC
a_DT
term_NN
that_TSUB
includes_VPRT
required_VBN [SUAV]
lease_NN
periods_NN
and_PHC
renewals_NN
deemed_VBD [PRIV]
to_TO
be_VB [SPAU] [PASS]
reasonably_RB
assured_VBN
at_PIN
the_DT
date_NN
of_PIN
acquisition_NOMZ
._.
Additionally_RB
,_,
the_DT
Issue_NN
requires_VPRT [SUAV] [THATD]
improvements_NOMZ
placed_VBN [WZPAST]
in_PIN
service_NN
significantly_RB
after_IN
and_CC
not_XX0
contemplated_VBN
at_PIN
or_CC
near_PLACE
the_DT
beginning_GER
of_PIN
the_DT
lease_NN
term_NN
to_TO
be_VB [PASS]
amortized_VBN
over_IN
the_DT
shorter_JJ
of_PIN
the_DT
useful_JJ
life_NN
of_PIN
the_DT
assets_NN
or_CC
a_DT
term_NN
that_TSUB
includes_VPRT
required_VBN [SUAV]
lease_NN
periods_NN
and_PHC
renewals_NN
deemed_VBD [PRIV]
to_TO
be_VB [SPAU] [PASS]
reasonably_RB
assured_VBN
at_PIN
the_DT
date_NN
the_DT
leasehold_NN
improvements_NOMZ
are_VPRT [PASS]
purchased_VBN
._.
The_DT
adoption_NOMZ
of_PIN
EITF_NN
05-6_CD
has_VPRT [PEAS]
had_VBN
no_SYNE
material_NN
impact_NN
on_PIN
the_DT
Companys_NN
consolidated_JJ
financial_JJ
position_NOMZ
,_,
results_NN
of_PIN
operations_NOMZ
or_CC
cash_NN
flows_NN
._.
SFAS_NN
153_CD
In_PIN
December_NN
2004_CD
,_,
the_DT
FASB_NN
issued_VBD
SFAS_NN
No._NN
._.
153_CD
,_,
Exchanges_NN
of_PIN
Non-monetary_JJ
Assets_NN
an_DT
amendment_NOMZ
of_PIN
APB_NN
Opinion_NN
No._NN
._.
153_CD
,_,
which_WDT [SERE]
amends_VPRT
APB_NN
Opinion_NN
No._NN
._.
29_CD
,_,
Accounting_GER
for_PIN
Non-monetary_JJ
Transactions_NOMZ
to_TO
eliminate_VB
the_DT
exception_NOMZ
for_PIN
non-monetary_JJ
exchanges_NN
of_PIN
similar_JJ
productive_JJ
assets_NN
and_CC
replaces_VPRT
it_PIT
with_PIN
a_DT
general_JJ
exception_NOMZ
for_PIN
exchanges_NN
of_PIN
non-monetary_JJ
assets_NN
that_TSUB
do_VPRT
not_XX0
have_VB
commercial_JJ
substance_NN
._.
153_CD
is_VPRT [BEMA]
effective_PRED
for_PIN
non-monetary_JJ
asset_NN
exchanges_NN
occurring_VBG [WZPRES]
in_PIN
fiscal_JJ
periods_NN
beginning_VBG [WZPRES]
after_IN
June_NN
15_CD
,_,
2005_CD
._.
153_CD
has_VPRT [PEAS]
had_VBN
no_SYNE
material_NN
impact_NN
on_PIN
the_DT
Companys_NN
consolidated_JJ
financial_JJ
position_NOMZ
,_,
results_NN
of_PIN
operations_NOMZ
or_CC
cash_NN
flows_NN
._.
ii_FW
To_TO
be_VB [PASS]
adopted_VBN
in_PIN
future_NN
periods_NN
EITF_NN
03-01_CD
In_PIN
March_NN
2004_CD
,_,
the_DT
EITF_NN
reached_VBD
a_DT
consensus_NN
on_PIN
Issue_NN
03-01_CD
,_,
The_DT
Meaning_GER
of_PIN
Other-Than-Temporary_NN
Impairment_NOMZ
and_CC
Its_PIT
Application_NOMZ
to_PIN
Certain_NN
Investments_NOMZ
EITF_NN
03-01_CD
._.
EITF_NN
03-01_CD
is_VPRT [BEMA]
applicable_PRED
to_PIN
a_DT
debt_NN
and_PHC
equity_NOMZ
securities_NOMZ
within_PIN
the_DT
scope_NN
of_PIN
SFAS_NN
No._NN
._.
115_CD
,_,
b_NN
debt_NN
and_PHC
equity_NOMZ
securities_NOMZ
within_PIN
the_DT
scope_NN
of_PIN
SFAS_NN
No._NN
._.
124_CD
and_CC
those_DEMP
held_VBN [PRIV]
by_PIN
an_DT
investor_NN
that_TSUB
reports_VPRT [PUBV]
a_DT
performance_NN
indicator_NN
,_,
and_ANDC
c_NN
equity_NOMZ
securities_NOMZ
not_XX0
within_PIN
the_DT
scope_NN
of_PIN
SFAS_NN
No._NN
._.
115_CD
and_CC
not_XX0
accounted_VBD
for_PIN
under_IN
the_DT
Accounting_GER
Principles_NN
Board_NN
Opinion_NN
18s_NN
equity_NOMZ
method_NN
e._FW
g._FW
cost_NN
method_NN
investments_NOMZ
._.
EITF_NN
03-01_CD
provides_VPRT
a_DT
step_NN
model_NN
to_TO
determine_VB [SUAV] [PRIV]
whether_IN [WHCL]
an_DT
investment_NOMZ
is_VPRT [PASS]
impaired_VBN
and_ANDC
if_COND
an_DT
impairment_NOMZ
is_VPRT [BEMA]
other-than-temporary_PRED
._.
In_CONJ
addition_NULL
,_,
it_PIT
requires_VPRT [SUAV]
that_THVC
investors_NN
provide_VPRT
certain_JJ
disclosures_NN
for_PIN
cost_NN
method_NN
investments_NOMZ
and_CC
,_,
if_COND
applicable_JJ
,_,
other_JJ
information_NOMZ
related_VBN [WZPAST]
specifically_RB
to_TO
cost_VB
method_NN
investments_NOMZ
,_,
such_JJ
as_IN
the_DT
aggregate_JJ
carrying_GER
amount_NN
of_PIN
cost_NN
method_NN
investments_NOMZ
,_,
the_DT
aggregate_JJ
amount_NN
of_PIN
cost_NN
method_NN
investments_NOMZ
that_TOBJ
the_DT
investor_NN
did_VBD
not_XX0
evaluate_VB
for_PIN
impairment_NOMZ
because_CAUS
an_DT
impairment_NOMZ
indicator_NN
was_VBD [BEMA]
not_XX0
present_PRED
,_,
and_ANDC
the_DT
situations_NOMZ
under_IN
which_WDT
the_DT
fair_JJ
value_NN
of_PIN
a_DT
cost_NN
method_NN
investment_NOMZ
is_VPRT [PASS]
not_XX0
estimated_VBN [PRIV]
._.
The_DT
disclosures_NN
relating_VBG [WZPRES]
to_TO
cost_VB
method_NN
investments_NOMZ
should_NEMD
not_XX0
be_VB [PASS]
aggregated_VBN
with_PIN
other_JJ
types_NN
of_PIN
investments_NOMZ
._.
The_DT
effective_JJ
date_NN
for_PIN
the_DT
prospective_JJ
application_NOMZ
of_PIN
the_DT
EITF_NN
03-01_CD
impairment_NOMZ
model_NN
to_PIN
all_QUAN
current_JJ
and_PHC
future_JJ
investments_NOMZ
has_VPRT [PEAS]
been_VBN [BYPA]
delayed_VBN
by_PIN
the_DT
FASB_NN
Issues_NN
FASB_NN
Staff_NN
Position_NOMZ
FSP_NN
EITF_NN
03-01-1_CD
._.
The_DT
disclosure_NN
requirements_NOMZ
are_VPRT [BEMA]
effective_PRED
for_PIN
annual_JJ
periods_NN
for_PIN
fiscal_JJ
years_NN
ending_VBG [WZPRES]
after_IN
June_NN
15_CD
,_,
2004_CD
._.
The_DT
Company_NN
does_VPRT
not_XX0
expect_VB [PRIV]
the_DT
adoption_NOMZ
of_PIN
EITF_NN
03-01_CD
to_TO
have_VB
a_DT
material_NN
impact_NN
on_PIN
its_PIT
consolidated_JJ
financial_JJ
position_NOMZ
,_,
results_NN
of_PIN
operations_NOMZ
or_CC
cash_NN
flows_NN
._.
90_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
91_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
Dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
3_CD
Summary_NN
of_PIN
significant_JJ
accounting_GER
policies_NN
continued_VBD
SFAS_NN
No._NN
._.
123R_CD
In_PIN
December_NN
2004_CD
,_,
the_DT
FASB_NN
issued_VBD
SFAS_NN
No._NN
._.
123R_CD
requires_VPRT [SUAV]
that_THVC
the_DT
cost_NN
resulting_VBG [WZPRES]
from_PIN
all_QUAN
share-based_JJ
payment_NOMZ
transactions_NOMZ
be_VB [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
financial_JJ
statements_NOMZ
at_PIN
fair_JJ
value_NN
and_CC
that_DEMO
excess_JJ
tax_NN
benefits_NN
be_VB [PASS]
reported_VBN [PUBV]
as_IN
a_DT
financing_GER
cash_NN
inflow_NN
rather_RB
than_PIN
as_IN
a_DT
reduction_NOMZ
of_PIN
taxes_NN
paid_VBN
._.
123R_CD
is_VPRT [BEMA]
effective_PRED
for_PIN
the_DT
Company_NN
from_PIN
January_NN
1_CD
,_,
2006_CD
._.
123R_CD
requires_VPRT [SUAV]
public_JJ
companies_NN
to_TO
account_VB
for_PIN
share-based_JJ
payments_NOMZ
using_VBG [WZPRES]
the_DT
modified-prospective_JJ
method_NN
and_CC
permits_VPRT
public_JJ
companies_NN
also_RB
to_TO
account_VB
for_PIN
share-based_JJ
payments_NOMZ
using_VBG [WZPRES]
the_DT
method_NN
._.
Under_IN
the_DT
modified-prospective_JJ
method_NN
,_,
from_PIN
the_DT
effective_JJ
date_NN
,_,
compensation_NOMZ
cost_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
based_VBN
on_PIN
the_DT
requirements_NOMZ
of_PIN
SFAS_NN
No._NN
._.
123R_CD
for_PIN
all_QUAN
new_JJ
share-based_JJ
awards_NN
and_CC
based_VBN
on_PIN
the_DT
requirements_NOMZ
of_PIN
SFAS_NN
No._NN
._.
123_CD
for_PIN
all_QUAN
awards_NN
granted_VBN [SUAV] [WZPAST]
prior_RB
to_PIN
the_DT
effective_JJ
date_NN
of_PIN
SFAS_NN
No._NN
._.
123R_CD
that_DEMP
remain_VPRT
unvested_JJ
on_PIN
the_DT
effective_JJ
date_NN
._.
The_DT
method_NN
permits_VPRT
companies_NN
to_TO
restate_VB
,_,
based_VBN [PASTP]
on_PIN
the_DT
amounts_NN
previously_TIME
recognized_VBN [PRIV]
under_IN
SFAS_NN
No._NN
._.
123_CD
for_PIN
pro-forma_FW
disclosure_NN
purposes_NN
,_,
either_CC
all_QUAN
prior_RB
periods_NN
presented_VBN
or_CC
prior_RB
interim_JJ
periods_NN
in_PIN
the_DT
year_NN
of_PIN
adoption_NOMZ
._.
123_CD
pro-forma_FW
disclosures_NN
given_VBN [WZPAST]
in_PIN
Note_NN
3_CD
m_NN
above_PLACE
show_NN
the_DT
impact_NN
of_PIN
the_DT
Company_NN
adopting_VBG [WZPRES]
the_DT
method_NN
in_PIN
prior_JJ
periods_NN
._.
123R_CD
,_,
the_DT
Company_NN
will_PRMD
adopt_VB
the_DT
method_NN
._.
151_CD
In_PIN
November_NN
2004_CD
,_,
the_DT
FASB_NN
issued_VBD
SFAS_NN
No._NN
._.
151_CD
,_,
Inventory_NN
Costs_NN
an_DT
amendment_NOMZ
of_PIN
ARB_NN
No._NN
._.
151_CD
clarifies_VPRT
that_DEMO
abnormal_JJ
amounts_NN
of_PIN
idle_JJ
facility_NOMZ
expense_NN
,_,
freight_NN
,_,
handling_VBG
costs_NN
,_,
and_ANDC
wasted_VBD
materials_NN
spoilage_NN
should_NEMD
be_VB [PASS]
recognized_VBN [PRIV]
as_IN
currentperiod_NN
charges_NN
and_CC
requires_VPRT [SUAV]
the_DT
allocation_NOMZ
of_PIN
fixed_JJ
production_NOMZ
overheads_NN
to_PIN
inventory_NN
based_VBN [WZPAST]
on_PIN
the_DT
normal_JJ
capacity_NOMZ
of_PIN
the_DT
production_NOMZ
facilities_NOMZ
._.
151_CD
is_VPRT [BEMA]
effective_PRED
for_PIN
fiscal_JJ
years_NN
beginning_VBG [WZPRES]
after_IN
June_NN
15_CD
,_,
2005_CD
._.
The_DT
Company_NN
does_VPRT
not_XX0
expect_VB [PRIV]
the_DT
adoption_NOMZ
of_PIN
SFAS_NN
No._NN
._.
151_CD
to_TO
have_VB
a_DT
material_NN
impact_NN
on_PIN
its_PIT
consolidated_JJ
financial_JJ
position_NOMZ
,_,
results_NN
of_PIN
operations_NOMZ
or_CC
cash_NN
flows_NN
._.
154_CD
,_,
Accounting_GER
Changes_NN
and_PHC
Error_NN
Corrections_NOMZ
replacement_NOMZ
of_PIN
APB_NN
Opinion_NN
No._NN
._.
154_CD
changes_NN
the_DT
accounting_GER
for_PIN
and_CC
reporting_VBG [PUBV]
of_PIN
a_DT
change_NN
in_PIN
accounting_GER
principle_NN
by_PIN
requiring_VBG [SUAV]
retrospective_JJ
application_NOMZ
to_TO
prior_RB
periods_NN
financial_JJ
statements_NOMZ
of_PIN
changes_NN
in_PIN
accounting_GER
principle_NN
unless_COND
impracticable_JJ
._.
154_CD
is_VPRT [BEMA]
effective_PRED
for_PIN
accounting_VBG
changes_NN
made_VBN [WZPAST]
in_PIN
fiscal_JJ
years_NN
beginning_VBG [WZPRES]
after_IN
December_NN
15_CD
,_,
2005_CD
._.
154_CD
will_PRMD
have_VB
no_SYNE
impact_NN
on_PIN
historical_JJ
results_NN
:_:
rather_CONJ
the_DT
impact_NN
depends_VPRT
upon_PIN
future_JJ
changes_NN
to_TO
accounting_VBG
principles_NN
._.
124-1_CD
In_PIN
November_NN
2005_CD
,_,
the_DT
FASB_NN
issued_VBD
FASB_NN
Staff_NN
Position_NOMZ
FSP_NN
FAS_NN
115-1_CD
and_CC
124-1_CD
,_,
The_DT
Meaning_GER
of_PIN
Other-Than-Temporary_NN
Impairment_NOMZ
and_CC
Its_PIT
Application_NOMZ
to_PIN
Certain_NN
Investments_NOMZ
._.
The_DT
guidance_NN
in_PIN
this_DEMO
FSP_NN
addresses_VPRT
the_DT
determination_NOMZ
of_PIN
when_RB
an_DT
investment_NOMZ
is_VPRT [PASS]
considered_VBN [PRIV]
impaired_VBN
,_,
whether_IN
that_DEMO
impairment_NOMZ
is_VPRT [BEMA]
other_PRED
than_PIN
temporary_JJ
,_,
and_ANDC
the_DT
measurement_NOMZ
of_PIN
an_DT
impairment_NOMZ
loss_NN
._.
The_DT
FSP_NN
also_RB
includes_VPRT
accounting_GER
considerations_NOMZ
subsequent_JJ
to_PIN
the_DT
recognition_NOMZ
of_PIN
an_DT
other-than-temporary_JJ
impairment_NOMZ
and_CC
requires_VPRT [SUAV]
certain_JJ
disclosures_NN
about_IN
unrealized_JJ
losses_NN
that_TSUB
have_VPRT [PEAS]
not_XX0
been_VBN [PASS]
recognized_VBN [PRIV]
as_IN
other-than-temporary_JJ
impairments_NOMZ
._.
115-1_CD
and_CC
SFAS_NN
124-1_CD
is_VPRT [BEMA]
effective_PRED
for_PIN
the_DT
Company_NN
in_PIN
the_DT
first_JJ
quarter_NN
of_PIN
fiscal_JJ
year_NN
2006_CD
._.
The_DT
Company_NN
does_VPRT
not_XX0
expect_VB [PRIV]
the_DT
adoption_NOMZ
of_PIN
FSP_NN
SFAS_NN
No._NN
._.
115-1_CD
and_CC
SFAS_NN
124-1_CD
to_TO
have_VB
a_DT
material_NN
impact_NN
on_PIN
its_PIT
consolidated_JJ
financial_JJ
position_NOMZ
,_,
results_NN
of_PIN
operations_NOMZ
or_CC
cash_NN
flows_NN
._.
EITF_NN
04-5_CD
In_PIN
June_NN
2005_CD
,_,
the_DT
EITF_NN
reached_VBD
a_DT
consensus_NN
regarding_VBG [WZPRES]
the_DT
issue_NN
,_,
Investors_NN
Accounting_GER
for_PIN
an_DT
Investment_NOMZ
in_PIN
a_DT
Limited_NN
Partnership_NN
When_RB
the_DT
Investor_NN
Is_VPRT [BEMA]
the_DT
Sole_NN
General_NN
Partner_NN
and_CC
the_DT
Limited_NN
Partners_NN
Have_VPRT
Certain_NN
Rights_NN
Issue_NN
,_,
on_PIN
how_RB
to_TO
evaluate_VB
whether_IN
a_DT
partnership_NN
should_NEMD
be_VB [BYPA]
consolidated_VBN
by_PIN
one_CD
of_PIN
its_PIT
partners_NN
._.
The_DT
scope_NN
of_PIN
this_DEMO
Issue_NN
is_VPRT [PASS]
limited_VBN
to_PIN
limited_JJ
partnerships_NN
or_CC
similar_JJ
entities_NOMZ
such_JJ
as_IN
limited_JJ
liability_NOMZ
companies_NN
that_TSUB
have_VPRT
governing_VBG
provisions_NN
that_TSUB
are_VPRT [BEMA]
the_DT
functional_JJ
equivalent_NN
of_PIN
a_DT
limited_JJ
partnership_NN
that_TSUB
are_VPRT [BEMA]
not_XX0
variable_JJ
interest_NN
entities_NOMZ
under_IN
FASB_NN
Interpretation_NOMZ
46_CD
R._NN
The_NN
EITF_NN
concluded_VBD [PRIV]
that_THVC
a_DT
general_JJ
partner_NN
or_CC
a_DT
group_NN
of_PIN
general_JJ
partners_NN
of_PIN
a_DT
limited_JJ
partnership_NN
is_VPRT [PASS]
presumed_VBN [PRIV]
to_TO
control_VB
the_DT
limited_JJ
partnership_NN
,_,
unless_COND
either_CC
the_DT
limited_JJ
partners_NN
have_VPRT
the_DT
substantive_JJ
ability_NOMZ
to_TO
dissolve_VB
the_DT
limited_JJ
partnership_NN
or_CC
otherwise_CONJ
remove_VB
the_DT
general_JJ
partner_NN
without_PIN
cause_NN
or_CC
the_DT
limited_JJ
partners_NN
have_VPRT
substantive_JJ
participating_VBG
rights_NN
._.
The_DT
guidance_NN
in_PIN
this_DEMO
Issue_NN
is_VPRT [BEMA]
effective_PRED
after_IN
June_NN
29_CD
,_,
2005_CD
for_PIN
general_JJ
partners_NN
of_PIN
all_QUAN
new_JJ
limited_JJ
partnerships_NN
formed_VBN
and_CC
for_PIN
existing_VBG
limited_JJ
partnerships_NN
for_PIN
which_WDT [PIRE]
the_DT
partnership_NN
agreements_NOMZ
are_VPRT [PASS]
modified_VBN
._.
For_PIN
general_JJ
partners_NN
in_PIN
all_QUAN
other_JJ
pre-existing_JJ
limited_JJ
partnerships_NN
,_,
the_DT
guidance_NN
in_PIN
this_DEMO
Issue_NN
is_VPRT [BEMA]
effective_JJ
no_RB
later_TIME
than_PIN
the_DT
beginning_GER
of_PIN
the_DT
first_JJ
reporting_GER
period_NN
in_PIN
fiscal_JJ
years_NN
beginning_VBG [WZPRES]
after_IN
December_NN
15_CD
,_,
2005_CD
._.
The_DT
Company_NN
will_PRMD
adopt_VB
EITF_NN
04-5_CD
at_PIN
the_DT
beginning_GER
of_PIN
the_DT
second_JJ
quarter_NN
of_PIN
fiscal_JJ
year_NN
2006_CD
and_CC
is_VPRT [SPAU]
currently_RB
reviewing_VBG
the_DT
impact_NN
this_DEMO
issue_NN
will_PRMD
have_VB
on_PIN
its_PIT
financial_JJ
statements_NOMZ
._.
y_RB
Statutory_JJ
accounts_NN
The_DT
consolidated_JJ
financial_JJ
statements_NOMZ
as_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
and_CC
2004_CD
,_,
and_ANDC
for_PIN
each_QUAN
of_PIN
the_DT
three_CD
years_NN
in_PIN
the_DT
period_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
,_,
do_VPRT
not_XX0
comprise_VB
statutory_JJ
accounts_NN
within_PIN
the_DT
meaning_GER
of_PIN
Section_NOMZ
240_CD
of_PIN
the_DT
UK_NN
Companies_NN
Act_NN
1985_CD
._.
Statutory_JJ
accounts_NN
prepared_VBN [WZPAST]
in_PIN
accordance_NN
with_PIN
generally_RB
accepted_VBN [PRIV]
accounting_GER
principles_NN
in_PIN
the_DT
UK_NN
for_PIN
the_DT
years_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
and_CC
2003_CD
,_,
have_VPRT [PEAS]
been_VBN [PASS]
delivered_VBN
to_PIN
the_DT
Registrar_NN
of_PIN
Companies_NN
for_PIN
England_NN
and_PHC
Wales_NN
._.
The_DT
auditors_NN
report_VPRT [PUBV]
on_PIN
those_DEMO
accounts_NN
was_VBD [BEMA]
unqualified_PRED
._.
z_SYM
Revisions_NN
During_PIN
2005_CD
,_,
the_DT
Company_NN
changed_VBD
the_DT
presentation_NOMZ
of_PIN
its_PIT
Statements_NOMZ
of_PIN
cash_NN
flows_VPRT
to_TO [SPIN]
separately_RB
present_VB
the_DT
cash_NN
flows_VPRT
from_PIN
discontinued_VBN
operations_NOMZ
within_PIN
the_DT
categories_NN
operating_VBG [WZPRES]
,_,
investing_VBG
and_PHC
financing_VBG
activities_NOMZ
,_,
which_WDT [SERE]
in_PIN
prior_JJ
periods_NN
were_VBD [PASS]
reported_VBN [PUBV]
on_PIN
a_DT
combined_VBN
basis_NN
as_IN
a_DT
single_JJ
amount_NN
._.
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
91_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
92_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
Dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
4_CD
Business_NOMZ
combinations_NOMZ
:_:
TKT_NN
acquisition_NOMZ
On_PIN
July_NN
27_CD
,_,
2005_CD
,_,
Shire_NN
completed_VBD
its_PIT
acquisition_NOMZ
of_PIN
TKT_NN
in_PIN
an_DT
all-cash_JJ
transaction_NOMZ
._.
The_DT
acquisition_NOMZ
was_VBD [BYPA]
effected_VBN
by_PIN
merging_VBG
a_DT
wholly-owned_JJ
subsidiary_NN
of_PIN
Shire_NN
with_PIN
and_CC
into_PIN
TKT_NN
,_,
with_PIN
TKT_NN
continuing_VBG [WZPRES]
as_IN
the_DT
surviving_VBG
corporation_NOMZ
._.
As_IN
consideration_NOMZ
,_,
Shire_NN
paid_VBD
to_PIN
TKTs_NN
stockholders_NN
$_$
37_CD
in_PIN
cash_NN
for_PIN
each_QUAN
share_NN
of_PIN
TKT_NN
common_JJ
stock_NN
outstanding_JJ
at_PIN
the_DT
time_NN
of_PIN
the_DT
acquisition_NOMZ
,_,
less_JJ
any_QUAN
applicable_JJ
withholding_GER
taxes_NN
._.
The_DT
total_JJ
cash_NN
consideration_NOMZ
for_PIN
the_DT
acquisition_NOMZ
of_PIN
TKT_NN
is_VPRT [PASS]
expected_VBN [PRIV]
to_TO
be_VB
approximately_RB
$_$
1.6_CD
billion_CD
,_,
subject_JJ
to_TO
change_VB
as_RB
may_POMD
be_VB [BYPA]
required_VBN [SUAV]
by_PIN
the_DT
appraisal_NN
rights_NN
process_NN
see_VPRT [PRIV]
below_PLACE
._.
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
,_,
shareholders_NN
owning_VBG [WZPRES]
approximately_RB
24.8_CD
million_CD
TKT_NN
shares_NN
being_VBG [WZPRES] [BEMA]
69_CD
%_NN
of_PIN
the_DT
36.2_CD
million_CD
TKT_NN
shares_NN
outstanding_JJ
at_PIN
the_DT
acquisition_NOMZ
date_NN
had_VBD [PEAS]
accepted_VBN [PRIV]
the_DT
offer_NN
and_CC
$_$
917.9_CD
million_CD
has_VPRT [PEAS]
been_VBN [PASS]
paid_VBN
to_PIN
them_TPP3
:_:
$_$
83.9_CD
million_CD
was_VBD [PASS]
paid_VBN
in_PIN
connection_NOMZ
with_PIN
TKT_NN
stock_NN
options_NOMZ
:_:
and_ANDC
$_$
170.1_CD
million_CD
in_PIN
connection_NOMZ
with_PIN
convertible_JJ
notes_NN
outstanding_JJ
at_PIN
the_DT
date_NN
of_PIN
acquisition_NOMZ
._.
In_PIN
connection_NOMZ
with_PIN
the_DT
acquisition_NOMZ
,_,
as_RB
at_PIN
December_NN
31_CD
,_,
2005_CD
,_,
the_DT
former_JJ
holders_NN
of_PIN
approximately_RB
11.3_CD
million_CD
shares_NN
of_PIN
TKT_NN
common_JJ
stock_NN
submitted_VBN [PUBV]
written_VBN [PUBV]
demands_NN
for_PIN
appraisal_NN
of_PIN
these_DEMO
shares_NN
and_CC
elected_VBN
not_XX0
to_TO
accept_VB [PRIV]
the_DT
$_$
37_CD
per_PIN
share_NN
merger_NN
consideration_NOMZ
._.
To_PIN
the_DT
extent_NN
that_TOBJ
these_DEMO
demands_NN
were_VBD [SPAU] [PASS]
validly_RB
asserted_VBN [PUBV]
in_PIN
accordance_NN
with_PIN
the_DT
applicable_JJ
requirements_NOMZ
of_PIN
Delaware_NN
law_NN
and_CC
these_DEMO
holders_NN
perfect_JJ
their_TPP3
rights_NN
thereunder_NN
,_,
such_JJ
holders_NN
will_PRMD
be_VB [PASS]
entitled_VBN
to_TO
receive_VB
the_DT
fair_JJ
value_NN
of_PIN
their_TPP3
shares_NN
as_IN
determined_VBN [SUAV] [PRIV]
by_PIN
the_DT
Delaware_NN
Court_NN
of_PIN
Chancery_NN
._.
The_DT
determination_NOMZ
of_PIN
fair_JJ
value_NN
of_PIN
the_DT
TKT_NN
shares_NN
will_PRMD
be_VB [PASS]
made_VBN
excluding_VBG
any_QUAN
element_NOMZ
of_PIN
value_NN
arising_VBG [WZPRES]
from_PIN
the_DT
transaction_NOMZ
,_,
such_JJ
as_IN
cost_NN
savings_GER
or_CC
business_NOMZ
synergies_NN
._.
The_DT
Delaware_NN
Court_NN
of_PIN
Chancery_NN
may_POMD
ascribe_VB
a_DT
valuation_NOMZ
to_PIN
the_DT
shares_NN
that_DEMP
is_VPRT [BEMA]
greater_PRED
than_PIN [STPR]
,_,
less_JJ
than_PIN
or_CC
equal_JJ
to_TO
$_$
37_CD
per_PIN
share_NN
and_CC
may_POMD
award_NN
interest_NN
on_PIN
the_DT
amount_NN
determined_VBN [SUAV] [PRIV] [WZPAST]
in_PIN
the_DT
appraisal_NN
process_NN
._.
Shire_NN
has_VPRT [PEAS]
recognized_VBN [PRIV]
a_DT
liability_NOMZ
in_PIN
respect_NN
of_PIN
the_DT
fair_JJ
value_NN
of_PIN
those_DEMO
TKT_NN
shareholders_NN
who_WP [WHSUB]
have_VPRT [PEAS]
asserted_VBN [PUBV]
appraisal_NN
rights_NN
based_VBN [WZPAST]
on_PIN
$_$
37_CD
per_PIN
share_NN
._.
If_COND
the_DT
court_NN
ascribes_VPRT
a_DT
different_JJ
valuation_NOMZ
to_TO
$_$
37_CD
this_DEMP
will_PRMD
result_VB
in_PIN
an_DT
adjustment_NOMZ
to_PIN
goodwill_NN
._.
In_CONJ
addition_NULL
,_,
the_DT
Company_NN
has_VPRT [PEAS]
recorded_VBN
a_DT
provision_NN
for_PIN
interest_NN
,_,
based_VBN [PASTP]
on_PIN
the_DT
$_$
37_CD
per_PIN
share_NN
amount_NN
,_,
of_PIN
$_$
7.7_CD
million_CD
for_PIN
the_DT
period_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
,_,
which_WDT [SERE]
has_VPRT [PEAS]
been_VBN [PASS]
charged_VBN
to_PIN
the_DT
statement_NOMZ
of_PIN
operations_NOMZ
._.
For_PIN
accounting_VBG
purposes_NN
,_,
the_DT
acquisition_NOMZ
of_PIN
TKT_NN
has_VPRT [PEAS]
been_VBN [PASS]
accounted_VBN
for_PIN
as_IN
a_DT
purchase_NN
business_NOMZ
combination_NOMZ
in_PIN
accordance_NN
with_PIN
SFAS_NN
No._NN
._.
Under_IN
the_DT
purchase_NN
method_NN
of_PIN
accounting_GER
,_,
the_DT
assets_NN
acquired_VBN
and_CC
the_DT
liabilities_NOMZ
assumed_VBD [PRIV]
from_PIN
TKT_NN
are_VPRT [PASS]
recorded_VBN
at_PIN
the_DT
date_NN
of_PIN
acquisition_NOMZ
at_PIN
their_TPP3
respective_JJ
fair_JJ
values_NN
._.
Financial_NN
statements_NOMZ
and_CC
reported_VBD [PUBV]
results_NN
of_PIN
operations_NOMZ
of_PIN
Shire_NN
will_PRMD
reflect_VB [PRIV]
these_DEMO
values_NN
,_,
with_PIN
the_DT
results_NN
of_PIN
TKT_NN
included_VBD
from_PIN
July_NN
27_CD
,_,
2005_CD
,_,
in_PIN
the_DT
statement_NOMZ
of_PIN
operations_NOMZ
._.
The_DT
following_GER
is_VPRT [BEMA]
an_DT
estimate_NN
of_PIN
the_DT
purchase_NN
price_NN
for_PIN
TKT_NN
:_:
$_$
000_CD
Common_JJ
stock_NN
Number_NN
of_PIN
shares_NN
of_PIN
TKT_NN
common_JJ
stock_NN
non-dissenting_JJ
24,809,126_CD
Price_NN
per_PIN
TKT_NN
share_NN
$_$
37.00_CD
917,937_CD
Number_NN
of_PIN
shares_NN
of_PIN
TKT_NN
common_JJ
stock_NN
dissenting_VBG [WZPRES]
11,349,150_CD
i_FPP1
Price_NN
per_PIN
TKT_NN
share_NN
$_$
37.00_CD
419,919_CD
Total_JJ
number_NN
of_PIN
shares_NN
of_PIN
TKT_NN
common_JJ
stock_NN
outstanding_JJ
as_IN
at_PIN
July_NN
27_CD
,_,
2005_CD
36,158,276_CD
1,337,856_CD
Stock_NN
options_NOMZ
Cash_NN
cost_NN
of_PIN
settling_VBG
TKT_NN
stock_NN
options_NOMZ
83,877_CD
Convertible_JJ
notes_NN
Nominal_JJ
value_NN
of_PIN
convertible_JJ
loan_NN
notes_NN
as_IN
at_PIN
July_NN
27_CD
,_,
2005_CD
in_PIN
$_$
000s_CD
85,000_CD
Conversion_NN
ratio_NN
into_PIN
TKT_NN
common_JJ
stock_NN
18.49_CD
Total_JJ
shares_NN
payable_JJ
upon_PIN
conversion_NN
4,597,080_CD
Price_NN
per_PIN
TKT_NN
share_NN
$_$
37.00_CD
Cost_NN
of_PIN
settling_VBG
convertible_JJ
notes_NN
170,092_CD
Direct_JJ
costs_NN
of_PIN
acquisition_NOMZ
37,491_CD
Total_JJ
estimated_VBN [PRIV]
purchase_NN
price_NN
1,629,316_CD
The_DT
estimated_VBN [PRIV]
purchase_NN
price_NN
stated_VBN [PUBV]
above_PLACE
has_VPRT [PEAS]
been_VBN [PASS]
allocated_VBN
on_PIN
a_DT
preliminary_JJ
basis_NN
according_VBG [WZPRES]
to_PIN
Shires_NN
estimate_NN
of_PIN
the_DT
fair_JJ
value_NN
of_PIN
assets_NN
acquired_VBN
and_CC
liabilities_NOMZ
assumed_VBD [PRIV]
._.
The_DT
fair_JJ
values_NN
of_PIN
certain_JJ
pre-acquisition_JJ
contingencies_NN
,_,
in_CONJ
particular_NULL
those_DEMP
relating_VBG
to_PIN
the_DT
Purported_NN
Class_NN
Action_NOMZ
Shareholder_NN
Suit_NN
see_VPRT [PRIV]
Note_NN
21_CD
d_SYM
for_PIN
further_JJ
details_NN
are_VPRT
yet_RB
to_TO
be_VB [PASS]
determined_VBN [SUAV] [PRIV]
._.
Shire_NN
currently_RB
does_VPRT
not_XX0
have_VB
sufficient_JJ
information_NOMZ
to_TO [SPIN]
reliably_RB
measure_VB
the_DT
contingencies_NN
._.
i_FPP1
In_CONJ
addition_NULL
to_PIN
the_DT
$_$
37_CD
per_PIN
TKT_NN
share_NN
,_,
interest_NN
of_PIN
$_$
7.7_CD
million_CD
has_VPRT [PEAS]
been_VBN [PASS]
accrued_VBN
._.
Total_JJ
liability_NOMZ
to_TO
dissenting_VBG
shareholders_NN
included_VBN [WZPAST]
in_PIN
the_DT
balance_NN
sheet_NN
is_VPRT
$_$
427.6_CD
million_CD
._.
92_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
93_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
Dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
4_CD
Business_NOMZ
combinations_NOMZ
:_:
TKT_NN
acquisition_NOMZ
continued_VBD
The_DT
purchase_NN
price_NN
was_VBD [PASS]
allocated_VBN
as_IN
follows_VPRT
:_:
Book_NN
value_NN
Adjustments_NOMZ
Fair_NN
value_NN
Notes_NN
$_$
000_CD
$_$
000_CD
$_$
000_CD
Assets_NN
Current_JJ
assets_NN
:_:
Cash_NN
and_PHC
cash_NN
equivalents_NN
56,814_CD
56,814_CD
Restricted_VBN
cash_NN
8,173_CD
8,173_CD
Short-term_JJ
investments_NOMZ
46,896_CD
46,896_CD
Accounts_NN
receivable_NN
,_,
net_JJ
28,361_CD
28,361_CD
Inventories_NN
a_DT
12,890_CD
88,879_CD
101,769_CD
Prepaid_NN
expenses_NN
and_CC
other_JJ
current_JJ
assets_NN
7,997_CD
7,997_CD
Total_JJ
current_JJ
assets_NN
161,131_CD
88,879_CD
250,010_CD
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
,_,
net_JJ
57,297_CD
57,297_CD
Goodwill_NN
39,038_CD
39,038_CD
on_PIN
TKT_NN
acquisition_NOMZ
c_NN
166,414_CD
166,414_CD
Other_JJ
intangible_JJ
assets_NN
,_,
net_JJ
d_SYM
20,210_CD
460,790_CD
481,000_CD
In-process_JJ
research_NN
and_PHC
development_NOMZ
e_SYM
673,000_CD
673,000_CD
Deferred_JJ
tax_NN
asset_NN
b_NN
96,833_CD
96,833_CD
Other_JJ
non-current_JJ
assets_NN
3,281_CD
3,281_CD
Total_JJ
assets_NN
280,957_CD
1,446,878_CD
1,727,835_CD
Liabilities_NOMZ
Current_NN
liabilities_NOMZ
:_:
Accounts_NN
payable_JJ
and_CC
accrued_VBN
expenses_NN
f_LS
35,365_CD
437_CD
35,802_CD
Deferred_JJ
tax_NN
liability_NOMZ
b_NN
36,440_CD
36,440_CD
Other_JJ
current_JJ
liabilities_NOMZ
24,471_CD
24,471_CD
Total_JJ
current_JJ
liabilities_NOMZ
59,836_CD
36,877_CD
96,713_CD
Other_JJ
long-term_JJ
liabilities_NOMZ
1,806_CD
1,806_CD
Total_JJ
liabilities_NOMZ
61,642_CD
36,877_CD
98,519_CD
Estimated_VBN [PRIV]
fair_JJ
value_NN
of_PIN
identifiable_JJ
assets_NN
acquired_VBN
and_CC
liabilities_NOMZ
assumed_VBD [PRIV]
219,315_CD
1_CD
,_,
410,001_CD
1,629,316_CD
The_DT
fair_JJ
values_NN
of_PIN
assets_NN
acquired_VBN
and_CC
liabilities_NOMZ
assumed_VBD [PRIV]
will_PRMD
be_VB [PASS]
determined_VBN [SUAV] [PRIV]
as_OSUB
soon_NULL
as_NULL
possible_JJ
and_CC
,_,
in_CONJ
any_NULL
event_NULL
,_,
no_RB
later_TIME
than_PIN
one_CD
year_NN
from_PIN
the_DT
acquisition_NOMZ
date_NN
if_COND
such_JJ
fair_JJ
values_NN
can_POMD
be_VB [PASS]
measured_VBN
in_PIN
this_DEMO
time_NN
frame_NN
._.
To_PIN
the_DT
extent_NN
that_TSUB
estimates_VPRT [PRIV]
need_NN
to_TO
be_VB [PASS]
adjusted_VBN
,_,
Shire_NN
will_PRMD
do_VB
so_RB
in_PIN
future_NN
periods_NN
in_PIN
accordance_NN
with_PIN
SFAS_NN
No._NN
._.
In_PIN
the_DT
fourth_JJ
quarter_NN
of_PIN
2005_CD
,_,
the_DT
following_VBG
estimates_NN
were_VBD [PASS]
adjusted_VBN
:_:
Fair_NN
value_NN
net_JJ
assets_NN
adjustment_NOMZ
Nature_NN
of_PIN
adjustment_NOMZ
$_$
000_CD
Change_NN
in_PIN
deferred_JJ
tax_NN
rate_NN
21,987_CD
Change_NN
in_PIN
deferred_JJ
tax_NN
asset_NN
on_PIN
TKT_NN
losses_NN
carried_VBD
forward_JJ
net_NN
of_PIN
valuation_NOMZ
allowances_NN
40,504_CD
Determination_NOMZ
of_PIN
the_DT
fair_JJ
value_NN
of_PIN
certain_JJ
contingent_JJ
liabilities_NOMZ
outstanding_JJ
at_PIN
the_DT
acquisition_NOMZ
date_NN
18,020_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
93_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
94_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
Dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
4_CD
Business_NOMZ
combinations_NOMZ
:_:
TKT_NN
acquisition_NOMZ
continued_VBD
a_DT
Inventory_NN
Components_NN
of_PIN
the_DT
increase_NN
in_PIN
fair_JJ
value_NN
for_PIN
acquired_VBN
inventory_NN
are_VPRT
as_IN
follows_VPRT
:_:
Book_NN
Fair_NN
value_NN
Fair_NN
value_NN
adjustment_NOMZ
value_NN
$_$
000_CD
$_$
000_CD
$_$
000_CD
Finished_VBN
goods_NN
3,377_CD
66,814_CD
70,191_CD
Work-in-process_JJ
7,027_CD
22,065_CD
29,092_CD
Raw_NN
materials_NN
2,486_CD
2,486_CD
12,890_CD
88,879_CD
101,769_CD
Finished_VBN
goods_NN
were_VBD [BEMA]
fair_PRED
valued_VBN
at_PIN
estimated_VBN [PRIV]
selling_GER
price_NN
less_CC
the_DT
sum_NN
of_PIN
costs_NN
of_PIN
disposal_NN
and_CC
a_DT
reasonable_JJ
profit_NN
allowance_NN
for_PIN
the_DT
selling_GER
effort_NN
of_PIN
the_DT
Company_NN
._.
Work_NN
in-process_NN
was_VBD [BEMA]
fair_PRED
valued_VBN
on_PIN
the_DT
same_JJ
basis_NN
less_RB
costs_NN
to_TO
complete_VB
._.
All_QUAN
cost_NN
of_PIN
product_NN
sales_NN
of_PIN
REPLAGAL_NN
,_,
since_OSUB
the_DT
acquisition_NOMZ
,_,
are_VPRT [BEMA]
at_PIN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
inventory_NN
acquired_VBN
._.
b_NN
Deferred_JJ
taxes_NN
The_DT
estimated_VBN [PRIV]
tax_NN
effects_NN
of_PIN
the_DT
acquisition_NOMZ
,_,
including_VBG
TKT_NN
trading_GER
losses_NN
and_CC
the_DT
effect_NN
of_PIN
the_DT
fair_JJ
value_NN
adjustments_NOMZ
for_PIN
inventory_NN
and_CC
other_JJ
intangible_JJ
assets_NN
are_VPRT
as_IN
follows_VPRT
:_:
$_$
000_CD
i_FPP1
Deferred_JJ
tax_NN
asset_NN
on_PIN
TKT_NN
losses_NN
carried_VBD
forward_JJ
net_NN
of_PIN
valuation_NOMZ
allowance_NN
of_PIN
$_$
60.3_CD
million_CD
long_JJ
term_NN
285,757_CD
Deferred_JJ
tax_NN
liability_NOMZ
on_PIN
other_JJ
intangible_JJ
assets_NN
long_JJ
term_NN
188,924_CD
Deferred_JJ
tax_NN
asset_NN
,_,
net_JJ
96,833_CD
Deferred_JJ
tax_NN
liability_NOMZ
on_PIN
inventory_NN
current_JJ
36,440_CD
Deferred_JJ
tax_NN
,_,
net_JJ
60,393_CD
i_FPP1
Any_QUAN
future_JJ
changes_NN
in_PIN
the_DT
valuation_NOMZ
allowance_NN
will_PRMD
be_VB [PASS]
reflected_VBN [PRIV]
in_PIN
the_DT
carrying_VBG
value_NN
of_PIN
goodwill_NN
._.
As_IN
noted_VBN [PRIV]
above_PLACE
,_,
in_PIN
the_DT
final_JJ
quarter_NN
of_PIN
2005_CD
the_DT
following_VBG
estimates_NN
relating_VBG [WZPRES]
to_TO
deferred_VBN
tax_NN
were_VBD [PASS]
adjusted_VBN
for_PIN
:_:
the_DT
deferred_JJ
tax_NN
rate_NN
has_VPRT [PEAS]
been_VBN [PASS]
adjusted_VBN
to_TO
reflect_VB [PRIV]
the_DT
US_FPP1
federal_JJ
rate_NN
and_PHC
state_NN
tax_NN
combined_VBN
41_CD
%_NN
rate_NN
that_TSUB
should_NEMD
apply_VB
to_TO
measure_VB
the_DT
deferred_JJ
tax_NN
liability_NOMZ
:_:
and_ANDC
the_DT
deferred_JJ
tax_NN
asset_NN
on_PIN
TKT_NN
losses_NN
,_,
which_WDT [SERE]
increased_VBD
as_CONJ
a_NULL
result_NULL
of_PIN
the_DT
identification_NOMZ
of_PIN
further_JJ
tax_NN
deductible_JJ
expenses_NN
in_PIN
prior_JJ
years_NN
._.
c_NN
Goodwill_NN
In_PIN
accordance_NN
with_PIN
the_DT
requirements_NOMZ
of_PIN
SFAS_NN
No._NN
._.
142_CD
,_,
Goodwill_NN
and_CC
Other_JJ
Intangible_NN
Assets_NN
SFAS_NN
No._NN
._.
142_CD
,_,
the_DT
goodwill_NN
associated_VBN [WZPAST]
with_PIN
the_DT
TKT_NN
acquisition_NOMZ
will_PRMD
not_XX0
be_VB [PASS]
amortized_VBN
but_CC
will_PRMD
be_VB [BEMA]
subject_PRED
to_PIN
the_DT
Companys_NN
impairment_NOMZ
review_NN
._.
Goodwill_NN
resulting_VBG [WZPRES]
from_PIN
this_DEMO
acquisition_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
allocated_VBN
to_PIN
the_DT
Pharmaceutical_NN
Products_NN
segment_NOMZ
._.
d_LS
Other_JJ
intangible_JJ
assets_NN
The_DT
acquired_VBN
identifiable_JJ
intangible_JJ
assets_NN
are_VPRT [BEMA]
attributable_PRED
to_PIN
the_DT
following_VBG
categories_NN
:_:
Book_NN
Fair_NN
value_NN
Fair_NN
value_NN
adjustment_NOMZ
value_NN
Asset_NN
life_NN
$_$
000_CD
$_$
000_CD
$_$
000_CD
years_NN
i_FPP1
Intellectual_NN
property_NN
335,000_CD
335,000_CD
1420_CD
ii_FW
Customer_NN
relationships_NN
14,909_CD
104,091_CD
119,000_CD
15_CD
ii_FW
Other_JJ
survey_NN
data_NN
5,301_CD
21,699_CD
27,000_CD
7_CD
20,210_CD
460,790_CD
481,000_CD
Notes_NN
i_FPP1
Relates_VPRT
to_PIN
REPLAGAL_NN
excluding_VBG [WZPRES]
US_FPP1
and_PHC
Japan_NN
and_PHC
DYNEPO_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
anemia_NN
associated_VBN [WZPAST]
with_PIN
kidney_NN
disease_NN
._.
ii_FW
Relates_VPRT
to_PIN
REPLAGAL_NN
excluding_VBG [WZPRES]
US_FPP1
and_PHC
Japan_NN
._.
Acquired_VBN
identifiable_JJ
intangible_JJ
assets_NN
have_VPRT [PEAS]
been_VBN [PASS]
allocated_VBN
to_PIN
the_DT
Pharmaceutical_NN
Products_NN
reporting_VBG [PUBV] [WZPRES]
segment_NOMZ
._.
Acquired_VBN
identifiable_JJ
intangible_JJ
assets_NN
represent_VPRT
the_DT
value_NN
associated_VBN [WZPAST]
with_PIN
developed_JJ
technology_NN
to_PIN
which_WDT [PIRE]
the_DT
Company_NN
has_VPRT
all_QUAN
associated_VBN
rights_NN
._.
These_DEMO
rights_NN
can_POMD
include_VB
the_DT
right_NN
to_TO
develop_VB
,_,
use_VB
,_,
market_NN
,_,
sell_VB
and_CC
or_CC
offer_NN
for_PIN
sale_NN
the_DT
technical_JJ
processes_NN
,_,
intellectual_JJ
property_NN
and_CC
institutional_JJ
understanding_GER
including_VBG [WZPRES]
the_DT
way_NN
in_PIN
which_WDT [PIRE]
compounds_VPRT
react_VB
in_PIN
the_DT
body_NN
,_,
an_DT
understanding_GER
of_PIN
the_DT
mechanisms_NN
of_PIN
action_NOMZ
which_WDT [WHSUB]
allow_VPRT [SUAV]
the_DT
compound_NN
to_TO
work_VB
and_CC
the_DT
knowledge_NN
related_VBN [WZPAST]
to_PIN
the_DT
associated_VBN
clinical_JJ
and_CC
marketing_GER
studies_NN
performed_VBN [WZPAST]
for_PIN
these_DEMO
compounds_NN
that_TSUB
were_VBD [PASS]
acquired_VBN
as_IN
part_NN
of_PIN
the_DT
transaction_NOMZ
with_PIN
respect_NN
to_PIN
products_NN
and_CC
or_CC
processes_VPRT
that_DEMP
have_VPRT [PEAS]
been_VBN [PASS]
developed_VBN
._.
94_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
95_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
Dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
4_CD
Business_NOMZ
combinations_NOMZ
:_:
TKT_NN
acquisition_NOMZ
continued_VBD
The_DT
fair_JJ
value_NN
of_PIN
all_QUAN
of_PIN
the_DT
identifiable_JJ
intangible_JJ
assets_NN
has_VPRT [PEAS]
been_VBN [PASS]
determined_VBN [SUAV] [PRIV]
using_VBG
an_DT
income_NN
approach_NN
on_PIN
a_DT
project-by-project_JJ
basis_NN
._.
This_DEMO
method_NN
starts_VPRT
with_PIN
a_DT
forecast_NN
of_PIN
all_QUAN
of_PIN
the_DT
expected_JJ
future_JJ
net_JJ
cash_NN
flows_VPRT
either_CC
generated_VBD
or_CC
saved_VBD
as_CONJ
a_NULL
result_NULL
of_PIN
ownership_NN
of_PIN
the_DT
intellectual_JJ
property_NN
,_,
the_DT
customer_NN
relationships_NN
and_CC
the_DT
other_JJ
intangible_JJ
assets_NN
._.
These_DEMO
cash_NN
flows_NN
are_VPRT [SPAU] [PASS]
then_RB
adjusted_VBN
to_PIN
present_JJ
value_NN
by_PIN
applying_VBG
an_DT
appropriate_JJ
discount_NN
rate_NN
that_TSUB
reflects_VPRT [PRIV]
the_DT
risk_NN
factors_NN
associated_VBN [WZPAST]
with_PIN
the_DT
cash_NN
flow_NN
streams_NN
._.
The_DT
forecast_NN
of_PIN
future_JJ
cash_NN
flows_VPRT
requires_VPRT [SUAV]
various_JJ
assumptions_NOMZ
to_TO
be_VB [PASS]
made_VBN
,_,
including_VBG
:_:
revenue_NN
that_DEMP
is_VPRT [BEMA]
reasonably_RB
likely_PRED
to_TO
result_VB
from_PIN
the_DT
sale_NN
of_PIN
products_NN
including_VBG [WZPRES]
the_DT
estimated_VBN [PRIV]
number_NN
of_PIN
units_NN
to_TO
be_VB [PASS]
sold_VBN
,_,
estimated_VBN [PRIV]
selling_GER
prices_NN
,_,
estimated_VBN [PRIV]
market_NN
penetration_NOMZ
and_CC
estimated_VBN [PRIV]
market_NN
share_NN
and_CC
year-over-year_JJ
growth_NN
rates_NN
over_IN
the_DT
product_NN
life_NN
cycles_NN
:_:
royalty_NN
or_CC
license_NN
fees_NN
saved_VBN [WZPAST]
by_PIN
owning_VBG
the_DT
intellectual_JJ
property_NN
associated_VBN [WZPAST]
with_PIN
the_DT
products_NN
:_:
cost_NN
of_PIN
sales_NN
for_PIN
the_DT
products_NN
using_VBG [WZPRES]
historical_JJ
data_NN
,_,
industry_NN
data_NN
or_CC
other_JJ
sources_NN
of_PIN
market_NN
data_NN
:_:
sales_NN
and_PHC
marketing_GER
expense_NN
using_VBG [WZPRES]
historical_JJ
data_NN
,_,
industry_NN
data_NN
or_CC
other_JJ
sources_NN
of_PIN
market_NN
data_NN
:_:
general_JJ
and_PHC
administrative_JJ
expenses_NN
:_:
research_NN
and_PHC
development_NOMZ
expenses_NN
:_:
and_ANDC
the_DT
estimated_VBN [PRIV]
life_NN
of_PIN
the_DT
products_NN
._.
The_DT
valuations_NOMZ
are_VPRT [PASS]
based_VBN
on_PIN
information_NOMZ
at_PIN
the_DT
time_NN
of_PIN
the_DT
acquisition_NOMZ
and_CC
the_DT
expectations_NOMZ
and_PHC
assumptions_NOMZ
that_TSUB
have_VPRT [PEAS]
been_VBN [PASS]
deemed_VBN [PRIV]
reasonable_JJ
by_PIN
the_DT
Companys_NN
management_NOMZ
._.
No_SYNE
assurance_NN
can_POMD
be_VB [PASS]
given_VBN
,_,
however_CONJ
,_,
that_THVC
the_DT
underlying_VBG
assumptions_NOMZ
or_CC
events_NN
associated_VBN [WZPAST]
with_PIN
such_JJ
assets_NN
will_PRMD
occur_VB
as_IN
projected_VBN
._.
For_PIN
these_DEMO
reasons_NN
,_,
among_PIN
others_NN
,_,
the_DT
actual_JJ
cash_NN
flows_NN
may_POMD
vary_VB
from_PIN
the_DT
forecast_NN
future_JJ
cash_NN
flows_NN
._.
e_LS
In-process_JJ
research_NN
and_PHC
development_NOMZ
As_IN
required_VBN [SUAV]
by_PIN
FASB_NN
Interpretation_NOMZ
No._NN
._.
2_CD
to_PIN
Business_NOMZ
Combinations_NOMZ
Accounted_NN
for_PIN
by_PIN
the_DT
Purchase_NN
Method_NN
FIN_NN
4_CD
,_,
the_DT
portion_NOMZ
of_PIN
the_DT
purchase_NN
price_NN
allocated_VBN [WZPAST]
to_PIN
in-process_JJ
research_NN
and_PHC
development_NOMZ
of_PIN
$_$
673_CD
million_CD
was_VBD [SPAU] [PASS]
immediately_TIME
expensed_VBN
._.
A_DT
project-by-project_JJ
valuation_NOMZ
using_VBG [WZPRES]
the_DT
guidance_NN
in_PIN
SFAS_NN
No._NN
._.
141_CD
and_CC
the_DT
American_NN
Institute_NN
of_PIN
Certified_NN
Public_NN
Accountants_NN
AICPA_NN
Practice_NN
Aid_NN
Assets_NN
Acquired_VBN [WZPAST]
in_PIN
a_DT
Business_NOMZ
Combination_NOMZ
to_TO
Be_VB [PASS]
Used_VBN
In_PIN
Research_NN
and_PHC
Development_NOMZ
Activities_NOMZ
:_:
A_DT
Focus_NN
on_PIN
Software_NN
,_,
Electronic_NN
Devices_NN
and_PHC
Pharmaceutical_NN
Industries_NN
has_VPRT [PEAS]
been_VBN [BYPA]
performed_VBN
by_PIN
independent_JJ
valuation_NOMZ
specialists_NN
to_TO
determine_VB [SUAV] [PRIV]
the_DT
fair_JJ
value_NN
of_PIN
research_NN
and_PHC
development_NOMZ
projects_NN
of_PIN
TKT_NN
which_WDT [WHSUB]
were_VBD [BEMA]
in-process_PRED
,_,
but_CC
not_XX0
yet_RB
completed_VBN
._.
The_DT
fair_JJ
value_NN
was_VBD [PASS]
determined_VBN [SUAV] [PRIV]
using_VBG
the_DT
income_NN
approach_NN
on_PIN
a_DT
project-by-project_JJ
basis_NN
._.
This_DEMO
method_NN
starts_VPRT
with_PIN
a_DT
forecast_NN
of_PIN
the_DT
expected_JJ
future_JJ
net_JJ
cash_NN
flows_NN
._.
These_DEMO
cash_NN
flows_NN
are_VPRT [SPAU] [PASS]
then_RB
adjusted_VBN
to_PIN
present_JJ
value_NN
by_PIN
applying_VBG
an_DT
appropriate_JJ
discount_NN
rate_NN
that_TSUB
reflects_VPRT [PRIV]
the_DT
projects_NN
stage_NN
of_PIN
completion_NOMZ
and_CC
other_JJ
risk_NN
factors_NN
._.
These_DEMO
other_JJ
risk_NN
factors_NN
can_POMD
include_VB
the_DT
nature_NN
of_PIN
the_DT
product_NN
,_,
the_DT
scientific_JJ
data_NN
associated_VBN [WZPAST]
with_PIN
the_DT
technology_NN
,_,
the_DT
current_JJ
patent_NN
situation_NOMZ
and_PHC
market_NN
competition_NOMZ
._.
The_DT
forecast_NN
of_PIN
future_JJ
cash_NN
flows_VPRT
required_VBN [SUAV]
various_JJ
assumptions_NOMZ
to_TO
be_VB [PASS]
made_VBN
including_VBG
:_:
revenue_NN
that_DEMP
is_VPRT [BEMA]
likely_PRED
to_TO
result_VB
from_PIN
specific_JJ
in-process_JJ
research_NN
and_PHC
development_NOMZ
projects_NN
,_,
including_VBG
estimated_VBN [PRIV]
number_NN
of_PIN
units_NN
to_TO
be_VB [PASS]
sold_VBN
,_,
estimated_VBN [PRIV]
selling_GER
prices_NN
,_,
estimated_VBN [PRIV]
market_NN
penetration_NOMZ
and_CC
estimated_VBN [PRIV]
market_NN
share_NN
and_CC
year-over-year_JJ
growth_NN
rates_NN
over_IN
the_DT
product_NN
life_NN
cycles_NN
:_:
cost_NN
of_PIN
sales_NN
related_VBN [WZPAST]
to_PIN
the_DT
potential_JJ
products_NN
using_VBG [WZPRES]
historical_JJ
data_NN
,_,
industry_NN
data_NN
or_CC
other_JJ
sources_NN
of_PIN
market_NN
data_NN
:_:
sales_NN
and_PHC
marketing_GER
expense_NN
using_VBG [WZPRES]
historical_JJ
data_NN
,_,
industry_NN
data_NN
or_CC
other_JJ
market_NN
data_NN
:_:
general_JJ
and_PHC
administrative_JJ
expenses_NN
:_:
and_ANDC
research_NN
and_PHC
development_NOMZ
expenses_NN
._.
In_CONJ
addition_NULL
the_DT
Company_NN
considered_VBN [PRIV]
:_:
the_DT
projects_NN
stage_NN
of_PIN
completion_NOMZ
:_:
the_DT
costs_NN
incurred_VBN [WZPAST]
to_PIN
date_NN
:_:
the_DT
projected_VBN
costs_NN
to_TO
complete_VB
:_:
the_DT
contribution_NOMZ
,_,
if_COND
any_QUAN
,_,
of_PIN
the_DT
acquired_VBN
identifiable_JJ
intangible_JJ
assets_NN
:_:
the_DT
projected_VBN
launch_NN
date_NN
of_PIN
the_DT
potential_JJ
product_NN
:_:
and_ANDC
the_DT
estimated_VBN [PRIV]
life_NN
of_PIN
the_DT
potential_JJ
product_NN
._.
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
95_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
96_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
Dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
4_CD
Business_NOMZ
combinations_NOMZ
:_:
TKT_NN
acquisition_NOMZ
continued_VBD
To_PIN
the_DT
extent_NN
that_TOBJ
the_DT
in-process_JJ
research_NN
and_PHC
development_NOMZ
project_NN
is_VPRT [PASS]
expected_VBN [PRIV]
to_TO
utilize_VB
the_DT
acquired_VBN
identified_VBN
intangible_JJ
assets_NN
,_,
the_DT
value_NN
of_PIN
the_DT
in-process_JJ
research_NN
and_PHC
development_NOMZ
project_NN
has_VPRT [PEAS]
been_VBN [PASS]
reduced_VBN
to_TO
reflect_VB [PRIV]
this_DEMO
utilization_NOMZ
._.
The_DT
acquired_VBN
identified_VBN
intangible_JJ
assets_NN
include_VPRT
the_DT
technical_JJ
processes_NN
,_,
intellectual_JJ
property_NN
,_,
and_ANDC
institutional_JJ
understanding_GER
with_PIN
respect_NN
to_PIN
products_NN
and_PHC
processes_NN
that_TSUB
have_VPRT [PEAS]
been_VBN [PASS]
completed_VBN
and_CC
that_DEMP
may_POMD
aid_VB
in_PIN
the_DT
development_NOMZ
of_PIN
future_JJ
products_NN
or_CC
processes_NN
._.
f_LS
Accounts_NN
payable_JJ
and_CC
accrued_VBN
expenses_NN
Included_VBD
in_PIN
Accounts_NN
payable_JJ
and_CC
accrued_VBN
expenses_NN
are_VPRT [BEMA]
the_DT
following_VBG
fair_JJ
value_NN
adjustments_NOMZ
:_:
i_FPP1
Restructuring_GER
costs_NN
An_DT
estimate_NN
of_PIN
restructuring_GER
costs_NN
that_TSUB
impact_VPRT
goodwill_NN
,_,
pursuant_JJ
to_PIN
EITF_NN
Issue_NN
No._NN
._.
95-3_CD
,_,
Recognition_NOMZ
of_PIN
Liabilities_NOMZ
in_PIN
Connection_NOMZ
with_PIN
Purchase_NN
Business_NOMZ
Combinations_NOMZ
EITF_NN
95-3_CD
._.
Such_JJ
costs_NN
total_JJ
$_$
2_CD
million_CD
and_CC
are_VPRT [PASS]
associated_VBN
with_PIN
the_DT
involuntary_JJ
termination_NOMZ
of_PIN
15_CD
TKT_NN
employees_NN
all_QUAN
of_PIN
whom_WP [PIRE]
had_VBD [PEAS]
left_VBN
the_DT
Company_NN
by_PIN
December_NN
31_CD
,_,
2005_CD
._.
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
,_,
$_$
1.5_CD
million_CD
had_VBD [PEAS]
been_VBN [PASS]
paid_VBN
and_CC
$_$
0.5_CD
million_CD
was_VBD [BEMA]
outstanding_PRED
:_:
and_ANDC
ii_FW
Deferred_JJ
revenue_NN
A_DT
fair_JJ
value_NN
adjustment_NOMZ
of_PIN
$_$
1.6_CD
million_CD
in_PIN
respect_NN
of_PIN
a_DT
deferred_JJ
revenue_NN
stream_NN
relating_VBG [WZPRES]
to_PIN
pre-acquisition_JJ
activities_NOMZ
of_PIN
TKT_NN
._.
Pro-forma_JJ
financial_JJ
information_NOMZ
The_DT
following_VBG
unaudited_JJ
pro-forma_FW
financial_JJ
information_NOMZ
presents_VPRT
the_DT
combined_VBN
results_NN
of_PIN
the_DT
operations_NOMZ
of_PIN
Shire_NN
and_PHC
TKT_NN
as_IN
if_COND
the_DT
acquisition_NOMZ
had_VBD [PEAS]
occurred_VBN
at_PIN
the_DT
beginning_GER
of_PIN
the_DT
periods_NN
presented_VBN
._.
The_DT
unaudited_JJ
pro-forma_FW
financial_JJ
information_NOMZ
is_VPRT
not_XX0
necessarily_RB
indicative_PRED
of_PIN
what_WP
the_DT
consolidated_JJ
results_NN
of_PIN
operations_NOMZ
actually_RB
would_PRMD
have_VB [PEAS]
been_VBN [PASS]
had_VBD
the_DT
acquisition_NOMZ
been_VBN [PASS]
completed_VBN
at_PIN
the_DT
dates_NN
indicated_VBD [PRIV]
._.
In_CONJ
addition_NULL
,_,
the_DT
unaudited_JJ
pro-forma_FW
financial_JJ
information_NOMZ
does_VPRT
not_XX0
purport_VB
to_TO
project_VB
the_DT
future_JJ
results_NN
of_PIN
operations_NOMZ
of_PIN
the_DT
combined_VBN
Company_NN
._.
2005_CD
2004_CD
Year_NN
to_PIN
December_NN
31_CD
,_,
$_$
000_CD
$_$
000_CD
Revenues_NN
1,652,875_CD
1,441,333_CD
Income_NN
before_IN
extraordinary_JJ
items_NN
and_CC
cumulative_JJ
effect_NN
of_PIN
change_NN
in_PIN
accounting_GER
principles_NN
220,034_CD
187,968_CD
Net_JJ
income_NN
220,034_CD
187,968_CD
Per_PIN
share_NN
amounts_NN
:_:
Net_JJ
income_NN
per_PIN
common_JJ
share_NN
basic_JJ
44.0_CD
37.9_CD
Net_JJ
income_NN
per_PIN
common_JJ
share_NN
diluted_VBN
43.5_CD
37.4_CD
The_DT
unaudited_JJ
pro-forma_FW
financial_JJ
information_NOMZ
above_PLACE
reflects_VPRT [PRIV]
the_DT
following_VBG
pro-forma_FW
adjustments_NOMZ
applied_VBD
using_VBG
the_DT
principles_NN
of_PIN
Article_NN
11_CD
of_PIN
Regulation_NOMZ
S-X_NN
under_IN
the_DT
Securities_NOMZ
Exchange_NN
Act_NN
of_PIN
1934_CD
:_:
i_FPP1
elimination_NOMZ
of_PIN
historical_JJ
amortization_NOMZ
expense_NN
recorded_VBN [WZPAST]
by_PIN
legacy_NN
TKT_NN
for_PIN
definite-lived_JJ
intangible_JJ
assets_NN
:_:
ii_FW
elimination_NOMZ
of_PIN
interest_NN
expense_NN
recorded_VBN [WZPAST]
by_PIN
legacy_NN
TKT_NN
on_PIN
convertible_JJ
loan_NN
notes_NN
:_:
iii_FW
an_DT
adjustment_NOMZ
to_TO
increase_VB
interest_NN
expense_NN
by_PIN
$_$
6_CD
million_CD
in_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
,_,
and_ANDC
$_$
8.1_CD
million_CD
in_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
,_,
to_TO
reflect_VB [PRIV]
the_DT
interest_NN
payable_JJ
to_TO
dissenting_VBG
shareholders_NN
:_:
iv_VB
an_DT
adjustment_NOMZ
to_TO
decrease_VB
interest_NN
income_NN
by_PIN
$_$
15_CD
million_CD
in_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
,_,
and_ANDC
$_$
17.4_CD
million_CD
in_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
,_,
to_TO
reflect_VB [PRIV]
the_DT
cash_NN
consideration_NOMZ
paid_VBN [WZPAST]
to_PIN
TKT_NN
shareholders_NN
,_,
option_NOMZ
holders_NN
and_CC
convertible_JJ
note_NN
holders_NN
:_:
and_ANDC
v_VB
an_DT
adjustment_NOMZ
to_TO
increase_VB
amortization_NOMZ
expense_NN
based_VBN [WZPAST]
on_PIN
the_DT
estimated_VBN [PRIV]
fair_JJ
value_NN
of_PIN
identifiable_JJ
intangible_JJ
assets_NN
from_PIN
the_DT
purchase_NN
price_NN
allocation_NOMZ
,_,
which_WDT [SERE]
are_VPRT
being_VBG [PASS]
amortized_VBN
over_IN
their_TPP3
estimated_VBN [PRIV]
useful_JJ
lives_NN
over_IN
a_DT
range_NN
of_PIN
720_CD
years_NN
,_,
of_PIN
approximately_RB
$_$
13.7_CD
million_CD
in_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
,_,
and_ANDC
$_$
23.4_CD
million_CD
in_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
._.
In_CONJ
addition_NULL
,_,
the_DT
unaudited_JJ
pro-forma_FW
financial_JJ
information_NOMZ
above_PLACE
excludes_VPRT
the_DT
following_VBG
material_NN
,_,
non-recurring_JJ
purchase_NN
accounting_GER
adjustments_NOMZ
in_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
,_,
as_IN
follows_VPRT
:_:
an_DT
in-process_JJ
research_NN
and_PHC
development_NOMZ
charge_NN
of_PIN
$_$
673_CD
million_CD
:_:
a_DT
$_$
41.9_CD
million_CD
charge_NN
relating_VBG [WZPRES]
to_PIN
the_DT
use_NN
or_CC
sale_NN
of_PIN
purchased_VBN
inventory_NN
that_TSUB
was_VBD [PASS]
written_VBN [PUBV]
up_RP
to_PIN
fair_JJ
value_NN
reported_VBN [PUBV] [WZPAST]
in_PIN
cost_NN
of_PIN
product_NN
sales_NN
:_:
and_ANDC
a_DT
$_$
17.2_CD
million_CD
credit_NN
relating_VBG [WZPRES]
to_PIN
the_DT
current_JJ
deferred_JJ
tax_NN
liability_NOMZ
with_PIN
regard_NN
to_PIN
the_DT
purchased_VBN
inventory_NN
charge_NN
in_PIN
cost_NN
of_PIN
product_NN
sales_NN
above_PLACE
._.
96_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
97_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
Dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
5_CD
Integration_NOMZ
costs_NN
In_PIN
connection_NOMZ
with_PIN
the_DT
acquisition_NOMZ
of_PIN
TKT_NN
the_DT
Companys_NN
management_NOMZ
approved_VBD
and_PHC
initiated_VBD
plans_NN
to_TO
restructure_VB
the_DT
operations_NOMZ
of_PIN
the_DT
enlarged_JJ
Company_NN
to_TO
eliminate_VB
duplicate_VB
facilities_NOMZ
and_CC
reduce_VB
costs_NN
._.
Integration_NOMZ
costs_NN
represent_VPRT
incremental_JJ
costs_NN
incurred_VBN [WZPAST]
by_PIN
the_DT
Company_NN
directly_RB
related_VBN
to_PIN
the_DT
absorption_NOMZ
of_PIN
the_DT
TKT_NN
business_NOMZ
into_PIN
the_DT
Company_NN
,_,
including_VBG
expenditures_NN
for_PIN
consulting_GER
and_PHC
systems_NN
integration_NOMZ
._.
The_DT
charges_NN
have_VPRT [PEAS]
been_VBN [PASS]
presented_VBN
as_IN
integration_NOMZ
costs_NN
in_PIN
the_DT
statement_NOMZ
of_PIN
operations_NOMZ
and_CC
are_VPRT [PASS]
accounted_VBN
for_PIN
solely_RB
within_PIN
the_DT
Pharmaceutical_NN
Products_NN
reporting_VBG [PUBV] [WZPRES]
segment_NOMZ
._.
Integration_NOMZ
costs_NN
expensed_VBN [WZPAST]
in_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
:_:
Costs_NN
recorded_VBD
Paid_VBN
in_PIN
in_PIN
year_NN
to_PIN
year_NN
to_PIN
December_NN
31_CD
,_,
December_NN
31_CD
,_,
Closing_GER
2005_CD
2005_CD
liability_NOMZ
Notes_NN
$_$
000_CD
$_$
000_CD
$_$
000_CD
Employee_NN
severance_NN
and_PHC
retention_NOMZ
payments_NOMZ
for_PIN
key_JJ
TKT_NN
employees_NN
7,031_CD
1,097_CD
5,934_CD
Information_NOMZ
technology_NN
costs_VPRT
1,049_CD
1,049_CD
Other_JJ
1,636_CD
1,436_CD
200_CD
9,716_CD
3,582_CD
6,134_CD
Current_JJ
liabilities_NOMZ
17_CD
8,916_CD
3,582_CD
5,293_CD
Other_JJ
long-term_JJ
liabilities_NOMZ
19 800 841_CD
9,716_CD
3,582_CD
6,134_CD
6_CD
Reorganizations_NOMZ
Actions_NOMZ
commenced_VBD
in_PIN
2005_CD
Sale_NN
of_PIN
the_DT
drug_NN
formulation_NOMZ
business_NOMZ
On_PIN
December_NN
22_CD
,_,
2005_CD
,_,
Shire_NN
sold_VBD
its_PIT
drug_NN
formulation_NOMZ
business_NOMZ
to_PIN
Supernus_NN
Pharmaceuticals_NN
,_,
Inc._NN
._.
Supernus_NN
,_,
a_DT
newly-formed_JJ
specialty_NN
pharmaceutical_JJ
company_NN
funded_VBN [WZPAST]
by_PIN
two_CD
venture_NN
capital_NN
companies_NN
._.
The_DT
sale_NN
resulted_VBD
in_PIN
:_:
a_DT
profit_NN
on_PIN
sale_NN
of_PIN
$_$
3.6_CD
million_CD
._.
Proceeds_NN
from_PIN
the_DT
sale_NN
included_VBD
an_DT
equity_NOMZ
interest_NN
of_PIN
less_JJ
than_PIN
10_CD
%_NN
in_PIN
Supernus_NN
,_,
which_WDT [SERE]
has_VPRT [PEAS]
been_VBN [PASS]
included_VBN
in_PIN
investments_NOMZ
in_PIN
private_JJ
companies_NN
see_VPRT [PRIV]
Note_VB [PRIV]
11_CD
at_PIN
its_PIT
fair_JJ
value_NN
of_PIN
$_$
3.9_CD
million_CD
._.
The_DT
fair_JJ
value_NN
was_VBD [BYPA]
determined_VBN [SUAV] [PRIV]
by_PIN
reference_NN
to_PIN
the_DT
cash_NN
invested_VBN [WZPAST]
in_PIN
Supernus_NN
by_PIN
the_DT
venture_NN
capital_NN
companies_NN
:_:
the_DT
transfer_NN
of_PIN
the_DT
lease_NN
on_PIN
the_DT
East_NN
Gude_NN
Drive_NN
,_,
Rockville_NN
premises_NN
to_PIN
Supernus_NN
,_,
with_PIN
Shire_NN
being_VBG [WZPRES] [PASS]
released_VBN
from_PIN
all_QUAN
obligations_NOMZ
under_IN
the_DT
lease_NN
by_PIN
the_DT
landlord_NN
:_:
an_DT
ongoing_JJ
projects_NN
agreement_NOMZ
relating_VBG [WZPRES]
to_PIN
services_NN
that_TOBJ
Supernus_NN
will_PRMD
continue_VB
to_TO
provide_VB
to_TO
Shire_VB
for_PIN
a_DT
transitional_JJ
period_NN
ending_VBG [WZPRES]
on_PIN
or_CC
about_IN
March_NN
31_CD
,_,
2006_CD
,_,
on_PIN
certain_JJ
Shire_NN
projects_NN
until_IN
the_DT
projects_NN
are_VPRT [PASS]
moved_VBN [SUAV]
to_PIN
third-party_JJ
suppliers_NN
:_:
and_ANDC
the_DT
severance_NN
of_PIN
28_CD
employees_NN
._.
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
,_,
16_CD
had_VBD [PEAS]
left_VBN
the_DT
Company_NN
,_,
and_ANDC
the_DT
remaining_VBG
employees_NN
are_VPRT [PASS]
expected_VBN [PRIV]
to_TO
leave_VB
by_PIN
March_NN
31_CD
,_,
2006_CD
._.
Severance_NN
payments_NOMZ
are_VPRT
being_VBG [PASS]
made_VBN
to_PIN
the_DT
former_JJ
employees_NN
over_IN
a_DT
42-week_JJ
period_NN
,_,
as_IN
required_VBN [SUAV]
by_PIN
local_JJ
regulations_NOMZ
._.
The_DT
sale_NN
has_VPRT [PEAS]
been_VBN [PASS]
reflected_VBN [PRIV]
in_PIN
the_DT
statement_NOMZ
of_PIN
operations_NOMZ
as_IN
follows_VPRT
:_:
Research_NN
and_CC
Other_JJ
income_NN
development_NOMZ
expense_NN
,_,
net_JJ
expense_NN
$_$
000_CD
$_$
000_CD
Gain_NN
on_PIN
disposition_NOMZ
3,561_CD
Employee_NN
severance_NN
1,216_CD
Other_JJ
costs_NN
192_CD
3,561_CD
1,408_CD
All_QUAN
items_NN
are_VPRT [PASS]
recorded_VBN
in_PIN
the_DT
Pharmaceutical_NN
Products_NN
segment_NOMZ
._.
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
97_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
98_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
Dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV] [THATD]
6_CD
Reorganizations_NOMZ
continued_VBD
Actions_NOMZ
commenced_VBN [WZPAST]
in_PIN
2004_CD
North_PLACE
American_JJ
site_NN
consolidation_NOMZ
As_IN
previously_TIME
disclosed_VBN [PUBV]
,_,
the_DT
Company_NN
began_VBD
a_DT
consolidation_NOMZ
of_PIN
its_PIT
North_PLACE
American_JJ
sites_NN
in_PIN
2004_CD
,_,
with_PIN
the_DT
aim_NN
of_PIN
decreasing_VBG
the_DT
number_NN
of_PIN
sites_NN
from_PIN
16_CD
to_PIN
four_CD
,_,
including_VBG [PRESP]
the_DT
opening_GER
of_PIN
a_DT
new_JJ
US_FPP1
headquarters_NN
office_NN
in_PIN
Wayne_NN
,_,
Pennsylvania_NN
._.
The_DT
Company_NN
recorded_VBN
reorganization_NOMZ
costs_NN
of_PIN
$_$
48.5_CD
million_CD
in_PIN
2004_CD
,_,
and_ANDC
$_$
9.3_CD
million_CD
in_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
._.
The_DT
primary_JJ
costs_NN
associated_VBN [WZPAST]
with_PIN
the_DT
site_NN
consolidation_NOMZ
included_VBD
:_:
severance_NN
costs_NN
relating_VBG [WZPRES]
to_PIN
137_CD
employees_NN
:_:
retention_NOMZ
payments_NOMZ
to_PIN
key_JJ
employees_NN
:_:
relocation_NOMZ
costs_NN
relating_VBG [WZPRES]
to_PIN
85_CD
employees_NN
who_WP [WHSUB]
were_VBD [PASS]
moved_VBN [SUAV]
to_PIN
Wayne_NN
,_,
Pennsylvania_NN
:_:
costs_NN
of_PIN
duplicate_VPRT
facilities_NOMZ
including_VBG [WZPRES]
lease_NN
exit_NN
costs_NN
:_:
and_ANDC
other_JJ
incremental_JJ
costs_NN
associated_VBN [WZPAST]
with_PIN
the_DT
site_NN
closures_NN
,_,
such_JJ
as_IN
legal_JJ
,_,
consultancy_NN
,_,
the_DT
write-down_NN
of_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
and_PHC
information_NOMZ
technology_NN
costs_NN
._.
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
,_,
all_QUAN
137_CD
employees_NN
had_VBD [PEAS]
left_VBN
the_DT
Company_NN
._.
The_DT
cost_NN
of_PIN
the_DT
employee_NN
severance_NN
was_VBD [SPAU] [PASS]
ratably_RB
recognized_VBN [PRIV]
over_IN
the_DT
period_NN
from_PIN
the_DT
communication_NOMZ
date_NN
to_PIN
the_DT
termination_NOMZ
date_NN
._.
In_CONJ
addition_NULL
,_,
all_QUAN
85_CD
of_PIN
those_DEMO
employees_NN
who_WP [WHSUB]
had_VBD [PEAS]
agreed_VBN [SUAV] [PUBV]
to_TO
relocate_VB
have_VB [PEAS]
relocated_VBN
._.
The_DT
cost_NN
of_PIN
relocation_NOMZ
was_VBD [PASS]
recorded_VBN
as_IN
it_PIT
was_VBD [PASS]
incurred_VBN
._.
The_DT
following_JJ
table_NN
presents_VPRT
the_DT
cost_NN
of_PIN
the_DT
reorganization_NOMZ
recorded_VBN [WZPAST]
to_PIN
date_NN
and_CC
the_DT
total_JJ
costs_NN
of_PIN
the_DT
reorganization_NOMZ
._.
Total_JJ
costs_NN
Total_JJ
costs_NN
recorded_VBN [WZPAST]
in_PIN
recorded_VBN
in_PIN
year_NN
to_PIN
year_NN
to_PIN
December_NN
31_CD
,_,
December_NN
31_CD
,_,
Total_JJ
costs_NN
of_PIN
2005_CD
2004_CD
reorganization_NOMZ
$_$
m_CD
$_$
m_CD
$_$
m_CD
Employee_NN
severance_NN
and_PHC
relocation_NOMZ
costs_NN
1.6_CD
33.8_CD
35.4_CD
Write-off_PIN
of_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
1.2_CD
1.2_CD
Consultancy_NN
costs_NN
0.5_CD
2.9_CD
3.4_CD
Duplicate_NN
facilities_NOMZ
7.2_CD
5.1_CD
12.3_CD
Information_NOMZ
technology_NN
costs_VPRT
2.1_CD
2.1_CD
Other_JJ
costs_NN
3.4_CD
3.4_CD
9.3_CD
48.5_CD
57.8_CD
These_DEMO
charges_NN
have_VPRT [PEAS]
been_VBN [PASS]
reflected_VBN [PRIV]
within_PIN
reorganization_NOMZ
costs_NN
in_PIN
the_DT
statement_NOMZ
of_PIN
operations_NOMZ
and_CC
are_VPRT [PASS]
accounted_VBN
for_PIN
solely_RB
within_PIN
the_DT
Pharmaceutical_NN
Products_NN
reporting_VBG [PUBV] [WZPRES]
segment_NOMZ
._.
As_IN
noted_VBN [PRIV]
above_PLACE
,_,
certain_JJ
of_PIN
the_DT
costs_NN
associated_VBN [WZPAST]
with_PIN
the_DT
reorganization_NOMZ
will_PRMD
be_VB [PASS]
paid_VBN
in_PIN
subsequent_JJ
periods_NN
._.
The_DT
following_VBG
provides_VPRT
a_DT
reconciliation_NOMZ
of_PIN
the_DT
liability_NOMZ
as_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
:_:
Costs_NN
recorded_VBN
Utilization_NOMZ
in_PIN
year_NN
to_PIN
in_PIN
year_NN
to_PIN
Opening_GER
December_NN
31_CD
,_,
December_NN
31_CD
,_,
Closing_GER
liability_NOMZ
2005_CD
2005_CD
liability_NOMZ
Notes_NN
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
Employee_NN
severance_NN
and_PHC
relocation_NOMZ
costs_NN
1.7_CD
1.6_CD
2.7_CD
0.6_CD
Consultancy_NN
costs_NN
0.5_CD
0.5_CD
Duplicate_NN
facilities_NOMZ
2.5_CD
7.2_CD
2.5_CD
7.2_CD
4.2_CD
9.3_CD
5.7_CD
7.8_CD
Current_JJ
liabilities_NOMZ
17_CD
1.7_CD
7.4_CD
5.7_CD
3.4_CD
Other_JJ
long-term_JJ
liabilities_NOMZ
19_CD
2.5_CD
1.9_CD
4.4_CD
4.2_CD
9.3_CD
5.7_CD
7.8_CD
The_DT
remaining_VBG
relocation_NOMZ
costs_NN
are_VPRT [PASS]
expected_VBN [PRIV]
to_TO
be_VB [PASS]
paid_VBN
in_PIN
2006_CD
._.
The_DT
duplicate_VPRT
facilities_NOMZ
costs_NN
will_PRMD
be_VB [PASS]
paid_VBN
over_IN
the_DT
remaining_VBG
life_NN
of_PIN
the_DT
relevant_JJ
leases_NN
,_,
which_WDT [SERE]
all_QUAN
expire_VPRT
before_IN
October_NN
31_CD
,_,
2012_CD
._.
98_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
99_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
Dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV] [THATD]
6_CD
Reorganizations_NOMZ
continued_VBD
The_DT
following_JJ
provides_VPRT
a_DT
reconciliation_NOMZ
of_PIN
the_DT
liability_NOMZ
as_IN
at_PIN
December_NN
31_CD
,_,
2004_CD
:_:
Costs_NN
recorded_VBN
Utilization_NOMZ
in_PIN
year_NN
to_PIN
in_PIN
year_NN
to_PIN
Opening_GER
December_NN
31_CD
,_,
December_NN
31_CD
,_,
Closing_GER
liability_NOMZ
2004_CD
2004_CD
liability_NOMZ
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
Employee_NN
severance_NN
and_PHC
relocation_NOMZ
costs_NN
33.8_CD
32.1_CD
1.7_CD
Write-off_PIN
of_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
1.2_CD
1.2_CD
Consultancy_NN
costs_VPRT
2.9_CD
2.9_CD
Duplicate_NN
facilities_NOMZ
5.1_CD
2.6_CD
2.5_CD
Information_NOMZ
technology_NN
costs_VPRT
2.1_CD
2.1_CD
Other_JJ
costs_NN
3.4_CD
3.4_CD
48.5_CD
44.3_CD
4.2_CD
iii_FW
Disposition_NOMZ
of_PIN
the_DT
vaccines_NN
business_NOMZ
On_PIN
September_NN
9_CD
,_,
2004_CD
the_DT
Company_NN
completed_VBD
the_DT
disposition_NOMZ
of_PIN
its_PIT
vaccines_NN
business_NOMZ
to_PIN
ID_NN
Biomedical_NN
Corporation_NOMZ
IDB_NN
._.
The_DT
total_JJ
consideration_NOMZ
for_PIN
the_DT
sale_NN
was_VBD
$_$
120_CD
million_CD
comprizing_VBG
$_$
30_CD
million_CD
of_PIN
cash_NN
received_VBN [WZPAST]
at_PIN
completion_NOMZ
,_,
$_$
30_CD
million_CD
of_PIN
cash_NN
held_VBN [PRIV] [WZPAST]
in_PIN
escrow_NN
and_CC
due_JJ
on_PIN
the_DT
first_JJ
anniversary_NN
of_PIN
completion_NOMZ
and_CC
$_$
60_CD
million_CD
received_VBN
at_PIN
completion_NOMZ
in_PIN
the_DT
form_NN
of_PIN
4,931,864_CD
subscription_NOMZ
receipts_NN
of_PIN
IDB_NN
._.
If_COND
,_,
prior_RB
to_PIN
January_NN
10_CD
,_,
2005_CD
,_,
IDB_NN
were_VBD
to_TO
raise_VB
up_RP
to_TO
$_$
60_CD
million_CD
from_PIN
equity_NOMZ
related_VBN
issuances_NN
,_,
then_RB
it_PIT
was_VBD [PASS]
required_VBN [SUAV]
under_IN
the_DT
terms_NN
of_PIN
the_DT
sale_NN
agreement_NOMZ
to_TO
redeem_VB
the_DT
subscription_NOMZ
receipts_NN
from_PIN
Shire_NN
for_PIN
$_$
60_CD
million_CD
._.
Accordingly_RB
,_,
following_VBG [PRESP]
the_DT
completion_NOMZ
of_PIN
such_EMPH
a_NULL
fund_NN
raising_VBG [WZPRES]
on_PIN
January_NN
7_CD
,_,
2005_CD
,_,
IDB_NN
redeemed_VBD
the_DT
subscription_NOMZ
receipts_NN
from_PIN
Shire_NN
for_PIN
$_$
60_CD
million_CD
in_PIN
cash_NN
._.
On_PIN
the_DT
first_JJ
anniversary_NN
of_PIN
completion_NOMZ
,_,
Shire_NN
received_VBD
the_DT
$_$
30_CD
million_CD
of_PIN
cash_NN
held_VBN [PRIV] [WZPAST]
in_PIN
escrow_NN
._.
As_IN
part_NN
of_PIN
the_DT
transaction_NOMZ
,_,
Shire_NN
entered_VBD
into_PIN
an_DT
agreement_NOMZ
to_TO
provide_VB
IDB_NN
with_PIN
a_DT
loan_NN
facility_NOMZ
of_PIN
up_RB
to_TO
$_$
100_CD
million_CD
,_,
which_WDT [SERE]
could_POMD
be_VB [PASS]
drawn_VBN
down_RB
over_IN
the_DT
four_CD
years_NN
following_VBG [WZPRES]
completion_NOMZ
._.
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
,_,
IDB_NN
had_VBD [PEAS]
drawn_VBN
down_IN
the_DT
entire_JJ
$_$
100_CD
million_CD
loan_NN
._.
It_PIT
was_VBD [PASS]
required_VBN [SUAV] [THATD]
that_DEMP
this_DEMO
facility_NOMZ
be_VB [BYPA]
used_VBN
by_PIN
IDB_NN
to_TO
fund_VB
the_DT
development_NOMZ
of_PIN
injectable_JJ
flu_NN
and_PHC
pipeline_NN
products_NN
within_PIN
the_DT
vaccines_NN
business_NOMZ
acquired_VBD
from_PIN
Shire_NN
._.
Drawings_GER
under_IN
the_DT
loan_NN
facility_NOMZ
are_VPRT [PASS]
segregated_VBN
into_PIN
two_CD
components_NN
:_:
i_FPP1
Drawings_GER
for_PIN
injectable_JJ
flu_NN
development_NOMZ
of_PIN
$_$
70.6_CD
million_CD
which_WDT
are_VPRT [BEMA]
repayable_PRED
out_PIN
of_PIN
income_NN
generated_VBN [WZPAST]
by_PIN
IDB_NN
on_PIN
future_JJ
non-Canadian_JJ
injectable_JJ
flu_NN
products_NN
,_,
subject_JJ
to_PIN
minimum_JJ
annual_JJ
repayments_NOMZ
in_PIN
respect_NN
of_PIN
the_DT
first_JJ
$_$
30_CD
million_CD
of_PIN
the_DT
drawing_GER
,_,
to_TO
be_VB [PASS]
made_VBN
between_PIN
2007_CD
and_CC
2017_CD
:_:
and_ANDC
ii_FW
Drawings_GER
for_PIN
pipeline_NN
development_NOMZ
of_PIN
$_$
29.4_CD
million_CD
which_WDT
are_VPRT [BEMA]
repayable_PRED
out_PIN
of_PIN
income_NN
generated_VBN [WZPAST]
by_PIN
IDB_NN
on_PIN
future_JJ
pipeline_NN
products_NN
and_CC
have_VPRT
no_DT
fixed_VBN
repayment_NOMZ
schedule_NN
._.
The_DT
transaction_NOMZ
gave_VBD
rise_NN
to_PIN
an_DT
overall_JJ
loss_NN
on_PIN
disposition_NOMZ
of_PIN
the_DT
vaccines_NN
business_NOMZ
of_PIN
$_$
41.1_CD
million_CD
,_,
recorded_VBN
as_IN
a_DT
loss_NN
on_PIN
disposition_NOMZ
at_PIN
completion_NOMZ
in_PIN
2004_CD
of_PIN
$_$
44.2_CD
million_CD
and_CC
a_DT
subsequent_JJ
provision_NN
release_NN
of_PIN
$_$
3.1_CD
million_CD
being_VBG [PASS]
recognized_VBN [PRIV]
during_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
._.
This_DEMO
net_JJ
loss_NN
on_PIN
disposition_NOMZ
of_PIN
$_$
41.1_CD
million_CD
comprises_VPRT
a_DT
gain_NN
on_PIN
disposition_NOMZ
of_PIN
net_JJ
assets_NN
of_PIN
$_$
28.9_CD
million_CD
together_RB
with_PIN
a_DT
provision_NN
for_PIN
a_DT
loss_NN
of_PIN
$_$
70_CD
million_CD
out_PIN
of_PIN
the_DT
$_$
100_CD
million_CD
loan_NN
facility_NOMZ
available_JJ
to_PIN
IDB_NN
._.
This_DEMO
provision_NN
was_VBD [PASS]
made_VBN
on_PIN
the_DT
basis_NN
that_TOBJ
those_DEMO
loan_NN
repayments_NOMZ
based_VBN [WZPAST]
solely_RB
on_PIN
future_JJ
sales_NN
of_PIN
flu_NN
and_PHC
pipeline_NN
products_NN
in_PIN
development_NOMZ
provided_VBN
no_SYNE
certainty_NN
of_PIN
recovery_NN
._.
The_DT
historical_JJ
consolidated_JJ
financial_JJ
statements_NOMZ
reflect_VPRT [PRIV]
the_DT
vaccines_NN
business_NOMZ
as_IN
a_DT
discontinued_VBN
operation_NOMZ
for_PIN
all_QUAN
periods_NN
presented_VBN
._.
The_DT
results_NN
of_PIN
the_DT
discontinued_VBN
operation_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
removed_VBN
from_PIN
all_QUAN
periods_NN
on_PIN
a_DT
line-by-line_JJ
basis_NN
from_PIN
product_NN
sales_NN
revenue_NN
to_PIN
income_NN
from_PIN
continuing_VBG
operations_NOMZ
._.
The_DT
net_JJ
loss_NN
from_PIN
the_DT
discontinued_VBN
operation_NOMZ
,_,
together_RB
with_PIN
the_DT
loss_NN
on_PIN
disposition_NOMZ
,_,
are_VPRT [PASS]
shown_VBN [PRIV]
as_IN
separate_JJ
line_NN
items_NN
._.
Operating_VBG
results_NN
of_PIN
the_DT
discontinued_VBN
operations_NOMZ
are_VPRT [PASS]
summarized_VBN
below_PLACE
._.
2004_CD
2003_CD
Year_NN
to_PIN
December_NN
31_CD
,_,
$_$
000_CD
$_$
000_CD
Revenues_NN
:_:
Product_NN
sales_NN
3,626_CD
25,531_CD
Total_JJ
revenues_NN
3,626_CD
25,531_CD
Costs_NN
and_PHC
expenses_NN
:_:
Cost_NN
of_PIN
product_NN
sales_NN
8,304_CD
19,954_CD
Research_NN
and_PHC
development_NOMZ
9,222_CD
20,879_CD
Selling_GER
,_,
general_JJ
and_PHC
administrative_JJ
5,614_CD
9,671_CD
Total_JJ
operating_GER
expenses_NN
23,140_CD
50,504_CD
Operating_GER
loss_NN
19,514_CD
24,973_CD
Other_JJ
expense_NN
income_NN
,_,
net_JJ
621_CD
3,087_CD
Loss_NN
from_PIN
discontinued_VBN
operations_NOMZ
20,135_CD
21,886_CD
Loss_NN
on_PIN
disposition_NOMZ
44,157_CD
64,292_CD
21,886_CD
At_PIN
December_NN
31_CD
,_,
2004_CD
,_,
the_DT
assets_NN
and_PHC
liabilities_NOMZ
of_PIN
the_DT
discontinued_VBN
vaccines_NN
operation_NOMZ
were_VBD
$_$
nil_JJ
._.
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
99_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
100_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
Dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV] [THATD]
6_CD
Reorganizations_NOMZ
continued_VBD
Actions_NOMZ
commenced_VBN [WZPAST]
in_PIN
2003_CD
i_FPP1
Closure_NN
of_PIN
Lead_JJ
Optimization_NOMZ
The_DT
closure_NN
of_PIN
Lead_JJ
Optimization_NOMZ
resulted_VBD
in_PIN
:_:
the_DT
severance_NN
of_PIN
134_CD
employees_NN
._.
As_IN
at_PIN
December_NN
2004_CD
,_,
all_QUAN
employees_NN
had_VBD [PEAS]
left_VBN
the_DT
Company_NN
:_:
a_DT
$_$
6_CD
million_CD
write-off_PIN
of_PIN
tangible_JJ
fixed_JJ
assets_NN
._.
These_DEMO
assets_NN
,_,
primarily_RB
laboratory_NN
equipment_NOMZ
,_,
were_VBD [BYPA]
used_VBN
by_PIN
Lead_JJ
Optimization_NOMZ
for_PIN
research_NN
and_PHC
development_NOMZ
and_CC
had_VBD
no_SYNE
alternative_JJ
use_NN
:_:
and_ANDC
the_DT
cancellation_NOMZ
,_,
to_PIN
the_DT
extent_NN
possible_JJ
,_,
of_PIN
contracts_NN
directly_RB
relating_VBG
to_PIN
Lead_JJ
Optimization_NOMZ
._.
The_DT
costs_NN
associated_VBN [WZPAST]
with_PIN
these_DEMO
actions_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
reflected_VBN [PRIV]
in_PIN
reorganization_NOMZ
costs_NN
in_PIN
the_DT
statement_NOMZ
of_PIN
operations_NOMZ
in_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2003_CD
and_CC
2004_CD
._.
There_EX
are_VPRT
no_SYNE
outstanding_JJ
liabilities_NOMZ
related_VBN [WZPAST]
to_PIN
the_DT
closure_NN
of_PIN
Lead_JJ
Optimization_NOMZ
at_PIN
December_NN
31_CD
,_,
2005_CD
._.
The_DT
following_VBG
provides_VPRT
a_DT
roll-forward_NN
of_PIN
the_DT
liability_NOMZ
to_PIN
December_NN
31_CD
,_,
2004_CD
:_:
Costs_NN
recorded_VBN
Utilization_NOMZ
in_PIN
year_NN
to_PIN
in_PIN
year_NN
to_PIN
Opening_GER
December_NN
31_CD
,_,
December_NN
31_CD
,_,
Closing_GER
liability_NOMZ
2004_CD
2004_CD
liability_NOMZ
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
Employee_NN
severance_NN
3,452_CD
118_CD
3,570_CD
Other_JJ
costs_NN
325_CD
9_CD
98_CD
236_CD
3,777_CD
127_CD
3,668_CD
236_CD
The_DT
following_VBG
provides_VPRT
a_DT
roll-forward_NN
of_PIN
the_DT
liability_NOMZ
as_IN
at_PIN
December_NN
31_CD
,_,
2003_CD
:_:
Costs_NN
recorded_VBN
Utilization_NOMZ
in_PIN
year_NN
to_PIN
in_PIN
year_NN
to_PIN
Opening_GER
December_NN
31_CD
,_,
December_NN
31_CD
,_,
Closing_GER
liability_NOMZ
2003_CD
2003_CD
liability_NOMZ
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
Employee_NN
severance_NN
6,425_CD
2,973_CD
3,452_CD
Write_VB [PUBV]
down_IN
of_PIN
tangible_JJ
fixed_JJ
assets_NN
6,026_CD
6,026_CD
Other_JJ
costs_NN
800 475 325_CD
13,251_CD
9,474_CD
3,777_CD
ii_FW
Disposition_NOMZ
of_PIN
North_NN
American_NN
facilities_NOMZ
Subsequent_JJ
to_PIN
the_DT
closure_NN
of_PIN
Lead_JJ
Optimization_NOMZ
and_CC
the_DT
decision_NN
to_TO
dispose_VB
of_PIN
the_DT
vaccines_NN
business_NOMZ
,_,
the_DT
Company_NN
began_VBD
an_DT
assessment_NOMZ
of_PIN
its_PIT
property_NN
needs_VPRT
in_PIN
Canada_NN
and_CC
the_DT
US_FPP1
._.
As_CONJ
a_NULL
result_NULL
of_PIN
this_DEMO
initial_JJ
process_NN
the_DT
Company_NN
decided_VBD [SUAV] [PRIV]
to_TO
dispose_VB
of_PIN
its_PIT
building_GER
in_PIN
Laval_NN
,_,
Canada_NN
and_CC
to_TO
relocate_VB
the_DT
employees_NN
._.
The_DT
Company_NN
also_RB
decided_VBD [SUAV] [PRIV]
to_TO
sell_VB
its_PIT
building_GER
in_PIN
Buffalo_NN
Grove_NN
,_,
US_FPP1
._.
As_IN
at_PIN
December_NN
31_CD
,_,
2003_CD
,_,
the_DT
Company_NN
had_VBD [PEAS]
obtained_VBN
valuations_NOMZ
of_PIN
the_DT
properties_NN
and_CC
entered_VBD
into_PIN
sale_NN
negotiations_NOMZ
with_PIN
third_JJ
parties_NN
on_PIN
the_DT
Laval_NN
property_NN
and_CC
was_VBD [SPAU]
actively_RB
seeking_VBG
buyers_NN
for_PIN
its_PIT
Buffalo_NN
Grove_NN
facility_NOMZ
._.
Based_VBN [PASTP]
on_PIN
these_DEMO
negotiations_NOMZ
,_,
the_DT
valuations_NOMZ
obtained_VBN
,_,
the_DT
limitations_NOMZ
on_PIN
use_NN
of_PIN
the_DT
building_GER
in_PIN
its_PIT
current_JJ
state_NN
and_CC
the_DT
overall_JJ
real_JJ
estate_NN
market_NN
,_,
the_DT
Company_NN
recorded_VBD
an_DT
impairment_NOMZ
charge_NN
of_PIN
$_$
10.7_CD
million_CD
in_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2003_CD
,_,
which_WDT [SERE]
is_VPRT [PASS]
included_VBN
in_PIN
reorganization_NOMZ
costs_NN
in_PIN
the_DT
consolidated_JJ
statement_NOMZ
of_PIN
operations_NOMZ
._.
The_DT
Company_NN
reclassified_VBD
to_PIN
prepaid_JJ
expenses_NN
and_CC
other_JJ
current_JJ
assets_NN
the_DT
assets_NN
held_VBN [PRIV] [WZPAST]
for_PIN
sale_NN
._.
The_DT
properties_NN
were_VBD [PASS]
disposed_VBN
of_PIN
in_PIN
2004_CD
._.
100_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
101_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
Dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
7_CD
Accounts_NN
receivable_NN
,_,
net_JJ
Trade_NN
receivables_NN
at_PIN
December_NN
31_CD
,_,
2005_CD
,_,
of_PIN
$_$
329.9_CD
million_CD
December_NN
31_CD
,_,
2004_CD
:_:
$_$
222.5_CD
million_CD
,_,
are_VPRT [PASS]
stated_VBN [PUBV]
net_NN
of_PIN
a_DT
provision_NN
for_PIN
doubtful_JJ
accounts_NN
and_PHC
sales_NN
discounts_NN
of_PIN
$_$
9.7_CD
million_CD
December_NN
31_CD
,_,
2004_CD
:_:
$_$
4.3_CD
million_CD
._.
The_DT
movement_NOMZ
in_PIN
the_DT
provision_NN
for_PIN
doubtful_JJ
accounts_NN
and_PHC
sales_NN
discounts_NN
is_VPRT
as_IN
follows_VPRT
:_:
2005 2004 2003_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
As_IN
at_PIN
January_NN
1_CD
,_,
4,264_CD
7,853_CD
4,585_CD
Charged_VBN
to_PIN
operations_NOMZ
51,060_CD
38,218_CD
42,841_CD
Released_VBN
to_PIN
income_NN
3,395_CD
Utilization_NOMZ
45,577_CD
38,412_CD
39,573_CD
As_IN
at_PIN
December_NN
31_CD
,_,
9,747_CD
4,264_CD
7,853_CD
Revenues_NN
are_VPRT [SPAU] [PASS]
mainly_RB
derived_VBN
in_PIN
the_DT
US_FPP1
69_CD
%_NN
of_PIN
total_JJ
revenues_NN
from_PIN
agreements_NOMZ
with_PIN
major_JJ
pharmaceutical_JJ
companies_NN
and_PHC
relationships_NN
with_PIN
pharmaceutical_JJ
wholesale_JJ
distributors_NN
and_CC
retail_JJ
pharmacy_NN
chains_NN
._.
Significant_JJ
customers_NN
are_VPRT [PASS]
disclosed_VBN [PUBV]
in_PIN
Note_NN
25_CD
._.
Such_JJ
clients_NN
have_VPRT
significant_JJ
cash_NN
resources_NN
and_ANDC
therefore_CONJ
any_QUAN
credit_NN
risk_NN
associated_VBN [WZPAST]
with_PIN
these_DEMO
transactions_NOMZ
is_VPRT [PASS]
considered_VBN [PRIV]
minimal_JJ
._.
8_CD
Inventories_NN
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2005_CD
2004_CD
$_$
000_CD
$_$
000_CD
Finished_VBN
goods_NN
63,315_CD
22,349_CD
Work-in-process_JJ
53,963_CD
11,831_CD
Raw_NN
materials_NN
18,779_CD
7,050_CD
136,057_CD
41,230_CD
The_DT
increase_NN
in_PIN
inventory_NN
is_VPRT [BEMA]
due_PRED
to_PIN
the_DT
acquisition_NOMZ
of_PIN
TKT_NN
see_VPRT [PRIV]
Note_NN
4_CD
._.
9_CD
Prepaid_NN
expenses_NN
and_CC
other_JJ
current_JJ
assets_NN
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2005_CD
2004_CD
Notes_NN
$_$
000_CD
$_$
000_CD
Prepaid_NN
expenses_NN
30,245_CD
31,401_CD
Income_NN
tax_NN
receivable_NN
40,802_CD
Value_NN
added_VBD [PUBV]
taxes_NN
receivable_JJ
10,185_CD
2,124_CD
Supplemental_NN
Executive_NN
Retirement_NOMZ
Plan_NN
SERP_NN
investment_NOMZ
28_CD
1,276_CD
1,784_CD
Subscription_NOMZ
receipts_NN
6_CD
60,000_CD
Cash_NN
held_VBN [PRIV] [WZPAST]
in_PIN
escrow_NN
6_CD
30,000_CD
Other_JJ
current_JJ
assets_NN
15,576_CD
11,962_CD
98,084_CD
137,271_CD
10_CD
Short-term_JJ
investments_NOMZ
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2005_CD
2004_CD
$_$
000_CD
$_$
000_CD
Institutional_JJ
and_CC
managed_VBD
cash_NN
funds_NN
6,947_CD
174,752_CD
Commercial_JJ
paper_NN
149,659_CD
6,947_CD
324,411_CD
In_PIN
July_NN
2005_CD
,_,
the_DT
Company_NN
liquidated_VBN
all_QUAN
short-term_JJ
investments_NOMZ
to_TO
provide_VB
funds_NN
for_PIN
the_DT
acquisition_NOMZ
of_PIN
TKT_NN
._.
The_DT
investments_NOMZ
balance_NN
at_PIN
December_NN
31_CD
,_,
2005_CD
,_,
was_VBD [PASS]
inherited_VBN
through_PIN
that_DEMO
acquisition_NOMZ
._.
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
101_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
102_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
Dollars_NN
,_,
except_PIN
where_RB
indicated_JJ
11_CD
Investments_NOMZ
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2005_CD
2004_CD
$_$
000_CD
$_$
000_CD
Investments_NOMZ
in_PIN
private_JJ
companies_NN
9,008_CD
2,451_CD
Available-for-sale_JJ
securities_NOMZ
18,131_CD
29,970_CD
Equity-method_JJ
investments_NOMZ
23,023_CD
30,846_CD
50,162_CD
63,267_CD
The_DT
Company_NN
recorded_VBN
impairments_NOMZ
of_PIN
$_$
2_CD
million_CD
on_PIN
its_PIT
investments_NOMZ
during_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
2004_CD
:_:
$_$
15.4_CD
million_CD
:_:
2003_CD
$_$
15.5_CD
million_CD
._.
All_QUAN
impairments_NOMZ
in_PIN
the_DT
three_CD
years_NN
presented_VBN [WZPAST]
were_VBD [PASS]
recorded_VBN
in_PIN
the_DT
Pharmaceutical_NN
Products_NN
segment_NOMZ
._.
a_DT
Investments_NOMZ
in_PIN
private_JJ
companies_NN
Additions_NOMZ
to_PIN
investments_NOMZ
in_PIN
private_JJ
companies_NN
included_VBD
a_DT
$_$
3.9_CD
million_CD
investment_NOMZ
in_PIN
Supernus_NN
less_JJ
than_PIN
10_CD
%_NN
of_PIN
total_JJ
equity_NOMZ
,_,
as_IN
part_NN
consideration_NOMZ
for_PIN
the_DT
sale_NN
of_PIN
the_DT
drug_NN
formulation_NOMZ
business_NOMZ
._.
The_DT
fair_JJ
value_NN
of_PIN
the_DT
investment_NOMZ
was_VBD [BYPA]
determined_VBN [SUAV] [PRIV]
by_PIN
reference_NN
to_TO
cash_VB
invested_VBN
in_PIN
Supernus_NN
by_PIN
the_DT
other_JJ
investors_NN
._.
During_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
the_DT
Company_NN
recorded_VBN
impairments_NOMZ
of_PIN
$_$
1.6_CD
million_CD
against_PIN
its_PIT
investments_NOMZ
in_PIN
private_JJ
companies_NN
based_VBN [WZPAST]
on_PIN
a_DT
decline_NN
in_PIN
the_DT
estimates_NN
of_PIN
their_TPP3
fair_JJ
value_NN
that_TOBJ
the_DT
Company_NN
believes_VPRT [PRIV]
are_VPRT [BEMA]
other-than-temporary_PRED
._.
During_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
the_DT
Company_NN
recorded_VBN
impairments_NOMZ
of_PIN
$_$
9.8_CD
million_CD
against_PIN
these_DEMO
investments_NOMZ
based_VBN [WZPAST]
on_PIN
changes_NN
in_PIN
the_DT
estimates_NN
of_PIN
their_TPP3
fair_JJ
value_NN
._.
This_DEMO
amount_NN
includes_VPRT
$_$
4.2_CD
million_CD
to_TO
reduce_VB
the_DT
value_NN
of_PIN
an_DT
investment_NOMZ
in_PIN
a_DT
private_JJ
company_NN
that_TSUB
gained_VBD
a_DT
listing_GER
on_PIN
March_NN
24_CD
,_,
2004_CD
:_:
the_DT
initial_JJ
listing_GER
price_NN
was_VBD
below_PLACE
the_DT
anticipated_JJ
flotation_NOMZ
price_NN
used_VBN
to_TO
value_VB
the_DT
investment_NOMZ
at_PIN
December_NN
31_CD
,_,
2003_CD
and_CC
the_DT
Company_NN
believed_VBD [PRIV]
the_DT
decline_NN
in_PIN
value_NN
was_VBD [BEMA]
other-than-temporary_PRED
._.
After_IN
the_DT
date_NN
of_PIN
the_DT
listing_VBG
the_DT
investment_NOMZ
was_VBD [PASS]
reclassified_VBN
to_PIN
available-for-sale_JJ
securities_NOMZ
and_CC
so_RB
any_QUAN
changes_NN
since_OSUB
the_DT
initial_JJ
listing_GER
date_NN
have_VPRT [PEAS]
been_VBN [PASS]
recorded_VBN
in_PIN
other_JJ
comprehensive_JJ
income_NN
._.
The_DT
changes_NN
in_PIN
fair_JJ
market_NN
value_NN
,_,
which_WDT [SERE]
resulted_VBD
in_PIN
the_DT
write-downs_NN
referred_VBD
to_PIN
above_PLACE
were_VBD [PASS]
based_VBN
on_PIN
the_DT
Companys_NN
estimates_NN
of_PIN
fair_JJ
value_NN
._.
These_DEMO
estimates_NN
were_VBD [PASS]
derived_VBN
from_PIN
financial_JJ
and_PHC
other_JJ
publicly_RB
available_JJ
information_NOMZ
such_JJ
as_IN
press_NN
releases_NN
and_CC
recent_JJ
capital_NN
raising_VBG [WZPRES]
activities_NOMZ
._.
b_NN
Available-for-sale_JJ
securities_NOMZ
Gain_NN
on_PIN
sale_NN
During_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
the_DT
Company_NN
sold_VBD
an_DT
investment_NOMZ
in_PIN
an_DT
available-for-sale_JJ
security_NOMZ
,_,
valued_VBN [PASTP]
at_PIN
$_$
6_CD
million_CD
,_,
realizing_VBG [PRIV] [PRESP]
a_DT
gain_NN
on_PIN
the_DT
sale_NN
of_PIN
$_$
3.9_CD
million_CD
._.
During_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
the_DT
Company_NN
sold_VBD
an_DT
investment_NOMZ
in_PIN
an_DT
available-for-sale_JJ
security_NOMZ
,_,
valued_VBN [PASTP]
at_PIN
$_$
11.9_CD
million_CD
,_,
realizing_VBG [PRIV] [PRESP]
a_DT
gain_NN
on_PIN
the_DT
sale_NN
of_PIN
$_$
14.8_CD
million_CD
2003_CD
:_:
$_$
nil_JJ
._.
Other-than-temporary_JJ
impairment_NOMZ
The_DT
Company_NN
recorded_VBN
other-than-temporary_JJ
impairments_NOMZ
of_PIN
$_$
0.4_CD
million_CD
,_,
$_$
1.6_CD
million_CD
and_CC
$_$
nil_CD
against_PIN
its_PIT
available-for-sale_JJ
securities_NOMZ
in_PIN
the_DT
years_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
,_,
2004_CD
and_CC
2003_CD
respectively_RB
._.
At_PIN
December_NN
31_CD
,_,
2005_CD
,_,
the_DT
Company_NN
had_VBD
no_SYNE
available-for-sale_JJ
investments_NOMZ
in_PIN
a_DT
significant_JJ
unrealized_JJ
loss_NN
position_NOMZ
for_PIN
which_WDT [PIRE]
other-than-temporary_JJ
impairments_NOMZ
have_VPRT [PEAS]
not_XX0
been_VBN [PASS]
recognized_VBN [PRIV]
._.
102_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
103_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
Dollars_NN
,_,
except_PIN
where_RB
indicated_JJ
11_CD
Investments_NOMZ
continued_VBD
c_NN
Equity_NOMZ
method_NN
investments_NOMZ
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2005_CD
2004_CD
$_$
000_CD
$_$
000_CD
GSK_NN
5,954_CD
6,179_CD
GeneChem_NN
Funds_NN
12,659_CD
18,343_CD
Other_JJ
4,410_CD
6,324_CD
23,023_CD
30,846_CD
i_FPP1
GSK_NN
The_NN
Company_NN
has_VPRT [PEAS]
accounted_VBN
for_PIN
its_PIT
commercialization_NOMZ
partnership_NN
with_PIN
GSK_NN
through_PIN
which_WDT [PIRE]
the_DT
products_NN
3TC_NN
and_PHC
ZEFFIX_NN
are_VPRT [PASS]
marketed_VBN
in_PIN
Canada_NN
,_,
using_VBG [PRESP]
the_DT
equity_NOMZ
method_NN
of_PIN
accounting_GER
._.
The_DT
Companys_NN
50_CD
%_NN
share_NN
of_PIN
the_DT
partnership_NN
is_VPRT [PASS]
included_VBN
within_PIN
Equity_NOMZ
in_PIN
losses_NN
earnings_GER
of_PIN
equity_NOMZ
method_NN
investees_NN
._.
ii_FW
GeneChem_NN
Funds_NN
The_DT
GeneChem_NN
Technologies_NN
Venture_NN
Fund_NN
and_CC
the_DT
GeneChem_NN
Therapeutics_NN
Venture_NN
Fund_NN
The_NN
Funds_NN
are_VPRT [BEMA]
Canadian_JJ
limited_JJ
partnerships_NN
investing_VBG [WZPRES]
in_PIN
healthcare_NN
research_NN
and_PHC
development_NOMZ
companies_NN
,_,
in_PIN
which_WDT [PIRE]
the_DT
Company_NN
owns_VPRT
30_CD
%_NN
and_CC
11_CD
%_NN
of_PIN
the_DT
issued_VBN
shares_NN
respectively_RB
._.
At_PIN
December_NN
31_CD
,_,
2005_CD
,_,
the_DT
Funds_NN
net_JJ
assets_NN
totaled_VBD
approximately_RB
$_$
71_CD
million_CD
2004_CD
:_:
$_$
107_CD
million_CD
._.
The_DT
Company_NN
is_VPRT [PASS]
involved_VBN
as_IN
a_DT
limited_JJ
partner_NN
and_CC
the_DT
general_JJ
partner_NN
of_PIN
the_DT
Funds_NN
:_:
involvement_NOMZ
in_PIN
the_DT
Funds_NN
dates_NN
from_PIN
between_PIN
1997_CD
and_CC
2000_CD
._.
The_DT
Companys_NN
exposure_NN
to_PIN
loss_NN
as_CONJ
a_NULL
result_NULL
of_PIN
its_PIT
involvement_NOMZ
with_PIN
the_DT
Funds_NN
is_VPRT [PASS]
limited_VBN
to_PIN
the_DT
carrying_VBG
value_NN
of_PIN
the_DT
investment_NOMZ
,_,
$_$
12.7_CD
million_CD
at_PIN
December_NN
31_CD
,_,
2005_CD
2004_CD
:_:
$_$
18.3_CD
million_CD
,_,
2003_CD
:_:
$_$
19.8_CD
million_CD
and_CC
its_PIT
commitment_NOMZ
to_PIN
further_JJ
investment_NOMZ
of_PIN
$_$
1.7_CD
million_CD
2004_CD
:_:
$_$
2.9_CD
million_CD
,_,
2003_CD
:_:
$_$
4.1_CD
million_CD
._.
During_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
,_,
the_DT
Company_NN
recorded_VBD
an_DT
impairment_NOMZ
of_PIN
$_$
4_CD
million_CD
against_PIN
the_DT
investment_NOMZ
in_PIN
the_DT
Funds_NN
following_VBG [WZPRES]
reviews_NN
of_PIN
the_DT
Funds_NN
investment_NOMZ
portfolios_NN
that_TSUB
identified_VBD
other-than-temporary_JJ
declines_NN
in_PIN
the_DT
value_NN
of_PIN
certain_JJ
private_JJ
and_CC
publicly_RB
quoted_VBN
securities_NOMZ
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
Funds_NN
._.
12_CD
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
,_,
net_JJ
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2005_CD
2004_CD
$_$
000_CD
$_$
000_CD
Land_NN
and_PHC
buildings_GER
157,242_CD
80,631_CD
Office_NN
furniture_NN
,_,
fittings_GER
and_PHC
equipment_NOMZ
91,142_CD
67,301_CD
Warehouse_NN
,_,
laboratory_NN
and_PHC
manufacturing_GER
equipment_NOMZ
44,080_CD
31,657_CD
Assets_NN
under_IN
construction_NOMZ
18,360_CD
3,166_CD
310,824_CD
182,755_CD
Less_RB
:_:
accumulated_VBN
depreciation_NOMZ
76,825_CD
51,404_CD
233,999_CD
131,351_CD
The_DT
increase_NN
in_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
net_NN
,_,
is_VPRT [BEMA]
principally_RB
due_PRED
to_PIN
the_DT
acquisition_NOMZ
of_PIN
TKT_NN
see_VPRT [PRIV]
Note_NN
4_CD
._.
Depreciation_NOMZ
expense_NN
for_PIN
the_DT
years_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
,_,
2004_CD
and_CC
2003_CD
was_VBD
$_$
32.7_CD
million_CD
,_,
$_$
22.5_CD
million_CD
and_CC
$_$
14.1_CD
million_CD
respectively_RB
._.
The_DT
expense_NN
in_PIN
2005_CD
included_VBD
a_DT
$_$
6.5_CD
million_CD
impairment_NOMZ
loss_NN
related_VBN [WZPAST]
to_PIN
the_DT
plant_NN
and_PHC
equipment_NOMZ
of_PIN
the_DT
drug_NN
formulation_NOMZ
business_NOMZ
._.
At_PIN
the_DT
time_NN
of_PIN
the_DT
impairment_NOMZ
loss_NN
,_,
the_DT
Company_NN
was_VBD
expecting_VBG [PRIV]
to_TO
close_VB
the_DT
business_NOMZ
and_CC
,_,
because_CAUS
the_DT
carrying_VBG
value_NN
of_PIN
the_DT
assets_NN
exceeded_VBD
the_DT
expected_JJ
future_JJ
cash_NN
flows_VPRT
resulting_VBG
from_PIN
the_DT
closure_NN
,_,
the_DT
assets_NN
were_VBD [PASS]
considered_VBN [PRIV]
impaired_VBN
._.
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
103_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
104_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
Dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
13_CD
Goodwill_NN
,_,
net_JJ
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2005_CD
2004_CD
$_$
000_CD
$_$
000_CD
Goodwill_NN
arising_VBG [WZPRES]
on_PIN
businesses_NOMZ
acquired_VBN
367,652_CD
235,396_CD
The_DT
increase_NN
in_PIN
the_DT
net_JJ
book_NN
value_NN
of_PIN
goodwill_NN
for_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
,_,
is_VPRT [PASS]
shown_VBN [PRIV]
in_PIN
the_DT
table_NN
below_PLACE
:_:
$_$
000_CD
As_IN
at_PIN
January_NN
1_CD
,_,
2005_CD
235,396_CD
Acquisitions_NOMZ
166,414_CD
Asset_NN
impairments_NOMZ
Disposals_NN
Foreign_NN
currency_NN
translation_NOMZ
34,158_CD
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
367,652_CD
The_DT
Company_NN
recognized_VBD [PRIV]
$_$
166_CD
million_CD
as_IN
goodwill_NN
on_PIN
acquisition_NOMZ
of_PIN
TKT_NN
see_VPRT [PRIV]
Note_NN
4_CD
,_,
in_PIN
accordance_NN
with_PIN
SFAS_NN
No._NN
._.
This_DEMO
goodwill_NN
is_VPRT [PASS]
recorded_VBN
in_PIN
the_DT
Pharmaceutical_NN
Products_NN
segment_NOMZ
._.
Goodwill_NN
by_PIN
operating_VBG
segment_NOMZ
In_PIN
prior_RB
reporting_VBG [PUBV]
periods_NN
,_,
the_DT
Companys_NN
internal_JJ
management_NOMZ
reporting_VBG [PUBV] [THATD] [WZPRES]
structure_NN
was_VBD [PASS]
based_VBN
on_PIN
a_DT
combination_NOMZ
of_PIN
geography_NN
and_PHC
function_NOMZ
._.
As_CONJ
a_NULL
result_NULL
the_DT
Company_NN
had_VBD
operating_VBG
segments_NOMZ
for_PIN
the_DT
US_FPP1
and_PHC
International_NN
sales_NN
and_PHC
marketing_GER
businesses_NOMZ
,_,
research_NN
and_PHC
development_NOMZ
costs_NN
and_CC
a_DT
Corporate_JJ
segment_NOMZ
which_WDT [WHSUB]
included_VBD
corporate_JJ
costs_NN
and_PHC
royalty_NN
income_NN
._.
Following_VBG [PRESP]
an_DT
internal_JJ
restructuring_GER
of_PIN
the_DT
business_NOMZ
,_,
management_NOMZ
has_VPRT [PEAS]
re-evaluated_VBN
and_PHC
amended_VBN
its_PIT
internal_JJ
reporting_GER
structures_NN
and_ANDC
as_CONJ
a_NULL
result_NULL
,_,
changed_VBD
its_PIT
reporting_GER
segments_NOMZ
._.
Effective_JJ
January_NN
1_CD
,_,
2005_CD
,_,
Shires_NN
internal_JJ
management_NOMZ
reporting_VBG [PUBV] [THATD] [WZPRES]
structures_NN
have_VPRT [PEAS]
been_VBN [PASS]
changed_VBN
to_TO
show_VB [PRIV]
two_CD
operating_VBG
segments_NOMZ
,_,
Pharmaceutical_NN
Products_NN
and_PHC
Royalties_NN
._.
The_DT
Pharmaceutical_NN
Products_NN
segment_NOMZ
comprises_VPRT
four_CD
therapeutic_JJ
areas_NN
:_:
CNS_NN
,_,
GI_NN
,_,
Shire_NN
HGT_NN
and_PHC
GP_NN
._.
The_DT
net_JJ
book_NN
value_NN
of_PIN
goodwill_NN
as_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
is_VPRT [BEMA]
all_QUAN
held_VBN [PRIV]
in_PIN
the_DT
Pharmaceutical_NN
Products_NN
segment_NOMZ
._.
14_CD
Other_JJ
intangible_JJ
assets_NN
,_,
net_JJ
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2005_CD
2004_CD
$_$
000_CD
$_$
000_CD
Other_JJ
intangible_JJ
assets_NN
:_:
Intellectual_NN
property_NN
rights_NN
acquired_VBD
978,869_CD
543,969_CD
Less_RB
:_:
accumulated_VBN
amortization_NOMZ
249_CD
,_,
565_CD
234,672_CD
729,304_CD
309,297_CD
The_DT
increase_NN
in_PIN
the_DT
net_JJ
book_NN
value_NN
of_PIN
other_JJ
intangible_JJ
assets_NN
for_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
is_VPRT [PASS]
shown_VBN [PRIV]
in_PIN
the_DT
table_NN
below_PLACE
:_:
Other_JJ
intangible_JJ
assets_NN
$_$
000_CD
As_IN
at_PIN
January_NN
1_CD
,_,
2005_CD
309,297_CD
Acquisitions_NOMZ
1,155,511_CD
In-process_JJ
research_NN
and_PHC
development_NOMZ
write-off_PIN
673,000_CD
Amortization_NOMZ
charged_VBN
45,266_CD
Asset_NN
impairments_NOMZ
5,632_CD
Disposals_NN
Foreign_NN
currency_NN
translation_NOMZ
11,606_CD
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
729,304_CD
The_DT
Company_NN
acquired_VBD
$_$
481_CD
million_CD
of_PIN
other_JJ
identifiable_JJ
intangible_JJ
assets_NN
,_,
net_NN
of_PIN
$_$
673_CD
million_CD
of_PIN
in-process_JJ
research_NN
and_PHC
development_NOMZ
expensed_VBD
to_PIN
the_DT
income_NN
statement_NOMZ
,_,
at_PIN
fair_JJ
value_NN
,_,
as_IN
part_NN
of_PIN
the_DT
acquisition_NOMZ
of_PIN
TKT_NN
._.
The_DT
weighted_JJ
average_JJ
amortization_NOMZ
period_NN
of_PIN
these_DEMO
assets_NN
is_VPRT [BEMA]
16.8_CD
years_NN
._.
These_DEMO
assets_NN
relate_VPRT
to_PIN
intellectual_JJ
property_NN
$_$
335_CD
million_CD
,_,
customer_NN
relationships_NN
$_$
119_CD
million_CD
and_CC
other_JJ
finite-lived_JJ
assets_NN
$_$
27_CD
million_CD
see_VPRT [PRIV]
Note_NN
4_CD
._.
104_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
105_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
Dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
14_CD
Other_JJ
intangible_JJ
assets_NN
,_,
net_JJ
continued_VBD
Amortization_NOMZ
charged_VBD
for_PIN
the_DT
three_CD
years_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
,_,
2004_CD
and_CC
2003_CD
was_VBD
$_$
45.3_CD
million_CD
,_,
$_$
38.7_CD
million_CD
and_CC
$_$
26.4_CD
million_CD
,_,
respectively_RB
._.
The_DT
useful_JJ
economic_JJ
lives_NN
of_PIN
all_QUAN
intangible_JJ
assets_NN
that_TSUB
continue_VPRT
to_TO
be_VB [PASS]
amortized_VBN
under_IN
SFAS_NN
No._NN
._.
142_CD
are_VPRT [PASS]
reviewed_VBN
periodically_RB
by_PIN
management_NOMZ
._.
During_PIN
2005_CD
,_,
management_NOMZ
became_VBD
aware_JJ
of_PIN
competitor_NN
intelligence_NN
,_,
which_WDT [SERE]
it_PIT
believed_VBD [PRIV]
would_PRMD
reduce_VB
the_DT
useful_JJ
economic_JJ
life_NN
of_PIN
one_CD
of_PIN
the_DT
Companys_NN
products_NN
._.
Consequently_CONJ
,_,
the_DT
Company_NN
has_VPRT [PEAS]
decreased_VBN
the_DT
useful_JJ
economic_JJ
life_NN
of_PIN
the_DT
product_NN
,_,
which_WDT [SERE]
has_VPRT [PEAS]
resulted_VBN
in_PIN
an_DT
additional_JJ
amortization_NOMZ
charge_NN
in_PIN
2005_CD
of_PIN
$_$
1.7_CD
million_CD
and_CC
will_PRMD
increase_VB
the_DT
expected_VBN [PRIV]
annual_JJ
amortization_NOMZ
charge_NN
from_PIN
2006_CD
by_PIN
$_$
6.8_CD
million_CD
._.
The_DT
effect_NN
of_PIN
this_DEMO
additional_JJ
charge_NN
is_VPRT
to_TO
reduce_VB
net_JJ
income_NN
in_PIN
2005_CD
by_PIN
$_$
1.2_CD
million_CD
and_CC
increase_VB
losses_NN
per_PIN
share_NN
by_PIN
0.2_CD
._.
Management_NOMZ
estimates_VPRT [PRIV]
that_THVC
the_DT
annual_JJ
amortization_NOMZ
charges_NN
in_PIN
respect_NN
of_PIN
intangible_JJ
fixed_VBN
assets_NN
held_VBD [PRIV]
as_RB
at_PIN
December_NN
31_CD
,_,
2005_CD
will_PRMD
average_VB
approximately_RB
$_$
90_CD
million_CD
for_PIN
each_QUAN
of_PIN
the_DT
five_CD
years_NN
to_PIN
December_NN
31_CD
,_,
2010_CD
._.
Estimated_VBN [PRIV]
amortization_NOMZ
expense_NN
can_POMD
be_VB [BYPA]
affected_VBN
by_PIN
various_JJ
factors_NN
including_VBG [WZPRES]
future_JJ
acquisitions_NOMZ
,_,
disposals_NN
of_PIN
product_NN
rights_NN
and_CC
the_DT
technological_JJ
advancement_NOMZ
and_CC
regulatory_JJ
approval_NN
of_PIN
competitor_NN
products_NN
._.
During_PIN
2005_CD
,_,
the_DT
Company_NN
recorded_VBN
impairments_NOMZ
of_PIN
$_$
5.6_CD
million_CD
._.
These_DEMO
impairments_NOMZ
resulted_VBD
from_PIN
the_DT
approval_NN
of_PIN
generic_JJ
versions_NN
of_PIN
AGRYLIN_NN
and_CC
the_DT
decision_NN
not_XX0
to_TO
support_VB
and_PHC
promote_VB
certain_JJ
non-core_JJ
products_NN
going_VBG [WZPRES]
forward_RB
._.
During_PIN
2004_CD
,_,
the_DT
Company_NN
recorded_VBN
impairments_NOMZ
of_PIN
$_$
13.5_CD
million_CD
._.
These_DEMO
impairments_NOMZ
resulted_VBD
from_PIN
a_DT
change_NN
of_PIN
operational_JJ
management_NOMZ
and_CC
their_TPP3
views_NN
of_PIN
the_DT
economic_JJ
value_NN
and_CC
strategic_JJ
worth_NN
of_PIN
the_DT
products_NN
concerned_VBN
,_,
which_WDT [SERE]
decreased_VBD
estimated_VBN [PRIV]
future_JJ
cash_NN
flows_NN
._.
During_PIN
2003_CD
the_DT
Company_NN
recorded_VBN
asset_NN
impairments_NOMZ
of_PIN
$_$
12.1_CD
million_CD
and_CC
an_DT
asset_NN
write-down_NN
of_PIN
$_$
15.4_CD
million_CD
._.
The_DT
asset_NN
impairments_NOMZ
of_PIN
$_$
12.1_CD
million_CD
resulted_VBD
from_PIN
a_DT
decline_NN
in_PIN
product_NN
prices_NN
,_,
which_WDT [SERE]
decreased_VBD
estimated_VBN [PRIV]
future_JJ
cash_NN
flows_NN
._.
The_DT
asset_NN
write-down_NN
of_PIN
$_$
15.4_CD
million_CD
resulted_VBD
from_PIN
a_DT
decision_NN
not_XX0
to_TO
renew_VB
product_NN
licenses_NN
that_TSUB
were_VBD
not_XX0
core_NN
to_PIN
the_DT
business_NOMZ
._.
15_CD
Other_JJ
non-current_JJ
assets_NN
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2005_CD
2004_CD
Notes_NN
$_$
000_CD
$_$
000_CD
SERP_NN
investment_NOMZ
28_CD
7,576_CD
7,698_CD
IDB_NN
loan_NN
6_CD
31,491_CD
30,000_CD
Other_JJ
assets_NN
3,840_CD
1,197_CD
42,907_CD
38,895_CD
Further_JJ
details_NN
of_PIN
the_DT
SERP_NN
investment_NOMZ
are_VPRT [PASS]
provided_VBN
in_PIN
Note_NN
28_CD
._.
The_DT
amount_NN
shown_VBN [PRIV]
above_PLACE
is_VPRT [BEMA]
the_DT
cash_NN
surrender_NN
value_NN
of_PIN
life_NN
insurance_NN
policies_NN
,_,
which_WDT [SERE]
is_VPRT [BYPA]
backed_VBN
by_PIN
short-term_JJ
investments_NOMZ
._.
A_DT
liability_NOMZ
of_PIN
$_$
4.6_CD
million_CD
is_VPRT [PASS]
included_VBN
within_PIN
Notes_NN
17_CD
and_CC
19_CD
2004_CD
:_:
$_$
5.5_CD
million_CD
._.
16_CD
Accounts_NN
payable_JJ
and_CC
accrued_VBN
expenses_NN
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2005_CD
2004_CD
Notes_NN
$_$
000_CD
$_$
000_CD
Trade_NN
accounts_NN
payable_JJ
70,958_CD
35,008_CD
Accrued_VBN
rebates_NN
Medicaid_NN
83,624_CD
84,758_CD
Accrued_VBN
rebates_NN
managed_VBD
care_NN
21,825_CD
14,667_CD
Sales_NN
return_VPRT
reserve_NN
31,788_CD
22,530_CD
Accrued_VBN
bonuses_NN
39,372_CD
23,171_CD
Accrued_VBN
coupons_NN
5,177_CD
15,869_CD
Research_NN
and_PHC
development_NOMZ
accruals_NN
22,108_CD
10,924_CD
Marketing_GER
accrual_NN
17,415_CD
26,095_CD
Accrued_VBN
royalties_NN
4,703_CD
8,250_CD
Accrued_VBN
rent_NN
7,284_CD
Deferred_JJ
revenue_NN
11,835_CD
14,472_CD
Reorganization_NOMZ
accrual_NN
6_CD
3,404_CD
1,936_CD
Accrued_VBN
settlement_NOMZ
costs_NN
13,000_CD
Other_JJ
accrued_VBN
expenses_NN
99,326_CD
53,551_CD
431,819_CD
311,231_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
105_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
106_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
Dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
17_CD
Other_JJ
current_JJ
liabilities_NOMZ
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2005_CD
2004_CD
Notes_NN
$_$
000_CD
$_$
000_CD
Income_NN
taxes_NN
payable_JJ
93,563_CD
42,521_CD
Deferred_JJ
payments_NOMZ
18,980_CD
Value_NN
added_VBD [PUBV]
taxes_NN
3,811_CD
SERP_NN
28_CD
1,277_CD
1,904_CD
Other_JJ
accrued_VBN
liabilities_NOMZ
7,342_CD
14,153_CD
105,993_CD
77,558_CD
18_CD
Long-term_JJ
debt_NN
i_FPP1
Multicurrency_NN
Revolving_GER
Facilities_NOMZ
Agreement_NOMZ
In_PIN
connection_NOMZ
with_PIN
the_DT
acquisition_NOMZ
of_PIN
TKT_NN
,_,
Shire_NN
and_CC
certain_JJ
members_NN
of_PIN
the_DT
Shire_NN
Group_NN
entered_VBD
into_PIN
a_DT
Multicurrency_NN
Revolving_GER
Facilities_NOMZ
Agreement_NOMZ
the_DT
Facilities_NOMZ
Agreement_NOMZ
with_PIN
ABN_NN
AMRO_NN
Bank_NN
N._NN
V._NN
Barclays_NN
Capital_NN
,_,
Citigroup_NN
Global_NN
Markets_NN
Limited_NN
,_,
HSBC_NN
Bank_NN
plc_NN
and_CC
The_DT
Royal_NN
Bank_NN
of_PIN
Scotland_NN
plc_VPRT
the_DT
Lenders_NN
on_PIN
June_NN
15_CD
,_,
2005_CD
._.
The_DT
Facilities_NOMZ
Agreement_NOMZ
comprises_VPRT
two_CD
credit_NN
facilities_NOMZ
:_:
i_FPP1
a_DT
committed_JJ
multicurrency_NN
three-year_JJ
revolving_JJ
loan_NN
facility_NOMZ
in_PIN
an_DT
aggregate_JJ
amount_NN
of_PIN
$_$
500_CD
million_CD
Facility_NOMZ
A_DT
and_CC
ii_FW
a_DT
committed_JJ
364_CD
day_NN
revolving_JJ
loan_NN
facility_NOMZ
in_PIN
an_DT
aggregate_JJ
amount_NN
of_PIN
$_$
300_CD
million_CD
Facility_NOMZ
B_NN
and_CC
,_,
together_RB
with_PIN
Facility_NOMZ
A_DT
,_,
the_DT
Facilities_NOMZ
._.
Shire_NN
has_VPRT [PEAS]
agreed_VBN [SUAV] [PUBV]
to_TO
act_VB
as_IN
guarantor_NN
for_PIN
any_QUAN
of_PIN
its_PIT
subsidiaries_NN
that_TSUB
borrow_VPRT
under_IN
the_DT
Facilities_NOMZ
Agreement_NOMZ
._.
Facility_NOMZ
A_DT
may_POMD
be_VB [PASS]
used_VBN
for_PIN
general_JJ
corporate_JJ
purposes_NN
,_,
including_VBG
financing_VBG
the_DT
purchase_NN
price_NN
and_CC
other_JJ
costs_NN
with_PIN
respect_NN
to_PIN
the_DT
acquisition_NOMZ
of_PIN
TKT_NN
including_VBG [WZPRES]
refinancing_GER
TKTs_NN
existing_VBG [WZPRES]
indebtedness_NOMZ
._.
Facility_NOMZ
B_NN
may_POMD
be_VB [PASS]
used_VBN
only_DWNT
for_PIN
financing_VBG
certain_JJ
milestone_NN
payments_NOMZ
due_JJ
under_IN
the_DT
agreement_NOMZ
between_PIN
Shire_NN
and_CC
,_,
inter_VB
alia_NN
,_,
New_NN
River_NN
Pharmaceuticals_NN
Inc._NN
._.
New_NN
River_NN
,_,
dated_VBN
January_NN
31_CD
,_,
2005_CD
._.
Facility_NOMZ
A_DT
terminates_NN
on_PIN
June_NN
15_CD
,_,
2008_CD
and_CC
Facility_NOMZ
B_NN
terminates_VPRT
on_PIN
June_NN
14_CD
,_,
2006_CD
._.
At_PIN
Shires_NN
request_NN
,_,
the_DT
Lenders_NN
may_POMD
agree_VB [SUAV] [PUBV]
to_PIN
successive_JJ
annual_JJ
extensions_NN
of_PIN
Facility_NOMZ
B_NN
,_,
but_CC
not_XX0
beyond_IN
the_DT
maturity_NOMZ
date_NN
of_PIN
Facility_NOMZ
A._NN
Alternatively_CONJ
,_,
Shire_NN
has_VPRT
the_DT
right_NN
to_TO
draw_VB
Facility_NOMZ
B_NN
or_CC
convert_VB
existing_VBG
loans_NN
under_IN
Facility_NOMZ
B_NN
into_PIN
a_DT
term_NN
loan_NN
with_PIN
the_DT
same_JJ
maturity_NOMZ
date_NN
as_IN
Facility_NOMZ
A._NN
The_NN
availability_NOMZ
of_PIN
loans_NN
under_IN
each_QUAN
of_PIN
the_DT
Facilities_NOMZ
is_VPRT [BEMA]
subject_PRED
to_PIN
customary_JJ
conditions_NOMZ
,_,
including_VBG [PRESP]
the_DT
absence_NN
of_PIN
any_QUAN
defaults_NN
thereunder_RB
and_CC
the_DT
accuracy_NN
in_PIN
all_QUAN
material_NN
respects_VPRT
of_PIN
Shires_NN
representations_NOMZ
and_PHC
warranties_NN
contained_VBD
therein_RB
._.
The_DT
Facilities_NOMZ
include_VPRT
representations_NOMZ
and_PHC
warranties_NN
,_,
covenants_NN
and_PHC
events_NN
of_PIN
default_NN
,_,
including_VBG
requirements_NOMZ
that_TSUB
Shires_VPRT
ratio_NN
of_PIN
Net_JJ
Debt_NN
to_PIN
EBITDA_NN
as_IN
defined_VBN
in_PIN
the_DT
Facilities_NOMZ
Agreement_NOMZ
not_XX0
exceed_VB
3.0_CD
to_PIN
1_CD
and_CC
that_THVC
the_DT
ratio_NN
of_PIN
EBITDA_NN
to_PIN
Net_JJ
Interest_NN
be_VB [BEMA]
not_XX0
less_PRED
than_PIN
4.0_CD
to_PIN
1_CD
,_,
both_DT
in_PIN
respect_NN
of_PIN
the_DT
most_EMPH
recently_TIME
ended_VBN
fiscal_JJ
year_NN
,_,
and_ANDC
limitations_NOMZ
on_PIN
the_DT
creation_NOMZ
of_PIN
liens_NN
,_,
disposal_NN
of_PIN
assets_NN
,_,
incurrence_NN
of_PIN
indebtedness_NOMZ
,_,
making_VBG [PRESP]
of_PIN
loans_NN
and_CC
giving_VBG
of_PIN
guarantees_NN
._.
Interest_NN
on_PIN
loans_NN
under_IN
the_DT
Facilities_NOMZ
will_PRMD
be_VB [BEMA]
payable_PRED
on_PIN
the_DT
last_JJ
day_NN
of_PIN
each_QUAN
interest_NN
period_NN
,_,
which_WDT [SERE]
period_NN
may_POMD
be_VB [BEMA]
one_CD
,_,
two_CD
,_,
three_CD
or_CC
six_CD
months_NN
at_PIN
the_DT
election_NOMZ
of_PIN
Shire_NN
or_CC
as_IN
otherwise_CONJ
agreed_VBN [SUAV] [PUBV]
with_PIN
the_DT
Lenders_NN
._.
The_DT
interest_NN
rate_NN
on_PIN
each_QUAN
loan_NN
for_PIN
each_QUAN
interest_NN
period_NN
is_VPRT [BEMA]
the_DT
percentage_NN
rate_NN
per_PIN
annum_NN
,_,
which_WDT [SERE]
is_VPRT [BEMA]
the_DT
aggregate_NN
of_PIN
the_DT
applicable_JJ
margin_NN
ranging_VBG [WZPRES]
from_PIN
0.35_CD
to_PIN
0.65_CD
%_NN
per_PIN
annum_NN
,_,
depending_VBG [PRESP]
on_PIN
the_DT
ratio_NN
of_PIN
Net_JJ
Debt_NN
to_PIN
EBITDA_NN
,_,
LIBOR_NN
,_,
and_ANDC
mandatory_JJ
cost_NN
,_,
if_COND
any_QUAN
as_IN
calculated_VBN [PRIV]
in_PIN
accordance_NN
with_PIN
Schedule_NN
5_CD
of_PIN
the_DT
Facilities_NOMZ
Agreement_NOMZ
._.
Shire_NN
shall_PRMD [SPAU]
also_RB
pay_VB
fees_NN
equal_JJ
to_PIN
35_CD
%_NN
per_PIN
annum_NN
of_PIN
the_DT
applicable_JJ
margin_NN
on_PIN
available_JJ
commitments_NOMZ
under_IN
Facility_NOMZ
A_DT
for_PIN
the_DT
availability_NOMZ
period_NN
applicable_JJ
to_PIN
Facility_NOMZ
A_DT
and_CC
20_CD
%_NN
per_PIN
annum_NN
of_PIN
the_DT
applicable_JJ
margin_NN
on_PIN
available_JJ
commitments_NOMZ
under_IN
Facility_NOMZ
B_NN
for_PIN
the_DT
availability_NOMZ
period_NN
applicable_JJ
to_PIN
Facility_NOMZ
B_NN
in_PIN
respect_NN
of_PIN
the_DT
period_NN
prior_RB
to_PIN
January_NN
1_CD
,_,
2007_CD
,_,
and_ANDC
30_CD
%_NN
per_PIN
annum_NN
of_PIN
the_DT
applicable_JJ
margin_NN
thereafter_RB
._.
Interest_NN
on_PIN
overdue_JJ
amounts_NN
under_IN
the_DT
Facilities_NOMZ
will_PRMD
accrue_VB
at_PIN
a_DT
rate_NN
,_,
which_WDT [SERE]
is_VPRT [BEMA]
one_CD
percent_NN
higher_JJ
than_PIN
the_DT
rates_NN
otherwise_CONJ
applicable_JJ
to_PIN
the_DT
loans_NN
under_IN
the_DT
Facilities_NOMZ
._.
Upon_PIN
a_DT
change_NN
of_PIN
control_NN
of_PIN
Shire_NN
or_CC
upon_PIN
the_DT
occurrence_NN
of_PIN
an_DT
event_NN
of_PIN
default_NN
and_CC
the_DT
expiration_NOMZ
of_PIN
any_QUAN
applicable_JJ
cure_NN
period_NN
,_,
the_DT
total_JJ
commitments_NOMZ
under_IN
the_DT
Facilities_NOMZ
may_POMD
be_VB [PASS]
canceled_VBN
,_,
all_QUAN
or_CC
part_NN
of_PIN
the_DT
loans_NN
,_,
together_RB
with_PIN
accrued_VBN
interest_NN
and_CC
all_QUAN
other_JJ
amounts_NN
accrued_VBN
or_CC
outstanding_JJ
may_POMD
be_VB [BEMA]
immediately_TIME
due_PRED
and_PHC
payable_PRED
and_CC
all_QUAN
or_CC
part_NN
of_PIN
the_DT
loans_NN
may_POMD
become_VB
payable_JJ
on_PIN
demand_NN
._.
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
,_,
the_DT
Company_NN
had_VBD [PEAS]
not_XX0
drawn_VBN
down_RP
on_PIN
these_DEMO
facilities_NOMZ
._.
ii_FW
TKT_FW
convertible_JJ
loan_NN
notes_NN
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
all_QUAN
of_PIN
TKTs_NN
1.25_CD
%_NN
2011_CD
Convertible_JJ
Notes_NN
had_VBD [PEAS]
been_VBN [PASS]
converted_VBN
and_PHC
redeemed_VBN
._.
iii_FW
Capital_NN
leases_VPRT
During_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
the_DT
Company_NN
served_VBD
notice_NN
to_TO
buy_VB
out_PIN
its_PIT
remaining_VBG
capital_NN
leases_NN
,_,
totaling_VBG
$_$
5.7_CD
million_CD
,_,
relating_VBG [PRESP]
to_PIN
its_PIT
manufacturing_GER
facility_NOMZ
in_PIN
Maryland_NN
._.
Repayment_NOMZ
of_PIN
the_DT
leases_NN
occurred_VBD
in_PIN
October_NN
2004_CD
._.
106_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
107_NN
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
Dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
19_CD
Other_JJ
long-term_JJ
liabilities_NOMZ
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2005_CD
2004_CD
Notes_NN
$_$
000_CD
$_$
000_CD
SERP_NN
28_CD
3,314_CD
3,591_CD
Long-term_JJ
bonuses_NN
4,796_CD
4,425_CD
Deferred_JJ
revenue_NN
5,939_CD
9,074_CD
Insurance_NN
provisions_NN
11,315_CD
9,274_CD
Deferred_VBN
rent_NN
7,283_CD
Onerous_JJ
lease_NN
provisions_NN
7,705_CD
3,988_CD
Other_JJ
accrued_VBN
liabilities_NOMZ
3,085_CD
1,807_CD
43,437_CD
32,159_CD
Deferred_JJ
revenue_NN
relates_VPRT
to_PIN
amounts_NN
received_VBN [WZPAST]
from_PIN
the_DT
out-licensing_GER
of_PIN
AGRYLIN_NN
,_,
FOSRENOL_NN
,_,
ELAPRASE_NN
and_PHC
REPLAGAL_NN
in_PIN
Japan_NN
and_CC
the_DT
global_JJ
out-licensing_GER
of_PIN
TROXATYL_NN
._.
The_DT
onerous_JJ
lease_NN
provisions_NN
at_PIN
December_NN
31_CD
,_,
2005_CD
include_VPRT
$_$
4.4_CD
million_CD
in_PIN
respect_NN
of_PIN
the_DT
North_PLACE
American_JJ
site_NN
consolidation_NOMZ
2004_CD
:_:
$_$
2.5_CD
million_CD
._.
20_CD
Financial_NN
instruments_NOMZ
The_DT
estimated_VBN [PRIV]
fair_JJ
value_NN
of_PIN
the_DT
Companys_NN
financial_JJ
instruments_NOMZ
as_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
and_CC
2004_CD
is_VPRT [PASS]
summarized_VBN
below_PLACE
._.
Certain_JJ
estimates_NN
and_PHC
judgments_NOMZ
were_VBD [PASS]
required_VBN [SUAV]
to_TO
develop_VB
the_DT
fair_JJ
value_NN
amounts_NN
._.
The_DT
fair_JJ
value_NN
amounts_NN
shown_VBN [PRIV]
below_PLACE
are_VPRT
not_XX0
necessarily_RB
indicative_PRED
of_PIN
the_DT
amounts_NN
that_TOBJ
the_DT
Company_NN
would_PRMD
realize_VB [PRIV]
upon_PIN
disposition_NOMZ
,_,
nor_SYNE
do_VPRT
they_TPP3
indicate_VPRT [PRIV]
the_DT
Companys_NN
intent_NN
or_CC
ability_NOMZ
to_TO
dispose_VB
of_PIN
the_DT
financial_JJ
instrument_NOMZ
._.
The_DT
following_VBG
methods_NN
and_PHC
assumptions_NOMZ
were_VBD [PASS]
used_VBN
to_TO
estimate_VB [PRIV]
the_DT
fair_JJ
value_NN
of_PIN
each_QUAN
material_NN
class_NN
of_PIN
financial_JJ
instrument_NOMZ
:_:
short-term_JJ
investments_NOMZ
commercial_JJ
paper_NN
and_CC
institutional_JJ
and_CC
managed_VBD
cash_NN
funds_NN
the_DT
carrying_GER
value_NN
approximates_VPRT
fair_JJ
value_NN
because_CAUS
of_PIN
the_DT
short-term_JJ
nature_NN
of_PIN
these_DEMO
instruments_NOMZ
:_:
restricted_JJ
cash_NN
the_DT
carrying_VBG
value_NN
either_CC
approximates_VPRT
fair_JJ
value_NN
because_CAUS
of_PIN
the_DT
short-term_JJ
nature_NN
of_PIN
the_DT
instruments_NOMZ
or_CC
equals_VPRT
the_DT
fair_JJ
value_NN
as_IN
such_JJ
instruments_NOMZ
are_VPRT [PASS]
marked_VBN
to_PIN
market_NN
:_:
investments_NOMZ
available-for-sale_JJ
securities_NOMZ
the_DT
carrying_GER
value_NN
of_PIN
non-current_JJ
investments_NOMZ
with_PIN
readily_RB
determinable_JJ
market_NN
values_NN
equals_VPRT
the_DT
fair_JJ
value_NN
as_IN
such_JJ
instruments_NOMZ
are_VPRT [PASS]
marked_VBN
to_PIN
market_NN
:_:
long-term_JJ
debt_NN
the_DT
fair_JJ
value_NN
of_PIN
long-term_JJ
debt_NN
is_VPRT [PASS]
estimated_VBN [PRIV]
based_VBN
on_PIN
the_DT
discounted_JJ
future_JJ
cash_NN
flows_VPRT
using_VBG
currently_RB
available_JJ
interest_NN
rates_NN
or_CC
,_,
where_RB
the_DT
debt_NN
instrument_NOMZ
is_VPRT [PASS]
traded_VBN
,_,
by_PIN
reference_NN
to_PIN
the_DT
market_NN
price_NN
:_:
IDB_NN
subscription_NOMZ
receipts_NN
the_DT
carrying_GER
value_NN
in_PIN
2004_CD
equals_VPRT
the_DT
fair_JJ
value_NN
as_IN
the_DT
subscription_NOMZ
receipts_NN
were_VBD [PASS]
repurchased_VBN
on_PIN
January_NN
7_CD
,_,
2005_CD
for_PIN
$_$
60_CD
million_CD
:_:
and_ANDC
derivatives_NN
derivative_JJ
instruments_NOMZ
comprise_VPRT
forward_RB
foreign_JJ
exchange_NN
contracts_NN
and_CC
foreign_JJ
exchange_NN
swaps_NN
._.
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
the_DT
Company_NN
had_VBD
five_CD
outstanding_JJ
forward_RB
foreign_JJ
exchange_NN
contracts_NN
with_PIN
a_DT
total_JJ
principal_JJ
amount_NN
of_PIN
$_$
206_CD
million_CD
equivalent_JJ
to_TO
manage_VB
the_DT
currency_NN
risk_NN
associated_VBN [WZPAST]
with_PIN
certain_JJ
intercompany_NN
loans_NN
._.
The_DT
Company_NN
does_VPRT
not_XX0
seek_VB
hedge_JJ
accounting_GER
treatment_NOMZ
for_PIN
these_DEMO
hedges_NN
and_ANDC
therefore_CONJ
changes_NN
in_PIN
the_DT
fair_JJ
value_NN
of_PIN
these_DEMO
derivatives_NN
are_VPRT [PASS]
accounted_VBN
for_PIN
in_PIN
the_DT
statement_NOMZ
of_PIN
operations_NOMZ
._.
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
there_EX
were_VBD
net_JJ
unrealized_JJ
gains_NN
of_PIN
$_$
2.6_CD
m_NN [BEMA]
on_PIN
these_DEMO
contracts_NN
._.
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
107_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
108_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
Dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
20_CD
Financial_NN
instruments_NOMZ
continued_VBD
The_DT
carrying_VBG
amounts_NN
and_CC
corresponding_JJ
fair_JJ
values_NN
of_PIN
financial_JJ
instruments_NOMZ
are_VPRT
as_IN
follows_VPRT
:_:
Carrying_VBG
amount_NN
Fair_NN
value_NN
December_NN
31_CD
,_,
2005_CD
Notes_NN
$_$
000_CD
$_$
000_CD
Financial_JJ
assets_NN
:_:
Short-term_JJ
investments_NOMZ
institutional_JJ
and_CC
managed_VBD
cash_NN
funds_NN
6,947_CD
6,947_CD
Restricted_VBN
cash_NN
30,568_CD
30,568_CD
Investments_NOMZ
available-for-sale_JJ
securities_NOMZ
11_CD
18,131_CD
18,131_CD
Other_JJ
current_JJ
assets_NN
derivatives_NN
2,554_CD
2,554_CD
Financial_NN
liabilities_NOMZ
:_:
Long-term_JJ
debt_NN
116_CD
116_CD
Carrying_VBG
amount_NN
Fair_NN
value_NN
December_NN
31_CD
,_,
2004_CD
Notes_NN
$_$
000_CD
$_$
000_CD
Financial_JJ
assets_NN
:_:
Short-term_JJ
investments_NOMZ
commercial_JJ
paper_NN
149,659_CD
149,659_CD
Short-term_JJ
investments_NOMZ
institutional_JJ
and_CC
managed_VBD
cash_NN
funds_NN
174,752_CD
175,185_CD
Restricted_VBN
cash_NN
21,627_CD
21,627_CD
Investments_NOMZ
available-for-sale_JJ
securities_NOMZ
11_CD
29,970_CD
29,970_CD
IDB_NN
subscription_NOMZ
receipts_NN
9_CD
60,000_CD
60,000_CD
Financial_NN
liabilities_NOMZ
:_:
Long-term_JJ
debt_NN
116_CD
117_CD
The_DT
carrying_VBG
amounts_NN
of_PIN
cash_NN
and_PHC
cash_NN
equivalents_NN
,_,
accounts_NN
receivable_JJ
,_,
accounts_NN
payable_JJ
and_CC
accrued_VBN
liabilities_NOMZ
approximate_JJ
fair_JJ
value_NN
because_CAUS
of_PIN
the_DT
short-term_JJ
maturity_NOMZ
of_PIN
these_DEMO
instruments_NOMZ
._.
21_CD
Commitments_NOMZ
and_PHC
contingencies_NN
a_DT
Leases_NN
Future_NN
minimum_NN
lease_NN
payments_NOMZ
presented_VBD
below_PLACE
include_VPRT
principal_JJ
lease_NN
payments_NOMZ
and_CC
other_JJ
fixed_VBN
executory_NN
fees_NN
under_IN
lease_NN
arrangements_NOMZ
as_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
:_:
Operating_GER
leases_VPRT
$_$
000_CD
2006_CD
26,110_CD
2007_CD
26,610_CD
2008_CD
24,847_CD
2009_CD
21,279_CD
2010_CD
16,737_CD
Thereafter_RB
50,016_CD
165,599_CD
i_FPP1
Operating_GER
leases_VPRT
The_DT
Company_NN
leases_VPRT
facilities_NOMZ
,_,
motor_NN
vehicles_NN
and_CC
certain_JJ
equipment_NOMZ
under_IN
operating_VBG
leases_NN
expiring_VBG [WZPRES]
through_PIN
2025_CD
._.
Lease_NN
and_CC
rental_JJ
expense_NN
included_VBD
in_PIN
selling_GER
,_,
general_JJ
and_PHC
administrative_JJ
expenses_NN
in_PIN
the_DT
accompanying_VBG
statements_NOMZ
of_PIN
operations_NOMZ
amounted_VBD
to_TO
$_$
20.6_CD
million_CD
,_,
$_$
15.3_CD
million_CD
and_CC
$_$
12.2_CD
million_CD
for_PIN
the_DT
years_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
,_,
2004_CD
and_CC
2003_CD
,_,
respectively_RB
._.
During_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
,_,
Shire_NN
Inc._NN
a_DT
wholly-owned_JJ
subsidiary_NN
of_PIN
Shire_NN
,_,
signed_VBD
two_CD
11-year_JJ
operating_GER
leases_NN
on_PIN
properties_NN
in_PIN
Wayne_NN
,_,
Pennsylvania_NN
._.
Shire_NN
US_FPP1
,_,
Inc._NN
another_DT
wholly-owned_JJ
subsidiary_NN
,_,
acts_VPRT
as_IN
guarantor_NN
in_PIN
respect_NN
of_PIN
these_DEMO
leases_NN
._.
The_DT
future_JJ
minimum_NN
lease_NN
payments_NOMZ
under_IN
the_DT
lease_NN
agreements_NOMZ
are_VPRT
$_$
57.6_CD
million_CD
in_PIN
aggregate_NN
._.
viii_FW
Restricted_VBN
cash_NN
in_PIN
respect_NN
of_PIN
leases_NN
At_PIN
December_NN
31_CD
,_,
2005_CD
the_DT
Company_NN
had_VBD
$_$
5.5_CD
million_CD
of_PIN
restricted_VBN
cash_NN
held_VBN [PRIV]
as_IN
collateral_NN
for_PIN
certain_JJ
equipment_NOMZ
leases_VPRT
2004_CD
:_:
$_$
5.3_CD
million_CD
._.
108_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
109_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
Dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
21_CD
Commitments_NOMZ
and_PHC
contingencies_NN
continued_VBD
b_NN
Letters_NN
of_PIN
credit_NN
and_PHC
guarantees_NN
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
the_DT
Company_NN
had_VBD
the_DT
following_VBG
letters_NN
of_PIN
credit_NN
:_:
i_FPP1
an_DT
irrevocable_JJ
standby_JJ
letter_NN
of_PIN
credit_NN
with_PIN
Barclays_NN
Bank_NN
plc_NN
,_,
in_PIN
the_DT
amount_NN
of_PIN
$_$
15_CD
million_CD
,_,
providing_VBG
security_NOMZ
on_PIN
the_DT
recoverability_NOMZ
of_PIN
insurance_NN
claims_NN
._.
The_DT
Company_NN
has_VPRT [PEAS]
restricted_VBN
cash_NN
of_PIN
$_$
15_CD
million_CD
,_,
as_IN
required_VBN [SUAV]
by_PIN
this_DEMO
letter_NN
of_PIN
credit_NN
:_:
and_ANDC
ix_VB
an_DT
irrevocable_JJ
standby_JJ
letter_NN
of_PIN
credit_NN
with_PIN
Bank_NN
of_PIN
America_NN
in_PIN
the_DT
amount_NN
of_PIN
$_$
7.9_CD
million_CD
,_,
providing_VBG
security_NOMZ
on_PIN
the_DT
payment_NOMZ
of_PIN
lease_NN
obligations_NOMZ
._.
The_DT
Company_NN
has_VPRT [PEAS]
restricted_VBN
cash_NN
of_PIN
$_$
7.9_CD
million_CD
,_,
as_IN
required_VBN [SUAV]
by_PIN
this_DEMO
letter_NN
of_PIN
credit_NN
._.
c_NN
Commitments_NOMZ
i_FPP1
DAYTRANA_NN
In_PIN
connection_NOMZ
with_PIN
the_DT
Companys_NN
acquisition_NOMZ
in_PIN
2003_CD
from_PIN
Noven_NN
Pharmaceuticals_NN
,_,
Inc._NN
._.
Noven_NN
of_PIN
the_DT
worldwide_JJ
sales_NN
and_PHC
marketing_GER
rights_NN
to_PIN
DAYTRANA_NN
,_,
Shire_NN
has_VPRT
an_DT
obligation_NOMZ
to_TO
make_VB
certain_JJ
payments_NOMZ
on_PIN
the_DT
achievement_NOMZ
of_PIN
the_DT
following_VBG
milestones_NN
:_:
$_$
50_CD
million_CD
upon_PIN
FDA_NN
approval_NN
of_PIN
the_DT
product_NN
,_,
which_WDT [SERE]
will_PRMD
be_VB [PASS]
capitalized_VBN
and_PHC
amortized_VBN
over_IN
its_PIT
useful_JJ
economic_JJ
life_NN
:_:
and_ANDC
up_RB
to_TO
$_$
75_CD
million_CD
,_,
linked_VBN [PASTP]
to_PIN
future_JJ
sales_NN
performance_NN
._.
An_DT
approvable_JJ
letter_NN
was_VBD [PASS]
received_VBN
from_PIN
the_DT
FDA_NN
on_PIN
December_NN
23_CD
,_,
2005_CD
._.
x_LS
NRP104_CD
In_PIN
connection_NOMZ
with_PIN
the_DT
Companys_NN
collaboration_NOMZ
with_PIN
New_NN
River_NN
to_TO
commercialize_VB
NRP104_NN
,_,
the_DT
Company_NN
has_VPRT
an_DT
obligation_NOMZ
to_TO
make_VB
certain_JJ
payments_NOMZ
on_PIN
the_DT
achievement_NOMZ
of_PIN
the_DT
following_VBG
milestones_NN
:_:
$_$
50_CD
million_CD
upon_PIN
the_DT
FDAs_NN
acceptance_NN
of_PIN
filing_NN
of_PIN
the_DT
NDA_NN
:_:
up_RP
to_TO
$_$
300_CD
million_CD
following_VBG
the_DT
first_JJ
commercial_JJ
sale_NN
of_PIN
the_DT
product_NN
,_,
depending_VBG [PRESP]
on_PIN
the_DT
characteristics_NN
of_PIN
the_DT
approved_VBN
product_NN
labeling_VBG [WZPRES]
:_:
$_$
100_CD
million_CD
on_PIN
achieving_VBG
a_DT
significant_JJ
sales_NN
target_NN
:_:
and_ANDC
$_$
5_CD
million_CD
following_VBG
the_DT
first_JJ
commercial_JJ
sale_NN
in_PIN
certain_JJ
specified_VBN
EU_NN
markets_NN
._.
An_DT
upfront_JJ
payment_NOMZ
of_PIN
$_$
50_CD
million_CD
was_VBD [PASS]
expensed_VBN
as_IN
an_DT
R&D_NN
cost_NN
during_PIN
the_DT
first_JJ
quarter_NN
of_PIN
2005_CD
._.
The_DT
NDA_NN
for_PIN
NRP104_NN
was_VBD [PASS]
filed_VBN
on_PIN
December_NN
6_CD
,_,
2005_CD
and_CC
accepted_VBD [PRIV]
for_PIN
review_NN
by_PIN
the_DT
FDA_NN
on_PIN
January_NN
26_CD
,_,
2006_CD
,_,
triggering_VBG [PRESP]
the_DT
$_$
50_CD
million_CD
milestone_NN
payment_NOMZ
,_,
which_WDT [SERE]
has_VPRT [SPAU] [PEAS]
now_TIME
been_VBN [PASS]
paid_VBN
._.
xi_FW
FOSRENOL_NN
patent_NN
rights_NN
In_PIN
connection_NOMZ
with_PIN
the_DT
Companys_NN
purchase_NN
of_PIN
the_DT
global_JJ
patents_NN
for_PIN
FOSRENOL_NN
from_PIN
AnorMed_NN
Inc._NN
in_PIN
2004_CD
,_,
the_DT
Company_NN
has_VPRT
outstanding_JJ
commitments_NOMZ
to_TO
pay_VB
AnorMED_NN
Inc._NN
$_$
6_CD
million_CD
when_RB
FOSRENOL_NN
is_VPRT [PASS]
approved_VBN
in_PIN
certain_JJ
European_JJ
countries_NN
and_CC
$_$
6_CD
million_CD
upon_PIN
receipt_NN
of_PIN
regulatory_JJ
approval_NN
in_PIN
Japan_NN
._.
xii_FW
Other_JJ
research_NN
and_PHC
development_NOMZ
commitments_NOMZ
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
,_,
the_DT
Company_NN
had_VBD
commitments_NOMZ
of_PIN
$_$
18_CD
million_CD
payable_JJ
on_PIN
achievement_NOMZ
of_PIN
specified_VBN
milestones_NN
for_PIN
products_NN
under_IN
development_NOMZ
in-licensed_JJ
from_PIN
third_JJ
parties_NN
,_,
of_PIN
which_WDT [PIRE]
$_$
6.6_CD
million_CD
is_VPRT [PASS]
committed_VBN
to_TO
be_VB [PASS]
paid_VBN
in_PIN
2006_CD
._.
xiii_FW
TKT_FW
shareholders_NN
seeking_VBG [WZPRES]
appraisal_NN
rights_NN
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
,_,
appraisal_NN
rights_NN
had_VBD [PEAS]
been_VBN [PASS]
asserted_VBN [PUBV]
in_PIN
respect_NN
of_PIN
approximately_RB
11.3_CD
million_CD
shares_NN
of_PIN
TKT_NN
common_JJ
stock_NN
._.
For_PIN
further_JJ
information_NOMZ
see_VPRT [PRIV]
section_NOMZ
d_SYM
below_PLACE
._.
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
the_DT
Company_NN
recorded_VBD
a_DT
liability_NOMZ
of_PIN
$_$
419.9_CD
million_CD
based_VBN
on_PIN
the_DT
merger_NN
consideration_NOMZ
of_PIN
$_$
37_CD
per_PIN
share_NN
for_PIN
the_DT
11.3_CD
million_CD
shares_NN
outstanding_JJ
at_PIN
that_DEMO
time_NN
plus_PIN
a_DT
provision_NN
for_PIN
interest_NN
of_PIN
$_$
7.7_CD
million_CD
that_DEMP
may_POMD
be_VB [BYPA]
awarded_VBN
by_PIN
the_DT
Court_NN
see_VB [PRIV]
Note_VB [PRIV]
27_CD
._.
Until_IN
such_JJ
time_NN
as_IN
the_DT
appraisal_NN
process_NN
is_VPRT [BEMA]
complete_PRED
the_DT
Company_NN
is_VPRT [BEMA]
unable_PRED
to_TO
determine_VB [SUAV] [PRIV]
the_DT
extent_NN
of_PIN
its_PIT
liability_NOMZ
._.
xiv_NN
Clinical_JJ
testing_GER
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
,_,
the_DT
Company_NN
had_VBD [PEAS]
committed_VBN
to_TO
pay_VB
approximately_RB
$_$
16.3_CD
million_CD
to_TO
contract_VB
vendors_NN
for_PIN
administering_VBG
and_PHC
executing_VBG
clinical_JJ
trials_NN
._.
The_DT
timing_NN
of_PIN
payments_NOMZ
is_VPRT
not_XX0
reasonably_RB
certain_PRED
as_IN
payments_NOMZ
are_VPRT [BEMA]
dependent_PRED
upon_PIN
actual_JJ
services_NN
performed_VBN [WZPAST]
by_PIN
the_DT
organizations_NOMZ
as_IN
determined_VBN [SUAV] [PRIV]
by_PIN
patient_JJ
enrollment_NOMZ
levels_NN
and_CC
related_JJ
activities_NOMZ
._.
However_CONJ
,_,
the_DT
Company_NN
expects_VPRT [PRIV]
to_TO
pay_VB
$_$
13.2_CD
million_CD
for_PIN
these_DEMO
commitments_NOMZ
throughout_PIN
2006_CD
as_IN
ongoing_JJ
trials_NN
are_VPRT [PASS]
completed_VBN
and_CC
the_DT
remainder_NN
in_PIN
2007_CD
._.
xv_NN
Contract_NN
manufacturing_VBG [WZPRES]
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
the_DT
Company_NN
had_VBD [PEAS]
committed_VBN
to_TO
pay_VB
approximately_RB
$_$
23.1_CD
million_CD
in_PIN
respect_NN
of_PIN
contract_NN
manufacturing_GER
over_IN
the_DT
next_JJ
12_CD
months_NN
._.
xvi_FW
Investment_NOMZ
commitments_NOMZ
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
the_DT
Company_NN
had_VBD
outstanding_JJ
commitments_NOMZ
to_TO
subscribe_VB
for_PIN
interests_NN
in_PIN
companies_NN
and_PHC
partnerships_NN
for_PIN
amounts_NN
totaling_VBG [WZPRES]
$_$
25.2_CD
million_CD
2004_CD
:_:
$_$
22_CD
million_CD
of_PIN
which_WDT [PIRE]
$_$
9.9_CD
million_CD
is_VPRT [PASS]
committed_VBN
in_PIN
2006_CD
and_CC
a_DT
further_JJ
$_$
2.9_CD
million_CD
could_POMD
be_VB [BEMA]
payable_PRED
in_PIN
2006_CD
,_,
depending_VBG [PRESP]
on_PIN
the_DT
timing_NN
of_PIN
capital_NN
calls_NN
._.
xvii_JJ
Manufacturing_GER
facilities_NOMZ
At_PIN
December_NN
31_CD
,_,
2005_CD
the_DT
Company_NN
had_VBD [PEAS]
committed_VBN
a_DT
total_NN
of_PIN
$_$
6.1_CD
million_CD
to_PIN
the_DT
expansion_NN
and_PHC
modification_NOMZ
of_PIN
its_PIT
manufacturing_GER
facilities_NOMZ
at_PIN
Owings_NN
Mills_NN
,_,
Maryland_NN
and_PHC
Cambridge_NN
,_,
Massachusetts_NN
._.
Of_PIN
this_DEMO
total_NN
,_,
$_$
3.2_CD
million_CD
is_VPRT
to_TO
facilitate_VB
the_DT
production_NOMZ
and_PHC
packaging_GER
of_PIN
additional_JJ
strategic_JJ
products_NN
and_CC
$_$
2.9_CD
million_CD
is_VPRT [BEMA]
for_PIN
the_DT
design_NN
and_PHC
construction_NOMZ
of_PIN
a_DT
technology_NN
center_NN
at_PIN
Owings_NN
Mills_NN
._.
All_QUAN
costs_NN
are_VPRT [PASS]
expected_VBN [PRIV]
to_TO
be_VB [PASS]
incurred_VBN
in_PIN
2006_CD
._.
xviii_NN
Basingstoke_NN
,_,
UK_NN
expansion_NN
The_DT
Company_NN
is_VPRT [BEMA]
in_PIN
the_DT
process_NN
of_PIN
expanding_VBG
its_PIT
UK_NN
headquarters_NN
at_PIN
Basingstoke_NN
,_,
UK_NN
._.
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
the_DT
Company_NN
had_VBD
an_DT
outstanding_JJ
commitment_NOMZ
of_PIN
$_$
4.5_CD
million_CD
,_,
which_WDT [SERE]
is_VPRT [PASS]
expected_VBN [PRIV]
to_TO
be_VB [PASS]
incurred_VBN
in_PIN
2006_CD
._.
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
109_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
110_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
Dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
21_CD
Commitments_NOMZ
and_PHC
contingencies_NN
continued_VBD
d_SYM
Legal_NN
proceedings_GER
General_NN
The_NN
Company_NN
accounts_VPRT
for_PIN
litigation_NOMZ
losses_NN
and_PHC
insurance_NN
claims_NN
and_PHC
provisions_NN
in_PIN
accordance_NN
with_PIN
SFAS_NN
No._NN
._.
5_CD
,_,
Accounting_GER
for_PIN
Contingencies_NN
SFAS_NN
No._NN
._.
5_CD
,_,
loss_NN
contingency_NN
provisions_NN
are_VPRT [PASS]
recorded_VBN
for_PIN
probable_JJ
losses_NN
when_RB
management_NOMZ
is_VPRT [BEMA]
able_PRED
to_TO [SPIN]
reasonably_RB
estimate_VB [PRIV]
the_DT
loss_NN
._.
Where_RB
the_DT
estimated_JJ
loss_NN
lies_VPRT
within_PIN
a_DT
range_NN
and_CC
no_SYNE
particular_JJ
amount_NN
within_PIN
that_DEMO
range_NN
is_VPRT [BEMA]
a_DT
better_JJ
estimate_NN
than_PIN
any_QUAN
other_JJ
amount_NN
,_,
the_DT
minimum_NN
amount_NN
is_VPRT [PASS]
recorded_VBN
._.
In_PIN
other_JJ
cases_NN
managements_NOMZ
best_JJ
estimate_NN
of_PIN
the_DT
loss_NN
is_VPRT [PASS]
recorded_VBN
._.
These_DEMO
estimates_NN
are_VPRT [PASS]
developed_VBN
substantially_RB
before_IN
the_DT
ultimate_JJ
loss_NN
is_VPRT [PASS]
known_VBN [PRIV]
and_CC
the_DT
estimates_NN
are_VPRT [PASS]
refined_VBN
in_PIN
each_QUAN
accounting_GER
period_NN
in_PIN
light_NN
of_PIN
additional_JJ
information_NOMZ
becoming_VBG [WZPRES]
known_VBN [PRIV]
._.
In_PIN
instances_NN
where_RB
the_DT
Company_NN
is_VPRT [BEMA]
unable_PRED
to_TO
develop_VB
a_DT
reasonable_JJ
estimate_NN
of_PIN
loss_NN
,_,
no_SYNE
litigation_NOMZ
loss_NN
is_VPRT [PASS]
recorded_VBN
at_PIN
that_DEMO
time_NN
._.
As_IN
information_NOMZ
becomes_VPRT
known_VBN [PRIV]
a_DT
loss_NN
provision_NN
is_VPRT [PASS]
set_VBN
up_RP
when_RB
a_DT
reasonable_JJ
estimate_NN
can_POMD
be_VB [PASS]
made_VBN
._.
The_DT
estimates_NN
are_VPRT [PASS]
reviewed_VBN
quarterly_JJ
and_CC
the_DT
estimates_NN
are_VPRT [PASS]
changed_VBN
when_RB
expectations_NOMZ
are_VPRT [PASS]
revised_VBN
._.
Any_QUAN
outcome_NN
upon_PIN
settlement_NOMZ
that_TSUB
deviates_VPRT
from_PIN
the_DT
Companys_NN
estimate_NN
may_POMD
result_VB
in_PIN
an_DT
additional_JJ
expense_NN
in_PIN
a_DT
future_JJ
accounting_GER
period_NN
._.
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
provisions_NN
for_PIN
litigation_NOMZ
losses_NN
,_,
insurance_NN
claims_NN
and_CC
other_JJ
disputes_NN
totaled_VBD
$_$
27.8_CD
million_CD
2004_CD
:_:
$_$
9.3_CD
million_CD
._.
Phentermine_NN
Shire_NN
US_FPP1
Inc._NN
._.
SUS_NN
,_,
a_DT
wholly-owned_JJ
subsidiary_NN
of_PIN
Shire_NN
,_,
is_VPRT [BEMA]
a_DT
defendant_NN
in_PIN
ten_NN
lawsuits_NN
still_RB
pending_VBG
in_PIN
both_DT
US_FPP1
federal_JJ
and_CC
state_NN
courts_NN
which_WDT [WHSUB]
seek_VPRT
damages_NN
for_PIN [STPR]
,_,
among_PIN
other_JJ
things_NN
,_,
personal_JJ
injury_NN
arising_VBG [WZPRES]
from_PIN
phentermine_NN
products_NN
supplied_VBD
for_PIN
the_DT
treatment_NOMZ
of_PIN
obesity_NOMZ
by_PIN
SUS_NN
and_CC
several_QUAN
other_JJ
pharmaceutical_JJ
companies_NN
._.
SUS_NN
,_,
formerly_TIME
known_VBN [PRIV]
as_IN
Shire_NN
Richwood_NN
Inc._NN
has_VPRT [PEAS]
been_VBN [PASS]
sued_VBN
as_IN
a_DT
manufacturer_NN
and_PHC
distributor_NN
of_PIN
phentermine_NN
,_,
an_DT
anorectic_NN
used_VBN [WZPAST]
in_PIN
the_DT
short-term_JJ
treatment_NOMZ
of_PIN
obesity_NOMZ
and_CC
one_CD
of_PIN
the_DT
products_NN
addressed_VBN [WZPAST]
by_PIN
the_DT
lawsuits_NN
._.
The_DT
suits_NN
relate_VPRT
to_TO
phentermine_VB
either_CC
alone_RB
or_CC
together_RB
with_PIN
fenfluramine_NN
or_CC
dexenfluramine_NN
._.
The_DT
lawsuits_NN
generally_RB
allege_VPRT [PUBV]
the_DT
following_VBG
claims_NN
:_:
the_DT
defendants_NN
marketed_VBN
phentermine_NN
and_CC
other_JJ
products_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
obesity_NOMZ
and_CC
misled_VBD
users_NN
about_IN
the_DT
products_NN
and_PHC
dangers_NN
associated_VBN [WZPAST]
with_PIN
them_TPP3
:_:
the_DT
defendants_NN
failed_VBD
adequately_RB
to_PIN
test_NN
phentermine_NN
individually_RB
and_ANDC
when_RB
taken_VBN
in_PIN
combination_NOMZ
with_PIN
the_DT
other_JJ
drugs_NN
:_:
and_ANDC
the_DT
defendants_NN
knew_VBD [PRIV]
or_CC
should_NEMD
have_VB [PEAS]
known_VBN [PRIV]
about_IN
the_DT
negative_JJ
effects_NN
of_PIN
the_DT
drugs_NN
and_CC
should_NEMD
have_VB [PEAS]
informed_VBN
the_DT
public_JJ
about_IN
such_JJ
risks_NN
and_CC
or_CC
failed_VBD
to_TO
provide_VB
appropriate_JJ
warning_GER
labels_NN
._.
SUS_NN
has_VPRT [PEAS]
been_VBN [PASS]
named_VBN
as_IN
a_DT
defendant_NN
in_PIN
a_DT
total_NN
of_PIN
4,199_CD
such_JJ
phentermine_NN
lawsuits_NN
,_,
in_PIN
respect_NN
of_PIN
which_WDT [PIRE]
SUS_NN
has_VPRT [PEAS]
been_VBN [PASS]
dismissed_VBN
as_IN
a_DT
defendant_NN
in_PIN
4,189_CD
cases_NN
._.
Five_CD
of_PIN
the_DT
ten_NN
remaining_VBG [WZPRES]
cases_NN
name_NN
Shire_NN
as_IN
a_DT
defendant_NN
,_,
but_CC
have_VPRT [PEAS]
not_XX0
been_VBN [PASS]
served_VBN
as_IN
required_VBN [SUAV]
by_PIN
state_NN
and_CC
federal_JJ
rules_NN
of_PIN
civil_JJ
procedure_NN
._.
It_PIT
is_VPRT [PASS]
expected_VBN [PRIV]
that_THVC
Shire_NN
will_PRMD
be_VB [PASS]
dismissed_VBN
from_PIN
the_DT
remaining_VBG
cases_NN
based_VBN [WZPAST]
upon_PIN
lack_NN
of_PIN
product_NN
identification_NOMZ
or_CC
agreement_NOMZ
of_PIN
the_DT
parties_NN
._.
SUS_NN
became_VBD
involved_VBN
with_PIN
phentermine_NN
through_PIN
its_PIT
acquisition_NOMZ
of_PIN
certain_JJ
assets_NN
of_PIN
Rexar_NN
Pharmacal_NN
Corporation_NOMZ
Rexar_NN
in_PIN
January_NN
1994_CD
._.
In_CONJ
addition_NULL
to_PIN
SUS_NN
potentially_RB
incurring_VBG
liability_NOMZ
as_CONJ
a_NULL
result_NULL
of_PIN
its_PIT
own_JJ
production_NOMZ
of_PIN
Oby-Cap_NN
,_,
a_DT
phentermine_JJ
product_NN
,_,
the_DT
plaintiffs_NN
may_POMD [SPAU]
additionally_RB
seek_VB
to_TO
impose_VB
liability_NOMZ
on_PIN
SUS_NN
as_IN
successor_NN
to_PIN
Rexar_NN
._.
SUS_NN
intends_VPRT [SUAV]
to_TO
defend_VB
vigorously_RB
all_QUAN
the_DT
lawsuits_NN
._.
SUS_NN
denies_VPRT [PUBV]
liability_NOMZ
on_PIN
a_DT
number_NN
of_PIN
grounds_NN
including_VBG [WZPRES]
lack_NN
of_PIN
scientific_JJ
evidence_NN
that_DEMO
phentermine_NN
,_,
properly_RB
prescribed_VBN
,_,
causes_VPRT
the_DT
alleged_JJ
side_NN
effects_NN
and_CC
that_THVC
SUS_NN
did_VBD
not_XX0
promote_VB
phentermine_NN
for_PIN
long-term_JJ
combined_VBN
use_NN
as_IN
part_NN
of_PIN
the_DT
fen_NN
phen_NN
diet_NN
._.
Accordingly_RB
,_,
SUS_NN
intends_VPRT [SUAV]
to_TO
defend_VB
vigorously_RB
any_QUAN
and_CC
all_QUAN
claims_NN
made_VBN [WZPAST]
against_PIN
the_DT
Company_NN
in_PIN
respect_NN
of_PIN
phentermine_NN
._.
Legal_JJ
expenses_NN
to_PIN
date_NN
have_VPRT [PEAS]
been_VBN [BYPA]
paid_VBN
by_PIN
Eon_NN
Labs_NN
,_,
Inc._NN
._.
Eon_NN
,_,
the_DT
supplier_NN
to_PIN
SUS_NN
,_,
or_CC
Eons_NN
insurance_NN
carriers_NN
but_CC
such_JJ
insurance_NN
is_VPRT [SPAU] [PASS]
now_TIME
exhausted_VBN
._.
Eon_NN
has_VPRT [PEAS]
agreed_VBN [SUAV] [PUBV]
to_TO
defend_VB
and_PHC
indemnify_VB
SUS_NN
in_PIN
this_DEMO
litigation_NOMZ
pursuant_JJ
to_PIN
an_DT
agreement_NOMZ
dated_VBN
November_NN
30_CD
,_,
2000_CD
between_PIN
Eon_NN
and_PHC
SUS_NN
._.
ADDERALL_NN
XR_NN
a_DT
Barr_NN
Laboratories_NN
,_,
Inc._NN
._.
Shires_NN
extended_VBD
release_NN
once_TIME
daily_JJ
version_NN
of_PIN
ADDERALL_NN
,_,
ADDERALL_NN
XR_NN
is_VPRT [BYPA]
covered_VBN
by_PIN
US_FPP1
patent_NN
No._NN
._.
6,322,819_CD
the_DT
819_CD
Patent_NN
and_PHC
US_FPP1
patent_NN
No._NN
._.
In_PIN
January_NN
2003_CD
the_DT
Company_NN
was_VBD [PASS]
notified_VBN
that_DEMO
Barr_NN
had_VBD [PEAS]
submitted_VBN [PUBV]
an_DT
ANDA_NN
under_IN
the_DT
Hatch-Waxman_NN
Act_NN
seeking_VBG [WZPRES]
permission_NN
to_TO
market_VB
its_PIT
generic_JJ
versions_NN
of_PIN
the_DT
5mg_JJ
,_,
10mg_JJ
,_,
15mg_JJ
,_,
20mg_JJ
,_,
25mg_JJ
and_PHC
30mg_JJ
strengths_NN
of_PIN
ADDERALL_NN
XR_NN
Barrs_NN
ANDA_NN
products_NN
prior_RB
to_PIN
the_DT
expiration_NOMZ
date_NN
of_PIN
the_DT
Companys_NN
819_CD
Patent_NN
,_,
and_ANDC
alleging_VBG [PUBV]
that_THVC
the_DT
819_CD
Patent_NN
is_VPRT [BYPA]
not_XX0
infringed_VBN
by_PIN
Barrs_NN
ANDA_NN
products_NN
._.
In_PIN
August_NN
2003_CD
Shire_NN
was_VBD [PASS]
notified_VBN
that_DEMO
Barr_NN
also_RB
was_VBD
seeking_VBG
permission_NN
to_TO
market_VB
its_PIT
ANDA_NN
products_NN
prior_RB
to_PIN
the_DT
expiration_NOMZ
date_NN
of_PIN
the_DT
300_CD
Patent_NN
and_CC
alleging_VBG [PUBV]
that_THVC
the_DT
300_CD
Patent_NN
is_VPRT [BEMA]
invalid_PRED
._.
Shire_NN
Laboratories_NN
,_,
Inc_NN
,_,
Shire_NN
Laboratories_NN
filed_VBD
suit_NN
against_PIN
Barr_NN
for_PIN
infringement_NOMZ
of_PIN
the_DT
819_CD
Patent_NN
in_PIN
February_NN
2003_CD
and_CC
for_PIN
infringement_NOMZ
of_PIN
the_DT
300_CD
Patent_NN
in_PIN
September_NN
2003_CD
._.
The_DT
schedules_NN
for_PIN
the_DT
lawsuits_NN
against_PIN
Barr_NN
with_PIN
respect_NN
to_PIN
the_DT
819_CD
and_CC
300_CD
Patents_NN
were_VBD [PASS]
consolidated_VBN
in_PIN
December_NN
2003_CD
._.
The_DT
Company_NN
is_VPRT
seeking_VBG
a_DT
ruling_NN
that_TSUB
Barrs_VPRT
ANDA_NN
and_PHC
ANDA_NN
products_NN
infringe_VPRT
the_DT
819_CD
and_CC
300_CD
Patents_NN
and_CC
that_THVC
its_PIT
ANDA_NN
should_NEMD
not_XX0
be_VB [PASS]
approved_VBN
before_IN
the_DT
expiration_NOMZ
date_NN
of_PIN
the_DT
patents_NN
._.
The_DT
Company_NN
is_VPRT [SPAU]
also_RB
seeking_VBG
injunctions_NOMZ
to_TO
prevent_VB
Barr_NN
from_PIN
commercializing_VBG
its_PIT
ANDA_NN
products_NN
before_IN
the_DT
expiration_NOMZ
of_PIN
the_DT
819_CD
and_CC
300_CD
Patents_NN
,_,
damages_NN
in_PIN
the_DT
event_NN
that_TOBJ
Barr_NN
should_NEMD
engage_VB
in_PIN
such_JJ
commercialization_NOMZ
,_,
and_ANDC
its_PIT
attorneys_NN
fees_NN
and_PHC
costs_NN
._.
On_PIN
September_NN
27_CD
,_,
2004_CD
Barr_NN
filed_VBD
an_DT
amended_VBN
Answer_NN
,_,
Affirmative_NN
Defense_NN
and_PHC
Counterclaim_NN
in_PIN
which_WDT [PIRE]
Barr_NN
added_VBD [PUBV]
the_DT
following_VBG
counterclaims_NN
:_:
invalidity_NOMZ
of_PIN
the_DT
819_CD
patent_NN
,_,
non-infringement_NOMZ
of_PIN
the_DT
300_CD
Patent_NN
and_PHC
unenforceability_NOMZ
of_PIN
the_DT
819_CD
and_CC
300_CD
Patents_NN
due_JJ
to_PIN
inequitable_JJ
conduct_NN
._.
Shire_NN
has_VPRT [PEAS]
asserted_VBN [PUBV]
affirmative_JJ
defenses_NN
,_,
alleging_VBG [PUBV]
,_,
among_PIN
other_JJ
things_NN
,_,
that_THVC
Barr_NN
has_VPRT [PEAS]
waived_VBN
its_PIT
right_NN
to_TO
assert_VB [PUBV] [THATD]
the_DT
counterclaims_NN
set_VBN [WZPAST]
forth_RB
in_PIN
its_PIT
September_NN
27_CD
,_,
2004_CD
amended_VBN
Answer_NN
._.
Under_IN
the_DT
Courts_NN
schedule_NN
summary_NN
judgment_NOMZ
motions_NOMZ
were_VBD
to_TO
be_VB [PASS]
filed_VBN
and_CC
fully_AMP
briefed_VBN
by_PIN
October_NN
14_CD
,_,
2005_CD
._.
Neither_SYNE
Shire_NN
nor_SYNE
Barr_NN
filed_VBD
summary_NN
judgment_NOMZ
motions_NOMZ
._.
On_PIN
December_NN
9_CD
,_,
2005_CD
,_,
the_DT
Court_NN
continued_VBD
the_DT
final_JJ
pre-trial_JJ
conference_NN
to_PIN
March_NN
10_CD
,_,
2006_CD
._.
Shires_NN
lawsuits_NN
triggered_VBD
stays_NN
of_PIN
final_JJ
FDA_NN
approval_NN
of_PIN
Barrs_NN
ANDA_NN
of_PIN
up_RB
to_PIN
30_CD
months_NN
from_PIN
the_DT
date_NN
of_PIN
the_DT
Companys_NN
receipt_NN
of_PIN
Barrs_NN
notice_NN
letters_NN
._.
The_DT
second_JJ
and_PHC
final_JJ
30-month_JJ
stay_NN
related_VBN [WZPAST]
to_PIN
the_DT
lawsuit_NN
regarding_VBG [WZPRES]
the_DT
300_CD
Patent_NN
expired_VBD
on_PIN
February_NN
18_CD
,_,
2006_CD
._.
As_IN
the_DT
stay_NN
has_VPRT [PEAS]
expired_VBN
,_,
the_DT
FDA_NN
may_POMD
approve_VB
Barrs_NN
ANDA_NN
,_,
subject_JJ
to_PIN
satisfaction_NOMZ
by_PIN
Barr_NN
of_PIN
the_DT
FDAs_NN
requirements_NOMZ
._.
Barr_NN
could_POMD
be_VB [BEMA]
in_PIN
a_DT
position_NOMZ
to_TO
market_VB
its_PIT
ANDA_NN
products_NN
upon_PIN
receipt_NN
of_PIN
final_JJ
FDA_NN
approval_NN
._.
On_PIN
October_NN
19_CD
,_,
2005_CD
Shire_NN
brought_VBD
another_DT
lawsuit_NN
against_PIN
Barr_NN
in_PIN
the_DT
Southern_NN
District_NN
of_PIN
New_NN
York_NN
alleging_VBG [PUBV] [WZPRES]
infringement_NOMZ
of_PIN
US_FPP1
Patent_NN
No._NN
._.
The_DT
Company_NN
is_VPRT
seeking_VBG
an_DT
injunction_NOMZ
to_TO
prevent_VB
Barr_NN
from_PIN
infringing_VBG
the_DT
768_CD
Patent_NN
,_,
damages_NN
in_PIN
the_DT
event_NN
that_TOBJ
Barr_NN
should_NEMD
commercialize_VB
its_PIT
ANDA_NN
Products_NN
,_,
attorneys_NN
fees_NN
and_PHC
costs_NN
._.
Barr_NN
has_VPRT [PEAS]
moved_VBN [SUAV]
to_TO
dismiss_VB
this_DEMO
action_NOMZ
asserting_VBG [PUBV] [WZPRES]
that_THVC
there_EX
is_VPRT
no_SYNE
subject_JJ
matter_NN
jurisdiction_NOMZ
._.
A_DT
hearing_GER
on_PIN
this_DEMO
motion_NOMZ
was_VBD [PASS]
held_VBN [PRIV]
on_PIN
February_NN
17_CD
,_,
2006_CD
._.
No_SYNE
decision_NN
on_PIN
this_DEMO
motion_NOMZ
has_VPRT [SPAU] [PEAS]
yet_RB
been_VBN [PASS]
made_VBN
._.
110_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
111_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
Dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
21_CD
Commitments_NOMZ
and_PHC
contingencies_NN
continued_VBD
ADDERALL_NN
XR_NN
continued_VBD
b_NN
Impax_NN
Laboratories_NN
Inc._NN
._.
In_PIN
November_NN
2003_CD
,_,
Shire_NN
was_VBD [PASS]
notified_VBN
that_DEMO
Impax_NN
Laboratories_NN
,_,
Inc._NN
._.
Impax_NN
had_VBD [PEAS]
submitted_VBN [PUBV]
an_DT
ANDA_NN
under_IN
the_DT
Hatch-Waxman_NN
Act_NN
seeking_VBG [WZPRES]
permission_NN
to_TO
market_VB
its_PIT
generic_JJ
version_NN
of_PIN
the_DT
30mg_JJ
strength_NN
of_PIN
ADDERALL_NN
XR_NN
Impaxs_NN
ANDA_NN
product_NN
prior_RB
to_PIN
the_DT
expiration_NOMZ
date_NN
of_PIN
the_DT
819_CD
and_CC
300_CD
Patents_NN
._.
In_PIN
December_NN
2003_CD
,_,
Shire_NN
Laboratories_NN
filed_VBD
suit_NN
against_PIN
Impax_NN
for_PIN
infringement_NOMZ
of_PIN
the_DT
819_CD
and_CC
300_CD
Patents_NN
._.
In_PIN
December_NN
2004_CD
,_,
Shire_NN
received_VBD
an_DT
additional_JJ
notification_NOMZ
from_PIN
Impax_NN
advising_VBG [WZPRES]
of_PIN
the_DT
filing_NN
of_PIN
an_DT
amendment_NOMZ
to_PIN
its_PIT
ANDA_NN
for_PIN
a_DT
generic_JJ
version_NN
of_PIN
the_DT
5mg_JJ
,_,
10mg_JJ
,_,
15mg_JJ
,_,
20mg_JJ
and_PHC
25mg_JJ
strengths_NN
of_PIN
ADDERALL_NN
XR_NN
in_CONJ
addition_NULL
to_PIN
the_DT
30mg_JJ
strength_NN
,_,
the_DT
subject_NN
of_PIN
Impaxs_NN
initial_JJ
ANDA_NN
submission_NN
._.
In_PIN
January_NN
2005_CD
,_,
Shire_NN
Laboratories_NN
filed_VBD
suit_NN
against_PIN
Impax_NN
for_PIN
infringement_NOMZ
of_PIN
the_DT
819_CD
and_CC
300_CD
Patents_NN
._.
As_IN
part_NN
of_PIN
the_DT
October_NN
19_CD
,_,
2005_CD
lawsuit_NN
against_PIN
Barr_NN
,_,
Shire_NN
also_RB
brought_VBD
suit_NN
in_PIN
the_DT
Southern_NN
District_NN
of_PIN
New_NN
York_NN
against_PIN
Impax_NN
for_PIN
infringing_VBG
the_DT
768_CD
Patent_NN
._.
Impax_NN
filed_VBD
a_DT
declaratory_JJ
judgment_NOMZ
action_NOMZ
in_PIN
Delaware_NN
alleging_VBG [PUBV] [WZPRES]
that_THVC
the_DT
768_CD
Patent_NN
was_VBD [BEMA]
invalid_PRED
and_CC
that_THVC
its_PIT
ANDA_NN
did_VBD
not_XX0
infringe_VB
the_DT
768_CD
Patent_NN
._.
On_PIN
January_NN
19_CD
,_,
2006_CD
,_,
Shire_NN
and_PHC
Impax_NN
announced_VBD [PUBV]
that_THVC
all_QUAN
pending_VBG
litigation_NOMZ
in_PIN
connection_NOMZ
with_PIN
Impaxs_NN
ANDA_NN
had_VBD [PEAS]
been_VBN [PASS]
settled_VBN
._.
As_IN
part_NN
of_PIN
the_DT
settlement_NOMZ
,_,
Impax_NN
confirmed_VBD [PUBV]
that_THVC
its_PIT
proposed_VBN [SUAV] [THATD]
generic_JJ
products_NN
infringe_VPRT
Shires_NN
819_CD
,_,
300_CD
and_CC
768_CD
Patents_NN
and_CC
that_THVC
the_DT
three_CD
patents_NN
are_VPRT [BEMA]
valid_PRED
and_PHC
enforceable_PRED
._.
Under_IN
the_DT
terms_NN
of_PIN
the_DT
settlement_NOMZ
agreement_NOMZ
,_,
Impax_NN
will_PRMD
be_VB [PASS]
permitted_VBN
to_PIN
market_NN
generic_JJ
versions_NN
of_PIN
ADDERALL_NN
XR_NN
in_PIN
the_DT
United_NN
States_NN
no_RB
later_TIME
than_PIN
January_NN
1_CD
,_,
2010_CD
and_CC
will_PRMD
pay_VB
Shire_NN
a_DT
royalty_NN
from_PIN
those_DEMO
sales_NN
._.
In_PIN
certain_JJ
situations_NOMZ
,_,
such_JJ
as_IN
the_DT
launch_NN
of_PIN
another_DT
generic_JJ
version_NN
of_PIN
ADDERALL_NN
XR_NN
,_,
Impax_NN
may_POMD
be_VB [PASS]
permitted_VBN
to_TO
enter_VB
the_DT
market_NN
as_IN
Shires_NN
authorized_VBD
generic_JJ
._.
No_SYNE
payments_NOMZ
to_PIN
Impax_NN
are_VPRT [PASS]
involved_VBN
in_PIN
the_DT
settlement_NOMZ
agreement_NOMZ
._.
The_DT
settlement_NOMZ
agreement_NOMZ
,_,
which_WDT [SERE]
was_VBD [BEMA]
effective_JJ
immediately_TIME
,_,
has_VPRT [PEAS]
been_VBN [PASS]
submitted_VBN [PUBV]
to_PIN
the_DT
United_NN
States_NN
Federal_NN
Trade_NN
Commission_NN
for_PIN
its_PIT
review_NN
,_,
as_IN
required_VBN [SUAV]
by_PIN
law_NN
._.
In_PIN
December_NN
2004_CD
,_,
Shire_NN
was_VBD [PASS]
notified_VBN
that_DEMO
Colony_NN
Pharmaceuticals_NN
,_,
Inc._NN
._.
Colony_NN
had_VBD [PEAS]
submitted_VBN [PUBV]
an_DT
ANDA_NN
under_IN
the_DT
Hatch-Waxman_NN
Act_NN
seeking_VBG [WZPRES]
permission_NN
to_TO
market_VB
its_PIT
generic_JJ
versions_NN
of_PIN
the_DT
5mg_JJ
,_,
10mg_JJ
,_,
15mg_JJ
,_,
20mg_JJ
,_,
25mg_JJ
and_PHC
30mg_JJ
strengths_NN
of_PIN
ADDERALL_NN
XR_NN
prior_RB
to_PIN
the_DT
expiration_NOMZ
date_NN
of_PIN
the_DT
Companys_NN
819_CD
and_CC
300_CD
Patents_NN
._.
Shire_NN
has_VPRT [PEAS]
chosen_VBN
not_XX0
to_TO
sue_VB
Colony_NN
._.
In_PIN
February_NN
2005_CD
,_,
Shire_NN
was_VBD [PASS]
notified_VBN
that_DEMO
Teva_NN
Pharmaceuticals_NN
,_,
Inc._NN
._.
Teva_NN
had_VBD [PEAS]
submitted_VBN [PUBV]
an_DT
ANDA_NN
under_IN
the_DT
Hatch-Waxman_NN
Act_NN
seeking_VBG [WZPRES]
permission_NN
to_TO
market_VB
its_PIT
generic_JJ
versions_NN
of_PIN
the_DT
10mg_JJ
and_PHC
30mg_JJ
strengths_NN
of_PIN
ADDERALL_NN
XR_NN
prior_RB
to_PIN
the_DT
expiration_NOMZ
date_NN
of_PIN
the_DT
Companys_NN
819_CD
and_CC
300_CD
Patents_NN
._.
In_PIN
June_NN
2005_CD
,_,
Shire_NN
was_VBD [PASS]
notified_VBN
that_DEMO
Teva_NN
had_VBD [PEAS]
amended_VBN
its_PIT
ANDA_NN
to_TO
seek_VB
permission_NN
to_PIN
market_NN
additional_JJ
strengths_NN
of_PIN
5mg_CD
,_,
15mg_CD
and_CC
20mg_CD
of_PIN
its_PIT
generic_JJ
ADDERALL_NN
XR_NN
prior_RB
to_PIN
the_DT
expiration_NOMZ
of_PIN
the_DT
819_CD
and_CC
300_CD
Patents_NN
._.
In_PIN
January_NN
2006_CD
,_,
Shire_NN
received_VBD
a_DT
third_JJ
notice_NN
letter_NN
that_TOBJ
Teva_NN
had_VBD
further_JJ
amended_VBN
its_PIT
ANDA_NN
to_TO
seek_VB
permission_NN
to_TO
market_VB
the_DT
25mg_JJ
strength_NN
generic_JJ
version_NN
of_PIN
ADDERALL_NN
XR_NN
prior_RB
to_PIN
the_DT
expiration_NOMZ
of_PIN
the_DT
819_CD
and_CC
300_CD
Patents_NN
._.
On_PIN
March_NN
2_CD
,_,
2006_CD
Shire_NN
filed_VBD
a_DT
lawsuit_NN
in_PIN
the_DT
Eastern_NN
District_NN
of_PIN
Pennsylvania_NN
alleging_VBG [PUBV] [WZPRES]
that_THVC
Tevas_NN
ANDA_NN
products_NN
infringe_VPRT
both_DT
the_DT
819_CD
and_CC
300_CD
Patents_NN
._.
The_DT
lawsuit_NN
will_PRMD
trigger_VB
a_DT
stay_NN
of_PIN
FDA_NN
approval_NN
of_PIN
Tevas_NN
25mg_JJ
strength_NN
product_NN
for_PIN
up_RB
to_PIN
30_CD
months_NN
from_PIN
the_DT
date_NN
of_PIN
the_DT
Companys_NN
receipt_NN
of_PIN
Tevas_NN
notice_NN
._.
There_EX
is_VPRT
no_SYNE
such_JJ
stay_NN
with_PIN
respect_NN
to_PIN
Tevas_NN
5mg_CD
,_,
10mg_CD
,_,
15mg_CD
,_,
20mg_JJ
and_PHC
30mg_JJ
strength_NN
versions_NN
of_PIN
ADDERALL_NN
XR_NN
._.
None_INPR
of_PIN
Barr_NN
,_,
Colony_NN
or_CC
Teva_NN
may_POMD
launch_VB
their_TPP3
generic_JJ
versions_NN
of_PIN
ADDERALL_NN
XR_NN
before_IN
they_TPP3
receive_VPRT
final_JJ
FDA_NN
approval_NN
of_PIN
their_TPP3
respective_JJ
ANDAs_NN
._.
The_DT
FDA_NN
may_POMD
grant_VB [SUAV]
180_CD
days_NN
of_PIN
generic_JJ
market_NN
exclusivity_NOMZ
to_PIN
Barr_NN
as_IN
the_DT
first_JJ
to_TO
file_VB
an_DT
ANDA_NN
for_PIN
a_DT
generic_JJ
version_NN
of_PIN
ADDERALL_NN
XR_NN
._.
Neither_SYNE
Colony_NN
nor_SYNE
Teva_NN
may_POMD
market_VB
their_TPP3
ANDA_NN
products_NN
until_IN
FDA_NN
final_JJ
approval_NN
of_PIN
their_TPP3
ANDAs_NN
and_CC
upon_PIN
the_DT
expiration_NOMZ
of_PIN
the_DT
first_JJ
to_PIN
files_NN
exclusivity_NOMZ
rights_NN
._.
In_PIN
August_NN
2003_CD
,_,
the_DT
Company_NN
was_VBD [PASS]
notified_VBN
that_DEMO
Nostrum_NN
Pharmaceuticals_NN
,_,
Inc._NN
._.
Nostrum_NN
had_VBD [PEAS]
submitted_VBN [PUBV]
an_DT
ANDA_NN
under_IN
the_DT
Hatch-Waxman_NN
Act_NN
seeking_VBG [WZPRES]
permission_NN
to_TO
market_VB
its_PIT
generic_JJ
version_NN
of_PIN
the_DT
300mg_JJ
strength_NN
of_PIN
CARBATROL_NN
Nostrums_NN
ANDA_NN
product_NN
prior_RB
to_PIN
the_DT
expiration_NOMZ
date_NN
of_PIN
the_DT
Companys_NN
US_FPP1
patents_NN
for_PIN
CARBATROL_NN
,_,
US_FPP1
patent_NN
No._NN
._.
5,912,013_CD
the_DT
013_CD
Patent_NN
and_PHC
US_FPP1
patent_NN
No._NN
._.
The_DT
notification_NOMZ
alleges_VPRT [PUBV]
that_THVC
the_DT
013_CD
and_CC
570_CD
Patents_NN
are_VPRT [BYPA]
not_XX0
infringed_VBN
by_PIN
Nostrums_NN
ANDA_NN
product_NN
._.
On_PIN
September_NN
18_CD
,_,
2003_CD
,_,
Shire_NN
Laboratories_NN
filed_VBD
suit_NN
against_PIN
Nostrum_NN
in_PIN
the_DT
United_NN
States_NN
District_NN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
New_NN
Jersey_NN
alleging_VBG [PUBV] [WZPRES]
infringement_NOMZ
of_PIN
these_DEMO
two_CD
patents_NN
by_PIN
Nostrums_NN
ANDA_NN
and_PHC
ANDA_NN
product_NN
._.
The_DT
Company_NN
was_VBD
seeking_VBG
a_DT
ruling_NN
that_TSUB
Nostrums_VPRT
ANDA_NN
infringes_VPRT
the_DT
013_CD
and_CC
570_CD
Patents_NN
and_CC
should_NEMD
not_XX0
be_VB [PASS]
approved_VBN
before_IN
the_DT
expiration_NOMZ
date_NN
of_PIN
the_DT
013_CD
and_CC
570_CD
Patents_NN
._.
The_DT
Company_NN
was_VBD [SPAU]
also_RB
seeking_VBG
an_DT
injunction_NOMZ
to_TO
prevent_VB
Nostrum_NN
from_PIN
commercializing_VBG
its_PIT
ANDA_NN
product_NN
before_IN
the_DT
expiration_NOMZ
of_PIN
the_DT
013_CD
and_CC
570_CD
Patents_NN
,_,
damages_NN
in_PIN
the_DT
event_NN
that_TOBJ
Nostrum_NN
should_NEMD
engage_VB
in_PIN
such_JJ
commercialization_NOMZ
,_,
as_RB
well_RB
as_IN
its_PIT
attorneys_NN
fees_NN
and_PHC
costs_NN
._.
On_PIN
January_NN
23_CD
,_,
2004_CD
,_,
the_DT
Company_NN
amended_VBD
the_DT
complaint_NN
to_TO
drop_VB
the_DT
allegations_NOMZ
with_PIN
respect_NN
to_PIN
the_DT
013_CD
Patent_NN
while_OSUB
maintaining_VBG [PUBV]
the_DT
suit_NN
with_PIN
respect_NN
to_PIN
the_DT
570_CD
Patent_NN
._.
By_PIN
way_NN
of_PIN
counterclaims_NN
Nostrum_NN
is_VPRT
seeking_VBG
a_DT
declaration_NOMZ
that_TOBJ
the_DT
570_CD
and_CC
013_CD
Patents_NN
are_VPRT [BYPA]
not_XX0
infringed_VBN
by_PIN
Nostrums_NN
ANDA_NN
product_NN
._.
Nostrum_NN
also_RB
was_VBD
seeking_VBG
actual_JJ
and_PHC
punitive_JJ
damages_NN
for_PIN
alleged_JJ
abuse_NN
of_PIN
process_NN
by_PIN
Shire_NN
._.
On_PIN
July_NN
12_CD
,_,
2004_CD
,_,
the_DT
Court_NN
dismissed_VBD
Nostrums_NN
abuse_NN
of_PIN
process_NN
counterclaim_NN
for_PIN
failure_NN
to_TO
state_VB [PUBV]
a_DT
claim_NN
upon_PIN
which_WDT [PIRE]
relief_NN
can_POMD
be_VB [PASS]
granted_VBN [SUAV]
._.
On_PIN
December_NN
10_CD
,_,
2004_CD
,_,
Nostrum_NN
filed_VBD
a_DT
summary_NN
judgment_NOMZ
motion_NOMZ
seeking_VBG [WZPRES]
a_DT
declaration_NOMZ
of_PIN
non-infringement_NOMZ
of_PIN
the_DT
570_CD
Patent_NN
._.
Shires_NN
opposition_NOMZ
to_PIN
this_DEMO
motion_NOMZ
was_VBD [PASS]
filed_VBN
on_PIN
January_NN
14_CD
,_,
2005_CD
._.
The_DT
Court_NN
heard_VBD [PRIV]
arguments_NOMZ
with_PIN
respect_NN
to_PIN
Nostrums_NN
motion_NOMZ
on_PIN
July_NN
15_CD
,_,
2005_CD
._.
At_PIN
the_DT
conclusion_NN
of_PIN
the_DT
hearing_VBG [PRIV] [THATD]
the_DT
Court_NN
denied_VBD [PUBV]
Nostrums_NN
motion_NOMZ
for_PIN
summary_NN
judgment_NOMZ
of_PIN
non-infringement_NOMZ
._.
The_DT
parties_NN
have_VPRT [PEAS]
been_VBN [BYPA]
directed_VBN
by_PIN
the_DT
Court_NN
to_TO
propose_VB [SUAV]
a_DT
schedule_NN
for_PIN
expert_NN
depositions_NOMZ
and_PHC
claim_NN
construction_NOMZ
briefing_GER
._.
No_SYNE
trial_NN
date_NN
has_VPRT [PEAS]
been_VBN [PASS]
set_VBN
._.
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
111_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
112_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
Dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
21_CD
Commitments_NOMZ
and_PHC
contingencies_NN
continued_VBD
Nostrum_NN
may_POMD
not_XX0
launch_VB
a_DT
generic_JJ
version_NN
of_PIN
CARBATROL_NN
before_IN
it_PIT
receives_VPRT
final_JJ
approval_NN
of_PIN
its_PIT
ANDA_NN
from_PIN
the_DT
FDA_NN
._.
The_DT
lawsuit_NN
triggered_VBD
a_DT
stay_NN
of_PIN
FDA_NN
approval_NN
of_PIN
up_RB
to_PIN
30_CD
months_NN
from_PIN
Shires_NN
receipt_NN
of_PIN
Nostrums_NN
notice_NN
letter_NN
._.
The_DT
30-month_JJ
stay_NN
expired_VBD
on_PIN
February_NN
6_CD
,_,
2006_CD
._.
Following_VBG
expiry_NN
of_PIN
the_DT
stay_NN
,_,
Nostrum_NN
could_POMD
be_VB [BEMA]
in_PIN
a_DT
position_NOMZ
to_TO
market_VB
its_PIT
300mg_JJ
extended-release_NN
carbamazepine_NN
product_NN
upon_PIN
FDA_NN
final_JJ
approval_NN
of_PIN
its_PIT
ANDA_NN
._.
GA-GCB_NN
In_PIN
January_NN
2005_CD
,_,
Genzyme_NN
Corporation_NOMZ
Genzyme_NN
filed_VBD
suit_NN
against_PIN
TKT_NN
in_PIN
the_DT
District_NN
Court_NN
of_PIN
Tel_NN
Aviv-Jaffa_NN
,_,
Israel_NN
,_,
claiming_VBG [PUBV]
that_THVC
TKTs_NN
Phase_NN
1_CD
2_CD
clinical_JJ
trial_NN
in_PIN
Israel_NN
evaluating_VBG [WZPRES]
GA-GCB_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
Gaucher_NN
Disease_NN
infringes_VPRT
one_CD
or_CC
more_EMPH
claims_NN
of_PIN
Genzymes_NN
Israeli_NN
Patent_NN
No._NN
._.
In_CONJ
addition_NULL
,_,
Genzyme_NN
filed_VBD
a_DT
motion_NOMZ
for_PIN
preliminary_JJ
injunction_NOMZ
,_,
including_VBG [PRESP]
a_DT
request_NN
for_PIN
an_DT
ex_FW
parte_FW
hearing_GER
and_PHC
relief_NN
on_PIN
the_DT
merits_NN
,_,
to_TO [SPIN]
immediately_TIME
seize_VB
and_PHC
destroy_VB
all_QUAN
GA-GCB_NN
being_VBG [WZPRES] [PASS]
used_VBN
to_TO
treat_VB
patients_NN
and_CC
to_TO
prevent_VB
TKT_NN
from_PIN
submitting_VBG [PUBV] [THATD]
data_NN
generated_VBD
from_PIN
the_DT
clinical_JJ
trial_NN
to_PIN
regulatory_JJ
agencies_NN
._.
In_PIN
March_NN
2005_CD
the_DT
District_NN
Court_NN
refused_VBD
to_TO
grant_VB [SUAV]
Genzymes_NN
motion_NOMZ
for_PIN
a_DT
preliminary_JJ
injunction_NOMZ
._.
The_DT
lawsuit_NN
was_VBD [PASS]
dismissed_VBN
in_PIN
January_NN
2006_CD
._.
DYNEPO_NN
In_PIN
April_NN
1997_CD
,_,
Amgen_NN
Inc._NN
._.
Amgen_NN
commenced_VBD
a_DT
patent_NN
infringement_NOMZ
action_NOMZ
against_PIN
TKT_NN
and_PHC
Sanofi-Aventis_NN
in_PIN
the_DT
United_NN
States_NN
District_NN
Court_NN
of_PIN
Massachusetts_NN
._.
In_PIN
January_NN
2001_CD
,_,
the_DT
United_NN
States_NN
District_NN
Court_NN
of_PIN
Massachusetts_NN
concluded_VBD [PRIV]
that_THVC
DYNEPO_NN
infringed_VBD
eight_CD
of_PIN
the_DT
18_CD
claims_NN
of_PIN
five_CD
patents_NN
that_TOBJ
Amgen_NN
had_VBD [PEAS]
asserted_VBN [PUBV]
._.
Amgen_NN
did_VBD
not_XX0
seek_VB
and_PHC
was_VBD [PASS]
not_XX0
awarded_VBN
monetary_JJ
damages_NN
._.
This_DEMO
decision_NN
was_VBD [SPAU] [PASS]
subsequently_TIME
appealed_VBN
to_PIN
the_DT
United_NN
States_NN
Court_NN
of_PIN
Appeals_NN
for_PIN
the_DT
Federal_NN
Circuit_NN
._.
In_PIN
January_NN
2003_CD
,_,
the_DT
United_NN
States_NN
Court_NN
of_PIN
Appeals_NN
for_PIN
the_DT
Federal_NN
Circuit_NN
issued_VBD
a_DT
decision_NN
affirming_VBG [PUBV] [WZPRES]
in_PIN
part_NN
and_CC
reversing_VBG
in_PIN
part_NN
the_DT
decision_NN
of_PIN
the_DT
United_NN
States_NN
District_NN
Court_NN
of_PIN
Massachusetts_NN
,_,
remanded_VBD
the_DT
action_NOMZ
to_PIN
the_DT
United_NN
States_NN
District_NN
Court_NN
of_PIN
Massachusetts_NN
for_PIN
further_JJ
proceedings_GER
and_CC
instructed_VBD [SUAV]
the_DT
United_NN
States_NN
District_NN
Court_NN
of_PIN
Massachusetts_NN
to_TO
reconsider_VB
the_DT
validity_NOMZ
of_PIN
Amgens_NN
patents_NN
in_PIN
the_DT
light_NN
of_PIN
potentially_RB
invalidating_VBG
prior_RB
art_NN
._.
In_PIN
October_NN
2004_CD
,_,
the_DT
United_NN
States_NN
District_NN
Court_NN
of_PIN
Massachusetts_NN
issued_VBD
a_DT
decision_NN
on_PIN
the_DT
remanded_VBN
issues_NN
,_,
finding_VBG [PRIV]
that_THVC
certain_JJ
claims_NN
related_VBN [WZPAST]
to_PIN
four_CD
patents_NN
held_VBN [PRIV] [WZPAST]
by_PIN
Amgen_NN
are_VPRT [BYPA]
infringed_VBN
by_PIN
TKT_NN
and_PHC
Sanofi-Aventis_NN
._.
In_PIN
December_NN
2004_CD
,_,
TKT_NN
and_PHC
Sanofi-Aventis_NN
filed_VBD
a_DT
notice_NN
of_PIN
appeal_NN
of_PIN
the_DT
decision_NN
of_PIN
the_DT
United_NN
States_NN
District_NN
Court_NN
of_PIN
Massachusetts_NN
to_PIN
the_DT
United_NN
States_NN
Court_NN
of_PIN
Appeals_NN
for_PIN
the_DT
Federal_NN
Circuit_NN
._.
An_DT
oral_JJ
hearing_GER
was_VBD [PASS]
held_VBN [PRIV]
at_PIN
the_DT
Federal_NN
Circuit_NN
in_PIN
December_NN
2005_CD
._.
No_SYNE
decision_NN
has_VPRT [PEAS]
been_VBN [PASS]
rendered_VBN
at_PIN
this_DEMO
time_NN
._.
If_COND
TKT_NN
and_PHC
Sanofi-Aventis_NN
are_VPRT [BEMA]
not_XX0
successful_PRED
in_PIN
the_DT
DYNEPO_NN
litigation_NOMZ
at_PIN
the_DT
appellate_JJ
level_NN
,_,
TKT_NN
and_PHC
Sanofi-Aventis_NN
would_PRMD
be_VB [PASS]
precluded_VBN
from_PIN
making_VBG
,_,
using_VBG
and_PHC
selling_VBG
DYNEPO_NN
in_PIN
the_DT
United_NN
States_NN
until_IN
the_DT
expiration_NOMZ
of_PIN
the_DT
relevant_JJ
patents_NN
._.
TKT_NN
is_VPRT [PASS]
required_VBN [SUAV]
to_TO
reimburse_VB
Sanofi-Aventis_NN
,_,
which_WDT [SERE]
controls_VPRT
the_DT
litigation_NOMZ
and_CC
is_VPRT
paying_VBG
the_DT
litigation_NOMZ
expenses_NN
,_,
for_PIN
50_CD
%_NN
of_PIN
the_DT
expenses_NN
incurred_VBN [WZPAST]
in_PIN
connection_NOMZ
with_PIN
the_DT
litigation_NOMZ
from_PIN
and_CC
after_IN
March_NN
26_CD
,_,
2004_CD
._.
In_PIN
the_DT
event_NN
that_DEMP
Sanofi-Aventis_NN
launches_VPRT
DYNEPO_NN
in_PIN
the_DT
US_FPP1
,_,
Sanofi-Aventis_NN
is_VPRT [PASS]
entitled_VBN
to_TO
deduct_VB
up_RP
to_PIN
50_CD
%_NN
of_PIN
any_QUAN
royalties_NN
that_DEMP
Sanofi-Aventis_NN
may_POMD [SPAU]
otherwise_CONJ
owe_VB
to_PIN
TKT_NN
with_PIN
respect_NN
to_PIN
the_DT
sale_NN
of_PIN
DYNEPO_NN
until_IN
then_RB
Sanofi-Aventis_NN
has_VPRT [PEAS]
recouped_VBN
the_DT
full_JJ
amount_NN
of_PIN
TKTs_NN
share_NN
of_PIN
the_DT
litigation_NOMZ
expenses_NN
._.
TKT_NN
has_VPRT
the_DT
right_NN
to_TO
control_VB
any_QUAN
other_JJ
litigation_NOMZ
that_TSUB
might_POMD
arise_VB
outside_PLACE
of_PIN
the_DT
United_NN
States_NN
and_CC
is_VPRT [BEMA]
responsible_PRED
for_PIN
all_QUAN
litigation_NOMZ
expenses_NN
incurred_VBN [WZPAST]
in_PIN
connection_NOMZ
with_PIN
such_JJ
litigation_NOMZ
from_PIN
and_CC
after_IN
March_NN
26_CD
,_,
2004_CD
._.
Gene_NN
activation_NOMZ
In_PIN
1996_CD
,_,
Applied_NN
Research_NN
Systems_NN
Holding_GER
N._NN
V._NN
a_DT
wholly-owned_JJ
subsidiary_NN
of_PIN
Serono_NN
S._NN
A._NN
Serono_NN
and_PHC
Cell_NN
Genesys_NN
,_,
became_VBD
involved_VBN
in_PIN
a_DT
patent_NN
interference_NN
involving_VBG [WZPRES]
Seronos_NN
US_FPP1
Patent_NN
No._NN
._.
5,272,071_CD
the_DT
071_CD
Patent_NN
,_,
which_WDT [SERE]
purportedly_RB
covers_VPRT
certain_JJ
methods_NN
of_PIN
gene_NN
activation_NOMZ
._.
In_PIN
June_NN
2004_CD
,_,
the_DT
Board_NN
of_PIN
Patent_NN
Appeals_NN
and_PHC
Interferences_NN
of_PIN
the_DT
US_FPP1
Patent_NN
and_PHC
Trademark_NN
Office_NN
PTO_NN
held_VBD [PRIV]
that_THVC
both_DT
Serono_NN
and_PHC
Cell_NN
Genesys_NN
were_VBD [PASS]
entitled_VBN
to_PIN
certain_JJ
claims_NN
in_PIN
their_TPP3
respective_JJ
patent_NN
and_PHC
patent_NN
application_NOMZ
,_,
and_ANDC
Serono_NN
and_PHC
Cell_NN
Genesys_NN
each_QUAN
appealed_VBD
the_DT
decision_NN
of_PIN
the_DT
interference_NN
to_PIN
the_DT
US_FPP1
District_NN
Court_NN
of_PIN
Massachusetts_NN
and_CC
the_DT
US_FPP1
District_NN
Court_NN
of_PIN
the_DT
District_NN
of_PIN
Columbia_NN
,_,
respectively_RB
._.
TKT_NN
was_VBD [BEMA]
not_XX0
a_DT
party_NN
to_PIN
this_DEMO
interference_NN
._.
In_PIN
August_NN
2004_CD
,_,
Serono_NN
served_VBD
TKT_NN
with_PIN
an_DT
amended_VBN
complaint_NN
in_PIN
the_DT
appeal_NN
of_PIN
the_DT
PTO_NN
decision_NN
that_TSUB
was_VBD [PASS]
filed_VBN
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
of_PIN
Massachusetts_NN
._.
The_DT
amended_VBN
complaint_NN
alleges_VPRT [PUBV]
that_THVC
TKT_NN
infringes_VPRT
Seronos_NN
071_CD
Patent_NN
._.
In_PIN
August_NN
2005_CD
,_,
the_DT
US_FPP1
District_NN
Court_NN
of_PIN
Massachusetts_NN
severed_VBD
and_PHC
stayed_VBD
the_DT
infringement_NOMZ
action_NOMZ
pending_VBG [WZPRES]
resolution_NOMZ
of_PIN
the_DT
interference_NN
claim_NN
at_PIN
the_DT
District_NN
Court_NN
level_NN
._.
Appraisal_NN
rights_NN
In_PIN
connection_NOMZ
with_PIN
Shires_NN
merger_NN
with_PIN
TKT_NN
,_,
former_JJ
holders_NN
of_PIN
approximately_RB
11.7_CD
million_CD
shares_NN
of_PIN
TKT_NN
common_JJ
stock_NN
submitted_VBN [PUBV]
written_VBN [PUBV]
demands_NN
to_PIN
the_DT
Delaware_NN
Court_NN
of_PIN
Chancery_NN
for_PIN
appraisal_NN
of_PIN
these_DEMO
shares_NN
and_CC
,_,
as_CONJ
a_NULL
result_NULL
,_,
elected_VBN
not_XX0
to_TO
accept_VB [PRIV]
the_DT
$_$
37_CD
per_PIN
share_NN
merger_NN
consideration_NOMZ
._.
On_PIN
October_NN
10_CD
,_,
2005_CD
,_,
at_PIN
the_DT
request_NN
of_PIN
one_CD
of_PIN
the_DT
holders_NN
to_TO
tender_VB
365,000_CD
shares_NN
at_PIN
the_DT
merger_NN
price_NN
of_PIN
$_$
37_CD
per_PIN
share_NN
,_,
TKT_NN
filed_VBD
a_DT
motion_NOMZ
to_TO
dismiss_VB
the_DT
holders_NN
demand_NN
._.
On_PIN
October_NN
12_CD
,_,
2005_CD
,_,
the_DT
Delaware_NN
Court_NN
of_PIN
Chancery_NN
granted_VBD [SUAV]
this_DEMO
motion_NOMZ
,_,
and_ANDC
the_DT
holder_NN
tendered_VBD
the_DT
shares_NN
at_PIN
the_DT
merger_NN
consideration_NOMZ
of_PIN
$_$
37_CD
per_PIN
share_NN
._.
Therefore_CONJ
,_,
as_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
,_,
former_JJ
holders_NN
of_PIN
approximately_RB
11.3_CD
million_CD
shares_NN
of_PIN
TKT_NN
common_JJ
stock_NN
maintained_VBD [PUBV]
written_VBN [PUBV]
demands_NN
for_PIN
appraisal_NN
of_PIN
these_DEMO
shares_NN
and_CC
have_VPRT [PEAS]
elected_VBN
not_XX0
to_TO
accept_VB [PRIV]
the_DT
$_$
37_CD
merger_NN
consideration_NOMZ
._.
In_PIN
November_NN
2005_CD
,_,
the_DT
Delaware_NN
Court_NN
of_PIN
Chancery_NN
approved_VBD
a_DT
consolidation_NOMZ
order_NN
filed_VBN [WZPAST]
by_PIN
TKT_NN
whereby_OSUB
actions_NOMZ
brought_VBN [WZPAST]
by_PIN
all_QUAN
petitioners_NN
have_VPRT [PEAS]
been_VBN [PASS]
consolidated_VBN
as_IN
one_CD
case_NN
._.
To_PIN
the_DT
extent_NN
that_TOBJ
the_DT
remaining_VBG
demands_NN
were_VBD [SPAU] [PASS]
validly_RB
asserted_VBN [PUBV]
in_PIN
accordance_NN
with_PIN
the_DT
applicable_JJ
requirements_NOMZ
of_PIN
Delaware_NN
law_NN
and_CC
the_DT
former_JJ
holders_NN
perfect_JJ
their_TPP3
rights_NN
thereunder_NN
,_,
such_JJ
former_JJ
holders_NN
will_PRMD
be_VB [PASS]
entitled_VBN
to_TO
receive_VB
the_DT
fair_JJ
value_NN
of_PIN
these_DEMO
shares_NN
as_IN
determined_VBN [SUAV] [PRIV]
by_PIN
the_DT
Delaware_NN
Court_NN
of_PIN
Chancery_NN
._.
The_DT
determination_NOMZ
of_PIN
fair_JJ
value_NN
will_PRMD
be_VB [PASS]
made_VBN
excluding_VBG
any_QUAN
element_NOMZ
of_PIN
value_NN
arising_VBG [WZPRES]
from_PIN
the_DT
transaction_NOMZ
,_,
such_JJ
as_IN
cost_NN
savings_GER
or_CC
business_NOMZ
synergies_NN
._.
112_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
113_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
Dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
21_CD
Commitments_NOMZ
and_PHC
contingencies_NN
continued_VBD
The_DT
total_JJ
consideration_NOMZ
for_PIN
the_DT
acquisition_NOMZ
of_PIN
TKT_NN
,_,
including_VBG
amounts_NN
payable_JJ
in_PIN
respect_NN
of_PIN
stock_NN
options_NOMZ
and_CC
convertible_JJ
securities_NOMZ
,_,
is_VPRT
approximately_RB
$_$
1.6_CD
billion_CD
at_PIN
the_DT
merger_NN
price_NN
of_PIN
$_$
37_CD
per_PIN
share_NN
._.
This_DEMP
could_POMD
change_VB
if_COND
Shire_NN
is_VPRT [PASS]
required_VBN [SUAV]
to_TO
pay_VB
a_DT
different_JJ
amount_NN
of_PIN
consideration_NOMZ
in_PIN
respect_NN
of_PIN
the_DT
approximately_RB
11.3_CD
million_CD
shares_NN
for_PIN
which_WDT [PIRE]
holders_NN
have_VPRT [PEAS]
asserted_VBN [PUBV]
appraisal_NN
rights_NN
._.
Until_IN
such_JJ
time_NN
as_IN
the_DT
appraisal_NN
process_NN
is_VPRT [BEMA]
complete_PRED
,_,
the_DT
Company_NN
is_VPRT [BEMA]
unable_PRED
to_TO
determine_VB [SUAV] [PRIV]
the_DT
extent_NN
of_PIN
its_PIT
liability_NOMZ
._.
Class_NN
action_NOMZ
shareholder_NN
suit_NN
In_PIN
January_NN
and_PHC
February_NN
2003_CD
,_,
various_JJ
parties_NN
filed_VBD
purported_JJ
class_NN
action_NOMZ
lawsuits_NN
against_PIN
TKT_NN
and_PHC
Richard_NN
Selden_NN
,_,
TKTs_NN
former_JJ
Chief_NN
Executive_NN
Officer_NN
,_,
in_PIN
the_DT
United_NN
States_NN
District_NN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
Massachusetts_NN
._.
The_DT
complaints_NN
generally_RB
allege_VPRT [PUBV]
securities_NOMZ
fraud_NN
during_PIN
the_DT
period_NN
from_PIN
January_NN
2001_CD
through_PIN
January_NN
2003_CD
._.
Each_QUAN
of_PIN
the_DT
complaints_NN
asserts_VPRT [PUBV]
claims_NN
under_IN
Section_NOMZ
10_CD
b_NN
of_PIN
the_DT
Securities_NOMZ
Exchange_NN
Act_NN
of_PIN
1934_CD
,_,
Rule_NN
10b-5_JJ
promulgated_VBN
thereunder_NN
,_,
and_ANDC
Section_NOMZ
20_CD
a_DT
of_PIN
the_DT
Exchange_NN
Act_NN
,_,
and_ANDC
alleges_VPRT [PUBV]
that_THVC
TKT_NN
and_CC
its_PIT
officers_NN
made_VBD
false_JJ
and_PHC
misleading_JJ
statements_NOMZ
and_CC
failed_VBD
to_TO
disclose_VB [PUBV]
material_NN
information_NOMZ
concerning_VBG [WZPRES]
the_DT
status_NN
and_PHC
progress_NN
for_PIN
obtaining_VBG
United_NN
States_NN
marketing_GER
approval_NN
of_PIN
TKTs_NN
REPLAGAL_NN
product_NN
to_TO
treat_VB
Fabry_NN
Disease_NN
during_PIN
that_DEMO
period_NN
._.
In_PIN
March_NN
2003_CD
,_,
various_JJ
plaintiffs_NN
filed_VBD
motions_NOMZ
to_TO
consolidate_VB
,_,
to_TO
appoint_VB
lead_JJ
plaintiff_NN
,_,
and_ANDC
to_TO
approve_VB
plaintiffs_NN
selections_NOMZ
of_PIN
lead_NN
plaintiffs_NN
counsel_NN
._.
In_PIN
April_NN
2003_CD
,_,
various_JJ
plaintiffs_NN
filed_VBD
a_DT
Joint_NN
Stipulation_NOMZ
and_PHC
Proposed_NN
Order_NN
of_PIN
Lead_JJ
Plaintiff_NN
Applicants_NN
to_TO
Consolidate_VB
Actions_NOMZ
,_,
to_TO
Appoint_VB
Lead_JJ
Plaintiffs_NN
and_CC
to_TO
Approve_VB
Lead_JJ
Plaintiffs_NN
Selection_NOMZ
of_PIN
Lead_JJ
Counsel_NN
,_,
Executive_NN
Committee_NN
and_PHC
Liaison_NN
Counsel_NN
._.
In_PIN
April_NN
2003_CD
,_,
the_DT
Court_NN
endorsed_VBD
the_DT
Proposed_NN
Order_NN
,_,
thereby_RB
consolidating_VBG
the_DT
various_JJ
matters_NN
under_IN
one_CD
matter_NN
:_:
In_PIN
re_NN
Transkaryotic_NN
Therapies_NN
,_,
Inc._NN
._.
Securities_NOMZ
Litigation_NOMZ
,_,
C._NN
A._NN
In_PIN
July_NN
2003_CD
,_,
the_DT
plaintiffs_NN
filed_VBD
a_DT
Consolidated_NN
and_PHC
Amended_NN
Class_NN
Action_NOMZ
Complaint_NN
the_DT
Amended_NN
Complaint_NN
against_PIN
TKT_NN
:_:
Dr_NN
Selden_NN
:_:
Daniel_NN
Geffken_NN
,_,
TKTs_NN
former_JJ
Chief_NN
Financial_NN
Officer_NN
:_:
Walter_NN
Gilbert_NN
,_,
Jonathan_NN
S._NN
Leff_NN
,_,
Rodman_NN
W._NN
Moorhead_NN
,_,
III_NN
,_,
and_ANDC
Wayne_NN
P._NN
Yetter_NN
,_,
then_RB
members_NN
of_PIN
TKTs_NN
Board_NN
of_PIN
Directors_NN
:_:
William_NN
R._NN
Miller_NN
and_PHC
James_NN
E._NN
Thomas_NN
,_,
former_JJ
members_NN
of_PIN
TKTs_NN
Board_NN
of_PIN
Directors_NN
:_:
and_ANDC
SG_NN
Cowen_NN
Securities_NOMZ
Corporation_NOMZ
,_,
Deutsche_NN
Bank_NN
Securities_NOMZ
Inc._NN
._.
Pacific_NN
Growth_NN
Equities_NOMZ
,_,
Inc._NN
and_PHC
Leerink_NN
Swann_NN
&_CC
Company_NN
,_,
underwriters_NN
of_PIN
TKTs_NN
common_JJ
stock_NN
in_PIN
prior_JJ
public_JJ
offerings_GER
._.
The_DT
Amended_NN
Complaint_NN
alleges_VPRT [PUBV]
securities_NOMZ
fraud_NN
during_PIN
the_DT
period_NN
from_PIN
January_NN
4_CD
,_,
2001_CD
,_,
through_PIN
January_NN
10_CD
,_,
2003_CD
._.
The_DT
Amended_NN
Complaint_NN
alleges_VPRT [PUBV]
that_THVC
the_DT
defendants_NN
made_VBD
false_JJ
and_PHC
misleading_JJ
statements_NOMZ
and_CC
failed_VBD
to_TO
disclose_VB [PUBV]
material_NN
information_NOMZ
concerning_VBG [WZPRES]
the_DT
status_NN
and_PHC
progress_NN
for_PIN
obtaining_VBG
United_NN
States_NN
marketing_GER
approval_NN
of_PIN
REPLAGAL_NN
during_PIN
that_DEMO
period_NN
._.
The_DT
Amended_NN
Complaint_NN
asserts_VPRT [PUBV]
claims_NN
against_PIN
Dr_NN
Selden_NN
and_PHC
TKT_NN
under_IN
Section_NOMZ
10_CD
b_NN
of_PIN
the_DT
Exchange_NN
Act_NN
and_PHC
Rule_NN
10b-5_JJ
promulgated_VBN
thereunder_NN
:_:
and_ANDC
against_PIN
Dr_NN
Selden_NN
under_IN
Section_NOMZ
20_CD
a_DT
of_PIN
the_DT
Exchange_NN
Act_NN
._.
The_DT
Amended_NN
Complaint_NN
also_RB
asserts_VPRT [PUBV] [THATD]
claims_NN
based_VBN [WZPAST]
on_PIN
TKTs_NN
public_JJ
offerings_GER
of_PIN
June_NN
29_CD
,_,
2001_CD
,_,
December_NN
18_CD
,_,
2001_CD
and_CC
December_NN
26_CD
,_,
2001_CD
,_,
against_PIN
each_QUAN
of_PIN
the_DT
defendants_NN
under_IN
Section_NOMZ
11_CD
of_PIN
the_DT
Securities_NOMZ
Act_NN
of_PIN
1933_CD
and_CC
against_PIN
Dr_NN
Selden_NN
under_IN
Section_NOMZ
15_CD
of_PIN
the_DT
Securities_NOMZ
Act_NN
:_:
and_ANDC
against_PIN
SG_NN
Cowen_NN
Securities_NOMZ
Corporation_NOMZ
,_,
Deutsche_NN
Bank_NN
Securities_NOMZ
Inc._NN
._.
Pacific_NN
Growth_NN
Equities_NOMZ
,_,
Inc._NN
and_PHC
Leerink_NN
Swann_NN
&_CC
Company_NN
under_IN
Section_NOMZ
12_CD
a_DT
2_CD
of_PIN
the_DT
Securities_NOMZ
Act_NN
._.
The_DT
plaintiffs_NN
seek_VPRT
equitable_JJ
and_PHC
monetary_JJ
relief_NN
,_,
an_DT
unspecified_JJ
amount_NN
of_PIN
damages_NN
,_,
with_PIN
interest_NN
,_,
and_ANDC
attorneys_NN
fees_NN
and_PHC
costs_NN
._.
In_PIN
September_NN
2003_CD
,_,
TKT_NN
filed_VBD
a_DT
motion_NOMZ
to_TO
dismiss_VB
the_DT
Amended_NN
Complaint_NN
._.
A_DT
hearing_GER
of_PIN
the_DT
motion_NOMZ
occurred_VBD
in_PIN
December_NN
2003_CD
._.
In_PIN
May_POMD
2004_CD
,_,
the_DT
United_NN
States_NN
District_NN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
Massachusetts_NN
issued_VBD
a_DT
Memorandum_NN
of_PIN
Decision_NN
and_PHC
Order_NN
denying_VBG [PUBV] [WZPRES]
in_PIN
part_NN
and_CC
granting_VBG [SUAV]
in_PIN
part_NN
TKTs_NN
motion_NOMZ
to_TO
dismiss_VB
the_DT
purported_JJ
class_NN
action_NOMZ
lawsuit_NN
._.
In_PIN
the_DT
Memorandum_NN
,_,
the_DT
Court_NN
found_VBD [PRIV]
several_QUAN
allegations_NOMZ
against_PIN
TKT_NN
arose_VBD
out_PIN
of_PIN
forward-looking_JJ
statements_NOMZ
protected_VBN [WZPAST]
by_PIN
the_DT
safe_JJ
harbor_NN
provisions_NN
of_PIN
the_DT
Private_JJ
Securities_NOMZ
Litigation_NOMZ
Reform_NN
Act_NN
of_PIN
1995_CD
PSLRA_NN
._.
The_DT
Court_NN
dismissed_VBD
those_DEMO
statements_NOMZ
as_IN
falling_VBG
within_PIN
the_DT
PSLRAs_NN
safe_JJ
harbor_NN
provisions_NN
._.
The_DT
Court_NN
also_RB
dismissed_VBD
claims_NN
based_VBN [WZPAST]
on_PIN
the_DT
public_JJ
offerings_GER
of_PIN
June_NN
29_CD
,_,
2001_CD
,_,
and_ANDC
December_NN
18_CD
,_,
2001_CD
,_,
because_CAUS
no_SYNE
plaintiff_NN
had_VBD
standing_VBG
to_TO
bring_VB
such_JJ
claims_NN
._.
The_DT
Court_NN
allowed_VBD [SUAV]
all_QUAN
other_JJ
allegations_NOMZ
to_TO
remain_VB
._.
In_PIN
June_NN
2004_CD
,_,
TKT_NN
submitted_VBD [PUBV] [THATD]
an_DT
unopposed_JJ
motion_NOMZ
seeking_VBG [WZPRES]
clarification_NOMZ
from_PIN
the_DT
Court_NN
that_TOBJ
the_DT
Memorandum_NN
dismissed_VBD
claims_NN
based_VBN [WZPAST]
on_PIN
the_DT
first_JJ
two_CD
offerings_GER
as_IN
to_PIN
all_QUAN
defendants_NN
._.
The_DT
Court_NN
granted_VBD [SUAV]
the_DT
motion_NOMZ
._.
In_PIN
July_NN
2004_CD
,_,
the_DT
plaintiffs_NN
voluntarily_RB
dismissed_VBD
all_QUAN
claims_NN
based_VBN [WZPAST]
on_PIN
the_DT
third_JJ
offering_GER
because_CAUS
no_SYNE
plaintiff_NN
had_VBD
standing_VBG
to_TO
bring_VB
such_JJ
claims_NN
._.
The_DT
plaintiffs_NN
subsequently_TIME
filed_VBD
a_DT
motion_NOMZ
seeking_VBG [WZPRES]
permission_NN
to_TO
notify_VB
certain_JJ
TKT_NN
investors_NN
of_PIN
the_DT
dismissal_NN
of_PIN
the_DT
claims_NN
based_VBN [WZPAST]
on_PIN
the_DT
offerings_GER
,_,
and_ANDC
to_TO
inform_VB
those_DEMO
investors_NN
of_PIN
their_TPP3
opportunity_NOMZ
to_TO
intervene_VB
in_PIN
the_DT
lawsuit_NN
._.
TKT_NN
filed_VBD
an_DT
opposition_NOMZ
to_PIN
this_DEMO
motion_NOMZ
in_PIN
July_NN
2004_CD
._.
A_DT
hearing_GER
on_PIN
this_DEMO
motion_NOMZ
was_VBD [PASS]
held_VBN [PRIV]
in_PIN
September_NN
2004_CD
._.
The_DT
Court_NN
denied_VBD [PUBV]
this_DEMO
motion_NOMZ
._.
TKT_NN
filed_VBD
an_DT
answer_NN
to_PIN
the_DT
Amended_NN
Complaint_NN
in_PIN
July_NN
2004_CD
._.
The_DT
plaintiffs_NN
then_RB
filed_VBD
a_DT
motion_NOMZ
for_PIN
class_NN
certification_NOMZ
in_PIN
July_NN
2004_CD
._.
TKT_NN
filed_VBD
an_DT
opposition_NOMZ
to_PIN
this_DEMO
motion_NOMZ
in_PIN
March_NN
2005_CD
,_,
and_ANDC
the_DT
plaintiffs_NN
filed_VBD
a_DT
reply_NN
in_PIN
April_NN
2005_CD
._.
A_DT
hearing_GER
on_PIN
class_NN
certification_NOMZ
was_VBD [PASS]
held_VBN [PRIV]
in_PIN
April_NN
2005_CD
._.
Following_VBG [PRESP]
that_DEMO
hearing_GER
,_,
TKT_NN
filed_VBD
a_DT
supplemental_JJ
brief_NN
in_PIN
opposition_NOMZ
to_PIN
the_DT
motion_NOMZ
for_PIN
class_NN
certification_NOMZ
and_CC
the_DT
plaintiffs_NN
filed_VBD
a_DT
supplemental_JJ
brief_NN
in_PIN
support_NN
of_PIN
the_DT
motion_NOMZ
._.
In_PIN
November_NN
2005_CD
,_,
the_DT
court_NN
granted_VBD [SUAV]
the_DT
plaintiffs_NN
motion_NOMZ
for_PIN
class_NN
certification_NOMZ
._.
On_PIN
September_NN
14_CD
,_,
2005_CD
,_,
the_DT
plaintiffs_NN
filed_VBD
a_DT
Notice_NN
of_PIN
Related_NN
Case_NN
Pursuant_NN
to_PIN
Local_JJ
Rule_NN
40.1_CD
G_NN
,_,
in_PIN
which_WDT [PIRE]
they_TPP3
appeared_VBD [SMP]
to_TO
seek_VB
reassignment_NOMZ
of_PIN
a_DT
matter_NN
filed_VBN [WZPAST]
on_PIN
September_NN
1_CD
,_,
2005_CD
,_,
entitled_VBN
Securities_NOMZ
and_PHC
Exchange_NN
Commission_NN
v._CC
Richard_NN
B._NN
Selden_NN
,_,
Civil_NN
Action_NOMZ
No._NN
._.
the_DT
SEC_NN
Action_NOMZ
,_,
to_PIN
the_DT
court_NN
considering_VBG [PRIV] [WZPRES]
this_DEMO
matter_NN
._.
On_PIN
September_NN
15_CD
,_,
2005_CD
,_,
the_DT
defendants_NN
filed_VBD
a_DT
response_NN
to_PIN
the_DT
notice_NN
,_,
opposing_VBG
reassignment_NOMZ
of_PIN
the_DT
SEC_NN
Action_NOMZ
._.
On_PIN
October_NN
7_CD
,_,
2005_CD
,_,
the_DT
plaintiffs_NN
filed_VBD
a_DT
memorandum_NN
in_PIN
response_NN
to_PIN
the_DT
defendants_NN
response_NN
._.
On_PIN
October_NN
21_CD
,_,
2005_CD
,_,
the_DT
Court_NN
entered_VBD
an_DT
Order_NN
,_,
which_WDT [SERE]
stated_VBD [PUBV]
that_THVC
it_PIT
did_VBD
not_XX0
deem_VB [PRIV] [THATD]
the_DT
cases_NN
related_VBN
under_IN
Local_JJ
Rule_NN
40.1_CD
._.
The_DT
Company_NN
is_VPRT [PASS]
obligated_VBN
to_TO
indemnify_VB
Dr_NN
Selden_NN
for_PIN
his_TPP3
costs_NN
incurred_VBN [WZPAST]
in_PIN
connection_NOMZ
with_PIN
the_DT
SEC_NN
Action_NOMZ
._.
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
113_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
114_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
Dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
22_CD
Shareholders_NN
equity_NOMZ
i_FPP1
Authorized_VBN
common_JJ
stock_NN
The_DT
authorized_VBN
stock_NN
of_PIN
Shire_NN
plc_NN
as_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
was_VBD [BEMA]
18,333,006,420_CD
ordinary_JJ
shares_NN
,_,
10,000,000_CD
special_JJ
voting_NN
shares_NN
,_,
50,000_CD
non-voting_JJ
preference_NN
shares_NN
and_CC
two_CD
deferred_JJ
ordinary_JJ
shares_NN
._.
The_DT
special_JJ
voting_NN
shares_NN
are_VPRT [BYPA]
held_VBN [PRIV]
by_PIN
a_DT
Voting_GER
Trustee_NN
,_,
providing_VBG [PRESP]
the_DT
holders_NN
of_PIN
exchangeable_JJ
shares_NN
in_PIN
Shire_NN
Acquisition_NOMZ
,_,
Inc._NN
with_PIN
as_RB
nearly_DWNT
as_IN
practicable_JJ
voting_NN
rights_NN
equivalent_NN
to_PIN
those_DEMP
attached_VBN
to_PIN
Shires_NN
ordinary_JJ
shares_NN
._.
The_DT
non-voting_JJ
preference_NN
shares_NN
and_CC
deferred_VBN
ordinary_JJ
shares_NN
were_VBD [PASS]
authorized_VBN
and_PHC
issued_VBN
for_PIN
the_DT
purpose_NN
of_PIN
the_DT
Scheme_NN
of_PIN
Arrangement_NOMZ
only_DWNT
and_CC
will_PRMD
be_VB [PASS]
redeemed_VBN
in_PIN
2006_CD
._.
ii_FW
Dividends_NN
Under_IN
English_NN
law_NN
,_,
Shire_NN
can_POMD
pay_VB
dividends_NN
only_DWNT
out_PIN
of_PIN
its_PIT
distributable_JJ
reserves_NN
,_,
defined_VBN
as_IN
the_DT
accumulated_VBN
realized_VBD [PRIV]
profits_NN
under_IN
UK_NN
generally_RB
accepted_VBD [PRIV]
accounting_GER
principles_NN
including_VBG [WZPRES]
reserves_NN
arising_VBG [WZPRES]
from_PIN
a_DT
reduction_NOMZ
of_PIN
share_NN
capital_NN
,_,
of_PIN
the_DT
parent_NN
Company_NN
,_,
Shire_NN
plc_NN
and_CC
not_XX0
the_DT
consolidated_JJ
Group_NN
,_,
so_RB
far_PLACE
as_IN
not_XX0
previously_TIME
utilized_VBN
by_PIN
distribution_NOMZ
or_CC
capitalization_NOMZ
,_,
less_JJ
accumulated_VBN
realized_VBN [PRIV]
losses_NN
,_,
so_RB
far_PLACE
as_IN
not_XX0
previously_TIME
written_VBN [PUBV]
off_PIN
in_PIN
a_DT
reduction_NOMZ
or_CC
reorganization_NOMZ
of_PIN
capital_NN
duly_RB
made_VBD
._.
Shire_NN
can_POMD
make_VB
a_DT
distribution_NOMZ
only_DWNT
if_COND
the_DT
distribution_NOMZ
does_VPRT
not_XX0
reduce_VB
its_PIT
net_JJ
assets_NN
below_PLACE
the_DT
aggregate_NN
of_PIN
the_DT
called-up_JJ
share_NN
capital_NN
and_CC
undistributable_JJ
reserves_NN
._.
Any_QUAN
dividends_NN
will_PRMD
be_VB [BEMA]
at_PIN
the_DT
discretion_NOMZ
of_PIN
the_DT
Board_NN
of_PIN
Directors_NN
,_,
will_PRMD
be_VB [PASS]
declared_VBN [PUBV]
in_PIN
US_FPP1
Dollars_NN
and_CC
will_PRMD
be_VB [PASS]
paid_VBN
in_PIN
Pounds_NN
Sterling_GER
to_PIN
Ordinary_NN
Shareholders_NN
,_,
US_FPP1
Dollars_NN
to_PIN
ADS_NN
holders_NN
and_CC
Canadian_JJ
Dollars_NN
to_PIN
Exchangeable_JJ
Shareholders_NN
._.
At_PIN
December_NN
31_CD
,_,
2005_CD
,_,
Shires_NN
distributable_JJ
reserves_NN
were_VBD
$_$
2,946_CD
million_CD
._.
iii_FW
Treasury_NN
stock_NN
The_DT
Company_NN
records_NN
the_DT
purchase_NN
of_PIN
its_PIT
own_JJ
shares_NN
as_IN
a_DT
reduction_NOMZ
of_PIN
shareholders_NN
equity_NOMZ
based_VBN [WZPAST]
on_PIN
the_DT
price_NN
paid_VBN [WZPAST]
for_PIN
the_DT
shares_NN
._.
On_PIN
December_NN
22_CD
,_,
2005_CD
the_DT
Company_NN
requested_VBD [SUAV]
its_PIT
Employee_NN
Share_NN
Ownership_NN
Trust_NN
to_TO
place_VB
an_DT
irrevocable_JJ
instruction_NOMZ
with_PIN
the_DT
Companys_NN
brokers_NN
to_TO
make_VB
purchases_NN
in_PIN
the_DT
open_JJ
market_NN
of_PIN
a_DT
fixed_VBN
number_NN
of_PIN
shares_NN
during_PIN
the_DT
period_NN
between_PIN
December_NN
23_CD
,_,
2005_CD
and_CC
February_NN
23_CD
,_,
2006_CD
,_,
the_DT
date_NN
the_DT
Company_NN
announced_VBD [PUBV]
its_PIT
full-year_JJ
results_NN
for_PIN
2005_CD
._.
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
a_DT
total_NN
of_PIN
191,016_CD
shares_NN
had_VBD [PEAS]
been_VBN [PASS]
purchased_VBN
under_IN
this_DEMO
purchase_NN
instruction_NOMZ
for_PIN
total_JJ
consideration_NOMZ
of_PIN
$_$
2.5_CD
million_CD
,_,
including_VBG
stamp_NN
duty_NN
and_PHC
broker_NN
commission_NN
._.
23_CD
Related_VBN
parties_NN
i_FPP1
Professional_NN
fees_NN
The_DT
Company_NN
incurred_VBN
professional_JJ
fees_NN
with_PIN
Stikeman_NN
Elliott_NN
,_,
a_DT
law_NN
firm_NN
in_PIN
which_WDT [PIRE]
the_DT
Hon_NN
James_NN
Grant_NN
,_,
a_DT
Non-executive_JJ
Director_NN
of_PIN
Shire_NN
,_,
is_VPRT [BEMA]
a_DT
partner_NN
,_,
totaling_VBG
$_$
0.5_CD
million_CD
for_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
2004_CD
:_:
$_$
2.1_CD
million_CD
:_:
2003_CD
:_:
$_$
0.8_CD
million_CD
._.
In_PIN
April_NN
2004_CD
Shire_NN
BioChem_NN
Inc._NN
._.
BioChem_NN
,_,
a_DT
subsidiary_NN
of_PIN
Shire_NN
,_,
sold_VBD
a_DT
Canadian_JJ
property_NN
to_PIN
NeuroChem_NN
Inc._NN
for_PIN
$_$
7.8_CD
million_CD
CAN$_NN
10.5_CD
million_CD
._.
Dr_NN
Bellini_NN
,_,
a_DT
Non-executive_JJ
Director_NN
of_PIN
Biochem_NN
and_CC
,_,
until_IN
May_POMD
10_CD
,_,
2003_CD
,_,
a_DT
Non-executive_JJ
Director_NN
of_PIN
Shire_NN
and_PHC
Mr_NN
Nordmann_NN
,_,
a_DT
Non-executive_JJ
Director_NN
of_PIN
Shire_NN
are_VPRT [BEMA]
both_DT
Directors_NN
of_PIN
NeuroChem_NN
Inc._NN
._.
Dr_NN
Bellini_NN
had_VBD
an_DT
indirect_JJ
substantial_JJ
interest_NN
in_PIN
the_DT
issued_VBN
share_NN
capital_NN
of_PIN
Neurochem_NN
Inc._NN
at_PIN
the_DT
time_NN
of_PIN
the_DT
transaction_NOMZ
._.
In_PIN
April_NN
2004_CD
,_,
the_DT
Company_NN
contributed_VBD
cash_NN
of_PIN
$_$
3.7_CD
million_CD
CAN$_NN
5_CD
million_CD
and_CC
equipment_NOMZ
and_CC
intellectual_JJ
property_NN
to_PIN
the_DT
start-up_NN
of_PIN
a_DT
new_JJ
Canadian-based_JJ
pharmaceutical_JJ
research_NN
and_PHC
development_NOMZ
organization_NOMZ
,_,
ViroChem_NN
Pharma_NN
Inc._NN
._.
ViroChem_NN
,_,
in_PIN
return_NN
for_PIN
an_DT
equity_NOMZ
interest_NN
and_PHC
royalties_NN
on_PIN
the_DT
sale_NN
of_PIN
certain_JJ
products_NN
subsequently_TIME
launched_VBN
by_PIN
ViroChem_NN
._.
In_PIN
April_NN
2005_CD
,_,
the_DT
Company_NN
contributed_VBD
cash_NN
of_PIN
$_$
4.1_CD
million_CD
CAN$_NN
5_CD
million_CD
to_PIN
ViroChem_NN
in_PIN
return_NN
for_PIN
an_DT
additional_JJ
equity_NOMZ
interest_NN
._.
Dr_NN
Bellini_NN
,_,
a_DT
Non-executive_JJ
Director_NN
of_PIN
BioChem_NN
and_CC
,_,
until_IN
May_POMD
10_CD
,_,
2003_CD
,_,
a_DT
Non-executive_JJ
Director_NN
of_PIN
Shire_NN
,_,
had_VBD
,_,
at_PIN
the_DT
time_NN
of_PIN
the_DT
transaction_NOMZ
,_,
an_DT
indirect_JJ
substantial_JJ
interest_NN
in_PIN
a_DT
company_NN
,_,
which_WDT [SERE]
is_VPRT [BEMA]
a_DT
co-investor_NN
of_PIN
ViroChem_NN
._.
The_DT
Company_NN
has_VPRT [PEAS]
undertaken_VBN
to_TO
invest_VB
an_DT
additional_JJ
$_$
4.3_CD
million_CD
CAN$_NN
5_CD
million_CD
in_PIN
ViroChem_NN
._.
In_PIN
October_NN
2005_CD
,_,
the_DT
Company_NN
sub-leased_VBD
its_PIT
office_NN
premises_NN
in_PIN
Newport_NN
to_PIN
Xanodyne_NN
Pharmaceuticals_NN
Inc._NN
._.
Dr_NN
James_NN
Cavanaugh_NN
,_,
the_DT
Non-executive_JJ
Chairman_NN
of_PIN
the_DT
Company_NN
,_,
is_VPRT [BEMA]
the_DT
Chairman_NN
of_PIN
Xanodyne_NN
Pharmaceuticals_NN
Inc._NN
._.
As_CONJ
a_NULL
result_NULL
of_PIN
the_DT
transaction_NOMZ
the_DT
Company_NN
will_PRMD
receive_VB
$_$
7.8_CD
million_CD
net_NN
of_PIN
inducements_NOMZ
in_PIN
lease_NN
income_NN
over_IN
the_DT
sub-lease_JJ
period_NN
from_PIN
Xanodyne_NN
._.
114_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
115_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
Dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
24_CD
Earnings_GER
per_PIN
share_NN
The_DT
following_VBG
table_NN
reconciles_NN
loss_NN
income_NN
from_PIN
continuing_VBG
operations_NOMZ
and_CC
the_DT
weighted_JJ
average_JJ
ordinary_JJ
shares_NN
outstanding_JJ
for_PIN
basic_JJ
and_PHC
diluted_JJ
earnings_GER
per_PIN
share_NN
for_PIN
the_DT
periods_NN
presented_VBN
:_:
2005 2004 2003_CD
Year_NN
to_PIN
December_NN
31_CD
,_,
$_$
000_CD
$_$
000_CD
$_$
000_CD
Loss_NN
income_NN
from_PIN
continuing_VBG
operations_NOMZ
413,968_CD
333,299_CD
297,937_CD
Loss_NN
from_PIN
discontinued_VBN
operations_NOMZ
,_,
net_NN
of_PIN
tax_NN
20,135_CD
21,886_CD
Gain_NN
loss_NN
on_PIN
disposition_NOMZ
of_PIN
discontinued_VBN
operations_NOMZ
3,125_CD
44,157_CD
Numerator_NN
for_PIN
basic_JJ
loss_NN
earnings_GER
per_PIN
share_NN
410,843_CD
269,007_CD
276,051_CD
Interest_NN
charged_VBN [WZPAST]
on_PIN
convertible_JJ
debt_NN
,_,
net_NN
of_PIN
tax_NN
3,421_CD
5,218_CD
Numerator_NN
for_PIN
diluted_JJ
loss_NN
earnings_GER
per_PIN
share_NN
410,843_CD
272,428_CD
281,269_CD
Year_NN
to_PIN
December_NN
31_CD
,_,
2005 2004 2003_CD
Weighted_JJ
average_JJ
number_NN
of_PIN
shares_NN
outstanding_JJ
Number_NN
of_PIN
shares_NN
Number_NN
of_PIN
shares_NN
Number_NN
of_PIN
Shares_NN
Basic_NN
500,243,137_CD
496,306,604_CD
498,212,826_CD
Effect_NN
of_PIN
dilutive_JJ
shares_NN
:_:
Share_NN
options_NOMZ
3,035,620_CD
1,859,076_CD
Convertible_JJ
debt_NN
11,858,416_CD
18,895,493_CD
Warrants_NN
66,792_CD
14,960,828_CD
20,754,569_CD
Diluted_NN
500,243,137_CD
511,267,432_CD
518,967,395_CD
Basic_JJ
earnings_GER
per_PIN
share_NN
:_:
Loss_NN
income_NN
from_PIN
continuing_VBG
operations_NOMZ
82.7_CD
67.2_CD
59.8_CD
Loss_NN
from_PIN
discontinued_VBN
operations_NOMZ
,_,
net_NN
of_PIN
tax_NN
4.1_CD
4.4_CD
Gain_NN
loss_NN
on_PIN
disposition_NOMZ
of_PIN
discontinued_VBN
operations_NOMZ
0.6_CD
8.9_CD
82.1_CD
54.2_CD
55.4_CD
Diluted_VBN
earnings_GER
per_PIN
share_NN
:_:
Loss_NN
income_NN
from_PIN
continuing_VBG
operations_NOMZ
82.7_CD
65.9_CD
58.4_CD
Loss_NN
from_PIN
discontinued_VBN
operations_NOMZ
,_,
net_NN
of_PIN
tax_NN
4.0_CD
4.2_CD
Gain_NN
loss_NN
on_PIN
disposition_NOMZ
of_PIN
discontinued_VBN
operations_NOMZ
0.6_CD
8.6_CD
82.1_CD
53.3_CD
54.2_CD
The_DT
share_NN
options_NOMZ
,_,
warrants_NN
and_CC
convertible_JJ
debt_NN
not_XX0
included_VBD
in_PIN
the_DT
calculation_NOMZ
of_PIN
the_DT
diluted_VBN
weighted_JJ
average_JJ
number_NN
of_PIN
shares_NN
are_VPRT [PASS]
shown_VBN [PRIV]
below_PLACE
:_:
2005 2004 2003_CD
i_FPP1
ii_FW
ii_FW
Year_NN
to_PIN
December_NN
31_CD
,_,
Number_NN
of_PIN
shares_NN
Number_NN
of_PIN
shares_NN
Number_NN
of_PIN
shares_NN
Share_NN
options_NOMZ
20,680,407_CD
16,640,724_CD
17,006,093_CD
Warrants_NN
1,346,407_CD
1,346,407_CD
Convertible_JJ
debt_NN
5,756_CD
22,032,570_CD
16,640,724_CD
18,352,500_CD
Notes_NN
i_FPP1
Not_XX0
included_VBN
as_IN
the_DT
Company_NN
made_VBD
a_DT
loss_NN
during_PIN
the_DT
calculation_NOMZ
period_NN
._.
ii_FW
Not_XX0
included_VBN
as_IN
the_DT
exercise_NN
price_NN
exceeded_VBD
the_DT
Companys_NN
average_JJ
share_NN
price_NN
during_PIN
the_DT
calculation_NOMZ
period_NN
._.
During_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
the_DT
Company_NN
recorded_VBD
a_DT
loss_NN
on_PIN
redemption_NOMZ
of_PIN
the_DT
convertible_JJ
loan_NN
notes_NN
of_PIN
$_$
7.4_CD
million_CD
,_,
which_WDT [SERE]
resulted_VBD
from_PIN
the_DT
write-off_PIN
of_PIN
unamortized_JJ
debt_NN
issuance_NN
costs_NN
._.
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
115_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
116_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
Dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV] [THATD]
25_CD
Segment_NOMZ
reporting_VBG [PUBV] [WZPRES]
SFAS_NN
No._NN
._.
131_CD
establishes_VPRT [PRIV]
standards_NN
for_PIN
reporting_VBG [PUBV]
information_NOMZ
about_IN
operating_VBG
segments_NOMZ
and_CC
related_VBN
disclosures_NN
,_,
products_NN
and_PHC
services_NN
,_,
geographic_JJ
areas_NN
and_CC
major_JJ
customers_NN
._.
Operating_VBG
segments_NOMZ
are_VPRT
components_NN
of_PIN
an_DT
enterprise_NN
about_IN
which_WDT
separate_JJ
financial_JJ
information_NOMZ
is_VPRT [BEMA]
available_PRED
that_DEMP
is_VPRT [PASS]
evaluated_VBN
regularly_RB
by_PIN
the_DT
chief_NN
operating_VBG [WZPRES]
decision-maker_NN
in_PIN
deciding_VBG [SUAV] [PRIV]
how_RB [WHCL]
to_TO
allocate_VB
resources_NN
and_CC
in_PIN
assessing_VBG
performance_NN
._.
Shire_NN
sells_VPRT
a_DT
number_NN
of_PIN
pharmaceutical_JJ
products_NN
in_PIN
multiple_JJ
geographic_JJ
markets_NN
across_PLACE
the_DT
world_NN
._.
The_DT
Company_NN
is_VPRT [SPAU]
continuously_RB
looking_VBG
to_TO
develop_VB
and_PHC
replenish_VB
the_DT
pharmaceutical_JJ
product_NN
pipeline_NN
and_CC
has_VPRT [PEAS]
continued_VBN
to_TO
focus_VB
on_PIN
meeting_VBG
the_DT
needs_NN
of_PIN
the_DT
specialist_NN
physician_NN
in_PIN
targeting_VBG
therapeutic_JJ
areas_NN
within_PIN
its_PIT
pool_NN
of_PIN
expertize_NN
._.
In_PIN
prior_RB
reporting_VBG [PUBV]
periods_NN
,_,
the_DT
Companys_NN
internal_JJ
management_NOMZ
reporting_VBG [PUBV] [THATD] [WZPRES]
structure_NN
was_VBD [PASS]
based_VBN
on_PIN
a_DT
combination_NOMZ
of_PIN
geography_NN
and_PHC
function_NOMZ
._.
As_CONJ
a_NULL
result_NULL
the_DT
Company_NN
provided_VBD
segment_NOMZ
information_NOMZ
,_,
which_WDT [SERE]
showed_VBD [PRIV]
geographic_JJ
sales_NN
and_PHC
costs_NN
for_PIN
the_DT
US_FPP1
and_PHC
International_NN
sales_NN
and_PHC
marketing_GER
businesses_NOMZ
,_,
research_NN
and_PHC
development_NOMZ
costs_NN
and_CC
a_DT
Corporate_JJ
segment_NOMZ
which_WDT [WHSUB]
included_VBD
corporate_JJ
costs_NN
and_PHC
royalty_NN
income_NN
._.
Effective_JJ
January_NN
1_CD
,_,
2005_CD
,_,
Shires_NN
internal_JJ
management_NOMZ
reporting_VBG [PUBV] [THATD] [WZPRES]
structures_NN
have_VPRT [PEAS]
been_VBN [PASS]
changed_VBN
to_TO
show_VB [PRIV]
two_CD
segments_NOMZ
,_,
Pharmaceutical_NN
Products_NN
and_PHC
Royalties_NN
._.
The_DT
Pharmaceutical_NN
Products_NN
segment_NOMZ
comprises_VPRT
four_CD
therapeutic_JJ
areas_NN
,_,
CNS_NN
,_,
GI_NN
,_,
Shire_NN
HGT_NN
and_PHC
GP_NN
and_CC
all_QUAN
products_NN
have_VPRT [PEAS]
been_VBN [PASS]
aggregated_VBN
for_PIN
reporting_VBG [PUBV]
purposes_NN
within_PIN
this_DEMO
segment_NOMZ
._.
The_DT
Company_NN
evaluates_VPRT
performance_NN
based_VBN [WZPAST]
on_PIN
revenue_NN
and_PHC
operating_GER
income_NN
._.
The_DT
Company_NN
does_VPRT
not_XX0
have_VB
inter-segment_JJ
transactions_NOMZ
._.
Prior_RB
period_NN
amounts_NN
have_VPRT [PEAS]
been_VBN [PASS]
reclassified_VBN
to_TO
conform_VB
to_PIN
the_DT
new_JJ
current_JJ
period_NN
presentation_NOMZ
._.
The_DT
Pharmaceutical_NN
Products_NN
segment_NOMZ
represents_VPRT
the_DT
Companys_NN
commercial_JJ
operations_NOMZ
and_PHC
costs_NN
in_PIN
respect_NN
of_PIN
products_NN
currently_RB
promoted_VBN
and_PHC
sold_VBN
together_RB
with_PIN
costs_NN
of_PIN
developing_VBG
projects_NN
for_PIN
future_JJ
commercialization_NOMZ
._.
The_DT
Royalties_NN
segment_NOMZ
represents_VPRT
royalties_NN
earned_VBN [WZPAST]
from_PIN
the_DT
out-licensing_GER
of_PIN
projects_NN
to_PIN
third_JJ
parties_NN
._.
These_DEMO
projects_NN
have_VPRT [PEAS]
been_VBN [PASS]
developed_VBN
and_PHC
commercialized_VBN
by_PIN
the_DT
third_JJ
party_NN
and_PHC
royalties_NN
are_VPRT
being_VBG [PASS]
received_VBN
on_PIN
the_DT
sale_NN
of_PIN
the_DT
commercialized_JJ
product_NN
._.
All_QUAN
Other_JJ
has_VPRT [PEAS]
been_VBN [PASS]
included_VBN
in_PIN
the_DT
table_NN
below_PLACE
in_PIN
order_NN
to_TO
reconcile_VB
the_DT
segments_NOMZ
to_PIN
the_DT
total_JJ
consolidated_JJ
figures_NN
._.
Costs_NN
have_VPRT [PEAS]
not_XX0
been_VBN [PASS]
allocated_VBN
to_PIN
Royalties_NN
below_PLACE
as_IN
the_DT
magnitude_NN
of_PIN
the_DT
costs_NN
incurred_VBN [WZPAST]
in_PIN
respect_NN
of_PIN
managing_VBG
this_DEMO
segment_NOMZ
is_VPRT [BEMA]
small_PRED
and_CC
the_DT
internal_JJ
reporting_GER
consequently_CONJ
does_VPRT
not_XX0
allocate_VB
costs_NN
to_PIN
this_DEMO
segment_NOMZ
._.
Assets_NN
that_TSUB
are_VPRT [BEMA]
directly_RB
attributable_PRED
to_PIN
the_DT
Royalty_NN
segment_NOMZ
have_VPRT [PEAS]
been_VBN [SPAU] [PASS]
separately_RB
disclosed_VBN [PUBV]
from_PIN
the_DT
Pharmaceutical_NN
Products_NN
segment_NOMZ
._.
Depreciation_NOMZ
from_PIN
manufacturing_VBG
plants_NN
$_$
3.5_CD
million_CD
is_VPRT [PASS]
included_VBN
in_PIN
cost_NN
of_PIN
product_NN
sales_NN
._.
116_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
117_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
Dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
25_CD
Segment_NOMZ
reporting_GER
continued_VBD
Pharmaceutical_NN
Segment_NOMZ
products_NN
Royalties_NN
sub-total_JJ
All_QUAN
other_JJ
Total_JJ
Year_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
Product_NN
sales_NN
1,112,457_CD
1,112,457_CD
1,112,457_CD
Royalties_NN
230,364_CD
230,364_CD
230,364_CD
Licensing_GER
and_PHC
development_NOMZ
13,479_CD
13,479_CD
Other_JJ
revenues_NN
6,907_CD
6,907_CD
Total_JJ
revenues_NN
1,112,457_CD
230,364_CD
1,342,821_CD
20,386_CD
1,363,207_CD
Cost_NN
of_PIN
product_NN
sales_NN
141,909_CD
141,909_CD
141,909_CD
Research_NN
and_PHC
development_NOMZ
192,958_CD
192,958_CD
3,307_CD
196,265_CD
Selling_GER
,_,
general_JJ
and_PHC
administrative_JJ
458,132_CD
458,132_CD
458,132_CD
i_FPP1
Depreciation_NOMZ
and_PHC
amortization_NOMZ
58,513_CD
58,513_CD
58,513_CD
Intangible_JJ
asset_NN
impairment_NOMZ
13,477_CD
13,477_CD
13,477_CD
Reorganization_NOMZ
costs_NN
48,469_CD
48,469_CD
48,469_CD
Total_JJ
operating_GER
expenses_NN
913,458_CD
913,458_CD
3,307_CD
916,765_CD
Operating_GER
income_NN
198,999_CD
230,364_CD
429,363_CD
17,079_CD
446,442_CD
Total_JJ
assets_NN
from_PIN
continuing_VBG
operations_NOMZ
2,653,984_CD
60,895_CD
2,714,879_CD
2,714,879_CD
Long-lived_JJ
assets_NN
785,930_CD
785,930_CD
785,930_CD
Capital_NN
expenditure_NN
on_PIN
long-lived_JJ
assets_NN
93,936_CD
93,936_CD
93,936_CD
i_FPP1
Depreciation_NOMZ
from_PIN
manufacturing_VBG
plants_NN
$_$
2.7_CD
million_CD
is_VPRT [PASS]
included_VBN
in_PIN
cost_NN
of_PIN
product_NN
sales_NN
._.
Depreciation_NOMZ
from_PIN
manufacturing_VBG
plants_NN
$_$
2.6_CD
million_CD
is_VPRT [PASS]
included_VBN
in_PIN
cost_NN
of_PIN
product_NN
sales_NN
._.
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
117_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
118_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
Dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
25_CD
Segment_NOMZ
reporting_GER
continued_VBD
Supplemental_NN
information_NOMZ
To_TO
improve_VB
comparability_NOMZ
between_PIN
periods_NN
for_PIN
investors_NN
,_,
the_DT
previous_JJ
reporting_GER
format_NN
has_VPRT [SPAU] [PEAS]
also_RB
been_VBN [PASS]
used_VBN
to_TO
report_VB [PUBV]
the_DT
current_JJ
period_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
together_RB
with_PIN
the_DT
previously_TIME
reported_VBN [PUBV]
segmental_JJ
analysis_NN
for_PIN
the_DT
periods_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
and_CC
December_NN
31_CD
,_,
2003_CD
._.
Whilst_OSUB
there_EX
is_VPRT
no_SYNE
requirement_NOMZ
to_TO
include_VB
this_DEMO
disclosure_NN
under_IN
SFAS_NN
No._NN
._.
131_CD
as_IN
the_DT
new_JJ
internal_JJ
reporting_GER
format_NN
has_VPRT [PEAS]
been_VBN [PASS]
used_VBN
for_PIN
the_DT
current_JJ
and_PHC
historic_JJ
period_NN
,_,
management_NOMZ
believes_VPRT [PRIV]
that_THVC
during_PIN
2005_CD
,_,
it_PIT
may_POMD
be_VB [BEMA]
useful_PRED
to_TO
include_VB
the_DT
previously_TIME
reported_VBN [PUBV]
segmental_JJ
analysis_NN
for_PIN
comparative_JJ
purposes_NN
._.
This_DEMO
internal_JJ
management-reporting_JJ
format_NN
is_VPRT [SPAU] [PASS]
no_RB
longer_RB
used_VBN
as_IN
the_DT
basis_NN
for_PIN
making_VBG
decisions_NN
within_PIN
the_DT
business_NOMZ
._.
Depreciation_NOMZ
from_PIN
manufacturing_VBG
plants_NN
$_$
3.5_CD
million_CD
is_VPRT [PASS]
included_VBN
within_PIN
cost_NN
of_PIN
product_NN
sales_NN
._.
Depreciation_NOMZ
and_PHC
amortization_NOMZ
relating_VBG [WZPRES]
to_PIN
research_NN
and_PHC
development_NOMZ
assets_NN
are_VPRT [PASS]
included_VBN
within_PIN
US_FPP1
and_PHC
International_NN
segments_NOMZ
._.
Depreciation_NOMZ
and_PHC
amortization_NOMZ
relating_VBG [WZPRES]
to_PIN
research_NN
and_PHC
development_NOMZ
assets_NN
are_VPRT [PASS]
included_VBN
in_PIN
US_FPP1
and_PHC
International_NN
segments_NOMZ
._.
118_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
119_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
Dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
25_CD
Segment_NOMZ
reporting_GER
continued_VBD
US_FPP1
International_NN
Corporate_NN
R&D_NN
Total_NN
Year_NN
to_PIN
December_NN
31_CD
,_,
2003_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
External_NN
revenues_NN
:_:
Product_NN
sales_NN
846,438_CD
157,869_CD
1,004,307_CD
Royalties_NN
14_CD
10,314_CD
193,245_CD
203,573_CD
Licensing_GER
and_PHC
development_NOMZ
3,376_CD
301_CD
3,677_CD
Other_JJ
revenues_NN
13_CD
13_CD
Total_JJ
revenues_NN
849,841_CD
168,484_CD
193,245_CD
1,211,570_CD
Cost_NN
of_PIN
product_NN
sales_NN
94,597_CD
48,563_CD
143,160_CD
ii_NN
Research_NN
and_PHC
development_NOMZ
194,902_CD
194,902_CD
Selling_GER
,_,
general_JJ
and_PHC
administrative_JJ
234,091_CD
80,968_CD
56,755_CD
371,814_CD
i_FPP1
ii_FW
Depreciation_NOMZ
and_PHC
amortization_NOMZ
19,278_CD
8,536_CD
26,804_CD
54,618_CD
Intangible_JJ
asset_NN
impairment_NOMZ
11,687_CD
15,802_CD
27,489_CD
Total_JJ
operating_GER
expenses_NN
359,653_CD
153,869_CD
83,559_CD
194,902_CD
791,983_CD
Operating_GER
income_NN
loss_NN
490,188_CD
14,615_CD
109,686_CD
194,902_CD
419,587_CD
Total_JJ
assets_NN
from_PIN
continuing_VBG
operations_NOMZ
697,460_CD
413,134_CD
1,269,300_CD
109,131_CD
2,489,025_CD
Long-lived_JJ
assets_NN
238,774_CD
233,313_CD
200,225_CD
46,691_CD
719,003_CD
Capital_NN
expenditure_NN
on_PIN
long-lived_JJ
assets_NN
18,324_CD
46,368_CD
15,827_CD
16,854_CD
97,373_CD
Notes_NN
i_FPP1
Included_VBN
in_PIN
depreciation_NOMZ
and_PHC
amortization_NOMZ
are_VPRT [BEMA]
the_DT
write-downs_NN
of_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
of_PIN
$_$
6_CD
million_CD
Corporate_JJ
segment_NOMZ
and_PHC
assets_NN
held_VBN [PRIV] [WZPAST]
for_PIN
resale_NN
of_PIN
$_$
10.7_CD
million_CD
Corporate_JJ
segment_NOMZ
._.
Depreciation_NOMZ
from_PIN
manufacturing_VBG
plants_NN
$_$
2.6_CD
million_CD
is_VPRT [PASS]
included_VBN
within_PIN
cost_NN
of_PIN
product_NN
sales_NN
._.
ii_FW
Costs_NN
associated_VBN [WZPAST]
with_PIN
the_DT
closure_NN
of_PIN
the_DT
Lead_JJ
Optimization_NOMZ
division_NN
and_CC
other_JJ
related_JJ
activities_NOMZ
in_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2003_CD
are_VPRT
:_:
Research_NN
and_PHC
development_NOMZ
$_$
7.2_CD
million_CD
and_CC
Depreciation_NOMZ
and_PHC
amortization_NOMZ
$_$
16.7_CD
million_CD
._.
These_DEMO
amounts_NN
are_VPRT [PASS]
reflected_VBN [PRIV]
in_PIN
reorganization_NOMZ
costs_NN
in_PIN
the_DT
statement_NOMZ
of_PIN
operations_NOMZ
._.
Material_NN
customers_NN
In_PIN
the_DT
periods_NN
set_VBN [WZPAST]
out_PIN
below_PLACE
,_,
certain_JJ
customers_NN
,_,
all_QUAN
within_PIN
the_DT
Pharmaceutical_NN
Products_NN
operating_VBG [WZPRES]
segment_NOMZ
,_,
accounted_VBD
for_PIN
greater_JJ
than_PIN
10_CD
%_NN
of_PIN
the_DT
Companys_NN
total_VPRT
revenues_NN
:_:
2005 2005 2004 2004_CD
2003_CD
2003_CD
Year_NN
to_PIN
December_NN
31_CD
,_,
$_$
000_CD
%_NN
revenue_NN
$_$
000_CD
%_NN
revenue_NN
$_$
000_CD
%_NN
revenue_NN
Cardinal_NN
Health_NN
Inc._NN
599,504_CD
37_CD
%_NN
339,136_CD
25_CD
%_NN
274,771_CD
23_CD
%_NN
McKesson_NN
Corp._NN
345,659_CD
22_CD
%_NN
303,965_CD
22_CD
%_NN
269,364_CD
22_CD
%_NN
Amerisource_NN
Bergen_NN
Corp._NN
154,724_CD
10_CD
%_NN
167,998_CD
12_CD
%_NN
175,856_CD
15_CD
%_NN
Walgreen_NN
Co._NN
156,578_CD
11_CD
%_NN
158,689_CD
13_CD
%_NN
Amounts_NN
outstanding_JJ
as_IN
at_PIN
December_NN
31_CD
,_,
in_PIN
respect_NN
of_PIN
these_DEMO
material_NN
customers_NN
were_VBD
as_IN
follows_VPRT
:_:
2005_CD
2004_CD
December_NN
31_CD
,_,
$_$
000_CD
$_$
000_CD
Cardinal_NN
Health_NN
Inc._NN
94,100_CD
28,178_CD
McKesson_NN
Corp._NN
47,230_CD
23,535_CD
Amerisource_NN
Bergen_NN
Corp._NN
20,365_CD
8,515_CD
Walgreen_NN
Co._NN
16,975_CD
161,695_CD
77,203_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
119_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
120_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
Dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
26_CD
Other_JJ
income_NN
expense_NN
,_,
net_JJ
2005 2004 2003_CD
Year_NN
to_PIN
December_NN
31_CD
,_,
Notes_NN
$_$
000_CD
$_$
000_CD
$_$
000_CD
SERP_NN
valuation_NOMZ
adjustment_NOMZ
489 264 175_CD
Impairment_NOMZ
of_PIN
long-term_JJ
investments_NOMZ
11_CD
1,973_CD
15,364_CD
15,540_CD
GeneChem_NN
Funds_NN
management_NOMZ
fee_NN
4,332_CD
4,036_CD
3,755_CD
Gain_NN
on_PIN
sale_NN
of_PIN
available-for-sale_JJ
security_NOMZ
11_CD
3,934_CD
14,805_CD
Gain_NN
on_PIN
sale_NN
of_PIN
drug_NN
formulation_NOMZ
business_NOMZ
3,561_CD
Foreign_NN
exchange_NN
1,396_CD
2,467_CD
6,716_CD
Other_JJ
998_CD
2,571_CD
2,319_CD
9,945_CD
3,845_CD
20,645_CD
27_CD
Interest_NN
expense_NN
Interest_NN
expense_NN
for_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
was_VBD
$_$
12_CD
million_CD
._.
Included_VBN [PASTP]
in_PIN
this_DEMO
amount_NN
was_VBD [BEMA]
a_DT
$_$
7.7_CD
million_CD
provision_NN
for_PIN
interest_NN
,_,
which_WDT [SERE]
may_POMD
be_VB [BYPA]
awarded_VBN
by_PIN
the_DT
court_NN
in_PIN
respect_NN
of_PIN
amounts_NN
due_JJ
to_PIN
former_JJ
holders_NN
of_PIN
approximately_RB
11.3_CD
million_CD
shares_NN
of_PIN
TKT_NN
common_JJ
stock_NN
who_WP [WHSUB]
have_VPRT [PEAS]
submitted_VBN [PUBV]
written_VBN [PUBV]
demands_NN
for_PIN
appraisal_NN
of_PIN
these_DEMO
shares_NN
._.
The_DT
provision_NN
was_VBD [PASS]
based_VBN
on_PIN
an_DT
estimate_NN
of_PIN
Shires_NN
average_JJ
marginal_JJ
cost_NN
of_PIN
borrowing_GER
from_PIN
the_DT
acquisition_NOMZ
date_NN
._.
In_CONJ
addition_NULL
,_,
Shire_NN
incurred_VBD
interest_NN
expense_NN
of_PIN
$_$
1.2_CD
million_CD
relating_VBG
to_PIN
the_DT
costs_NN
of_PIN
a_DT
bridging_VBG
loan_NN
to_TO
finance_VB
the_DT
TKT_NN
acquisition_NOMZ
._.
In_PIN
2004_CD
interest_NN
expense_NN
of_PIN
$_$
12.3_CD
million_CD
2003_CD
:_:
$_$
9.5_CD
million_CD
included_VBD
the_DT
write-off_PIN
of_PIN
$_$
7.4_CD
million_CD
of_PIN
deferred_VBN
financing_GER
costs_NN
following_VBG [WZPRES]
the_DT
redemption_NOMZ
of_PIN
$_$
370.1_CD
million_CD
of_PIN
convertible_JJ
loan_NN
notes_NN
during_PIN
2004_CD
and_CC
the_DT
interest_NN
expense_NN
prior_RB
to_PIN
the_DT
redemption_NOMZ
of_PIN
$_$
4.2_CD
million_CD
._.
28_CD
Retirement_NOMZ
benefits_NN
a_DT
Personal_JJ
defined_VBN
contribution_NOMZ
pension_NN
plans_VPRT
The_DT
Company_NN
makes_VPRT
contributions_NOMZ
to_TO
defined_VBN
contribution_NOMZ
retirement_NOMZ
plans_NN
that_TSUB
together_RB
cover_VPRT
substantially_RB
all_QUAN
employees_NN
._.
For_PIN
the_DT
defined_VBN
contribution_NOMZ
retirement_NOMZ
plans_NN
,_,
the_DT
level_NN
of_PIN
the_DT
Companys_NN
contribution_NOMZ
is_VPRT [PASS]
fixed_VBN
at_PIN
a_DT
set_VBN
percentage_NN
of_PIN
employees_NN
pay_VPRT
._.
Company_NN
contributions_NOMZ
to_PIN
personal_JJ
defined_VBN
contribution_NOMZ
pension_NN
plans_NN
totaled_VBD
$_$
14.1_CD
million_CD
,_,
$_$
9_CD
million_CD
and_CC
$_$
16.1_CD
million_CD
for_PIN
the_DT
years_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
,_,
2004_CD
and_CC
2003_CD
,_,
respectively_RB
,_,
and_ANDC
were_VBD [PASS]
charged_VBN
to_PIN
operations_NOMZ
as_IN
they_TPP3
became_VBD
payable_JJ
._.
b_NN
Defined_VBN
benefit_NN
pension_NN
plans_NN
i_FPP1
The_DT
Roberts_NN
SERP_NN
The_NN
Roberts_NN
SERP_NN
is_VPRT [BEMA]
for_PIN
some_QUAN
US_FPP1
employees_NN
of_PIN
Roberts_NN
Pharmaceutical_NN
Corporation_NOMZ
Roberts_NN
who_WP [WHSUB]
met_VBD
certain_JJ
age_NN
and_PHC
service_NN
requirements_NOMZ
._.
Shire_NN
acquired_VBD
Roberts_NN
in_PIN
1999_CD
,_,
and_ANDC
the_DT
plan_NN
was_VBD [PASS]
discontinued_VBN
in_PIN
2000_CD
._.
There_EX
were_VBD
no_SYNE
contributions_NOMZ
payable_JJ
by_PIN
the_DT
Company_NN
in_PIN
respect_NN
of_PIN
2005_CD
._.
The_DT
Company_NN
paid_VBD
a_DT
lump_NN
sum_NN
of_PIN
$_$
18_CD
million_CD
into_PIN
the_DT
Roberts_NN
SERP_NN
,_,
which_WDT [SERE]
was_VBD [PASS]
accounted_VBN
for_PIN
as_IN
a_DT
fair_JJ
value_NN
adjustment_NOMZ
on_PIN
the_DT
acquisition_NOMZ
of_PIN
Roberts_NN
to_TO
make_VB
good_JJ
the_DT
deficit_NN
on_PIN
this_DEMO
scheme_NN
at_PIN
the_DT
time_NN
of_PIN
acquisition_NOMZ
._.
This_DEMO
lump_NN
sum_NN
payment_NOMZ
has_VPRT [PEAS]
led_VBN
to_PIN
the_DT
Company_NN
having_VBG [WZPRES]
no_SYNE
future_JJ
liability_NOMZ
under_IN
the_DT
SERP_NN
,_,
which_WDT [SERE]
has_VPRT [PEAS]
been_VBN [PASS]
closed_VBN
to_PIN
new_JJ
members_NN
with_PIN
contributions_NOMZ
no_RB
longer_RB
payable_JJ
by_PIN
existing_VBG
members_NN
._.
Assets_NN
are_VPRT [PASS]
set_VBN
aside_RB
to_TO
fund_VB
these_DEMO
benefits_NN
in_PIN
a_DT
Rabbi_NN
Trust_NN
._.
The_DT
legal_JJ
form_NN
of_PIN
the_DT
trust_NN
is_VPRT [BEMA]
such_OSUB
that_NULL
the_DT
assets_NN
held_VBD [PRIV]
to_TO
cover_VB
the_DT
pension_NN
liabilities_NOMZ
are_VPRT [BEMA]
available_PRED
to_PIN
the_DT
general_JJ
creditors_NN
of_PIN
the_DT
Company_NN
on_PIN
winding_VBG
up_RP
._.
Accordingly_RB
,_,
the_DT
assets_NN
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
trust_NN
are_VPRT
not_XX0
plan_VB
assets_NN
and_CC
are_VPRT [PASS]
recorded_VBN
on_PIN
the_DT
balance_NN
sheet_NN
._.
In_PIN
accordance_NN
with_PIN
EITF_NN
97-14_CD
,_,
Accounting_GER
for_PIN
Deferred_NN
Compensation_NOMZ
Arrangements_NOMZ
Where_RB
Amounts_VPRT
Earned_VBN
Are_VPRT [PASS]
Held_VBN [PRIV]
in_PIN
a_DT
Rabbi_NN
Trust_NN
and_CC
Invested_VBN
the_DT
assets_NN
and_PHC
liabilities_NOMZ
of_PIN
$_$
7.6_CD
million_CD
and_CC
$_$
4.6_CD
million_CD
,_,
respectively_RB
,_,
are_VPRT [PASS]
shown_VBN [PRIV]
on_PIN
the_DT
balance_NN
sheet_NN
within_PIN
the_DT
categories_NN
Other_JJ
non-current_JJ
assets_NN
,_,
Other_JJ
current_JJ
liabilities_NOMZ
and_CC
Other_JJ
non-current_JJ
liabilities_NOMZ
._.
ii_FW
The_DT
Shire_NN
SERP_NN
The_NN
Shire_NN
SERP_NN
defined_VBD
benefit_NN
scheme_NN
is_VPRT [BEMA]
an_DT
unfunded_JJ
arrangement_NOMZ
:_:
the_DT
benefits_NN
are_VPRT [BEMA]
payable_PRED
to_PIN
certain_JJ
senior_JJ
US_FPP1
employees_NN
as_IN
lump_NN
sums_NN
on_PIN
leaving_VBG
the_DT
Companys_NN
employment_NOMZ
or_CC
earlier_TIME
due_JJ
to_PIN
death_NN
,_,
disability_NOMZ
or_CC
termination_NOMZ
._.
The_DT
amount_NN
of_PIN
benefit_NN
is_VPRT [PASS]
based_VBN
on_PIN
the_DT
value_NN
of_PIN
notional_JJ
contributions_NOMZ
increased_VBN [WZPAST]
with_PIN
earned_VBN
investment_NOMZ
returns_NN
as_IN
if_COND
they_TPP3
were_VBD [PASS]
invested_VBN
in_PIN
investments_NOMZ
of_PIN
the_DT
employees_NN
choice_NN
._.
The_DT
entire_JJ
benefit_NN
liability_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
recognized_VBN [PRIV]
on_PIN
the_DT
balance_NN
sheet_NN
._.
120_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
121_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
Dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
29_CD
Income_NN
taxes_NN
The_DT
components_NN
of_PIN
pre_NN
tax_NN
income_NN
from_PIN
continuing_VBG
operations_NOMZ
are_VPRT
as_IN
follows_VPRT
:_:
2005 2004 2003_CD
Year_NN
to_PIN
December_NN
31_CD
,_,
$_$
000_CD
$_$
000_CD
$_$
000_CD
UK_NN
70,318_CD
67,363_CD
76,267_CD
US_FPP1
61,162_CD
265,770_CD
285,221_CD
In-process_JJ
research_NN
and_PHC
development_NOMZ
673,000_CD
Other_JJ
jurisdictions_NOMZ
220,635_CD
261,487_CD
197,393_CD
Sub-total_JJ
320,885_CD
459,894_CD
406,347_CD
Equity_NOMZ
Investees_NN
1,000_CD
2,508_CD
1,057_CD
The_DT
provision_NN
for_PIN
income_NN
taxes_NN
by_PIN
location_NOMZ
of_PIN
the_DT
taxing_VBG
jurisdiction_NOMZ
for_PIN
the_DT
years_NN
to_PIN
December_NN
31_CD
,_,
consisted_VBN [PASTP]
of_PIN
the_DT
following_GER
:_:
2005 2004 2003_CD
Year_NN
to_PIN
December_NN
31_CD
,_,
$_$
000_CD
$_$
000_CD
$_$
000_CD
Current_JJ
income_NN
taxes_NN
:_:
UK_NN
corporation_NOMZ
tax_NN
7,417_CD
746_CD
US_FPP1
federal_JJ
tax_NN
16,740_CD
98,668_CD
101,174_CD
US_FPP1
state_NN
and_CC
local_JJ
taxes_NN
7,325_CD
5,107_CD
4,313_CD
Other_JJ
jurisdictions_NOMZ
39,123_CD
36,417_CD
18,792_CD
Total_JJ
current_JJ
taxes_NN
70,605_CD
140,938_CD
124,279_CD
Deferred_JJ
taxes_NN
:_:
UK_NN
corporation_NOMZ
tax_NN
5,418_CD
482_CD
9,696_CD
US_FPP1
federal_JJ
tax_NN
8,167_CD
12,171_CD
3,647_CD
US_FPP1
state_NN
and_CC
local_JJ
taxes_NN
3,293_CD
104_CD
180_CD
Other_JJ
jurisdictions_NOMZ
27,520_CD
922_CD
30,449_CD
Total_JJ
deferred_JJ
taxes_NN
21,478_CD
11,835_CD
16,926_CD
Total_JJ
income_NN
taxes_NN
attributable_JJ
to_TO
continuing_VBG
operations_NOMZ
92,083_CD
129,103_CD
107,353_CD
Total_JJ
income_NN
taxes_NN
attributable_JJ
to_TO
discontinued_VBN
operations_NOMZ
Total_JJ
income_NN
taxes_NN
92,083_CD
129,103_CD
107,353_CD
The_DT
reconciliation_NOMZ
of_PIN
income_NN
from_PIN
continuing_VBG
operations_NOMZ
before_IN
income_NN
taxes_NN
and_PHC
equity_NOMZ
in_PIN
net_JJ
losses_NN
income_NN
of_PIN
associates_NN
and_CC
discontinued_VBN
operations_NOMZ
to_PIN
the_DT
provision_NN
for_PIN
income_NN
taxes_NN
is_VPRT [PASS]
shown_VBN [PRIV]
in_PIN
the_DT
table_NN
below_PLACE
:_:
2005 2004 2003_CD
Year_NN
to_PIN
December_NN
31_CD
,_,
$_$
000_CD
$_$
000_CD
$_$
000_CD
Loss_NN
income_NN
from_PIN
continuing_VBG
operations_NOMZ
before_IN
income_NN
taxes_NN
and_PHC
equity_NOMZ
in_PIN
net_JJ
losses_NN
income_NN
of_PIN
associates_NN
and_CC
discontinued_VBN
operations_NOMZ
320,885_CD
459,894_CD
406,347_CD
UK_NN
Corporation_NOMZ
tax_NN
rate_NN
30_CD
%_NN
30_CD
%_NN
30_CD
%_NN
Adjustments_NOMZ
to_TO
derive_VB
effective_JJ
rate_NN
:_:
Non-deductible_JJ
items_NN
:_:
Permanent_JJ
differences_NN
9.4_CD
%_NN
2.0_CD
%_NN
1.1_CD
%_NN
In-process_JJ
research_NN
and_PHC
development_NOMZ
62.9_CD
%_NN
Other_JJ
items_NN
:_:
Change_NN
in_PIN
valuation_NOMZ
allowance_NN
6.7_CD
%_NN
3.3_CD
%_NN
7.1_CD
%_NN
Difference_NN
in_PIN
taxation_NOMZ
rates_NN
0.4_CD
%_NN
0.6_CD
%_NN
11.2_CD
%_NN
Prior_RB
year_NN
adjustment_NOMZ
1.0_CD
%_NN
4.5_CD
%_NN
2.1_CD
%_NN
Change_NN
in_PIN
prior_JJ
year_NN
tax_NN
rates_NN
0.7_CD
%_NN
Other_JJ
0.2_CD
%_NN
0.5_CD
%_NN
2.7_CD
%_NN
Provision_NN
for_PIN
income_NN
taxes_NN
on_PIN
continuing_VBG
operations_NOMZ
28.7_CD
%_NN
28.1_CD
%_NN
26.4_CD
%_NN
Differences_NN
between_PIN
Shires_NN
fiscal_JJ
2005_CD
effective_JJ
tax_NN
rate_NN
and_CC
its_PIT
statutory_JJ
rate_NN
of_PIN
30_CD
%_NN
principally_RB
result_VB
from_PIN
the_DT
effect_NN
of_PIN
the_DT
acquisition_NOMZ
of_PIN
TKT_NN
and_CC
the_DT
impact_NN
of_PIN
the_DT
accounting_GER
for_PIN
costs_NN
associated_VBN [WZPAST]
with_PIN
the_DT
write-off_PIN
of_PIN
in-process_JJ
research_NN
and_PHC
development_NOMZ
._.
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
121_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
122_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
Dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
29_CD
Income_NN
taxes_NN
continued_VBD
The_DT
significant_JJ
components_NN
of_PIN
deferred_JJ
income_NN
tax_NN
assets_NN
and_PHC
liabilities_NOMZ
and_CC
their_TPP3
balance_NN
sheet_NN
classifications_NOMZ
,_,
as_RB
at_PIN
December_NN
31_CD
,_,
are_VPRT
as_IN
follows_VPRT
:_:
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2005_CD
2004_CD
$_$
000_CD
$_$
000_CD
Deferred_VBN
tax_NN
assets_NN
:_:
Deferred_JJ
revenue_NN
6,375_CD
5,866_CD
Inventory_NN
and_PHC
warranty_NN
provisions_NN
12,197_CD
5,928_CD
Losses_NN
carried_VBD
forward_RB
417,877_CD
194,523_CD
Provisions_NN
for_PIN
product_NN
returns_NN
and_CC
doubtful_JJ
accounts_NN
28,268_CD
7,586_CD
Restructuring_GER
50,318_CD
25,200_CD
Intangibles_NN
19,389_CD
Other_JJ
44,845_CD
29,234_CD
Gross_NN
deferred_VBN
tax_NN
assets_NN
579,269_CD
268,337_CD
Less_RB
:_:
valuation_NOMZ
allowance_NN
235,121_CD
152,915_CD
344,148_CD
115,422_CD
Deferred_JJ
tax_NN
liabilities_NOMZ
:_:
Excess_NN
of_PIN
tax_NN
value_NN
over_IN
book_NN
value_NN
of_PIN
assets_NN
227,968_CD
37,311_CD
Net_JJ
deferred_JJ
tax_NN
assets_NN
116,180_CD
78,111_CD
Balance_NN
sheet_NN
classifications_NOMZ
:_:
Deferred_JJ
tax_NN
assets_NN
current_JJ
54,186_CD
70,387_CD
Deferred_JJ
tax_NN
assets_NN
non-current_JJ
61,994_CD
7,724_CD
116,180_CD
78,111_CD
The_DT
approximate_JJ
net_JJ
operating_GER
loss_NN
carry-forwards_NN
as_IN
at_PIN
December_NN
31_CD
,_,
are_VPRT
as_IN
follows_VPRT
:_:
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2005_CD
2004_CD
$_$
000_CD
$_$
000_CD
US_FPP1
federal_JJ
tax_NN
NOLs_NN
270,277_CD
25,416_CD
US_FPP1
state_NN
tax_NN
NOLs_NN
99,386_CD
93,542_CD
UK_NN
NOLs_NN
227,755_CD
246,966_CD
Canadian_JJ
NOLs_NN
153,235_CD
438,523_CD
Foreign_JJ
tax_NN
jurisdictions_NOMZ
82,885_CD
100,808_CD
The_DT
tax_NN
losses_NN
shown_VBN [PRIV]
above_PLACE
have_VPRT
the_DT
following_VBG
expiration_NOMZ
dates_NN
:_:
December_NN
31_CD
,_,
2005_CD
$_$
000_CD
Within_PIN
1_CD
year_NN
27,133_CD
Within_PIN
12_CD
years_NN
13,925_CD
Within_PIN
23_CD
years_NN
14,941_CD
Within_PIN
34_CD
years_NN
18,784_CD
Within_PIN
45_CD
years_NN
22,534_CD
Within_PIN
56_CD
years_NN
10,219_CD
Within_PIN
67_CD
years_NN
3,943_CD
After_IN
7_CD
years_NN
288,813_CD
Available_JJ
indefinitely_RB
433,245_CD
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
,_,
the_DT
Company_NN
had_VBD
a_DT
valuation_NOMZ
allowance_NN
of_PIN
$_$
235_CD
million_CD
to_TO
reduce_VB
its_PIT
deferred_JJ
tax_NN
assets_NN
to_TO
estimated_VBN [PRIV]
realizable_JJ
value_NN
._.
The_DT
valuation_NOMZ
allowance_NN
relates_VPRT
to_PIN
the_DT
deferred_VBN
tax_NN
assets_NN
arising_VBG [WZPRES]
from_PIN
operating_VBG
loss_NN
carry-forwards_NN
and_PHC
capital_NN
loss_NN
carry-forwards_NN
._.
The_DT
utilization_NOMZ
of_PIN
operating_VBG
loss_NN
carry-forwards_NN
is_VPRT [PASS]
restricted_VBN
to_PIN
the_DT
taxable_JJ
income_NN
of_PIN
the_DT
subsidiary_NN
generating_VBG [WZPRES]
the_DT
losses_NN
._.
In_CONJ
addition_NULL
,_,
capital_NN
loss_NN
carry-forwards_NN
can_POMD [SPAU]
only_DWNT
be_VB [PASS]
offset_VBN
against_PIN
capital_NN
gains_NN
._.
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
,_,
based_VBN [PASTP]
upon_PIN
the_DT
level_NN
of_PIN
historical_JJ
taxable_JJ
income_NN
and_PHC
projections_NOMZ
for_PIN
future_JJ
taxable_JJ
income_NN
over_IN
the_DT
periods_NN
in_PIN
which_WDT [PIRE]
the_DT
temporary_JJ
differences_NN
are_VPRT [PASS]
anticipated_VBN [PRIV]
to_TO
reverse_VB
,_,
and_ANDC
reasonable_JJ
and_PHC
feasible_JJ
tax-planning_JJ
strategies_NN
,_,
management_NOMZ
believes_VPRT [PRIV] [THATD]
it_PIT
is_VPRT [BEMA]
more_EMPH
likely_PRED
than_PIN
not_XX0
that_DEMO
the_DT
Company_NN
will_PRMD
realize_VB [PRIV]
the_DT
benefits_NN
of_PIN
these_DEMO
deductible_JJ
differences_NN
,_,
net_NN
of_PIN
the_DT
valuation_NOMZ
allowances_NN
._.
However_CONJ
,_,
the_DT
amount_NN
of_PIN
the_DT
deferred_JJ
tax_NN
asset_NN
considered_VBN [PRIV]
realizable_JJ
could_POMD
be_VB [PASS]
adjusted_VBN
in_PIN
the_DT
future_NN
if_COND
estimates_NN
of_PIN
taxable_JJ
income_NN
are_VPRT [PASS]
revised_VBN
._.
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
,_,
we_FPP1
have_VPRT [PEAS]
not_XX0
made_VBN
a_DT
tax_NN
provision_NN
on_PIN
approximately_RB
$_$
1.7_CD
billion_CD
of_PIN
unremitted_JJ
earnings_GER
of_PIN
our_FPP1
international_JJ
subsidiaries_NN
._.
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
,_,
these_DEMO
earnings_GER
are_VPRT [PASS]
expected_VBN [PRIV]
to_TO
be_VB [PASS]
reinvested_VBN
overseas_PLACE
._.
Because_CAUS
of_PIN
complexity_NOMZ
,_,
it_PIT
is_VPRT [BEMA]
not_XX0
practical_PRED
to_TO
compute_VB
the_DT
estimated_VBN [PRIV]
deferred_VBN
tax_NN
liability_NOMZ
on_PIN
these_DEMO
earnings_GER
._.
122_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
123_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
Dollars_NN
,_,
except_PIN
where_RB
indicated_JJ
30_CD
Equity_NOMZ
in_PIN
losses_NN
earnings_GER
of_PIN
equity_NOMZ
method_NN
investees_VPRT
2005 2004 2003_CD
Year_NN
to_PIN
December_NN
31_CD
,_,
Notes_NN
$_$
000_CD
$_$
000_CD
$_$
000_CD
GSK_NN
11_CD
5,325_CD
4,433_CD
3,495_CD
GeneChem_NN
Funds_NN
11_CD
3,962_CD
75_CD
Other_JJ
2,363_CD
2,000_CD
4,552_CD
1,000_CD
2,508_CD
1,057_CD
31_CD
Share-based_JJ
compensation_NOMZ
plans_NN
Historically_NN
the_DT
Company_NN
has_VPRT [PEAS]
granted_VBN [SUAV]
options_NOMZ
to_PIN
Directors_NN
and_PHC
employees_NN
over_IN
ordinary_JJ
shares_NN
under_IN
six_CD
stock_NN
option_NOMZ
plans_NN
._.
On_PIN
November_NN
28_CD
,_,
2005_CD
the_DT
ordinary_JJ
shareholders_NN
of_PIN
Shire_NN
approved_VBD
the_DT
adoption_NOMZ
of_PIN
the_DT
Shire_NN
plc_NN
Portfolio_NN
Share_NN
Plan_NN
Parts_NN
A_NN
and_PHC
B_NN
,_,
a_DT
new_JJ
share_NN
based_VBN
compensation_NOMZ
plan_NN
,_,
which_WDT [SERE]
provides_VPRT
for_PIN
stock-settled_JJ
share_NN
appreciation_NOMZ
rights_NN
and_PHC
performance_NN
share_NN
awards_NN
to_TO
be_VB [PASS]
made_VBN
to_PIN
Directors_NN
and_PHC
employees_NN
over_IN
ordinary_JJ
shares_NN
and_CC
American_JJ
depositary_JJ
shares_NN
._.
No_SYNE
further_JJ
awards_NN
will_PRMD
be_VB [PASS]
made_VBN
under_IN
the_DT
previous_JJ
stock_NN
option_NOMZ
plans_NN
._.
The_DT
following_VBG
awards_NN
were_VBD [BEMA]
outstanding_PRED
as_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
:_:
Expiration_NOMZ
Compensation_NOMZ
Number_NN
of_PIN
period_NN
from_PIN
Scheme_NN
type_NN
awards_NN
date_NN
of_PIN
issue_NN
Vesting_JJ
period_NN
Executive_NN
Scheme_NN
Stock_NN
options_NOMZ
1,176,784_CD
10_CD
years_NN
3_CD
years_NN
,_,
subject_JJ
to_PIN
performance_NN
criteria_NN
2000_CD
Executive_NN
Scheme_NN
Stock_NN
options_NOMZ
22,787,658_CD
10_CD
years_NN
3_CD
years_NN
,_,
subject_JJ
to_PIN
performance_NN
criteria_NN
Sharesave_NN
Scheme_NN
Stock_NN
options_NOMZ
337,371_CD
6_CD
months_NN
after_IN
vesting_VBG
3_CD
or_CC
5_CD
years_NN
Stock_NN
Purchase_NN
Plan_NN
Stock_NN
options_NOMZ
640,777_CD
On_PIN
vesting_VBG
date_NN
27_CD
months_NN
SLI_NN
Plan_NN
Stock_NN
options_NOMZ
2,567_CD
10_CD
years_NN
Immediate_NN
on_PIN
acquisition_NOMZ
by_PIN
Shire_NN
BioChem_NN
Plan_NN
Stock_NN
options_NOMZ
3,525,582_CD
10_CD
years_NN
Immediate_NN
on_PIN
acquisition_NOMZ
by_PIN
Shire_NN
Total_NN
stock_NN
option_NOMZ
awards_NN
28,470,739_CD
Portfolio_NN
Share_NN
Plan_NN
Part_NN
A_NN
Stock-settled_JJ
share_NN
appreciation_NOMZ
3_CD
years_NN
,_,
subject_JJ
to_PIN
performance_NN
criteria_NN
rights_NN
ordinary_JJ
shares_NN
449,490_CD
5_CD
years_NN
for_PIN
executive_NN
Directors_NN
only_DWNT
Portfolio_NN
Share_NN
Plan_NN
Part_NN
A_NN
Stock-settled_JJ
share_NN
appreciation_NOMZ
3_CD
years_NN
,_,
subject_JJ
to_PIN
performance_NN
criteria_NN
i_FPP1
rights_NN
ADSs_NN
2,812,176_CD
5_CD
years_NN
for_PIN
executive_NN
Directors_NN
only_DWNT
Total_JJ
Portfolio_NN
Share_NN
Plan_NN
Part_NN
A_NN
3,261,666_CD
Portfolio_NN
Share_NN
Plan_NN
Part_NN
B_NN
Performance_NN
shares_NN
3_CD
years_NN
,_,
subject_JJ
to_PIN
performance_NN
criteria_NN
for_PIN
executive_NN
Directors_NN
only_DWNT
i_FPP1
For_PIN
the_DT
purposes_NN
of_PIN
this_DEMO
table_NN
ADSs_NN
have_VPRT [PEAS]
been_VBN [PASS]
converted_VBN
into_PIN
ordinary_JJ
shares_NN
._.
One_CD
ADS_NN
is_VPRT [BEMA]
equivalent_PRED
to_PIN
three_CD
ordinary_JJ
shares_NN
._.
a_DT
Stock_NN
option_NOMZ
plans_VPRT
i_FPP1
Shire_FW
Pharmaceuticals_NN
Executive_NN
Share_NN
Option_NOMZ
Scheme_NN
Parts_NN
A_NN
and_PHC
B_NN
Executive_NN
Scheme_NN
Options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
Executive_NN
Scheme_NN
are_VPRT [BEMA]
subject_PRED
to_PIN
performance_NN
criteria_NN
and_CC
can_POMD
not_XX0
be_VB [PASS]
exercised_VBN
in_PIN
full_JJ
,_,
unless_COND
Shires_NN
ordinary_JJ
share_NN
price_NN
increases_NN
at_PIN
a_DT
compound_NN
rate_NN
of_PIN
at_PIN
least_JJ
20.5_CD
%_NN
per_PIN
annum_NN
over_IN
a_DT
minimum_JJ
three-year_JJ
measurement_NOMZ
period_NN
._.
If_COND
Shires_NN
ordinary_JJ
share_NN
price_NN
increases_NN
at_PIN
a_DT
compound_NN
rate_NN
of_PIN
14.5_CD
%_NN
per_PIN
annum_NN
over_IN
a_DT
minimum_JJ
three-year_JJ
measurement_NOMZ
period_NN
,_,
60_CD
%_NN
of_PIN
the_DT
options_NOMZ
may_POMD
be_VB [PASS]
exercised_VBN
._.
If_COND
the_DT
share_NN
price_NN
does_VPRT
not_XX0
meet_VB
these_DEMO
conditions_NOMZ
at_PIN
any_QUAN
time_NN
,_,
none_INPR
of_PIN
the_DT
options_NOMZ
will_PRMD
become_VB
exercisable_JJ
._.
ii_FW
Shire_FW
plc_FW
2000_CD
Executive_NN
Share_NN
Option_NOMZ
Scheme_NN
2000_CD
Executive_NN
Scheme_NN
Options_NOMZ
granted_VBN [SUAV]
under_IN
this_DEMO
scheme_NN
are_VPRT [BEMA]
exercisable_JJ
subject_NN
to_PIN
certain_JJ
performance_NN
criteria_NN
._.
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
123_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
124_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
Dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
31_CD
Share-based_JJ
compensation_NOMZ
plans_NN
continued_VBD
The_DT
performance_NN
criteria_NN
were_VBD [PASS]
reviewed_VBN
in_PIN
2002_CD
to_TO
ensure_VB [SUAV] [PRIV] [THATD]
the_DT
criteria_NN
reflected_VBD [PRIV]
the_DT
market_NN
in_PIN
which_WDT [PIRE]
Shire_NN
operates_VPRT
._.
Given_VBN
Shires_NN
development_NOMZ
,_,
it_PIT
was_VBD [PASS]
considered_VBN [PRIV]
appropriate_JJ
that_THAC
an_DT
earnings_GER
per_PIN
share-based_JJ
measure_NN
should_NEMD
be_VB [PASS]
adopted_VBN
in_PIN
place_NN
of_PIN
share_NN
price_NN
growth_NN
targets_NN
._.
The_DT
performance_NN
criteria_NN
are_VPRT [PASS]
based_VBN
on_PIN
real_JJ
growth_NN
in_PIN
the_DT
diluted_JJ
earnings_GER
per_PIN
share_NN
reported_VBN [PUBV] [WZPAST]
in_PIN
the_DT
Companys_NN
Form_NN
10-K_NN
under_IN
US_FPP1
GAAP_NN
,_,
adjusted_VBN
to_TO
ensure_VB [SUAV] [PRIV]
a_DT
consistent_JJ
basis_NN
of_PIN
measurement_NOMZ
,_,
as_IN
approved_VBN
by_PIN
the_DT
Remuneration_NOMZ
Committee_NN
,_,
including_VBG [PRESP]
the_DT
add_VB [PUBV]
back_RB
of_PIN
significant_JJ
one_CD
time_NN
items_NN
option_NOMZ
EPS_NN
._.
Therefore_CONJ
,_,
the_DT
performance_NN
criteria_NN
were_VBD [PASS]
amended_VBN
so_OSUB
that_NULL
an_DT
option_NOMZ
would_PRMD
become_VB
exercisable_JJ
in_PIN
full_JJ
if_COND
Shires_NN
option_NOMZ
EPS_NN
growth_NN
over_IN
a_DT
three-year_JJ
period_NN
from_PIN
the_DT
date_NN
of_PIN
award_NN
exceeds_VPRT
the_DT
UK_NN
Retail_NN
Prices_NN
Index_NN
RPI_NN
for_PIN
the_DT
following_VBG
tranches_NN
of_PIN
grants_NN
:_:
Options_NOMZ
with_PIN
a_DT
grant_NN
value_NN
of_PIN
up_RB
to_PIN
100_CD
%_NN
of_PIN
salary_NN
RPI_NN
plus_PIN
9_CD
%_NN
directors_NN
,_,
RPI_NN
plus_PIN
15_CD
%_NN
Between_PIN
101_CD
%_NN
and_CC
200_CD
%_NN
of_PIN
salary_NN
RPI_NN
plus_PIN
15_CD
%_NN
Between_PIN
201_CD
%_NN
and_CC
300_CD
%_NN
of_PIN
salary_NN
RPI_NN
plus_PIN
21_CD
%_NN
Over_IN
301_CD
%_NN
of_PIN
salary_NN
RPI_NN
plus_PIN
27_CD
%_NN
The_DT
new_JJ
earnings_GER
per_PIN
share_NN
performance_NN
criteria_NN
apply_VPRT
to_PIN
options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
2000_CD
Executive_NN
Scheme_NN
from_PIN
August_NN
2002_CD
._.
iii_FW
Shire_FW
Pharmaceuticals_NN
Sharesave_NN
Scheme_NN
Sharesave_NN
Scheme_NN
Options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
Sharesave_NN
Scheme_NN
are_VPRT [PASS]
granted_VBN [SUAV]
with_PIN
an_DT
exercise_NN
price_NN
equal_JJ
to_PIN
80_CD
%_NN
of_PIN
the_DT
mid-market_JJ
price_NN
on_PIN
the_DT
day_NN
before_IN
invitations_NOMZ
are_VPRT [PASS]
issued_VBN
to_PIN
employees_NN
._.
iv_FW
Shire_FW
plc_FW
Employee_NN
Stock_NN
Purchase_NN
Plan_NN
Stock_NN
Purchase_NN
Plan_NN
Under_IN
the_DT
Stock_NN
Purchase_NN
Plan_NN
,_,
options_NOMZ
are_VPRT [PASS]
granted_VBN [SUAV]
with_PIN
an_DT
exercise_NN
price_NN
equal_JJ
to_PIN
85_CD
%_NN
of_PIN
the_DT
fair_JJ
market_NN
value_NN
of_PIN
a_DT
share_NN
on_PIN
the_DT
enrolment_NOMZ
date_NN
the_DT
first_JJ
day_NN
of_PIN
the_DT
offering_GER
period_NN
or_CC
the_DT
exercise_NN
date_NN
the_DT
last_JJ
day_NN
of_PIN
the_DT
offering_GER
period_NN
,_,
whichever_WDT
is_VPRT [BEMA]
the_DT
lower_JJ
._.
v_NN
Pharmavene_NN
1991_CD
Stock_NN
Option_NOMZ
Plan_NN
SLI_NN
Plan_NN
Options_NOMZ
issued_VBN
under_IN
the_DT
SLI_NN
Plan_NN
were_VBD [SPAU] [PASS]
originally_TIME
granted_VBN [SUAV]
over_IN
shares_NN
in_PIN
SLI_NN
,_,
formerly_TIME
Pharmavene_NN
Inc._NN
a_DT
company_NN
acquired_VBN [WZPAST]
by_PIN
the_DT
Company_NN
on_PIN
March_NN
23_CD
,_,
1997_CD
._.
Exercise_NN
of_PIN
these_DEMO
options_NOMZ
results_NN
in_PIN
the_DT
option_NOMZ
holder_NN
receiving_VBG [WZPRES]
ordinary_JJ
shares_NN
in_PIN
Shire_NN
._.
As_CONJ
a_NULL
result_NULL
of_PIN
the_DT
acquisition_NOMZ
of_PIN
SLI_NN
,_,
and_ANDC
in_PIN
accordance_NN
with_PIN
the_DT
terms_NN
of_PIN
the_DT
original_JJ
share_NN
option_NOMZ
plan_NN
,_,
all_QUAN
options_NOMZ
granted_VBN [SUAV]
under_IN
that_DEMO
plan_NN
became_VBD
immediately_TIME
capable_JJ
of_PIN
exercise_NN
._.
It_PIT
is_VPRT [PASS]
intended_VBN [SUAV]
that_THVC
no_SYNE
further_JJ
options_NOMZ
will_PRMD
be_VB [PASS]
granted_VBN [SUAV]
under_IN
the_DT
SLI_NN
Plan_NN
._.
vi_FW
BioChem_NN
Stock_NN
Option_NOMZ
Plan_NN
BioChem_NN
Plan_NN
Following_VBG [WZPRES]
the_DT
acquisition_NOMZ
of_PIN
BioChem_NN
Pharma_NN
Inc._NN
on_PIN
May_POMD
11_CD
,_,
2001_CD
,_,
the_DT
BioChem_NN
Stock_NN
Option_NOMZ
Plan_NN
was_VBD [PASS]
amended_VBN
such_OSUB
that_NULL
options_NOMZ
over_IN
BioChem_NN
Pharma_NN
Inc._NN
s_VPRT [BEMA]
common_JJ
stock_NN
became_VBD
options_NOMZ
over_IN
ordinary_JJ
shares_NN
of_PIN
Shire_NN
._.
A_DT
summary_NN
of_PIN
the_DT
status_NN
of_PIN
the_DT
Companys_NN
stock_NN
option_NOMZ
plans_NN
as_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
,_,
2004_CD
and_CC
2003_CD
and_CC
of_PIN
the_DT
related_JJ
transactions_NOMZ
during_PIN
the_DT
periods_NN
then_RB
ended_VBD
is_VPRT [PASS]
presented_VBN
below_PLACE
:_:
Weighted_JJ
average_JJ
exercise_NN
price_NN
Number_NN
of_PIN
Year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
shares_NN
Outstanding_JJ
as_IN
at_PIN
beginning_GER
of_PIN
period_NN
5.85_CD
27,343,625_CD
Granted_VBN [SUAV]
5.88_CD
8,733,811_CD
Exercised_VBN
4.53_CD
4,701,699_CD
Forfeited_NN
8.17_CD
2,904,998_CD
Outstanding_JJ
as_IN
at_PIN
end_NN
of_PIN
period_NN
5.85_CD
28,470,739_CD
Exercisable_JJ
as_IN
at_PIN
end_NN
of_PIN
period_NN
7.97_CD
7,987,369_CD
8,156,000_CD
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
under_IN
the_DT
2000_CD
Executive_NN
Scheme_NN
._.
These_DEMO
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
with_PIN
exercise_NN
prices_NN
equivalent_JJ
to_PIN
the_DT
market_NN
value_NN
on_PIN
the_DT
date_NN
of_PIN
grant_NN
._.
The_DT
weighted_JJ
average_JJ
fair_JJ
value_NN
of_PIN
options_NOMZ
granted_VBN [SUAV] [WZPAST]
was_VBD [BEMA]
3.08_CD
._.
124_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
125_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
Dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
31_CD
Share-based_JJ
compensation_NOMZ
plans_NN
continued_VBD
110,647_CD
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
under_IN
the_DT
Sharesave_NN
Scheme_NN
at_PIN
a_DT
price_NN
of_PIN
5.13_CD
._.
These_DEMO
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
with_PIN
an_DT
exercise_NN
price_NN
equal_JJ
to_PIN
80_CD
%_NN
of_PIN
the_DT
mid-market_JJ
price_NN
on_PIN
the_DT
day_NN
before_IN
invitations_NOMZ
were_VBD [PASS]
issued_VBN
to_PIN
employees_NN
._.
The_DT
weighted_JJ
average_JJ
fair_JJ
value_NN
of_PIN
options_NOMZ
granted_VBN [SUAV] [WZPAST]
was_VBD [BEMA]
3.24_CD
._.
36,690_CD
and_CC
430,474_CD
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
under_IN
the_DT
Stock_NN
Purchase_NN
Plan_NN
at_PIN
a_DT
price_NN
of_PIN
5.86_CD
and_CC
5.85_CD
,_,
respectively_RB
._.
These_DEMO
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
with_PIN
an_DT
exercise_NN
price_NN
equal_JJ
to_PIN
85_CD
%_NN
of_PIN
the_DT
mid-market_JJ
price_NN
on_PIN
the_DT
day_NN
before_IN
invitations_NOMZ
were_VBD [PASS]
issued_VBN
to_PIN
employees_NN
._.
The_DT
weighted_JJ
average_JJ
fair_JJ
value_NN
of_PIN
options_NOMZ
granted_VBN [SUAV] [WZPAST]
was_VBD [BEMA]
2.00_CD
._.
Weighted_JJ
average_JJ
exercise_NN
price_NN
Number_NN
of_PIN
Year_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
shares_NN
Outstanding_JJ
as_IN
at_PIN
beginning_GER
of_PIN
period_NN
6.10_CD
25,995,543_CD
Granted_VBN [SUAV]
5.14_CD
6,966,411_CD
Exercised_VBN
3.71_CD
2,097,716_CD
Forfeited_NN
7.58_CD
3,520,613_CD
Outstanding_JJ
as_IN
at_PIN
end_NN
of_PIN
period_NN
5.85_CD
27,343,625_CD
Exercisable_JJ
as_IN
at_PIN
end_NN
of_PIN
period_NN
8.65_CD
8,728,709_CD
6,665,144_CD
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
under_IN
the_DT
2000_CD
Executive_NN
Scheme_NN
._.
The_DT
weighted_JJ
average_JJ
fair_JJ
value_NN
of_PIN
options_NOMZ
granted_VBN [SUAV] [WZPAST]
was_VBD [BEMA]
2.78_CD
._.
94,861_CD
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
under_IN
the_DT
Sharesave_NN
Scheme_NN
at_PIN
a_DT
price_NN
of_PIN
3.74_CD
._.
The_DT
weighted_JJ
average_JJ
fair_JJ
value_NN
of_PIN
options_NOMZ
granted_VBN [SUAV] [WZPAST]
was_VBD [BEMA]
2.31_CD
._.
173,613_CD
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
under_IN
the_DT
Stock_NN
Purchase_NN
Plan_NN
at_PIN
a_DT
price_NN
of_PIN
3.92_CD
._.
In_PIN
relation_NOMZ
to_PIN
a_DT
grant_NN
under_IN
the_DT
Stock_NN
Purchase_NN
Plan_NN
at_PIN
a_DT
price_NN
of_PIN
8.06_CD
in_PIN
2001_CD
,_,
an_DT
additional_JJ
32,793_CD
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
at_PIN
a_DT
price_NN
of_PIN
4.58_CD
on_PIN
the_DT
2004_CD
maturity_NOMZ
date_NN
._.
The_DT
weighted_JJ
average_JJ
fair_JJ
value_NN
of_PIN
options_NOMZ
granted_VBN [SUAV] [WZPAST]
was_VBD [BEMA]
1.28_CD
._.
Weighted_JJ
average_JJ
exercise_NN
price_NN
Number_NN
of_PIN
Year_NN
to_PIN
December_NN
31_CD
,_,
2003_CD
shares_NN
Outstanding_JJ
as_IN
at_PIN
beginning_GER
of_PIN
period_NN
7.17_CD
20,051,297_CD
Granted_VBN [SUAV]
3.52_CD
9,407,852_CD
Exercised_VBN
2.86_CD
1,039,439_CD
Forfeited_NN
6.31_CD
2,424,167_CD
Outstanding_JJ
as_IN
at_PIN
end_NN
of_PIN
period_NN
6.10_CD
25,995,543_CD
Exercisable_JJ
as_IN
at_PIN
end_NN
of_PIN
period_NN
7.15_CD
8,989,450_CD
8,819,199_CD
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
under_IN
the_DT
2000_CD
Executive_NN
Scheme_NN
._.
These_DEMO
options_NOMZ
were_VBD [PASS]
issued_VBN
with_PIN
exercise_NN
prices_NN
equivalent_JJ
to_PIN
the_DT
market_NN
value_NN
on_PIN
the_DT
date_NN
of_PIN
grant_NN
._.
The_DT
weighted_JJ
average_JJ
fair_JJ
value_NN
of_PIN
options_NOMZ
granted_VBN [SUAV] [WZPAST]
was_VBD [BEMA]
1.93_CD
._.
182,639_CD
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
under_IN
the_DT
Sharesave_NN
Scheme_NN
at_PIN
a_DT
price_NN
of_PIN
3.86_CD
._.
The_DT
weighted_JJ
average_JJ
fair_JJ
value_NN
of_PIN
options_NOMZ
granted_VBN [SUAV] [WZPAST]
was_VBD [BEMA]
2.56_CD
._.
406,014_CD
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
under_IN
the_DT
Stock_NN
Purchase_NN
Plan_NN
at_PIN
a_DT
price_NN
of_PIN
4.09_CD
._.
The_DT
weighted_JJ
average_JJ
fair_JJ
value_NN
of_PIN
options_NOMZ
granted_VBN [SUAV] [WZPAST]
was_VBD [BEMA]
2.55_CD
._.
Options_NOMZ
outstanding_JJ
as_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
have_VPRT
the_DT
following_VBG
characteristics_NN
:_:
Weighted_JJ
Weighted_JJ
average_NN
exercise_NN
average_JJ
exercise_NN
price_NN
of_PIN
options_NOMZ
Number_NN
of_PIN
price_NN
of_PIN
options_NOMZ
Exercise_NN
prices_NN
Weighted_VBN
average_JJ
outstanding_JJ
options_NOMZ
exercisable_JJ
Number_NN
of_PIN
options_NOMZ
outstanding_JJ
remaining_VBG
life_NN
exercisable_JJ
5,651,719_CD
0.01_CD
4.00_CD
6.8_CD
3.46_CD
26,547_CD
3.19_CD
14,772,839_CD
4.01_CD
6.00_CD
8.1_CD
5.36_CD
2,070,405_CD
5.19_CD
5,739,709_CD
6.01_CD
10.00_CD
4.3_CD
7.05_CD
3,669,918_CD
7.20_CD
2,306,472_CD
10.01_CD
13.00_CD
4.0_CD
11.84_CD
2,220,499_CD
11.89_CD
28,470,739_CD
7,987,369_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
125_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
126_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
Dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
31_CD
Share-based_JJ
compensation_NOMZ
plans_NN
continued_VBD
b_NN
Stock-settled_JJ
share_NN
appreciation_NOMZ
rights_NN
Portfolio_NN
Share_NN
Plan_NN
Part_NN
A_NN
Stock-settled_JJ
share_NN
appreciation_NOMZ
rights_NN
granted_VBN [SUAV]
under_IN
the_DT
Portfolio_NN
Share_NN
Plan_NN
Part_NN
A_NN
are_VPRT [BEMA]
exercisable_JJ
subject_NN
to_PIN
certain_JJ
performance_NN
criteria_NN
._.
In_PIN
respect_NN
of_PIN
any_QUAN
award_NN
made_VBD
to_PIN
executive_JJ
Directors_NN
performance_NN
conditions_NOMZ
will_PRMD
be_VB [PASS]
based_VBN
on_PIN
relative_JJ
total_JJ
shareholder_NN
return_NN
._.
Vesting_VBG
will_PRMD
depend_VB
on_PIN
relative_JJ
total_JJ
shareholder_NN
return_NN
performance_NN
against_PIN
two_CD
comparator_NN
groups_NN
._.
For_PIN
one-third_NN
of_PIN
the_DT
award_NN
,_,
the_DT
comparator_NN
group_NN
will_PRMD
be_VB [BEMA]
the_DT
Financial_NN
Times_NN
Stock_NN
Exchange_NN
100_CD
constituents_NN
excluding_VBG [WZPRES]
financial_JJ
institutions_NOMZ
and_CC
for_PIN
two-thirds_NN
of_PIN
the_DT
award_NN
the_DT
comparator_NN
group_NN
will_PRMD
be_VB [BEMA]
a_DT
group_NN
of_PIN
international_JJ
companies_NN
from_PIN
the_DT
pharmaceutical_JJ
sector_NN
._.
In_CONJ
addition_NULL
,_,
before_IN
awards_NN
granted_VBN [SUAV] [WZPAST]
to_PIN
executive_JJ
Directors_NN
will_PRMD
vest_NN
,_,
the_DT
Committee_NN
must_NEMD
be_VB [PASS]
satisfied_VBN
that_DEMO
the_DT
underlying_VBG
performance_NN
of_PIN
the_DT
Company_NN
is_VPRT [BEMA]
sufficient_PRED
to_TO
justify_VB
this_DEMP
._.
Where_RB
median_JJ
performance_NN
is_VPRT [PASS]
achieved_VBN
,_,
1_CD
33_CD
3_CD
%_NN
of_PIN
stock-settled_JJ
share_NN
appreciation_NOMZ
rights_NN
will_PRMD
vest_NN
,_,
rising_VBG [PRESP]
on_PIN
a_DT
straight-line_JJ
basis_NN
to_PIN
full_JJ
vesting_GER
at_PIN
upper_JJ
quartile_JJ
performance_NN
._.
Awards_RB
granted_VBN [SUAV]
to_PIN
employees_NN
below_PLACE
executive_JJ
Director_NN
level_NN
will_PRMD
not_XX0
be_VB [BEMA]
subject_PRED
to_PIN
performance_NN
conditions_NOMZ
._.
Once_TIME
awards_NN
have_VPRT [PEAS]
vested_VBN
,_,
participants_NN
will_PRMD
have_VB
until_IN
the_DT
fifth_JJ
anniversary_NN
of_PIN
the_DT
date_NN
of_PIN
grant_NN
to_TO
exercise_VB
their_TPP3
awards_NN
._.
A_DT
summary_NN
of_PIN
the_DT
status_NN
of_PIN
the_DT
Companys_NN
stock-settled_VBD
share_NN
appreciation_NOMZ
rights_NN
as_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
and_CC
of_PIN
the_DT
related_JJ
transactions_NOMZ
during_PIN
the_DT
periods_NN
then_RB
ended_VBD
is_VPRT [PASS]
presented_VBN
below_PLACE
:_:
Year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
Weighted_JJ
average_JJ
exercise_NN
price_NN
Number_NN
of_PIN
Ordinary_NN
shares_NN
shares_NN
Outstanding_JJ
as_IN
at_PIN
beginning_GER
of_PIN
period_NN
Granted_VBN [SUAV]
7.17_CD
449,490_CD
Exercised_VBN
Forfeited_NN
Outstanding_JJ
as_IN
at_PIN
end_NN
of_PIN
period_NN
7.17_CD
449,490_CD
Exercisable_JJ
as_IN
at_PIN
end_NN
of_PIN
period_NN
449,490_CD
stock-settled_JJ
share_NN
appreciation_NOMZ
rights_NN
were_VBD [PASS]
granted_VBN [SUAV]
over_IN
ordinary_JJ
shares_NN
under_IN
the_DT
Portfolio_NN
Share_NN
Plan_NN
Part_NN
A._NN
The_NN
weighted_JJ
average_NN
fair_JJ
value_NN
of_PIN
options_NOMZ
granted_VBN [SUAV] [WZPAST]
in_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
is_VPRT [BEMA]
2.85_CD
._.
Stock-settled_JJ
share_NN
appreciation_NOMZ
rights_NN
over_IN
ordinary_JJ
shares_NN
outstanding_JJ
as_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
have_VPRT
the_DT
following_VBG
characteristics_NN
:_:
Weighted_JJ
Weighted_JJ
average_NN
exercise_NN
average_JJ
exercise_NN
price_NN
of_PIN
options_NOMZ
Number_NN
of_PIN
price_NN
of_PIN
options_NOMZ
Exercise_NN
prices_NN
Weighted_VBN
average_JJ
outstanding_JJ
options_NOMZ
exercisable_JJ
Number_NN
of_PIN
options_NOMZ
outstanding_JJ
remaining_VBG
life_NN
exercisable_JJ
449,490_CD
6.01_CD
10.00_CD
4.9_CD
7.17_CD
Year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
Weighted_JJ
average_JJ
exercise_NN
price_NN
Number_NN
of_PIN
American_JJ
Depositary_NN
Shares_NN
$_$
ADSs_JJ
Outstanding_JJ
as_IN
at_PIN
beginning_GER
of_PIN
period_NN
Granted_VBN [SUAV]
37.80_CD
940,392_CD
Exercised_VBN
Forfeited_NN
37.70_CD
3,000_CD
Outstanding_JJ
as_IN
at_PIN
end_NN
of_PIN
period_NN
37.80_CD
937,392_CD
Exercisable_JJ
as_IN
at_PIN
end_NN
of_PIN
period_NN
940,392_CD
stock-settled_JJ
share_NN
appreciation_NOMZ
rights_NN
were_VBD [PASS]
granted_VBN [SUAV]
over_IN
American_JJ
Depositary_NN
Shares_NN
equivalent_JJ
to_PIN
2,821,176_CD
ordinary_JJ
shares_NN
under_IN
the_DT
Portfolio_NN
Share_NN
Plan_NN
Part_NN
A._NN
The_NN
937,392_CD
stock-settled_JJ
share_NN
appreciation_NOMZ
rights_NN
over_IN
ADSs_NN
outstanding_JJ
at_PIN
December_NN
31_CD
,_,
2005_CD
are_VPRT [BEMA]
equivalent_PRED
to_PIN
2,812,176_CD
ordinary_JJ
shares_NN
._.
The_DT
average_JJ
fair_JJ
value_NN
of_PIN
options_NOMZ
granted_VBN [SUAV] [WZPAST]
in_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
is_VPRT
$_$
14.92_CD
._.
126_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
127_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
In_PIN
thousands_NN
of_PIN
US_FPP1
Dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
31_CD
Share-based_JJ
compensation_NOMZ
plans_NN
continued_VBD
Stock-settled_JJ
share_NN
appreciation_NOMZ
rights_NN
over_IN
American_JJ
Depositary_NN
Shares_NN
outstanding_JJ
as_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
have_VPRT
the_DT
following_VBG
characteristics_NN
:_:
Weighted_JJ
Weighted_JJ
average_NN
exercise_NN
average_JJ
exercise_NN
price_NN
of_PIN
options_NOMZ
Number_NN
of_PIN
price_NN
of_PIN
options_NOMZ
Exercise_NN
prices_NN
Weighted_VBN
average_JJ
outstanding_JJ
options_NOMZ
exercisable_JJ
Number_NN
of_PIN
options_NOMZ
outstanding_JJ
$_$
remaining_JJ
life_NN
$_$
exercisable_JJ
$_$
2,812,176_CD
35.01_CD
40.00_CD
4.9_CD
37.80_CD
c_NN
Performance_NN
share_NN
plan_NN
Portfolio_NN
Share_NN
Plan_NN
Part_NN
B_NN
Performance_NN
share_NN
awards_NN
granted_VBN [SUAV]
under_IN
the_DT
Portfolio_NN
Share_NN
Plan_NN
Part_NN
B_NN
are_VPRT [BEMA]
exercisable_JJ
subject_NN
to_PIN
certain_JJ
performance_NN
criteria_NN
._.
For_PIN
one-third_NN
of_PIN
an_DT
award_NN
,_,
the_DT
comparator_NN
group_NN
will_PRMD
be_VB [BEMA]
the_DT
Financial_NN
Times_NN
Stock_NN
Exchange_NN
100_CD
constituents_NN
excluding_VBG [WZPRES]
financial_JJ
institutions_NOMZ
and_CC
for_PIN
two-thirds_NN
of_PIN
the_DT
award_NN
the_DT
comparator_NN
group_NN
will_PRMD
be_VB [BEMA]
a_DT
group_NN
of_PIN
international_JJ
companies_NN
from_PIN
the_DT
pharmaceutical_JJ
sector_NN
._.
In_CONJ
addition_NULL
,_,
before_IN
awards_NN
granted_VBN [SUAV] [WZPAST]
to_PIN
executive_JJ
Directors_NN
will_PRMD
vest_NN
,_,
the_DT
Committee_NN
must_NEMD
be_VB [PASS]
satisfied_VBN
1_CD
that_DEMO
the_DT
underlying_VBG
performance_NN
of_PIN
the_DT
Company_NN
is_VPRT [BEMA]
sufficient_PRED
to_TO
justify_VB
this_DEMP
._.
Where_RB
median_JJ
performance_NN
is_VPRT [PASS]
achieved_VBN
,_,
33_CD
3_CD
%_NN
of_PIN
stock-settled_JJ
share_NN
appreciation_NOMZ
rights_NN
will_PRMD
vest_NN
,_,
rising_VBG [PRESP]
on_PIN
a_DT
straight-line_JJ
basis_NN
to_PIN
full_JJ
vesting_GER
at_PIN
upper_JJ
quartile_JJ
performance_NN
._.
At_PIN
December_NN
31_CD
,_,
2005_CD
no_SYNE
awards_NN
had_VBD [PEAS]
been_VBN [PASS]
made_VBN
._.
32_CD
Subsequent_JJ
event_NN
IDB_NN
loan_NN
repayment_NOMZ
On_PIN
February_NN
10_CD
,_,
2006_CD
the_DT
Company_NN
received_VBD
notice_NN
from_PIN
IDB_NN
that_TOBJ
it_PIT
intended_VBD [SUAV]
to_TO
repay_VB
in_PIN
full_JJ
all_QUAN
drawings_GER
for_PIN
injectable_JJ
flu_NN
development_NOMZ
of_PIN
$_$
70.6_CD
million_CD
,_,
together_RB
with_PIN
accrued_VBN
and_PHC
capitalized_VBN
interest_NN
of_PIN
$_$
8.1_CD
million_CD
see_VPRT [PRIV]
Note_NN
6_CD
._.
The_DT
Company_NN
received_VBD
the_DT
$_$
78.7_CD
million_CD
outstanding_JJ
on_PIN
February_NN
14_CD
,_,
2006_CD
._.
The_DT
amounts_NN
outstanding_JJ
in_PIN
respect_NN
of_PIN
drawings_GER
for_PIN
pipeline_NN
development_NOMZ
principal_JJ
drawings_GER
of_PIN
$_$
29.4_CD
million_CD
,_,
are_VPRT [BEMA]
unaffected_PRED
by_PIN
this_DEMO
repayment_NOMZ
._.
Quarterly_JJ
results_NN
of_PIN
operations_NOMZ
unaudited_JJ
The_DT
following_VBG
table_NN
presents_NN
summarized_VBN
unaudited_JJ
quarterly_JJ
results_NN
for_PIN
the_DT
years_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
and_CC
2004_CD
._.
ii_FW
During_PIN
Q3_NN
2004_CD
the_DT
Company_NN
recorded_VBD
a_DT
loss_NN
on_PIN
redemption_NOMZ
of_PIN
the_DT
convertible_JJ
loan_NN
notes_NN
of_PIN
$_$
7.4_CD
million_CD
,_,
which_WDT [SERE]
resulted_VBD
from_PIN
the_DT
write-off_PIN
of_PIN
unamortized_JJ
debt_NN
issuance_NN
costs_NN
._.
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
127_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
128_CD
Five-year_JJ
review_NN
In_PIN
thousands_NN
of_PIN
US_FPP1
Dollars_NN
,_,
except_PIN
where_RB
indicated_VBN [PRIV]
Selected_VBN
financial_JJ
data_NN
The_DT
selected_VBN
consolidated_JJ
financial_JJ
data_NN
presented_VBN
below_PLACE
as_RB
at_PIN
December_NN
31_CD
,_,
2005_CD
and_CC
2004_CD
and_CC
for_PIN
each_QUAN
of_PIN
the_DT
three_CD
years_NN
in_PIN
the_DT
period_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
were_VBD [PASS]
derived_VBN
from_PIN
the_DT
audited_JJ
consolidated_JJ
financial_JJ
statements_NOMZ
of_PIN
the_DT
Company_NN
,_,
included_VBD
herein_NN
._.
The_DT
selected_VBN
consolidated_JJ
financial_JJ
data_NN
presented_VBN
below_PLACE
as_RB
at_PIN
December_NN
31_CD
,_,
2003_CD
,_,
2002_CD
and_CC
2001_CD
and_CC
for_PIN
the_DT
two_CD
years_NN
to_PIN
December_NN
31_CD
,_,
2002_CD
were_VBD [PASS]
derived_VBN
from_PIN
the_DT
audited_JJ
consolidated_JJ
financial_JJ
statements_NOMZ
of_PIN
the_DT
Company_NN
,_,
which_WDT [SERE]
are_VPRT [PASS]
not_XX0
included_VBN
herein_NN
._.
Certain_JJ
amounts_NN
reported_VBN [PUBV] [WZPAST]
in_PIN
previous_JJ
years_NN
have_VPRT [PEAS]
been_VBN [PASS]
reclassified_VBN
to_TO
conform_VB
to_PIN
the_DT
2005_CD
presentation_NOMZ
._.
These_DEMP
were_VBD [BEMA]
in_PIN
respect_NN
of_PIN
the_DT
implementation_NOMZ
of_PIN
the_DT
new_JJ
business_NOMZ
model_NN
in_PIN
2004_CD
and_CC
the_DT
closure_NN
of_PIN
Lead_JJ
Optimization_NOMZ
together_RB
with_PIN
the_DT
exit_NN
of_PIN
certain_JJ
properties_NN
in_PIN
2003_CD
._.
Included_VBN [PASTP]
in_PIN
2001_CD
were_VBD
$_$
29.7_CD
million_CD
of_PIN
asset_NN
impairment_NOMZ
charges_NN
,_,
$_$
83.5_CD
million_CD
of_PIN
merger_NN
transaction_NOMZ
expenses_NN
and_CC
$_$
10.2_CD
million_CD
of_PIN
costs_NN
in_PIN
relation_NOMZ
to_PIN
the_DT
disposition_NOMZ
of_PIN
certain_JJ
assets_NN
._.
All_QUAN
of_PIN
these_DEMO
costs_NN
were_VBD [BEMA]
in_PIN
relation_NOMZ
to_PIN
the_DT
merger_NN
with_PIN
BioChem_NN
in_PIN
2001_CD
._.
ii_FW
Total_JJ
other_JJ
income_NN
expense_NN
,_,
net_JJ
includes_VPRT
interest_NN
receivable_NN
and_CC
payable_JJ
,_,
the_DT
gain_NN
or_CC
loss_NN
on_PIN
the_DT
sale_NN
of_PIN
assets_NN
,_,
impairment_NOMZ
of_PIN
long-term_JJ
investments_NOMZ
and_CC
transactional_JJ
foreign_JJ
exchange_NN
._.
In_PIN
2005_CD
it_PIT
includes_VPRT
$_$
3.9_CD
million_CD
on_PIN
the_DT
sale_NN
of_PIN
a_DT
portfolio_NN
investment_NOMZ
and_CC
$_$
3.6_CD
million_CD
on_PIN
the_DT
sale_NN
of_PIN
the_DT
drug_NN
formulation_NOMZ
business_NOMZ
._.
In_PIN
2004_CD
it_PIT
includes_VPRT
$_$
14.9_CD
million_CD
on_PIN
the_DT
sale_NN
of_PIN
a_DT
portfolio_NN
investment_NOMZ
._.
See_VB [PRIV]
Note_VB [PRIV]
26_CD
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
in_PIN
this_DEMO
Form_NN
10-K_NN
._.
In_PIN
2001_CD
there_EX
was_VBD
a_DT
$_$
55.7_CD
million_CD
write-down_NN
of_PIN
investments_NOMZ
related_VBN [WZPAST]
to_PIN
the_DT
BioChem_NN
merger_NN
._.
iii_FW
As_CONJ
a_NULL
consequence_NULL
of_PIN
the_DT
adoption_NOMZ
of_PIN
SFAS_NN
No._NN
._.
142_CD
with_PIN
effect_NN
from_PIN
January_NN
1_CD
,_,
2002_CD
,_,
the_DT
amortization_NOMZ
expense_NN
included_VBD
in_PIN
2001_CD
in_PIN
the_DT
selected_VBN
consolidated_JJ
financial_JJ
data_NN
presented_VBN [WZPAST]
is_VPRT [BEMA]
not_XX0
on_PIN
a_DT
consistent_JJ
basis_NN
of_PIN
accounting_GER
with_PIN
subsequent_JJ
periods_NN
._.
Net_JJ
income_NN
for_PIN
2001_CD
would_PRMD
have_VB [PEAS]
been_VBN
$_$
49.5_CD
million_CD
if_COND
goodwill_NN
had_VBD [PEAS]
not_XX0
been_VBN [PASS]
amortized_VBN
._.
128_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
129_CD
Statement_NOMZ
of_PIN
Directors_NN
responsibilities_NOMZ
Directors_NN
responsibilities_NOMZ
The_DT
Directors_NN
are_VPRT [BEMA]
responsible_PRED
for_PIN
keeping_VBG
proper_JJ
accounting_GER
records_NN
The_DT
Directors_NN
are_VPRT [BEMA]
responsible_PRED
for_PIN
preparing_VBG
the_DT
Annual_JJ
Report_NN
and_CC
the_DT
which_WDT
disclose_VPRT [PUBV]
with_PIN
reasonable_JJ
accuracy_NN
at_PIN
any_QUAN
time_NN
the_DT
financial_JJ
financial_JJ
statements_NOMZ
._.
The_DT
Directors_NN
have_VPRT [PEAS]
chosen_VBN
to_TO
prepare_VB
accounts_NN
position_NOMZ
of_PIN
the_DT
Company_NN
,_,
for_PIN
safeguarding_VBG
the_DT
assets_NN
,_,
for_PIN
taking_VBG
for_PIN
the_DT
Group_NN
in_PIN
accordance_NN
with_PIN
International_NN
Financial_NN
Reporting_GER
reasonable_JJ
steps_NN
for_PIN
the_DT
prevention_NOMZ
and_PHC
detection_NOMZ
of_PIN
fraud_NN
and_CC
other_JJ
Standards_NN
IFRS_NN
and_CC
for_PIN
the_DT
Company_NN
in_PIN
accordance_NN
with_PIN
United_NN
irregularities_NOMZ
and_CC
for_PIN
the_DT
preparation_NOMZ
of_PIN
a_DT
Directors_NN
Report_NN
and_PHC
Kingdom_NN
Generally_RB
Accepted_JJ
Accounting_GER
Practice_NN
UK_NN
GAAP_NN
._.
Directors_NN
Remuneration_NOMZ
Report_NN
which_WDT [WHSUB]
comply_VPRT
with_PIN
the_DT
requirements_NOMZ
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
._.
In_PIN
the_DT
case_NN
of_PIN
UK_NN
GAAP_NN
accounts_NN
,_,
the_DT
Directors_NN
are_VPRT [PASS]
required_VBN [SUAV]
to_TO
prepare_VB
financial_JJ
statements_NOMZ
for_PIN
each_QUAN
financial_JJ
year_NN
which_WDT [WHSUB]
give_VPRT
a_DT
true_JJ
and_PHC
fair_JJ
The_DT
Directors_NN
are_VPRT [BEMA]
responsible_PRED
for_PIN
the_DT
maintenance_NN
and_PHC
integrity_NOMZ
of_PIN
the_DT
view_NN
of_PIN
the_DT
state_NN
of_PIN
affairs_NN
of_PIN
the_DT
Company_NN
and_CC
of_PIN
the_DT
profit_NN
or_CC
loss_NN
Company_NN
website_NN
._.
Legislation_NOMZ
in_PIN
the_DT
United_NN
Kingdom_NN
governing_VBG [WZPRES]
the_DT
of_PIN
the_DT
Company_NN
for_PIN
that_DEMO
period_NN
._.
In_PIN
preparing_VBG
these_DEMO
financial_JJ
statements_NOMZ
,_,
preparation_NOMZ
and_PHC
dissemination_NOMZ
of_PIN
financial_JJ
statements_NOMZ
differs_VPRT
from_PIN
the_DT
Directors_NN
are_VPRT [PASS]
required_VBN [SUAV]
to_TO
:_:
legislation_NOMZ
in_PIN
other_JJ
jurisdictions_NOMZ
._.
select_JJ
suitable_JJ
accounting_GER
policies_NN
and_CC
then_RB
apply_VB
them_TPP3
consistently_RB
:_:
make_VB
judgments_NOMZ
and_PHC
estimates_NN
that_TSUB
are_VPRT [BEMA]
reasonable_PRED
and_PHC
prudent_PRED
:_:
and_ANDC
state_NN
whether_IN
applicable_JJ
accounting_GER
standards_NN
have_VPRT [PEAS]
been_VBN [PASS]
followed_VBN
._.
In_PIN
the_DT
case_NN
of_PIN
IFRS_NN
accounts_NN
,_,
International_NN
Accounting_GER
Standard_NN
1_CD
requires_VPRT [SUAV]
that_THVC
financial_JJ
statements_NOMZ
present_JJ
fairly_RB
for_PIN
each_QUAN
financial_JJ
year_NN
the_DT
Companys_NN
financial_JJ
position_NOMZ
,_,
financial_JJ
performance_NN
and_PHC
cash_NN
flows_NN
._.
This_DEMP
requires_VPRT [SUAV]
the_DT
faithful_JJ
representation_NOMZ
of_PIN
the_DT
effects_NN
of_PIN
transactions_NOMZ
,_,
other_JJ
events_NN
and_PHC
conditions_NOMZ
in_PIN
accordance_NN
with_PIN
the_DT
definitions_NOMZ
and_PHC
recognition_NOMZ
criteria_NN
for_PIN
assets_NN
,_,
liabilities_NOMZ
,_,
income_NN
and_PHC
expenses_NN
set_VBN [WZPAST]
out_PIN
in_PIN
the_DT
International_NN
Accounting_GER
Standards_NN
Boards_NN
Framework_NN
for_PIN
the_DT
preparation_NOMZ
and_PHC
Presentation_NOMZ
of_PIN
Financial_NN
Statements_NOMZ
._.
In_PIN
virtually_RB
all_QUAN
circumstances_NN
,_,
a_DT
fair_JJ
presentation_NOMZ
will_PRMD
be_VB [BYPA]
achieved_VBN
by_PIN
compliance_NN
with_PIN
all_QUAN
applicable_JJ
International_NN
Financial_NN
Reporting_GER
Standards_NN
._.
Directors_NN
are_VPRT [SPAU] [PASS]
also_RB
required_VBN [SUAV]
to_TO
:_:
properly_RB
select_JJ
and_CC
apply_VB
accounting_GER
policies_NN
:_:
present_JJ
information_NOMZ
,_,
including_VBG
accounting_GER
policies_NN
,_,
in_PIN
a_DT
manner_NN
that_TSUB
provides_VPRT
relevant_JJ
,_,
reliable_JJ
,_,
comparable_JJ
and_PHC
understandable_JJ
information_NOMZ
:_:
and_ANDC
provide_VB
additional_JJ
disclosures_NN
when_RB
compliance_NN
with_PIN
the_DT
specific_JJ
requirements_NOMZ
in_PIN
International_NN
Financial_NN
Reporting_GER
Standards_NN
is_VPRT [BEMA]
insufficient_PRED
to_TO
enable_VB
users_NN
to_TO
understand_VB [PRIV]
the_DT
impact_NN
of_PIN
particular_JJ
transactions_NOMZ
,_,
other_JJ
events_NN
and_PHC
conditions_NOMZ
on_PIN
the_DT
entitys_NN
financial_JJ
position_NOMZ
and_CC
financial_JJ
performance_NN
._.
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
129_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
130_CD
Summary_NN
financial_JJ
statement_NOMZ
IFRS_NN
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2005_CD
General_NN
Business_NOMZ
review_NN
The_DT
summary_NN
financial_JJ
statement_NOMZ
does_VPRT
not_XX0
contain_VB
sufficient_JJ
A_DT
review_NN
of_PIN
the_DT
Groups_NN
business_NOMZ
and_CC
important_JJ
events_NN
during_PIN
the_DT
information_NOMZ
to_TO
allow_VB [SUAV]
for_PIN
as_RB
full_JJ
an_DT
understanding_GER
of_PIN
the_DT
results_NN
year_NN
and_CC
likely_JJ
future_NN
developments_NOMZ
is_VPRT [PASS]
set_VBN
out_PIN
in_PIN
the_DT
Chairmans_NN
and_PHC
state_NN
of_PIN
affairs_NN
of_PIN
the_DT
Company_NN
or_CC
Group_NN
and_CC
of_PIN
the_DT
policies_NN
statement_NOMZ
,_,
the_DT
Chief_NN
Executive_NN
Officers_NN
review_NN
,_,
the_DT
financial_JJ
review_NN
and_PHC
arrangements_NOMZ
concerning_VBG [WZPRES]
Directors_NN
remuneration_NOMZ
,_,
as_RB
would_PRMD
and_CC
the_DT
Directors_NN
remuneration_NOMZ
report_NN
in_PIN
the_DT
full_JJ
UK_NN
statutory_JJ
annual_JJ
be_VB [BYPA]
provided_VBN
by_PIN
the_DT
full_JJ
annual_JJ
financial_JJ
statements_NOMZ
and_PHC
reports_NN
._.
accounts_NN
,_,
which_WDT [SERE]
are_VPRT [BEMA]
similar_PRED
to_PIN
the_DT
statements_NOMZ
contained_VBN [WZPAST]
in_PIN
the_DT
annual_JJ
The_DT
summary_NN
financial_JJ
statement_NOMZ
is_VPRT [PASS]
prepared_VBN
in_PIN
accordance_NN
with_PIN
review_NN
at_PIN
the_DT
front_NN
of_PIN
this_DEMO
document_NOMZ
which_WDT [WHSUB]
form_VPRT
part_NN
of_PIN
this_DEMO
summary_NN
International_NN
Financial_NN
Reporting_GER
Standards_NN
IFRS_NN
._.
information_NOMZ
,_,
the_DT
full_JJ
UK_NN
statutory_JJ
accounts_NN
,_,
the_DT
auditors_NN
report_VPRT [PUBV]
on_PIN
those_DEMO
accounts_NN
and_CC
the_DT
Directors_NN
report_NN
should_NEMD
be_VB [PASS]
consulted_VBN
._.
Details_NN
of_PIN
post_NN
balance_NN
sheet_NN
events_NN
are_VPRT [PASS]
contained_VBN
within_PIN
the_DT
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
._.
In_PIN
accordance_NN
with_PIN
Section_NOMZ
239_CD
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
shareholders_NN
have_VPRT
a_DT
right_NN
and_CC
can_POMD
elect_VB
to_TO
obtain_VB
the_DT
full_JJ
report_NN
Directors_NN
and_PHC
accounts_NN
free_JJ
of_PIN
charge_NN
by_PIN
writing_VBG [PUBV]
to_TO
:_:
The_DT
Directors_NN
who_WP [WHSUB]
served_VBD
during_PIN
the_DT
year_NN
were_VBD
as_IN
follows_VPRT
:_:
The_DT
Company_NN
Secretary_NN
Dr_NN
James_NN
Cavanaugh_NN
Shire_NN
plc_NN
Chairman_NN
,_,
Non-executive_JJ
Director_NN
Hampshire_NN
International_NN
Business_NOMZ
Park_NN
and_PHC
Chairman_NN
of_PIN
the_DT
Nomination_NOMZ
Committee_NN
Chineham_NN
Basingstoke_NN
Mr_NN
Matthew_NN
Emmens_NN
Hampshire_NN
Chief_NN
Executive_NN
Officer_NN
RG24_NN
8EP_NN
Mr_NN
Angus_NN
Russell_NN
The_NN
full_JJ
UK_NN
statutory_JJ
annual_JJ
accounts_NN
are_VPRT [PASS]
signed_VBN
on_PIN
behalf_NN
Chief_NN
Financial_NN
Officer_NN
of_PIN
the_DT
Board_NN
by_PIN
AC_NN
Russell_NN
,_,
Chief_NN
Financial_NN
Officer_NN
._.
Dr_NN
Barry_NN
Price_NN
The_NN
Companys_NN
auditors_NN
have_VPRT [PEAS]
given_VBN
an_DT
unqualified_JJ
report_NN
on_PIN
the_DT
Senior_JJ
Non-executive_JJ
Director_NN
statutory_JJ
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2005_CD
._.
and_ANDC
Chairman_NN
of_PIN
the_DT
Remuneration_NOMZ
Committee_NN
The_NN
report_NN
did_VBD
not_XX0
contain_VB
any_QUAN
statement_NOMZ
under_IN
Section_NOMZ
237_CD
2_CD
or_CC
3_CD
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
._.
The_DT
Hon_NN
James_NN
Grant_NN
Non-executive_JJ
Director_NN
Summary_NN
Directors_NN
report_VPRT [PUBV]
Results_NN
and_PHC
dividends_NN
Mr_NN
Ronald_NN
Nordmann_NN
For_PIN
the_DT
year_NN
to_PIN
31_CD
December_NN
2005_CD
,_,
the_DT
Companys_NN
total_NN
revenues_NN
Non-executive_JJ
Director_NN
increased_VBN [WZPAST]
by_PIN
17_CD
%_NN
to_TO
$_$
1,599.3_CD
million_CD
,_,
compared_VBN
to_TO
$_$
1,363.2_CD
million_CD
in_PIN
2004_CD
._.
Net_JJ
loss_NN
for_PIN
the_DT
year_NN
to_PIN
31_CD
December_NN
2005_CD
was_VBD
$_$
177.4_CD
million_CD
Mr_NN
Robin_NN
Buchanan_NN
compared_VBD
to_PIN
net_JJ
income_NN
of_PIN
$_$
96.5_CD
million_CD
in_PIN
2004_CD
._.
The_DT
results_NN
for_PIN
Non-executive_JJ
Director_NN
2005_CD
include_VPRT
a_DT
$_$
527_CD
million_CD
impairment_NOMZ
of_PIN
the_DT
goodwill_NN
that_TSUB
arose_VBD
on_PIN
the_DT
acquisition_NOMZ
of_PIN
BioChem_NN
Pharma_NN
Inc._NN
2004_CD
:_:
$_$
132.6_CD
million_CD
Mr_NN
David_NN
Kappler_NN
impairment_NOMZ
recorded_VBN
._.
Non-executive_JJ
Director_NN
and_PHC
Chairman_NN
of_PIN
the_DT
Audit_NN
Committee_NN
The_DT
net_JJ
assets_NN
of_PIN
the_DT
Group_NN
as_IN
at_PIN
31_CD
December_NN
2005_CD
were_VBD
$_$
4,083.1_CD
million_CD
2004_CD
:_:
$_$
4,244.9_CD
million_CD
._.
Mr_NN
Patrick_NN
Langlois_NN
Non-executive_JJ
Director_NN
In_PIN
respect_NN
of_PIN
the_DT
six_CD
months_NN
to_PIN
31_CD
December_NN
2005_CD
the_DT
Board_NN
appointed_VBN
11_CD
November_NN
2005_CD
resolved_VBN [SUAV]
to_TO
pay_VB
a_DT
second_JJ
interim_JJ
dividend_NN
of_PIN
4.419_CD
per_PIN
ordinary_JJ
share_NN
2004_CD
:_:
3.85_CD
US_FPP1
per_PIN
share_NN
._.
Together_RB
with_PIN
the_DT
first_JJ
interim_JJ
payment_NOMZ
of_PIN
1.8246_CD
US_FPP1
per_PIN
ordinary_JJ
share_NN
,_,
2004_CD
:_:
1.82_CD
per_PIN
share_NN
,_,
this_DEMP
represents_VPRT
total_JJ
dividends_NN
for_PIN
2005_CD
of_PIN
6.2436_CD
per_PIN
ordinary_JJ
share_NN
2004_CD
:_:
5.67_CD
per_PIN
share_NN
._.
This_DEMP
is_VPRT [BEMA]
consistent_PRED
with_PIN
Shires_NN
stated_VBD [PUBV]
policy_NN
of_PIN
paying_VBG
a_DT
dividend_NN
Tatjana_NN
May_POMD
semi-annually_RB
,_,
set_VBN [PASTP]
in_PIN
US_FPP1
per_PIN
share_NN
ADS_NN
,_,
with_PIN
the_DT
first_JJ
interim_JJ
Company_NN
Secretary_NN
payment_NOMZ
in_PIN
each_QUAN
year_NN
being_VBG [WZPRES] [PASS]
maintained_VBN [PUBV]
at_PIN
a_DT
consistent_JJ
level_NN
._.
Any_QUAN
22_CD
March_NN
2006_CD
growth_NN
will_PRMD
come_VB
through_PIN
increasing_VBG
the_DT
second_JJ
interim_JJ
dividend_NN
in_PIN
a_DT
financial_JJ
year_NN
._.
130_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
131_CD
Summary_NN
financial_JJ
statement_NOMZ
IFRS_NN
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2005_CD
Independent_NN
Auditors_NN
Statement_NOMZ
to_PIN
the_DT
Members_NN
of_PIN
Shire_NN
plc_NN
:_:
Basis_NN
of_PIN
opinion_NN
We_FPP1
have_VPRT [PEAS]
examined_VBN
the_DT
summary_NN
financial_JJ
statement_NOMZ
which_WDT [WHSUB]
comprises_VPRT
We_FPP1
conducted_VBD
our_FPP1
work_NN
in_PIN
accordance_NN
with_PIN
bulletin_NN
1999_CD
6_CD
the_DT
summary_NN
Directors_NN
report_NN
,_,
consolidated_JJ
income_NN
statement_NOMZ
,_,
The_DT
Auditors_NN
Statement_NOMZ
on_PIN
the_DT
Summary_NN
Financial_NN
Statement_NOMZ
issued_VBD
consolidated_JJ
statement_NOMZ
of_PIN
recognized_VBN [PRIV]
income_NN
and_PHC
expense_NN
,_,
by_PIN
the_DT
Auditing_GER
Practices_NN
Board_NN
for_PIN
use_NN
in_PIN
the_DT
United_NN
Kingdom_NN
._.
consolidated_JJ
balance_NN
sheet_NN
,_,
consolidated_JJ
cash_NN
flow_NN
statement_NOMZ
and_PHC
Notes_NN
14_CD
of_PIN
the_DT
summary_NN
financial_JJ
statement_NOMZ
._.
Opinion_NN
In_PIN
our_FPP1
opinion_NN
,_,
the_DT
summary_NN
financial_JJ
statement_NOMZ
is_VPRT [BEMA]
consistent_PRED
with_PIN
This_DEMO
report_NN
is_VPRT [PASS]
made_VBN
solely_RB
to_PIN
the_DT
Companys_NN
members_NN
,_,
as_IN
a_DT
body_NN
,_,
in_PIN
the_DT
full_JJ
annual_JJ
accounts_NN
,_,
the_DT
Directors_NN
report_NN
and_CC
the_DT
Directors_NN
accordance_NN
with_PIN
section_NOMZ
251_CD
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
._.
Our_FPP1
work_NN
has_VPRT [PEAS]
remuneration_VBN
report_NN
of_PIN
Shire_NN
plc_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2005_CD
been_VBN [PASS]
undertaken_VBN
so_OSUB
that_NULL
we_FPP1
might_POMD
state_VB [PUBV]
to_PIN
the_DT
Companys_NN
members_NN
and_PHC
complies_NN
with_PIN
the_DT
applicable_JJ
requirements_NOMZ
of_PIN
Section_NOMZ
251_CD
those_DEMO
matters_NN
we_FPP1
are_VPRT [PASS]
required_VBN [SUAV]
to_PIN
state_NN
to_PIN
them_TPP3
in_PIN
an_DT
auditors_NN
report_NN
and_CC
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
and_CC
the_DT
regulations_NOMZ
made_VBD
thereunder_RB
._.
To_PIN
the_DT
fullest_JJ
extent_NN
permitted_VBN [WZPAST]
by_PIN
law_NN
,_,
we_FPP1
do_VPRT
not_XX0
The_DT
auditors_NN
report_VPRT [PUBV]
on_PIN
the_DT
Groups_NN
annual_JJ
accounts_NN
was_VBD [BEMA]
unqualified_PRED
._.
accept_VB [PRIV]
or_CC
assume_VB [PRIV]
responsibility_NOMZ
to_PIN
anyone_QUPR
other_JJ
than_PIN
the_DT
Company_NN
and_CC
the_DT
Companys_NN
members_NN
as_IN
a_DT
body_NN
,_,
for_PIN
our_FPP1
audit_NN
work_NN
,_,
for_PIN
this_DEMO
report_NN
,_,
Deloitte_NN
&_CC
Touche_NN
LLP_NN
or_CC
for_PIN
the_DT
opinions_NN
we_FPP1
have_VPRT [PEAS]
formed_VBN
._.
Chartered_NN
Accountants_NN
and_PHC
Registered_NN
Auditors_NN
Reading_VBG [WZPRES]
,_,
UK_NN
Respective_NN
responsibilities_NOMZ
of_PIN
Directors_NN
and_PHC
auditors_NN
22_CD
March_NN
2006_CD
The_DT
Directors_NN
are_VPRT [BEMA]
responsible_PRED
for_PIN
preparing_VBG
the_DT
annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
in_PIN
accordance_NN
with_PIN
applicable_JJ
law_NN
._.
Our_FPP1
responsibility_NOMZ
is_VPRT
to_TO
report_VB [PUBV]
to_PIN
you_SPP2
our_FPP1
opinion_NN
on_PIN
the_DT
consistency_NN
of_PIN
the_DT
summary_NN
financial_JJ
statement_NOMZ
with_PIN
the_DT
full_JJ
annual_JJ
accounts_NN
,_,
the_DT
Directors_NN
report_NN
and_CC
the_DT
Directors_NN
remuneration_NOMZ
report_NN
,_,
and_ANDC
its_PIT
compliance_NN
with_PIN
the_DT
relevant_JJ
requirements_NOMZ
of_PIN
Section_NOMZ
251_CD
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
and_CC
the_DT
regulations_NOMZ
made_VBD
thereunder_RB
._.
We_FPP1
report_VPRT [PUBV]
whether_IN [WHCL]
the_DT
auditors_NN
opinion_NN
on_PIN
the_DT
full_JJ
annual_JJ
accounts_NN
was_VBD [BEMA]
unqualified_PRED
or_CC
qualified_VBN
._.
We_FPP1
also_RB
read_VBD
the_DT
other_JJ
information_NOMZ
contained_VBN [WZPAST]
in_PIN
the_DT
annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
as_IN
described_VBN
in_PIN
the_DT
contents_NN
section_NOMZ
,_,
and_ANDC
consider_VB [PRIV]
the_DT
implications_NOMZ
for_PIN
our_FPP1
report_NN
if_COND
we_FPP1
become_VPRT
aware_JJ
of_PIN
any_QUAN
apparent_JJ
misstatements_NOMZ
or_CC
material_NN
inconsistencies_NN
with_PIN
the_DT
summary_NN
financial_JJ
statement_NOMZ
._.
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
131_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
132_CD
Summary_NN
financial_JJ
statement_NOMZ
IFRS_NN
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2005_CD
Consolidated_NN
income_NN
statement_NOMZ
2005_CD
2004_CD
$_$
000_CD
$_$
000_CD
Continuing_VBG
operations_NOMZ
:_:
Revenue_NN
1,599,316_CD
1,363,207_CD
Cost_NN
of_PIN
sales_NN
215,336_CD
142,557_CD
Gross_NN
profit_NN
1,383,980_CD
1,220,650_CD
Research_NN
and_PHC
development_NOMZ
287,146_CD
210,974_CD
Selling_GER
,_,
general_JJ
and_PHC
administrative_JJ
including_VBG
$_$
526,956,000_CD
2004_CD
:_:
$_$
132,576,000_CD
goodwill_NN
impairment_NOMZ
1,255,707_CD
718,890_CD
Operating_GER
loss_NN
profit_NN
158,873_CD
290,786_CD
Investment_NOMZ
revenues_NN
35,300_CD
21,901_CD
Finance_NN
costs_NN
17,420_CD
14,771_CD
Share_NN
of_PIN
post_NN
tax_NN
loss_NN
profit_NN
from_PIN
associates_NN
and_CC
joint_JJ
ventures_NN
1,000_CD
4,508_CD
Loss_NN
profit_NN
before_IN
tax_NN
141,993_CD
302,424_CD
Taxation_NOMZ
38,510_CD
141,623_CD
Loss_NN
profit_NN
for_PIN
the_DT
year_NN
from_PIN
continuing_VBG
operations_NOMZ
180,503_CD
160,801_CD
Discontinued_VBN
operations_NOMZ
:_:
Profit_NN
loss_NN
for_PIN
the_DT
year_NN
from_PIN
discontinued_VBN
operations_NOMZ
3,125_CD
64,292_CD
Loss_NN
profit_NN
for_PIN
the_DT
year_NN
177,378_CD
96,509_CD
Loss_NN
earnings_GER
per_PIN
share_NN
expressed_VBN [WZPAST]
in_PIN
per_PIN
share_NN
basic_JJ
35.5_CD
19.4_CD
diluted_VBN
35.5_CD
19.3_CD
Loss_NN
earnings_GER
per_PIN
share_NN
from_PIN
continuing_VBG
operations_NOMZ
expressed_VBN [WZPAST]
in_PIN
per_PIN
share_NN
basic_JJ
36.1_CD
32.4_CD
diluted_VBN
36.1_CD
32.2_CD
Consolidated_NN
statement_NOMZ
of_PIN
recognized_VBN [PRIV]
income_NN
and_PHC
expense_NN
2005_CD
2004_CD
$_$
000_CD
$_$
000_CD
Loss_NN
profit_NN
for_PIN
the_DT
year_NN
177,378_CD
96,509_CD
Exchange_NN
differences_NN
on_PIN
translation_NOMZ
of_PIN
foreign_JJ
operations_NOMZ
28,855_CD
34,066_CD
Unrealised_JJ
holding_VBG [PRIV]
gain_NN
on_PIN
available-for-sale_JJ
securities_NOMZ
9,226_CD
Net_JJ
loss_NN
gain_NN
recognized_VBD [PRIV]
directly_RB
to_PIN
equity_NOMZ
19,629_CD
34,066_CD
Total_JJ
recognized_VBN [PRIV]
expense_NN
income_NN
for_PIN
the_DT
year_NN
197,007_CD
130,575_CD
132_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
133_CD
Summary_NN
financial_JJ
statement_NOMZ
IFRS_NN
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2005_CD
Consolidated_NN
balance_NN
sheet_NN
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2005_CD
2004_CD
$_$
000_CD
$_$
000_CD
Assets_NN
Non-current_JJ
assets_NN
Goodwill_NN
2,209,460_CD
2,246,220_CD
Other_JJ
intangible_JJ
assets_NN
1,394,677_CD
322,258_CD
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
218,199_CD
128,202_CD
Deferred_JJ
tax_NN
assets_NN
67,283_CD
85,041_CD
Investments_NOMZ
accounted_VBD
for_PIN
using_VBG
equity_NOMZ
method_NN
23,023_CD
30,848_CD
Available-for-sale_JJ
investments_NOMZ
27,139_CD
76,550_CD
Other_JJ
receivables_NN
42,907_CD
38,895_CD
3,982,688_CD
2,928,014_CD
Current_JJ
assets_NN
Inventories_NN
136,057_CD
41,230_CD
Trade_NN
and_CC
other_JJ
receivables_NN
387,206_CD
299,817_CD
Current_JJ
tax_NN
assets_NN
27,983_CD
Trading_GER
investments_NOMZ
6,947_CD
324,845_CD
Cash_NN
and_PHC
cash_NN
equivalents_NN
656,456_CD
1,111,477_CD
Restricted_VBN
cash_NN
30,568_CD
21,627_CD
1,245,217_CD
1,798,996_CD
Total_JJ
assets_NN
5,227,905_CD
4,727,010_CD
Liabilities_NOMZ
and_PHC
shareholders_NN
equity_NOMZ
Non-current_JJ
liabilities_NOMZ
Borrowings_GER
4,704_CD
4,242_CD
Trade_NN
and_CC
other_JJ
payables_NN
18,036_CD
12,963_CD
Deferred_JJ
tax_NN
liabilities_NOMZ
127,691_CD
Long-term_JJ
provisions_NN
25,401_CD
26,232_CD
175,832_CD
43,437_CD
Current_JJ
liabilities_NOMZ
Borrowings_GER
2,667_CD
2,420_CD
Trade_NN
and_CC
other_JJ
payables_NN
435,725_CD
344,367_CD
Liability_NOMZ
to_TO
dissenting_VBG
shareholders_NN
427,609_CD
Current_JJ
tax_NN
liabilities_NOMZ
94,416_CD
46,757_CD
Provisions_NN
8,523_CD
45,097_CD
968,940_CD
438,641_CD
Total_JJ
liabilities_NOMZ
1,144,772_CD
482,078_CD
Shareholders_NN
equity_NOMZ
Share_NN
capital_NN
42,728_CD
36,083_CD
Share_NN
premium_NN
2,977_CD
4,883,219_CD
Treasury_NN
shares_NN
2,813_CD
264_CD
Exchangeable_JJ
shares_NN
101,248_CD
195,830_CD
Capital_NN
reduction_NOMZ
reserve_NN
2,946,490_CD
Capital_NN
reserve_NN
4,729_CD
Other_JJ
reserve_NN
2,099,652_CD
36,121_CD
Retained_VBN
earnings_GER
1,107,149_CD
910,786_CD
Total_JJ
shareholders_NN
equity_NOMZ
4,083,133_CD
4,244,932_CD
Total_JJ
liabilities_NOMZ
and_PHC
shareholders_NN
equity_NOMZ
5,227,905_CD
4,727,010_CD
The_DT
summary_NN
financial_JJ
statement_NOMZ
was_VBD [BYPA]
approved_VBN
by_PIN
the_DT
Board_NN
of_PIN
Directors_NN
and_CC
authorised_VBN
for_PIN
issue_NN
on_PIN
22_CD
March_NN
2006_CD
and_CC
signed_VBN
on_PIN
its_PIT
behalf_NN
by_PIN
:_:
A_DT
Russell_NN
Director_NN
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
133_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
134_CD
Summary_NN
financial_JJ
statement_NOMZ
IFRS_NN
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2005_CD
Consolidated_NN
cash_NN
flow_NN
statement_NOMZ
2005_CD
2004_CD
$_$
000_CD
$_$
000_CD
Net_JJ
cash_NN
flows_VPRT
from_PIN
operating_VBG
activities_NOMZ
401,187_CD
465,762_CD
Cash_NN
flow_NN
from_PIN
investing_VBG
activities_NOMZ
Movement_NOMZ
in_PIN
restricted_JJ
cash_NN
768_CD
24,847_CD
Purchase_NN
of_PIN
subsidiary_NN
undertaking_GER
,_,
net_NN
of_PIN
cash_NN
and_PHC
cash_NN
equivalents_NN
1,114,048_CD
Expense_NN
of_PIN
acquisitions_NOMZ
37,491_CD
Loan_NN
made_VBN [WZPAST]
to_PIN
ID_NN
Biomedical_NN
Corporation_NOMZ
IDB_NN
43,162_CD
56,838_CD
Purchase_NN
of_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
71,946_CD
49,746_CD
Purchase_NN
of_PIN
intangible_JJ
assets_NN
92,139_CD
42,293_CD
Purchases_NN
of_PIN
financial_JJ
assets_NN
7,700_CD
6,124_CD
Net_JJ
decrease_NN
increase_NN
in_PIN
current_JJ
financial_JJ
assets_NN
366,731_CD
20,282_CD
Proceeds_NN
from_PIN
sale_NN
of_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
PP&E_NN
1,169_CD
4,360_CD
Proceeds_NN
from_PIN
sale_NN
of_PIN
intangible_JJ
assets_NN
3,701_CD
Proceeds_NN
from_PIN
sale_NN
of_PIN
financial_JJ
assets_NN
10,135_CD
26,733_CD
Proceeds_NN
from_PIN
PP&E_NN
held_VBD [PRIV]
for_PIN
sale_NN
11,289_CD
Proceeds_NN
from_PIN
sale_NN
of_PIN
drug_NN
formulation_NOMZ
business_NOMZ
557_CD
Proceeds_NN
from_PIN
sale_NN
of_PIN
discontinued_VBN
business_NOMZ
92,236_CD
34,912_CD
Interest_NN
received_VBD
34,203_CD
21,901_CD
Dividend_NN
received_VBN [WZPAST]
from_PIN
associates_NN
3,774_CD
1,450_CD
Dividend_NN
from_PIN
joint_JJ
venture_NN
4,710_CD
4,043_CD
Investing_VBG
activities_NOMZ
of_PIN
discontinued_VBN
business_NOMZ
12,715_CD
Net_JJ
cash_NN
used_VBN [WZPAST]
in_PIN
investing_VBG
activities_NOMZ
853,739_CD
54,762_CD
Cash_NN
flows_VPRT
from_PIN
financing_VBG
activities_NOMZ
Proceeds_NN
from_PIN
issuance_NN
of_PIN
ordinary_JJ
shares_NN
,_,
net_JJ
771_CD
Proceeds_NN
from_PIN
exercise_NN
of_PIN
share_NN
options_NOMZ
37,113_CD
13,416_CD
Purchase_NN
of_PIN
treasury_NN
shares_NN
2,480_CD
264_CD
Redemption_NOMZ
of_PIN
2_CD
%_NN
guaranteed_VBN [PUBV]
convertible_JJ
loan_NN
notes_NN
2011_CD
370,109_CD
Movement_NOMZ
in_PIN
finance_NN
lease_NN
obligations_NOMZ
708_CD
5,351_CD
Dividends_NN
paid_VBD
28,460_CD
8,905_CD
Net_JJ
cash_NN
from_PIN
used_VBN
in_PIN
financing_GER
activities_NOMZ
6,881_CD
370,442_CD
Net_JJ
decrease_NN
increase_NN
in_PIN
cash_NN
and_PHC
cash_NN
equivalents_NN
445,671_CD
40,558_CD
Cash_NN
and_PHC
cash_NN
equivalents_NN
at_PIN
beginning_GER
of_PIN
year_NN
1,111,477_CD
1,063,362_CD
Effect_NN
of_PIN
foreign_JJ
currency_NN
translation_NOMZ
9,350_CD
7,557_CD
Cash_NN
and_PHC
cash_NN
equivalents_NN
at_PIN
end_NN
of_PIN
year_NN
656,456_CD
1,111,477_CD
134_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
135_CD
Summary_NN
financial_JJ
statement_NOMZ
IFRS_NN
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2005_CD
1_CD
Basis_NN
of_PIN
preparation_NOMZ
The_DT
summary_NN
financial_JJ
statement_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
under_IN
IFRS_NN
in_PIN
accordance_NN
with_PIN
the_DT
accounting_GER
policies_NN
set_VBN [WZPAST]
out_PIN
in_PIN
the_DT
full_JJ
UK_NN
statutory_JJ
annual_JJ
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2005_CD
._.
2_CD
Directors_NN
remuneration_JJ
Executive_NN
remuneration_NOMZ
policy_NN
The_DT
Remuneration_NOMZ
Committee_NN
considers_VPRT [PRIV]
that_THVC
an_DT
effective_JJ
remuneration_NOMZ
policy_NN
,_,
aligned_VBN [PASTP]
to_PIN
the_DT
Companys_NN
business_NOMZ
needs_NN
,_,
is_VPRT [BEMA]
important_PRED
to_PIN
the_DT
Companys_NN
success_NN
._.
It_PIT
directly_RB
impacts_VPRT
the_DT
Companys_NN
ability_NOMZ
to_TO
recruit_VB
,_,
retain_VB
and_PHC
motivate_VB
high_JJ
calibre_NN
executives_NN
who_WP [WHSUB]
deliver_VPRT
sustained_VBN
value_NN
to_PIN
shareholders_NN
and_CC
build_VB
the_DT
Company_NN
for_PIN
long-term_JJ
success_NN
._.
The_DT
Remuneration_NOMZ
Committee_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
developing_VBG
,_,
reviewing_VBG
and_PHC
overseeing_VBG
the_DT
implementation_NOMZ
of_PIN
the_DT
Companys_NN
compensation_NOMZ
and_PHC
benefits_NN
policy_NN
._.
The_DT
Remuneration_NOMZ
Committee_NN
regularly_RB
monitors_VPRT
the_DT
effectiveness_NOMZ
of_PIN
the_DT
policy_NN
and_CC
reviews_VPRT
this_DEMO
policy_NN
based_VBN [WZPAST]
on_PIN
independent_JJ
analysis_NN
and_PHC
advice_NN
,_,
an_DT
understanding_GER
of_PIN
the_DT
business_NOMZ
drivers_NN
and_CC
competitive_JJ
environment_NOMZ
in_PIN
which_WDT [PIRE]
the_DT
Company_NN
operates_VPRT
and_CC
ongoing_JJ
dialogue_NN
with_PIN
shareholders_NN
._.
The_DT
Companys_NN
executive_NN
compensation_NOMZ
and_PHC
benefits_NN
policy_NN
is_VPRT [PASS]
based_VBN
on_PIN
the_DT
following_VBG
principles_NN
:_:
base_NN
pay_NN
is_VPRT [PASS]
market_NN
driven_VBN
utilising_VBG
a_DT
blended_JJ
US_FPP1
UK_NN
market_NN
comparison_NN
,_,
and_ANDC
is_VPRT [PASS]
targeted_VBN
at_PIN
or_CC
around_PLACE
the_DT
median_NN
relative_JJ
to_PIN
the_DT
comparison_NN
:_:
the_DT
Annual_JJ
Incentive_NN
Plan_NN
is_VPRT [BEMA]
performance-based_PRED
and_CC
is_VPRT [PASS]
linked_VBN
to_PIN
the_DT
achievement_NOMZ
of_PIN
an_DT
appropriate_JJ
mix_NN
of_PIN
corporate_JJ
and_PHC
individual_JJ
performance_NN
targets_NN
._.
The_DT
Annual_JJ
Incentive_NN
Plan_NN
allows_VPRT [SUAV]
the_DT
Company_NN
to_TO
measure_VB
and_PHC
reward_VB
progress_NN
against_PIN
its_PIT
strategic_JJ
goals_NN
and_CC
is_VPRT [SPAU] [PASS]
closely_RB
tied_VBN
to_PIN
delivery_NN
of_PIN
sustained_JJ
shareholder_NN
value_NN
:_:
share-based_JJ
compensation_NOMZ
is_VPRT [BEMA]
a_DT
key_JJ
element_NOMZ
of_PIN
the_DT
Companys_NN
remuneration_NOMZ
policy_NN
as_IN
it_PIT
aligns_VPRT
the_DT
interests_NN
of_PIN
the_DT
Companys_NN
executives_NN
with_PIN
the_DT
interests_NN
of_PIN
its_PIT
shareholders_NN
._.
This_DEMO
element_NOMZ
of_PIN
compensation_NOMZ
also_RB
utilises_VPRT
a_DT
blended_JJ
US_FPP1
UK_NN
market_NN
comparison_NN
to_TO
determine_VB [SUAV] [PRIV]
face_NN
value_NN
of_PIN
awards_NN
to_PIN
executive_JJ
Directors_NN
:_:
benefits_NN
programs_NN
are_VPRT [BEMA]
locally_PLACE
competitive_PRED
and_CC
provide_VB
for_PIN
the_DT
welfare_NN
and_PHC
well-being_NN [BEMA]
of_PIN
our_FPP1
employees_NN
and_CC
their_TPP3
families_NN
:_:
the_DT
Committee_NN
currently_RB
aims_VPRT
for_PIN
variable_JJ
compensation_NOMZ
to_TO
represent_VB
over_IN
two-thirds_NN
of_PIN
total_JJ
remuneration_NOMZ
:_:
and_ANDC
the_DT
Committee_NN
believes_VPRT [PRIV]
that_THVC
executive_NN
Directors_NN
should_NEMD
be_VB [PASS]
encouraged_VBN
to_TO
own_VB
shares_NN
in_PIN
the_DT
Company_NN
in_PIN
order_NN
to_TO
ensure_VB [SUAV] [PRIV]
the_DT
alignment_NOMZ
of_PIN
their_TPP3
interests_NN
with_PIN
those_DEMO
of_PIN
the_DT
Companys_NN
shareholders_NN
._.
Share_NN
ownership_NN
guidelines_NN
became_VBD
effective_JJ
in_PIN
2006_CD
._.
Aggregate_NN
Directors_NN
remuneration_VPRT
The_DT
total_JJ
amounts_NN
for_PIN
Directors_NN
remuneration_NOMZ
and_CC
other_JJ
benefits_NN
were_VBD
as_IN
follows_VPRT
:_:
2005_CD
2004_CD
$_$
000_CD
$_$
000_CD
Emoluments_NOMZ
4,289_CD
4,751_CD
Post-employment_NOMZ
benefits_NN
488_CD
450_CD
Amounts_NN
receivable_JJ
under_IN
long-term_JJ
incentive_NN
schemes_NN
159_CD
Termination_NOMZ
benefits_NN
1,172_CD
Gains_NN
on_PIN
exercise_NN
of_PIN
share_NN
options_NOMZ
194_CD
216_CD
4,971_CD
6,748_CD
The_DT
numbers_NN
of_PIN
Directors_NN
who_WP [WHSUB]
were_VBD
members_NN
of_PIN
Group_NN
retirement_NOMZ
schemes_NN
were_VBD
as_IN
follows_VPRT
:_:
2005_CD
2004_CD
Number_NN
Number_NN
Defined_NN
contribution_NOMZ
schemes_NN
2_CD
3_CD
Defined_VBN
benefit_NN
scheme_NN
SERP_NN
1_CD
1_CD
The_DT
above_PLACE
amounts_NN
for_PIN
remuneration_NOMZ
include_VPRT
the_DT
following_VBG
in_PIN
respect_NN
of_PIN
the_DT
highest-paid_JJ
Director_NN
:_:
2005_CD
2004_CD
$_$
000_CD
$_$
000_CD
Aggregate_JJ
emoluments_NOMZ
2,286_CD
2,601_CD
Pension_NN
contributions_NOMZ
323_CD
227_CD
2,609_CD
2,828_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
135_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
136_CD
Summary_NN
financial_JJ
statement_NOMZ
IFRS_NN
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2005_CD
Directors_NN
emoluments_VPRT
Cash_NN
Non-cash_JJ
benefits_NN
benefits_NN
Total_JJ
Total_JJ
Salary_NN
Incentive_NN
Fees_NN
in_PIN
kind_NN
in_PIN
kind_NN
2005_CD
2004_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
Executive_NN
i_FPP1
v_FW
Mr_NN
Matthew_NN
Emmens_NN
1,049_CD
1,208_CD
29_CD
2,286_CD
2,601_CD
ii_FW
Mr_NN
Angus_NN
Russell_NN
652_CD
415_CD
26_CD
10_CD
1,103_CD
1,126_CD
ii_FW
vi_FW
Dr_FW
Wilson_NN
Totten_NN
469_CD
Total_NN
Executive_NN
1,701_CD
1,623_CD
55_CD
10_CD
3,389_CD
4,196_CD
Non-executive_JJ
i_FPP1
Dr_FW
James_NN
Cavanaugh_NN
364 364 137_CD
iii_FW
Dr_FW
Barry_NN
Price_NN
132 132 110_CD
i_FPP1
The_DT
Hon_NN
James_NN
Grant_NN
82_CD
82_CD
73_CD
i_FPP1
Mr_NN
Ronald_NN
Nordmann_NN
114_CD
114_CD
99_CD
iii_NN
Mr_NN
Robin_NN
Buchanan_NN
87_CD
87_CD
73_CD
iii_NN
Mr_NN
David_NN
Kappler_NN
109_CD
109_CD
63_CD
iv_NN
vii_FW
Mr_NN
Patrick_NN
Langlois_NN
12_CD
12_CD
Total_JJ
Non-executive_JJ
900 900 555_CD
Total_JJ
1,701_CD
1,623_CD
900_CD
55_CD
10_CD
4,289_CD
4,751_CD
Notes_NN
i_FPP1
Paid_NN
in_PIN
$_$
._.
v_FW
The_DT
Company_NN
underwent_VBD
a_DT
major_JJ
internal_JJ
reorganisation_NOMZ
in_PIN
2004_CD
,_,
which_WDT [SERE]
resulted_VBD
in_PIN
the_DT
Company_NN
selecting_VBG [WZPRES]
Philadelphia_NN
as_IN
its_PIT
US_FPP1
corporate_JJ
headquarters_NN
._.
vi_FW
Dr_FW
Totten_FW
stepped_VBD
down_RP
as_IN
a_DT
Director_NN
of_PIN
the_DT
Company_NN
on_PIN
25_CD
May_POMD
2004_CD
._.
vii_FW
Mr_NN
Langlois_NN
was_VBD [PASS]
appointed_VBN
a_DT
Non-executive_JJ
Director_NN
on_PIN
11_CD
November_NN
2005_CD
._.
136_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
137_CD
Summary_NN
financial_JJ
statement_NOMZ
IFRS_NN
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2005_CD
Performance_NN
graph_NN
The_DT
graphs_NN
shown_VBN [PRIV]
set_VBN
out_PIN
the_DT
Total_JJ
Shareholder_NN
Return_NN
TSR_NN
for_PIN
the_DT
three_CD
and_CC
five_CD
years_NN
ending_VBG [WZPRES]
31_CD
December_NN
2005_CD
._.
The_DT
graphs_NN
compare_VPRT
the_DT
performance_NN
of_PIN
a_DT
hypothetical_JJ
100_CD
holding_GER
of_PIN
the_DT
Companys_NN
shares_NN
with_PIN
that_DEMO
of_PIN
a_DT
holding_GER
of_PIN
shares_NN
in_PIN
the_DT
FTSE_NN
100_CD
index_NN
excluding_VBG [WZPRES]
financial_JJ
institutions_NOMZ
and_CC
with_PIN
a_DT
holding_GER
in_PIN
a_DT
group_NN
comprised_VBD
of_PIN
the_DT
following_VBG
pharma_NN
companies_NN
:_:
Novo_NN
Nordisk_NN
,_,
Schering_GER
AG_NN
,_,
Serono_NN
,_,
Altana_NN
,_,
UCB_NN
,_,
Lundbeck_NN
,_,
Forest_NN
Labs_NN
,_,
Allergan_NN
,_,
Sepracor_NN
,_,
Cephalon_NN
,_,
Watson_NN
,_,
Biovail_NN
,_,
King_NN
,_,
Valeant_NN
,_,
Medicis_NN
and_PHC
Kos_NN
._.
This_DEMO
comparator_NN
group_NN
is_VPRT [BEMA]
a_DT
blend_VB
of_PIN
US_FPP1
and_PHC
UK_NN
companies_NN
with_PIN
sector_NN
,_,
size_NN
,_,
complexity_NOMZ
and_CC
international_JJ
characteristics_NN
similar_JJ
to_PIN
those_DEMO
of_PIN
the_DT
Company_NN
._.
These_DEMO
comparisons_NN
will_PRMD [SPAU]
also_RB
be_VB [PASS]
used_VBN
to_TO
determine_VB [SUAV] [PRIV]
achievement_NOMZ
of_PIN
performance_NN
conditions_NOMZ
relating_VBG [WZPRES]
to_PIN
the_DT
Annual_JJ
Incentive_NN
Plan_NN
and_PHC
Portfolio_NN
Share_NN
Plan_NN
._.
The_DT
three-year_JJ
graph_NN
tracks_VPRT
the_DT
TSR_NN
performance_NN
since_OSUB
the_DT
Company_NN
started_VBD
to_TO
implement_VB
its_PIT
new_JJ
strategic_JJ
plan_NN
under_IN
new_JJ
management_NOMZ
._.
Change_NN
in_PIN
Three-year_JJ
historical_JJ
TSR_NN
performance_NN
._.
Change_NN
in_PIN
value_NN
of_PIN
a_DT
hypothetical_JJ
100_CD
holding_GER
over_IN
three_CD
years_NN
._.
value_NN
of_PIN
a_DT
hypothetical_JJ
100_CD
holding_GER
over_IN
five_CD
years_NN
._.
160 200 180 140_CD
160 120 140 100_CD
120_CD
80_CD
100_CD
80_CD
60_CD
60_CD
40_CD
40_CD
20_CD
20_CD
0_CD
0_CD
31.12.00_CD
31.12.01_CD
31.12.02_CD
31.12.03_CD
31.12.04_CD
31.12.05_CD
31.12.02_CD
31.12.03_CD
31.12.04_CD
31.12.05_CD
Shire_NN
TSR_NN
Shire_NN
TSR_NN
Ex-financials_NN
FTSE_NN
100_CD
TSR_NN
Ex-financials_NN
FTSE_NN
100_CD
TSR_NN
Comparator_NN
group_NN
TSR_NN
Comparator_NN
group_NN
TSR_NN
3_CD
Loss_NN
earnings_GER
per_PIN
ordinary_JJ
share_NN
EPS_NN
Basic_JJ
EPS_NN
is_VPRT [BYPA]
calculated_VBN [PRIV]
by_PIN
dividing_VBG
the_DT
loss_NN
earnings_GER
attributable_JJ
to_PIN
ordinary_JJ
shareholders_NN
by_PIN
the_DT
weighted_JJ
average_JJ
number_NN
of_PIN
ordinary_JJ
shares_NN
outstanding_JJ
during_PIN
the_DT
year_NN
,_,
excluding_VBG [PRESP]
those_DEMP
held_VBN [PRIV]
in_PIN
the_DT
employee_NN
share_NN
trust_NN
,_,
which_WDT [SERE]
are_VPRT [PASS]
treated_VBN
as_IN
canceled_VBN
._.
For_PIN
diluted_VBN
EPS_NN
,_,
the_DT
weighted_JJ
average_JJ
number_NN
of_PIN
ordinary_JJ
shares_NN
in_PIN
issue_NN
is_VPRT [PASS]
adjusted_VBN
to_TO
assume_VB [PRIV]
conversion_NN
of_PIN
all_QUAN
dilutive_JJ
potential_JJ
ordinary_JJ
shares_NN
._.
For_PIN
the_DT
year_NN
to_PIN
31_CD
December_NN
2005_CD
share_NN
options_NOMZ
to_TO
purchase_VB
approximately_RB
20.7_CD
million_CD
ordinary_JJ
shares_NN
and_PHC
warrants_NN
to_TO
purchase_VB
1.3_CD
million_CD
ordinary_JJ
shares_NN
were_VBD [BEMA]
not_XX0
dilutive_PRED
and_CC
were_VBD [SPAU] [PASS]
therefore_CONJ
excluded_VBN
from_PIN
the_DT
computation_NOMZ
of_PIN
diluted_VBN
EPS_NN
._.
The_DT
$_$
370_CD
million_CD
loan_NN
note_NN
convertible_JJ
debt_NN
was_VBD [PASS]
excluded_VBN
from_PIN
the_DT
calculation_NOMZ
of_PIN
weighted_JJ
average_JJ
number_NN
of_PIN
shares_NN
for_PIN
diluted_VBN
EPS_NN
in_PIN
2004_CD
as_IN
it_PIT
was_VBD [BEMA]
not_XX0
dilutive_PRED
._.
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
137_CD
Shire_NN
plc_NN
Value_NN
of_PIN
hypothetical_JJ
100_CD
holding_VBG [PRIV]
Value_NN
of_PIN
hypothetical_JJ
100_CD
holding_VBG [PRIV]
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
138_CD
Summary_NN
financial_JJ
statement_NOMZ
IFRS_NN
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2005_CD
Reconciliations_NOMZ
of_PIN
the_DT
earnings_GER
and_CC
weighted_JJ
average_JJ
number_NN
of_PIN
shares_NN
used_VBN [WZPAST]
in_PIN
the_DT
calculations_NOMZ
are_VPRT [PASS]
set_VBN
out_PIN
below_PLACE
._.
Weighted_JJ
average_JJ
Loss_NN
number_NN
of_PIN
Per-share_JJ
2005_CD
$_$
000_CD
shares_NN
amount_NN
Basic_JJ
and_PHC
diluted_JJ
EPS_NN
Loss_NN
attributable_JJ
to_PIN
ordinary_JJ
shareholders_NN
177,378_CD
500,243,137_CD
35.5_CD
Weighted_VBN
average_JJ
Earnings_GER
number_NN
of_PIN
Per-share_JJ
2004_CD
$_$
000_CD
shares_NN
amount_NN
Basic_JJ
EPS_NN
Earnings_GER
attributable_JJ
to_PIN
ordinary_JJ
shareholders_NN
96,509_CD
496,306,604_CD
19.4_CD
Effect_NN
of_PIN
dilutive_JJ
securities_NOMZ
Share_NN
options_NOMZ
3,035,620_CD
0.1_CD
Warrants_NN
66,792_CD
Diluted_NN
EPS_NN
96,509_CD
499,409,016_CD
19.3_CD
Loss_NN
earnings_GER
per_PIN
share_NN
from_PIN
continuing_VBG
and_PHC
discontinued_VBN
operations_NOMZ
:_:
Weighted_JJ
average_JJ
Loss_NN
number_NN
of_PIN
Per-share_JJ
2005_CD
$_$
000_CD
shares_NN
amount_NN
Basic_JJ
and_PHC
diluted_JJ
EPS_NN
Loss_NN
from_PIN
continuing_VBG
operations_NOMZ
180,503_CD
500,243,137_CD
36.1_CD
Gain_NN
from_PIN
discontinued_VBN
operations_NOMZ
3,125_CD
500,243,137_CD
0.6_CD
Weighted_VBN
average_JJ
Earnings_GER
number_NN
of_PIN
Per-share_JJ
2004_CD
$_$
000_CD
shares_NN
amount_NN
Basic_JJ
EPS_NN
Profit_NN
from_PIN
continuing_VBG
operations_NOMZ
160,801_CD
496,306,604_CD
32.4_CD
Loss_NN
from_PIN
discontinued_VBN
operations_NOMZ
64,292_CD
496,306,604_CD
13.0_CD
Diluted_NN
EPS_NN
Profit_NN
from_PIN
continuing_VBG
operations_NOMZ
160,801_CD
499,409,016_CD
32.2_CD
Loss_NN
from_PIN
discontinued_VBN
operations_NOMZ
64,292_CD
499,409,016_CD
12.9_CD
138_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
139_CD
Summary_NN
financial_JJ
statement_NOMZ
IFRS_NN
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2005_CD
4_CD
Loss_NN
profit_NN
for_PIN
the_DT
year_NN
2005_CD
2004_CD
$_$
000_CD
$_$
000_CD
The_DT
following_JJ
items_NN
have_VPRT [PEAS]
been_VBN [PASS]
included_VBN
in_PIN
arriving_VBG
at_PIN
the_DT
loss_NN
profit_NN
from_PIN
continuing_VBG
operations_NOMZ
:_:
Staff_NN
costs_NN
:_:
wages_NN
and_PHC
salaries_NN
234,425_CD
179,174_CD
social_JJ
security_NOMZ
costs_NN
20,674_CD
15,333_CD
pensions_NN
costs_NN
defined_VBN
contribution_NOMZ
plans_NN
13,461_CD
8,722_CD
pensions_NN
costs_NN
defined_VBN
benefit_NN
plans_NN
607_CD
284_CD
share-based_JJ
payments_NOMZ
to_PIN
Directors_NN
and_PHC
employees_NN
27,383_CD
15,815_CD
296,550_CD
219,328_CD
Inventories_NN
:_:
cost_NN
of_PIN
inventories_NN
recognized_VBN [PRIV]
as_IN
expense_NN
included_VBN [WZPAST]
in_PIN
cost_NN
of_PIN
sales_NN
184,353_CD
119,943_CD
inventory_NN
write-down_NN
included_VBD
in_PIN
cost_NN
of_PIN
sales_NN
9,432_CD
3,788_CD
Depreciation_NOMZ
of_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
:_:
owned_VBN
assets_NN
20,099_CD
20,140_CD
under_IN
finance_NN
leases_NN
2,904_CD
2,528_CD
Impairment_NOMZ
of_PIN
goodwill_NN
526,956_CD
132,576_CD
Impairment_NOMZ
of_PIN
intangible_JJ
assets_NN
4,410_CD
19,626_CD
Impairment_NOMZ
of_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
6,458_CD
1,587_CD
Amortisation_NOMZ
of_PIN
intangible_JJ
assets_NN
included_VBN [WZPAST]
in_PIN
selling_GER
,_,
general_JJ
and_PHC
administrative_JJ
expenses_NN
all_QUAN
acquired_VBN
49,516_CD
42,138_CD
Operating_GER
lease_NN
rentals_NN
:_:
property_NN
,_,
plant_NN
and_PHC
machinery_NN
14,445_CD
6,563_CD
other_JJ
2,673_CD
3,495_CD
Profit_NN
on_PIN
disposal_NN
of_PIN
financial_JJ
assets_NN
4,100_CD
14,805_CD
Impairment_NOMZ
of_PIN
financial_JJ
assets_NN
1,974_CD
17,455_CD
Net_JJ
foreign_JJ
exchange_NN
losses_NN
10,212_CD
2,466_CD
Reorganisation_NOMZ
costs_NN
2,301_CD
55,505_CD
Integration_NOMZ
costs_NN
11,727_CD
Government_NOMZ
grants_NN
towards_PIN
research_NN
26_CD
Auditors_NN
remuneration_NOMZ
for_PIN
audit_NN
services_NN
5,121_CD
5,401_CD
Accounts_NN
payable_JJ
to_PIN
Deloitte_NN
&_CC
Touche_NN
LLP_NN
and_CC
their_TPP3
associates_NN
by_PIN
the_DT
Group_NN
in_PIN
respect_NN
of_PIN
non-audit_JJ
services_NN
were_VBD
$_$
2.8_CD
million_CD
2004_CD
:_:
$_$
4.9_CD
million_CD
._.
A_DT
more_EMPH
detailed_JJ
analysis_NN
of_PIN
auditors_NN
remuneration_NOMZ
on_PIN
a_DT
worldwide_JJ
basis_NN
is_VPRT [PASS]
provided_VBN
below_PLACE
._.
2005_CD
2004_CD
Year_NN
to_PIN
December_NN
31_CD
,_,
$_$
000_CD
$_$
000_CD
i_FPP1
Audit_NN
fees_NN
2,731_CD
3,253_CD
ii_FW
Audit-related_JJ
fees_NN
2,390_CD
2,148_CD
iii_FW
Tax_NN
fees_NN
2,066_CD
4,734_CD
iv_NN
All_QUAN
other_JJ
fees_NN
708_CD
183_CD
Total_JJ
fees_NN
7,895_CD
10,318_CD
Notes_NN
i_FPP1
Audit_NN
fees_NN
consisted_VBD
of_PIN
audit_NN
work_NN
only_DWNT
the_DT
Independent_NN
Registered_NN
Public_NN
Accountant_NN
can_POMD [SPAU]
reasonably_RB
be_VB [PASS]
expected_VBN [PRIV]
to_TO
perform_VB
,_,
such_JJ
as_IN
statutory_JJ
audits_NN
and_CC
included_VBD
the_DT
audit_NN
of_PIN
managements_NOMZ
assessment_NOMZ
that_TOBJ
the_DT
Group_NN
maintained_VBD [PUBV]
effective_JJ
internal_JJ
control_NN
over_IN
10-K_JJ
financial_JJ
reporting_GER
and_CC
the_DT
audit_NN
of_PIN
the_DT
effectiveness_NOMZ
of_PIN
the_DT
Groups_NN
internal_JJ
control_NN
over_IN
10-K_JJ
financial_JJ
reporting_GER
._.
ii_FW
Audit_NN
related_JJ
fees_NN
consist_VPRT
of_PIN
work_NN
generally_RB
only_DWNT
the_DT
Independent_NN
Registered_NN
Public_NN
Accountant_NN
can_POMD [SPAU]
reasonably_RB
be_VB [PASS]
expected_VBN [PRIV]
to_TO
perform_VB
,_,
such_JJ
as_IN
procedures_NN
relating_VBG [WZPRES]
to_PIN
regulatory_JJ
filings_GER
._.
iii_FW
Tax_NN
fees_NN
consisted_VBD
principally_RB
of_PIN
assistance_NN
with_PIN
matters_NN
related_VBN [WZPAST]
to_PIN
compliance_NN
,_,
planning_GER
and_PHC
advice_NN
in_PIN
various_JJ
tax_NN
jurisdictions_NOMZ
._.
iv_NN
All_QUAN
other_JJ
fees_NN
relate_VPRT
to_TO
assisting_VBG
the_DT
remuneration_NOMZ
committee_NN
and_CC
corporate_JJ
responsibility_NOMZ
._.
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
139_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
140_CD
Shire_NN
head_NN
ofce_NN
and_CC
main_JJ
operating_GER
locations_NOMZ
Shire_NN
plc_NN
Shire_NN
Italia_NN
S._NN
p._NN
A._NN
Chief_NN
Executive_NN
Officer_NN
:_:
Matthew_NN
Emmens_NN
Managing_VBG [WZPRES]
Director_NN
:_:
Gian_NN
Piero_NN
Reverberi_NN
Hampshire_NN
International_NN
Business_NOMZ
Park_NN
Via_PIN
Provinciale_NN
Lucchese_NN
,_,
70_CD
Basingstoke_NN
,_,
Hampshire_NN
RG24_NN
8EP_NN
50019_CD
Sesto_NN
F._NN
No_SYNE
FI_NN
United_NN
Kingdom_NN
Italy_NN
Tel_NN
44_CD
0_CD
1256 894000_CD
Tel_NN
39_CD
0_CD
55 3025050_CD
Fax_NN
44_CD
0_CD
1256 894708_CD
Fax_NN
39_CD
0_CD
55 3025051_CD
Shire_NN
Pharmaceuticals_NN
Ltd_NN
Shire_NN
Pharmaceuticals_NN
Iberica_NN
SL_NN
Managing_VBG [WZPRES]
Director_NN
:_:
John_NN
Freeman_NN
Managing_VBG [WZPRES]
Director_NN
:_:
Jos_NN
Antonio_NN
Senz_NN
fide_NN
Broto_NN
Hampshire_NN
International_NN
Business_NOMZ
Park_NN
P_NN
Pintor_NN
Rosales_NN
,_,
n_NN
40_CD
,_,
Bajo_NN
Izda_NN
._.
Basingstoke_NN
,_,
Hampshire_NN
RG24_NN
8EP_NN
28008_CD
Madrid_NN
United_NN
Kingdom_NN
Spain_NN
Tel_NN
44_CD
0_CD
1256 894000_CD
Tel_NN
34 915 500 691_CD
Fax_NN
44_CD
0_CD
1256 894708_CD
Fax_NN
34 915 493 695_CD
Shire_NN
Pharmaceuticals_NN
Ireland_NN
Ltd_NN
Shire_NN
US_FPP1
Manufacturing_GER
Inc._NN
._.
General_NN
Manager_NN
:_:
Brian_NN
Martin_NN
Executive_NN
Vice_NN
President_NN
Building_GER
1A_NN
,_,
Citylink_NN
Business_NOMZ
Park_NN
Global_NN
Supply_NN
Chain_NN
&_CC
Quality_NOMZ
:_:
John_NN
Lee_NN
Old_NN
Naas_NN
Road_NN
,_,
Dublin_NN
12_CD
11200_CD
Gundry_NN
Lane_NN
Ireland_NN
Owings_NN
Mills_NN
,_,
Maryland_NN
21117_CD
Tel_NN
353_CD
1_CD
429_CD
7700_CD
USA_NN
Fax_NN
353_CD
1_CD
429_CD
7701_CD
Tel_NN
1_CD
410 413 1000_CD
Fax_NN
1_CD
410 413 2000_CD
Shire_NN
Pharmaceutical_NN
Contracts_NN
Ltd_NN
Singapore_NN
representative_JJ
office_NN
Shire_NN
BioChem_NN
Inc._NN
._.
Managing_VBG
Director_NN
:_:
Tony_NN
Ooi_NN
Vice_NN
President_NN
and_PHC
LiFung_NN
Centre_NN
General_NN
Manager_NN
:_:
Claude_NN
Perron_NN
5_CD
B_NN
,_,
Toh_NN
Guan_NN
Road_NN
East_NN
,_,
#_#
03-09A_CD
2250_CD
Alfred-Nobel_NN
Blvd._NN
._.
Suite_NN
500_CD
Singapore_NN
608829_CD
Ville_NN
Saint-Laurent_NN
,_,
Qubec_NN
H4S_NN
2C9_NN
Tel_NN
65 6665 2795_CD
Canada_NN
Fax_NN
65 6665 2797_CD
Tel_NN
1_CD
514 787 2300_CD
Fax_NN
1_CD
514 787 2427_CD
Shire_NN
Deutschland_NN
GmbH_NN
&_CC
Co_NN
KG_NN
Managing_VBG [WZPRES]
Director_NN
:_:
Leonhard_NN
Terp_NN
Shire_NN
Human_NN
Generic_NN
Therapies_NN
Siegburger_NN
Strae_NN
126_CD
Executive_NN
Vice_NN
President_NN
D-50679_NN
Kln_NN
and_PHC
General_NN
Manager_NN
:_:
David_NN
Pendergast_NN
Germany_NN
700_CD
Main_NN
Street_NN
Tel_NN
49_CD
221_CD
8_CD
80_CD
47_CD
30_CD
Cambridge_NN
,_,
Massachusetts_NN
02139_CD
Fax_NN
49_CD
221_CD
8_CD
80_CD
47_CD
41_CD
USA_NN
Tel_NN
1_CD
617 349 0200_CD
Shire_NN
France_NN
S._NN
A._NN
Fax_NN
1_CD
617 613 4004_CD
Managing_VBG
Director_NN
:_:
Vincent_NN
Lucet_NN
88_CD
,_,
rue_NN
du_NN
Dme_NN
92514_CD
Boulogne-Billancourt_NN
Cedex_NN
France_NN
Tel_NN
33_CD
0_CD
146_CD
10_CD
90_CD
00_CD
Fax_NN
33_CD
0_CD
146_CD
08_CD
21_CD
49_CD
140_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
141_CD
Shareholder_NN
information_NOMZ
Registered_NN
office_NN
address_NN
US_FPP1
Shareholders_NN
Hampshire_NN
International_NN
Business_NOMZ
Park_NN
i_FPP1
ADSs_NN
Basingstoke_NN
,_,
Hampshire_NN
RG24_NN
8EP_NN
The_NN
Companys_NN
American_NN
Depository_NN
Shares_NN
ADSs_NN
,_,
each_QUAN
representing_VBG
United_NN
Kingdom_NN
three_CD
ordinary_JJ
shares_NN
,_,
are_VPRT [PASS]
listed_VBN
on_PIN
the_DT
NASDAQ_NN
national_JJ
market_NN
under_IN
Registered_NN
in_PIN
England_NN
the_DT
symbol_NN
SHPGY_NN
._.
The_DT
Company_NN
files_VPRT
reports_NN
and_CC
other_JJ
documents_NOMZ
No._NN
._.
05492592_CD
with_PIN
the_DT
Securities_NOMZ
and_PHC
Exchange_NN
Commission_NN
SEC_NN
which_WDT [WHSUB]
are_VPRT [BEMA]
available_PRED
for_PIN
inspection_NOMZ
and_PHC
copying_GER
at_PIN
the_DT
SECs_NN
public_JJ
reference_NN
Investor_NN
relations_NOMZ
facilities_NOMZ
or_CC
can_POMD
be_VB [BYPA]
obtained_VBN
by_PIN
writing_VBG [PUBV]
to_PIN
the_DT
Company_NN
Secretary_NN
._.
Europe_NN
and_CC
Rest_VB
of_PIN
the_DT
World_NN
:_:
Cla_NN
Rosenfeld_NN
Tel_NN
44_CD
0_CD
1256 894160_CD
ii_FW
ADS_NN
Depositary_NN
Fax_NN
44_CD
0_CD
1256 894708_CD
Morgan_NN
Guaranty_NN
Trust_NN
Company_NN
of_PIN
New_NN
York_NN
is_VPRT [BEMA]
the_DT
depositary_NN
for_PIN
Email_NN
investorrelations@uk_NN
._.
com_NN
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
ADSs_NN
._.
All_QUAN
enquiries_NN
concerning_VBG [WZPRES]
ADS_NN
records_NN
,_,
certificates_NN
or_CC
transfer_NN
of_PIN
ordinary_JJ
shares_NN
into_PIN
ADSs_NN
should_NEMD
North_NN
America_NN
:_:
Brian_NN
Piper_NN
be_VB [PASS]
addressed_VBN
to_TO
:_:
Tel_NN
1_CD
484 595 8800_CD
Fax_NN
1_CD
484 595 8151_CD
Morgan_NN
Guaranty_NN
Trust_NN
Company_NN
of_PIN
New_NN
York_NN
Email_NN
bpiper@us_FPP1
._.
com_NN
PO_NN
Box_NN
8205_CD
Boston_NN
,_,
Massachusetts_NN
02266-8205_CD
www_NN
._.
com_NN
USA_NN
Tel_NN
1_CD
781 575 4328_CD
Registrars_NN
and_CC
transfer_VB
office_NN
Fax_NN
1_CD
781 575 4088_CD
All_QUAN
administrative_JJ
enquiries_NN
relating_VBG [WZPRES]
to_PIN
shareholdings_GER
should_NEMD
be_VB [PASS]
addressed_VBN
to_PIN
Lloyds_NN
TSB_NN
Registrars_NN
,_,
clearly_RB
stating_VBG [PUBV]
the_DT
registered_VBN
Canadian_JJ
Shareholders_NN
shareholders_NN
name_NN
and_PHC
address_NN
._.
i_FPP1
Exchangeable_JJ
Shares_NN
of_PIN
Shire_NN
Acquisition_NOMZ
Inc._NN
._.
Exchangeable_JJ
shares_NN
in_PIN
Shire_NN
Acquisition_NOMZ
Inc._NN
are_VPRT [BEMA]
convertible_PRED
into_PIN
three_CD
Lloyds_NN
TSB_NN
Registrars_NN
ordinary_JJ
shares_NN
of_PIN
Shire_NN
or_CC
one_CD
ADS_NN
representing_VBG [WZPRES]
three_CD
ordinary_JJ
shares_NN
Customer_NN
Services_NN
,_,
The_DT
Causeway_NN
of_PIN
Shire_NN
._.
Exchangeable_JJ
shares_NN
trade_NN
on_PIN
the_DT
Toronto_NN
Stock_NN
Exchange_NN
Worthing_GER
,_,
West_NN
Sussex_NN
BN99_NN
6DA_NN
under_IN
the_DT
symbol_NN
SHQ_NN
._.
Shires_NN
ordinary_JJ
shares_NN
are_VPRT [PASS]
listed_VBN
on_PIN
the_DT
United_NN
Kingdom_NN
London_NN
Stock_NN
Exchange_NN
and_PHC
Shires_NN
ADSs_NN
are_VPRT [PASS]
listed_VBN
on_PIN
the_DT
NASDAQ_NN
Tel_NN
44 870 600 3970_CD
national_JJ
market_NN
._.
ii_FW
Trustee_NN
for_PIN
Exchangeable_JJ
Shareholders_NN
Natcan_NN
Trust_NN
Company_NN
,_,
a_DT
wholly_RB
owned_VBN
subsidiary_NN
of_PIN
the_DT
National_NN
Bank_NN
of_PIN
Canada_NN
,_,
acts_VPRT
as_IN
Trustee_NN
for_PIN
Exchangeable_JJ
Shareholders_NN
._.
All_QUAN
enquiries_NN
concerning_VBG [WZPRES]
Exchangeable_JJ
Share_NN
records_NN
or_CC
conversions_NN
of_PIN
Exchangeable_JJ
Shares_NN
into_PIN
ordinary_JJ
shares_NN
of_PIN
Shire_NN
or_CC
ADSs_NN
should_NEMD
be_VB [PASS]
addressed_VBN
to_TO
:_:
Natcan_NN
Trust_NN
Company_NN
1100_CD
University_NOMZ
Street_NN
Suite_NN
900_CD
Montreal_NN
,_,
Qubec_NN
H3B_NN
2G7_NN
Canada_NN
Tel_NN
1_CD
514 871 7171_CD
1_CD
800 341 1419_CD
Fax_NN
1_CD
514 871 7442_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
141_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
142_CD
Shire_NN
Trade_NN
Marks_NN
Cautionary_NN
statements_NOMZ
Shire_NN
Trade_NN
Marks_NN
Cautionary_NN
statements_NOMZ
ADDERALL_NN
XR_NN
mixed_JJ
salt_NN
of_PIN
a_DT
single_JJ
entity_NOMZ
amphetamine_NN
Statements_NOMZ
included_VBD
herein_NN
that_TSUB
are_VPRT [BEMA]
not_XX0
historical_JJ
facts_NN
are_VPRT
forwardADDERALL_NN
mixed_JJ
salt_NN
of_PIN
a_DT
single_JJ
entity_NOMZ
amphetamine_NN
looking_VBG [WZPRES]
statements_NOMZ
._.
Such_JJ
forward-looking_JJ
statements_NOMZ
involve_VPRT
a_DT
AGRYLIN_NN
anagrelide_NN
hydrochloride_NN
number_NN
of_PIN
risks_NN
and_PHC
uncertainties_NN
and_CC
are_VPRT [BEMA]
subject_PRED
to_TO
change_VB
at_PIN
any_QUAN
AMATINE_NN
midodrine_NN
hydrochloride_NN
time_NN
._.
In_PIN
the_DT
event_NN
such_JJ
risks_NN
or_CC
uncertainties_NN
materialize_VPRT
,_,
Shires_NN
CALCICHEW_NN
calcium_NN
carbonate_NN
results_NN
could_POMD
be_VB [SPAU] [PASS]
materially_RB
affected_VBN
._.
The_DT
risks_NN
and_PHC
uncertainties_NN
CARBATROL_NN
carbamazepine_NN
include_VPRT
,_,
but_CC
are_VPRT [PASS]
not_XX0
limited_VBN
to_TO
,_,
risks_NN
associated_VBN [WZPAST]
with_PIN
:_:
the_DT
inherent_JJ
COLAZIDE_NN
balsalazide_NN
uncertainty_NN
of_PIN
pharmaceutical_JJ
research_NN
,_,
product_NN
development_NOMZ
,_,
DAYTRANA_NN
methylphenidate_NN
transdermal_NN
system_NN
manufacturing_GER
and_PHC
commercialization_NOMZ
:_:
the_DT
impact_NN
of_PIN
competitive_JJ
ELAPRASE_NN
idursulfase_NN
products_NN
,_,
including_VBG
,_,
but_CC
not_XX0
limited_VBN
to_TO
,_,
the_DT
impact_NN
of_PIN
those_DEMO
on_PIN
Shires_NN
EQUETRO_NN
carbamazepine_NN
Attention_NOMZ
Deficit_NN
and_PHC
Hyperactivity_NOMZ
Disorder_NN
ADHD_NN
franchise_NN
:_:
patents_NN
,_,
FOSRENOL_NN
lanthanum_NN
carbonate_NN
including_VBG [WZPRES]
,_,
but_CC
not_XX0
limited_VBN
to_TO
,_,
legal_JJ
challenges_NN
relating_VBG [WZPRES]
to_PIN
Shires_NN
ADHD_NN
GENE-ACTIVATED_NN
GA-GCB_NN
glucocerebrosidase_NN
franchise_NN
:_:
government_NOMZ
regulation_NOMZ
and_PHC
approval_NN
,_,
including_VBG
,_,
but_CC
not_XX0
MESAVANCE_NN
mesalamine_NN
limited_VBN
to_TO
,_,
the_DT
expected_VBN [PRIV]
product_NN
approval_NN
dates_NN
of_PIN
SPD503_CD
ADHD_NN
,_,
PROAMATINE_NN
midodrine_NN
hydrochloride_NN
SPD465_CD
ADHD_NN
,_,
MESAVANCE_NN
SPD476_NN
ulcerative_JJ
colitis_NN
,_,
REMINYL_NN
galantamine_NN
hydrobromide_NN
ELAPRASE_NN
idursulfase_NN
Hunter_NN
Syndrome_NN
,_,
and_ANDC
NRP104_NN
ADHD_NN
,_,
UK_NN
and_PHC
Republic_NN
of_PIN
Ireland_NN
including_VBG [WZPRES]
its_PIT
scheduling_GER
classification_NOMZ
by_PIN
the_DT
Drug_NN
Enforcement_NOMZ
REMINYL_NN
XL_NN
galantamine_NN
hydrobromide_NN
Administration_NOMZ
in_PIN
the_DT
United_NN
States_NN
:_:
Shires_NN
ability_NOMZ
to_TO
benefit_VB
from_PIN
its_PIT
UK_NN
and_PHC
Republic_NN
of_PIN
Ireland_NN
acquisition_NOMZ
of_PIN
Transkaryotic_NN
Therapies_NN
,_,
Inc._NN
:_:
Shires_NN
ability_NOMZ
to_TO
secure_VB
REPLAGAL_NN
agalsidase_JJ
alfa_IN
new_JJ
products_NN
for_PIN
commercialization_NOMZ
and_CC
or_CC
development_NOMZ
:_:
and_ANDC
other_JJ
SOLARAZE_NN
diclofenac_NN
sodium_NN
3_CD
%_NN
risks_NN
and_PHC
uncertainties_NN
detailed_VBN [WZPAST]
from_PIN
time_NN
to_PIN
time_NN
in_PIN
Shires_NN
filings_GER
and_PHC
TROXATYL_NN
troxacitabine_VBD
its_PIT
predecessor_NN
registrant_NN
Shire_NN
Pharmaceuticals_NN
Group_NN
plcs_VPRT
filings_GER
VANIQA_NN
eflornithine_NN
hydrochloride_NN
with_PIN
the_DT
US_FPP1
Securities_NOMZ
and_PHC
Exchange_NN
Commission_NN
,_,
including_VBG
Shires_NN
XAGRID_NN
anagrelide_NN
hydrochloride_NN
Annual_JJ
Report_NN
on_PIN
Form_NN
10-K_NN
for_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
._.
Third-party_JJ
Trade_NN
Marks_NN
The_NN
statements_NOMZ
of_PIN
the_DT
individuals_NN
and_CC
medical_JJ
practitioners_NN
appearing_VBG [SMP] [WZPRES]
3TC_NN
lamivudine_NN
trade_NN
mark_NN
of_PIN
GSK_NN
in_PIN
the_DT
operating_GER
review_NN
on_PIN
pages_NN
1635_CD
of_PIN
this_DEMO
document_NOMZ
have_VPRT [PEAS]
been_VBN [BEMA]
COMBIVIR_JJ
trade_NN
mark_NN
of_PIN
GSK_NN
made_VBN [WZPAST]
by_PIN
and_CC
represent_VB
the_DT
views_NN
of_PIN
the_DT
named_VBN
individuals_NN
._.
The_DT
views_NN
DYNEPO_NN
trade_NN
mark_NN
of_PIN
Aventis_NN
Pharma_NN
Holdings_GER
GmbH_NN
represented_VBD
are_VPRT [BEMA]
those_DEMO
of_PIN
the_DT
named_VBN
medical_JJ
practitioners_NN
and_CC
should_NEMD
EPIVIR_NN
trade_NN
mark_NN
of_PIN
GSK_NN
not_XX0
necessarily_RB
be_VB [PASS]
taken_VBN
to_TO
represent_VB
the_DT
views_NN
of_PIN
Shire_NN
._.
EPIVIR-HBV_JJ
trade_NN
mark_NN
of_PIN
GSK_NN
HEPTOVIR_NN
trade_NN
mark_NN
of_PIN
GSK_NN
PENTASA_NN
mesalamine_NN
trade_NN
mark_NN
of_PIN
Ferring_GER
AS_NN
RAZADYNE_NN
trade_NN
mark_NN
of_PIN
Johnson_NN
&_CC
Johnson_NN
RAZADYNE_NN
ER_NN
trade_NN
mark_NN
of_PIN
Johnson_NN
&_CC
Johnson_NN
REMINYL_NN
trade_NN
mark_NN
of_PIN
Johnson_NN
&_CC
Johnson_NN
,_,
excluding_VBG
UK_NN
and_PHC
Republic_NN
of_PIN
Ireland_NN
REMINYL_NN
XL_NN
galantamine_NN
hydrobromide_NN
trade_NN
mark_NN
of_PIN
Johnson_NN
&_CC
Johnson_NN
,_,
excluding_VBG
UK_NN
and_PHC
Republic_NN
of_PIN
Ireland_NN
TRIZIVIR_NN
trade_NN
mark_NN
of_PIN
GSK_NN
ZEFFIX_NN
lamivudine_NN
trade_NN
mark_NN
of_PIN
GSK_NN
142_CD
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
143_CD
Glossary_NN
of_PIN
terms_NN
Animo_NN
acid_NN
MPS_NN
Society_NN
An_DT
organic_JJ
compound_NN
containing_VBG [WZPRES]
an_DT
amino_JJ
group_NN
NH_NN
,_,
a_DT
carboxylic_JJ
Society_NN
._.
2_CD
acid_NN
group_NN
COOH_NN
,_,
and_ANDC
any_QUAN
of_PIN
various_JJ
side_NN
groups_NN
,_,
especially_RB
any_QUAN
of_PIN
the_DT
20_CD
compounds_NN
that_TSUB
have_VPRT
the_DT
basic_JJ
formula_NN
NH_NN
CHRCOOH_NN
,_,
2_CD
and_CC
that_DEMO
link_NN
together_RB
by_PIN
peptide_NN
bonds_NN
to_TO
form_VB
proteins_NN
or_CC
that_DEMO
function_NOMZ
One_CD
of_PIN
a_DT
series_NN
of_PIN
inherited_VBN
metabolic_JJ
disorders_NN
affecting_VBG [WZPRES]
a_DT
type_NN
of_PIN
as_IN
chemical_NN
messengers_NN
and_CC
as_IN
intermediates_NN
in_PIN
metabolism_NN
._.
complex_JJ
carbohydrate_NN
called_VBD
a_DT
mucopolysaccharide_NN
that_DEMP
is_VPRT [PASS]
deposited_VBN
in_PIN
body_NN
tissues_NN
because_CAUS
the_DT
person_NN
lacks_VPRT
the_DT
specific_JJ
enzyme_NN
needed_VBN
Animo_NN
acid_NN
sequence_NN
to_TO
metabolize_VB
it_PIT
._.
Peptide_NN
sequence_NN
or_CC
amino_JJ
acid_NN
sequence_NN
is_VPRT [BEMA]
the_DT
order_NN
in_PIN
which_WDT [PIRE]
amino_JJ
acid_NN
residues_NN
,_,
connected_VBN [PASTP]
by_PIN
peptide_NN
bonds_NN
,_,
lie_VPRT
in_PIN
the_DT
chain_NN
._.
NICE_NN
The_NN
sequence_NN
is_VPRT [SPAU] [PASS]
generally_RB
reported_VBN [PUBV]
from_PIN
the_DT
N-terminal_JJ
end_NN
containing_VBG [WZPRES]
UK_NN
National_NN
Institute_NN
of_PIN
Clinical_NN
Excellence_NN
._.
free_JJ
amino_JJ
group_NN
to_PIN
the_DT
C-terminal_JJ
end_NN
containing_VBG [WZPRES]
free_JJ
carboxyl_NN
group_NN
._.
Peptide_NN
sequence_NN
is_VPRT [SPAU] [PASS]
often_RB
called_VBN
protein_NN
sequence_NN
if_COND
it_PIT
represents_VPRT
the_DT
Pharmacovigilance_NN
primary_JJ
structure_NN
of_PIN
a_DT
protein_NN
._.
The_DT
pharmacological_JJ
science_NN
relating_VBG [WZPRES]
to_PIN
the_DT
detection_NOMZ
,_,
assessment_NOMZ
,_,
understanding_GER
and_PHC
prevention_NOMZ
of_PIN
adverse_JJ
effects_NN
,_,
particularly_RB
long-term_JJ
Carbohydrate_NN
structure_NN
and_CC
short-term_JJ
side_NN
effects_NN
,_,
of_PIN
medicines_NN
Source_NN
:_:
The_DT
Importance_NN
In_PIN
glycoproteins_NN
,_,
in_CONJ
addition_NULL
to_PIN
the_DT
amino_JJ
acid_NN
backbone_NN
or_CC
otherwise_CONJ
of_PIN
Pharmacovigilance_NN
,_,
WHO_WP
2002_CD
._.
referred_VBD
to_PIN
as_IN
a_DT
protein_NN
,_,
other_JJ
molecules_NN
are_VPRT [PASS]
conjugated_VBN
to_PIN
the_DT
protein_NN
in_CONJ
particular_NULL
places_NN
,_,
such_JJ
as_IN
carbohydrates_NN
._.
Carbohydrates_NN
means_VPRT [PRIV]
sugars_NN
Phase_NN
1_CD
or_CC
chains_NN
of_PIN
sugars_NN
._.
A_DT
single_JJ
sugar_NN
is_VPRT [BEMA]
a_DT
monosaccharide_NN
,_,
a_DT
long_JJ
chain_NN
Clinical_JJ
trials_NN
usually_RB
conducted_VBN
in_PIN
healthy_JJ
human_JJ
volunteers_NN
would_PRMD
be_VB [BEMA]
a_DT
polysaccharide_NN
,_,
etc._FW
._.
These_DEMO
sugars_NN
are_VPRT [BEMA]
important_PRED
for_PIN
activity_NOMZ
to_TO
determine_VB [SUAV] [PRIV]
if_COND
a_DT
drug_NN
candidate_NN
is_VPRT [BEMA]
safe_PRED
for_PIN
more_EMPH
extensive_JJ
testing_GER
._.
and_ANDC
are_VPRT
also_RB
part_NN
of_PIN
the_DT
uptake_NN
mechanism_NN
for_PIN
the_DT
protein_NN
within_PIN
cells_NN
and_PHC
tissues_NN
._.
Phase_NN
2_CD
Clinical_JJ
trials_NN
conducted_VBN [WZPAST]
in_PIN
patients_NN
with_PIN
relevant_JJ
disease_NN
to_TO
assess_VB
CHADD_NN
the_DT
safety_NN
and_PHC
efficacy_NN
of_PIN
the_DT
drug_NN
candidate_NN
._.
Children_NN
and_PHC
adults_NN
with_PIN
attention_NOMZ
deficit_NN
hyperactivity_NOMZ
disorder_NN
._.
Phase_NN
3_CD
Glycoproteins_NN
Clinical_NN
trials_NN
conducted_VBN [WZPAST]
in_PIN
the_DT
target_NN
patient_NN
population_NOMZ
to_PIN
Any_QUAN
of_PIN
a_DT
group_NN
of_PIN
conjugated_JJ
proteins_NN
that_TSUB
contain_VPRT
a_DT
carbohydrate_NN
comprehensively_RB
assess_VB
the_DT
safety_NN
and_PHC
efficacy_NN
of_PIN
the_DT
drug_NN
candidate_NN
._.
Pivotal_JJ
study_NN
Immunogenic_NN
A_NN
major_JJ
clinical_JJ
trial_NN
that_TSUB
has_VPRT
a_DT
significant_JJ
impact_NN
on_PIN
the_DT
labeling_VBG
Producing_GER
an_DT
immune_JJ
response_NN
._.
Lysosomal_NN
Platelet_NN
Membrane-enclosed_JJ
compartment_NOMZ
in_PIN
cells_NN
,_,
containing_VBG [PRESP]
many_QUAN
A_DT
constituent_NN
of_PIN
blood_NN
that_TSUB
help_VPRT
form_VB
clots_NN
to_TO
control_VB
bleeding_GER
._.
hydrolytic_JJ
enzymes_NN
:_:
where_RB
large_JJ
molecules_NN
and_CC
cellular_JJ
components_NN
are_VPRT [PASS]
broken_VBN
down_RP
._.
Pre-clinical_JJ
study_NN
Studies_NN
of_PIN
compounds_NN
conducted_VBN [WZPAST]
in_PIN
the_DT
laboratory_NN
,_,
in_PIN
isolated_JJ
tissues_NN
,_,
Lysosomal_NN
Storage_NN
Diseases_NN
LSDs_NN
or_CC
in_PIN
living_VBG
animals_NN
._.
Are_VPRT [BEMA]
a_DT
group_NN
of_PIN
which_WDT [PIRE]
over_IN
forty_NN
disorders_NN
are_VPRT [SPAU] [PASS]
currently_RB
known_VBN [PRIV]
that_THVC
result_NN
from_PIN
defects_NN
in_PIN
lysosomal_JJ
function_NOMZ
._.
Proof_NN
of_PIN
Concept_NN
study_NN
A_DT
study_NN
intended_VBN [SUAV]
to_TO
show_VB [PRIV]
that_THVC
a_DT
hypothesis_NN
or_CC
concept_NN
is_VPRT [BEMA]
valid_PRED
._.
MHRA_NN
Medicine_NN
and_PHC
Healthcare_NN
products_NN
Regulatory_NN
agency_NN
._.
Molecule_NN
The_NN
smallest_JJ
particle_NN
of_PIN
a_DT
substance_NN
that_TSUB
retains_VPRT
the_DT
chemical_NN
and_CC
physical_JJ
properties_NN
of_PIN
the_DT
substance_NN
and_CC
is_VPRT [PASS]
composed_VBN
of_PIN
two_CD
or_CC
more_EMPH
atoms_NN
:_:
a_DT
group_NN
of_PIN
like_IN
or_CC
different_JJ
atoms_NN
held_VBN [PRIV] [WZPAST]
together_RB
by_PIN
chemical_NN
forces_NN
._.
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
143_CD
Shire_NN
plc_NN
6361_CD
Accounts_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:57_CD
Page_NN
144_CD
Designed_VBN
and_PHC
produced_VBN
by_PIN
Bostock_NN
and_PHC
Pollitt_NN
Limited_NN
,_,
London_NN
The_DT
paper_NN
used_VBN [WZPAST]
in_PIN
this_DEMO
publication_NOMZ
is_VPRT [PASS]
made_VBN
from_PIN
100_CD
%_NN
recycled_JJ
fibers_NN
sourced_VBD
entirely_AMP
from_PIN
post_NN
consumer_NN
waste_NN
,_,
is_VPRT [BEMA]
Elemental_JJ
Chlorine_NN
Free_NN
ECF_NN
and_CC
is_VPRT [PASS]
accredited_VBN
to_PIN
ISO_NN
14001_CD
._.
6361_CD
Cover_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:56_CD
Page_NN
fc2_CD
Shire_NN
plc_NN
Annual_JJ
review_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
2005_CD
6361_CD
Cover_NN
2005_CD
._.
qxd_NN
24_CD
4_CD
06_CD
12:56_CD
Page_NN
fc1_CD
Shire_NN
plc_NN
Annual_JJ
review_NN
and_PHC
summary_NN
finan_NN
Hampshire_NN
International_NN
Business_NOMZ
Park_NN
Shire_NN
plc_NN
Basingstoke_NN
,_,
Hampshire_NN
RG24_NN
8EP_NN
United_NN
Kingdom_NN
Tel_NN
44_CD
0_CD
1256 894000_CD
Fax_NN
44_CD
0_CD
1256 894708_CD
www_NN
._.
